

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:09:10 ; Search time 1392 Seconds

Title: us-10-664-775-2

Perfect score: 3572

Sequence: 1 gtcaggagggcgcagtg.....gcacacacgacgaagctt 3572

Scoring table: IDENTITY NUC (without alignments)

Gapop 10.0 , Gapext 0.5

Searched: 1612 seqs, 761339 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,

and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID Description

C	1	28.8	0.8	612	1	ABQ47969	Oligonucleotide fo
C	2	28.8	0.8	612	1	ABQ47968	Oligonucleotide fo
C	3	28.7	0.8	267	1	AAK45604	Human bone marrow
C	4	28.7	0.8	267	1	AAK19599	Human brain expres
C	5	28.7	0.8	267	1	ABK45284	Human liver single
C	6	28.7	0.8	267	1	ABK19876	Human genome-deriv
C	7	28.6	0.8	373	1	ABL80716	Human ovarian can
C	8	28.6	0.8	517	1	ABV98643	Human pancreatic c
C	9	27.7	0.8	1843	1	AAAF54035	Human pancreatic C co
C	10	27.7	0.8	1843	1	AAAF54050	Human protein C ge
C	11	27.7	0.8	1843	1	ABN97175	Gene #3673 used to
C	12	27.2	0.8	387	1	ABK30271	Human G-protein-co
C	13	26.2	0.7	237	1	ABK68927	DNA encoding novel
C	14	26.2	0.7	683	1	AAQ63794	Bovine trypsin gen
C	15	26.2	0.7	699	1	AAAF81479	DNA encoding recom
C	16	26.2	0.7	701	1	AAQ63795	Bovine met-phe-try
C	17	26.2	0.7	702	1	AAAF81479	Bovine trypsinogen
C	18	26.2	0.7	702	1	AAAF81479	DNA encoding a try
C	19	26.2	0.7	828	1	AAAF81479	Pig lung protease
C	20	26.2	0.7	1151	1	AAAF81479	Human secreted pro
C	21	25.8	0.7	497	1	ABV97824	Human pancreatic c
C	22	25.6	0.7	2438	1	AAAF81479	Factor IX/Factor V
C	23	25.4	0.7	1036	1	AAAF81479	Human procrasin-li
C	24	25.4	0.7	1036	1	AAAF81479	DNA encoding huma
C	25	25.2	0.7	1036	1	AAAF81479	DNA encoding huma
C	26	25.2	0.7	448	1	ABV97809	Human pancreatic c
C	27	25.0	0.7	882	1	ABN85394	Partial Human NOVI
C	28	24.8	0.7	2177	1	AAAF81479	Partial Factor VII
C	29	24.6	0.7	1151	1	AAAF81479	Human secreted pro
C	30	24.6	0.7	1352	1	AAAF81479	CDNA encoding nove
C	31	24.6	0.7	1352	1	AAAF81479	Human cDNA encodin
C	32	24.6	0.7	1352	1	AAAF81479	Human cDNA encodin
C	33	24.6	0.7	1352	1	AAAF81479	CDNA encoding nove

34	24.6	0.7	1352	1	AAAF81479	CDNA encoding nove
35	24.6	0.7	1352	1	AAAF81479	Human cDNA encodin
36	24.6	0.7	1378	1	AAAF81479	CDNA clone encodin
37	24.6	0.7	1378	1	AAAF81479	Protein PRO343 CDN
38	24.6	0.7	1378	1	AAAF81479	CDNA encoding nove
39	24.6	0.7	1378	1	AAAF81479	Human PRO343 CDNA
40	24.6	0.7	1378	1	AAAF81479	Human PRO343 CDNA
41	24.6	0.7	1378	1	AAAF81479	Human PRO polynuci
42	24.6	0.7	1378	1	AAAF81479	CDNA encoding huma
43	24.6	0.7	1378	1	AAAF81479	Human cDNA for sec
44	24.6	0.7	1378	1	AAAF81479	Novel human secret
45	24.6	0.7	1378	1	AAAF81479	Human cDNA encodin
46	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
47	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
48	24.6	0.7	1378	1	AAAF81479	CDNA encoding huma
49	24.6	0.7	1378	1	AAAF81479	Human secreted / t
50	24.6	0.7	1378	1	AAAF81479	Novel human secret
51	24.6	0.7	1378	1	AAAF81479	Human secreted / t
52	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
53	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
54	24.6	0.7	1378	1	AAAF81479	Human cDNA encodin
55	24.6	0.7	1378	1	AAAF81479	Human PRO polynuci
56	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
57	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
58	24.6	0.7	1378	1	AAAF81479	Human PRO polynuci
59	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
60	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
61	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
62	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
63	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
64	24.6	0.7	1378	1	AAAF81479	Human PRO polynuci
65	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
66	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
67	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
68	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
69	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
70	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
71	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
72	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
73	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
74	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
75	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
76	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
77	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
78	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
79	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
80	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
81	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
82	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
83	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
84	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
85	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
86	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
87	24.6	0.7	1378	1	AAAF81479	Human secreted/tra
88	24.6	0.7	1378	1	AAAF81479	Novel growth facto
89	24.6	0.7	1378	1	AAAF81479	Plant microsateili
90	24.6	0.7	1378	1	AAAF81479	Bovine EST associ
91	24.6	0.7	1378	1	AAAF81479	Colon tumour relat
92	24.6	0.7	1378	1	AAAF81479	Human colon tumour
93	24.6	0.7	1378	1	AAAF81479	Partial Human NOVI
94	24.6	0.7	1378	1	AAAF81479	Activation constru
95	24.6	0.7	1378	1	AAAF81479	Nucleotide sequenc
96	24.6	0.7	1378	1	AAAF81479	Human NOVI14b, pros
97	24.6	0.7	1378	1	AAAF81479	Activation constru
98	24.6	0.7	1378	1	AAAF81479	Nucleotide sequenc
99	24.6	0.7	1378	1	AAAF81479	Human factor X cod
100	24.6	0.7	1378	1	AAAF81479	Human gene express
101	24.6	0.7	1378	1	AAAF81479	Farnesyl transfera
102	24.6	0.7	1378	1	AAAF81479	Human pancreatic c
103	24.6	0.7	1378	1	AAAF81479	Histocompatibility
104	24.6	0.7	1378	1	AAAF81479	Substance P antise
105	24.6	0.7	1378	1	AAAF81479	Human adenosine re
106	24.6	0.7	1378	1	AAAF81479	Human substance P

C 107	23	0.6	250	1	ABZ96022	Human substance P	180	21.2	0.6	1529	1	AAQ12680	PAP-I-protein C fu
C 108	23	0.6	370	1	ABX46375	Bovine EST associa	C 181	21.2	0.6	6098	1	ABX14193	Plasmod PLN174 for
C 109	23	0.6	381	1	ABV97874	Bovine pancreatic c	C 182	21	0.6	237	1	ABL28111	Drosophila melanog
C 110	23	0.6	2438	1	ANM60065	Factor IX/factor V	C 183	21	0.6	291	1	ASZ72491	Sorghum calcone s
C 111	22.8	0.6	231	1	ACG55669	Human differential	C 184	21	0.6	292	1	AAH57326	Human pancreas spe
C 112	22.8	0.6	231	1	ACD81661	Human destructive	C 185	21	0.6	631	1	ACC46452	Human difth protei
C 113	22.8	0.6	255	1	AAD54232	Streptomyces amphi	C 186	21	0.6	950	1	ABL65438	Lung cancer relate
C 114	22.8	0.6	356	1	ABX36877	Bovine EST associa	C 187	21	0.6	933	1	AAV59135	Nucleotide sequenc
C 115	22.8	0.6	399	1	ABX35924	Bovine EST associa	C 188	21	0.6	951	1	ADA05757	Human NOV25a encod
C 116	22.6	0.6	468	1	AAI11607	Probe #1540 for ge	C 189	21	0.6	1551	1	AAQ06059	Angiotensin conver
C 117	22.6	0.6	468	1	ABR53297	Human foetal liver	C 190	21	0.6	2422	1	AAQ00396	cDNA encoding fact
C 118	22.6	0.6	468	1	ABR53297	Probe #1586 used t	C 191	21	0.6	2422	1	AAQ00396	Factor VII encodin
C 119	22.6	0.6	468	1	ABA44875	Human breast cell	C 192	21	0.6	2422	1	AAQ00396	Factor VII encodin
C 120	22.6	0.6	468	1	AAK03070	Probe #1536 for ge	C 193	21	0.6	2422	1	AAQ00396	Human Factor VII p
C 121	22.6	0.6	468	1	AAK03070	Human brain expres	C 194	21	0.6	2422	1	AAQ00396	Human NOV8a encodi
C 122	22.6	0.6	468	1	AAI01533	Probe #1524 used t	C 195	21	0.6	2422	1	AAQ00396	Factor VII cDNA of
C 123	22.6	0.6	2177	1	AAI01533	Partial Factor VII	C 196	20.9	0.6	432	1	AAQ00396	Bovine EST associa
C 124	22.4	0.6	186	1	ABV76724	Human ORF1671 cDNA	C 197	20.8	0.6	197	1	ABV97483	Human pancreatic c
C 125	22.4	0.6	317	1	ABV97959	Human pancreatic c	C 198	20.8	0.6	252	1	ABN18436	Human ORFX polynuc
C 126	22.3	0.6	253	1	ABV70944	Single nucleotide	C 199	20.8	0.6	281	1	ABV74708	Corn tassal-derive
C 127	22.2	0.6	397	1	ABV97709	Human pancreatic c	C 200	20.8	0.6	323	1	AAQ40441	Human secreted pro
C 128	22	0.6	234	1	ABV98476	Human pancreatic c	C 201	20.8	0.6	380	1	AAQ59116	Human cancer relat
C 129	22	0.6	397	1	ABV98476	Human prostate exp	C 202	20.8	0.6	396	1	ABX44887	Bovine EST associa
C 130	22	0.6	432	1	ABX49447	Bovine EST associa	C 203	20.8	0.6	400	1	AAQ59112	Human cancer relat
C 131	22	0.6	534	1	ABX44157	cDNA #97 encoding	C 204	20.8	0.6	545	1	ABX67855	Human foetal liver
C 132	22	0.6	741	1	AAI01633	Human spleen cryps	C 205	20.8	0.6	545	1	ABX41612	Human liver single
C 133	22	0.6	744	1	AAI04001	Human pancreatic t	C 206	20.8	0.6	1338	1	AAI99982	Human FVII encodin
C 134	22	0.6	744	1	AAI04000	Human pancreatic t	C 207	20.8	0.6	1352	1	AAQ11085	cDNA encoding nove
C 135	22	0.6	744	1	AAI03999	Human pancreatic t	C 208	20.8	0.6	1352	1	AAQ11085	Human cDNA encodin
C 136	22	0.6	790	1	AAI24548	Human pancreatic t	C 209	20.8	0.6	1352	1	ABK72087	Human cDNA encodin
C 137	22	0.6	853	1	ABZ3087	Trypsinogen-like p	C 210	20.8	0.6	1352	1	ABK72087	cDNA encoding nove
C 138	21.8	0.6	121	1	ABZ3087	Factor IX mutation	C 211	20.8	0.6	1352	1	AAQ41621	cDNA encoding nove
C 139	21.8	0.6	121	1	ABZ3087	Factor IX mutation	C 212	20.8	0.6	1352	1	AAQ41621	Human cDNA encodin
C 140	21.8	0.6	121	1	ABZ3087	Factor IX mutation	C 213	20.8	0.6	1357	1	AAI99983	Human FVII express
C 141	21.8	0.6	121	1	ABZ3087	Factor IX mutation	C 214	20.8	0.6	1366	1	AAQ32168	Human low density
C 142	21.8	0.6	224	1	ABZ3087	Probe #14645 for g	C 215	20.8	0.6	1754	1	AAQ13357	Human protein C ge
C 143	21.8	0.6	224	1	ABZ3087	Human foetal liver	C 216	20.8	0.6	1754	1	AAQ13357	Protein C precursor
C 144	21.8	0.6	224	1	AAI50074	Probe #18760 used	C 217	20.8	0.6	1755	1	AAQ12849	Human protein C
C 145	21.8	0.6	224	1	AAI50074	Probe #15285 for g	C 218	20.8	0.6	1755	1	AAQ12849	Human protein C
C 146	21.8	0.6	224	1	AAI50074	Human bone marrow	C 219	20.8	0.6	1756	1	AAQ12849	Human protein C
C 147	21.8	0.6	224	1	AAI50074	Human brain expres	C 220	20.6	0.6	228	1	AAQ02548	cDNA sequence enco
C 148	21.8	0.6	224	1	AAI50074	Human liver single	C 221	20.6	0.6	228	1	AAQ02548	Human secreted pro
C 149	21.8	0.6	224	1	AAI50074	Human genome-deriv	C 222	20.6	0.6	312	1	ADA49305	Maize gene conferr
C 150	21.8	0.6	361	1	ABX4370	Bovine EST associa	C 223	20.6	0.6	312	1	ADA49305	Bovine EST associa
C 151	21.8	0.6	522	1	ABK44151	cDNA #91 encoding	C 224	20.6	0.6	717	1	AAQ11346	Single nucleotide
C 152	21.8	0.6	711	1	AAI48492	Human serine prote	C 225	20.6	0.6	1843	1	AAQ54035	Human protein C co
C 153	21.6	0.6	268	1	AAQ49395	Mettlyr human prota	C 226	20.6	0.6	1843	1	AAQ54035	Human protein C ge
C 154	21.6	0.6	281	1	AAQ05663	Human proinsulin g	C 227	20.6	0.6	1843	1	ABN97175	Gene #3673 used to
C 155	21.6	0.6	281	1	AAQ05663	hpi gene. Homo sa	C 228	20.6	0.6	1982	1	ADG79050	Human protein modi
C 156	21.6	0.6	360	1	ACG03539	Synthetic DNA ecod	C 229	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 157	21.6	0.6	360	1	ACG03539	HIV p15RnaseH opt.	C 230	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 158	21.6	0.6	372	1	ABX37095	Bovine EST associa	C 231	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 159	21.6	0.6	427	1	ABX37095	Murine transport a	C 232	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 160	21.6	0.6	6098	1	ABX14193	Plasmod PLN174 for	C 233	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 161	21.4	0.6	144	1	ABR84477	Human estrogen re	C 234	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 162	21.4	0.6	172	1	AAQ58758	Human transmembran	C 235	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 163	21.4	0.6	243	1	AAA49060	Shut O-N-lang DNA	C 236	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 164	21.4	0.6	380	1	ABV99158	Human pancreatic c	C 237	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 165	21.4	0.6	612	1	ABQ47966	Oligonucleotide fo	C 238	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 166	21.4	0.6	612	1	ABQ47966	Oligonucleotide fo	C 239	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 167	21.2	0.6	177	1	ABR74567	Human foetal liver	C 240	20.4	0.6	121	1	ABA79567	Factor IX mutation
C 168	21.2	0.6	177	1	AAI55048	Probe #23734 used	C 241	20.4	0.6	268	1	AAQ72259	Single nucleotide
C 169	21.2	0.6	177	1	ABK48213	Human bone marrow	C 242	20.4	0.6	270	1	ADA49152	Maize gene conferr
C 170	21.2	0.6	177	1	ABK48213	Human liver single	C 243	20.4	0.6	285	1	AAH57325	Human pancreas spe
C 171	21.2	0.6	231	1	ABK76610	Bacillus lichenifo	C 244	20.4	0.6	290	1	ABU71211	Human tassal-derive
C 172	21.2	0.6	273	1	AAI23284	Human ORFX polynuc	C 245	20.4	0.6	334	1	AAV89281	Gene fragment HEPA
C 173	21.2	0.6	280	1	AAI23284	Human breast cance	C 246	20.4	0.6	335	1	AAV89281	EST clone CG175.
C 174	21.2	0.6	505	1	ABK30273	Human G-protein-co	C 247	20.4	0.6	394	1	AAAD58761	Human transmembran
C 175	21.2	0.6	609	1	ADA50533	Human protease gen	C 248	20.4	0.6	717	1	AAA61659	cDNA encoding mous
C 176	21.2	0.6	888	1	ABK31769	DNA encoding novel	C 249	20.4	0.6	1383	1	ABK86038	Synthetic DNA enco
C 177	21.2	0.6	918	1	AAI67198	Nucleotide sequenc	C 250	20.4	0.6	1386	1	AAQ90024	Nascent human prot
C 178	21.2	0.6	1130	1	AAI67198	Fusion gene of pro							
C 179	21.2	0.6	1166	1	AAI67198	Zymogen activation							

ALIGNMENTS

RESULT 1
ABQ47969/C
ID ABQ47969 standard; DNA; 612 BP.

XX AC ABQ47969;
XX DT 12-JUL-2002 (first entry)
XX DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34560.

XX KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
XX KW drug; side effect; cancer; central nervous system; cardiovascular;
XX KW gastrointestinal; respiratory system; single nucleotide polymorphism;
XX KW SNP; cell differentiation; ds.

XX OS Homo sapiens.
XX PN WO200218632-A2.
XX PD 07-MAR-2002.
XX PF 01-SEP-2001; 2001WO-EP010074.
XX PR 01-SEP-2000; 2000DE-01043826.
XX PR 05-SEP-2000; 2000DE-01044543.
XX PA (EPIC-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;
XX DR WPI; 2002-371829/40.

XX PT Determining the degree of cytosine methylation in genomic DNA, useful for
XX PT diagnosis and prognosis, comprises selective hybridization of amplicons
XX PT from chemically treated DNA.

XX PS Claim 12; 56pp + Sequence Listing; 56pp; German.

XX CC This invention describes a novel method for determining the degree of
XX CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
XX CC genomic sample of DNA. The sample is treated chemically to convert
XX CC cytosine (C) but not methylated C, to uracil, then part of the genomic
XX CC DNA that contains the target C is amplified to form a labeled amplicon.
XX CC The amplicon is hybridised to two classes, each with at least one member,
XX CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
XX CC degree of hybridisation to both classes is determined from the label on
XX CC the amplicon. From the ratio of labels hybridised to the two classes of
XX CC oligomers, the degree of methylation is calculated. The method is used:
XX CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
XX CC and of a wide range of diseases, e.g. cancer, disorders of the central
XX CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
XX CC particularly by detecting mutations or single nucleotide polymorphisms
XX CC (SNP's); and (ii) for differentiation of cell or tissue types and for
XX CC investigating cell differentiation. The method allows the methylation
XX CC status of many C residues to be determined simultaneously. ABQ13410-
XX CC ABQ54121 represent genomic DNA sequences used to illustrate the method
XX CC for determining the degree of cytosine methylation described in the
XX CC disclosure of the invention

XX SQ Sequence 612 BP; 232 A; 219 C; 72 G; 89 T; 0 U; 0 Other;
Query Match 0.8%; Score 28.8; DB 1; Length 612;
Best Local Similarity 58.0%; Pred. No. 1.6;
Matches 51; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 3207 TCTTTGATACAGCTTCAGTTCATGCTTTTAAATAAGTTTTTTTTTTTTTTTA 3266
DB 280 TTTTGAAGATTTTCGGGTTTTTCGAAGGAGTATTGTTTTTTTGTATTTTTTTT 221

QY 3267 AGCAATGTCATTCTTTGTGAGTTTGA 3294

Db 220 AGGAGTTCGGTCGTAGTTTTTTTAGGA 193

RESULT 2
ABQ47968
ID ABQ47968 standard; DNA; 612 BP.

XX AC ABQ47968;
XX DT 12-JUL-2002 (first entry)
XX DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34559.

XX KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
XX KW drug; side effect; cancer; central nervous system; cardiovascular;
XX KW gastrointestinal; respiratory system; single nucleotide polymorphism;
XX KW SNP; cell differentiation; ds.

XX OS Homo sapiens.
XX PN WO200218632-A2.
XX PD 07-MAR-2002.
XX PF 01-SEP-2001; 2001WO-EP010074.
XX PR 01-SEP-2000; 2000DE-01043826.
XX PR 05-SEP-2000; 2000DE-01044543.
XX PA (EPIC-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;
XX DR WPI; 2002-371829/40.

XX PT Determining the degree of cytosine methylation in genomic DNA, useful for
XX PT diagnosis and prognosis, comprises selective hybridization of amplicons
XX PT from chemically treated DNA.

XX PS Claim 12; 56pp + Sequence Listing; 56pp; German.

XX CC This invention describes a novel method for determining the degree of
XX CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
XX CC genomic sample of DNA. The sample is treated chemically to convert
XX CC cytosine (C) but not methylated C, to uracil, then part of the genomic
XX CC DNA that contains the target C is amplified to form a labeled amplicon.
XX CC The amplicon is hybridised to two classes, each with at least one member,
XX CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
XX CC degree of hybridisation to both classes is determined from the label on
XX CC the amplicon. From the ratio of labels hybridised to the two classes of
XX CC oligomers, the degree of methylation is calculated. The method is used:
XX CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
XX CC and of a wide range of diseases, e.g. cancer, disorders of the central
XX CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
XX CC particularly by detecting mutations or single nucleotide polymorphisms
XX CC (SNP's); and (ii) for differentiation of cell or tissue types and for
XX CC investigating cell differentiation. The method allows the methylation
XX CC status of many C residues to be determined simultaneously. ABQ13410-
XX CC ABQ54121 represent genomic DNA sequences used to illustrate the method
XX CC for determining the degree of cytosine methylation described in the
XX CC disclosure of the invention

XX SQ Sequence 612 BP; 89 A; 72 C; 219 G; 232 T; 0 U; 0 Other;
Query Match 0.8%; Score 28.8; DB 1; Length 612;
Best Local Similarity 58.0%; Pred. No. 1.6;
Matches 51; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 3207 TCTTTGATACAGCTTCAGTTCATGCTTTTAAATAAGTTTTTTTTTTTTTTTA 3266
DB 333 TTTTGAAGATTTTCGGGTTTTTCGAAGGAGTATTGTTTTTTTGTATTTTTTTT 392

	Query Match	0.8%; Score 28.7; DB 1; Length 267;
	Best Local Similarity	56.8%; Pred. No.1.3;
	Matches 71; Conservative 0; Mismatches 53; Indels 1; Gaps 1;	
QY	2601	GATGCTGGAGGGATTCCGGCGCAGGAGGAACGAGGCACACAGAGTACAGATGCCTGGA 2660
Dd	147	CAGCAGGAGAAGGAGGAGGAAAGAGGAGGAGAGGAGGAGGAGGAGGAGG-AGGA 89
QY	2661	TGGCATCACTCACTTCGATGCGACTGTGATCTTGCGTGAACTTCCTGGAGTTTGGTCATGGACAG 2720
Dd	88	GGAGCAGAAGCAGGAGGAGGAGGAGCAGAACGAGGAGGAGGAGGTTGAAGGAGGAGGAGGAGGAGGA 29
QY	2721	GGAGG 2725
Dd	28	GGAGG 24

RESULT 6
ABS19876/C
ID ABS19876 standard; DNA; 267 bp.
XX
AC ABS19876;

19-AUG-2002 (first entry)

Human genome-derived single exon probe ORF from lung SEQ ID No 19867.

Human; ds; single exon probe; asthma; lung cancer; COPD; ILD; chronic obstructive pulmonary disease; interstitial lung disease; familial idiopathic pulmonary fibrosis; neurofibromatosis; tuberous sclerosis; Gaucher's disease; Niemann-Pick disease; Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemorrhoidosis; pulmonary histiocytosis; lymphangioleiomyomatosis; Kargener syndrome; pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia; primary ciliary dyskinesia; pulmonary hypertension; hyaline membrane disease; open reading frame; ORF.

Homo sapiens.

WO200186003-A2.

15-NOV-2001.

30-JAN-2001; 2001WO-US0000665.

04-FEB-2000; 2000US-0180312P.

26-MAY-2000; 2000US-0207456P.

30-JUN-2000; 2000US-00608408.

03-AUG-2000; 2000US-00632366.

21-SEP-2000; 2000US-0234687P.

27-SEP-2000; 2000US-0236359P.

04-OCT-2000; 2000GB-00024263.

(MOLE-) MOLECULAR DYNAMICS INC.

Penn SG, Hanzel DK, Chen W, Rank DR;
WPT; 2002-114183/15.

Spatially-addressable set of single exon nucleic acid probes, used to measure gene expression in human lung samples.

Claim 4; SEQ ID NO 19867; 634pp; English.

The invention relates to a spatially-addressable set of single exon nucleic acid probes for measuring gene expression in a sample derived from human lung comprising single exon nucleic acid probes having one or 12614 nucleic acid sequences mentioned in the specification, or their complements or the 12387 open reading frames derived from the 12614 probes. Also included are a microarray comprising the novel set of probes; the novel set of probes which hybridise at high stringency to a nucleic acid expressed in the human lung; measuring gene expression in a sample derived from human lung, comprising (a) contacting the array with a collection of detectably labeled nucleic acids derived from human lung mRNA, and (b) measuring the label detectably bound to each probe of the array; identifying exons in a eukaryotic genome, comprising (a) algorithmically predicting at least one exon from genomic sequences of the eukaryote; and (b) detecting specific hybridisation of detectably labeled nucleic acids from eukaryote lung mRNA, to a single exon probe having a fragment identical to the predicted exon, the probe is included in the above mentioned microarray; assigning exons to a single gene, comprising (a) identifying exons from genomic sequence by the method above and (b) measuring the expression of each of the exons in several tissues and/or cell types using hybridisation to a single exon microarrays having a probe with the exon, where a common pattern of expression of the exons in the tissues and/or cell types indicates that the exons should be assigned to a single gene; a peptide comprising one of 12011 sequences, mentioned in the specification, or encoded by the probes/open reading frames (ORF). The probes are used for gene expression analysis, and for identifying exons in a gene, particularly using human lung derived mRNA and for the study of lung diseases such as asthma, cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary haemorrhoidosis, pulmonary

XX	23-APR-2002 (first entry)	
DT	Human G-protein-coupled protease #41.	
XX		
XX	Human; ss; gene; G-protein-coupled protease; gene therapy; transgenic;	
XX	protease mediated disorder; proliferative disorder;	
KW	differentiative disorder; developmental disorder;	
KW	haematopoietic disorder.	
XX		
OS	Homo sapiens.	
XX		
XX	US63311427-B1.	
PN		
XX	18-DEC-2001.	
PD		
XX		
PF	26-WAR-1999; 98US-00280116.	
XX		
PR	26-MAR-1999; 99US-00280116.	
XX	(MILL-) MILLENNIUM PHARM INC.	
PA		
XX	Robison KE;	
PI		
XX	WPI; 2002-129545/17.	
DR		
XX	New polynucleotides encoding protease homologs of the G-protein-coupled	
PT	protease family, useful in identifying agonists and antagonists for	
PT	diagnosis and treatment of protease mediated disorders.	
XX		
XX	Disclosure; Col 95-96; 246pp; English.	
PS		
XX		
CC	The invention relates to an isolated human protease nucleic acid molecule	
CC	comprising a nucleotide sequence of 546 base pairs, one of 288 fully	
CC	defined in the specification. Also disclosed are production of an	
CC	isolated polypeptide encoded by the nucleic acid, comprising introducing	
CC	the nucleic acid into a host cell and culturing under conditions to	
CC	express the protein from the nucleic acid, use of an antibody to detect	
CC	the encoded protein in a sample and to modulate its in vivo activity,	
CC	identifying agents that bind to the protein and identification of a	
CC	polynucleotide agent that modulates the expression of the nucleic acid or	
CC	its complement (i.e. gene therapy). The nucleic acid can be used to	
CC	identify an agent that modulates the expression or activity of the	
CC	nucleic acid, and can be used to isolate the protein. The nucleic acid	
CC	can be used in diagnostic assays for determining nucleic acid expression	
CC	as well as activity in the context of a biological sample (e.g., blood,	
CC	serum, cells, tissue) to determine whether an individual has a disease or	
CC	disorder, or is at risk of developing a disease or disorder, associated	
CC	with aberrant expression or activity of the nucleic acid. The nucleic	
CC	acid can be used to detect mutations in protease genes and gene	
CC	expression products such as mRNA. The nucleic acid can be used as	
CC	hybridisation probes to detect naturally-occurring genetic mutations in a	
CC	protease gene. The nucleic acid can be used in drug screening methods to	
CC	identify agonists and antagonists that can be used to diagnose and treat	
CC	such protease mediated disorders e.g., proliferative, differentiative,	
CC	developmental or haematopoietic disorders. The nucleic acid can be used	
CC	as probes, primers, in biological assays, to determine patterns of gene	
CC	expression, to design ribozymes and to construct transgenic animals. The	
CC	present sequence represents one of the 288 disclosed human G-protein-	
CC	coupled protease cDNA sequences	
XX		
SQ	Sequence 387 BP; 80 A; 130 C; 103 G; 67 T; 0 U; 7 Other;	

	Query Match	0.88;	Score 27.2;	DB 1;	Length 387;
	Best Local Similarity	72.9%;	Pred.No. 3.7;		
	Matches 35;	Conservative 0;	Mismatches 13;	Indels 0;	Gaps 0;
Qy	3247	TTTTTTTTTTTTTTTTTTTT	AAAAAGATGTCATCTTTT	TGTGAAGTTTGA	3294
Db	387	TTTTTTTTTTTTTTTTTTTT	TCTTAAACAGATGCATTT	TAATGGGAATCTAA	340

RESULT 13

AAS68927
 ID AAS68927 standard; cDNA; 237 BP.
 XX
 XX AAS68927;
 AC
 XX
 XX 13-FEB-2002 (first entry)
 DT
 XX
 XX DNA encoding novel human diagnostic protein #4731.
 DE
 XX
 XX Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
 XX
 XX
 OS Homo sapiens.
 XX
 XX WO200175067-A2.
 PN
 XX
 XX 11-OCT-2001.
 PD
 XX
 XX 30-MAR-2001; 2001WO-US008631.
 PF
 XX
 XX 31-MAR-2000; 2000US-00540217.
 PR
 XX
 XX 23-AUG-2000; 2000US-00649167.
 PR
 XX
 XX (HYSE-) HYSEQ INC.
 PA
 XX
 XX Drmanac RT, Liu C, Tang YT;
 PI
 XX
 XX WPI: 2001-639362/73.
 DR
 XX
 XX P-PSDB; ABG04740.
 DR
 XX
 XX New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity.
 PT
 XX
 XX Claim 1; SEQ ID NO 4731; 103pp; English.
 PS
 XX
 XX The invention relates to isolated polynucleotide (I) and polypeptide (II)
 CC sequences. (I) is useful as hybridisation probes, polymerase chain
 CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
 CC and in recombinant production of (II). The polynucleotides are also used
 CC in diagnostics as expressed sequence tags for identifying expressed
 CC genes. (II) is useful in gene therapy techniques to restore normal
 CC activity of (III) or to treat disease states involving (II). (II) is
 CC useful for generating antibodies against it, detecting or quantitating a
 CC polypeptide in tissue, as molecular weight markers and as a food
 CC supplement. (II) and its binding partners are useful in medical imaging
 CC of sites expressing (II). (I) and (II) are useful for treating disorders
 CC involving aberrant protein expression or biological actions. The
 CC polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. AAS64197-AAS94564 represent novel human diagnostic
 CC coding sequences of the invention. Note: The sequence data for this
 CC patent did not appear in the printed specification, but was obtained in
 CC electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX Sequence 237 BP; 97 A; 34 C; 82 G; 24 T; 0 U; 0 Other;
 XX

	Query Match	0.7%	Score 26.2;	DB 1;	Length 237;	
	Best Local Similarity	52.3%;	Prod. No. S.9;			
	Matches 58;	Conservative 0;	Mismatches 53;	Indels 0;	Gaps 0;	
QY	968	ACTCGAATGC	AAAGTAGG	AAGAACAACCACTCGAGTACAGCGAAAATTGGCCCTTG	1027	
Dδ	52	AGTCGAATCC	CAGGAGGAGGAGGAGGAGGAGCAGGAGGAGGAGGAGGAGGAGG	111		
QY	1028	GAATACCGAAT	GAAGCAGGCGCAAGACTAATAGAGTTTTGCCAAGAAAATG	1078		
Dδ	112	CAGCAGCAGAGAGG	AAGAAAGAACAGAAAGAACAGAGAGAACAGAACAGAGAG	162		

RESULT 14
AAQ63794
ID AAQ63794 standard; DNA; 683 BP.
XX
XX
AC AAQ63794;
XX
XX 25-MAR-2003 (revised)
DT 01-DEC-1994 (first entry)
XX
XX Bovine trypsin gene.
DE
XX Cattle; cow; trypsin; enzyme; protease; proinsulin; insulin; hormone;
KW plasmid PRMG4; ds.
XX
XX Bos taurus.
XX
XX Key Location/Qualifiers
FH CDS 4..675
FT /*tag= a
FT
XX EP597681-A1.
PN
XX 18-MAY-1994.
PD
XX 10-NOV-1993; 93EP-00308959.
XX
XX 13-NOV-1992; 92US-00977703.
XX
XX (ELIL) LILLY & CO ELI.
PA
XX Greaney MG, Rosteck PR;
PI
XX WPI; 1994-160671/20.
DR
XX Expression vectors for bovine trypsin and bovine trypsinogen - for
PT cleavage of zymogens into active drugs, e.g. pro-insulin conversion into
PT insulin.
XX
XX Disclosure; Page 25; 35pp; English.
PS
XX This gene is expressed in a recombinant host, e.g. E. coli, using plasmid
CC PRMG4. The encoded bovine trypsin gene may be expressed recombinantly and
CC is able to cleave zymogens into active drugs, e.g. pro-insulin conversion
CC into insulin. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 683 BP; 134 A; 223 C; 172 G; 154 T; 0 U; 0 Other;
Query Match 0.7%; Score 26.2; DB 1; Length 683;
Best Local Similarity 53.4%; Pred. No. 8;
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;
QY 821 TCCAGGCAACCACTTCAATATCAGTATCCAGTCTATGCCCAACCAAGTATGCTG 880
DB 208 TCCAGTCCATCGTGACCGCGTCTAGCACTCCCAACTCTGAACATGACATCATGCTG 267
QY 881 AAGAAGCTGAAGTTGAACGGTCCCTATGAAGACCTACAGACCT 923
DB 268 ATCAAGCTCAAGTCGGCGGCATCCCTGAACCTCCCGGTGGCCT 310
RESULT 15
AAA08526
ID AAA08526 standard; DNA; 699 BP.
XX
XX AAA08526;
XX
XX 19-JUL-2000 (first entry)
DT
XX DNA encoding recombinant trypsin.
DE
XX Recombinant trypsin; trypsinogen analogue; mutated bovine trypsinogen;
KW leader sequence; trypsin activity; recombinant protein production;
XX

XX inactive zymogen; ss.
XX
OS Synthetic.
OS Bos taurus.
XX
XX Key Location/Qualifiers
FH CDS 4..699
FT /*tag= a
FT /product= "trypsin"
FT sig_peptide 10..24
FT /*tag= b
FT /note= "leader sequence"
FT mat_peptide 25..696
FT /*tag= c
FT /product= "trypsin"
XX
XX WO200017332-A1.
PN
XX 30-MAR-2000.
PD
XX 15-SEP-1999; 99WO-US021047.
XX
XX 21-SEP-1998; 98US-0101213P.
XX
XX (ELIL) LILLY & CO ELI.
PA
XX Hanquier JM, Hershberger CL, Desplancq D, Larson JL, Rosteck PR;
PI
XX WPI; 2000-283565/24.
DR P-PSDB; AAY91926.
XX
XX New trypsinogen analog useful for the production of recombinant trypsin
PT has a modified leader sequence not cleavable by trypsin or trypsin-like
PT enzymes.
XX
XX Claim 11; Page 49-50; 56pp; English.
PS
XX This sequence encodes a claimed recombinant trypsin. The trypsin is
CC produced by cleavage of a trypsinogen analogue (AAY91925). A wild type
CC bovine trypsinogen was mutated to destroy the trypsin cleavage site. The
CC lys residue present in the leader sequence of the native bovine
CC trypsinogen protein was mutated to an Asp residue. The vector was
CC constructed such that DNA encoding a (Glu-Ala)2 peptide was inserted
CC between the C-terminus of the alpha factor signal and the N-terminus of
CC the trypsinogen analogue leader sequence to improve the yield of the
CC secreted protein. The specification claims an isolated trypsinogen
CC analogue comprising a protein having trypsin activity and a leader
CC sequence having at least two amino acids which are not Lys or Arg. The
CC trypsin derived from the recombinant trypsinogen is useful for the
CC characterization of other proteins, and in the manufacture of other
CC recombinant bioproducts, for example to cleave leader sequences from
CC small recombinant proteins expressed initially as fusion proteins. The
CC present method provides for expression of an inactive zymogen form that
CC is soluble and properly folded yet is not activated until after
CC purification from fermentation broth or cell extracts. This is
CC accomplished through the expression of a single chain trypsinogen
CC analogue where the leader sequence is modified such that it lacks a
CC trypsin-like enzyme cleavage site. Specifically the trypsinogen analogues
CC of the present invention lack a lysine or arginine in the N-terminal
CC leader sequence of the protein to prevent auto-activation or activation
CC by endogenous host cell enzymes
XX
SQ Sequence 699 BP; 139 A; 221 C; 178 G; 161 T; 0 U; 0 Other;
Query Match 0.7%; Score 26.2; DB 1; Length 699;
Best Local Similarity 53.4%; Pred. No. 8;
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;
QY 821 TCCAGGCAACCACTTCAATATCAGTATCCAGTCTATGCCCAACCAAGTATGCTG 880
DB 229 TCCAGTCCATCGTGACCGCGTCTAGCACTCCCAACTCTGAACATGACATCATGCTG 288
QY 881 AAGAAGCTGAAGTTGAACGGTCCCTATGAAGACCTACAGACCT 923

Db 289 ATCAAGCTCAAGTCGCGGCATCCCTGAACTCCCGCTGGCCT 331

RESULT 16
AAF81479
ID AAF81479 standard; DNA; 699 BP.
AC AAF81479;
XX AAF81479;
DT 06-JUN-2001 (first entry)
XX Bovine met-phe-trypsinogen coding sequence.
DE Trypsinogen; bovine; trypsin; serine protease; ds.
XX Bos sp.
XX Key Location/Qualifiers
FT CDS 4...699
FT /*tag= a
FT /product= "Trypsinogen"
XX WO200119970-A2.
XX 22-MAR-2001.
XX 05-SEP-2000; 2000WO-US020813.
XX 15-SEP-1999; 98US-0154019P.
XX (ELIL) LILLY & CO ELI.
XX Hanquier JM, Hershberger CL, Larson JL, Rosteck PR;
XX WPI; 2001-273425/28.
XX P-PSDB; AAB80953.
XX New chymotrypsin-free trypsin and trypsinogen useful for manufacturing
recombinant protein pharmaceuticals and pure trypsin.
XX Claim 20; Fig 1; 55pp; English.
XX The present sequence is the coding sequence for bovine met-phe-
trypsinogen. Trypsin is a serine protease which cleaves the peptide bond
on the carboxy-terminus of basic amino acid residues. Trypsin is
synthesised in a slightly longer catalytically inactive form:
trypsinogen, which itself is cleaved (leader sequence removed) to give
trypsin. The leader sequence of the protein encoded by the present
sequence consists of ((Asp)4-Lys) and is present at the amino-terminus.
The protein encoded by the present sequence has two additional residues
at the amino terminus: Met and Phe. Bovine met-phe-trypsinogen is useful
for the manufacture of recombinant protein pharmaceuticals. High purity
trypsin products are produced by expressing trypsinogen inside a
prokaryotic cell which is then isolated and activated to form trypsin
XX Sequence 699 BP; 139 A; 221 C; 178 G; 161 T; 0 U; 0 Other;

Query Match 0.7%; Score 26.2; DB 1; Length 699;
Best Local Similarity 53.4%; Pred. No. 9;
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 821 TCCAAGGCAACCAATTCATATCAAGTATCCAACTCTATGCCCAACCAAGTATGCTG 880
Db 229 TCCAAGTCCATGTCGACCCGCTCTCAACTCCCAACTCTGAACAATGACATCATGCTG 288
QY 881 AAGAGCTGAAGTGAACGGTCCCTATGAAGACCTTACAAGACCT 923
Db 289 ATCAAGCTCAAGTCGCGGCATCCCTGAACTCCCGCTGGCCT 331

RESULT 17
AAQ63795

ID AAQ63795 standard; DNA; 701 BP.
XX AAQ63795;
XX 25-MAR-2003 (revised)
DT 01-DEC-1994 (first entry)
XX Bovine trypsinogen gene.
XX Cattle; cow; trypsinogen; enzyme; protease; proinsulin; insulin; hormone;
KW plasmid pRMG4; ss.
XX Bos taurus.
XX Key Location/Qualifiers
FT CDS 4...694
FT /*tag= a
XX EP597681-A1.
XX 18-MAY-1994.
XX 10-NOV-1993; 93EP-00308959.
XX 13-NOV-1992; 92US-00977703.
XX (ELIL) LILLY & CO ELI.
XX Greaney MG, Rosteck PR;
XX WPI; 1994-160671/20.
XX Expression vectors for bovine trypsin and bovine trypsinogen - for
cleavage of zymogens into active drugs, e.g. pro-insulin conversion into
insulin.
XX Disclosure; Page 27; 35pp; English.
XX This gene is expressed in a recombinant host, e.g. E. coli, using plasmid
pRMG7. The encoded bovine trypsinogen gene may be expressed recombinantly
and is able to cleave zymogens into active drugs, e.g. pro-insulin
conversion into insulin. (Updated on 25-MAR-2003 to correct PN field.)
XX Sequence 701 BP; 141 A; 222 C; 180 G; 158 T; 0 U; 0 Other;

Query Match 0.7%; Score 26.2; DB 1; Length 701;
Best Local Similarity 53.4%; Pred. No. 8;
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 821 TCCAAGGCAACCAATTCATATCAAGTATCCAACTCTATGCCCAACCAAGTATGCTG 880
Db 226 TCCAAGTCCATGTCGACCCGCTCTCAACTCCCAACTCTGAACAATGACATCATGCTG 285
QY 881 AAGAGCTGAAGTGAACGGTCCCTATGAAGACCTTACAAGACCT 923
Db 286 ATCAAGCTCAAGTCGCGGCATCCCTGAACTCCCGCTGGCCT 328

RESULT 18
AAQ63795
ID AAQ63795 standard; DNA; 702 BP.
XX AAQ63795;
XX 19-JUL-2000 (first entry)
XX DNA encoding a trypsinogen analogue.
XX Trypsinogen analogue; mutated bovine trypsinogen; leader sequence;
KW trypsin activity; recombinant protein production; inactive zymogen; ss.
XX Synthetic.
XX Bos taurus.

```

XX PH Key Location/Qualifiers
XX FT misc_RNA 1..12
XX FT /*tag= a
XX FT /note= "linker peptide"
XX FT sig_peptide 13..29
XX FT /*tag= b
XX FT /note= "leader sequence"
XX FT mat_peptide 30..599
XX FT /*tag= c
XX FT /product= "trypsin"
XX PN WO200017332-A1.
XX PN 30-MAR-2000.
XX PD
XX PF 15-SEP-1999; 99WO-US021047.
XX PR 21-SEP-1998; 98US-0101213P.
XX PA (ELIL ) LILLY & CO ELI.
XX PI Hanquier JM, Hershberger CL, Desplancq D, Larson JL, Rostock PR;
XX PI WPI; 2000-283565/24.
XX DR P-PSDB; AAY91925.
XX
XX New trypsinogen analog useful for the production of recombinant trypsin
XX PT has a modified leader sequence not cleavable by trypsin or trypsin-like
XX PT enzymes.
XX
XX Claim 11; Page 45-47; 56pp; English.
XX
XX This sequence encodes a trypsinogen analogue. The wild type bovine
XX trypsinogen was mutated to destroy the trypsin cleavage site. The lys
XX residue present in the leader sequence of the native bovine trypsinogen
XX protein was mutated to an Asp residue. The vector was constructed such
XX that DNA encoding a (Glu-Ala)2 peptide was inserted between the C-
XX terminus of the alpha factor signal and the N-terminus of the trypsinogen
XX analogue leader sequence to improve the yield of the secreted protein.
XX The specification claims an isolated trypsinogen analogue comprising a
XX protein having trypsin activity and a leader sequence having at least two
XX amino acids which are not Lys or Arg. A recombinantly produced trypsin
XX (AAY91926) is also claimed. The trypsin derived from the recombinant
XX trypsinogen is useful for the characterization of other proteins, and in
XX the manufacture of other recombinant bioproducts, for example to cleave
XX leader sequences from small recombinant proteins expressed initially as
XX fusion proteins. The present method provides for expression of an
XX inactive zymogen form that is soluble and properly folded yet is not
XX activated until after purification from fermentation broth or cell
XX extracts. This is accomplished through the expression of a single chain
XX trypsinogen analogue where the leader sequence is modified such that it
XX lacks a trypsin-like enzyme cleavage site. Specifically the trypsinogen
XX analogues of the present invention lack a lysine or arginine in the N-
XX terminal leader sequence of the protein to prevent auto-activation or
XX activation by endogenous host cell enzymes
XX
XX Sequence 702 BP; 141 A; 221 C; 181 G; 159 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 26.2; DB 1; Length 702;
XX Best Local Similarity 53.4%; Pred. No. 8;
XX Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;
XX
XX QY 821 TCCAGGCAACCATTCATATCAGTATCCAGTCTATGCCCAACCAAGTAATGCTG 880
XX Db
XX 232 TCCAGTCTATGTCGACCGCTCTCTACAACTCCAACTCTGAACATGATCATGCTG 291
XX
XX QY 881 AAGAAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCT 923
XX Db
XX 292 ATCAAGCTCAAGTCCGCGGATCTCCTGAATCTCCGCGTGCCT 334
XX
XX RESULT 19

```

```

AAA07168
XX ID AAA07168 standard; DNA; 828 BP.
XX AC AAA07168;
XX DT 16-JUN-2000 (first entry)
XX DE Pig lung protease coding sequence.
XX KW Protease; pig; virus activator; inhibitor identification; influenza;
XX KW Viral infection; ss.
XX OS Sus scrofa.
XX PN WO200011193-A1.
XX PD 02-MAR-2000.
XX PF 23-AUG-1999; 99WO-JF004529.
XX PR 24-AUG-1998; 98JP-00237240.
XX PA (SANY ) SANKYO CO LTD.
XX PI Yamashita M, Iida K, Kido H;
XX DR WPI; 2000-224708/19.
XX DR P-PSDB; AAY81826.
XX
XX PT New pig lung protease with virus activation activity is used for
XX PT screening potential inhibitors of virus infection, especially of
XX PT influenza virus.
XX
XX Claim 9; Page 54-56; 65pp; Japanese.
XX
XX This sequence encodes the protease of the invention, and was derived from
XX pig lung. The protease has virus activation activity. The protease can be
XX used for the identification of potential inhibitors of infection by
XX viruses such as influenza
XX
XX Query Match 0.7%; Score 26.2; DB 1; Length 828;
XX Best Local Similarity 49.6%; Pred. No. 8.4;
XX Matches 67; Conservative 0; Mismatches 68; Indels 0; Gaps 0;
XX
XX QY 2534 TGCTAAGCTGAACCTCCAGTACTTTGGCCACTGATCAGAGAGCTGACTCACTGGAAA 2593
XX Db
XX 11 TGCTGGTGTGGCGCTGCGCCCTCTGTGAGCTGTCTCCACACGGCCCCCCCCCAGGCC 70
XX
XX QY 2594 AGACCTTGATCTGGGAGGAGTTGGGGGAGGAGAGAGGGGACACAGAGATGAGAT 2653
XX Db
XX 71 AGGCGCTGGAGGAGGAGGAGGATCTGGCGGAGAAAGAGCCCTGGGCAAGTGGCCCT 130
XX
XX QY 2654 GGCTGGATGGCATCA 2668
XX Db
XX 131 GGCAGGTGAGCCTGA 145
XX
XX RESULT 20
XX AAD08286/c
XX ID AAD08286 standard; cDNA; 1151 BP.
XX AC AAD08286;
XX DT 08-AUG-2001 (first entry)
XX DE Human secreted protein-encoding gene 4 cDNA clone HWH1H10, SEQ ID NO: 14.
XX KW Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
XX KW foetal abnormality; developmental abnormality; haematopoietic disorder;
XX KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
XX
XX

```

KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW inflammation; neurological disorder; Alzheimer's disease; food additive;
KW angiotensin disorder; kidney disorder; gastrointestinal disorder; allergy;
KW pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW cell culture; chemotaxis; vulnery; binding partner identification;
KW gene therapy; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 42..914
FT FT /*tag= a
FT FT /product= "Human secreted protein precursor"
FT FT sig_peptide 42..107
FT FT /*tag= b
FT FT mat_peptide 108..911
FT FT /*tag= c
FT FT /product= "Mature human secreted protein"
XX
XX WO200136440-A1.
XX
XX 25-MAY-2001.
XX
XX 15-NOV-2000; 2000WO-US031282.
XX
XX 19-NOV-1999; 99US-0156414P.
XX 21-JUL-2000; 2000US-0219665P.
XX
XX (HUYA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Komatsoulis GA, Birse CR, Moore PA;
XX
XX WPI; 2001-343795/36.
XX P-PSDB; AAE03821.
XX
XX Isolated nucleic acid molecule encoding a human secreted protein is used
XX in preventing, treating or ameliorating a medical condition.
XX
XX Claim 1; Page 440-441; 553pp; English.
XX
XX AAD08283-AAD08355 represent cDNAs corresponding to 23 human secreted
XX protein genes, and AAE03818-AAE03870 represent the proteins they encode.
XX AAE03871-AAE03896 represent human secreted protein fragments or variants.
XX The secreted proteins and their genes are useful for preventing, treating
XX or ameliorating medical conditions, e.g., by protein or gene therapy.
XX Pathological conditions can be diagnosed by determining the amount of the
XX new protein in a sample or by determining the presence of mutations in
XX the new genes. Specific uses are described for each of the 23 genes,
XX based on the tissues in which they are most highly expressed, and include
XX developing products for the diagnosis or treatment of proliferative
XX disorders, cancer, tumours, foetal and developmental abnormalities,
XX haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
XX diseases (e.g., rheumatoid arthritis), inflammation, allergies,
XX neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
XX cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
XX psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
XX angiotensin disorders, kidney disorders, gastrointestinal disorders,
XX pregnancy-related disorders, endocrine disorders, and infections. The
XX proteins can also be used to aid wound healing and epithelial cell
XX proliferation, to prevent skin aging due to sunburn, to maintain organs
XX before transplantation, for supporting cell culture of primary tissues,
XX to regenerate tissues, to identify their cognate ligands or binding
XX partners, and in chemotaxis, and can be used as a food additive or
XX preservative to modify storage properties. Antibodies specific for a
XX protein of the invention can be used in alleviating symptoms associated
XX with the disorders mentioned above, and in diagnostic immunoassays e.g.,
XX radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The
XX present sequence represents a human secreted protein-encoding cDNA of the
XX invention
XX
SQ Sequence 1151 BP; 252 A; 370 C; 336 G; 193 T; 0 U; 0 Other;

Query Match 0.7%; Score 36.2; DB 1; Length 1151;

Best Local Similarity 63.5%; Pred. No. 9.2;
Matches 40; Conservative 0; Mismatches 23; Indels 0; Gaps 0;
QY 3226 TTCTATGCGCTTTAATAAGTTTTTTTTTTTTTTTTTAAAGAAATGTCATCTCTGTG 3285
Db 1146 TTTTITTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCACAGGCTGGTTTATTCG 1087
QY 3286 AAG 3288
Db 1086 GAG 1084
RESULT 21
ID ABV97824 standard; cDNA; 497 BP.
XX AC ABV97824;
XX DT 14-JAN-2003 (first entry)
XX DE Human pancreatic cancer expressed cDNA SEQ ID NO 3232.
XX KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
XX KW cyrostatic; tumour; gene; ss.
XX OS Homo sapiens.
XX PN WO200260317-A2.
XX PD 08-AUG-2002.
XX PF 30-JAN-2002; 2002WO-US002781.
XX PR 30-JAN-2001; 2001US-0265305P.
XX PR 31-JAN-2001; 2001US-0265682P.
XX PR 09-FEB-2001; 2001US-0267568P.
XX PR 21-MAR-2001; 2001US-0278651P.
XX PR 28-APR-2001; 2001US-0287112P.
XX PR 16-MAY-2001; 2001US-0291631P.
XX PR 12-JUL-2001; 2001US-0305484P.
XX PR 20-AUG-2001; 2001US-0313999P.
XX PR 27-NOV-2001; 2001US-0333626P.
XX (CORI-) CORIXA CORP.
XX Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;
XX WPI; 2002-627435/67.
XX
XX New isolated polynucleotide and pancreatic tumor polypeptides, useful for
XX diagnosing, preventing and/or treating cancer, particularly pancreatic
XX cancer.
XX
XX Claim 1; SEQ ID NO 3232; 300pp + Sequence Listing; English.
XX
XX The invention relates to an isolated polynucleotide (I) comprising: (a)
XX any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)
XX complements of (a); (c) sequences consisting of at least 20 contiguous
XX residues of (a); (d) sequences that hybridize to (a), under moderately
XX stringent conditions; (e) sequences having at least 75% or 90% identity
XX to (a); or (f) degenerate variants of (a). Polypeptides (ABP88596-
XX ABP88637) encoded by (I) and oligonucleotide can be used to detect cancer
XX in a patient and compositions comprising polypeptides, polynucleotides,
XX antibodies, fusion proteins, T cell populations and antigen presenting
XX cells expressing the polypeptide are useful in treating pancreatic cancer
XX and stimulating an immune response. The polynucleotides can be used as
XX probes or primers for nucleic acid hybridisation, in the design and
XX preparation of ribozyme molecules for inhibiting expression of the tumour
XX polypeptides and proteins in the tumour cells, in vaccines and for gene
XX therapy. Note: The sequence data for this patent did not form part of the
XX printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pat_sequences

SQ Sequence 497 BP; 113 A; 118 C; 122 G; 121 T; 0 U; 23 Other;

Query Match 0.7%; Score 25.8; DB 1; Length 497;

Best Local Similarity 65.5%; Pred. No. 9.3; Mismatches 0; Gaps 0;

Matches 36; Conservative 0; Indels 19; Gaps 0;

QY 3233 GCTTTAATAAGCTTTTTTTTTTTTTTTTTTTTTTTTAAAGATGTCATCTTTGTGAA 3287

Db 5 GCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAAGCAGGTCANTTTATGTGA 59

RESULT 22

AAN60065/c

ID AAN60065 standard; DNA; 2438 BP.

XX AC AAN60065;

XX 25-MAR-2003 (revised)

DT 31-OCT-2002 (revised)

DT 23-MAY-1991 (first entry)

XX Factor IX/Factor VII cDNA fusion.

XX Factor VII; Factor IX; DNA construct.

XX Unidentified.

XX Key Location/Qualifiers

FT CDS 7..1368

FT /*tag= a

XX EP200421-A.

XX 10-DEC-1986.

XX 16-APR-1986; 8SEP-00302855.

XX 17-APR-1985; 85US-00724311.

PR 16-DEC-1985; 85US-00810002.

XX (ZYMO) ZYMOGENETICS INC.

XX Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;

XX WPI; 1986-326899/50.

DR P-PSDB; AAP60057.

XX DNA construct used to transfect hosts - to produce protein which

PT activates to give factor VIIa.

XX Disclosure; fig 7; 55pp; English.

XX The cDNA is a fusion of Factor IX and Factor VII. It is used to express

CC Factor IX and Factor VII. cDNA encoding Factor VII can be used in DNA

CC construct which contains a nucleotide sequence encoding a protein which,

CC on activation, has the same biological activity for blood coagulation as

CC Factor VIIa. The nucleotide codes at least partially for Factor VII and

CC comprises a sequence encoding a calcium binding domain joined to a second

CC sequence downstream of this encoding a catalytic domain for the serine

CC protease activity of Factor VIIa. The calcium binding domain comprises a

CC gene encoding Factor VII, IX, X, protein C, prothrombin or Protein S. The

CC construct is used to transfect host cells to produce the protein which,

CC on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing

CC OS field.) (Updated on 25-MAR-2003 to correct PA field.)

XX Sequence 2438 BP; 658 A; 670 C; 666 G; 444 T; 0 U; 0 Other;

Query Match 0.7%; Score 25.6; DB 1; Length 2438;

Best Local Similarity 70.8%; Pred. No. 16;

Matches 34; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 3218 AGCTTCAGTCTATGGCTTTAATAAGTTTTTTTTTTTTTTTTTTTTTTTTTTT 3265

Db 2422 AGCTGAATTCCTT 2375

RESULT 23

ABA94395/c

ID ABA94395 standard; cDNA; 265 BP.

XX AC ABA94395;

XX 26-MAR-2002 (first entry)

XX Human prostatic-like enzyme polynucleotide sequence.

XX Prostatic-like enzyme; human; prostatic-like serine protease; cytostatic;

KW antiatherosclerotic; virucide; osteopathic; antiinflammatory; vasotropic;

KW neuroprotective; gene therapy; antisense therapy; ss.

XX Homo sapiens.

XX WO200198466-A2.

XX 27-DEC-2001.

XX 22-JUN-2001; 2001WO-EP007116.

XX 23-JUN-2000; 2000US-0213474P.

XX 22-MAR-2001; 2001US-0277612P.

XX (FARB) BAYER AG.

XX Xiao Y;

XX WPI; 2002-114575/15.

XX Novel human prostatic-like enzyme polypeptide and polynucleotide which

PT can be regulated for treating metastasis of malignant cells,

PT inflammation, atherosclerosis, neurodegenerative disease and pathogenic

PT infection.

XX Example; Fig 4; 125pp; English.

XX The invention relates to human prostatic-like enzyme polypeptides and

CC polynucleotides. The enzyme can be expressed by standard recombinant

CC methodology. The polypeptide, polynucleotide and modulators are useful

CC for treating diseases like metastasis of malignant cells, tumour

CC angiogenesis, inflammation, chronic obstructive pulmonary disease (COPD),

CC atherosclerosis, neurodegenerative disease and pathogenic infection,

CC particularly viral infection. The prostatic-like enzyme gene provides a

CC therapeutic target of decreasing the enzyme activity, in particular for

CC treating or preventing metastatic cancer. Neurodegenerative diseases

CC include for e.g. prion protein amyloid plaques of Genstmann-Straussler

CC Syndrome, Creutzfeldt-Jakob disease and Scrapie. The agonists and

CC antagonists of the polypeptide may be useful to treat osteoporosis,

CC Paget's disease, degradation of bone implants particularly dental

CC implants. Altered levels of human prostatic-like enzyme activity inhibit

CC both smooth muscle cell proliferation and lipid accumulation and inhibit

CC the progression of restenosis and atherosclerosis. Anti-human prostatic-

CC like serine protease antibodies are useful for immunodetection and

CC diagnosis of micrometastases, autoimmune lesions and renal failure in

CC biopsy specimens, plasma samples and body fluids. The present sequence

CC represents a human prostatic-like enzyme polynucleotide sequence

XX Sequence 265 BP; 46 A; 99 C; 72 G; 45 T; 0 U; 3 Other;

Query Match 0.7%; Score 25.4; DB 1; Length 265;

Best Local Similarity 63.3%; Pred. No. 9.9;

Matches 38; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 2603 TGCTGGAGGGATTTGGGGCAGGAGGAGAGGGAGGAGGATGAGATGGTGATG 2662

Db 138 TTCAGGAGGGAGGGGTGCTGGGCACAGGAGGGAGGACTCCGGAGGCTGGGAGCTGGGTG 79

RESULT 24

AAA61697
ID AAA61697 standard; CDNA; 1036 BP.
XX
AC AAA61697;
XX
DT 23-OCT-2000 (first entry)
XX
DE cDNA encoding human serine protease BSSP4 (hBSSP4) SEQ ID NO:5.
XX
KW BSSP4; serine protease; human; hBSSP4; mouse; mBSSP4; brain;
XX
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;
XX
KW oedema; dropsy; cancer; inflammation; prostate; testis; bone; ss.
XX
OS Homo sapiens.
XX
PN WO200031277-A1.
XX
PD 02-JUN-2000.
XX
PF 19-NOV-1999; 99WO-JP006472.
XX
PR 20-NOV-1998; 98JP-00347813.
XX
PA (FUSO) FUSO PHARM IND LTD.
XX
PI Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;
XX
WPI: 2000-400084/34.
XX
P-PSDB; AAB11702.
XX
PT Serine protease BSSP4 and antibodies recognizing BSSP4 for assay and
XX
PT diagnosis of diseases in which BSSP4 expression is altered.
XX
PS Claim 6; Page 71-73; 111pp; Japanese.
XX
CC The invention relates to novel serine proteases designated BSSP4
XX
CC (AAB11700-B11709), and to nucleic acids encoding them (AAA61695-A61704,
XX
CC AAA61799). The invention also relates to vectors and transformants
XX
CC comprising BSSP4 nucleic acids; transgenic animals in which the
XX
CC expression level of BSSP4 can be varied; and an mBSSP4 knockout mouse.
XX
CC The invention additionally encompasses anti-BSSP4 antibodies and methods
XX
CC of production of such antibodies, methods of BSSP4 detection using the
XX
CC antibodies, and the use of BSSP4 proteins or fragments as diagnostic
XX
CC markers for certain medical conditions. Nucleotides encoding BSSP4 were
XX
CC initially isolated in a human brain cDNA library using degenerate PCR
XX
CC primers (AAA61714-A61715) based on conserved regions of serine proteases.
XX
CC The BSSP4 serine proteases and nucleotides encoding them are useful in
XX
CC detecting homologues, mutants and polymorphic variants in biological
XX
CC samples (e.g., blood, urine, brain, prostate gland and testis) as
XX
CC diagnostic markers for diseases associated with altered BSSP4 expression
XX
CC levels. Such diseases include Alzheimer's disease, oedema (dropsy),
XX
CC cancer or inflammation of brain, prostate, testis or bone. Sequences
XX
CC AAA61695-A61703 and AAA61799 represent cDNAs encoding human BSSP4
XX
CC variants (hBSSP4), and sequence AAA61704 represents cDNA encoding murine
XX
CC BSSP4 (mBSSP4).

RESULT 25

Query Match 0.7%; Score 25.4; DB 1; Length 1036;
Best Local Similarity 53.5%; Pred. No. 15;
Matches 53; Conservative 0; Mismatches 46; Indels 0; Gaps 0;
QY 2983 TCTATTACTTAAATCCACTTATTTTATGATTTTCTTAATAAATCCAGTCTCTT 3042
DB 911 TTTTGTATATAATGATGATTTTATAGTATTTTGAACCCCTGCCACATATCTT 970
QY 3043 TTTTATAAAGACATTTAAATTTTAAATTTCTTTTCTTTAG 3081
DB 971 ATTATTCCTCAATTCATTAATTTATTTATTTCTTCCAG 1009

AAA61697/c

ID AAA61697 standard; CDNA; 1036 BP.
XX
AC AAA61697;
XX
DT 23-OCT-2000 (first entry)
XX
DE cDNA encoding human serine protease BSSP4 (hBSSP4) SEQ ID NO:5.
XX
KW BSSP4; serine protease; human; hBSSP4; mouse; mBSSP4; brain;
XX
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;
XX
KW oedema; dropsy; cancer; inflammation; prostate; testis; bone; ss.
XX
OS Homo sapiens.
XX
PN WO200031277-A1.
XX
PD 02-JUN-2000.
XX
PF 19-NOV-1999; 99WO-JP006472.
XX
PR 20-NOV-1998; 98JP-00347813.
XX
PA (FUSO) FUSO PHARM IND LTD.
XX
PI Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;
XX
WPI: 2000-400084/34.
XX
P-PSDB; AAB11702.
XX
PT Serine protease BSSP4 and antibodies recognizing BSSP4 for assay and
XX
PT diagnosis of diseases in which BSSP4 expression is altered.
XX
PS Claim 6; Page 71-73; 111pp; Japanese.
XX
CC The invention relates to novel serine proteases designated BSSP4
XX
CC (AAB11700-B11709), and to nucleic acids encoding them (AAA61695-A61704,
XX
CC AAA61799). The invention also relates to vectors and transformants
XX
CC comprising BSSP4 nucleic acids; transgenic animals in which the
XX
CC expression level of BSSP4 can be varied; and an mBSSP4 knockout mouse.
XX
CC The invention additionally encompasses anti-BSSP4 antibodies and methods
XX
CC of production of such antibodies, methods of BSSP4 detection using the
XX
CC antibodies, and the use of BSSP4 proteins or fragments as diagnostic
XX
CC markers for certain medical conditions. Nucleotides encoding BSSP4 were
XX
CC initially isolated in a human brain cDNA library using degenerate PCR
XX
CC primers (AAA61714-A61715) based on conserved regions of serine proteases.
XX
CC The BSSP4 serine proteases and nucleotides encoding them are useful in
XX
CC detecting homologues, mutants and polymorphic variants in biological
XX
CC samples (e.g., blood, urine, brain, prostate gland and testis) as
XX
CC diagnostic markers for diseases associated with altered BSSP4 expression
XX
CC levels. Such diseases include Alzheimer's disease, oedema (dropsy),
XX
CC cancer or inflammation of brain, prostate, testis or bone. Sequences
XX
CC AAA61695-A61703 and AAA61799 represent cDNAs encoding human BSSP4
XX
CC variants (hBSSP4), and sequence AAA61704 represents cDNA encoding murine
XX
CC BSSP4 (mBSSP4).

Query Match

0.7%; Score 25.2; DB 1; Length 1036;
Best Local Similarity 71.7%; Pred. No. 16;
Matches 33; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
QY 3245 TTTTATTTTATTTTATTTTATTTTAAAGATGATCTATTTCTTGAAGTT 3290
DB 1028 TTTTATTTTATTTTATTTTATTTTCTGGAGATAATATTTATTTGAAT 983

RESULT 26

ABV97809
ID ABV97809 standard; CDNA; 448 BP.
XX
AC ABV97809;
XX
XX

CC	with the disorders mentioned above, and in diagnostic immunoassays e.g.,	22-AUG-2000;	2000US-0226686P
CC	radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The	PR 22-AUG-2000;	2000US-0221782P
CC	present sequence represents a human secreted protein-encoding cDNA of the	PR 23-AUG-2000;	2000US-0227009P
CC	invention	PR 30-AUG-2000;	2000US-0228924P
XX		PR 01-SEP-2000;	2000US-0228287P
XX		PR 01-SEP-2000;	2000US-0229343P
XX		PR 01-SEP-2000;	2000US-0229344P
XX		PR 01-SEP-2000;	2000US-0229345P
XX		PR 03-SEP-2000;	2000US-0229501P
XX		PR 05-SEP-2000;	2000US-0229513P
XX		PR 06-SEP-2000;	2000US-0230437P
XX		PR 06-SEP-2000;	2000US-0230438P
XX		PR 08-SEP-2000;	2000US-0231242P
XX		PR 08-SEP-2000;	2000US-0231243P
XX		PR 08-SEP-2000;	2000US-0231244P
XX		PR 08-SEP-2000;	2000US-0231413P
XX		PR 08-SEP-2000;	2000US-0231414P
XX		PR 08-SEP-2000;	2000US-0232080P
XX		PR 12-SEP-2000;	2000US-0231968P
XX		PR 14-SEP-2000;	2000US-0232397P
XX		PR 14-SEP-2000;	2000US-0232398P
XX		PR 14-SEP-2000;	2000US-0232399P
XX		PR 14-SEP-2000;	2000US-0232400P
XX		PR 14-SEP-2000;	2000US-0232401P
XX		PR 14-SEP-2000;	2000US-0233063P
XX		PR 14-SEP-2000;	2000US-0233065P
XX		PR 21-SEP-2000;	2000US-0234223P
XX		PR 21-SEP-2000;	2000US-0234274P
XX		PR 25-SEP-2000;	2000US-0234997P
XX		PR 25-SEP-2000;	2000US-0234998P
XX		PR 26-SEP-2000;	2000US-0235484P
XX		PR 27-SEP-2000;	2000US-0235834P
XX		PR 27-SEP-2000;	2000US-0235835P
XX		PR 29-SEP-2000;	2000US-0236327P
XX		PR 29-SEP-2000;	2000US-0236367P
XX		PR 29-SEP-2000;	2000US-0236368P
XX		PR 29-SEP-2000;	2000US-0236370P
XX		PR 02-OCT-2000;	2000US-0236802P
XX		PR 02-OCT-2000;	2000US-0237037P
XX		PR 02-OCT-2000;	2000US-0237038P
XX		PR 02-OCT-2000;	2000US-0237039P
XX		PR 02-OCT-2000;	2000US-0237040P
XX		PR 13-OCT-2000;	2000US-0239935P
XX		PR 13-OCT-2000;	2000US-0239937P
XX		PR 20-OCT-2000;	2000US-0240960P
XX		PR 20-OCT-2000;	2000US-0241121P
XX		PR 20-OCT-2000;	2000US-0241175P
XX		PR 20-OCT-2000;	2000US-0241786P
XX		PR 20-OCT-2000;	2000US-0241787P
XX		PR 20-OCT-2000;	2000US-0241808P
XX		PR 20-OCT-2000;	2000US-0241809P
XX		PR 20-OCT-2000;	2000US-0241825P
XX		PR 01-NOV-2000;	2000US-0244617P
XX		PR 08-NOV-2000;	2000US-0246475P
XX		PR 08-NOV-2000;	2000US-0246476P
XX		PR 08-NOV-2000;	2000US-0246477P
XX		PR 08-NOV-2000;	2000US-0246478P
XX		PR 08-NOV-2000;	2000US-0246523P
XX		PR 08-NOV-2000;	2000US-0246524P
XX		PR 08-NOV-2000;	2000US-0246525P
XX		PR 08-NOV-2000;	2000US-0246527P
XX		PR 08-NOV-2000;	2000US-0246528P
XX		PR 08-NOV-2000;	2000US-0246529P
XX		PR 08-NOV-2000;	2000US-0246532P
XX		PR 08-NOV-2000;	2000US-0246609P
XX		PR 08-NOV-2000;	2000US-0246610P
XX		PR 08-NOV-2000;	2000US-0246611P
XX		PR 08-NOV-2000;	2000US-0246613P

PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0251989P.
PR 06-DEC-2000; 2000US-0251719P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 11-DEC-2000; 2000US-0251990P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX WPI; 2001-465566/50.
XX P-PSDB; AAU23215.
XX
XX Novel polypeptides and polynucleotides useful for diagnosing, preventing,
XX treating neural, immune system, muscular, reproductive, pulmonary,
XX cardiovascular, renal, proliferative disorders and cancerous diseases.
XX
XX Claim 4; SEQ ID NO 311; 1180PP; English.
XX
XX The present invention relates to the isolation of novel human enzyme
XX polypeptides (AAU22915-AAU23814), and the cDNA and genomic sequences
XX encoding them. The enzyme polypeptides of the invention may comprise the
XX functional classes of oxidoreductases, transferases, hydrolases, lyases,
XX isomerases or ligases. The sequences of the invention are useful in the
XX diagnosis, treatment, prevention and/or prognosis of a wide range of
XX disorders including hyperproliferative disorders (e.g. cancer),
XX immunodeficiency disorders (e.g. AIDS) autoimmune disorders (e.g.
XX arthritis), neurological disorders (e.g. Alzheimer's disease), metabolic
XX disorders (e.g. phenylketonuria), inflammatory disorders (e.g. asthma),
XX cardiovascular disorders (e.g. atherosclerosis), blood-related disorders
XX (e.g. haemophilia), reproductive disorders (e.g. infertility) and
XX infectious disorders (e.g. influenza). The polynucleotides of the
XX invention can also be used in gene therapy. AAU40785-AAU41684 represent
XX cDNA sequences encoding for the novel human enzyme polypeptides of the
XX invention. Note: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 1352 BP; 238 A; 446 C; 407 G; 261 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 24.6; DB 1; Length 1352;
XX Best Local Similarity 53.7%; Pred. No. 26;
XX Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
XX
XX 2963 TCTATTACCTTAAATGACCTTTTATTTTATTTTCTTAAATAAATCCAGTCCTTCT 3042
XX 1241 TTTTGTATATATATGATGATTTTATAGTATTTTACCTGCGCCACATATCTT 1300

OY 3043 TTTTAAAAAGACTTTAAATTTATTTATTTCTCT 3077
DB 1301 ATTATTTCTCCCAATTTCAATAAATTTATTTCT 1335
RESULT 31
AAS26942
ID AAS26942 standard; cDNA; 1352 BP.
XX AAS26942;
XX
XX 07-NOV-2001 (first entry)
XX Human cDNA encoding a novel secreted protein, SEQ ID 134.
XX
XX Human; immunosuppressive; antiarthritic; ss; antineumatic; cytostatic;
XX cardiac; vasotropic; cerebroprotective; nootropic; neuroprotective;
XX antibacterial; virucide; fungicide; ophthalmological; vulnery;
XX secreted protein; rheumatoid arthritis; hyperproliferative disorder;
XX cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
XX cerebral ischaemia; angiogenesis; nervous system disorder;
XX Alzheimer's disease; infection; ocular disorder; corneal infection;
XX wound healing; epithelial cell proliferation; skin ageing; food additive;
XX preservative; antiproliferative.
XX
XX Homo sapiens.
XX WO200155441-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001320.
XX
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
XX 24-FEB-2000; 2000US-0184564P.
XX 02-MAR-2000; 2000US-0186350P.
XX 16-MAR-2000; 2000US-0189874P.
XX 17-MAR-2000; 2000US-0190076P.
XX 18-APR-2000; 2000US-0198123P.
XX 19-MAY-2000; 2000US-0205515P.
XX 07-JUN-2000; 2000US-0209467P.
XX 28-JUN-2000; 2000US-0214886P.
XX 30-JUN-2000; 2000US-0215135P.
XX 07-JUL-2000; 2000US-0216647P.
XX 07-JUL-2000; 2000US-0216880P.
XX 11-JUL-2000; 2000US-0217487P.
XX 11-JUL-2000; 2000US-0217486P.
XX 14-JUL-2000; 2000US-0218290P.
XX 26-JUL-2000; 2000US-0220963P.
XX 14-AUG-2000; 2000US-0220964P.
XX 14-AUG-2000; 2000US-0224518P.
XX 14-AUG-2000; 2000US-0224519P.
XX 14-AUG-2000; 2000US-0225213P.
XX 14-AUG-2000; 2000US-0225214P.
XX 14-AUG-2000; 2000US-0225267P.
XX 14-AUG-2000; 2000US-0225268P.
XX 14-AUG-2000; 2000US-0225270P.
XX 14-AUG-2000; 2000US-0225447P.
XX 14-AUG-2000; 2000US-0225757P.
XX 14-AUG-2000; 2000US-0225758P.
XX 14-AUG-2000; 2000US-0225759P.
XX 18-AUG-2000; 2000US-0226279P.
XX 22-AUG-2000; 2000US-0226681P.
XX 22-AUG-2000; 2000US-0226868P.
XX 23-AUG-2000; 2000US-0227182P.
XX 30-AUG-2000; 2000US-0227009P.
XX 30-AUG-2000; 2000US-0228924P.
XX 01-SEP-2000; 2000US-0229287P.
XX 01-SEP-2000; 2000US-0229343P.
XX 01-SEP-2000; 2000US-0229344P.

[illegible]

11-JUL-2000;	2000US-0217496P.	PR	01-NOV-2000;	2000US-0244617P.
14-JUL-2000;	2000US-0218290P.	PR	08-NOV-2000;	2000US-0246474P.
26-JUL-2000;	2000US-0220963P.	PR	08-NOV-2000;	2000US-0246475P.
26-JUL-2000;	2000US-0220964P.	PR	08-NOV-2000;	2000US-0246476P.
14-AUG-2000;	2000US-0224518P.	PR	08-NOV-2000;	2000US-0246477P.
14-AUG-2000;	2000US-0224519P.	PR	08-NOV-2000;	2000US-0246478P.
14-AUG-2000;	2000US-0225211P.	PR	08-NOV-2000;	2000US-0246523P.
14-AUG-2000;	2000US-0225214P.	PR	08-NOV-2000;	2000US-0246524P.
14-AUG-2000;	2000US-0225266P.	PR	08-NOV-2000;	2000US-0246525P.
14-AUG-2000;	2000US-0225267P.	PR	08-NOV-2000;	2000US-0246526P.
14-AUG-2000;	2000US-0225268P.	PR	08-NOV-2000;	2000US-0246527P.
14-AUG-2000;	2000US-0225270P.	PR	08-NOV-2000;	2000US-0246528P.
14-AUG-2000;	2000US-0225447P.	PR	08-NOV-2000;	2000US-0246532P.
14-AUG-2000;	2000US-0225757P.	PR	08-NOV-2000;	2000US-0246609P.
14-AUG-2000;	2000US-0225758P.	PR	08-NOV-2000;	2000US-0246610P.
14-AUG-2000;	2000US-0225759P.	PR	08-NOV-2000;	2000US-0246611P.
18-AUG-2000;	2000US-0226279P.	PR	08-NOV-2000;	2000US-0246613P.
22-AUG-2000;	2000US-0226681P.	PR	17-NOV-2000;	2000US-0249207P.
22-AUG-2000;	2000US-0226686P.	PR	17-NOV-2000;	2000US-0249208P.
22-AUG-2000;	2000US-0227182P.	PR	17-NOV-2000;	2000US-0249209P.
23-AUG-2000;	2000US-0227009P.	PR	17-NOV-2000;	2000US-0249210P.
30-AUG-2000;	2000US-0228924P.	PR	17-NOV-2000;	2000US-0249211P.
01-SEP-2000;	2000US-0228928P.	PR	17-NOV-2000;	2000US-0249212P.
01-SEP-2000;	2000US-0223343P.	PR	17-NOV-2000;	2000US-0249213P.
01-SEP-2000;	2000US-0223344P.	PR	17-NOV-2000;	2000US-0249214P.
01-SEP-2000;	2000US-0223345P.	PR	17-NOV-2000;	2000US-0249215P.
05-SEP-2000;	2000US-0223509P.	PR	17-NOV-2000;	2000US-0249216P.
05-SEP-2000;	2000US-0223511P.	PR	17-NOV-2000;	2000US-0249217P.
06-SEP-2000;	2000US-0230437P.	PR	17-NOV-2000;	2000US-0249218P.
06-SEP-2000;	2000US-0230438P.	PR	17-NOV-2000;	2000US-0249244P.
08-SEP-2000;	2000US-0231242P.	PR	17-NOV-2000;	2000US-0249245P.
08-SEP-2000;	2000US-0231243P.	PR	17-NOV-2000;	2000US-0249246P.
08-SEP-2000;	2000US-0231244P.	PR	17-NOV-2000;	2000US-0249256P.
08-SEP-2000;	2000US-0231411P.	PR	17-NOV-2000;	2000US-0249257P.
08-SEP-2000;	2000US-0231412P.	PR	17-NOV-2000;	2000US-0249259P.
08-SEP-2000;	2000US-0232080P.	PR	17-NOV-2000;	2000US-0249300P.
08-SEP-2000;	2000US-0232081P.	PR	01-DEC-2000;	2000US-0250160P.
12-SEP-2000;	2000US-0231968P.	PR	01-DEC-2000;	2000US-0250391P.
14-SEP-2000;	2000US-0233239P.	PR	05-DEC-2000;	2000US-0251030P.
14-SEP-2000;	2000US-0232398P.	PR	05-DEC-2000;	2000US-0251988P.
14-SEP-2000;	2000US-0232399P.	PR	05-DEC-2000;	2000US-0256719P.
14-SEP-2000;	2000US-0232400P.	PR	06-DEC-2000;	2000US-0251479P.
14-SEP-2000;	2000US-0232401P.	PR	08-DEC-2000;	2000US-0251856P.
14-SEP-2000;	2000US-0232403P.	PR	08-DEC-2000;	2000US-0251868P.
14-SEP-2000;	2000US-0233063P.	PR	08-DEC-2000;	2000US-0251869P.
14-SEP-2000;	2000US-0233064P.	PR	08-DEC-2000;	2000US-0251989P.
21-SEP-2000;	2000US-0233065P.	PR	08-DEC-2000;	2000US-0251990P.
21-SEP-2000;	2000US-0234223P.	PR	11-DEC-2000;	2000US-0254097P.
25-SEP-2000;	2000US-0234274P.	PR	05-JAN-2001;	2000US-0259678P.
25-SEP-2000;	2000US-0234997P.	PR	17-JAN-2001;	2001US-00764853.
26-SEP-2000;	2000US-0235484P.	PR	17-JAN-2001;	2001US-00764856.
27-SEP-2000;	2000US-0235834P.	PR	17-JAN-2001;	2001US-00764864.
27-SEP-2000;	2000US-0235836P.	PR	17-JAN-2001;	2001US-00764867.
29-SEP-2000;	2000US-023632			


```
PR 17-JAN-2001; 2001WO-US001340.
PR 17-JAN-2001; 2001WO-US001341.
PR 17-JAN-2001; 2001WO-US001344.
PR 17-JAN-2001; 2001WO-US001345.
PR 17-JAN-2001; 2001WO-US001347.
PR 17-JAN-2001; 2001WO-US001348.
PR 17-JAN-2001; 2001WO-US001360.
XX
XX (ROSE/) ROSEN C A.
PA (RUBI/) RUBIN S M.
PA (BARA/) BARASH S C.

Query Match 0.7%; Score 24.6; DB 1; Length 1352;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTTTACTTAATGCACTTATTTTATTCATTTTCTAATAAAATCCAGTCCTTGT 3042
DB 1241 TTGTGCTATATAAGTTAATGATTTTATAGGTATTTGTAACTCCGCCACATATCTT 1300

QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077
DB 1301 ATTTATCCCAATTCATATAAATTAATTTATCT 1335

RESULT 34
AAS41621
ID AAS41621 standard; cDNA; 1352 BP.
XX
AC AAS41621;
XX
DT 17-DEC-2001 (first entry)
XX
DE cDNA encoding novel human enzyme polypeptide #837.
XX
KW Human; oxidoreductase enzyme; transferase; hydrolase; lyase; isomerase;
KW ligase; hyperproliferative disorder; immunodeficiency disorder;
KW autoimmune disorder; neurological disorder; metabolic disorder;
KW inflammatory disorder; cardiovascular disorder; reproductive disorder;
KW blood-related disorder; infectious disorder; gene therapy; cytostatic;
KW anti arthritic; nephrotropic; anticoagulant; ss.
XX
OS Homo sapiens.
XX
XX WO200155301-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001239.
XX
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
XX 24-FEB-2000; 2000US-0184664P.
XX 02-MAR-2000; 2000US-0186350P.
XX 16-MAR-2000; 2000US-0189874P.
XX 17-MAR-2000; 2000US-0190076P.
XX 18-APR-2000; 2000US-0198123P.
XX 19-MAY-2000; 2000US-020515P.
XX 07-JUN-2000; 2000US-0209467P.
XX 28-JUN-2000; 2000US-0214886P.
XX 30-JUN-2000; 2000US-0215135P.
XX 07-JUL-2000; 2000US-0216647P.
XX 07-JUL-2000; 2000US-0216880P.
XX 11-JUL-2000; 2000US-0217487P.
XX 11-JUL-2000; 2000US-0217496P.
XX 14-JUL-2000; 2000US-0218290P.
XX 26-JUL-2000; 2000US-0220963P.
XX 26-JUL-2000; 2000US-0220964P.
XX 14-AUG-2000; 2000US-0224518P.
XX 14-AUG-2000; 2000US-0224519P.
XX 14-AUG-2000; 2000US-0225213P.
XX 14-AUG-2000; 2000US-0225214P.
XX 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0232403P.
PR 14-SEP-2000; 2000US-0232404P.
PR 14-SEP-2000; 2000US-0232423P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234977P.
PR 25-SEP-2000; 2000US-0234978P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239355P.
PR 13-OCT-2000; 2000US-0239377P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
```

08-NOV-2000; 2000US-0246526P.
08-NOV-2000; 2000US-0246527P.
08-NOV-2000; 2000US-0246528P.
08-NOV-2000; 2000US-0246532P.
08-NOV-2000; 2000US-0246609P.
08-NOV-2000; 2000US-0246610P.
08-NOV-2000; 2000US-0246611P.
08-NOV-2000; 2000US-0246613P.
17-NOV-2000; 2000US-0249207P.
17-NOV-2000; 2000US-0249208P.
17-NOV-2000; 2000US-0249209P.
17-NOV-2000; 2000US-0249210P.
17-NOV-2000; 2000US-0249211P.
17-NOV-2000; 2000US-0249212P.
17-NOV-2000; 2000US-0249213P.
17-NOV-2000; 2000US-0249214P.
17-NOV-2000; 2000US-0249215P.
17-NOV-2000; 2000US-0249216P.
17-NOV-2000; 2000US-0249217P.
17-NOV-2000; 2000US-0249218P.
17-NOV-2000; 2000US-0249244P.
17-NOV-2000; 2000US-0249245P.
17-NOV-2000; 2000US-0249264P.
17-NOV-2000; 2000US-0249265P.
17-NOV-2000; 2000US-0249297P.
17-NOV-2000; 2000US-0249299P.
17-NOV-2000; 2000US-0249300P.
01-DEC-2000; 2000US-0250160P.
01-DEC-2000; 2000US-0250391P.
03-DEC-2000; 2000US-0251030P.
03-DEC-2000; 2000US-0251988P.
06-DEC-2000; 2000US-0256719P.
08-DEC-2000; 2000US-0251479P.
08-DEC-2000; 2000US-0251556P.
08-DEC-2000; 2000US-0251868P.
08-DEC-2000; 2000US-0251869P.
08-DEC-2000; 2000US-0251989P.
08-DEC-2000; 2000US-0251990P.
11-DEC-2000; 2000US-0254097P.
05-JAN-2001; 2001US-0259678P.
(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-465566/50.
P-PSDB; AAU23751.
Novel polypeptides and polynucleotides useful for diagnosing, preventing, treating neural, immune system, muscular, reproductive, pulmonary, cardiovascular, renal, proliferative disorders and cancerous diseases.
Claim 4; SEQ ID NO 847; 1180pp; English.
The present invention relates to the isolation of novel human enzyme polypeptides (AAU2915-AAU3814), and the cDNA and genomic sequences encoding them. The enzyme polypeptides of the invention may comprise the functional classes of oxidoreductases, transferases, hydrolases, lyases, isomerases or ligases. The sequences of the invention are useful in the diagnosis, treatment, prevention and/or prognosis of a wide range of disorders including hyperproliferative disorders (e.g. cancer), immunodeficiency disorders (e.g. AIDS) autoimmune disorders (e.g. arthritis), neurological disorders (e.g. Alzheimer's disease), metabolic disorders (e.g. phenylketonuria), inflammatory disorders (e.g. asthma), cardiovascular disorders (e.g. atherosclerosis), blood-related disorders (e.g. haemophilia), reproductive disorders (e.g. infertility) and infectious disorders (e.g. influenza). The polynucleotides of the invention can also be used in gene therapy. AAU40785-AAU41694 represent cDNA sequences encoding for the novel human enzyme polypeptides of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 1352 BP; 237 A; 444 C; 408 G; 260 T; 0 U; 3 Other;
Query Match 0.7%; Score 24.6; DB 1; Length 1352;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTAAATGCACTTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042
Db 1231 TTTTGTGATATAATGTTAATGATTTTATAGGTAATTTGTAACCTGCCACATATCTT 1290
QY 3043 TTTTATAAAGACATTTAAATTAATTAATTTCTCT 3077
Db 1291 ATTATTCCTCCAATTTCAATAAATTTATTTCT 1325
RESULT 35
AAS26943
ID AAS26943 standard; cDNA; 1352 BP.
XX
AC AAS26943;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human cDNA encoding a novel secreted protein, SEQ ID 135.
XX
KW Human; immunosuppressive; antiarthritic; ss; antirheumatic; cytostatic;
KW cardiac; vasotropic; cerebroprotective; neurotropic; neuroprotective;
KW antibacterial; virucide; fungicide; opthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX
OS Homo sapiens.
XX
PN WO200155441-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001320.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214986P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 11-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 14-JUL-2000; 2000US-0217496P.
PR 26-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225269P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.

Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTTTACTTTAATGCACTTATTTTATTTGATTTTCTAATAAAATCCAGTCCTTGT 3042
Db 1231 TTTTGTGTATATAAAGTTTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1290
QY 3043 TTTTAAAGACTTTAAATTTAATTTCTCT 3077
Db 1291 ATTTATCTCCCAATTTCAATAAATTTATTTCTCT 1325

RESULT 36

AA587259
ID AAX87259 standard; cDNA; 1378 BP.

XX AAX87259;

XX AC AAX87259;

XX 27-SEP-1999 (first entry)

XX cDNA clone encoding human PRO343, amplified in tumour cells.

XX PRO343; UNQ302; cancer; tumour; diagnosis; therapy; human; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 53..1006

XX /tag= a

XX sig_peptide 53..148

XX /tag= b

XX mat_peptide 149..1003

XX /tag= c

XX WO9935170-A2.

XX 15-JUL-1999.

XX 05-JAN-1999; 99WO-US000106.

XX 05-JAN-1998; 98US-0070440P.

XX 29-APR-1998; 98US-0083500P.

XX 22-MAY-1998; 98US-0086414P.

XX 10-JUN-1998; 98US-0088742P.

XX 10-NOV-1998; 98US-0107783P.

XX 20-NOV-1998; 98US-0109304P.

XX (GETH) GENENTECH INC.

XX Botstein D, Goddard A, Gurney AL, Hillan KJ, Lawrence DA, Roy MA;

XX Wood WI;

XX WPI; 1999-430385/36.

XX P-PSDB; AAY06482.

XX Antibody against proteins expressed in neoplastic cells, useful for tumor

XX diagnosis and treatment.

XX Example 1; Fig 11; 162pp; English.

XX This is the nucleotide sequence of cDNA clone DNA43318 (ATCC 209481)

XX coding for human PRO343 (UNQ302) (see AAY06482). The clone was isolated

XX from a foetal lung library. Amplification of DNA43318 (chromosome 16) was

XX SQ

Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match

Best Local Similarity, 53.7%; Pred. No. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY

2983

TCATTTTACTTTAATGCACTTATTTTATTTGATTTTCTAATAAAATCCAGTCCTTGT 3042

Db

1272

TTTTGTGTATATAAAGTTTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331

QY

3043

TTTTTAAAGACTTTAAATTTAATTTCTCT 3077

Db

1332

ATTTATCTCCCAATTTCAATAAATTTATTTCTCT 1366

RESULT 37

AA587262

ID AAX52262 standard; DNA; 1378 BP.

XX AAX52262;

XX 25-JUN-1999 (first entry)

XX Protein PRO343 cDNA clone DNA43318-1217.

XX Secreted protein; transmembrane protein; human; enterocolitis;

XX Zollinger-Ellison syndrome; gastrointestinal ulceration;

XX congenital microvillus atrophy; skin disease; cell growth;

XX abnormal keratinocyte differentiation; psoriasis; epithelial cancer;

XX Parkinson's disease; Alzheimer's disease; ALS; neuropathy; fibromodulin;

XX dermal scarring; Usher Syndrome; Atrophia areata; anti-thrombotic;

XX wound healing; tissue repair; ss.

XX Homo sapiens.

XX WO9914328-A2.

XX 25-MAR-1999.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059122P.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 15-OCT-1997; 97US-0062125P.

XX 17-OCT-1997; 97US-0062285P.

XX 17-OCT-1997; 97US-0062287P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0062814P.

XX 24-OCT-1997; 97US-0062816P.

XX 24-OCT-1997; 97US-0063045P.

XX 24-OCT-1997; 97US-0063120P.

XX 24-OCT-1997; 97US-0063121P.

XX 24-OCT-1997; 97US-0063127P.

XX 24-OCT-1997; 97US-0063128P.

XX 27-OCT-1997; 97US-0063327P.

XX 27-OCT-1997; 97US-0063329P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063542P.

XX 28-OCT-1997; 97US-0063544P.

XX 28-OCT-1997; 97US-0063549P.

XX 28-OCT-1997; 97US-0063550P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063435P.

XX 29-OCT-1997; 97US-0063704P.

XX 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 XX
 PA (GETH) GENENTECH INC.

XX Wood WI, Gurney AL, Goddard A, Pennica D, Chen J, Yuan J;
 PI Botstein D, Gurney AL, Goddard A, Pennica D, Chen J, Yuan J;
 XX WFI; 1999-229533/19.
 DR P-PSDB; AAY13391.

XX New isolated human genes and polypeptides used in, e.g. treatment of
 PT gastrointestinal ulceration.

XX Claim 2; Fig 97; 320pp; English.
 XX AAX52213-74 encode secreted and transmembrane human proteins, and are
 CC obtained from cDNA libraries, prepared from fetal lung, fetal kidney,
 CC fetal brain, fetal liver and fetal retina. The encoded polypeptides have
 CC specific uses based on their homology to known polypeptides, e.g. PRO211
 CC and PRO217 can be used for disorders associated with the preservation and
 CC maintenance of gastrointestinal mucosa and the repair of acute and
 CC chronic mucosal lesions (e.g. enterocolitis, Zollinger-Ellison syndrome,
 CC gastrointestinal ulceration and congenital microvillus atrophy), skin
 CC diseases associated with abnormal keratinocyte differentiation (e.g.
 CC psoriasis, epithelial cancers such as lung squamous cell carcinoma of the
 CC vulva and gliomas), potent effects on cell growth and development,
 CC diseases related to growth or survival of nerve cells including
 CC Parkinson's disease, Alzheimer's disease, ALS, neuropathies or cancer.
 CC PRO265 can be used as for fibromodulin, e.g. for reducing dermal
 CC scarring. PRO264 can be used as a target for anti-tumor drugs. PRO333 may
 CC be used in the treatment of Usher Syndrome or Atrophia areata; PRO269 can
 CC be used as an anti-thrombotic agent; PRO287 polypeptides and portions may
 CC have therapeutic applications in wound healing and tissue repair; PRO317
 CC can be used for treating problems of the kidney, uterus, endometrium,
 CC blood vessels, or related tissue, e.g. in the heart of genital tract.
 XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTTTACTTTAATTCGACCTATTATTTATGATTTTCTAATAAATCCAGTCTTGT 3042
 DB 1272 TTTTGCTATATAAAGTAAATGATTTTATAGGATTATTTGTAACCTGCCACATATCTT 1331

OY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077
 DB 1332 ATTATTCCTCCAAATTTCAATAAATTAATTTCTCT 1366

RESULT 38
 AAA46914
 ID AAA46914 standard; cDNA; 1378 BP.
 XX
 AC AAA46914;

XX 03-OCT-2000 (first entry)
 XX cDNA encoding novel polypeptide PRO343.

XX PRO201; PRO292; PRO327; PRO1265; PRO344; PRO343; PRO347; PRO357; PRO715;
 XX PRO1017; PRO1112; PRO509; PRO853; PRO882; tumour cell; tumorigenesis;
 XX cancer; neoplastic cell growth; cell proliferation; ss.

XX Homo sapiens.

XX Key Location/Qualifiers
 XX CDS 53..1007
 XX /*tag= a

XX WO2000037640-A2.

XX 29-JUN-2000.

XX 16-DEC-1999; 99WO-US030095.

XX 22-DEC-1998; 98US-0113296P.

XX 08-MAR-1999; 99WO-US005028.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 15-SEP-1999; 99WO-US021090.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 02-DEC-1999; 99WO-US028565.

XX (GETH) GENENTECH INC.

XX Botstein D, Goddard A, Gurney AL, Hillan K, Lawrence DA, Roy MA;
 XX Wood WI;
 XX WFI; 2000-452188/39.
 XX P-PSDB; AAY93689.

XX New anti-polypeptide antibody useful in the treatment and diagnosis of
 PT neoplastic cell growth and proliferation.

XX Claim 50; Fig 11; 220pp; English.

XX The present sequence encodes a novel human polypeptide. The specification
 CC describes novel polypeptides designated PRO201, PRO292, PRO327, PRO1265,
 CC PRO344, PRO343, PRO347, PRO357, PRO715, PRO1017, PRO112, PRO509, PRO853
 CC and PRO882. These genes are amplified in the genome of tumour cells. The
 CC polypeptides are believed to contribute to tumorigenesis. The
 CC polypeptides are useful target for the identification of certain cancers,
 CC and may act as predictors of the prognosis of tumour treatment.
 CC Antibodies against these polypeptides are useful in the treatment and
 CC diagnosis of neoplastic cell growth and proliferation in mammals

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTTTACTTTAATTCGACCTATTATTTATGATTTTCTAATAAATCCAGTCTTGT 3042
 DB 1272 TTTTGCTATATAAAGTAAATGATTTTATAGGATTATTTGTAACCTGCCACATATCTT 1331

OY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077
 DB 1332 ATTATTCCTCCAAATTTCAATAAATTAATTTCTCT 1366

RESULT 39
 ADC78574
 ID ADC78574 standard; cDNA; 1378 BP.
 XX

```

AC ADC78574;
XX 01-JAN-2004 (first entry)
XX Human PRO343 cDNA.
DE
XX
XX antiinflammatory; antiulcer; cytostatic; antipsoriatic; antiparkinsonian;
XX neurotropic; neuroprotective; vasotropic; chemotactic; angiogenic;
XX neurotrophic; osteopathic; antiasthmatic; antiarthritic; antineumatic;
XX antiatherosclerotic; cardiatic; antidiabetic; cerebroprotective;
XX thrombolytic; immunomodulator; enterocolitis; Zollinger-Ellison syndrome;
XX gastrointestinal ulceration; psoriasis; cancer; Parkinson's disease;
XX Alzheimer's; ALS; neuropathy; dermal scarring; wound healing;
XX nerve repair; thrombosis; bone; cartilage formation; angiogenesis;
XX asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disorder;
XX atherosclerosis; cardiac injury; infertility; premature aging; AIDS;
XX diabetes; stroke; gene therapy; transgenic; PRO; human; ss; gene.
XX
OS Homo sapiens.
XX
XX WO200015796-A2.
XX
XX 23-MAR-2000.
XX
XX 15-SEP-1999; 99WO-US021090.
XX
XX 16-SEP-1998; 98WO-US019330.
XX
XX (GETH ) GENENTECH INC.
XX
XX Chen J, Goddard A, Gurney AL, Hillan K, Pennica D, Wood WI;
XX Yuan J;
XX
XX WPI; 2000-271434/23.
XX
XX P-PSDB; ADC78575.
XX
XX Novel nucleic acids encoding secreted and transmembrane polypeptides with
XX homology, e.g. to growth and cancer-associated antigens.
XX
XX Claim 2; SEQ ID NO 262; 355pp; English.
XX
XX The invention relates to a novel nucleic acid encoding a PRO polypeptide.
XX The polypeptides and polynucleotides of the invention may be useful as
XX research tools and as therapeutics for treating enterocolitis, Zollinger-
XX Ellison syndrome, gastrointestinal ulceration, psoriasis, cancer,
XX Parkinson's disease, Alzheimer's disease, ALS, neuropathies, dermal
XX scarring and wound healing, nerve repair, thrombosis, bone and/or
XX cartilage formation, angiogenesis, asthma, rheumatoid arthritis, multiple
XX sclerosis, inflammatory disorders, atherosclerosis, cardiac injury,
XX infertility, premature aging, AIDS, diabetes complications and stroke.
XX The molecules may also be utilised during gene therapy procedures and
XX transgenic animal production. The current sequence is that of the human
XX PRO cDNA of the invention.
XX
XX
XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 24.6; DB 1; Length 1378;
XX Best Local Similarity 53.7%; Pred. No. 26;
XX Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
XX
XX QY 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTTAATAAATCCAGTCCTTGT 3042
XX DB 1272 TTTTGTGTATATAATGTTATGATTTTATAGGTTATTTGACCCGCGCACATATCTT 1331
XX
XX QY 3043 TTTTATAAAGACTTAAATTAATTTATTTCTCT 3077
XX DB 1332 ATTATTCCTCCAAATTCATAAATATTATTCT 1366
XX
XX
XX RESULT 40
XX AAF72420
XX ID AAF72420 standard; cDNA; 1378 BP.
XX
XX

```

```

AC AAF72420;
XX 24-APR-2001 (first entry)
XX Human PRO343 cDNA.
DE
XX
XX Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
XX antiparkinsonian neurotropic; neuroprotective; vulnerary; cardiatic;
XX antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
XX antiarthritic; antinfertility; antidiabetic; antiviral; diabetes;
XX ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
XX ischaemia; inflammation; ss.
XX
XX Homo sapiens.
XX
XX WO200104311-A1.
XX
XX 18-JAN-2001.
XX
XX 22-FEB-2000; 2000WO-US004414.
XX
XX 07-JUL-1999; 99US-0143048P.
XX 26-JUL-1999; 99US-0145698P.
XX 28-JUL-1999; 99US-0146222P.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 05-JAN-2000; 2000WO-US000219.
XX
XX (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
XX Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
XX Godowski PJ, Grimaldi CU, Gurney AL, Hillan KJ, Kijavini LJ;
XX Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
XX Williams PM, Wood WI;
XX
XX WPI; 2001-081051/09.
XX P-PSDB; AAB80259.
XX
XX Sixty one nucleic acids encoding PRO polypeptides which are useful in the
XX treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous
XX cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's
XX disease).
XX
XX Claim 2; Fig 97; 393pp; English.
XX
XX The present sequence is one of sixty one nucleic acids encoding novel
XX secreted and transmembrane PRO polypeptides. The PRO polypeptides are
XX useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
XX squamous cell carcinoma), gastrointestinal disorders (e.g.
XX enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
XX Parkinson's disease), wound repair, cardiovascular disorders (e.g.
XX endometrial bleeding, angiogenesis, ischaemias such as coronary ischaemia,
XX atherosclerosis), inflammatory disorders (e.g. asthma, rheumatoid
XX arthritis, multiple sclerosis), infertility, AIDS and diabetes and
XX retinal disorders such as retinitis pigmentosa. The PRO nucleic acids
XX have applications in molecular biology, including use as hybridization
XX probes, and in chromosome and gene mapping.
XX
XX
XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 24.6; DB 1; Length 1378;
XX Best Local Similarity 53.7%; Pred. No. 26;
XX

```


CC assays, biochemical screening assays, immunoassays and cell-based assays.
 CC This sequence represents a human PRO polynucleotide of the invention

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCATTTTAACTTAAATGACCTTATTTTATTTGATTTTCTAATAAAACCCAGTCCTTCT 3042
 Db 1272 TTTTGTAATAAATGTTAATGATTTTATAGTATTTGTACCTGCCACATATCTT 1331
 OY 3043 TTTTAAAGACTTTAAATTTATTAATTTCTCT 3077
 Db 1332 ATTTATCCCTCAATTCATTAATTTATTTCT 1366

RESULT 42

ACA58507
 ID ACA58507 standard; cDNA; 1378 BP.

XX AC ACA58507;

XX DT 10-JUN-2003 (first entry)

XX cDNA encoding human PRO polypeptide #48.

XX Human; secreted and transmembrane protein; PRO polypeptide; cancer;
 KW Alzheimer's disease; ischaemia; cytostatic; neurotropic; vasotropic;
 KW neuroprotective; gene; ss.

XX Homo sapiens.

XX US2002192659-A1.

XX 19-DEC-2002.

XX 10-JUL-2001; 2001US-00902853.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059123P.

XX 17-SEP-1997; 97US-0059125P.

XX 17-SEP-1997; 97US-0059127P.

XX 17-SEP-1997; 97US-0059129P.

XX 17-SEP-1997; 97US-0059131P.

XX 17-SEP-1997; 97US-0059133P.

XX 17-SEP-1997; 97US-0059135P.

XX 17-SEP-1997; 97US-0059137P.

XX 17-SEP-1997; 97US-0059139P.

XX 17-SEP-1997; 97US-0059141P.

XX 17-SEP-1997; 97US-0059143P.

XX 17-SEP-1997; 97US-0059145P.

XX 17-SEP-1997; 97US-0059147P.

XX 17-SEP-1997; 97US-0059149P.

XX 17-SEP-1997; 97US-0059151P.

XX 17-SEP-1997; 97US-0059153P.

XX 17-SEP-1997; 97US-0059155P.

XX 17-SEP-1997; 97US-0059157P.

XX 17-SEP-1997; 97US-0059159P.

XX 17-SEP-1997; 97US-0059161P.

XX 17-SEP-1997; 97US-0059163P.

PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 01-DEC-1998; 98WO-US025108.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 30-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00665350.

(GETH) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;

WPI; 2003-361832/34.
 P-PSDB; ABU71492.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 97; 474pp; English.

The present invention relates to the isolation of novel human secreted and transmembrane proteins (PRO polypeptides), and the polynucleotide sequences encoding them. The polynucleotide sequences are useful in molecular biology, as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide sequences may also be used in preparing PRO polypeptides by recombinant techniques, and in generating either transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or

CC their antibodies are useful in preparing a medicament for treating a
CC condition responsive to the polypeptide or antibody, such as cancer,
CC Alzheimer's disease or ischaemia, and in various diagnostic assays. The
CC present sequence encodes a human PRO polypeptide of the invention
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.78; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.78; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTACTTAAATGCGACTTATTTTATGATTTTCTATAAATCCAGTCTGTG 3042
DB 1272 TTTTGTGTATATAAATGTAATGATTTTATAGTATTGTAACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAGACTTTAAATTAATTAATTTCTCT 3077
DB 1332 ATTATCCCAATTCATTAATTAATTTATTTCT 1366

RESULT 43

ACA60214
ID ACA60214 standard; cDNA; 1378 BP.

XX ACA60214;

AC ACA60214;

DT 12-JUN-2003 (first entry)

DE Human cDNA for secreted/transmembrane protein PRO343.

KW Human; ss; Gene; secreted protein; transmembrane protein; PRO;

KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003003530-A1.

PD 02-JAN-2003.

XX 11-JUL-2001; 2001US-00304011.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059123P.

XX 17-SEP-1997; 97US-0059125P.

XX 17-SEP-1997; 97US-0059127P.

XX 17-SEP-1997; 97US-0059129P.

XX 17-SEP-1997; 97US-0059131P.

XX 17-SEP-1997; 97US-0059133P.

XX 17-SEP-1997; 97US-0059135P.

XX 17-SEP-1997; 97US-0059137P.

XX 17-SEP-1997; 97US-0059139P.

XX 17-SEP-1997; 97US-0059141P.

XX 17-SEP-1997; 97US-0059143P.

XX 17-SEP-1997; 97US-0059145P.

XX 17-SEP-1997; 97US-0059147P.

XX 17-SEP-1997; 97US-0059149P.

XX 17-SEP-1997; 97US-0059151P.

XX 17-SEP-1997; 97US-0059153P.

PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065893P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US025108.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.

(GETH) GENENTECH INC.

Askenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
Williams PM, Wood WI;

WPI; 2003-329602/31.

P-PSDB; ABU1938.

New transmembrane polypeptides and nucleic acids encoding the
polypeptides, useful in gene therapy, in chromosome identification, as
chromosome markers, in generating probes and in tissue typing.

Claim 2; Fig 97; 484pp; English.

The invention relates to an isolated nucleic acid with at least 80%
nucleic acid sequence identity to a nucleotide sequence encoding one of
61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a
PRO protein extracellular domain. Also included are a vector comprising
the PRO nucleic acid, a host cell comprising the vector, producing a PRO
polypeptide (by culturing the host cell for the expression of the PRO
polypeptide, and recovering the PRO polypeptide from the cell culture),
an isolated PRO polypeptide (having at least 80% sequence identity to: (

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PW, Wood WI;
XX WPI; 2003-370793/35.
DR P-PSDB; ABC01821.
XX
XX New genes and secreted and transmembrane polypeptides (e.g. PRO245 or
PT PRO335), useful for treating or diagnosing e.g. Alzheimer's disease,
PT cancers, hemorrhage, rheumatoid arthritis, diabetes, cirrhosis, ischemia
PT or strokes.
XX
XX Claim 2; Fig 97; 482pp; English.
PS
CC The invention describes a new isolated nucleic acid molecule comprising
CC the full length coding sequence of the DNA deposited with the American
CC Type Culture Collection (e.g. ATCC Deposit No. 209258), or a sequence
CC with at least 80% identity to a DNA encoding a PRO polypeptide comprising
CC any of 61 sequences having 164-1119 amino acids fully defined in the
CC specification. The PRO polypeptides or polynucleotides are useful as
CC pharmaceuticals, diagnostics, biosensors or bioreactors. These are
CC particularly useful for detecting or treating e.g. Parkinson's disease,
CC Alzheimer's disease, inflammations, nephritis, wound healing, nerve
CC repair, collateral blood vessel formation, cancers (e.g. colorectal
CC cancer), haemorrhage (or reduce risk for haemorrhage), rheumatoid
CC arthritis, diabetes, cirrhosis of the liver, fibrosis of the lungs,
CC restenosis, dermal fibrotic conditions (e.g. keloids or scarring),
CC ischaemia, strokes, hypertension, heart attacks, atherosclerosis, or
CC infertility in mammals (e.g. humans, dogs, cats, cattle, horses, sheep,
CC pigs, goats, or rabbits). The PRO polypeptides are useful as targets for
CC therapeutic intervention in these diseases, and diagnostic determination
CC of the presence of these diseases. The PRO polypeptides are also useful
CC as molecular weight markers, or for chromosome identification. The PRO
CC genes are useful as hybridisation probes, or for screening libraries of
CC human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC therapy, particularly for replacing a defective gene. This sequence
CC encodes a novel human secreted and transmembrane PRO polypeptide
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTCTTAAATGCACTTATTTATTTATTTCTTAAATCAATCAATCTTCT 3042
Db 1272 TTTTGTATATAAAGTTTAAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077
Db 1332 ATTATTCCTCAATTTCAATAAATTTATTTCT 1356

RESULT 45
ABX71662
ID ABX71662 standard; cDNA; 1378 BP.
XX
XX AC ABX71662;
XX
XX DT 10-MAR-2003 (first entry)
XX
XX DE Human cDNA encoding secreted/transmembrane protein PRO343.
XX
XX Human; PRO; secreted protein; transmembrane protein; enterocolitis;
KW gastrointestinal ulceration; skin disease; ss; gene;
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
KW squamous cell carcinoma; Alzheimer's disease; Parkinson's disease;
KW amyotrophic lateral sclerosis; inflammatory disease;
KW rheumatoid arthritis; asthma; multiple sclerosis; organ failure;
KW atherosclerosis; cardiac injury; infertility; birth defect;
KW premature aging; AIDS; acquired immunodeficiency syndrome; cancer;
KW diabetic complication; wound repair.

XX Homo sapiens.
OS US2002132240-A1.
XX
XX 19-SEP-2002.
PD
PF 18-JUL-2001; 2001US-00909320.
XX
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066468P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US025108.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028584.
PR 02-DEC-1999; 99WO-US028585.

PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	20-DEC-1999;	99WO-US030999.	
PR	06-JAN-2000;	2000WO-US000219.	
PR	11-FEB-2000;	2000WO-US003565.	
PR	22-FEB-2000;	2000WO-US004414.	
PR	24-FEB-2000;	2000WO-US005004.	
PR	02-MAR-2000;	2000WO-US005841.	
PR	20-MAR-2000;	2000WO-US007377.	
PR	30-MAR-2000;	2000WO-US008439.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	24-AUG-2000;	2000WO-US023328.	
PR	18-SEP-2000;	2000US-00665350.	
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;		
PI	Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;		
PI	Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IU;		
PI	Macher JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;		
PI	Williams PM, Wood WI;		
XX			
DR	WPI; 2003-147434/14.		
DR	P-PSDB; ABU54394.		
XX			
PT	New PRO polypeptides and nucleic acid molecules, useful in diagnosing or		
PT	treating inflammatory diseases, organ failure, atherosclerosis, cardiac		
PT	injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's		
PT	disease.		
XX			
PS	Claim 2; Fig 97; 473pp; English.		
XX			
CC	The invention relates to an isolated PRO polypeptide having at least 80%		
CC	amino acid sequence identity to: (a) any one of 61 fully defined amino		
CC	acid sequences given in the specification (appearing as ABU54347-		
CC	ABU54407); (b) an amino acid sequence encoded by the nucleotide sequence		
CC	deposited under American Type Culture Collection (accession numbers		
CC	listed in the specification); (c) any one of the PRO sequences which		
CC	lack its associated signal peptide; (d) an extracellular domain of the		
CC	PRO polypeptide with its associated signal peptide; or (e) an		
CC	extracellular domain of the PRO polypeptide which lacks its associated		
CC	signal peptide. Also include are the nucleic acids encoding the PRO		
CC	polypeptides, vectors, host cells and anti-PRO antibodies. The PRO		
CC	polypeptides and nucleic acids are useful in diagnosing or treating		
CC	enterocolitis, gastrointestinal ulceration, skin diseases associated with		
CC	abnormal keratinocyte differentiation, e.g. psoriasis or epithelial		
CC	cancers such as squamous cell carcinoma, Alzheimer's disease, Parkinson's		
CC	disease, amyotrophic lateral sclerosis, inflammatory diseases, e.g.		
CC	rheumatoid arthritis, asthma or multiple sclerosis, organ failure,		
CC	atherosclerosis, cardiac injury, infertility, birth defects, premature		
CC	aging, AIDS, cancer, diabetic complications, or mutations in general. The		
CC	polypeptides are also useful for wound repair and associated therapies		
CC	concerned with re-growth of tissue. The nucleotide sequences may be used		
CC	as hybridisation probes in chromosome and gene mapping, or in generating		
CC	antisense RNA and DNA. PRO nucleic acids are also useful in preparing PRO		
CC	polypeptides, in assays to identify other proteins or molecules involved		
CC	in binding reaction, to generate transgenic animals or knockout animals,		
CC	which in turn are useful in the development and screening of		
CC	therapeutically useful reagents, for chromosome identification, and		
CC	tissue typing. The PRO polypeptides and nucleic acid molecules are also		
CC	useful in gene therapy, and as molecular weight markers for protein		
CC	electrophoresis purposes. The anti-PRO antibodies may be used in		
CC	diagnostic assays for PRO, or for the affinity purification of PRO from		
CC	recombinant cell culture or natural sources. The present sequence encodes		
CC	a PRO polypeptide		
XX			
SQ	Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;		
	Query Match 0.7%; Score 24.6; DB 1; Length 1378;		
	Best Local Similarity 53.7%; Pred. No. 26;		
	Matches 5; Conservative 0; Mismatches 44; Indels 0; Gaps 0;		

Qy	2983	TCATATTTACTTTAATGCACTATTTTATGATTTTCTAATAAATCCAGTCCTTGT	3042
Db	1272	TTTTGTATATAAATGTTAAATGATTTTATAGTATTGTAACCTGCCACATATCTT	1331
Qy	3043	TTTTTTAAAAGACATTTAAAATTAATTTCTCT	3077
Db	1332	ATTATTCCTCCAAATTCATTAATTTATTTCT	1366
RESULT 46			
ACH06994			
ID	ACH06994	standard; cDNA; 1378 BP.	
XX			
AC	ACH06994;		
XX			
DT	08-OCT-2003	(first entry)	
XX			
DE	Human secreted/transmembrane polypeptide PRO343 cDNA.		
XX			
KW	Human; gene; ss; abnormal bleeding; gynaecological disease; asthma;		
KW	hysterectomy; angiogenesis; coronary ischaemic condition; skin disease;		
KW	gastrointestinal mucosa disorder; acute mucosal lesion; neuropathy; AIDS;		
KW	chronic mucosal lesion; abnormal keratinocyte differentiation; psoriasis;		
KW	Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;		
KW	uncontrolled cell growth; cancer; blood coagulation cascade; thrombosis;		
KW	haemorrhage; endometrial bleeding; angiogenesis; wound healing; tumour;		
KW	tissue repair; rheumatoid arthritis; multiple sclerosis; tissue typing.		
XX			
OS	Homo sapiens.		
XX			
FN	US2003044839-A1.		
XX			
PD	06-MAR-2003.		
XX			
PF	10-JUL-2001; 2001US-00902903.		
XX			
PR	17-SEP-1997;	97US-0059113P.	
PR	17-SEP-1997;	97US-0059115P.	
PR	17-SEP-1997;	97US-0059117P.	
PR	17-SEP-1997;	97US-0059119P.	
PR	17-SEP-1997;	97US-0059121P.	
PR	17-SEP-1997;	97US-0059122P.	
PR	17-SEP-1997;	97US-0059184P.	
PR	18-SEP-1997;	97US-0059263P.	
PR	18-SEP-1997;	97US-0059268P.	
PR	18-SEP-1997;	97US-0062125P.	
PR	18-SEP-1997;	97US-0062128P.	
PR	17-OCT-1997;	97US-0062287P.	
PR	17-OCT-1997;	97US-0062287P.	
PR	21-OCT-1997;	97US-0063486P.	
PR	24-OCT-1997;	97US-0062814P.	
PR	24-OCT-1997;	97US-0062816P.	
PR	24-OCT-1997;	97US-0063045P.	
PR	24-OCT-1997;	97US-0063120P.	
PR	24-OCT-1997;	97US-0063121P.	
PR	24-OCT-1997;	97US-0063127P.	
PR	24-OCT-1997;	97US-0063128P.	
PR	27-OCT-1997;	97US-0063327P.	
PR	27-OCT-1997;	97US-0063329P.	
PR	28-OCT-1997;	97US-0063541P.	
PR	28-OCT-1997;	97US-0063542P.	
PR	28-OCT-1997;	97US-0063544P.	
PR	28-OCT-1997;	97US-0063549P.	
PR	28-OCT-1997;	97US-0063550P.	
PR	28-OCT-1997;	97US-0063564P.	
PR	29-OCT-1997;	97US-0063435P.	
PR	29-OCT-1997;	97US-0063704P.	
PR	29-OCT-1997;	97US-0063732P.	
PR	29-OCT-1997;	97US-0063734P.	
PR	29-OCT-1997;	97US-0063735P.	
PR	29-OCT-1997;	97US-0063738P.	
PR	29-OCT-1997;	97US-0064215P.	
PR	31-OCT-1997;	97US-0063870P.	

PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 12-NOV-1997; 97US-0064809P.
 PR 17-NOV-1997; 97US-0065186P.
 PR 18-NOV-1997; 97US-0065846P.
 PR 21-NOV-1997; 97US-0065853P.
 PR 24-NOV-1997; 97US-0066120P.
 PR 24-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 02-DEC-1997; 97US-0069425P.
 PR 14-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0099803P.
 PR 10-SEP-1998; 98US-010018824.
 PR 14-SEP-1998; 98US-0100262P.
 PR 16-SEP-1998; 98US-01019177.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98US-01019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98US-03025108.
 PR 22-DEC-1998; 98US-0113296P.
 PR 07-JUL-1999; 99US-0143048P.
 PR 26-JUL-1999; 99US-0145888P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99US-05020594.
 PR 13-SEP-1999; 99US-05020944.
 PR 15-SEP-1999; 99US-05021090.
 PR 15-SEP-1999; 99US-05021547.
 PR 05-OCT-1999; 99US-05023089.
 PR 29-NOV-1999; 99US-05028214.
 PR 30-NOV-1999; 99US-05028313.
 PR 01-DEC-1999; 99US-05028301.
 PR 02-DEC-1999; 99US-05028564.
 PR 16-DEC-1999; 99US-05028565.
 PR 20-DEC-1999; 99US-05030095.
 PR 20-DEC-1999; 99US-05030911.
 PR 20-DEC-1999; 99US-05030999.
 PR 05-JAN-2000; 2000US-05000219.
 PR 11-FEB-2000; 2000US-05003565.
 PR 22-FEB-2000; 2000US-05004414.
 PR 24-FEB-2000; 2000US-05005004.
 PR 02-MAR-2000; 2000US-05005841.
 PR 20-MAR-2000; 2000US-05007377.
 PR 30-MAR-2000; 2000US-05008439.
 PR 22-MAY-2000; 2000US-05014042.
 PR 02-JUN-2000; 2000US-05015264.
 PR 28-JUL-2000; 2000US-05020710.
 PR 24-AUG-2000; 2000US-05023328.
 PR 18-SEP-2000; 2000US-050665350.
 (GETH) GENENTECH INC.
 PA Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX WPI; 2003-492258/46.
 DR P-PSDB; ABO47409.
 XX
 XX
 PT Novel secreted and transmembrane polypeptides and polynucleotides
 FT encoding them useful for treating abnormal bleeding involved in
 FT gynecological diseases, skin diseases and neurodegenerative diseases.
 XX
 PS Claim 3; Fig 97; 478pp; English.
 XX

CC The invention relates to an isolated PRO polypeptide. PRO317 is useful in
 CC diagnosing or treating abnormal bleeding involved in gynecological
 CC diseases e.g. to avoid or lessen the need for hysterectomy. PRO317 may
 CC also be useful as an agent that affects angiogenesis and PRO317 is useful
 CC in anti-tumour indications or in treating coronary ischaemic conditions.
 CC PRO211 and PRO217 polypeptides are useful for treating disorders
 CC associated with the preservation and maintenance of gastrointestinal
 CC mucosa and the repair of acute and chronic mucosal lesions, skin diseases
 CC associated with abnormal keratinocyte differentiation (e.g. psoriasis).
 CC PRO187 polypeptide is useful for treating Parkinson's disease,
 CC Alzheimer's disease, amyotrophic lateral sclerosis (ALS), neuropathies
 CC and disease related to uncontrolled cell growth, e.g. cancer. PRO219
 CC polypeptide plays a regulatory role in the blood coagulation cascade.
 CC PRO246 polypeptides which serves as tumour specific antigens may be
 CC exploited as therapeutic targets for anti-tumour drugs. PRO269
 CC polypeptide is useful as an antithrombotic agent with reduced risk for
 CC haemorrhage as compared with heparin. PRO317 polypeptide is useful in
 CC treating endometrial bleeding angiogenesis. PRO287 polypeptides and
 CC portion have therapeutic applications in wound healing and tissue repair.
 CC PRO234 polypeptides are useful for treating asthma, rheumatoid arthritis,
 CC psoriasis and multiple sclerosis. The polypeptide and its nucleic acid
 CC are useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC present sequence represents cDNA encoding a human secreted/transmembrane
 CC PRO polypeptide
 XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTTAATTCGACTTATTTTATGATTTTCTTAATAAATCCAGTCCTTGT 3042
 Db |||||
 QY 1272 TTGTGTATATAAAGTATGATTTTATGATTTTCTTAATAAATCCAGTCCTTGT 1331
 Db |||||
 QY 3043 TTTTAAAGACCTTTAAATTTATTAATTTCTCT 3077
 Db |||||
 QY 1332 ATTATCTCTCAATTCATTAATTTATTTCT 1366
 Db |||||

RESULT 47

ABX96231

ID ABX96231 standard; cDNA; 1378 BP.

XX AC ABX96231;

XX DT 13-MAY-2003 (first entry)

XX DE Human secreted/transmembrane protein cDNA, #50.

XX KW Human; gene; ss; PRO; secreted; transmembrane; pharmaceutical;
 KW diagnostic; biosensor; bioreactor; therapeutic; hyperplasia;
 KW endometriosis; cancer; tumour; ischaemia; coronary arterial disease;
 KW polycystic kidney disease; renal failure; inflammatory response; asthma;
 KW rheumatoid arthritis; psoriasis; multiple sclerosis; gene therapy;
 KW cytostatic; gynecological; cardiant; nephrotropic; hepatotropic;
 KW antiinflammatory.

XX OS Homo sapiens.

XX FN US2002160374-A1.

XX PD 31-OCT-2002.

XX PF 12-JUL-2001; 2001US-00905291.

XX PR 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059115P.

XX PR 17-SEP-1997; 97US-0059117P.

RESULT 49

CC disorders, in gene therapy, for chromosome identification, as chromosome
CC marker, and for generating probes for polymerase chain reaction (PCR),
CC Northern analysis, Southern analysis and Western analysis. PRO antibody
CC is useful in diagnostic assays for PRO, e.g. detecting its expression in
CC specific cells, tissues or serum and for affinity purification of PRO
CC from recombinant cell culture or natural sources. The polypeptide or its
CC antibody is useful for the preparation of medicament for treating
CC conditions which is responsive to the PRO polypeptide or anti-PRO
CC antibody e.g. tumour. The polypeptide and the nucleic acid is useful for
CC tissue typing. The polypeptide is useful for treating obesity, diabetes
CC or hypo- or hyper-insulinaemia and cardiac insufficiency disorders, for
CC inhibiting tumour growth, enhances vascular permeability and immune
CC response, for inducing regeneration of auditory hair cells and for
CC treating hearing loss in mammals and for treating bone and/or cartilage
CC disorders such as sports injuries and arthritis. The present sequence
CC represents cDNA encoding a human secreted and transmembrane PRO
CC polypeptide
XX
XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
Query Match 0.78; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.74; Fred. NO. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGCACTTATTTTATTCATTTTCTATTAATAAAATCCAGTCCTGT 3042
Db 1272 TTGTGCTATATAAATGCTTAATGATTTTATAGTATTTTGTACCCCTGCCACATATCTT 1331
QY 3043 TTTTAAAAGACTTTAAATTTATTAATTTCTCT 3077
Db 1332 ATTATTCCTCCCAATTCATTAATTAATTTATTTCT 1366
RESULT 50
ACA55022
ID ACA55022 standard; cDNA; 1378 BP.
XX
XX ACA55022;
XX
XX 05-JUN-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO343 cDNA.
XX
XX Human; secreted and transmembrane protein; gene therapy; psoriasis;
XX enterocolitis; gastrointestinal ulceration; skin disease;
XX keratinocyte differentiation; epithelial cancer; Alzheimer's disease;
XX squamous cell carcinoma; Parkinson's disease; inflammatory disease;
XX amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;
XX multiple sclerosis; organ failure; atherosclerosis; cardiac injury;
XX infertility; birth defect; premature aging; AIDS; cancer;
XX diabetic complication; wound repair; tissue re-growth; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003017463-A1.
XX
XX 23-JAN-2003.
XX
XX 11-JUL-2001; 2001US-00903640.
XX
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059463P.
XX 18-SEP-1997; 97US-0059466P.
XX 18-SEP-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 31-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065893P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-008026P.
PR 10-SEP-1998; 98US-0099803P.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98US-0100262P.
PR 17-SEP-1998; 98US-0100585P.
PR 17-SEP-1998; 98US-0100585P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99US-0146222P.
PR 13-SEP-1999; 99US-0146222P.
PR 15-SEP-1999; 99US-0146222P.
PR 15-SEP-1999; 99US-0146222P.
PR 05-OCT-1999; 99US-0146222P.
PR 29-NOV-1999; 99US-0146222P.
PR 30-NOV-1999; 99US-0146222P.
PR 01-DEC-1999; 99US-0146222P.
PR 02-DEC-1999; 99US-0146222P.
PR 16-DEC-1999; 99US-0146222P.
PR 20-DEC-1999; 99US-0146222P.
PR 20-DEC-1999; 99US-0146222P.
PR 05-JAN-2000; 2000US-0000219.
PR 11-FEB-2000; 2000US-0003565.
PR 22-FEB-2000; 2000US-0004414.
PR 02-MAR-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 20-MAR-2000; 2000US-0007377.
PR 30-MAR-2000; 2000US-0008439.

PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00665350.
 XX (GETH) GENENTECH INC.
 PA
 XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI GoGowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX WPI; 2003-341586/32.
 DR P-PSDB; ABU69669.
 XX
 XX New PRO polypeptides and nucleic acid molecules, useful in diagnosing or
 PT treating inflammatory diseases, organ failure, atherosclerosis, cardiac
 PT injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's
 PT disease.
 PT
 XX Claim 2; Fig 97; 473pp; English.
 PS
 XX The invention describes sixty one nucleic acids encoding PRO polypeptides
 CC (secreted and transmembrane). The PRO polypeptides and nucleic acids are
 CC useful in diagnosing or treating enterocolitis, gastrointestinal
 CC ulceration, skin diseases associated with abnormal keratinocyte
 CC differentiation, e.g. psoriasis or epithelial cancers such as squamous
 CC cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic
 CC lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,
 CC asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac
 CC injury, infertility, birth defects, premature aging, AIDS, cancer,
 CC diabetic complications, or mutations in general. The polypeptides are
 CC also useful for wound repair and associated therapies concerned with re-
 CC growth of tissue. The PRO polypeptides and nucleic acid molecules are
 CC also useful in gene therapy, and as molecular weight markers for protein
 CC electrophoresis purposes. The anti-PRO antibodies may be used in
 CC diagnostic assays for PRO, or for the affinity purification of PRO from
 CC recombinant cell culture or natural sources. This sequence encodes a
 CC novel human PRO polypeptide
 XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 QY 2983 TCTATTACTTTAATGCACATTTATTTATGATTTCTTAATAAATCCAGTCCTTGT 3042
 DB 1272 TTTCTGTATATAAATGTTAATGATTTTATAGGTATTGTAACCTGCCACATACTT 1331
 QY 3043 TTTTATAAAGACATTAAATATATATTTCTCT 3077
 DB 1332 ATTATCTCTCAATTCAATAAATATTATTATCT 1366
 RESULT 51
 ACD19857
 ID ACD19857 standard; cDNA; 1378 BP.
 XX
 AC ACD19857;
 XX
 XX 22-AUG-2003 (first entry)
 DT
 XX Human secreted / transmembrane polypeptide PRO343 cDNA.
 DE
 XX Human; ss: gene; gene therapy; apoptosis; bleeding; tumour; ALS;
 KW synaological disease; hysterectomy; angiogenesis; skin disease; cancer;
 KW coronary ischaemic condition; gastrointestinal mucosa disorder; asthma;
 KW mucosal lesion repair; keratinocyte differentiation; psoriasis;
 KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;
 KW neuropathy; blood coagulation cascade disorder; thrombosis; haemorrhage;

KW neurodegenerative disease; endometrial bleeding; wound healing;
 KW tissue repair; rheumatoid arthritis; multiple sclerosis; tissue typing.
 XX Homo sapiens.
 OS
 XX US2003027143-A1.
 PN
 XX 06-FEB-2003.
 PD
 XX 16-JUL-2001; 2001US-00906838.
 PF
 XX 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059124P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 15-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063542P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063549P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 29-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064509P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-NOV-1997; 97US-0066772P.
 PR 12-DEC-1997; 97US-0066840P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-009803P.
 PR 14-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98US-0100262P.
 PR 16-SEP-1998; 98WO-US019177.
 PR 17-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98US-0100858P.
 PR 13-OCT-1998; 98WO-US019437.
 PR 20-OCT-1998; 98US-0104080P.
 PR 01-DEC-1998; 98US-0109304P.
 PR 01-DEC-1998; 98WO-US025108.

PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065653P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-0069455P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0099803P.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98US-0100262P.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98WO-US025108.
 PR 22-DEC-1998; 98US-0113296P.
 PR 07-JUL-1999; 99US-0143048P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005044.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 30-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-006665350.

(GETH) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX WPI; 2003-765473/72.
 DR P-ESDB; ADB29468.

XX Novel isolated native PRO polypeptide useful for treating Parkinson's
 PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal

PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usher
 PT syndrome.
 PS Claim 2; Fig 97; 469pp: English.
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 and the nucleic acid encoding them. The polypeptides can be used to raise
 antibodies that specifically bind to the PRO polypeptide, for linking a
 bioactive molecule to a cell expressing a PRO protein and for modulating
 at least one biological activity of a cell. PRO polypeptides are useful
 for detecting other PRO polypeptides in a sample and for linking a
 bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 polypeptide antibodies are useful for modulating the biological activity
 of a cell expressing PRO polypeptides. PRO polypeptides are also useful
 for treating disorders associated with the preservation and maintenance
 of gastrointestinal mucosa and the repair of acute and chronic mucosal
 lesions, skin diseases associated with abnormal keratinocyte
 differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's
 diseases, amyotrophic lateral sclerosis (ALS), neuropathies and
 additionally, disease related to uncontrolled cell growth, e.g. cancer.
 PRO polypeptides also serve as tumour specific antigens which may be
 exploited as therapeutic targets for anti-tumour drugs, and are also
 employed therapeutically in vivo for lessening the effects of viral
 infection. The PRO polypeptides can be also used in assays to determine
 if it has a role in neurodegenerative diseases or their reversal, as an
 antithrombotic agent with reduced risk for haemorrhage as compared with
 heparin, in treating other PRO-associated disorders, in modulating
 endometrial bleeding angiogenesis, and may also have an effect on kidney
 tissue. PRO polypeptides and their portions affect the expression of
 genes which have a role in apoptosis. The polynucleotides are useful in
 molecular biology including uses as hybridisation probes for cDNA library
 to isolate the full-length PRO cDNA or to isolate other cDNAs, in
 chromosome and gene mapping, in the generation of antisense RNA and DNA,
 for preparing PRO polypeptides, for generating transgenic animals or
 knockout animals which are useful in the development and screening of
 therapeutically useful reagents, as probes and for the genetic analysis
 of individuals with genetic disorders as well as for recombinantly
 expressing the protein and for chromosome identification. The proteins
 are useful as molecular marker for protein electrophoresis purposes, as
 therapeutic agents, for screening compounds to identify those that mimic
 the PRO polypeptide (agonists) or prevent the effect of the PRO
 polypeptide (antagonists). The polynucleotides and proteins are useful
 for tissue typing. PRO antibodies are useful for immunohistochemical
 staining and/or assay of sample fluids. Anti-PRO antibodies are useful in
 diagnostic assays for PRO e.g. detecting its expression in specific
 cells, tissues or serum and for affinity purification of PRO from
 recombinant cell culture or natural sources. The PRO genes may also be
 used in gene therapy, particularly for replacing a defective gene. The
 sequence presented is a gene encoding a PRO polynucleotide of the
 invention.

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2983 TCTATTTTACTTTAATGACACTATTTTATGATTTTCTAATAAATCAGCTCTGT 3042
 Db 1272 TTTTGTATATAATGTTAATGATTTTATGATTTTCTAATAAATCAGCTCTGT 1331
 Qy 3043 TTTTAAAAAGACITTTAAATTTATTTATTTCTCT 3077
 Db 1332 ATTATTCCTCAATTCATTAATTTATTTCT 1366

RESULT 53

ID ADAL8323 standard; cDNA; 1378 BP.
 XX ADAL8323

AC ADAL8323;
 XX DT 20-NOV-2003 (first entry)

XX	Human secreted/transmembrane protein cDNA, #52.	PR	10-SEP-1998;	98WO-US018824.	XX
DE		PR	14-SEP-1998;	98US-0100262F.	PR
XX		PR	14-SEP-1998;	98WO-US019177.	PR
KW	Human; gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;	PR	16-SEP-1998;	98WO-US019330.	PR
KW	mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;	PR	17-SEP-1998;	98US-0100858P.	PR
KW	Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis;	PR	17-SEP-1998;	98WO-US019437.	PR
KW	ALS; neuropathy; cell growth; cancer; tumour; viral infection;	PR	13-OCT-1998;	98US-0104080P.	PR
KW	neurodegenerative disease; antithrombotic agent; haemorrhage;	PR	20-NOV-1998;	98US-0109104P.	PR
KW	endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;	PR	01-DEC-1998;	98WO-US02510P.	PR
KW	tissue typing; immunohistochemical staining; gene therapy; neotropic;	PR	22-DEC-1998;	98US-0113296P.	PR
XX	neuroprotective; cytostatic; virucide; anticoagulant.	PR	07-JUL-1999;	99US-0143048P.	PR
XX		PR	26-JUL-1999;	99US-0145698P.	PR
OS	Homo sapiens.	PR	28-JUL-1999;	99US-0146222P.	PR
XX		PR	08-SEP-1999;	99WO-US020594.	PR
PN	US2003039971-A1.	PR	13-SEP-1999;	99WO-US020944.	PR
XX		PR	15-SEP-1999;	99WO-US021090.	PR
PD	27-FEB-2003.	PR	05-SEP-1999;	99WO-US021547.	PR
XX		PR	15-OCT-1999;	99WO-US023089.	PR
XX		PR	29-NOV-1999;	99WO-US038214.	PR
XX	16-JUL-2001; 2001US-00906646.	PR	30-NOV-1999;	99WO-US038313.	PR
PR	17-SEP-1997;	PR	01-DEC-1999;	99WO-US048301.	PR
PR	17-SEP-1997;	PR	02-DEC-1999;	99WO-US048564.	PR
PR	17-SEP-1997;	PR	02-DEC-1999;	99WO-US048565.	PR
PR	17-SEP-1997;	PR	16-DEC-1999;	99WO-US030095.	PR
PR	17-SEP-1997;	PR	20-DEC-1999;	99WO-US030911.	PR
PR	17-SEP-1997;	PR	20-DEC-1999;	99WO-US030999.	PR
PR	17-SEP-1997;	PR	05-JAN-2000;	2000WO-US000219.	PR
PR	18-SEP-1997;	PR	11-FEB-2000;	2000WO-US003565.	PR
PR	18-SEP-1997;	PR	22-FEB-2000;	2000WO-US004414.	PR
PR	18-SEP-1997;	PR	24-FEB-2000;	2000WO-US005004.	PR
PR	15-OCT-1997;	PR	02-MAR-2000;	2000WO-US005841.	PR
PR	17-OCT-1997;	PR	20-MAR-2000;	2000WO-US007377.	PR
PR	17-OCT-1997;	PR	30-MAR-2000;	2000WO-US008439.	PR
PR	21-OCT-1997;	PR	22-MAY-2000;	2000WO-US014042.	PR
PR	24-OCT-1997;	PR	02-JUN-2000;	2000WO-US015264.	PR
PR	24-OCT-1997;	PR	28-JUL-2000;	2000WO-US020710.	PR
PR	24-OCT-1997;	PR	24-AUG-2000;	2000WO-US023328.	PR
PR	24-OCT-1997;	PR	18-SEP-2000;	2000US-00665350.	PR
PR	24-OCT-1997;	XX			XX
PR	24-OCT-1997;	PA	(GETH) GENENTECH INC.		PA
PR	24-OCT-1997;	XX			XX
PR	27-OCT-1997;	PI	Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;		PI
PR	28-OCT-1997;	PI	Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;		PI
PR	28-OCT-1997;	PI	GoGowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;		PI
PR	28-OCT-1997;	PI	Mather JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tunas D;		PI
PR	28-OCT-1997;	PI	Williams PM, Wood WI;		PI
PR	28-OCT-1997;	XX			XX
PR	28-OCT-1997;	DR	WPI; 2003-503392/47.		DR
PR	28-OCT-1997;	DR	P-PSDE; ADA18324.		DR
PR	29-OCT-1997;	XX			XX
PR	29-OCT-1997;	PT	New secreted and transmembrane polypeptides useful for treating skin,		PT
PR	29-OCT-1997;	PT	neurodegenerative diseases, asthma, rheumatoid arthritis, psoriasis and		PT
PR	29-OCT-1997;	PT	multiple sclerosis.		PT
PR	29-OCT-1997;	XX			XX
PR	29-OCT-1997;	XX	Claim 2; SEQ ID NO 262; 471pp; English.		XX
PR	31-OCT-1997;	XX			XX
PR	31-OCT-1997;	XX	The invention discloses isolated PRO secreted/transmembrane polypeptides		XX
PR	31-OCT-1997;	CC	and the nucleic acid encoding them. The polypeptides can be used to raise		CC
PR	03-NOV-1997;	CC	antibodies that specifically bind to the PRO polypeptide, for linking a		CC
PR	03-NOV-1997;	CC	bioactive molecule to a cell expressing a PRO protein and for modulating		CC
PR	12-NOV-1997;	CC	at least one biological activity of a cell. PRO polypeptides are useful		CC
PR	17-NOV-1997;	CC	for detecting other PRO polypeptides in a sample and for linking a		CC
PR	18-NOV-1997;	CC	bioactive molecule to a cell expressing a PRO polypeptide. The PRO		CC
PR	21-NOV-1997;	CC	polypeptide antibodies are useful for modulating the biological activity		CC
PR	21-NOV-1997;	CC	of a cell expressing PRO polypeptides. PRO polypeptides are also useful		CC
PR	24-NOV-1997;	CC	for treating disorders associated with the preservation and maintenance		CC
PR	24-NOV-1997;	CC	of gastrointestinal mucosa and the repair of acute and chronic mucosal		CC
PR	24-NOV-1997;	CC	lesions, skin diseases associated with abnormal keratinocyte		CC
PR	24-NOV-1997;	CC	differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's		CC
PR	25-NOV-1997;	CC	diseases, amyotrophic lateral sclerosis (ALS), neuropathies and		CC
PR	25-NOV-1997;	CC	additionally, disease related to uncontrolled cell growth, e.g. cancer.		CC
PR	12-DEC-1997;	CC	PRO polypeptides also serves as tumour specific antigens which may be		CC
PR	04-JUN-1998;	CC	exploited as therapeutic targets for anti-tumour drugs, and are also		CC
PR	10-SEP-1998;	CC			CC

CC employed therapeutically in vivo for lessening the effects of viral
 CC infection. The PRO polypeptides can be also used in assays to determine
 CC if it has a role in neurodegenerative diseases or their reversal, as an
 CC antithrombotic agent with reduced risk for haemorrhage as compared with
 CC heparin, in treating other PRO-associated disorders, in modulating
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney
 CC tissue. PRO polypeptides and their portions affect the expression of
 CC genes which have a role in apoptosis. The polynucleotides are useful in
 CC molecular biology including uses as hybridisation probes for cDNA library
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs in
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
 CC for preparing PRO polypeptides, for generating transgenic animals or
 CC knockout animals which are useful in the development and screening of
 CC therapeutically useful reagents, as probes and for the genetic analysis
 CC of individuals with genetic disorders as well as for recombinantly
 CC expressing the protein and for chromosome identification. The proteins
 CC are useful as molecular marker for protein electrophoresis purposes, as
 CC therapeutic agents, (agonists) or screening compounds to identify those that mimic
 CC the PRO polypeptide, (agonists) or prevent the effect of the PRO
 CC polypeptide (antagonists). The polynucleotides and proteins are useful
 CC for tissue typing. PRO antibodies are useful for immunohistochemical
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in
 CC diagnostic assays for PRO e.g. detecting its expression in specific
 CC cells, tissues or serum and for affinity purification of PRO from
 CC recombinant cell culture or natural sources. The PRO genes may also be
 CC used in gene therapy, particularly for replacing a defective gene. The
 CC sequence presented is a gene encoding a PRO polynucleotide of the
 CC invention.

XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;

Best Local Similarity 53.7%; Pred. No. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTACTTTAATTCGACTTATTTTATTTATTTTCTATAAATCCAGTCCTTCT 3042
 Db 1272 TTTTGTATATAAATGTAATGATTTTATAGTATTTGTAACCTGCCCCATATCTT 1331
 OY 3043 TTTTAAAAAGACTTTAAATATTATTTCTCT 3077
 Db 1332 ATTATTCCTCAATTCATAAATATTATTTCT 1366

RESULT 54

ACD67004 ID ACD67004 standard; cDNA; 1378 BP.

XX AC ACD67004;

XX XE 17-SEP-2003 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein PRO343.

XX XX Human; ss; gene; PRO; secreted and transmembrane protein; inflammation;
 KW rheumatoid arthritis; psoriasis; multiple sclerosis; atherosclerosis;
 KW infertility; birth defect; premature aging; malignancy; cancer; stroke;
 KW heart attack; hypertension; gastrointestinal ulceration;
 KW Parkinson's disease; Alzheimer's disease; AIDS; cholesterol uptake;
 KW wound healing; tissue repair; gene therapy.

XX OS Homo sapiens.

XX XX US2003045693-A1.

XX PN 06-MAR-2003.

XX PD 11-JUL-2001; 2001US-00903749.

XX PF 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059115P.

XX PR 17-SEP-1997; 97US-0059117P.

XX PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 15-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 24-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063412P.
 PR 28-OCT-1997; 97US-0063542P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063549P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063722P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0099803P.
 PR 14-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98US-0100262P.
 PR 16-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-010304P.
 PR 01-DEC-1998; 98WO-US025108.
 PR 22-DEC-1998; 98US-0113296P.
 PR 07-JUL-1999; 98US-0143048P.
 PR 26-JUL-1999; 98US-0145698P.
 PR 28-JUL-1999; 98US-0145222P.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 01-DEC-1999; 98WO-US028301.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030055.

PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00665350.
 XX (GETH) GENENTECH INC.
 XX PA
 XX PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PZ Pilvaroff B, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kilavin DJ;
 PI Mather JP, Pan J, Faoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WJ;
 XX WPI; 2003-512316/48.
 DR P-PSDB; ABO32803.
 DR XX
 XX PT New genes and secreted and transmembrane polypeptides (e.g. PRO245 or
 PT PRO1868), useful for treating or diagnosing e.g. cancers, atherosclerosis, infertility, stroke, AIDS or multiple sclerosis in
 PT mammals.
 PT XX
 PS Claim 2; Fig 97; 476pp; English.
 XX CC The invention relates to an isolated nucleic acid molecule comprising a
 CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
 CC 61 PRO (secreted and transmembrane protein) polypeptides appearing as
 CC ABO32786-ABO32816; or (b) any of 61 nucleotide sequences having 50-405bp
 CC fully defined in the specification; or the full length coding sequence of
 CC any these 61 nucleotide sequences. Also included are the isolated PRO
 CC polypeptide (lacking its associated signal peptide or an extracellular
 CC domain of the PRO polypeptide, with or lacking its associated signal
 CC peptide), a vector comprising the nucleic acid molecule, a host cell
 CC comprising the vector (used to produce the PRO polypeptide), a chimeric
 CC molecule comprising the PRO polypeptide fused to a heterologous amino
 CC acid sequence, an anti-PRO antibody, detecting PRO245 or PRO1868
 CC polypeptide in a sample suspected of containing any of these PRO
 CC polypeptides, linking a bioactive molecule to a cell expressing a PRO245
 CC or PRO1868 polypeptide and modulating at least one biological activity of
 CC a cell expressing the PRO245 or PRO1868 polypeptide. The PRO polypeptides
 CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
 CC or bioreactors. These are particularly useful for diagnosing or treating
 CC e.g. inflammations, rheumatoid arthritis, psoriasis, multiple sclerosis,
 CC atherosclerosis, infertility, birth defects, premature aging, malignancy
 CC (e.g. cancers), strokes, heart attacks, hypertension, gastrointestinal
 CC ulcerations, Parkinson's diseases, Alzheimer's disease, or AIDS in
 CC mammals. These are also useful for modulating cholesterol uptake in the
 CC body, and in wound healing or tissue repair. The PRO polypeptides are
 CC useful in drug screening. The PRO polypeptides are also useful as
 CC molecular weight markers, or for chromosome identification. The PRO genes
 CC are useful as hybridisation probes, or for screening libraries of human
 CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
 CC therapy, particularly for replacing a defective gene. The present
 CC sequence is a cDNA encoding a PRO polypeptide
 XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 QY 2983 TCTATTTACTTATTCACCTATTTTATTTGATTTTCTATTAATAAATCCAGTCCTCT 3042
 DB 1272 TTTTGTGATATAAATGTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331

QY 3043 TTTTAAAGAGACTTTAAATTAATTAATTTCTCT 3077
 DB 1332 ATTATTCCTCCAATTTCAATAAATTTATTTCT 1366
 RESULT 55
 ACD83165
 ID ACD83165 standard; cDNA; 1378 BP.
 XX ACD83165;
 AC ACD83165;
 XX DT 22-SEP-2003 (first entry)
 XX DE Human PRO polynucleotide #48.
 XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
 KW abnormal bleeding; gynaecological disease; hysterectomy; mucosal lesion;
 KW coronary ischaemic condition; gastrointestinal mucosa; skin disease; ALS;
 KW keratinocyte differentiation; psoriasis; Parkinson's disease; asthma;
 KW Alzheimer's disease; rheumatoid arthritis; multiple sclerosis; cancer;
 KW amyotrophic lateral sclerosis; neuropathy; uncontrolled cell growth.
 XX OS Homo sapiens.
 XX PN US2003044793-A1.
 XX PD 06-MAR-2003.
 XX PF 11-JUL-2001; 2001US-00903786.
 XX PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 15-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 24-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063341P.
 PR 28-OCT-1997; 97US-0063342P.
 PR 28-OCT-1997; 97US-0063344P.
 PR 28-OCT-1997; 97US-0063349P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Filvaroff E, Forst S, Gao W, Gerber H, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ, Macher JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D, Williams PM, Wood WI, WPI; 2003-521801/49. P-PSDS; ADA16299. XX New genes encoding for secreted and transmembrane PRO polypeptides, useful for treating e.g. cardiac insufficiency disorders, wounds, cancers, obesity, diabetes, hyperinsulinemia, hypoinsulinemia, or arthritis. PS Claim 2; SEQ ID NO 262; 476pp; English. XX The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing C-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinemia, hypoinsulinemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a gene encoding a PRO polynucleotide of the invention. SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other; Query Match 0.7%; Score 24.6; DB 1; Length 1378; Best Local Similarity 53.7%; Pred. No. 26; Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0; QY 2983 TCTATTTTACTTTTAAATCCACTTTATTTTATTTGATTTTCTAATAAATCCAGTCTCT 3042 DB 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGTATTTTGACCTGCCCATATCTT 1331 QY 3043 TTTTAAAAAGACTTTAAATTAATTTCTCT 3077 DB 1332 ATTTATTCCTCCAAATTTCAATAAATTTATTTCT 1366

(GETH) GENENTECH INC.,

polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. PRO polypeptides are also useful for treating disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions, skin diseases associated with abnormal keratinocyte differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's diseases, amyotrophic lateral sclerosis (ALS), neuropathies and, additionally, disease related to uncontrolled cell growth, e.g. cancer. PRO polypeptides also serve as tumour specific antigens which may be exploited as therapeutic targets for anti-tumour drugs, and are also employed therapeutically in vivo for lessening the effects of viral infection. The PRO polypeptides can be also used in assays to determine if it has a role in neurodegenerative diseases or their reversal, as an antithrombotic agent with reduced risk for haemorrhage as compared with heparin, in treating other PRO-associated disorders, in modulating endometrial bleeding angiogenesis, and may also have an effect on kidney tissue. PRO polypeptides and their portions affect the expression of genes which have a role in apoptosis. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a gene encoding a PRO polynucleotide of the invention.

Sequence 1378 BP; 235 A; 451 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTCACCTTAAATGCACTTATTTTATTTGATTTTCTTAATAAATCCAGTCTCTGT 3042
DB 1272 TTTTGTATATAATGTTATGATTTTATAGGTATTTGACCTGCGCCATATCTT 1331
QY 3043 TTTTAAAGACCTTAAATTAATTAATTTCTCT 3077
DB 1332 ATTTATCTCCAAATTCATAAATATTATTATCT 1366

RESULT 58

ACD23343
ID ACD23343 standard; cDNA; 1378 BP.

XX ACD23343;

XX ACD23343;

XX 26-AUG-2003 (first entry)

XX Human PRO polynucleotide #48.

XX Human; PRO; gene; ss; Parkinson's disease; Alzheimer's disease; ALS;
XX amyotrophic lateral sclerosis; neuropathy; cancer; viral infection; AIDS;
XX Usher's syndrome; haemorrhage; enterocolitis; Zollinger-Ellison syndrome;
XX gastrointestinal ulceration; congenital microvillus atrophy; psoriasis;
XX skin disease; endometrial bleeding; angiogenesis; ischaemic condition;
XX asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disease;
XX atherosclerosis; infertility; birth defect; premature aging; stroke;
XX diabetic complication.

OS Homo sapiens.
XX US2003064367-A1.
XX 03-APR-2003.
XX 13-JUL-2001; 2001US-00904485.
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 24-OCT-1997; 97US-0063127P.
XX 24-OCT-1997; 97US-0063128P.
XX 27-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063542P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063549P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063435P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063732P.
XX 29-OCT-1997; 97US-0063734P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 29-OCT-1997; 97US-0064215P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065246P.
XX 18-NOV-1997; 97US-0065533P.
XX 21-NOV-1997; 97US-0066120P.
XX 21-NOV-1997; 97US-0066364P.
XX 24-NOV-1997; 97US-0066453P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066511P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-NOV-1997; 97US-0066772P.
XX 25-NOV-1997; 97US-0066840P.
XX 12-DEC-1997; 97US-0069425P.
XX 04-JUN-1998; 98US-0088026P.
XX 10-SEP-1998; 98US-0099803P.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98US-0100262P.
XX 16-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98US-0100598P.
XX 17-SEP-1998; 98WO-US019437.
XX 13-OCT-1998; 98US-0104080P.
XX 20-NOV-1998; 98US-0109304P.
XX 01-DEC-1998; 98WO-US025108.
XX 22-DEC-1998; 98US-0113296P.
XX 07-JUL-1999; 99US-0143048P.
XX 26-JUL-1999; 99US-0145698P.

PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99NO-US020594.
 PR 13-SEP-1999; 99NO-US020594.
 PR 15-SEP-1999; 99NO-US021090.
 PR 15-SEP-1999; 99NO-US021547.
 PR 05-OCT-1999; 99NO-US023089.
 PR 29-NOV-1999; 99NO-US028214.
 PR 30-NOV-1999; 99NO-US028313.
 PR 01-DEC-1999; 99NO-US028301.
 PR 02-DEC-1999; 99NO-US028564.
 PR 02-DEC-1999; 99NO-US028565.
 PR 16-DEC-1999; 99NO-US030095.
 PR 20-DEC-1999; 99NO-US030911.
 PR 05-JAN-2000; 99NO-US030999.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-0065350.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WJ;
 XX
 XX WPI; 2003-567176/53.
 DR P-PSDB; ABO17541.
 XX
 PT Novel isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for
 PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic
 PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.
 XX
 PS Claim 2; Fig 97; 477pp; English.
 XX
 CC The invention relates to human PRO polypeptides and the polynucleotides
 CC encoding them. The polypeptides and polynucleotides are used for treating
 CC diseases related to growth or survival of nerve cells such as Parkinson's
 CC disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and
 CC neuropathies, diseases related to uncontrolled cell growth such as
 CC cancer, viral infections, Usher's syndrome, haemorrhage, enterocolitis,
 CC Zollinger-Ellison syndrome, gastrointestinal ulceration, congenital
 CC macrovillus atrophy, skin diseases such as psoriasis and epithelial
 CC cancers, endometrial bleeding, angiogenesis, ischaemic conditions,
 CC asthma, rheumatoid arthritis, multiple sclerosis, inflammatory diseases,
 CC atherosclerosis, cardiac injury, infertility, birth defects, premature
 CC aging, AIDS, stroke and diabetic complications. The polynucleotides are
 CC also useful in chromosome and gene mapping. This sequence represents a
 CC human PRO polynucleotide of the invention
 XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 QY 2983 TCTATTACTTAACTGACCTATTTTATTGATTTTCTTAAATAAATCCAGTCCTTGT 3042
 DB 1272 TTTTGTGATATAATGTAATGATTTTATGATTTTGTACCTGCCACATATCTT 1331
 QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTT 3077
 DB 1332 ATTTATCTCCTCAATTTCAATAAATTAATTTCTT 1366

RESULT 59
 ADA16722
 ID ADA16722 standard; cDNA; 1378 BP.
 XX
 AC ADA16722;
 XX
 DT 06-NOV-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein cDNA, #52.
 XX
 KW Human; Gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;
 KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;
 KW Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis;
 KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;
 KW neurodegenerative disease; antithrombotic agent; haemorrhage;
 KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy; nontropic;
 KW neuroprotective; cytostatic; virucide; anticoagulant.
 XX
 OS Homo sapiens.
 XX
 PN US2003039969-A1.
 XX
 PD 27-FEB-2003.
 XX
 PF 12-JUL-2001; 2001US-00904786.
 XX
 PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 15-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 27-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063341P.
 PR 28-OCT-1997; 97US-0063342P.
 PR 28-OCT-1997; 97US-0063344P.
 PR 28-OCT-1997; 97US-0063349P.
 PR 28-OCT-1997; 97US-0063500P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 31-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 03-NOV-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064609P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-00655846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.

24-NOV-1997; 97US-00665456P.
24-NOV-1997; 97US-0066511P.
24-NOV-1997; 97US-0066770P.
24-NOV-1997; 97US-0066772P.
25-NOV-1997; 97US-0066840P.
12-DEC-1997; 97US-0069445P.
04-JUN-1998; 98US-0088026P.
10-SEP-1998; 98US-0099803P.
10-SEP-1998; 98MO-US018824.
14-SEP-1998; 98US-0100262P.
14-SEP-1998; 98MO-US019177.
16-SEP-1998; 98MO-US019330.
17-SEP-1998; 98US-0100858P.
17-SEP-1998; 98MO-US019437.
13-OCT-1998; 98US-0104080P.
20-NOV-1998; 98US-0109304P.
01-DEC-1998; 98MO-US025108.
22-DEC-1998; 98US-0112396P.
27-JUL-1999; 99US-0143048P.
26-JUL-1999; 99US-0145698P.
08-SEP-1999; 99US-0146222P.
15-SEP-1999; 99MO-US020594.
15-SEP-1999; 99MO-US021090.
15-SEP-1999; 99MO-US021547.
05-OCT-1999; 99MO-US023089.
29-NOV-1999; 99MO-US028214.
30-NOV-1999; 99MO-US028313.
01-DEC-1999; 99MO-US028301.
02-DEC-1999; 99MO-US028564.
02-DEC-1999; 99MO-US028565.
16-DEC-1999; 99MO-US030095.
20-DEC-1999; 99MO-US020944.
20-DEC-1999; 99MO-US030911.
20-DEC-1999; 99MO-US030999.
05-JAN-2000; 2000MO-US000219.
11-FEB-2000; 2000MO-US003565.
22-FEB-2000; 2000MO-US004414.
24-FEB-2000; 2000MO-US005004.
02-MAR-2000; 2000MO-US005841.
30-MAR-2000; 2000MO-US007377.
22-MAY-2000; 2000MO-US008439.
02-JUN-2000; 2000MO-US014042.
28-JUL-2000; 2000MO-US015264.
24-AUG-2000; 2000MO-US020710.
18-SEP-2000; 2000MO-US023328.
18-SEP-2000; 2000US-00665350.
PA (GETH) GENENTECH INC.
XX
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI. 2003-503391/47.
DR P-PSDB; ADA16723.
XX
XX
XX New secreted and transmembrane PRO polypeptides e.g. PRO187, which is a
PT member of the epidermal growth factor-8 (EGF-8) family of proteins,
PT useful for treating cancer.
XX
XX Claim 2; SEQ ID NO 262; 471pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful

CC for treating disorders associated with the preservation and maintenance
CC of gastrointestinal mucosa and the repair of acute and chronic
CC lesions, skin diseases associated with abnormal keratinocyte
CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's
CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and
CC additionally, disease related to uncontrolled cell growth, e.g. cancer.
CC PRO polypeptides also serves as tumour specific antigens which may be
CC exploited as therapeutic targets for anti-tumour drugs, and are also
CC employed therapeutically in vivo for lessening the effects of viral
CC infection. The PRO polypeptides can be also used in assays to determine
CC if it has a role in neurodegenerative diseases or their reversal, as an
CC antithrombotic agent with reduced risk for haemorrhage as compared with
CC heparin, in treating other PRO-associated disorders, in modulating
CC endometrial bleeding angiogenesis, and may also have an effect on kidney
CC tissue. PRO polypeptides and their portions affect the expression of
CC genes which have a role in apoptosis. The polynucleotides are useful in
CC molecular biology including uses as hybridisation probes for cDNA library
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC for preparing PRO polypeptides, for generating transgenic animals or
CC knockout animals which are useful in the development and screening of
CC therapeutically useful reagents, as probes and for the genetic analysis
CC of individuals with genetic disorders as well as for recombinantly
CC expressing the protein and for chromosome identification. The proteins
CC are useful as molecular marker for protein electrophoresis purposes, as
CC therapeutic agents, for screening compounds to identify those that mimic
CC the PRO polypeptide (agonists) or prevent the effect of the PRO
CC polypeptide (antagonists). The polynucleotides and proteins are useful
CC for tissue typing. PRO antibodies are useful for immunohistochemical
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in
CC diagnostic assays for PRO e.g. detecting its expression in specific
CC cells, tissues or serum and for affinity purification of PRO from
CC recombinant cell culture or natural sources. The PRO genes may also be
CC used in gene therapy, particularly for replacing a defective gene. The
CC sequence presented is a gene encoding a PRO polynucleotide of the
CC invention.
XX
XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;

Best Local Similarity 53.7%; Pred. No. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTTAATTCGACTTATTTTATTCGATTTTCTAATAAATCCAGTCCTTGT 3042

Db 1272 TTTCGTATATAAAGTTAATGATTTTATAGGTATTTGTAACCCGCCACATATCTT 1331

QY 3043 TTTTAAAAAGACITTTAAATATATATTTCTCT 3077

Db 1332 ATTATTCCTCAATTTCAATAAATTTATTTATCT 1366

RESULT 60

ADAL13151
ID ADA13151 standard; cDNA; 1378 BP.

XX AC ADA13151;

XX DT 06-NOV-2003 (first entry)

XX DE Human secreted/transmembrane protein cDNA, #52.

XX KW Human; gene: ss; PRO; secreted; transmembrane; gastrointestinal mucosa;
KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;
KW Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis;
KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;
KW neurodegenerative disease; antithrombotic agent; haemorrhage;
KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy; neurotropic;
KW neuroprotective; cytostatic; virucide; anticoagulant.

XX OS Homo sapiens.

XX

PR 24-AUG-2000; 2000WO-US023328.
FR 18-SEP-2000; 2000US-00665350.
XX (GETH) GENENTECH INC.
PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Garber H, Gritzstein ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Klijavin IG;
PI Mather JP, Pan J, Paoni NF, Roy WA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2003-755103/71.
DR P-PSDB; ADA42020.
DR
XX
XX New PRO polypeptides useful for treating Parkinson's disease,
PT enterocolitis, Zollinger-Ellison syndrome gastrointestinal ulceration,
PT Alzheimer's disease, amyotrophic lateral sclerosis and Usher syndrome.
XX
XX Claim 2; SEQ ID NO 262; 469pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful
CC for treating disorders associated with the preservation and maintenance
CC of gastrointestinal mucosa and the repair of acute and chronic mucosal
CC lesions, skin diseases associated with abnormal keratinocyte
CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's
CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and
CC additionally, disease related to uncontrolled cell growth, e.g. cancer.
CC PRO polypeptides also serve as tumour specific antigens which may be
CC exploited as therapeutic targets for anti-tumour drugs, and are also
CC employed therapeutically in vivo for lessening the effects of viral
CC infection. The PRO polypeptides can be also used in assays to determine
CC if it has a role in neurodegenerative diseases or their reversal, as an
CC antithrombotic agent with reduced risk for haemorrhage as compared with
CC heparin, in treating other PRO-associated disorders, in modulating
CC endometrial bleeding angiogenesis, and may also have an effect on kidney
CC tissue. PRO polypeptides and their portions affect the expression of
CC genes which have a role in apoptosis. The polynucleotides are useful in
CC molecular biology including uses as hybridisation probes for cDNA library
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC for preparing PRO polypeptides, for generating transgenic animals or
CC knockout animals which are useful in the development and screening of
CC therapeutically useful reagents, as probes and for the genetic analysis
CC of individuals with genetic disorders as well as for recombinantly
CC expressing the protein and for chromosome identification. The proteins
CC are useful as molecular marker for protein electrophoresis purposes, as
CC therapeutic agents, for screening compounds to identify those that mimic
CC the PRO polypeptide (agonists) or prevent the effect of the PRO
CC polypeptide (antagonists). The polynucleotides and proteins are useful
CC for tissue typing. PRO antibodies are useful for immunohistochemical
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in
CC diagnostic assays for PRO e.g. detecting its expression in specific
CC cells, tissues or serum and for affinity purification of PRO from
CC recombinant cell culture or natural sources. The PRO genes may also be
CC used in gene therapy, particularly for replacing a defective gene. The
CC sequence presented is a gene encoding a PRO polynucleotide of the
CC invention.
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred.No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTTTACCTTAATGACCTATTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042

Db 1272 TTTTGTGTATATAAGCTTAATGATTTTATAGTATTGTAACCTGCCACATATCTT 1331
OY 3043 TTTTAAAAAGACTTTAAAAATTATTAAATTTCTCT 3077
Db 1332 ATTATTCCTCCCAATTTCAATAAATTTATTATTTCT 1366
RESULT 62
ADA17366
ID ADA17366 standard; cDNA; 1378 BP.
XX
AC ADA17366;
XX
XX 20-NOV-2003 (first entry)
XX Human secreted/transmembrane protein cDNA, #52.
XX
XX Human; Gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;
KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;
KW Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis;
KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;
KW neurodegenerative disease; antithrombotic agent; haemorrhage;
KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy; neurotropic;
KW neuroprotective; cytostatic; virucide; anticoagulant.
XX
OS Homo sapiens.
XX
XX US2003017498-A1.
XX
XX 23-JAN-2003.
XX
XX 17-JUL-2001; 2001US-00908093.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 17-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062314P.
PR 24-OCT-1997; 97US-0062316P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063341P.
PR 28-OCT-1997; 97US-0063342P.
PR 28-OCT-1997; 97US-0063344P.
PR 28-OCT-1997; 97US-0063349P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063722P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065984P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066433P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-NOV-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0066840P.
PR 04-JUN-1998; 98US-0069425P.
PR 10-SEP-1998; 98US-0088036P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0100824P.
PR 14-SEP-1998; 98US-0100826P.
PR 16-SEP-1998; 98US-0100827P.
PR 17-SEP-1998; 98US-0100830P.
PR 17-SEP-1998; 98US-0100838P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0105304P.
PR 01-DEC-1998; 98US-0105308P.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99US-0200594P.
PR 13-SEP-1999; 99US-0200944P.
PR 15-SEP-1999; 99US-0201030P.
PR 15-SEP-1999; 99US-0201547P.
PR 05-OCT-1999; 99US-0203089P.
PR 29-NOV-1999; 99US-0208214P.
PR 30-NOV-1999; 99US-0208313P.
PR 01-DEC-1999; 99US-0208301P.
PR 01-DEC-1999; 99US-0208304P.
PR 02-DEC-1999; 99US-0208565P.
PR 16-DEC-1999; 99US-0208565P.
PR 20-DEC-1999; 99US-0208565P.
PR 20-DEC-1999; 99US-0208565P.
PR 05-JAN-2000; 2000US-0000219P.
PR 11-FEB-2000; 2000US-0000414P.
PR 22-FEB-2000; 2000US-0000414P.
PR 24-FEB-2000; 2000US-0000504P.
PR 20-MAR-2000; 2000US-0000584P.
PR 30-MAR-2000; 2000US-0000737P.
PR 22-MAY-2000; 2000US-0000843P.
PR 02-JUN-2000; 2000US-0015264P.
PR 28-JUL-2000; 2000US-0020710P.
PR 24-AUG-2000; 2000US-0023328P.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WT;
XX
XX WPI; 2003-531434/50.
DR P-PSDB; ADA17367.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or
PT PRO3868, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; SEQ ID NO 262; 475pp; English.
PS The invention discloses isolated PRO secreted/transmembrane polypeptides
XX and the nucleic acid encoding them. The polypeptides can be used to raise
CC

CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful
CC for treating disorders associated with the preservation and maintenance
CC of gastrointestinal mucosa and the repair of acute and chronic mucosal
CC lesions, skin diseases associated with abnormal keratinocyte
CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's
CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and
CC additionally, disease related to uncontrolled cell growth, e.g. cancer.
CC PRO polypeptides also serves as tumour specific antigens which may be
CC exploited as therapeutic targets for anti-tumour drugs and are also
CC employed therapeutically in vivo for lessening the effects of viral
CC infection. The PRO polypeptides can be also used in assays to determine
CC if it has a role in neurodegenerative diseases or their reversal, as an
CC antithrombotic agent with reduced risk for haemorrhage as compared with
CC heparin, in treating other PRO-associated disorders, in modulating
CC endometrial bleeding angiogenesis, and may also have an effect on kidney
CC tissue. PRO polypeptides and their portions affect the expression of
CC genes which have a role in apoptosis. The polynucleotides are useful in
CC molecular biology including uses as hybridisation probes for cDNA library
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC for preparing PRO polypeptides, for generating transgenic animals or
CC knockout animals which are useful in the development and screening of
CC therapeutically useful reagents, as probes and for the genetic analysis
CC of individuals with genetic disorders as well as for recombinantly
CC expressing the protein and for chromosome identification. The proteins
CC are useful as molecular marker for protein electrophoresis purposes, as
CC therapeutic agents, for screening compounds to identify those that mimic
CC the PRO polypeptide (agonists) or prevent the effect of the PRO
CC polypeptide (antagonists). The polynucleotides and proteins are useful
CC for tissue typing. PRO antibodies are useful for immunohistochemical
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in
CC diagnostic assays for PRO e.g. detecting its expression in specific
CC cells, tissues or serum and for affinity purification of PRO from
CC recombinant cell culture or natural sources. The PRO genes may also be
CC used in gene therapy, particularly for replacing a defective gene. The
CC sequence presented is a gene encoding a PRO polynucleotide of the
XX invention.

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.78; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.78; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAAATGCGACTTTATTTTATTTGATTTTCTAATAAAATCCAGTCCTCT 3042
Db 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGGTATTTGTAACCCCTGCCACATATCT 1331

QY 3043 TTTTAAAAGACTTTAAATTTATTAATTTCTCT 3077

Db 1332 ATTATTCCTCCCAATTTCAATAAATTTATTTCT 1366

RESULT 63

ADA42869

ID ADA42869 standard; cDNA; 1378 BP.

XX ADA42869;

XX ADA42869;

XX 20-NOV-2003 (first entry)

XX Human secreted/transmembrane protein cDNA, #52.

XX Human; gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;
KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;
KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;
KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;

neurodegenerative disease; antithrombotic agent; haemorrhage;
endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;
tissue typing; immunohistochemical staining; gene therapy; nootropic;
neuroprotective; cytostatic; virucide; anticoagulant.

Homo sapiens.
US2003054351-A1.
20-MAR-2003.

13-JUL-2001; 2001US-00904462.
17-SEP-1997; 97US-0059113P.
17-SEP-1997; 97US-0059115P.
17-SEP-1997; 97US-0059117P.
17-SEP-1997; 97US-0059119P.
17-SEP-1997; 97US-0059121P.
17-SEP-1997; 97US-0059123P.
17-SEP-1997; 97US-0059184P.
18-SEP-1997; 97US-0059263P.
18-SEP-1997; 97US-0059266P.
15-OCT-1997; 97US-0062125P.
17-OCT-1997; 97US-0062288P.
17-OCT-1997; 97US-0062289P.
21-OCT-1997; 97US-0063486P.
24-OCT-1997; 97US-0062814P.
24-OCT-1997; 97US-0063045P.
24-OCT-1997; 97US-0063120P.
24-OCT-1997; 97US-0063121P.
24-OCT-1997; 97US-0063127P.
27-OCT-1997; 97US-0063327P.
27-OCT-1997; 97US-0063329P.
28-OCT-1997; 97US-0063544P.
28-OCT-1997; 97US-0063545P.
28-OCT-1997; 97US-0063546P.
28-OCT-1997; 97US-0063549P.
28-OCT-1997; 97US-0063550P.
28-OCT-1997; 97US-0063556P.
29-OCT-1997; 97US-0063435P.
29-OCT-1997; 97US-0063704P.
29-OCT-1997; 97US-0063732P.
29-OCT-1997; 97US-0063734P.
29-OCT-1997; 97US-0063735P.
29-OCT-1997; 97US-0063738P.
29-OCT-1997; 97US-0064215P.
31-OCT-1997; 97US-0063870P.
31-OCT-1997; 97US-0064103P.
03-NOV-1997; 97US-0064248P.
07-NOV-1997; 97US-0064809P.
12-NOV-1997; 97US-0065186P.
17-NOV-1997; 97US-0065846P.
18-NOV-1997; 97US-0065693P.
21-NOV-1997; 97US-0066120P.
21-NOV-1997; 97US-0066364P.
24-NOV-1997; 97US-0066453P.
24-NOV-1997; 97US-0066469P.
24-NOV-1997; 97US-0066511P.
24-NOV-1997; 97US-0066770P.
24-NOV-1997; 97US-0066772P.
25-NOV-1997; 97US-0066840P.
12-DEC-1997; 97US-0069425P.
04-JUN-1998; 98US-0088026P.
10-SEP-1998; 98US-0098033P.
10-SEP-1998; 98WO-US018824.
14-SEP-1998; 98US-0100262P.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98US-0100859P.
17-SEP-1998; 98WO-US019437.
13-OCT-1998; 98US-0104080P.

20-NOV-1998; 98US-0109304P.
01-DEC-1998; 98WO-US025108.
22-DEC-1998; 98US-0113296P.
07-JUL-1999; 99US-0143048P.
26-JUL-1999; 99US-0145698P.
28-JUL-1999; 99US-0146222P.
08-SEP-1999; 99WO-US020594.
13-SEP-1999; 99WO-US020944.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
01-DEC-1999; 99WO-US028301.
02-DEC-1999; 99WO-US028564.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030399.
05-JAN-2000; 2000WO-US000219.
11-FEB-2000; 2000WO-US003565.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US005004.
02-MAR-2000; 2000WO-US005941.
20-MAR-2000; 2000WO-US007377.
30-MAR-2000; 2000WO-US008439.
22-MAY-2000; 2000WO-US014042.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
24-AUG-2000; 2000WO-US023328.
18-SEP-2000; 2000US-00665350.

(GETH) GENENTECH INC.

Askenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,
Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ;
Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
Williams PM, Wood WI;
WPI; 2003-755052/71.
P-PSDB; ADA2870.

Novel isolated secreted and transmembrane PRO polypeptide, useful for
tissue typing, treating Parkinson's disease, Alzheimer's disease, birth
defects, cancer.

Claim 2; SEQ ID NO 262; 464pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides
and the nucleic acid encoding them. The polypeptides can be used to raise
antibodies that specifically bind to the PRO polypeptide, for linking a
biactive molecule to a cell expressing a PRO protein and for modulating
at least one biological activity of a cell. PRO polypeptides are useful
for detecting other PRO polypeptides in a sample and for linking a
biactive molecule to a cell expressing a PRO polypeptide. The PRO
polypeptide antibodies are useful for modulating the biological activity
of a cell expressing PRO polypeptides. PRO polypeptides are also useful
for treating disorders associated with the preservation and maintenance
of gastrointestinal mucosa and the repair of acute and chronic mucosal
lesions, skin diseases associated with abnormal keratinocyte
differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's
disease, amyotrophic lateral sclerosis (ALS), neuropathies and
additionally, disease related to uncontrolled cell growth, e.g. cancer.
PRO polypeptides also serve as tumour specific antigens which may be
exploited as therapeutic targets for anti-tumour drugs, and are also
employed therapeutically in vivo for lessening the effects of viral
infection. The PRO polypeptides can be also used in assays to determine
if it has a role in neurodegenerative diseases or their reversal, as an
antithrombotic agent with reduced risk for haemorrhage as compared with
heparin, in treating other PRO-associated disorders, in modulating
endometrial bleeding angiogenesis, and may also have an effect on kidney
tissue. PRO polypeptides and their portions affect the expression of

PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00665350.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PO, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WJ;
 XX
 DR WPI; 2003-567190/53.
 DR P-PSDB; ABO17602.
 XX
 PT Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers.
 XX
 PS Claim 2; Fig 97; 471pp; English.
 XX
 CC The invention relates to human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC polypeptides are useful for detecting PRO polypeptides and for linking a
 CC bioactive molecule to a cell expressing the polypeptides, where the
 CC bioactive molecule is a toxin, radiolabel or an antibody. The bioactive
 CC material causes the death of the cell. The polypeptides or antibodies
 CC specific to the polypeptides are useful for modulating at least one
 CC biological activity of a cell expressing the polypeptides. The
 CC polypeptides are useful for treating disorders associated with leukocyte
 CC homing such as asthma, rheumatoid arthritis, psoriasis and multiple
 CC sclerosis, repair of acute and chronic mucosal lesions such as
 CC enterocolitis and Zollinger Ellison syndrome and for identifying agonists
 CC or antagonists of the polypeptides. The polynucleotides are useful as
 CC hybridization probes, in chromosome and gene mapping, in generation of
 CC generating probes for polymerase chain reaction (PCR), Northern analysis,
 CC Southern analysis and Western analysis. This sequence represents a human
 CC PRO polynucleotide of the invention
 XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
 Query Match 0.78; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.74; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 QY 2983 TCATTTTACTTTAAATGCACTATTTTATTCATTTTCTAATAAAATCCAGTCTCT 3042
 D3 1272 TTGTGATATAAATGCTTAATGATTTTATAGTATTTGTACCTGCCACATATCTT 1331
 QY 3043 TTTTAAAAGACTTTAAATTTATTAATTTCTCT 3077
 D3 1332 ATTATTCCTCAATTTCAATAAATTTATTTATTTCT 1366
 RESULT 65
 ADB77788
 ID ADB77788 standard; cDNA; 1378 BP.
 XX
 AC ADB77788;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein cDNA, #52.
 XX
 KW Human; gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;
 KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;
 KW Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis;
 KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;
 KW neurodegenerative disease; antithrombotic agent; haemorrhage;
 KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;

KW tissue typing; immunohistochemical staining; gene therapy; nootropic;
 KW neuroprotective; cytostatic; virucide; anticoagulant.
 OS Homo sapiens.
 XX

US2003077654-A1.
 XX
 PD 24-APR-2003.
 XX
 XX 10-JUL-2001; 2001US-00902759.
 PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 15-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 24-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 28-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063542P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063549P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065933P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0099803P.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98US-0100262P.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98WO-US025108.

CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
 CC for preparing PRO polypeptides, for generating transgenic animals or
 CC knockout animals which are useful in the development and screening of
 CC therapeutically useful reagents, as probes and for the genetic analysis
 CC of individuals with genetic disorders as well as for recombinationally
 CC expressing the protein and for chromosome identification. The proteins
 CC are useful as molecular marker for protein electrophoresis purposes, as
 CC therapeutic agents, for screening compounds to identify those that mimic
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO
 CC polypeptide (antagonists). The polynucleotides and proteins are useful
 CC for tissue typing. PRO antibodies are useful for immunohistochemical
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in
 CC diagnostic assays for PRO e.g. detecting its expression in specific
 CC cells, tissues or serum and for affinity purification of PRO from
 CC recombinant cell culture or natural sources. The PRO genes may also be
 CC used in gene therapy, particularly for replacing a defective gene. The
 CC sequence presented is a gene encoding a PRO polynucleotide of the
 CC invention.

XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2993 TCTATTTTACTTTAATTCGCACCTATTTTATTTTATTTTCTAATAAATCCAGTCTTCT 3042
 DB 1272 TTTTGTGATATAAATGTTATGATTTTATAGGTATTTTGAACCTGCCACATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAATTTTAAATTTTCT 3077
 DB 1332 ATTATTTCTCCATTTTCAATAAATTTTATTTCT 1366

RESULT 66
 ADB74924
 ID ADB74924 standard; cDNA; 1378 BP.
 XX AC ADB74924;
 XX DT 04-DEC-2003 (first entry)
 XX DE Human secreted/transmembrane protein cDNA, #52.
 XX Human; gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;
 KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;
 KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;
 KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;
 KW neurodegenerative disease; antithrombotic agent; haemorrhage;
 KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy; neurotropic;
 KW neuroprotective; cytostatic; virucide; anticoagulant.
 XX Homo sapiens.
 OS
 XX US2003082542-A1.
 FN
 XX 01-MAY-2003.
 PD
 XX 17-JUL-2001; 2001US-00907979.
 PF
 XX 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059124P.
 PR 18-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 15-OCT-1997; 97US-0059266P.
 PR 17-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.

22-DEC-1998; 98US-0113296P.
 27-JUL-1999; 99US-0143048P.
 26-JUL-1999; 99US-0145698P.
 28-JUL-1999; 99US-0146222P.
 08-SEP-1999; 99WO-US020594.
 13-SEP-1999; 99WO-US020944.
 15-SEP-1999; 99WO-US021090.
 15-SEP-1999; 99WO-US021547.
 09-OCT-1999; 99WO-US023089.
 29-NOV-1999; 99WO-US028214.
 30-NOV-1999; 99WO-US028313.
 01-DEC-1999; 99WO-US028301.
 02-DEC-1999; 99WO-US028564.
 16-DEC-1999; 99WO-US028565.
 16-DEC-1999; 99WO-US030095.
 20-DEC-1999; 99WO-US030911.
 20-DEC-1999; 99WO-US030999.
 05-JAN-2000; 2000WO-US000219.
 11-FEB-2000; 2000WO-US003585.
 22-FEB-2000; 2000WO-US004414.
 24-FEB-2000; 2000WO-US005004.
 02-MAR-2000; 2000WO-US005841.
 30-MAR-2000; 2000WO-US007377.
 30-MAR-2000; 2000WO-US008439.
 22-MAY-2000; 2000WO-US014042.
 26-JUL-2000; 2000WO-US015264.
 24-AUG-2000; 2000WO-US020710.
 18-SEP-2000; 2000US-00665350.
 XX (GETH) GENENTECH INC.

PA Ashkenazi A, Borstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Pilyavoff E, Fong S, Gao W, Garber H, Gerritsen ME, Goddard A;
 PI Godowski PU, Grimaldi JC, Gurney AU, Hillan KJ, Kljavin IU;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PN, Wood WI;
 XX WPI; 2003-765399/72.
 DR P-PSDB; ADB77789.

XX New isolated secreted and transmembrane polypeptide, useful for treating
 PT diseases, e.g. Parkinson's disease, Alzheimer's disease, amyotrophic
 PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.
 XX Claim 2; Fig 97; 467pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful
 CC for treating disorders associated with the preservation and maintenance
 CC of gastrointestinal mucosa and the repair of acute and chronic mucosal
 CC lesions. Skin diseases associated with abnormal keratinocyte
 CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's
 CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and
 CC additionally, disease related to uncontrolled cell growth, e.g. cancer.
 CC PRO polypeptides also serve as tumour specific antigens which may be
 CC exploited as therapeutic targets for anti-tumour drugs, and are also
 CC employed therapeutically in vivo for lessening the effects of viral
 CC infection. The PRO polypeptides can be also used in assays to determine
 CC if it has a role in neurodegenerative diseases or their reversal, as an
 CC antithrombotic agent with reduced risk for haemorrhage as compared with
 CC heparin, in treating other PRO-associated disorders, in modulating
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney
 CC tissue. PRO polypeptides and their portions affect the expression of
 CC genes which have a role in apoptosis. The polynucleotides are useful in
 CC molecular biology including uses as hybridisation probes for cDNA library

PR 17-OCT-1997; 97US-0063287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0063816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063670P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0065120P.
PR 21-NOV-1997; 97US-0065364P.
PR 24-NOV-1997; 97US-0065453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0068422P.
PR 04-JUN-1998; 98US-0086028P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028554.
PR 02-DEC-1999; 99WO-US028585.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
PA (GETH) GENENTECH INC.
XX
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kiljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX
DR WPI: 2003-765412/72.
DR P-PSDB; ADE74925.
XX
XX
PT Novel isolated native PRO polypeptide useful for tissue typing,
PT modulating biological activity of cell, as molecular weight markers in
PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison
PT syndrome.
XX
XX
PS Claim 2; Fig 97; 475pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful
CC for treating disorders associated with the preservation and maintenance
CC of gastrointestinal mucosa and the repair of acute and chronic mucosal
CC lesions, skin diseases associated with abnormal keratinocyte
CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's
CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and
CC additionally, disease related to uncontrolled cell growth, e.g. cancer.
CC PRO polypeptides also serve as tumour specific antigens which may be
CC exploited as therapeutic targets for anti-tumour drugs, and are also
CC employed therapeutically in vivo for lessening the effects of viral
CC infection. The PRO polypeptides can be also used in assays to determine
CC if it has a role in neurodegenerative diseases or their reversal, as an
CC antithrombotic agent with reduced risk for haemorrhage as compared with
CC heparin, in treating other PRO-associated disorders, in modulating
CC tumourial bleeding angiogenesis, and may also have an effect on kidney
CC tissue. PRO polypeptides and their portions affect the expression of
CC genes which have a role in apoptosis. The polynucleotides are useful in
CC molecular biology including uses as hybridisation probes for cDNA library
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC for preparing PRO polypeptides, for generating transgenic animals or
CC knockout animals which are useful in the development and screening of
CC therapeutically useful reagents, as probes and for the genetic analysis
CC of individuals with genetic disorders as well as for recombinantly
CC expressing the protein and for chromosome identification. The proteins
CC are useful as molecular marker for protein electrophoresis purposes, as
CC therapeutic agents, for screening compounds to identify those that mimic
CC the PRO polypeptide (agonists) or prevent the effect of the PRO
CC polypeptide (antagonists). The polynucleotides and proteins are useful
CC for tissue typing. PRO antibodies are useful for immunochemical
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in
CC diagnostic assays for PRO e.g. detecting its expression in specific
CC cells, tissues or serum and for affinity purification of PRO from
CC recombinant cell culture or natural sources. The PRO genes may also be
CC used in gene therapy, particularly for replacing a defective gene. The
CC sequence presented is a gene encoding a PRO polynucleotide of the
CC invention.
XX
XX
SO Sequence 1378 BP 235 A 461 C 412 G 270 T 0 M 0 AA

PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 18-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98WO-US0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 02-DEC-1998; 98WO-US013296P.
PR 07-JUL-1999; 99US-0143048P.
PR 28-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030399.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX (GETH) GENENTECH INC.
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IG;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2003-540675/51.
DR P-PSDB; ADC39771.
XX
XX Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating skin, neurodegenerative diseases, as an
PT antithrombotic agent and for inducing endothelial cell apoptosis.
PS Claim 2; SEQ ID NO 262; 477pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC retinal T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re

CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypohinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polypeptide of the invention.
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTCCTTAATTCGACCTTATTTTATTTATTTTCTTAATAAATCCAGCTCTTCT 3042
DB 1272 TTTTGTATATTAATGTTATGATTTTATAGGTATTGTAACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077
DB 1332 ATTATTCTCCAAATTCATAATTAATTTATTTCT 1366

RESULT 69
ADC40284
ID ADC40284 standard; cDNA; 1378 BP.
XX
XX ADC40284;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human secreted/transmembrane protein cDNA, #52.
DE
XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypohinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
XX Homo sapiens.
OS
XX US2003059829-A1.
PN
XX 27-MAR-2003.
XX
XX 13-JUL-2001; 2001US-00905381.
PF
XX 17-SEP-1997; 97US-0059113P.
PR

PR 17-SEP-1997; 97US-00591115P.
PR 17-SEP-1997; 97US-00591117P.
PR 17-SEP-1997; 97US-00591119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 31-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 03-NOV-1997; 97US-0064103P.
PR 07-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066164P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066456P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-NOV-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0093803P.
PR 10-SEP-1998; 98US-0118624.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-0109304P.
PR 27-DEC-1998; 98US-0113256P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 26-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99US-0146222P.
PR 13-SEP-1999; 99US-02020594.
PR 15-SEP-1999; 99US-02020594.
PR 15-SEP-1999; 99US-02021090.
PR 05-OCT-1999; 99US-02021547.
PR 29-NOV-1999; 99US-02021089.
PR 30-NOV-1999; 99US-02028214.
PR 01-DEC-1999; 99US-02028313.
PR 01-DEC-1999; 99US-02028301.

PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
PA
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Garritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-540676/51.
DR P-PSDB; ADC40285.
DR
XX
XX Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating skin, neurodegenerative diseases, as an
PT antithrombotic agent and for inducing endothelial cell apoptosis.
XX
XX Claim 2; SEQ ID NO 262; 473pp; English.
PS
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its

CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polypeptide of the invention.

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTCATTAATGCACTTATTTTATTCATTTTCTAATAAAATCCAGTCCTCTG 3042
DB 1272 TTTTGTATATAAAGTTTAAATGTTTATAGTATTTGTAACCTGCCACATATCTT 1331

QY 3043 TTTTAAAAAGACTTTTAAATTTTAAATTTCTCT 3077
DB 1332 ATTATTCCTCAATTTCAATAAATTATTATTTCT 1366

RESULT 70
ADC19108
ID ADC19108 standard; cDNA; 1378 BP.
XX
XX
XX AC ADC19108;
XX
XX
XX 18-DEC-2003 (first entry)
XX
XX Human secreted/transmembrane protein cDNA, #52.
XX
XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
XX hypotension; bone disorder; cartilage disorder; sport injury;
XX arthritis; cardiac; vulvar; cytostatic; ophthalmological;
XX osteopathic; anarthritic; anorectic.
XX
XX Homo sapiens.
XX
XX
XX US2003036061-A1.
XX
XX 20-FEB-2003.
XX
XX 18-JUL-2001; 2001US-00909204.
XX
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059124P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 24-OCT-1997; 97US-0063127P.
XX 24-OCT-1997; 97US-0063128P.
XX 27-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063542P.
28-OCT-1997; 97US-0063544P.
28-OCT-1997; 97US-0063549P.
28-OCT-1997; 97US-0063550P.
28-OCT-1997; 97US-0063564P.
29-OCT-1997; 97US-0063435P.
29-OCT-1997; 97US-0063704P.
29-OCT-1997; 97US-0063732P.
29-OCT-1997; 97US-0063734P.
29-OCT-1997; 97US-0063735P.
29-OCT-1997; 97US-0063738P.
31-OCT-1997; 97US-0064215P.
31-OCT-1997; 97US-0063870P.
31-OCT-1997; 97US-0064103P.
31-OCT-1997; 97US-0064248P.
07-NOV-1997; 97US-0064809P.
12-NOV-1997; 97US-0065186P.
17-NOV-1997; 97US-0065846P.
18-NOV-1997; 97US-0065693P.
21-NOV-1997; 97US-0066120P.
21-NOV-1997; 97US-0066364P.
24-NOV-1997; 97US-0066453P.
24-NOV-1997; 97US-0066468P.
24-NOV-1997; 97US-0066511P.
24-NOV-1997; 97US-0066770P.
25-NOV-1997; 97US-0066772P.
25-NOV-1997; 97US-0066840P.
12-DEC-1997; 97US-0069425P.
04-JUN-1998; 98US-0088028P.
10-SEP-1998; 98US-0099803P.
10-SEP-1998; 98US-0099804P.
14-SEP-1998; 98US-0100262P.
14-SEP-1998; 98US-0100263P.
16-SEP-1998; 98US-0100264P.
17-SEP-1998; 98US-0100858P.
17-SEP-1998; 98US-0100859P.
13-OCT-1998; 98US-0104080P.
20-NOV-1998; 98US-0109304P.
01-DEC-1998; 98US-0109305P.
22-DEC-1998; 98US-0113296P.
27-JUL-1999; 98US-0143049P.
26-JUL-1999; 98US-0145698P.
28-JUL-1999; 98US-0146222P.
08-SEP-1999; 99US-0020594P.
13-SEP-1999; 99US-0020595P.
15-SEP-1999; 99US-0021090P.
15-SEP-1999; 99US-0021547P.
05-OCT-1999; 99US-0023089P.
29-NOV-1999; 99US-0028214P.
30-NOV-1999; 99US-0028313P.
01-DEC-1999; 99US-0028301P.
02-DEC-1999; 99US-0028564P.
02-DEC-1999; 99US-0028565P.
16-DEC-1999; 99US-0030095P.
20-DEC-1999; 99US-0030911P.
20-DEC-1999; 99US-0030999P.
05-JAN-2000; 2000US-0000219P.
11-FEB-2000; 2000US-0003565P.
22-FEB-2000; 2000US-0004414P.
24-FEB-2000; 2000US-0005004P.
02-MAR-2000; 2000US-0005841P.
20-MAR-2000; 2000US-0007377P.
30-MAR-2000; 2000US-0008439P.
22-MAY-2000; 2000US-0014042P.
02-JUN-2000; 2000US-0015264P.
28-JUL-2000; 2000US-0020710P.
24-AUG-2000; 2000US-0023328P.
18-SEP-2000; 2000US-00655350P.

(GETH) GENENTECH INC.
Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PU, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI William PM, Wood WI;
 XX WPI: 2003-615762/58.
 DR P-PSDB; ADC19109.

XX Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers.

XX Claim 2; SEQ ID NO 262; 476pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
 CC proliferation of endothelial cells, modulating the proliferation of
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
 CC differentiation of chondrocytes. In particular, these are useful for
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
 CC hypoplasia, or bone or cartilage disorders (e.g. sports injuries or
 CC arthritis) in mammals. PRO polypeptides and their portions affect the
 CC expression of genes which have a role in cell death. The polynucleotides
 CC are useful in molecular biology including uses as hybridisation probes
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
 CC and DNA, for preparing PRO polypeptides, for generating transgenic
 CC animals or knockout animals which are useful in the development and
 CC screening of therapeutically useful reagents, as probes and for the
 CC genetic analysis of individuals with genetic disorders as well as for
 CC recombinantly expressing the protein and for chromosome identification.
 CC The proteins are useful as molecular marker for protein electrophoresis
 CC purposes, as therapeutic agents, for screening compounds to identify
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
 CC useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequence presented is a gene encoding a PRO
 CC polynucleotide of the invention.

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 QY 2983 TCTATTTTACCTTAAATGCACCTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042
 DB 1272 TTTTGTGTATATAATGTTAATGATTTTATAGTATTTGTACCTGCCACATATCTT 1331
 QY 3043 TTTTAAAGACTTTAAATATTTTAAATTTTCTCT 3077
 DB 1332 ATTTATTCCTCCAAATTTCAATAAATTTATTTATCTT 1366

RESULT 71

ADC34408
 ID ADC34408 standard; cDNA; 1378 BP.
 XX
 AC ADC34408;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein cDNA, #52.
 XX
 KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy; proliferation;
 KW neonatal heart; vascular endothelial growth factor; VEGF; retinal neuron;
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
 KW hypoplasia; bone disorder; cartilage disorder; sport injury;
 KW arthritis; cardiac; vulnerable; cyclostatic; ophthalmological;
 KW osteopathic; antiarthritic; anorectic.
 XX
 OS Homo sapiens.
 XX
 PN US2003036094-A1.
 XX
 PD 20-FEB-2003.
 XX
 XX 13-JUL-2001; 2001US-00904820.
 PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 15-OCT-1997; 97US-006125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063122P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 24-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063542P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063549P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 29-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0065466P.
 PR 24-NOV-1997; 97US-0065511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 24-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 10-JUN-1998; 98US-0080026P.
 PR 10-SEP-1998; 98US-0098033P.
 PR 10-SEP-1998; 98WO-US01824.
 PR 14-SEP-1998; 98WO-US01824.
 PR 14-SEP-1998; 98WO-US01826P.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019330.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98WO-US025108.
 PR 22-DEC-1998; 98US-0113296P.
 PR 07-JUL-1999; 99US-0143048P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US003365.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00665350.
 PR XX (GETH) GENENTECH INC.
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 PR WPI: 2003-615763/58.
 DR P-PSDB; ADC34409.
 PR XX
 PT Novel secreted and transmembrane polypeptides and polynucleotides
 PT encoding them useful for treating cancers, asthma, rheumatoid arthritis,
 PT neurological diseases, and skin diseases.
 PR XX
 PS Claim 2; SEQ ID NO 262; 478pp; English.
 PR XX
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or

CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
 CC proliferation of endothelial cells, modulating the proliferation of
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
 CC differentiation of chondrocytes. In particular, these are useful for
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
 CC hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
 CC arthritis) in mammals. PRO polypeptides and their portions affect the
 CC expression of genes which have a role in cell death. The polynucleotides
 CC are useful in molecular biology including uses as hybridisation probes
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
 CC cDNAs in chromosome and gene mapping, in the generation of antisense RNA
 CC and DNA, for preparing PRO polypeptides, for generating transgenic
 CC animals or knockout animals which are useful in the development and
 CC screening of therapeutically useful reagents, as probes and for the
 CC genetic analysis of individuals with genetic disorders as well as for
 CC recombinantly expressing the protein and for chromosome identification.
 CC The proteins are useful as molecular marker for protein electrophoresis
 CC purposes, as therapeutic agents, for screening compounds to identify
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
 CC useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequence presented is a gene encoding a PRO
 CC polypeptide of the invention.
 PR XX

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 QY 2983 TCTATTTTACTTTAATGCGACTTATTTTATTTATTTCTTCTATAAAATCCAGCTCTTGT 3042
 DB 1272 TTTTGTATATAAATGTTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331
 QY 3043 TTTTAAAGACTTTAAATTTATTTATTTCTCT 3077
 DB 1332 ATTTATCTTCAATTTCAATAATTTATTTCT 1366
 RESULT 72
 ADC29463
 ID ADC29463 standard; cDNA; 1378 BP.
 XX
 AC ADC29463;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein cDNA, #52.
 KW Human; Gene; ss; PRO; secreted; transmembrane; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy;
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
 KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;
 KW arthritis; cardiant; vulnery; cytotatic; ophthalmological;
 KW osteopathic; antiarthritic; anorectic.
 XX
 OS Homo sapiens.
 XX

CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polynucleotide of the invention.

XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTAATGACATATTTTATTTTCTATTAATAAATCCAGTCTTCT 3042
DB 1272 TTTTGTATATAAATGTAATGATTTTATAGTATTTTAACTCCGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAATTTTAAATTTCTCT 3077
DB 1332 ATTATTCCTCAATTCATTAATTTATTTCT 1366

RESULT 73
ADC28994
ID ADC28994 standard; cDNA; 1378 BP.
XX AC ADC28994;
XX AC ADC28994;
XX AC ADC28994;
DT 18-DEC-2003 (first entry)
XX Human secreted/transmembrane protein cDNA, #52.
XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypotension; bone disorder; cartilage disorder; sport injury;
KW osteopathic; arthritic; anorectic.

XX Homo sapiens.
XX OS
XX US2003049677-A1.
XX 13-MAR-2003.
XX 17-JUL-2001; 2001US-00907794.
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059124P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065939P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066164P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088036P.
PR 10-SEP-1998; 98US-009803P.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0145222P.
PR 08-SEP-1999; 99WO-US020534.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.

PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Grittisen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-615797/58.
DR P-FSDB; ADC28995.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating skin, neurodegenerative diseases, as an
PT antithrombotic agent and for inducing endothelial cell apoptosis.
XX
PS Claim 2; SEQ ID NO 262; 470pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polynucleotide of the invention.
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTTTACTTTAATGACCTTTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGTAATAAGCTTAATGATTTTATGATTTTCTAATAAATCCAGTCCTTGT 1331

QY 3043 TTTTAAAAAGACCTTTAAATTTATTTATTTATTTCTCT 3077
Db 1332 ATTATTCCTCCCAATTTCAATAAATTTATTTCT 1366

RESULT 74
ADC40879
ID ADC40879 standard; cDNA; 1378 BP.
XX
AC ADC40879;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #52.
XX
KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypotension; bone disorder; cartilage disorder; sports injury;
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
PN US2003054400-A1.
XX
PD 20-MAR-2003.
XX
PF 10-JUL-2001; 2001US-00902692.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059124P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062135P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 31-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 03-NOV-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.

and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or PFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosum), obesity, diabetes, hyperinsulinaemia, hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a gene encoding a PRO polypeptide of the invention.

Sequence 1378 BF: 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

2983 TCTATTTTACTTTTAAATGACCTATTTTTTATGATTTTTTCTAATAAAATCCAGTCCCTTGT 3045
1272 TTTTGTGCTATATAAATGTTTAAATGATTTTTTATAGTATTTTGAACCTGCCCAATATCTT 1331

y
3043 TTTTATAAAGACITTAATAATTAATTCTCT 3077
||| - ||| ||| ||| ||| |||
b
1332 ATTTATTCCTCAATTCATAAAATATTTATCT 1366

RESULT 75
DC19536
D ADC19536 standard: cDNA: 1378 BP.

ADC19536;

18-DEC-2003 (first entry)

Human secreted/transmembrane protein cDNA, #52.

Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
tissue typing; immunohistochemical staining; gene therapy;

neonatal heart; vascular endothelial growth factor; VEGF; proliferation; endothelial cell; stimulated T-lymphocyte; retinal neuron; rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

1

cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
arthritis; cardiac; vulvar; cytostatic; ophthalmological;
osteopathic; antiarthritic; anorectic.

Homo sapiens.

US2003054441-A1.

20-MAR-2003.

12-JUL-2001; 2001US-00905056.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059119P.

17-SEP-1997; 97US-0059121P.

17-SEP-1997; 97US-0059122P.

17-SEP-1997; 97US-0059124P.

18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.

15-OCT-1997; 97US-0062125P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0062884P.

24-OCT-1997; 97US-0062886P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063121P.

24-OCT-1997; 97US-0063122P.

27-OCT-1997; 97US-0063327P.

27-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063542P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063549P.

28-OCT-1997; 97US-0063550P.

28-OCT-1997; 97US-0063554P.

29-OCT-1997; 97US-0063435P.

29-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063732P.

29-OCT-1997; 97US-0063734P.

29-OCT-1997; 97US-0063735P.

29-OCT-1997; 97US-0063738P.

29-OCT-1997; 97US-0064215P.

31-OCT-1997; 97US-0063870P.

31-OCT-1997; 97US-0064103P.

03-NOV-1997; 97US-0064248P.

07-NOV-1997; 97US-0064809P.

12-NOV-1997; 97US-0065186P.

17-NOV-1997; 97US-0065846P.

18-NOV-1997; 97US-0065933P.

21-NOV-1997; 97US-0066120P.

21-NOV-1997; 97US-0066364P.

21-NOV-1997; 97US-0066453P.

24-NOV-1997; 97US-0066466P.

24-NOV-1997; 97US-0066511P.

24-NOV-1997; 97US-0066770P.

25-NOV-1997; 97US-0066772P.

13-OCT-1998; 98US-0104080P.
20-NOV-1998; 98US-0109304P.
01-DEC-1998; 98WO-US025108.
22-DEC-1998; 98US-0113296P.
07-JUL-1999; 98US-0143048P.
26-JUL-1999; 98US-0145698P.
28-JUL-1999; 99US-0146222P.
08-SEP-1999; 99WO-US020594.
13-SEP-1999; 99WO-US020944.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
01-DEC-1999; 99WO-US028301.
02-DEC-1999; 99WO-US028564.
16-DEC-1999; 99WO-US028565.
20-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.
05-JAN-2000; 2000WO-US000219.
11-FEB-2000; 2000WO-US003565.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US005004.
02-MAR-2000; 2000WO-US005841.
30-MAR-2000; 2000WO-US007377.
30-MAR-2000; 2000WO-US008439.
22-MAY-2000; 2000WO-US014042.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
24-AUG-2000; 2000WO-US023328.
18-SEP-2000; 2000US-00665350.

(GETH) GENENTECH INC.

Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
William PM, Wood W;

WPI; 2003-695902/66.
P-PSDB; ADC19537.

Novel isolated PRO polypeptide useful for treating Parkinson's disease,
enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration,
Alzheimer's disease, amyotrophic lateral sclerosis.

Claim 2; SEQ ID NO 262; 478pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides
and the nucleic acid encoding them. The polypeptides can be used to raise
antibodies that specifically bind to the PRO polypeptide, for linking a
biactive molecule to a cell expressing a PRO protein and for modulating
at least one biological activity of a cell. PRO polypeptides are useful
for detecting other PRO polypeptides in a sample and for linking a
biactive molecule to a cell expressing a PRO polypeptide. The PRO
polypeptide antibodies are useful for modulating the biological activity
of a cell expressing PRO polypeptides. The PRO polypeptides or
polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
bioreactors. These are useful for stimulating hypertrophy of neonatal
heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
proliferation of endothelial cells, modulating the proliferation of
stimulated T-lymphocytes, enhancing the survival or proliferation of
retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
cells, modulating glucose or PFA uptake, inducing proliferation and/or re-
differentiation of chondrocytes. In particular, these are useful for
detecting or treating cardiac insufficiency disorders, wounds, cancerous
tumours, retinal disorders or injuries (e.g. loss of sight due to
retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
arthritis) in mammals. PRO polypeptides and their portions affect the
expression of genes which have a role in cell death. The polynucleotides

CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polynucleotide of the invention.

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTAAATGCACTTATTTTATTCATTTTCTAATAAATCCAGTCTCTCT 3042
DB 1272 TTTTGTATATAAATGTAATGATTTTATAGTATTGTAAACCTGCCACATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAAAATTATTAATTTCTCT 3077
DB 1332 ATTATTCCTCAATTCATTAATTTATTTATTTCT 1366

RESULT 76
ADC33984
ID ADC33984 standard; cDNA; 1378 BP.
XX AC ADC33984;
XX AC ADC33984;
XX DT 18-DEC-2003 (first entry)
XX DE Human secreted/transmembrane protein cDNA, #52.
XX KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnery; cytotatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.

XX OS Homo sapiens.
XX US2003073077-A1.
XX PN 17-APR-2003.
XX PD 12-JUL-2001; 2001US-00905088.
XX PF 17-SEP-1997; 97US-0059113P.
XX PR 17-SEP-1997; 97US-0059115P.
XX PR 17-SEP-1997; 97US-0059117P.
XX PR 17-SEP-1997; 97US-0059119P.
XX PR 17-SEP-1997; 97US-0059121P.
XX PR 17-SEP-1997; 97US-0059122P.
XX PR 17-SEP-1997; 97US-0059124P.
XX PR 18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.
15-OCT-1997; 97US-0062125P.
17-OCT-1997; 97US-0062285P.
17-OCT-1997; 97US-0062287P.
21-OCT-1997; 97US-0063486P.
24-OCT-1997; 97US-0062814P.
24-OCT-1997; 97US-0062816P.
24-OCT-1997; 97US-0063045P.
24-OCT-1997; 97US-0063120P.
24-OCT-1997; 97US-0063121P.
24-OCT-1997; 97US-0063127P.
24-OCT-1997; 97US-0063128P.
27-OCT-1997; 97US-0063327P.
27-OCT-1997; 97US-0063329P.
28-OCT-1997; 97US-0063541P.
28-OCT-1997; 97US-0063542P.
28-OCT-1997; 97US-0063544P.
28-OCT-1997; 97US-0063549P.
28-OCT-1997; 97US-0063550P.
28-OCT-1997; 97US-0063564P.
29-OCT-1997; 97US-0063435P.
29-OCT-1997; 97US-0063704P.
29-OCT-1997; 97US-0063732P.
29-OCT-1997; 97US-0063734P.
29-OCT-1997; 97US-0063735P.
29-OCT-1997; 97US-0063738P.
29-OCT-1997; 97US-0064215P.
31-OCT-1997; 97US-0063870P.
31-OCT-1997; 97US-0064103P.
03-NOV-1997; 97US-0064248P.
07-NOV-1997; 97US-0064809P.
12-NOV-1997; 97US-0065186P.
17-NOV-1997; 97US-0065846P.
18-NOV-1997; 97US-0065693P.
21-NOV-1997; 97US-0066120P.
21-NOV-1997; 97US-0066364P.
24-NOV-1997; 97US-0066453P.
24-NOV-1997; 97US-0066466P.
24-NOV-1997; 97US-0066511P.
24-NOV-1997; 97US-0066770P.
24-NOV-1997; 97US-0066772P.
25-NOV-1997; 97US-0066840P.
12-DEC-1997; 97US-0069425P.
04-JUN-1998; 98US-0088026P.
10-SEP-1998; 98US-009803P.
10-SEP-1998; 98WO-US018924.
14-SEP-1998; 98US-0100262P.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98US-0100858P.
17-SEP-1998; 98WO-US019437.
13-OCT-1998; 98US-010408P.
20-NOV-1998; 98US-0109304P.
01-DEC-1998; 98WO-US025108.
22-DEC-1998; 98US-0113296P.
07-JUL-1999; 99US-0143048P.
26-JUL-1999; 99US-0145698P.
28-JUL-1999; 99US-0146222P.
08-SEP-1999; 99WO-US020534.
13-SEP-1999; 99WO-US020944.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
01-DEC-1999; 99WO-US028301.
02-DEC-1999; 99WO-US028584.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.
05-JAN-2000; 2000WO-US000219.
11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00663350.
 XX (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Klijavin IU;
 PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart FA, Tumas D;
 PI Williams PM, Wood WI;
 XX WPI; 2003-695953/66.
 DR P-ESDB; ADC33985.
 XX
 PT Novel isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for
 PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic
 PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.
 XX
 PS Claim 2: SEQ ID NO 262; 476pp; English.
 XX
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
 CC proliferation of endothelial cells, modulating the proliferation of
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
 CC differentiation of chondrocytes. In particular, these are useful for
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
 CC arthritis) in mammals. PRO polypeptides and their portions affect the
 CC expression of genes which have a role in cell death. The polynucleotides
 CC are useful in molecular biology including uses as hybridisation probes
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
 CC and DNA, for preparing PRO polypeptides, for generating transgenic
 CC animals or knockout animals which are useful in the development and
 CC screening of therapeutically useful reagents, as probes and for the
 CC genetic analysis of individuals with genetic disorders as well as for
 CC recombinantly expressing the protein and for chromosome identification.
 CC The proteins are useful as molecular marker for protein electrophoresis
 CC purposes, as therapeutic agents, for screening compounds to identify
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
 CC useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequence presented is a gene encoding a PRO
 CC polypeptide of the invention.
 XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 QY 2983 TCTATTTTACTTTAATTCGACACTTATTTTATTTGATTTTCTAATAAATCCAGTCCTTGT 3042
 Db 1272 TTTTGTGTATATAATGTTAATGATTTTATAGGTATTTGTAAACCTGCCACATATCTT 1331
 QY 3043 TTTTATAAAGACTTTTAAATTTATTAATTTCTCT 3077
 Db 1332 ATTATTCCTCCATTTCAATAAATTTATTTCT 1366
 RESULT 77
 ADC13054
 ID ADC13054 standard; cDNA; 1378 BP.
 XX
 AC ADC13054;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein cDNA, #52.
 XX
 KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy;
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;
 KW arthritis; cardiant; vulnary; cytostatic; ophthalmological;
 KW osteopathic; antiarthritic; anorectic.
 XX
 OS Homo sapiens.
 XX
 XX US2003073079-A1.
 XX 17-APR-2003.
 XX 17-JUL-2001; 2001US-00907575.
 PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059283P.
 PR 18-SEP-1997; 97US-0059286P.
 PR 15-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 24-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063272P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063542P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063549P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 18-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0099803P.
 PR 14-SEP-1998; 98US-01001824.
 PR 14-SEP-1998; 98US-0100462P.
 PR 16-SEP-1998; 98US-01001917.
 PR 16-SEP-1998; 98US-01001930.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98US-01019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98US-0109304P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 07-JUL-1999; 99US-0143048P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99US-0200594.
 PR 13-SEP-1999; 99US-0200944.
 PR 15-SEP-1999; 99US-0202109P.
 PR 15-SEP-1999; 99US-02021547.
 PR 05-OCT-1999; 99US-0203089.
 PR 28-NOV-1999; 99US-02028214.
 PR 30-NOV-1999; 99US-02028313.
 PR 01-DEC-1999; 99US-02028301.
 PR 02-DEC-1999; 99US-02028564.
 PR 02-DEC-1999; 99US-02028565.
 PR 16-DEC-1999; 99US-02030911.
 PR 20-DEC-1999; 99US-02030999.
 PR 05-JAN-2000; 2000US-0200219.
 PR 11-FEB-2000; 2000US-02003565.
 PR 22-FEB-2000; 2000US-02004414.
 PR 24-FEB-2000; 2000US-02005004.
 PR 02-MAR-2000; 2000US-02005841.
 PR 20-MAR-2000; 2000US-02007377.
 PR 30-MAR-2000; 2000US-02008439.
 PR 22-MAY-2000; 2000US-02014042.
 PR 02-JUN-2000; 2000US-02015264.
 PR 28-JUL-2000; 2000US-02020710.
 PR 24-AUG-2000; 2000US-02023328.
 PR 18-SEP-2000; 2000US-00665350.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KU, Kljavin IU;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX
 DR WPI: 2003-743809/70.
 DR P-FSDB; ADC13055.
 XX

PT Novel isolated secreted and transmembrane PRO polypeptides e.g. PRO245
 PT and PRO1869, useful for treating e.g. Parkinson's disease, Alzheimer's
 PT disease, amyotrophic lateral sclerosis, cancer, neuropathies, diabetes and
 PT psoriasis.
 XX Claim 2; SEQ ID NO 262; 473pp; English.
 XX
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
 CC proliferation of endothelial cells, modulating the proliferation of
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
 CC differentiation of chondrocytes. In particular, these are useful for
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
 CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
 CC arthritis) in mammals. PRO polypeptides and their portions affect the
 CC expression of genes which have a role in cell death. The polynucleotides
 CC are useful in molecular biology including uses as hybridisation probes
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
 CC and DNA, for preparing PRO polypeptides, for generating transgenic
 CC animals or knockout animals which are useful in the development and
 CC screening of therapeutically useful reagents, as probes and for the
 CC genetic analysis of individuals with genetic disorders as well as for
 CC recombinantly expressing the protein and for chromosome identification.
 CC The proteins are useful as molecular marker for protein electrophoresis
 CC purposes, as therapeutic agents, for screening compounds to identify
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
 CC useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequence presented is a gene encoding a PRO
 CC polynucleotide of the invention.
 XX
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other; .

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTAAATTCGACTTATTTTATTTATTTTCTTAATAAATCAGTCCTTGT 3042
 Db 1272 TTTTGTATATAAATGTAATGATTTTATAGGTAATTTACCTGCCACATATCTT 1331
 QY 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077
 Db 1332 ATTTATCTCCCAATTTCAATAAATTTATTTCT 1366

RESULT 78
 ADC12506
 ID ADC12506 standard; cDNA; 1378 BP.
 XX
 AC ADC12506;
 XX
 DT 18-DEC-2003 (first entry)

XX Human secreted/transmembrane protein cDNA, #52.
DE Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypotension; bone disorder; cartilage disorder; sport injury;
KW arthritis; candidant; vulnarary; cytostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.
OS Homo sapiens.
XX US2003082541-A1.
XX 01-MAY-2003.
XX 10-JUL-2001; 2001US-00902713.
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059124P.
PR 18-SEP-1997; 97US-0059283P.
PR 18-SEP-1997; 97US-0059286P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018924.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 02-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020534.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004114.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US010442.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX (GETH) GENENTECH INC.
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goodard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IG;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI: 2003-743881/70.
DR P-PSDB; ADC12507.
XX New secreted transmembrane PRO polypeptides and nucleic acids encoding
PT the polypeptides, useful in gene therapy, in identifying chromosomes, as
PT chromosome markers, in generating probes and in tissue typing.
XX Claim 2; SEQ ID NO 262; 487pp; English.
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial

CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polynucleotide of the invention.

XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCATTTTACTTAAATGCGCTATTTTATTTTATTTTCTTATATAAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTCTATATAAATGTTAATGATTTTATAGTATTTTGTACCCGCCACATATCTT 1331
QY 3043 TTTTAAAGACTTTTAAATTTTATTTCTCT 3077
Db 1332 ATTATTCCTCCAAATTCATAAATTTATTTCT 1366

RESULT 79
ADD05061
ID ADD05061 standard; cDNA; 1378 BP.
XX
AC ADD05061;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #52.
XX
KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; Glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiant; vulnary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
OS Homo sapiens.
XX
PN US2003104469-A1.
XX
PD 05-JUN-2003.
XX
PF 17-JUL-2001; 2001US-00907652.

PR 17-SEP-1997; 97US-00591113P.
PR 17-SEP-1997; 97US-00591115P.
PR 17-SEP-1997; 97US-00591117P.
PR 17-SEP-1997; 97US-00591119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063130P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 29-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 31-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064803P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0086028P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099803P.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98US-0100262P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-010304P.
PR 01-DEC-1998; 98US-010304P.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99US-0200594P.
PR 13-SEP-1999; 99US-0200944P.
PR 15-SEP-1999; 99US-0201090P.
PR 15-SEP-1999; 99US-0201547P.
PR 05-OCT-1999; 99US-0203089P.
PR 29-NOV-1999; 99US-0208214P.
PR 30-NOV-1999; 99US-0208313P.

PR 27-OCT-1997; 97US-0063339P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0054215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0098003P.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 18-SEP-1998; 98WO-US018824.
PR 13-OCT-1998; 98US-0104080P.
PR 30-NOV-1998; 98US-0103304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 98US-0143048P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 30-NOV-1999; 98WO-US028214.
PR 01-DEC-1999; 98WO-US028313.
PR 02-DEC-1999; 98WO-US028301.
PR 02-DEC-1999; 98WO-US028584.
PR 16-DEC-1999; 98WO-US028565.
PR 20-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 05-JAN-2000; 98WO-US030999.
PR 05-FEB-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
(GETH) GENENTECH INC.
PA XX
XX

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI: 2003-801226/75.
DR P-PSDB; ADD04068.
XX
XX Novel isolated native PRO polypeptide useful for treating Parkinson's
PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal
PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usher
PT syndrome.
XX
XX Claim 2; SEQ ID NO 262; 487pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, injuries or
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for PRO e.g. detecting its
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polypeptide of the invention.
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
OY 2983 TCTATTTTACTTAAATGCACCTATTATTTTATTTGATTTTCTAATAAATCCAGTCTTGT 3042
DB 1272 TTTTGCTATATAAAGCTTAATGATTTTATAGTATTTCACCTGCCACATATCTT 1331
OY 3043 TTTTAAAAAGACTTTAAATTTAATTTCTCT 3077
DB 1332 ATTATTCCCTCCCAATTTCAATAAATTTATTCTT 1366

CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polypeptide of the invention.
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTACTTTATTCGACATTTATTTATTTGATTTTCTTAATAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGATATAAATGTTAATGATTTTATAGGTATTTGTAACCCGCCACATATCTT 1331
QY 3043 TTTTATAAAGACATTAAATTAATTTCTCT 3077
Db 1332 ATTATTCCTCCATTTCAATAAATTTATTTCT 1366
RESULT 82
ADE34895
ID ADE34895 standard; cDNA; 1378 BP.
XX
AC ADE34895;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #52.
XX
KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulvarey; cytostatic; ophthalmological;
KW
osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
FN US2003077583-A1.
XX
PD 24-APR-2003.
XX
PF 13-JUL-2001; 2001US-00905075.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0062486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-00631045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065893P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 26-NOV-1997; 97US-0066480P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113256P.

PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US021089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 16-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, KJ'avin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX
DR WPI; 2003-777194/73.
DR P-PSDB; ADE34896.
XX
XX
PT New isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for
PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic
PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.
XX
XX
PS Claim 2; SEQ ID NO 262; 474pp; English.
XX
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic

CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polynucleotide of the invention.
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2983 TCTATTTTACTTTAATGCACTTATTTTATTTGATTTTCTAATAAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAATGTTAATGATTTTATAGTATTTGTAAACCTGCCACATATCTT 1331
Qy 3043 TTTTAAAAAGACTTTAAATTTAATTTCTCT 3077
Db 1332 ATTATTCCTCAATTCATAAATTTATTTCT 1366
RESULT 83
ADE79340
ID ADE79340 standard; cDNA; 1378 BP.
XX
AC ADE79340;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #52.
XX
KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cyrostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
XX US2003135025-A1.
XX
PD 17-JUL-2003.
XX
XX 12-JUL-2001; 2001US-00904992.
PF
PF 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 31-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 31-OCT-1997; 97US-0064249P.
PR 31-OCT-1997; 97US-0064809P.
PR 31-OCT-1997; 97US-0065186P.
PR 12-NOV-1997; 97US-0065848P.
PR 17-NOV-1997; 97US-0065693P.
PR 18-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 21-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 12-DEC-1997; 98US-0088026P.
PR 10-SEP-1998; 98US-0098003P.
PR 10-SEP-1998; 98US-0098003P.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98US-0101917P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0103304P.
PR 01-DEC-1998; 98US-0103304P.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 98US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 26-JUL-1999; 99US-0145698P.
PR 08-SEP-1999; 99US-020594.
PR 13-SEP-1999; 99US-020594.
PR 15-SEP-1999; 99US-020594.
PR 15-SEP-1999; 99US-020594.
PR 05-OCT-1999; 99US-0203089.
PR 30-NOV-1999; 99US-0203213.
PR 30-NOV-1999; 99US-0203213.
PR 01-DEC-1999; 99US-0203201.
PR 02-DEC-1999; 99US-0202856P.
PR 02-DEC-1999; 99US-0202856P.
PR 20-DEC-1999; 99US-030095.
PR 20-DEC-1999; 99US-030095.
PR 05-JAN-2000; 99US-030099.
PR 11-FEB-2000; 2000US-0000219.
PR 22-FEB-2000; 2000US-0003565.
PR 24-FEB-2000; 2000US-0004414.
PR 02-MAR-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 20-MAR-2000; 2000US-0007377.
PR 30-MAR-2000; 2000US-0008439.
PR 22-MAY-2000; 2000US-0014042.
PR 02-JUN-2000; 2000US-0015264.
PR 28-JUL-2000; 2000US-0020710.
PR 24-AUG-2000; 2000US-0023328.
PR 18-SEP-2000; 2000US-00665350.
XX (GETH) GENENTECH INC.
PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
XX Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen MS, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavani IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2004-031331/03.
DR P-PSDB; ADE79341.
XX New nucleic acid encoding a PRO polypeptide, for producing a recombinant PRO polypeptide and for treating e.g. cancer, infertility, kidney disorders, and cardiac disfunctions.
PT Claim 2; SEQ ID NO 262; 473pp; English.
XX The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a gene encoding a PRO polynucleotide of the invention.
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
Query March 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTCACCTTAATGCACTTATTTTATTCATTTTCTTAATAAATCCAGTCCTTCT 3042
 Db 1272 TTTTGTATATAAATGTTTAAATGATTTTATAGTATTTGTAAACCTGCCACATATCTT 1331
 QY 3043 TTTTAAAAAGACTTTAAATTTAAATTTCTCT 3077
 Db 1332 ATTATTCCTCAATTCATAAATTTATTTCT 1366

RESULT 84
 ADE79764
 ID ADE79764 standard; cDNA; 1378 BP.
 XX AC ADE79764;
 XX DT 29-JAN-2004 (first entry)
 XX Human secreted/transmembrane protein cDNA, #52.
 DE Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy;
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
 KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
 KW hypotension; bone disorder; cartilage disorder; sport injury;
 KW arthritis; cardiac; vulvular; cytostatic; ophthalmological;
 KW osteopathic; antiarthritic; anorectic.
 XX OS Homo sapiens.
 XX US2003130489-A1.
 XX 10-JUL-2003.
 XX 11-JUL-2001; 2001US-00903806.
 XX 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059119P.
 PR 17-SEP-1997; 97US-0059121P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 15-OCT-1997; 97US-0062125P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 24-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063542P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063549P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.

PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 21-NOV-1997; 97US-0066384P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0099803P.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98US-0100262P.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98WO-US025108.
 PR 22-DEC-1998; 98US-0113266P.
 PR 07-JUL-1999; 99US-0143048P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000WO-US0665350.
 XX (GETH) GENENTECH INC.
 XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX WPI; 2004-020353/02.
 DR P-PSDB; ADE79765.
 XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor or for tissue typing.
 XX Claim 2; SEQ ID NO 262; 480pp; English.
 PS

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a gene encoding a PRO
CC polynucleotide of the invention.
XX
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTTAATGCACTTATTTTATTGATTTTCTAATAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGGTATTTGTAACCTGCCACATATCTT 1331

QY 3043 TTTTAAAGACTTTAAATTTAATTTCTCT 3077
Db 1332 ATTTATCTCTCAATTAATAAATTTATTTCT 1366

RESULT 85
ADE73440
ID ADE73440 standard; cDNA; 1378 BP.
XX
AC ADE73440;
DT
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #52.
XX
XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW

KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnery; cytostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
PN US2003129592-A1.
XX
XX 10-JUL-2003.
PF
PF 13-JUL-2001; 2001US-00905449.
XX
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0084248P.
PR 07-NOV-1997; 97US-0084809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 14-SEP-1998; 98WO-US018624.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98WO-US025108.
 PR 27-DEC-1998; 98US-0113296P.
 PR 07-JUL-1999; 99US-0143048P.
 PR 28-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US0213089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US000355.
 PR 22-FEB-2000; 2000WO-US000414.
 PR 24-FEB-2000; 2000WO-US000504.
 PR 02-MAR-2000; 2000WO-US0005841.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 18-SEP-2000; 2000US-00665350.
 (GETH) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;

WPI; 2004-020333/02.
 P-PSDB; ADE73441.

PT New nucleic acids encoding polypeptides designated PRO have sequence
 PT identity to various secreted proteins and transmembrane proteins and are
 PT useful in molecular techniques and as therapeutic agents.

PS Claim 2; SEQ ID NO 262; 474pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
 CC proliferation of endothelial cells, modulating the proliferation of
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
 CC differentiation of chondrocytes. In particular, these are useful for
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, injuries or
 CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or

CC arthritis) in mammals. PRO polypeptides and their portions affect the
 CC expression of genes which have a role in cell death. The polynucleotides
 CC are useful in molecular biology including uses as hybridisation probes
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
 CC and DNA, for preparing PRO polypeptides, for generating transgenic
 CC animals or knockout animals which are useful in the development and
 CC screening of therapeutically useful reagents, as probes and for the
 CC genetic analysis of individuals with genetic disorders as well as for
 CC recombinantly expressing the protein and for chromosome identification.
 CC The proteins are useful as molecular marker for protein electrophoresis
 CC purposes, as therapeutic agents, for screening compounds to identify
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
 CC useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequence presented is a gene encoding a PRO
 CC polypeptide of the invention.

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 26;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTTAATGACCTTATTTTATTCGATTTTCTAATAAATCCAGTCTTGT 3042
 DB 1272 TTTTGTATATAAATGTTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331
 QY 3043 TTTTAAAGAGCTTTAAATTTATTAATTTCTCT 3077
 DB 1332 ATTTATTCCTCCAATTTCAATAAATTTATTTCT 1366

RESULT 86
 ADE73975

ID ADE73975 standard; cDNA; 1378 BP.

XX ADE73975;

AC ADE73975;
 XX 29-JAN-2004 (first entry)

DE Human secreted/transmembrane protein cDNA, #52.

KW Human; gene, ss; PRO; secreted; transmembrane; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy;
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia; injury;
 KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;
 KW osteopathic; antiarthritic; anorectic.

OS Homo sapiens.

XX US2003148370-A1.

XX 07-AUG-2003.

XX 13-JUL-2001; 2001US-00904838.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063129P.
PR 27-OCT-1997; 97US-0063322P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065848P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099803P.
PR 14-SEP-1998; 98US-0010082P.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98US-0100930P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-0045108.
PR 21-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99US-0020594.
PR 13-SEP-1999; 99US-0020944.
PR 15-SEP-1999; 99US-0021090.
PR 15-SEP-1999; 99US-0021547.
PR 05-OCT-1999; 99US-0023089.
PR 29-NOV-1999; 99US-0028214.
PR 30-NOV-1999; 99US-0028313.
PR 01-DEC-1999; 99US-0028301.
PR 02-DEC-1999; 99US-0028564.
PR 02-DEC-1999; 99US-0028565.
PR 16-DEC-1999; 99US-0030095.
PR 20-DEC-1999; 99US-0030911.
PR 20-DEC-1999; 99US-0030999.

PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi A, Rotstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KD, Kiljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI: 2004-020440/02.
DR P-PSDB: ADE73976.
XX
XX Isolated secreted and transmembrane PRO nucleic acids and the proteins
PT they encode, e.g. PRO245, PRO269 and PRO1868, useful for preventing,
PT diagnosing and treating e.g. disorders relating to blood coagulation.
XX
XX Claim 2; SEQ ID NO 262; 1pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing C-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to reinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a gene encoding a PRO polypeptide of the invention.

```
XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTCTTAAATGCACTTATTTTATGATTTTCTTAATAAATCCAGTCTTCT 3042
Db TTTTGTATATAAATGTTAATGATTTTATAGTATTTGTAACTGCCCAATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCT 3077
Db ATTTATCTCCCAATTCATTAATTAATTTATCT 1366

RESULT 87
AAT27590
ID AAT27590 standard; DNA; 132 BP.
XX AC AAT27590;
XX DT 25-MAR-2003 (revised)
XX DT 06-AUG-1996 (first entry)
XX DE Novel growth factor domain fragment B DNA.
XX KW Tissue plasminogen activator; tPA; alpha2-plasmin inhibitor;
XX KW fibrinolytic; thrombolytic; fibrin; thrombosis; blood clotting;
XX KW protein engineering; growth factor domain; Factor IX; ds.
XX OS Synthetic.
XX PN US5504001-A.
XX PD 02-APR-1996.
XX PF 06-JUN-1994; 94US-00254485.
XX PR 25-NOV-1987; 87US-00125629.
XX PR 28-JAN-1992; 92US-00827587.
XX PA (ZYMO ) ZYMOGENETICS INC.
XX PI Foster DC;
XX DR WPI; 1996-187699/19.
XX DR P-PSDB; AAR96225.
XX PT Hybrid plasminogen activator comprises human tPA activator and N-terminal
XX PT crosslinking domain from alpha2-plasmin inhibitor - useful to treat
XX PT thrombosis and image blood clots.
XX PS Example 6; Fig 15; 35pp; English.
XX CC Amino acid substitutions are designed in the growth factor domain of
XX CC tissue plasminogen activator (tPA) with the goal of disrupting possible
XX CC specific receptor interactions. Oligonucleotides (AAR27589-92) encoding
XX CC the growth factor region replacement domains A-D (AAR96224-27) were
XX CC generated from 14 different oligonucleotides. Fragment B results in
XX CC replacement of tPA amino acids 52-91 with the entire growth factor region
XX CC of human Factor IX. Mutant tPAs were expressed in BHK cells and
XX CC characterised for plasma half life and fibrin binding properties.
XX CC (Updated on 25-MAR-2003 to correct PF field.)
XX SQ Sequence 132 BP; 39 A; 15 C; 28 G; 50 T; 0 U; 0 Other;
Query Match 0.7%; Score 24.2; DB 1; Length 132;
Best Local Similarity 53.8%; Pred. No. 17;
Matches 50; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 2915 TCTCTACTTATTAAATTTGGGATTTAACTATTTCTCAATGACTTGTATTCTAATAT 2974
Db TTTTGTATATAAATGTTAATGATTTTATAGTATTTGTAACTGCCCAATATCTT 1331
```

```
Db 1 TCGGTACCTGTTAAATCTTGTGAATCTAATCCTTGTTCTTAATGGAGGATCTTGAAGAT 60
QY 2975 TTACTTATTTCTTATTTTACTTTTAAATGCACTTAT 3007
Db 61 GATATTAATTCATATGAATGTTGTGTCTCTTTT 93

RESULT 88
AAA31550
ID AAA31550 standard; DNA; 260 BP.
XX AC AAA31550;
XX DT 05-JUL-2000 (first entry)
XX DE Plant microsatellite marker #511.
XX KW Plant microsatellite sequence; core repeat sequence; detection; probe;
XX KW DNA polymorphism; genome mapping; physical mapping; fingerprinting;
XX KW variety identification; genetic variability evaluation; primer; ss.
XX OS Eucalyptus grandis.
XX PN WO9967421-A1.
XX PD 29-DEC-1999.
XX PF 25-JUN-1999; 99WO-NZ000092.
XX PR 25-JUN-1998; 98US-00105307.
XX PA (GENE-) GENESIS RES & DEV CORP LTD.
XX PA (FLET-) FLETCHER CHALLENGE FOREST LTD.
XX PI Havukkala IJ, Bloksberg LN, Glenn M;
XX DR WPI; 2000-116958/10.
XX PT New plant microsatellite markers and associated flanking species for the
XX PT detection of polymorphic genetic markers.
XX PS Claim 1; Page 227; 392pp; English.
XX CC Sequences AAA31040-A32093 represent novel plant microsatellite sequences
XX CC and associated flanking species. The sequences comprise a central core
XX CC repeat sequence, especially selected from the sequences AAA32094-A32096
XX CC with left and right flanking sequences. The polynucleotide sequences can
XX CC be used in the detection of DNA polymorphisms, in genome mapping, in
XX CC physical mapping, in positional cloning of genes, in variety
XX CC identification and in evaluation of genetic variability within and
XX CC between plant tissues, populations, cultivars, species and species
XX CC groups. They may also be used to design hybridization probes for
XX CC oligonucleotide fingerprinting and library screening and to design
XX CC primers for microsatellite-primed PCR. Microsatellite markers are useful
XX CC to locate specific economically useful genes in plant genomes
XX SQ Sequence 260 BP; 51 A; 101 C; 64 G; 44 T; 0 U; 0 Other;
Query Match 0.7%; Score 23.6; DB 1; Length 260;
Best Local Similarity 61.3%; Pred. No. 30;
Matches 36; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 868 ACCAGTAATGCTGAAGAAGTGAAGTTGAACGGTCTCTATGAAGACCTACAGACCTTTTA 927
Db AGCAGACATGGCGAGGGGCTGCCTGAAGGGGACATGAAGGCCACACGACATGCT 137

QY 928 GA 929
Db 138 GA 139

RESULT 89
ABX42370/c
```

XX	XX	ABX42370 standard; cDNA; 361 BP.	XX	XX	260	TGCTTCCAAATTCAGTAGTTTCTCAGTGTGTTTCAAAAACITGTCGTCTTCTTCCAAA	200
XX	AC	ABX42370;	QY	2979	TTATTTCTATTTTACTTTAAATTCAC	3004	
XX	DT	20-FEB-2003 (first entry)	DB	200	GTACATTTTCTTCTTTTACATCTCT	175	
XX	XX	Bovine EST associated with lactation/muscle/fat deposition #7535.	RESULT	90			
XX	DE	Bovine; ss; EST; expressed sequence tag; lactation; LMFD;	AAI29377				
XX	KW	muscle deposition; fat deposition; genome mapping; gene identification;	ID	AAI29377	standard; cDNA; 596 BP.		
XX	KW	gene analysis; cattle breeding.	XX	AC	AAI29377;		
XX	XX	Bos Taurus.	XX	DT	12-OCT-2001 (first entry)		
XX	XX	US2002137139-A1.	XX	XX	Colon tumor related determined cDNA sequence for clone R0096.E09.		
XX	XX	26-SEP-2002.	DE	XX	Human; immunotherapy; diagnosis; colon cancer; colon tumour; immunogenic;		
XX	XX	24-SEP-2001; 2001US-00960352.	KW	KW	gene therapy; vaccine; colonic cancer; ss.		
XX	XX	12-JAN-1999; 99US-0115707P.	XX	OS	Homc sapiens.		
XX	PR	11-JAN-2000; 2000US-00480902.	XX	PN	WO200149716-A2.		
XX	XX	(BYAT/) BYATT J C.	XX	XX	12-JUL-2001.		
XX	PA	(NATH/) MATHIALAGAN N.	XX	XX	29-DEC-2000; 2000WO-US035596.		
XX	PA	(TAON/) TAO N.	XX	XX	30-DEC-1999; 99US-00476296.		
XX	PA	(WARR/) WARREN W C.	XX	XX	10-JAN-2000; 2000US-00480321.		
XX	XX	Byatt JC, Mathialagan N, Tao N, Warren WC;	XX	XX	15-FEB-2000; 2000US-00504629.		
XX	XX	WPI; 2003-110599/10.	XX	XX	06-MAR-2000; 2000US-00519444.		
XX	XX	New nucleic acid associated with lactation, and muscle and fat	XX	XX	19-MAY-2000; 2000US-00575251.		
XX	PT	deposition, useful for genome mapping, gene identification and analysis,	XX	XX	29-JUN-2000; 2000US-00609448.		
XX	PT	cattle breeding, or for genetically improving cattle.	XX	XX	28-AUG-2000; 2000US-00649811.		
XX	XX	Claim 2; SEQ ID NO 7535; 245pp; English.	XX	PA	(CORI-) CORIXA CORP.		
XX	XX	The invention relates to a purified nucleic acid molecule associated with	XX	XX	Xu J, Lodes MJ, Secretist H, Benson DR, Meagher MJ, Stoik JA;		
XX	CC	lactation or muscle and fat deposition (designated LMFD), derived from	PI	PI	King GE, Wang T, Jiang Y;		
XX	CC	cattle, and the LMFD nucleic acid can specifically hybridise to a second	XX	XX	WPI; 2001-441847/47.		
XX	CC	nucleic acid molecule comprising any of 15112 nucleotide sequences,	XX	XX	Colon tumor associated proteins and nucleic acids useful for the		
XX	CC	appearing as ABX34836-ABX49947, or complements of them. Also included are	XX	PT	prevention, diagnosis and treatment of colonic cancer.		
XX	CC	(1) a transformed cell having a nucleic acid comprising an LMFD nucleic	XX	XX	Claim 2; Page 390-391; 472pp; English.		
XX	CC	acid linked to a promoter and a 3' non-translated sequence that	XX	PS	The present invention describes colon tumour associated proteins (I) and		
XX	CC	functions in the cell to cause termination of transcription and addition	XX	CC	the polynucleotides (II) that encode them. (I) have cytostatic activity		
XX	CC	of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and	XX	CC	(I) and (II) can be used in gene therapy and vaccine production. (I) and		
XX	CC	(2) determining a level or pattern of a molecule in a bovine cell or	XX	CC	(II) may be used in the prevention, diagnosis and treatment of diseases		
XX	CC	tissue comprising: (a) incubating a marker nucleic acid (comprising any	XX	CC	associated with inappropriate colon tumour associated protein (TCAP)		
XX	CC	of the 15112 nucleic acid sequences or its complement or fragment) with a	XX	CC	expression, such as colonic cancer. For example, (I) and (II) may be used		
XX	CC	complementary nucleic acid molecule obtained from the bovine cell or	XX	CC	to treat disorders associated with decreased expression by rectifying		
XX	CC	tissue, where hybridisation between the marker nucleic acid and the	XX	CC	mutations or deletions in a patient's genome that affect the activity of		
XX	CC	complementary nucleic acid permits the detection of the molecule; and (b)	XX	CC	TCAPs by expressing inactive proteins or to supplement the patients own		
XX	CC	detecting the level or pattern of the complementary nucleic acid; where	XX	CC	production of them. Additionally, (II) may be used to produce the TCAP		
XX	CC	the detection of the complementary nucleic acid is predictive of the	XX	CC	proteins, by inserting the nucleic acids into a host cell culturing the		
XX	CC	level or pattern of the molecule. The LMFD nucleic acid is used for	XX	CC	cell to express the protein. (II) and its complementary sequences may		
XX	CC	determining a level or pattern of a molecule in a bovine cell or tissue.	XX	CC	also be used as DNA probes in diagnostic polymerase chain reaction (PCR)		
XX	CC	It is useful for genome mapping, gene identification and analysis, cattle	XX	CC	and hybridisation assays to detect and quantitate the presence of similar		
XX	CC	breeding, preparation of constructs for use in cattle gene expression, or	XX	CC	nucleic acids in samples, and therefore which patients may be in need of		
XX	CC	for genetically improving cattle. The present sequence is one of the	XX	CC	restorative therapy. (I) may also be used as antigens in the production		
XX	CC	15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The	XX	CC	of antibodies against TCAPs and in assays to identify modulators of TCAP		
XX	CC	present sequence was not shown in the specification but was obtained in	XX	CC	expression and activity. Anti-(I) antibodies and antagonists may also be		
XX	CC	electronic format from the USPTO web site:	XX	CC	used to down regulate TCAP expression and activity. The anti-(I)		
XX	CC	seqdata.uspto.gov/sequence.html?docID=20020137139	XX	CC	antibodies may also be used as diagnostic agents for detecting the		
XX	XX	Sequence 361 BP; 117 A; 62 C; 83 G; 99 T; 0 U; 0 Other;	XX	CC	presence of TCAPs in samples (e.g. by enzyme linked immunosorbant assay		
XX	XX	Query Match 0.7%; Score 23.6; DB 1; Length 361;	XX	CC	(ELISA)). AAI28460 to AAI29512 and AAI24494 to AAI24523 represent		
XX	XX	Best Local Similarity 54.7%; Pred. No. 33;	XX</				

SQ Sequence 596 BP; 106 A; 172 C; 212 G; 105 T; 0 U; 1 Other;
Query Match 0.7%; Score 23.4; DB 1; Length 596;
Best Local Similarity 49.4%; Pred. No. 42;
Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
2560 GGCACCTGATCAGAGAGCTGACTCACTGGAAGAACCTCTGATGCTGGAGGGATTGGG 2619
41 GGCACATGACCCAGCCAGTGCAGTGCAGTGGAGGCGTTGGGAGAGGCGTTGGC 100
2620 GGCAGAGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2679
101 TGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 160
2680 G-----ACGTGAGTCTGGTGAGTCACTCTGAGTGGTGGTGGTGGTGGTGGTGG 2725
161 GAGTGCATGTCGCCCTCGGAGGCGCCCTCTGGAGGTAGTGGGTTGGGGGATG 212

RESULT 91
ABZ33563
ID ABZ33563 standard; cDNA; 596 BP.
XX AC ABZ33563;
XX AC ABZ33563;
XX 30-JAN-2003 (first entry)
XX Human colon tumour cDNA for clone R0096:509 SEQ ID NO:931.
XX Human; colon cancer; colon tumour; immunotherapy; diagnosis; cancer;
XX tumour; immune response; immunostimulant; cytostatic; vaccine; gene; ss.
XX Homo sapiens.
XX WO200283070-A2.
XX 24-OCT-2002.
XX 09-APR-2002; 2002WO-US011475.
XX 10-APR-2001; 2001US-00833263.
XX 03-AUG-2001; 2001US-00922217.
XX 19-DEC-2001; 2001US-00025380.
XX (CORI-) CORIXA CORP.
XX Xu J, Lodes MJ, Secrist H, Benson DR, Meagher MJ, Stolk JA;
XX Wang T, Jiang Y, Smith CL, King GE, Wang A, Clapper JD, Skeiky YAW;
XX Fanger GR, Vedvick TS, Carter D;
XX WPI; 2003-067548/06.
XX New polynucleotide, useful for the preparation of a composition for
XX stimulating an immune response against, or treating, cancer.
XX Disclosure; Page 392; 537pp; English.
XX The present invention describes compounds (I) for the immunotherapy and
XX diagnosis of colon cancer. Also described: (1) a method for detecting the
XX presence of cancer in a patient; (2) a method for stimulating and/or
XX expanding T cells specific for a tumour protein; (3) an isolated T cell
XX population comprising T cells prepared by the method of (2); (4) a method
XX for stimulating an immune response in a patient; (5) a method for
XX treating cancer in a patient; and (6) a method for inhibiting the
XX development of cancer in a patient. (1) have immunostimulant and
XX cytostatic activities and can be used in vaccines. ABZ32646 to ABZ33725
XX and ABP5343 to ABP5391 represent human colon cancer/tumour related
XX sequences used in the exemplification of the present invention

SQ Sequence 596 BP; 106 A; 172 C; 212 G; 105 T; 0 U; 1 Other;
Query Match 0.7%; Score 23.4; DB 1; Length 596;
Best Local Similarity 49.4%; Pred. No. 42;
Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
2560 GGCACCTGATCAGAGAGCTGACTCACTGGAAGAACCTCTGATGCTGGAGGGATTGGG 2619
41 GGCACATGACCCAGCCAGTGCAGTGCAGTGGAGGCGTTGGGAGAGGCGTTGGC 100
2620 GGCAGAGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2679
101 TGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 160
2680 G-----ACGTGAGTCTGGTGAGTCACTCTGAGTGGTGGTGGTGGTGGTGGTGG 2725
161 GAGTGCATGTCGCCCTCGGAGGCGCCCTCTGGAGGTAGTGGGTTGGGGGATG 212

RESULT 92
ABN85395/c
ID ABN85395 standard; DNA; 882 BP.
XX AC ABN85395;
XX AC ABN85395;
XX 21-OCT-2002 (first entry)
XX Partial Human NOV14a DNA sequence, 162662716.
XX Human; NOV14a; cytostatic; Cardiant; Antiinflammatory; Immunosuppressive;
XX Antiallergic; Haemostatic; Anti-HIV; Antidiabetic; Anorectic;
XX Antiasthmatic; Nephrotropic; Hepatotropic; Neuroprotective; Nootropic;
XX Antibacterial; Virucide; Antiparasitic; Relaxant; Anticonvulsant;
XX Gene Therapy; NOV; cancer; heart disease; inflammation;
XX autoimmune disorder; allergy; blood disorder; AIDS; diabetes; obesity;
XX asthma; IGA nephropathy; cirrhosis; arthritis; 162662716;
XX Alzheimer's disease; infection; stroke; muscular dystrophy; epilepsy;
XX wasting disorder; prostatic-like protein; chromosome 16; ds.
XX Homo sapiens.
XX WO200255704-A2.
XX 18-JUL-2002.
XX 09-JAN-2002; 2002WO-US000554.
XX 09-JAN-2001; 2001US-0260417P.
XX 10-JAN-2001; 2001US-0260831P.
XX 28-FEB-2001; 2001US-0272338P.
XX 09-MAR-2001; 2001US-0274876P.
XX 18-APR-2001; 2001US-0284704P.
XX (CURA-) CURAGEN CORP.
XX Padigar M, Li L, Zerhusen BD, Casman SJ, Shenoy S, Spytek KA;
XX Zhong M, Gangolli EA, Burgess CE, Patuturajan M, Vernet CM;
XX Taylor S, Tchernev VT, Miller CE, Guo X, Boldog FL, Grosse WM;
XX Alsobrook JP, Gerlach V, Edinger S, Rothenberg ME, Ellerman K;
XX Macdougall J, Malyankar U, Millet I, Peyman J, Smithson G;
XX Gunther E, Stone DJ;
XX WPI; 2002-590674/63.
XX NOVX polypeptides and encoding polynucleotides, useful for preventing or
XX treating NOVX-associated disorders e.g. cancer, inflammation, or
XX Alzheimer's disease, and in chromosome mapping, tissue typing or
XX pharmacogenomics.
XX Claim 9; Page 100; 358pp; English.
XX The present sequence is an insert assembly sequence for NOV14a protein.
XX NOV14a is a prostatic-like protein, and the NOV14a coding sequence of the
XX localises to chromosome 16. The NOV proteins and coding sequences of the
XX invasions are useful for treating or preventing NOV-associated disorders
XX or in the manufacture of a medicament for treating the disorders, such as
XX cancer, heart disease, inflammation, autoimmune disorders, allergies,

CC	blood disorders, AIDS, diabetes, obesity, asthma, IgA nephropathy.
CC	cirrhosis, arthritis, Alzheimer's disease, infections (e.g. bacterial,
CC	viral, parasitic), stroke, muscular dystrophy, epilepsy, and other
CC	wasting disorders associated with chronic diseases
XX	
SEQ	Sequence 882 BP; 155 A; 303 C; 254 G; 160 T; 0 U; 0 Other;
	Query Match 0.7%; Score 23.4; DB 1; Length 882;
	Best local similarity 49.4%; Pred. No. 47;
	Matches 83; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
Qy	2560 GGCACCTGATCAGAAAGCTGACTCTCGAAGAAGCCCTGATCTGGAGGAGATTGGG 2619
Db	450 GGCCACATGATGCCCCAGCCAGTGCAGTGCAGTGAGGCCGTGGGGAAGAGCGCGTTGGC 391
Qy	2620 GCCAGGAGGAGAAAGGGACGACAGAGGATGAGATGGTGGATGGCATCATCTGATCGATG 2679
Db	390 TGCAGGAGGCGAGATGGCGCCCGATGTAGCGGGAAGGTATGGTCTCTGATGTTGGAG 331
Qy	2680 G-----ACGTGAGTCTGGGTGGAATCTCTGGAGTTGGTGTAGCGACAGGAGG 2725
b	330 GAGTCGCAATGTCGCCCTGGAGACCTCTCTGAGCTAGCTGGGTGGGGGATG 279

RESULT 93
AAC87796/c
ID AAC87796 standard; DNA; 1142 BP.
XX
AC AAC87796;
XX
AC AAC87796;
XX
DT 02-MAR-2001 (first entry)
XX
DE Activation construct CPEK2-6XHis-TAG fusion gene vector SEQ ID NO:8.
XX
KW Activation construct; catalytic; fusion gene; expression vector;
XX proteolysis; serine protease; zymogen precursor; characterisation;
KW analysis; modulator; identification; ds.
XX
OS Homo sapiens.
OS Synthetic.
OS
PN WO200066709-A2.
XX
PD 09-NOV-2000.
XX
PF 13-APR-2000; 200WO-US009973.
XX
PR 30-APR-1999; 99US-00303162.
XX
PA (ORTH) ORTHO-MCNEIL PHARM RES INC.
XX
PI Darrow A, Qi J, Andrade-Gordon P;
XX
DR WPI; 2000-687533/57.
XX
PT Expression vector for producing recombinantly producing serine protease
PT domains, comprising a presequence, a prosequence, and a cloning site for
PT the insertion of catalytic domain cassette.
XX
PS Claim 7; Page 40-41; 89pp; English.
XX
CC The present invention describes an expression vector (I) comprising in
CC frame and in order, a presequence, a prosequence, and a cloning site for
CC the in frame insertion of catalytic domain cassette. (I) can be used as a
CC modulator of proteins expressed from a zymogen activation construct. The
CC recombinant catalytic domain of serine protease is useful for identifying
CC compounds modulating the activity of proteases is expressed and activated
CC from the zymogen activation construct. A method from the present
CC invention comprises combining a modulator of the recombinant catalytic
CC domain of a protease and measuring an effect of the modulator on the
CC protein preferably inhibiting or enhancing its enzymatic activity or
CC stimulation or inhibition of proteolysis mediated by the expressed
CC catalytic domain. The present sequence represents a specifically claimed

CC	fusion gene with a human serine protease catalytic domain from the	
CC	present invention	
XX		
XX	Sequence 1142 BP; 235 A; 360 C; 303 G; 244 T; 0 U; 0 Other;	
XX		
XX	Query Match 0.7%; Score 23.4; DB 1; Length 1142;	
XX	Best Local Similarity 49.4%; Pred. No. 50;	
XX	Matches 8; Conservative 0; Mismatches 81; Indels 6; Gaps 1;	
XX		
QY	2560	GGCCACCTGATCAGAGAGCTACTCACTGGAAAAAGACCCCTGATGCTGGAGGATGGG 2619
Db	537	GGCCACATGACCCAGCCAGTCAGTGACGTGGAGGCCCTTGGGGAAGAGGCGTTGGC 478
QY	2620	GGCAGGAGNAGAGGGACACACAGAGATGAGATGCTGGATGGCATCACTGACTCGATG 2679
Db	477	TGCAGGAGGCAGATGGCCCGGATGTAGCCGGAGAGGTGATGGTCTGCTGATTGGAG 418
QY	2680	G-----ACGTGAGTCTGGTGTAACCTCTGGAGTTGGTGATGACACGGAGG 2725
Db	417	GAGTGCATGTCCCTCGGGAGCCCTCTGGAGGTAGCTGGGGTGGGGATG 366
XX		
XX	RESULT 94	
XX	AAF55268/c	
XX	ID	AAF55268 standard; DNA; 1142 BP.
XX	AC	AAF55268;
XX	XX	
XX	DT	29-MAY-2001 (first entry)
XX	DE	
XX	XX	Nucleotide sequence of catalytic domain in CFEK2-6XHIS-TAG.
XX	KW	Expression vector; zymogen precursor; serine protease; prostaticin;
XX	KW	protease; inflammation; reproduction; epidermal tissue; skin care;
XX	KW	neurological tissue; laundry detergent; stain-removing solution;
XX	KW	prolactin; protease EK; ds.
XX	OS	Synthetic.
XX	XX	
XX	Key	Location/Qualifiers
XX	CDS	13..972
XX	FT	/*tag= a
XX	FT	13..78
XX	FT	/*tag= b
XX	FT	/note= "chymotrypsinogen presequence"
XX	FT	162..951
XX	FT	mat_peptide
XX	FT	/*tag= c
XX	FT	/note= "prostaticin"
XX	XX	
XX	PN	WO200116289-A2.
XX	XX	
XX	PD	08-MAR-2001.
XX	XX	
XX	PF	14-AUG-2000; 2000WO-US022283.
XX	XX	
XX	PR	31-AUG-1999; 99US-00386642.
XX	XX	
XX	PA	(ORTH) ORTHO-MCNEIL PHARM INC.
XX	XX	
XX	PI	Darrow A, Qi J, Andrade-Gordon P;
XX	XX	
XX	XX	WPI; 2001-218523/22.
DR	DR	P-PSDB; AAB67541.
XX	XX	
XX	PT	An expression vector for the expression of inactive zymogen proteases
XX	PT	useful for therapeutic or commercial products comprises a pre-sequence, a
XX	PT	pro-sequence and a cloning site for in frame insertion of a catalytic
XX	PT	domain cassette.
XX	XX	
PS	Claim 7; Fig 4A-D; 175pp; English.	
XX		
XX	The specification describes an expression vector system that will permit,	
CC	through limited proteolysis, the activation of expressed zymogen	
CC		

CC precursors of serine proteases (e.g. prostatic) in a highly controlled
CC and reproducible fashion. The expression vector comprises, in frame and
CC in order, a pre-sequence, a pro-sequence and a cloning site for in frame
CC insertion of a catalytic domain cassette. The expression vectors of the
CC invention are useful for the expression of heterologous inactive zymogen
CC proteases that can subsequently be proteolytically processed to generate
CC the active enzyme product. The active enzyme product can be useful for
CC directly treating diseases associated with inflammatory, reproductive,
CC epidermal or neurological tissue or for identifying modulators of
CC protease activity which can be used for treatment. The proteases can also
CC be used in commercial products, e.g. laundry detergents, stain-removing
CC solutions and skin care products. The present sequence represents the
CC catalytic domain in an expression vector of the invention. The construct
CC encodes a prostatic protease sequence
XX
SQ Sequence 1142 BP; 235 A; 360 C; 303 G; 244 T; 0 U; 0 Other;

Query Match 0.7%; Score 23.4; DB 1; Length 1142;
Best Local Similarity 49.4%; Pred. No. 50;
Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
QY 2560 GGCCACCTGATCAGAGAGTGAAGTCACTCAGGAAAGACCTGATCTGGAGGGATTGGG 2619
DB 537 GGCCACATGACCCACCCAGTACAGTGCAGTGGAGGCGGTGGGAGAGGCGTTGGC 478
QY 2620 GGCCAGGAGGAGAGGAGGAGGAGGAGGATGAGATGCTGGATCACTGATCTGATG 2679
DB 477 TGCAGGAGGAGGAGGAGGAGGAGGAGGATGAGGAGGAGGAGGAGGAGGAGGAGG 418
QY 2680 G-----ACGTGAGTCTGGGTGAACCTCTGGAGTTGGTATGACAGGAGG 2725
DB 417 GAGTGAATGTGCGCCCTGGAGAGCCCTCTGGAGGAGTGTGGGTTGGGAGT 366

RESULT 95
ABN85393/c
ID ABN85393 standard; DNA; 1161 BP.
XX AC ABN85393;
XX 21-OCT-2002 (first entry)
XX Human NOV14b, prostatic-like protein, coding sequence.
XX Human; NOV14b; cytosolic; Cardiac; Antiinflammatory; Immunosuppressive;
XX Antiallergic; Haemostatic; Anti-HIV; Antidiabetic; Anorectic;
XX Antiasthmatic; Nephrotropic; Hepatotropic; Neuroprotective; Nootropic;
XX Antibacterial; Virucide; Antiparasitic; Relaxant; Anticonvulsant;
XX Gene Therapy; NOV; cancer; heart disease; inflammation;
XX autoimmune disorder; allergy; blood disorder; AIDS; diabetes; obesity;
XX asthma; IGA nephropathy; cirrhosis; arthritis; Alzheimer's disease;
XX infection; stroke; muscular dystrophy; epilepsy; wasting disorder;
XX prostatic-like protein; chromosome 16; gene; ds.
XX Homo sapiens.

XX Key Location/Qualifiers
XX CDS 1..1161
XX /*tag=a
XX /*product="NOV14b"
XX WO200255704-A2.
XX 18-JUL-2002.
XX 09-JAN-2002; 2002WO-US000554.
XX 09-JAN-2001; 2001US-0260417P.
XX 10-JAN-2001; 2001US-0260831P.
XX 28-FEB-2001; 2001US-0272338P.
XX 09-MAR-2001; 2001US-0274876P.
XX 18-APR-2001; 2001US-0284704P.

PA
XX
PI
PI
PI
PI
PI
PI
XX
DR
DR
PT
PT
PT
PT
XX
PS
XX
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
XX
SQ

Claim 9; Page 99; 358pp; English.

The present sequence is a coding sequence for a NOV protein. The NOV proteins and coding sequences are useful for treating or preventing NOV-associated disorders or in the manufacture of a medicament for treating the disorders, such as cancer, heart disease, inflammation, autoimmune disorders, allergies, blood disorders, AIDS, diabetes, obesity, asthma, IGA nephropathy, cirrhosis, arthritis, Alzheimer's disease, infections (e.g. bacterial, viral, parasitic), stroke, muscular dystrophy, epilepsy, and other wasting disorders associated with chronic diseases. NOV14b is a prostatic-like protein, and the NOV14b coding sequence localises to chromosome 16

Sequence 1161 BP; 219 A; 349 C; 364 G; 229 T; 0 U; 0 Other;

Query Match 0.7%; Score 23.4; DB 1; Length 1161;
Best Local Similarity 49.4%; Pred. No. 51;
Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
QY 2560 GGCCACCTGATCAGAGAGTGAAGTCACTCAGGAAAGACCTGATCTGGAGGGATTGGG 2619
DB 738 GGCCACATGACCCACCCAGTACAGTGCAGTGGAGGCGGTGGGAGAGGCGTTGGC 679
QY 2620 GGCCAGGAGGAGAGGAGGAGGAGGATGAGATGCTGGATCACTGATCTGATG 2679
DB 678 TGCAGGAGGAGGAGGAGGAGGAGGATGAGGAGGAGGAGGAGGAGGAGGAGG 619
QY 2680 G-----ACGTGAGTCTGGGTGAACCTCTGGAGTTGGTATGACAGGAGG 2725
DB 618 GAGTGAATGTGCGCCCTGGAGAGCCCTCTGGAGGAGTGTGGGTTGGGAGT 567

RESULT 96
AAC87795/c
ID AAC87795 standard; DNA; 1169 BP.

XX AAC87795;
XX 02-MAR-2001 (first entry)
XX Activation construct PFEX2-6XHis-TAG fusion gene vector SEQ ID NO:7.
XX Activation construct; catalytic; fusion gene; expression vector;
XX proteolysis; serine protease; zymogen precursor; characterisation;
XX analysis; modulator; identification; ds.
XX Homo sapiens.
XX Synthetic.
XX WO200066709-A2.
XX 09-NOV-2000.
XX 13-APR-2000; 2000WO-US0009973.
XX 30-APR-1999; 99US-00303162.

XX (ORTH) ORTHO-MCNEIL PHARM RES INC.
XX Darrow A, Qi J, Andrade-Gordon P;
XX WPI; 2000-687533/67.
XX Expression vector for producing recombinantly producing serine protease
PT domains, comprising a presequence, a prosequence, and a cloning site for
PT the insertion of catalytic domain cassette.
XX Claim 7; Page 39-40; 89pp; English.
XX The present invention describes an expression vector (I) comprising in
CC frame and in order, a presequence, a prosequence, and a cloning site for
CC the in frame insertion of catalytic domain cassette. (I) can be used as a
CC modulator of proteins expressed from a zymogen activation construct. The
CC recombinant catalytic domain of serine protease is useful for identifying
CC compounds modulating the activity of proteases is expressed and activated
CC from the zymogen activation construct. A method from the present
CC invention comprises combining a modulator of the recombinant catalytic
CC domain of a protease and measuring an effect of the modulator on the
CC stimulation or inhibition of proteolysis mediated by the expressed
CC catalytic domain. The present sequence represents a specifically claimed
CC fusion gene with a human serine protease catalytic domain from the
CC present invention
XX Sequence 1169 BP; 248 A; 358 C; 313 G; 250 T; 0 U; 0 Other;
Query Match 0.7%; Score 23.4; DB 1; Length 1169;
Best Local Similarity 49.4%; Pred. No. 51;
Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
QY 2560 GGCCACCTGATCAGAGAGCTGACTCACTGGAAAGACCTGATGCTGGAGGGATTGGG 2619
Db 564 GGCCACATGACCCAGCAGTACAGTCAGTGAGGCGGTGGGAGGAGCGGTGGC 505
QY 2620 GGCAGGAGGAGAGGGGACGACAGAGGATGAGATGGCTGGATGCGATCACTGCTGATG 2679
Db 504 TGCAGGAGGAGGAGGCGCGATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAG 445
QY 2680 G-----ACGTGAGTCTGGGTGAACCTCGGTGATGTCGACAGAGGAGG 2725
Db 444 GAGTGCATGTCGCCCTGGAGCCCTCTCTGGAGGTAGTGGGTGGGGGATG 393
RESULT 97
ID AAF55267/c
AC AAF55267;
DT 29-MAY-2001 (first entry)
DE Nucleotide sequence of catalytic domain in PFEK2-6XHIS-TAG.
XX Expression vector; zymogen precursor; serine protease; prostatic;
KW protease; inflammation; reproduction; epidermal tissue; skin care;
KW neurological tissue; laundry detergent; stain-removing solution;
KW prolactin; protease EK; ds.
XX Synthetic.
XX Key Location/Qualifiers
FH 13..999
FT CDS /*tag= a
FT sig_peptide 13..99 /*tag= b
FT /*note= "chymotrypsinogen presequence"
FT mat_peptide 190..972 /*tag= c
FT /*note= "prostatic"

XX WO200116289-A2.
XX 08-MAR-2001.
XX 14-AUG-2000; 2000WO-US022283.
XX 31-AUG-1999; 99US-00386642.
XX (ORTH) ORTHO-MCNEIL PHARM INC.
XX Darrow A, Qi J, Andrade-Gordon P;
XX WPI; 2001-218523/22.
XX P-PSDB; AAB57540.
XX An expression vector for the expression of inactive zymogen proteases
PT useful for therapeutic or commercial products comprises a pre-sequence, a
PT pro-sequence and a cloning site for in frame insertion of a catalytic
PT domain cassette.
XX Claim 7; Fig 3A-D; 175pp; English.
XX The specification describes an expression vector system that will permit,
CC through limited proteolysis, the activation of expressed zymogen
CC precursors of serine proteases (e.g. prostatic) in a highly controlled
CC and reproducible fashion. The expression vector comprises, in frame and
CC in order, a pre-sequence, a pro-sequence and a cloning site for in frame
CC insertion of a catalytic domain cassette. The expression vectors of the
CC invention are useful for the expression of heterologous inactive zymogen
CC proteases that can subsequently be proteolytically processed to generate
CC the active enzyme product. The active enzyme product can be useful for
CC directly treating diseases associated with inflammatory, reproductive,
CC epidermal or neurological tissue or for identifying modulators of
CC protease activity which can be used for treatment. The proteases can also
CC be used in commercial products, e.g. laundry detergents, stain-removing
CC solutions and skin care products. The present sequence represents the
CC catalytic domain in an expression vector of the invention. The construct
CC encodes a prostatic protease sequence
XX Sequence 1169 BP; 248 A; 358 C; 313 G; 250 T; 0 U; 0 Other;
Query Match 0.7%; Score 23.4; DB 1; Length 1169;
Best Local Similarity 49.4%; Pred. No. 51;
Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
QY 2560 GGCCACCTGATCAGAGAGCTGACTCACTGGAAAGACCTGATGCTGGAGGGATTGGG 2619
Db 564 GGCCACATGACCCAGCAGTACAGTCAGTGAGGCGGTGGGAGGAGCGGTGGC 505
QY 2620 GGCAGGAGGAGAGGGGACGACAGAGGATGAGATGGCTGGATGCGATCACTGCTGATG 2679
Db 504 TGCAGGAGGAGGAGGCGCGATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAG 445
QY 2680 G-----ACGTGAGTCTGGGTGAACCTCGGTGATGTCGACAGAGGAGG 2725
Db 444 GAGTGCATGTCGCCCTGGAGCCCTCTCTGGAGGTAGTGGGTGGGGGATG 393
RESULT 98
ID AAF54031/c
AC AAF54031;
XX 08-FEB-2001 (first entry)
XX Human factor X coding sequence.
XX Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric protein;
KW fusion protein; coagulation factor; Factor X; Factor VII; Protein S;
KW Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;
KW ds.

XX DR WPI; 1999-167446/14.

XX PT Determination of HLA class I group type of a subject - using group

XX PT specific untranslated region primer pair.

XX XX Disclosure; Fig 13; 195pp; English.

XX XX The present invention describes a method using novel primers involving

CC the PCR-based determination of histocompatibility locus antigen B (HLA-B)

CC Class I group type. Determining the HLA-B Class I group type of a subject

CC comprises: (i) combining a group-specific untranslated region primer pair

CC with a target DNA sample from the subject under conditions such that

CC primer-based amplification of the target DNA may occur; and (ii)

CC determining whether a nucleic acid product is produced by the

CC amplification; where the ability of the primer pair to produce a nucleic

CC acid product is associated with a particular HLA group type. The method

CC can be used for HLA-B typing. In the method, the initial group specific

CC amplification allows a PCR based separation of haplotypes in 95% of

CC patient samples. It permits the resolution of cis/trans linkages of

CC heterozygote sequencing results which cannot be achieved with other

CC protocols. AAX37845 to AAX38286 represent DNA sequence used in the

CC exemplification of the present invention

XX XX

XX SQ Sequence 244 BP; 31 A; 91 C; 90 G; 32 T; 0 U; 0 Other;

Query Match 0.6%; Score 23; DB 1; Length 244;

Best Local Similarity 60.3%; Pred. No. 42;

Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 2691 GGCTGAACCTCTGACCTGCTGATGACACAGGAGGCTCTCTCTGCGGGATTTCATGGGGT 2750

DB |||||

QY 67 GGGGCGACCGGCGCTAGCTGGGGGATGGGAGTGGTACCTGCCCGCCCGGGGT 8

DB |||||

QY 2751 CAC 2753

DB |||||

DB 7 CAC 5

RESULT 103

AAT76438/C

ID AAT76438 standard; DNA; 250 BP.

XX AC AAT76438;

XX DT 16-SEP-1997 (first entry)

XX DE Substance P antisense oligonucleotide.

XX XX Asthma; airway epithelium; adenosine free; cystic fibrosis;

KW chronic obstructive pulmonary disease; bronchitis; ss.

XX OS Synthetic.

XX OS WO9640162-A1.

XX PN 19-DEC-1996.

XX PD

XX PF 06-JUN-1996; 96WO-US009306.

XX XX

XX PR 07-JUN-1995; 95US-00474497.

XX XX

XX PA (UYEC-) UNIV EAST CAROLINA.

XX XX

XX PI Nyce JW; Metzger WJ;

XX XX WPI; 1997-051871/05.

XX DR

XX XX Treatment of airway diseases such as asthma - by topically applying

PT adenosine-free antisense oligonucleotide to airway epithelium of

XX subject.

XX XX

XX PS Example 5; Page 39; 71pp; English.

XX CC A method for treating airway disease in a subject has been produced,

CC which involves the topical administration of an essentially adenosine

CC free antisense oligonucleotide (ON) to the airway epithelium of the

CC subject. The present sequence is an antisense oligonucleotide specific

CC for the substance P, targeted at the initiation codon. The method can be

CC used to treat airway diseases such as cystic fibrosis, asthma, chronic

CC obstructive pulmonary disease, bronchitis and other airway diseases

CC characterised by an inflammatory response. By eliminating adenosine from

CC the antisense ON, its liberation upon antisense degradation is prevented,

CC thereby preventing adenosine-induced bronchoconstriction in patients with

CC hyper-reactive airways

XX SQ Sequence 250 BP; 1 A; 64 C; 70 G; 65 T; 0 U; 50 Other;

Query Match 0.6%; Score 23; DB 1; Length 250;

Best Local Similarity 38.5%; Pred. No. 43;

Matches 52; Conservative 26; Mismatches 57; Indels 0; Gaps 0;

QY 184 AACTAGTCAATCTAATCATCACTAGGACCAAGAGCTGTCTTAACTCAATGAATAGCCA 243

DB |||||

DB 238 AACCAGAGAAACTCAGCACCCCGCGGACGVCVCGCGCAAAAACCAACAVGAAAVCCV 179

QY 244 TGCCCGTGGGGCAACCAAGATGGGAGGTCATGCTGGAGAGATCTGACAGATGTGGTC 303

DB |||||

DB 178 CGVGGCCVGGCAGVCVVVVVVVGVGVCCVCCAGCVCVGVVGGCAGAAAVAGGAGC 119

QY 304 CACTGGAGAGGGAA 318

DB |||||

DB 118 CAAVGAAGVAVCGAA 104

RESULT 104

AAX54759/C

ID AAX54759 standard; DNA; 250 BP.

XX AC AAX54759;

XX XX

XX DT 05-JUL-1999 (first entry)

XX XX Substance P antisense oligonucleotide fragment.

DE DE

KW Antisense oligonucleotide; multiple target; antisense treatment;

KW impaired respiration; inflammation; lung disease;

KW pulmonary vasoconstriction; inflammation; allergic rhinitis;

KW acute asthma; allergy; asthma; impeded respiration;

KW respiratory distress syndrome; pain; cystic fibrosis;

KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;

KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;

KW colon cancer; breast cancer; lung cancer; pancreatic cancer;

KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;

KW prostate cancer; ss.

XX OS Synthetic.

XX OS WO9913886-A1.

XX PN 25-MAR-1999.

XX PD

XX PF 17-SEP-1998; 98WO-US019419.

XX XX

XX PR 17-SEP-1997; 97US-0059160P.

XX PR 09-JUN-1998; 98US-00093972.

XX XX

XX PA (UYEC-) UNIV EAST CAROLINA.

XX XX

XX PI Nyce JW;

XX XX WPI; 1999-229400/19.

XX DR

XX XX New antisense oligonucleotides used in treatment of, e.g. pulmonary

PT vasoconstriction.

XX PT

XX XX

PS Disclosure; Page 59; 120pp; English.

XX The specification describes antisense oligonucleotides (AA52869-X55271) directed against at least 2 mRNAs selected from target genes, coding and non-coding regions of RNAs corresponding to target genes, gene initiation codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-end and the juxta-section between coding and non-coding regions and all segments of RNAs encoding proteins associated with one or more diseases, conditions or mixtures. The antisense oligonucleotides may be derived from sequences AA55180-271. These multiple target oligonucleotides (specifically AA55180-271) can be used for the antisense treatment of diseases and conditions. Typical diseases and conditions are those associated with impaired respiration and inflammation, including lung diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis, acute asthma, allergies, asthma, impaired respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukemias, lymphomas e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as well as all types of cancers which may metastasize or have metastasized to the lungs, including breast and prostate cancer

XX Sequence 250 BP; 1 A; 64 C; 70 G; 65 T; 0 U; 50 Other;

SQ Query Match 0.6%; Score 23; DB 1; Length 250;
Best Local Similarity 38.5%; Pred. No. 43;
Matches 52; Conservative 26; Mismatches 57; Indels 0; Gaps 0;

QY 184 AACTAGTCAATCTAATCACTAGGACACAGCCCTGTCTAATCACTAAGTAAGCA 243
DB 238 AACACAGAACTCAGACCCCGGGACVCGCGGCAAAVCAACVCAAAVCCV 179

QY 244 TGCCCGTGGGCAACCAAGATGGCAGTCTATGGTGAGAGATCTGACAGATGTGTC 303
DB 178 CGVGGCCVGGCAGVGVVWVVCVGVCCACVCGVGVVVGCAAGAAVAGGAGC 119

QY 304 CACTGGAGAGGGAA 318
DB 118 CAAGVAGVAVCGAA 104

RESULT 105
AA34206/c
ID AAA34206 standard; DNA; 250 BP.

AC AAA34206;

XX 28-JUL-2000 (first entry)

XX Human adenosine receptor related polynucleotide SEQ ID NO:1895.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide; phosphorothioate; impaired respiration; inflammation; allergy; allergic disease; bronchoconstriction; inhibitor; antiinflammatory; antiasthmatic; cycostatic; analgesic; impaired airway; lung disease; ischaemic condition; pulmonary vasoconstriction; asthma; respiratory distress syndrome; pain; cystic fibrosis; emphysema; pulmonary hypertension; chronic obstructive pulmonary disease; COPD; cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

XX WO200009525-A2.

XX 24-FEB-2000.

XX 03-AUG-1999; 99WO-US017712.

XX 03-AUG-1998; 98US-0095212P.

XX (UYEC-) UNIV EAST CAROLINA.

XX

PI Nyce JW;

XX WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary vasoconstriction, inflammation, allergies, asthma, hypertension, PT bronchitis, emphysema, respiratory distress syndrome, ischemia or PT cancers.

XX Disclosure; Page 503; 1343pp; English.

PS The present invention describes a new composition comprising an antisense oligonucleotide (ON) with low adenosine (up to 15%), which targets nucleic acids involved in bronchoconstriction, allergies, and/or inflammation. The ON can have antiinflammatory, antiasthmatic, antiallergic, cycostatic and analgesic activities. The compositions are useful for the treatment of diseases associated with inflammation, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject. They can be used for treating e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma, impaired respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukemias, lymphomas, carcinomas, and cancers which may metastasize to the lungs, including breast and prostate cancer. The reduction of the adenosine content of the ONs reduces side effects. The A-containing ONs break down with the release of deoxyadenosine which activates adenosine receptors causing bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the nucleotide sequences given in the sequence listing from the present invention, which correspond to SEQ ID NO:1 to 185, and then the last 185 sequences are also called SEQ ID NO:1 to 185, but the sequences differ from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to AAA3992) are specifically claimed ONs from the present invention. N.B. Sequences given in the disclosure of the present invention do not match up with their corresponding SEQ ID NO: sequences given in the sequence CC listing

XX Sequence 250 BP; 1 A; 64 C; 70 G; 65 T; 0 U; 50 Other;

SQ Query Match 0.6%; Score 23; DB 1; Length 250;
Best Local Similarity 38.5%; Pred. No. 43;
Matches 52; Conservative 26; Mismatches 57; Indels 0; Gaps 0;

QY 184 AACTAGTCAATCTAATCACTAGGACACAGCCCTGTCTAATCACTAAGTAAGCA 243
DB 238 AACACAGAACTCAGACCCCGGGACVCGCGGCAAAVCAACVCAAAVCCV 179

QY 244 TGCCCGTGGGCAACCAAGATGGCAGTCTATGGTGAGAGATCTGACAGATGTGTC 303
DB 178 CGVGGCCVGGCAGVGVVWVVCVGVCCACVCGVGVVVGCAAGAAVAGGAGC 119

QY 304 CACTGGAGAGGGAA 318
DB 118 CAAGVAGVAVCGAA 104

RESULT 106
AAF20328/c
ID AAF20328 standard; DNA; 250 BP.

XX AAF20328;

XX 14-MAR-2001 (first entry)

XX Human substance P polynucleotide fragment #1895.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy; human; airway disorder; bronchoconstriction; lung inflammation; surfactant depletion; respiratory; bronchodilator; antiinflammatory; immunosuppressive; antiasthmatic; analgesic; hypotensive; cycostatic; respiratory obstruction; pulmonary obstruction; impaired respiration; surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS; respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;

Db 238 AACGAGAGAACTCAGCAGCCCGGGGAGVCGGCGCAAAAVCAACAVGAAAVCCV 179
Qy 244 TGCCCGTGGGCAACCAAGATGGGAGGTCATGTTGGAGAGATCTGACAGAAATGGTTC 303
Db 178 CGVGGCCVGGCAGCVVVVVVWCVGVCVCCACVCGAGCVVVVGGCAGAGAAVAGGACC 119
Qy 304 CACTGGAGAGGGNA 318
Db 118 CAAVGAAGVAVCGGAA 104

RESULT 108
ABX46375
ID ABX46375 standard; cDNA; 370 BP.
XX
AC ABX46375;
XX
XX 21-FEB-2003 (first entry)
XX
XX Bovine EST associated with lactation/muscle/fat deposition #11540.
XX
XX Bovine; ss; EST; expressed sequence tag; lactation; LMPD;
KW muscle deposition; fat deposition; genome mapping; gene identification;
KW gene analysis; cattle breeding.
XX
XX Bos Taurus.
XX
XX US2002137139-A1.
XX
XX 26-SEP-2002.
XX
XX 24-SEP-2001; 2001US-00960352.
XX
XX 12-JAN-1999; 99US-0115707P.
XX
XX 11-JAN-2000; 2000US-00480902.
XX
XX (BYAT/) BYATT J C.
PA (NATH/) NATHIALAGAN N.
PA (TAON/) TAO N.
PA (WARR/) WARREN W C.
XX
XX
XX Byatt JC, Nathialagan N, Tao N, Warren WC;
XX WPI; 2003-110599/10.
XX
XX New nucleic acid associated with lactation, and muscle and fat
PT deposition, useful for genome mapping, gene identification and analysis,
PT cattle breeding, or for genetically improving cattle.
XX
XX Claim 2; SEQ ID NO 11540; 245pp; English.
XX
XX The invention relates to a purified nucleic acid molecule associated with
CC lactation or muscle and fat deposition (designated LMPD), derived from
CC cattle, and the LMPD nucleic acid can specifically hybridize to a second
CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
CC appearing as ABX34836-ABX49947, or complements of them. Also included are
CC ; (1) a transformed cell having a nucleic acid comprising an LMPD nucleic
CC acid linked to a promoter and a 3' non-translated sequence that
CC functions in the cell to cause termination of transcription and addition
CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
CC (2) determining a level or pattern of a molecule in a bovine cell or
CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
CC of the 15112 nucleic acid sequences or its complement or fragment) with a
CC complementary nucleic acid molecule obtained from the bovine cell or
CC tissue, where hybridisation between the marker nucleic acid and the
CC complementary nucleic acid permits the detection of the molecule; and (b)
CC detecting the level or pattern of the complementary nucleic acid, where
CC the detection of the complementary nucleic acid is predictive of the
CC level or pattern of the molecule. The LMPD nucleic acid is used for
CC determining a level or pattern of a molecule in a bovine cell or tissue.
CC It is useful for genome mapping, gene identification and analysis, cattle
CC breeding, preparation of constructs for use in cattle gene expression, or
CC for genetically improving cattle. The present sequence is one of the

CC 15112 bovine LMPD EST (expressed sequence tag) nucleic acids. Note: The
CC present sequence was not shown in the specification but was obtained in
CC electronic format from the USPTO web site:
CC seqdata.uspto.gov/sequence.html?DocID=20020137139
XX
SQ Sequence 370 BP; 126 A; 58 C; 77 G; 109 T; 0 U; 0 Other;
Query Match 0.6%; Score 23; DB 1; Length 370;
Best Local Similarity 54.0%; Pred. NO. 47;
Matches 47; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
Qy 1560 ATAAAGCATCTCAATGCAGAGTTCACAGAACTTCCAAAGATCTTCAAGCTGCTTTAGAA 1619
Db 78 ATGAAGGAAATATGTCATATATACCAAGGTGTCCTCGATTAAGGAA 137
Qy 1620 AAGTCAGAGGACCAAGACCAAAATG 1646
Db 138 AAAACAAGCTCACATAAAGAAAATG 164

RESULT 109
ABV97874
ID ABV97874 standard; cDNA; 381 BP.
XX
AC ABV97874;
XX
XX 14-JAN-2003 (first entry)
XX
XX Human pancreatic cancer expressed cDNA SEQ ID NO 3282.
XX
XX Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
KW cytostatic; tumour; gene; ss.
XX
XX Homo sapiens.
XX
XX W0200260317-A2.
XX
XX 08-AUG-2002.
XX
XX 30-JAN-2002; 2002WO-US002781.
XX
XX 30-JAN-2001; 2001US-0265305P.
PR 31-JAN-2001; 2001US-0265682P.
PR 09-FEB-2001; 2001US-0267568P.
PR 21-MAR-2001; 2001US-0278651P.
PR 28-APR-2001; 2001US-0287112P.
PR 16-MAY-2001; 2001US-0291631P.
PR 12-JUL-2001; 2001US-0305484P.
PR 20-AUG-2001; 2001US-0313999P.
PR 27-NOV-2001; 2001US-0333626P.
XX
XX (CORI-) CORIXA CORP.
XX
XX Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;
XX WPI; 2002-627435/67.
XX
XX New isolated polynucleotide and pancreatic tumor polypeptides, useful for
PT diagnosing, preventing and/or treating cancer, particularly pancreatic
PT cancer.
XX
XX Claim 1; SEQ ID NO 3282; 300pp + Sequence Listing; English.
XX
XX The invention relates to an isolated polynucleotide (I) comprising: (a)
CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)
CC complements of (a); (c) sequences consisting of at least 20 contiguous
CC residues of (a); (d) sequences that hybridize to (a) under moderately
CC stringent conditions; (e) sequences having at least 75% or 90% identity
CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-
CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer
CC in a patient and compositions comprising polypeptides, polynucleotides,
CC antibodies, fusion proteins, T cell populations and antigen presenting
CC cells expressing the polypeptide are useful in treating pancreatic cancer

XX
CC TIERU.) (OPDated ON Z3-19AR

Best Local Similarity	79.4%	Pred: No. 47;
Matches	27: Conservative	0: Mismatches
		7: Indels
		0: Gaps
		0:

CC polyketide biosynthesis. The present sequence is *S. amnibiosporus*
 CC lactimidomycin ORF2 DNA
 XX
 SQ Sequence 255 BP; 51 A; 75 C; 84 G; 45 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22.8; DB 1; Length 255;
 Best Local Similarity 56.8%; Pred. No. 49;
 Matches 42; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
 QY 981 AGTAGGAAGCAAGAAACACCTGGAGTAACAGGCAAAATTTGGCTTGGAAATACGGAATGA 1040
 Db 5 AGCAGGAACCTCAAGCAGTACATGGAAGACGAGTTCATGTTTCGAGTTCGAGATCA 64
 QY 1041 AGCAGGGCCAAAGAC 1054
 Db 65 CCGAGGACACCGAC 78
 RESULT 114
 ABX36877/c
 ID ABX36877 standard; cDNA; 356 BP.
 XX
 AC ABX36877;
 XX
 DT 20-FEB-2003 (first entry)
 XX
 DE Bovine EST associated with lactation/muscle/fat deposition #2042.
 XX
 KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;
 XX muscle deposition; fat deposition; genome mapping; gene identification;
 KW gene analysis; cattle breeding.
 XX
 OS Bos Taurus.
 XX
 XX US2002137139-A1.
 PN
 XX
 PD 26-SEP-2002.
 XX
 XX 24-SEP-2001; 2001US-00960352.
 PF
 XX
 PR 12-JAN-1999; 99US-0115707P.
 PR 11-JAN-2000; 2000US-00480902.
 XX
 XX (BYAT/) BYATT J C.
 PA (MATH/) MATHIALAGAN N.
 PA (TAON/) TAO N.
 PA (WARE/) WARREN W C.
 XX
 Byatt JC, Mathialagan N, Tao N, Warren WC;
 WPI; 2003-110599/10.
 XX
 PT New nucleic acid associated with lactation, and muscle and fat
 PT deposition, useful for genome mapping, gene identification and analysis,
 PT cattle breeding, or for genetically improving cattle.
 XX
 XX Claim 2; SEQ ID NO 2042; 245pp; English.
 XX
 CC The invention relates to a purified nucleic acid molecule associated with
 CC lactation or muscle and fat deposition (designated LMFD), derived from
 CC cattle, and the LMFD nucleic acid can specifically hybridise to a second
 CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
 CC appearing as ABX34836-ABX49947, or complements of them. Also included are
 CC (1) a transformed cell having a nucleic acid comprising an LMFD nucleic
 CC acid linked to a promoter and a 3' non-translated sequence that
 CC functions in the cell to cause termination of transcription and addition
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
 CC (2) determining a level or pattern of a molecule in a bovine cell or
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
 CC of the 15112 nucleic acid sequences or its complement or fragment) with a
 CC complementary nucleic acid molecule obtained from the bovine cell or
 CC tissue, where hybridisation between the marker nucleic acid and the
 CC complementary nucleic acid permits the detection of the molecule; and (b)

CC acid linked to a promoter and a 3' non-translated sequence that
CC functions in the cell to cause termination of transcription and addition
CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
CC (2) determining a level or pattern of a molecule in a bovine cell or
CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
CC of the 15112 nucleic acid sequences or its complement or fragment) with a
CC complementary nucleic acid molecule obtained from the bovine cell or
CC tissue, where hybridisation between the marker nucleic acid and the
CC complementary nucleic acid permits the detection of the molecule; and (b)
CC detecting the level or pattern of the complementary nucleic acid, where
CC the detection of the complementary nucleic acid is predictive of the
CC level or pattern of the molecule. The LMFD nucleic acid is used for
CC determining a level or pattern of a molecule in a bovine cell or tissue.
CC It is useful for genome mapping, gene identification and analysis, cattle
CC breeding, preparation of constructs for use in cattle gene expression, or
CC for genetically improving cattle. The present sequence is one of the
CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The
CC present sequence was not shown in the specification but was obtained in
CC electronic format from the USPTO web site:
CC seqdata.uspto.gov/sequence.html?docID=20020137139
XX
SQ Sequence 399 BP; 83 A; 120 C; 120 G; 75 T; 0 U; 1 Other;

Query Match 0.6%; Score 22.8; DB 1; Length 399;
Best Local Similarity 56.8%; Pred. No. 55;
Matches 42; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 2651 GATGCTGGATGATCTACTGCTGATGAGTGGTGGTGAAGTCTCTGGAGTTGG 2710
DB 154 GCTGCTCTCTGAGAACATGATGATGAGGAGTGGTGTCTGGAAATCCCGAATGG 95
QY 2711 TGATGGACAGGAG 2724
DB 94 TCACGACAGTAAG 81

RESULT 116
AA111607
ID AA111607 standard; DNA; 468 BP.

XX AC AA111607;
XX
XX 12-OCT-2001 (first entry)
DE Probe #1540 for gene expression analysis in human cervical cell sample.
DE Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer; ss.

XX OS Homo sapiens.
XX
XX WO200157278-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US0006970.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632365.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DX, Chen W, Rank DR;
XX
XX WPI; 2001-488901/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human cervical epithelial cells.

XX Claim 25; SEQ ID NO 1540; 487pp; English.
XX
XX The present invention relates to human single exon nucleic acid probes
XX (SENP). The present sequence is one such probe. The SENPs are derived
XX from human HeLa cells. The SENPs can be used to produce a single exon
XX microarray, which can be used for measuring human gene expression in a
XX sample derived from human cervical epithelial cells. By measuring gene
XX expression, the probes are therefore useful in grading and/or staging of
XX diseases of the cervix, notably cervical cancer. Note: The sequence data
XX for this patent did not form part of the printed specification, but was
XX obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 468 BP; 122 A; 106 C; 129 G; 111 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 22.6; DB 1; Length 468;
XX Best Local Similarity 60.7%; Pred. No. 65;
XX Matches 37; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 2608 GGAGGGATTGGGGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGATC 2667
DB 79 GGAGGGAGTGGGGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGATC 138

QY 2668 A 2668
DB 139 A 139

RESULT 117
ABA53297
ID ABA53297 standard; DNA; 468 BP.

XX AC ABA53297;
XX
XX 01-FEB-2002 (first entry)
XX
XX Human foetal liver single exon nucleic acid probe #1602.
XX Human; foetal liver; gene expression; single exon nucleic acid probe; ss.

XX OS Homo sapiens.
XX
XX WO200157277-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000669.

XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632365.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DX, Chen W, Rank DR;
XX
XX WPI; 2001-483447/52.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human fetal liver.

XX Claim 1; SEQ ID NO 1602; 639pp + Sequence Listing; English.
XX
XX The invention relates to a single exon nucleic acid probe for measuring
XX human gene expression in a sample derived from human foetal liver. The
XX single exon nucleic acid probes may be used for predicting, measuring and
XX displaying gene expression in samples derived from human fetal liver. The
XX present sequence is a single exon nucleic acid probe of the invention.

XX DT 09-OCT-2001 (first entry)

XX KW Probe #1524 used to measure gene expression in human breast sample.

XX DE Probe; human; breast disease; breast cancer; development disorder; ss;

XX KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.

XX OS Homo sapiens.

XX PN W0200157270-A2.

XX XX 09-AUG-2001.

XX XX 29-JAN-2001; 2001WO-US000661.

XX PF 04-FEB-2000; 2000US-0180312P.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 30-JUN-2000; 2000US-00608408.

XX PR 03-AUG-2000; 2000US-00632366.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PA (MOLE-) MOLECULAR DYNAMICS INC.

XX XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX XX WPI; 2001-476286/51.

XX XX Novel single exon nucleic acid probe used to measuring gene expression in

XX XX a human breast.

XX PS Claim 25; SEQ ID NO 1524; 322bp; English.

XX CC The present invention relates to novel single exon nucleic acid probes.

XX CC measuring human gene expression in a human breast sample, where the probe

XX CC hybridises at high stringency to a nucleic acid expressed in the human

XX CC breast. The probes are useful for predicting, diagnosing, grading,

XX CC staging, monitoring and prognosing diseases of the human breast,

XX CC particularly those diseases with polygenic aetiology. The diseases

XX CC include: breast cancer, disorders of development, inflammatory diseases

XX CC of the breast, fibrocystic changes, proliferative breast disease and non-

XX CC carcinoma tumours. Note: The sequence data for this patent did not form

XX CC part of the printed specification, but was obtained in electronic format

XX CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 468 BP; 122 A; 106 C; 129 G; 111 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.6; DB 1; Length 468;

Best Local Similarity 60.7%; Pred. No. 65;

Matches 37; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 2608 GGAGGGATTGGGGCAGGAGAGAGGGGACGACAGAGGATGAGATGGCTGGATGGCATC 2667

DB 79 GGAGGGAGTGGGGCAGCAGAGATGCAGGGGGCAACATGCTAACTGGGTATTGACACC 138

QY 2668 A 2668

DB 139 A 139

RESULT 123

AAN60063

ID AAN60063 standard; cDNA; 2177 BP.

XX AC AAN60063;

XX AC AAN60063;

XX DT 25-MAR-2003 (revised)

XX DT 31-OCT-2002 (revised)

XX DT 23-MAY-1991 (first entry)

DE Partial Factor VII cDNA.

XX KW Factor VII; Factor VIIa; DNA construct.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT CDS 13..1128

XX FT /*tag= a

XX PN EP200421-A.

XX PD 10-DEC-1986.

XX PF 16-APR-1986; 86EP-00302855.

XX PR 17-APR-1985; 85US-00724311.

XX PR 16-DEC-1985; 85US-00810002.

XX PA (ZYMO) ZYMOGENETICS INC.

XX PI Hagen FS, Murry MJ, Berkner KL, Inasley MY, Woodbury RG, Gray CL;

XX DR WPI; 1986-326899/50.

XX DR P-PSDB; AAP60055.

XX PT DNA construct used to transfect hosts - to produce protein which

XX PT activates to give factor VIIa.

XX PS Disclosure; Fig 1A; 55pp; English.

XX CC The partial factor VII cDNA sequence is produced by joining portions of

XX CC cDNA clones lambda VII2115 and lambda VII1923. It is used in a DNA

XX CC construct which contains a nucleotide sequence encoding a protein which,

XX CC on activation, has the same biological activity for blood coagulation as

XX CC factor VIIa. The nucleotide codes at least partially for Factor VII and

XX CC comprises a sequence encoding a calcium binding domain joined to a second

XX CC sequence downstream of this encoding a catalytic domain for the serine

XX CC protease activity of Factor VIIa. The calcium binding domain comprises a

XX CC gene encoding Factor VII, IX, X, Protein C, prothrombin or protein S. The

XX CC construct is used to transfect host cells to produce the protein which,

XX CC on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing

XX CC OS field.) (Updated on 25-MAR-2003 to correct PA field.)

XX SQ Sequence 2177 BP; 569 A; 624 C; 605 G; 379 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.6; DB 1; Length 2177;

Best Local Similarity 48.8%; Pred. No. 94;

Matches 61; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

QY 2186 TGTGAGATTATTTTGGGGGGCTCCAAATCACTGCAGATGGTGAAGTCAAGCATGA 2245

DB 2045 TTCTCCCTTCGCTGGGTGCGGGTGCACAGACTATTCCCACTGCTTCCAGCTTCA 2104

QY 2246 AATTAAAGACACTTACCTCTGGAGAGAAAGTTAACCACTAGATAGCATATTGAAA 2305

DB 2105 CATTAACGGTGGCTGCTCTCCGCAAAAAA 2164

QY 2306 GCAGA 2310

DB 2165 AAAAA 2169

RESULT 124

ABN76724/c

ID ABN76724 standard; cDNA; 186 BP.

XX AC ABN76724;

XX AC ABN76724;

XX DT 08-JUL-2002 (first entry)

XX DE Human ORF1671 cDNA, SEQ ID NO:3341.

Human; ORF; open reading frame; ORFX; drug screening; diagnosis;
 disease monitoring; cytokine; cell proliferation; cell differentiation;
 immune modulation; haematopoiesis regulation; tissue growth;
 angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic;
 thrombolytic; tumour inhibition; bodily characteristic; fertility;
 behaviour; cancer; proliferative disorder; neurological disorder;
 cardiovascular disease; immune system disorder; organ transplantation;
 tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
 hypothyroidism; cholesterol ester storage disease; infection; vulnery;
 vasotropic; antipsoriatic; antidiabetic; cytostatic; neurotropic;
 neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
 cardiant; hypertensive; antithyroid; antiinflammatory; immunomodulator;
 dermatological; analgesic; virucide; antibacterial; fungicide; gene; ss.
 OS
 XX Homo sapiens.
 XX
 PN WO200190366-A2.
 XX
 PD 29-NOV-2001.
 XX
 PF 24-MAY-2001; 2001WO-US017076.
 XX
 PR 24-MAY-2000; 2000US-0206690P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Leach MD, Shinkets RA;
 XX
 XX WPI; 2002-106200/14.
 DR P-PSDB; ABP32898.
 DR
 XX

Novel human polypeptides and polynucleotides useful for diagnosing,
 preventing and treating cardiovascular disease, neurodegenerative,
 hyperproliferative disorders and disorders related to organ
 transplantation.
 Claim 1; Page 1094; 2508pp; English.
 Sequences ABP1028-ABP3561 represent 4534 novel human proteins
 designated ORF (open reading frame) 1-4534, and sequences ABN75054-
 ABN79587 represent cDNAs encoding them. The invention also encompasses
 polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
 referred to as ORFX) proteins, polynucleotides at least 85% identical to
 the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
 polynucleotides, the recombinant production of ORFX proteins, antibodies
 specific for ORFX proteins, methods of detecting ORFX polynucleotides and
 polypeptides, methods of screening for modulators of ORFX expression or
 activity, and methods of screening individuals for a predisposition to an
 ORFX-associated disorder. The ORFX proteins of the invention have a wide
 range of biological activities, such as cytokine, cell proliferation,
 cell differentiation, immune modulation, haematopoiesis regulation,
 tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
 chemokinetic activity, haemostatic activity, thrombolytic activity,
 receptor/ligand, antiinflammatory activity, tumour inhibition activity,
 and antiinfective activity, and may also be involved in the determination
 of bodily characteristics, fertility and behaviour. ORFX proteins,
 nucleic acids and antibodies may be used in the treatment of cancers,
 neuroproliferative disorders such as psoriasis and benign tumours,
 neurological disorders such as epilepsy and Alzheimer's disease,
 cardiovascular diseases, immune system disorders, disorders related to
 organ transplantation, disorders of tissue growth and regeneration,
 diseases such as diabetes mellitus, hypothyroidism, and cholesterol
 storage disease, and infectious diseases caused by viral, bacterial,
 fungal and other pathogens. ORFX nucleic acids may also be used as a
 source of primers and probes, in the detection of ORFX genomic sequences
 or transcripts, in the identification and cloning of homologous
 sequences, in genetic diagnosis, and in forensic biology. The ORFX
 nucleic acids may additionally be used to produce transgenic animals
 which may be useful for studying the function and/or activity of ORFX
 protein, and in drug screening. The ORFX proteins may also be used as
 immunogens to generate specific antibodies, which are useful in the
 diagnosis, treatment and monitoring of ORFX-associated diseases

SQ Sequence 186 BP; 37 A; 66 C; 51 G; 32 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22.4; DB 1; Length 186;
 Best Local Similarity 53.4%; Pred. No. 57;
 Matches 47; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
 QY 2670 TGACTCGATGACGACGTCTGGGTGAACTCCTCGAGTTGTGATGACAGGAGGCGCTG 2729
 Db 149 TGGCCCGGTTCAGGTGGCGGTAGATGAAGTTCAAGTTCAGGCCCGGGTGGTCCGCCAGTGC 89
 QY 2730 TCCTCGCGCGATTCATGGGGTCACAAAG 2757
 Db 88 GCAGCGGGCGCTGATGTCTCAGTAG 61

RESULT 125
 ABV97959/c
 ID ABV97959 standard; cDNA; 317 BP.
 XX
 AC ABV97959;
 XX
 DT 14-JAN-2003 (first entry)
 XX
 DE Human pancreatic cancer expressed cDNA SEQ ID NO 3367.
 XX
 DE Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
 KW cytostatic; tumour; gene; ss.
 KW
 XX Homo sapiens.
 OS
 XX WO200260317-A2.
 XX
 PD 08-AUG-2002.
 XX
 PF 30-JAN-2002; 2002WO-US002781.
 XX
 PR 30-JAN-2001; 2001US-0265305P.
 PR 31-JAN-2001; 2001US-0265682P.
 PR 09-FEB-2001; 2001US-0267568P.
 PR 21-MAR-2001; 2001US-0278651P.
 PR 28-APR-2001; 2001US-0287112P.
 PR 16-MAY-2001; 2001US-0291631P.
 PR 12-JUL-2001; 2001US-0305484P.
 PR 20-AUG-2001; 2001US-0333999P.
 PR 27-NOV-2001; 2001US-0333626P.
 XX
 (CORI-) CORIXA CORP.
 XX
 PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;
 DR WPI; 2002-627435/67.

New isolated polynucleotide and pancreatic tumor polypeptides, useful for
 diagnosing, preventing and/or treating cancer, particularly pancreatic
 cancer.

Claim 1; SEQ ID NO 3367; 300pp + Sequence Listing; English.

The invention relates to an isolated polynucleotide (I) comprising: (a)
 any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)
 complements of (a); (c) sequences consisting of at least 20 contiguous
 residues of (a); (d) sequences that hybridize to (a), under moderately
 stringent conditions; (e) sequences having at least 75% or 90% identity
 to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-
 CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer
 in a patient and compositions comprising polypeptides, polynucleotides,
 antibodies, fusion proteins, T cell populations and antigen presenting
 cells expressing the polypeptide are useful in treating pancreatic cancer
 and stimulating an immune response. The polynucleotides can be used as
 probes or primers for nucleic acid hybridization, in the design and
 preparation of ribozyme molecules for inhibiting expression of the tumour
 polypeptides and proteins in the tumour cells, in vaccines and for gene
 therapy. Note: The sequence data for this patent did not form part of the

CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 317 BP; 95 A; 79 C; 76 G; 67 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22.4; DB 1; Length 317;
 Best Local Similarity 62.5%; Pred. No. 66;
 Matches 35; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 3245 TTTTCTTCAAGTTTGAATGGCTAGCTAATCTTTGAGATTTTGAATGC 3300
 DB 311 TTTTCTTCAAGTTTGAATGGCTAGCTAATCTTTGAGATTTTGAATGC 256
 RESULT 126
 AAC70944/C
 ID AAC70944 standard; DNA; 253 BP.
 XX
 AC AAC70944;
 XX
 DT 09-FEB-2001 (first entry)
 XX
 DE Single nucleotide polymorphism containing sequence #258.
 XX
 KW Single nucleotide polymorphism; SNP; human; genetic disease;
 KW disease susceptibility; cardiovascular system; endocrine system;
 KW neurological system; forensic testing; paternity testing; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200058519-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 30-MAR-2000; 2000WO-US008440.
 XX
 PR 31-MAR-1999; 99US-0127248P.
 XX
 PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFY-) AFYMETRIX INC.
 XX
 PI Altschuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
 PI Lipshutz RJ, Patil N, Sklar P;
 XX
 WPI; 2000-611722/58.
 DR
 XX
 PT Nucleic acid selected from one of 106 genes comprising single nucleotide
 PT polymorphisms, allele-specific oligonucleotides to the genes are useful
 PT for phenotypic correlations, forensics, paternity testing, medicine and
 PT genetic analysis.
 XX
 PS Claim 1; Fig 5; 214pp; English.
 XX
 CC The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases. Note: The degenerate codon within the sequence represents the
 CC position of an SNP, for example the letter S represents a polymorphism
 CC where the nucleotide may be C or G
 XX
 SQ Sequence 253 BP; 92 A; 41 C; 58 G; 61 T; 0 U; 1 Other;
 Query Match 0.6%; Score 22.3; DB 1; Length 253;
 Best Local Similarity 50.7%; Pred. No. 65;
 Matches 77; Conservative 0; Mismatches 72; Indels 3; Gaps 1;
 QY 3131 CTTTCTCAAGTTTGAATGGCTAGCTAATCTTTGAGATTTTGAATGC 3190
 DB 311 TTTTCTTCAAGTTTGAATGGCTAGCTAATCTTTGAGATTTTGAATGC 256

Db 176 CTTCCCTCCTCCCTAGCGGCGACAGATCATCTTATGGTTATTTATGCTCTGTA 117
 QY 3191 TCCTTAAATTCATATTTCTTTGATAACAGCTTCAGTTCCTATGCTTTAATAAGTTTTT 3250
 Db 116 TCTCTTCTGGCACTCTTCGTTGTGTC---CTAAGGGTATCTTGGCTTCTGGAGAGTATT 60
 QY 3251 TTTTCTTCTTTTAAAGAAATCTCATTTCTTT 3282
 Db 59 TTGTAATTTCTGAAAAAAATTTTGTGTT 28

RESULT 127
 ABV97709
 ID ABV97709 standard; cDNA; 397 BP.
 XX
 AC ABV97709;
 XX
 DT 14-JAN-2003 (first entry)
 XX
 DE Human pancreatic cancer expressed cDNA SEQ ID NO 3117.
 XX
 KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
 KW cytostatic; tumour; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200260317-A2.
 XX
 PD 08-AUG-2002.
 XX
 PF 30-JAN-2002; 2002WO-US002781.
 XX
 PR 30-JAN-2001; 2001US-0265305P.
 PR 31-JAN-2001; 2001US-0265682P.
 PR 09-FEB-2001; 2001US-0267568P.
 PR 21-MAR-2001; 2001US-0278651P.
 PR 28-APR-2001; 2001US-0287112P.
 PR 16-MAY-2001; 2001US-0291631P.
 PR 12-JUL-2001; 2001US-0305484P.
 PR 20-AUG-2001; 2001US-0313999P.
 PR 27-NOV-2001; 2001US-0333626P.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;
 WPI; 2002-627435/67.
 DR
 XX
 PT New isolated polynucleotide and pancreatic tumor polypeptides, useful for
 PT diagnosing, preventing and/or treating cancer, particularly pancreatic
 PT cancer.
 XX
 PS Claim 1; SEQ ID NO 3117; 300pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated polynucleotide (I) comprising: (a)
 CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV93145); (b)
 CC complements of (a); (c) sequences consisting of at least 20 contiguous
 CC residues of (a); (d) sequences that hybridize to (a), under moderately
 CC stringent conditions; (e) sequences having at least 75% or 90% identity
 CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-
 CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer
 CC in a patient and compositions comprising polypeptides, polynucleotides,
 CC antibodies, fusion proteins, T cell populations and antigen presenting
 CC cells expressing the polypeptide are useful in treating pancreatic cancer
 CC and stimulating an immune response. The polynucleotides can be used as
 CC probes or primers for nucleic acid hybridisation, in the design and
 CC preparation of ribozyme molecules for inhibiting expression of the tumour
 CC polypeptides and proteins in the tumour cells, in vaccines and for gene
 CC therapy. Note: The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 397 BP; 84 A; 97 C; 89 G; 112 T; 0 U; 15 Other;

Db 310 TTTCACATATGATCTTAAAAAATGAATACCAAAACCAAGATCTCTCTTAAAA 251
 QY 1323 CCTAAATCCATCC 1336
 Db 250 TGAATTTAATCC 237
 RESULT 130
 ABX49447/c
 ID ABX49447 standard; cDNA; 432 BP.
 XX
 AC ABX49447;
 DT 21-FEB-2003 (first entry)
 XX
 DE Bovine EST associated with lactation/muscle/fat deposition #14612.
 XX
 KW Bovine; ss: EST; expressed sequence tag; lactation; LMFD;
 KW muscle deposition; fat deposition; genome mapping; gene identification;
 KW gene analysis; cattle breeding.
 XX
 OS Bos Taurus.
 XX
 PN US2002137139-A1.
 XX
 PD 26-SEP-2002.
 XX
 PF 24-SEP-2001; 2001US-00960352.
 XX
 PR 12-JAN-1999; 99US-0115707P.
 PR 11-JAN-2000; 2000US-00480902.
 XX
 PA (BYAT/) BYATT J C.
 PA (MATH/) MATHIALAGAN N.
 PA (TAON/) TAO N.
 PA (WARR/) WARREN W C.
 XX
 PI Byatt JC, Mathialagan N, Tao N, Warren WC;
 XX
 DR WPI; 2003-110599/10.
 XX
 PT New nucleic acid associated with lactation, and muscle and fat
 PT deposition, useful for genome mapping; gene identification and analysis,
 PT cattle breeding, or for genetically improving cattle.
 XX
 PS Claim 2; SEQ ID NO 14612; 245pp; English.
 XX
 CC The invention relates to a purified nucleic acid molecule associated with
 CC lactation or muscle and fat deposition (designated LMFD), derived from
 CC cattle, and the LMFD nucleic acid can specifically hybridize to a second
 CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
 CC appearing as ABX34836-ABX49947, or complements of them. Also included are
 CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic
 CC acid linked to a promoter and a 3' non-translated sequence that
 CC functions in the cell to cause termination of transcription and addition
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
 CC (2) determining a level or pattern of a molecule in a bovine cell or
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
 CC of the 15112 nucleic acid sequences or its complement or fragment) with a
 CC complementary nucleic acid molecule obtained from the bovine cell or
 CC tissue, where hybridisation between the marker nucleic acid and the
 CC complementary nucleic acid permits the detection of the molecule; and (b)
 CC detecting the level or pattern of the complementary nucleic acid, where
 CC the detection of the complementary nucleic acid is predictive of the
 CC level or pattern of the molecule. The LMFD nucleic acid is used for
 CC determining a level or pattern of a molecule in a bovine cell or tissue.
 CC It is useful for genome mapping, gene identification and analysis, cattle
 CC breeding, preparation of constructs for use in cattle gene expression, or
 CC for genetically improving cattle. The present sequence is one of the
 CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The
 CC present sequence was not shown in the specification but was obtained in
 CC electronic format from the USPTO web site:

CC seqdata.uspto.gov/sequence.html?docID=20020137139
 XX
 SQ Sequence 432 BP; 140 A; 69 C; 107 G; 116 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22; DB 1; Length 432;
 Best Local Similarity 53.5%; Fred. No. 91;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
 QY 2919 TACTTATTATTTGGGATTTTAACTATTCTTCAATGACTGTTGTTTCAATATTAC 2978
 Db 267 TCGTTCCAAAATTCAGTAGTTTCTCAGTGTGTTTCAAAAACCTCTCGTCTTCAAAA 208
 QY 2979 TTATTCTATTATTACTTTAAATTCACCT 3004
 Db 207 CTACATTTTCTCTTTACATTTCTCT 182
 RESULT 131
 ABX44157/c
 ID ABX44157 standard; cDNA; 534 BP.
 XX
 AC ABX44157;
 XX
 DT 21-MAY-2002 (first entry)
 XX
 DE cDNA #97 encoding human pancreatic tumour protein.
 XX
 KW Human; pancreatic tumour protein; immune response; pancreatic cancer;
 KW development of cancer; cancer progression; cytostatic; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200212331-A2.
 XX
 PD 14-FEB-2002.
 XX
 PF 06-AUG-2001; 2001WO-US024619.
 XX
 PR 07-AUG-2000; 2000US-0223130P.
 PR 30-JAN-2001; 2001US-0265447P.
 PR 15-MAY-2001; 2001US-0291201P.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Pyle RA, Xu J, Kalos MD;
 XX
 DR WPI; 2002-241741/29.
 XX
 PT Novel polynucleotide encoding pancreatic tumor polypeptides, useful in
 PT pharmaceutical compositions, e.g. vaccines, for treating pancreatic
 PT cancers.
 XX
 PS Claim 1; Page 144; 167pp; English.
 XX
 CC The present invention relates to the isolation of cDNA sequences encoding
 CC human pancreatic tumour proteins. The polynucleotide sequences encoding
 CC human pancreatic tumour proteins are useful for stimulating an immune
 CC response in a patient and treating pancreatic cancer in a patient. A host
 CC cell that expresses these polynucleotides is useful for determining the
 CC presence of cancer in a patient. A composition comprising the
 CC polynucleotide, its encoded protein, or an antibody that binds to the
 CC protein may be used in the diagnosis, prevention and/or treatment of
 CC diseases, particularly pancreatic cancer. The sequences of the invention
 CC are also useful in pharmaceutical compositions, e.g. vaccines, for the
 CC diagnosis and treatment of pancreatic cancer. Such compositions may be
 CC useful for inhibiting the development of cancer in a patient, or as
 CC markers for the progression of cancer. The polynucleotide sequences may
 CC also be used as probes or primers for nucleic acid hybridisation assays.
 CC ABX44061-ABX44209 represent cDNA sequences encoding for human pancreatic
 CC tumour proteins
 XX
 SQ Sequence 534 BP; 110 A; 164 C; 137 G; 121 T; 0 U; 2 Other;


```
Query Match      0.6%; Score 22; DB 1; Length 534;
Best Local Similarity 63.0%; Pred. No. 96;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

OY  921 CCTTTAGAACTAACACCCAAAAGAGATGTCCTTCTCATTATAGGGGACTGGAA 974
DB  64 CCTCAGAGTGTAGCCGCCCAACATCTTGTCATCATCAATCAAGGGGGACGAA 11

RESULT 132
AAN81633/C
ID  AAN81633 standard; DNA; 741 BP.
XX
AC  AAN81633;
XX
25-MAR-2003 (revised)
DT  07-NOV-1990 (first entry)
XX
DE  Human spleen trypsin III (trypsinogen III).
XX
KW  Human spleen plasminogen; trauma lesions; ss.
XX
OS  Homo sapiens.
XX
FH  Key
FT  CDS
FT  1..741
FT  /*tag= a
FT  /product= "human spleen plasminogen III."
XX
PN  JP63160582-A.
XX
PD  04-JUL-1988.
XX
PF  25-DEC-1986; 86JP-00307770.
XX
PR  25-DEC-1986; 86JP-00307770.
XX
PA  (SANY ) SANKYO CO LTD.
XX
WPI; 1988-224890/32.
DR  P-PSDB; AAP81243.
XX
Human spleen trypsin - used to treat lesions or trauma, without
PT  hypersensitive allergic side effects.
XX
PS  Claim 8+9; Page 3; 9pp; Japanese.
XX
Expression vectors E.coli LE 392 and YA 21 are preferable for mass
CC  production, and animal cells or B.subtilis are suitable for the
CC  production of an enzyme of similar activity to that of natural human
CC  spleen trypsinogen. Culturing the recombinant cells produced the desired
CC  trypsin as insoluble protein in inclusion bodies and the trypsin can be
CC  isolated by lysing the cells by a suitable method. The trypsin was then
CC  isolated and purified. The product is used in the treatment of lesions or
CC  trauma, eg burnis, gangrene, abscesses, injury etc. (Updated on 25-MAR-
XX  2003 to correct PA field.)
XX
Sequence 741 BP; 160 A; 214 C; 200 G; 167 T; 0 U; 0 Other;

Query Match      0.6%; Score 22; DB 1; Length 741;
Best Local Similarity 63.0%; Pred. No. 1e+02;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

OY  921 CCTTTAGAACTAACACCCAAAAGAGATGTCCTTCTCATTATAGGGGACTGGAA 974
DB  94 CCTCAGAGTGTAGCCGCCCAACATCTTGTCATCATCAATCTTGTCATCAAGGGGGACGAA 41

RESULT 133
AAT04001/C
ID  AAT04001 standard; cDNA to mRNA; 744 BP.
XX
AC  AAT04001;
XX
25-MAR-2003 (revised)
DT  19-MAR-1996 (first entry)
XX
DE  Human pancreatic trypsin III cDNA.
XX
KW  Pancreatic trypsin III; trypsinogen; human; hydrolysis; ds.
XX
OS  Homo sapiens.
XX
FH  Key
FT  CDS
FT  1..744
FT  /*tag= a
FT  /product= "pancreatic_trypsin_III"
XX
PN  JP07184655-A.
XX
PD  25-JUL-1995.
XX
```

```
XX  25-MAR-2003 (revised)
DT  19-MAR-1996 (first entry)
XX
DE  Human pancreatic trypsin III cDNA.
XX
KW  Pancreatic trypsin III; trypsinogen; human; hydrolysis; ds.
XX
OS  Homo sapiens.
XX
FH  Key
FT  CDS
FT  1..744
FT  /*tag= a
FT  /product= "pancreatic_trypsin_III"
XX
PN  JP07184655-A.
XX
PD  25-JUL-1995.
XX
PF  25-DEC-1986; 94JP-00311512.
XX
PR  25-DEC-1986; 86JP-00307770.
XX
PA  (SANY ) SANKYO CO LTD.
XX
WPI; 1995-287966/38.
XX
Novel human pancreatic trypsin III - can be easily produced by
PT  recombinant methods.
XX
PS  Claim 4; Page 9; 11pp; Japanese.
XX
AAT03999-T04001 are all human cDNA sequences which code for pancreatic
CC  trypsin III (AAR87203), the sequences differ only in their stop codons.
CC  The cDNA molecules can be used in the recombinant production of trypsin
CC  which can be used as a drug to treat diseases wherein trypsin production
CC  is impaired. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ  Sequence 744 BP; 161 A; 214 C; 201 G; 168 T; 0 U; 0 Other;

Query Match      0.6%; Score 22; DB 1; Length 744;
Best Local Similarity 63.0%; Pred. No. 1e+02;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

OY  921 CCTTTAGAACTAACACCCAAAAGAGATGTCCTTCTCATTATAGGGGACTGGAA 974
DB  94 CCTCAGAGTGTAGCCGCCCAACATCTTGTCATCATCAATCTTGTCATCAAGGGGGACGAA 41

RESULT 134
AAT04000/C
ID  AAT04000 standard; cDNA to mRNA; 744 BP.
XX
AC  AAT04000;
XX
25-MAR-2003 (revised)
DT  19-MAR-1996 (first entry)
XX
DE  Human pancreatic trypsin III cDNA.
XX
KW  Pancreatic trypsin III; trypsinogen; human; hydrolysis; ds.
XX
OS  Homo sapiens.
XX
FH  Key
FT  CDS
FT  1..744
FT  /*tag= a
FT  /product= "pancreatic_trypsin_III"
XX
PN  JP07184655-A.
XX
PD  25-JUL-1995.
XX
```

PF 25-DEC-1986; 94JP-00311512.
 XX 25-DEC-1986; 86JP-00307770.
 XX (SANY) SANKYO CO LTD.
 PA WPI; 1995-287966/38.
 DR P-PSDB; AAR82703.
 XX Novel human pancreatic trypsin III - can be easily produced by
 PT recombinant methods.
 XX Claim 3; Page 7-8; 11pp; Japanese.
 XX AAT03999-T04001 are all human cDNA sequences which code for pancreatic
 CC trypsin III (AAR87203), the sequences differ only in their stop codons.
 CC The cDNA molecules can be used in the recombinant production of trypsin
 CC which can be used as a drug to treat diseases wherein trypsin production
 CC is impaired. (Updated on 25-MAR-2003 to correct PF field.)
 XX SQ Sequence 744 BP; 161 A; 214 C; 201 G; 168 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22; DB 1; Length 744;
 Best Local Similarity 63.0%; Pred. No. 1e+02;
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
 QY 921 CCTTTAGAACTAACACCCCAAAAGATGTCCTTCTCATTATAGGGGACTGGAA 974
 DB 94 CCTCACAGGTGTAGCCCCCAACAATCTTGTCTCATCTGTCACAAAGGGGACAGCAA 41
 RESULT 135
 AAT03999/c
 ID AAT03999 standard; cDNA to mRNA; 744 BP.
 AC AAT03999;
 XX 25-MAR-2003 (revised)
 DT 19-MAR-1996 (first entry)
 XX Human pancreatic trypsin III cDNA.
 XX Pancreatic trypsin III; trypsinogen; human; hydrolysis; ds.
 OS Homo sapiens.
 XX Key Location/Qualifiers
 FH 1..744
 FT CDS
 FT /*tag= a
 FT /product= "pancreatic_trypsin_III"
 XX JP07184655-A.
 XX 25-JUL-1995.
 XX 25-DEC-1986; 94JP-00311512.
 XX 25-DEC-1986; 86JP-00307770.
 XX (SANY) SANKYO CO LTD.
 PA WPI; 1995-287966/38.
 DR P-PSDB; AAR87203.
 XX Novel human pancreatic trypsin III - can be easily produced by
 PT recombinant methods.
 XX Claim 2; Page 6-7; 11pp; Japanese.
 XX AAT03999-T04001 are all human cDNA sequences which code for pancreatic
 CC trypsin III (AAR87203), the sequences differ only in their stop codons.
 CC The cDNA molecules can be used in the recombinant production of trypsin
 CC which can be used as a drug to treat diseases wherein trypsin production

CC is impaired. (Updated on 25-MAR-2003 to correct PF field.)
 XX SQ Sequence 744 BP; 162 A; 214 C; 200 G; 168 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22; DB 1; Length 744;
 Best Local Similarity 63.0%; Pred. No. 1e+02;
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
 QY 921 CCTTTAGAACTAACACCCCAAAAGATGTCCTTCTCATTATAGGGGACTGGAA 974
 DB 94 CCTCACAGGTGTAGCCCCCAACAATCTTGTCTCATCTGTCACAAAGGGGACAGCAA 41
 RESULT 136
 AAV24548/c
 ID AAV24548 standard; cDNA; 790 BP.
 AC AAV24548;
 XX 16-SEP-1998 (first entry)
 DT Trypsinogen-like protein coding sequence.
 DE Trypsinogen-like protein; human; ds.
 OS Homo sapiens.
 XX Key Location/Qualifiers
 FH 1..723
 FT CDS
 FT /*tag= a
 FT /product= "trypsinogen-like protein"
 XX JP10099080-A.
 XX 21-APR-1998.
 XX 26-SEP-1996; 96JP-00273923.
 XX 26-SEP-1996; 96JP-00273923.
 XX (SHIS) SHISEIDO CO LTD.
 XX WPI; 1998-289873/26.
 DR P-PSDB; AAW57740.
 XX DNA encoding trypsinogen-like protein - used for recombinant production
 PT of the protein.
 XX Claim 1; Page 4-5; 7pp; Japanese.
 XX This sequence represents the gene of the invention, and encodes a human
 CC trypsinogen-like protein
 XX SQ Sequence 790 BP; 183 A; 234 C; 205 G; 168 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22; DB 1; Length 790;
 Best Local Similarity 63.0%; Pred. No. 1e+02;
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
 QY 921 CCTTTAGAACTAACACCCCAAAAGATGTCCTTCTCATTATAGGGGACTGGAA 974
 DB 73 CCTCACAGGTGTAGCCCCCAACAATCTTGTCTCATCTGTCACAAAGGGGACAGCAA 20
 RESULT 137
 ABZ35087/c
 ID ABZ35087 standard; cDNA; 853 BP.
 AC ABZ35087;
 XX 05-FEB-2003 (first entry)
 DT Human gene expression profile polynucleotide SEQ ID NO 199.
 XX DE

XX Human; artery; endothelium; umbilical; vein; aorta; pulmonary artery;
KW bronchial epithelium; prostate; muscle; lung fibroblast; osteoblast;
KW tumour; microarray; genome mapping; antibiotic; antiviral; antifungal;
KW gene expression; gene; ss.
XX Homo sapiens.
XX WO200274979-A2.
XX 26-SEP-2002.
XX 20-MAR-2002; 2002WO-US008456.
XX 20-MAR-2001; 2001US-0276947P.
XX (ORTH) ORTHO CLINICAL DIAGNOSTICS INC.
XX Wan J, Wang Y;
XX WPI, 2002-740862/80.
XX New gene expression profile generated from primary, endothelial,
PT epithelial, and muscle cell types, useful for identifying disease
PT pathologies involving alterations of gene expression, e.g. cancer.
XX Claim 5; Page 405; 850pp; English.
XX The invention relates to a gene expression profile comprising one or more
CC genes (AB234889-AB235692) and generated from a cell type. The cell type
CC is a coronary artery endothelium, umbilical artery or vein endothelium,
CC aortic endothelium, dermal microvascular endothelium, pulmonary artery
CC endothelium, myometrium microvascular endothelium, keratinocyte
CC epithelium, bronchial epithelium, mammary epithelium, prostate
CC epithelium, renal cortical epithelium, renal proximal tubule epithelium,
CC small airway epithelium, renal epithelium, umbilical artery smooth
CC muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle,
CC dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes,
CC aortic smooth muscle, mesangial cells, coronary artery smooth muscle,
CC bronchial smooth muscle, uterine smooth muscle, lung fibroblast,
CC osteoblasts or prostate stromal cell. The gene expression profile is used
CC for determining the level of RNA expression for a sample, determining the
CC phenotype of a cell and distinguishing cell types. The gene or a protein
CC expression profile is useful in identifying disease pathologies involving
CC alterations of gene expression. The assessment of expression profiles may
CC provide meaningful information with respect to tumour type and stage,
CC treatment methods, and prognosis. The gene or protein expression profile
CC may also be used for creating microarrays. The microarray is useful for
CC genetic and physical mapping of genomes, DNA sequencing, genetic or
CC medical diagnosis, genotyping of organisms, confirming cell or tissue
CC identifications and in identifying promising antibiotics, antiviral or
CC antifungal agents
XX SQ Sequence 853 BP; 192 A; 253 C; 231 G; 177 T; 0 U; 0 Other;
Query Match 0.6%; Score 22; DB 1; Length 853;
Best Local Similarity 63.0%; Pred. No. 1.1e+02;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 921 CCTTTAGACTACACCCAAAGAGATGCTCTTCTCATTTATAGGGGACTGGAA 974
Db 137 CCTCAGGCTGAGCCCCCAACAACTTCTGTCATCTGTCACAAAGGGGACAGCA 84
RESULT 138
ABA79599/C
ID ABA79599 standard; DNA; 121 BP.
XX ABA79599;
XX ABA79599;
XX 24-JAN-2002 (first entry)
DT
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2445.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;
KW antileptic; ss.
XX Homo sapiens.
XX WO200173002-A2.
XX 04-OCT-2001.
XX 27-MAR-2001; 2001WO-US009761.
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192179P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX (UYDE) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI, 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX Claim 7; Page 183; 294pp; English.
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX SQ Sequence 121 BP; 29 A; 28 C; 16 G; 48 T; 0 U; 0 Other;
Query Match 0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 72;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTTCCTCAAGGCAACCAATTCATCA 844
Db 72 GAAGTTTGTGAAACACTGAAAGAACAGTGTGATTTCCACATAATACCTTCAGATGCA 13
QY 845 CAGTA 849
Db 12 GAGCA 8
RESULT 139
ABA79602
ID ABA79602 standard; DNA; 121 BP.
XX

AC ABA79602;
 XX 24-JAN-2002 (first entry)
 XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2448..
 DE Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 XX retinoblastoma; BRCA1, BRCA2, CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisticking; antianaemic; haemostatic;
 KW antileptic; ss.
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 XX
 XX 27-MAR-2000; 2000US-0192176P.
 XX
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 01-JUN-2000; 2000US-0208538P.
 PR
 XX 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 183; 294pp; English.
 PS
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 XX Sequence 121 BP; 49 A; 16 C; 28 G; 28 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 21.8; DB 1; Length 121;
 Best Local Similarity 58.5%; Pred. No. 72;
 Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTCTTTGTTTCCAGGCAACCATTCATCA 844
 DB 52 GAAGTTTTCGAAACACTGAAAGACAGTGTATTTCCATATATACCTTCAGATGCA 111
 QY 845 CAGTA 849
 DB 112 GAGCA 116

RESULT 140
 ABA79603/C
 ID ABA79603 standard; DNA; 121 BP.
 XX
 AC ABA79603;
 XX
 XX 24-JAN-2002 (first entry)
 DE
 XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2449.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1, BRCA2, CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisticking; antianaemic; haemostatic;
 KW antileptic; ss.
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 XX
 XX 27-MAR-2000; 2000US-0192176P.
 XX
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 01-JUN-2000; 2000US-0208538P.
 PR
 XX 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 183; 294pp; English.
 PS
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 XX Sequence 121 BP; 28 A; 28 C; 16 G; 49 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 21.8; DB 1; Length 121;
 Best Local Similarity 58.5%; Pred. No. 72;
 Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTCTTTGTTTCCAGGCAACCATTCATCA 844
 DB 70 GAAGTTTTCGAAACACTGAAAGACAGTGTATTTCCATATATACCTTCAGATGCA 111


```
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000666.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488990/53.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX hearts.
XX
XX Claim 4; SEQ ID NO 15265; 530pp; English.
XX
XX The present invention relates to single exon nucleic acid probes for
XX measuring human gene expression in a sample derived from human heart. The
XX present sequence is one such probe. The probes may be used for
XX predicting, measuring and displaying gene expression in samples derived
XX from the human heart via microarrays. By measuring gene expression, the
XX probes are useful for predicting, diagnosing, grading, staging,
XX monitoring and prognosing diseases of the human heart and vascular system
XX e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
XX congenital heart disease. Note: The sequence data for this patent did not
XX form part of the printed specification, but was obtained in electronic
XX format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 224 BP; 46 A; 50 C; 97 G; 31 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 21.8; DB 1; Length 224;
XX Best Local Similarity 51.5%; Pred. No. 86;
XX Matches 50; Conservative 0; Mismatches 47; Indels 0; Gaps 0;
XX
XX 2655 GCTGGATGGCATCACTGATCGATGACGTGAGTCTGGTGAACCTCTGGAGTTGGTGAT 2714
XX 12 GCTGAACGAGAGAGAGAGACCCGGGAGGAGGACGTGCGAGAGCTGCAGGAGATGGTGCA 71
XX
XX 2715 GGACAGGAGGCGCTCTCTCGCGCGGATTTCATGGGGTC 2751
XX 72 GCGCGAGGCGGCTCTCGGGGAGGAGCTGCGCGTGCC 108
XX
XX RESULT 146
XX AAK44064
XX ID AAK44064 standard; DNA; 224 BP.
XX
XX AC AAK44064;
XX
XX DT 06-NOV-2001 (first entry)
XX
XX Human bone marrow expressed single exon probe SEQ ID NO: 18621.
XX
XX Human; bone marrow expressed exon; gene expression analysis; probe;
XX microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
XX Homo sapiens.
XX
XX WO200157276-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488990/53.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX hearts.
XX
XX Claim 4; SEQ ID NO 15265; 530pp; English.
XX
XX The present invention relates to single exon nucleic acid probes for
XX measuring human gene expression in a sample derived from human heart. The
XX present sequence is one such probe. The probes may be used for
XX predicting, measuring and displaying gene expression in samples derived
XX from the human heart via microarrays. By measuring gene expression, the
XX probes are useful for predicting, diagnosing, grading, staging,
XX monitoring and prognosing diseases of the human heart and vascular system
XX e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
XX congenital heart disease. Note: The sequence data for this patent did not
XX form part of the printed specification, but was obtained in electronic
XX format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 224 BP; 46 A; 50 C; 97 G; 31 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 21.8; DB 1; Length 224;
XX Best Local Similarity 51.5%; Pred. No. 86;
XX Matches 50; Conservative 0; Mismatches 47; Indels 0; Gaps 0;
XX
XX 2655 GCTGGATGGCATCACTGATCGATGACGTGAGTCTGGTGAACCTCTGGAGTTGGTGAT 2714
XX 12 GCTGAACGAGAGAGAGAGACCCGGGAGGAGGACGTGCGAGAGCTGCAGGAGATGGTGCA 71
XX
XX 2715 GGACAGGAGGCGCTCTCTCGCGCGGATTTCATGGGGTC 2751
XX 72 GCGCGAGGCGGCTCTCGGGGAGGAGCTGCGCGTGCC 108
XX
XX RESULT 146
XX AAK44064
XX ID AAK44064 standard; DNA; 224 BP.
XX
XX AC AAK44064;
XX
XX DT 06-NOV-2001 (first entry)
XX
XX Human bone marrow expressed single exon probe SEQ ID NO: 18621.
XX
XX Human; bone marrow expressed exon; gene expression analysis; probe;
XX microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
XX Homo sapiens.
XX
XX WO200157276-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX
```

```
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488990/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human bone marrow.
XX
XX Example 4; SEQ ID NO 18621; 658pp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX bone marrow. They can be used to measure gene expression in bone marrow
XX samples, which may enable the improved diagnosis and treatment of cancers
XX such as lymphoma, leukaemia and myeloma. The present sequence is one of
XX the probes of the invention
XX
XX Sequence 224 BP; 46 A; 50 C; 97 G; 31 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 21.8; DB 1; Length 224;
XX Best Local Similarity 51.5%; Pred. No. 86;
XX Matches 50; Conservative 0; Mismatches 47; Indels 0; Gaps 0;
XX
XX 2655 GCTGGATGGCATCACTGATCGATGACGTGAGTCTGGTGAACCTCTGGAGTTGGTGAT 2714
XX 12 GCTGAACGAGAGAGAGAGACCCGGGAGGAGGACGTGCGAGAGCTGCAGGAGATGGTGCA 71
XX
XX 2715 GGACAGGAGGCGCTCTCTCGCGCGGATTTCATGGGGTC 2751
XX 72 GCGCGAGGCGGCTCTCGGGGAGGAGCTGCGCGTGCC 108
XX
XX RESULT 147
XX AAK18172
XX ID AAK18172 standard; DNA; 224 BP.
XX
XX AC AAK18172;
XX
XX DT 05-NOV-2001 (first entry)
XX
XX Human brain expressed single exon probe SEQ ID NO: 18163.
XX
XX Human; brain expressed exon; gene expression analysis; probe; microarray;
XX Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
XX ss.
XX
XX Homo sapiens.
XX
XX WO200157275-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488990/53.
XX
```


DE XX cDNA #91 encoding human pancreatic tumour protein.
KW Human; pancreatic tumour protein; immune response; pancreatic cancer;
KW development of cancer; cancer progression; cytostatic; gene; ss.
XX
OS Homo sapiens.
XX WO200212331-A2.
XX 14-FEB-2002.
XX
XX 06-AUG-2001; 2001WO-US024619.
XX
XX 07-AUG-2000; 2000US-0223130P.
XX 30-JAN-2001; 2001US-0265447P.
XX 15-MAY-2001; 2001US-0291201P.
XX (CORI-) CORIXA CORP.
XX
XX Pyle RA, Xu J, Kalos MD;
XX WPI; 2002-241741/29.
XX
XX Novel polynucleotide encoding pancreatic tumor polypeptides, useful in
XX pharmaceutical compositions, e.g. vaccines, for treating pancreatic
XX cancers.
XX
XX Claim 1; Page 142; 167pp; English.
XX
XX The present invention relates to the isolation of cDNA sequences encoding
XX human pancreatic tumour proteins. The polynucleotide sequences encoding
XX human pancreatic tumour proteins are useful for stimulating an immune
XX response in a patient and treating pancreatic cancer in a patient. A host
XX cell that expresses these polynucleotides is useful for determining the
XX presence of cancer in a patient. A composition comprising the
XX polynucleotide, its encoded protein, or an antibody that binds to the
XX protein may be used in the diagnosis, prevention and/or treatment of
XX diseases, particularly pancreatic cancer. The sequences of the invention
XX are also useful in pharmaceutical compositions, e.g. vaccines, for the
XX diagnosis and treatment of pancreatic cancer. Such compositions may be
XX useful for inhibiting the development of cancer in a patient, or as
XX markers for the progression of cancer. The polynucleotide sequences may
XX also be used as probes or primers for nucleic acid hybridisation assays.
XX ABK44061-ABK44209 represent cDNA sequences encoding for human pancreatic
XX tumour proteins
XX
XX Sequence 522 BP; 110 A; 162 C; 132 G; 116 T; 0 U; 2 Other;
SQ
Query Match 0.6%; Score 21.8; DB 1; Length 522;
Best Local Similarity 62.7%; Pred. No. 1.1e+02;
Matches 32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 921 CCGTTTGAAGCTTAACACCCAAAGATGCTCTCTATTATAGGGGACTG 971
Db 52 CCTCACAGATGATAGCCCCACGACGATCTTGTATCATCATCAAGGGGNCNG 2
RESULT 152
AAL48492
ID AAL48492 standard; DNA; 711 BP.
XX
XX AAL48492;
XX
XX 11-OCT-2002 (first entry)
XX
XX Human serine protease MP493 related coding sequence.
XX
XX Human; serine protease; MP493; cancer; kidney disease; lung disease;
KW protein coordinate data; cytostatic; antiasthmatic; anti-allergic;
KW anti-inflammatory; virucide; immunomodulator; gene; ds.
XX
XX Homo sapiens.
XX
XX
XX
FH Key Location/Qualifiers
FT 1..711
FT /*tag= a
FT /product= "unknown protein"
FT /partial
FT /note= "no start or stop codon"
XX
XX WO200259295-A1.
XX
XX 01-AUG-2002.
XX
XX 23-JAN-2002; 2002WO-JP000465.
XX
XX 23-JAN-2001; 2001JP-00014963.
XX (MOCH) MOCHIDA PHARM CO LTD.
XX
XX Nakamura Y, Sugano S, Matsusue T, Okamoto A, Okawa K;
XX WPI; 2002-566849/60.
XX P-PSDB; AAO18403.
XX
XX Transmembrane serine protease MP493 for diagnosis of and developing drugs
XX for cancer, kidney diseases and lung diseases e.g. asthma, allergy,
XX bronchitis, pneumonectasis, pancreatitis and nephritis.
XX
XX Claim 2; Page 158; 163pp; Japanese.
XX
XX The present invention provides the protein and coding sequences of a
XX human serine protease designated MP493. The sequences can be used in the
XX diagnosis of and development of drugs for treating cancer, kidney and
XX lung diseases, for example asthma, allergy, bronchitis, pneumonectasis,
XX viral diseases, shock, multiple organ failure, pancreatitis and
XX nephritis. The present sequence is a coding sequence shown in the
XX exemplification of the invention
XX
XX Sequence 711 BP; 149 A; 205 C; 212 G; 145 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 21.8; DB 1; Length 711;
Best Local Similarity 56.2%; Pred. No. 1.2e+02;
Matches 41; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
QY 185 ACTAGTCAATCTAATCACATAGGACACAGCCTTGTCTAATCAATGAAGTAAAGCCAT 244
Db 188 ACATATCCAGCCCATCCACTTGGTGAGAGATGCTTACCACACCAAGTACAGCCAA 247
QY 245 GCCCGTGGGGCAA 257
Db 248 AGAGGCTGGGCAA 260
RESULT 153
AAQ43935/c
ID AAQ43935 standard; DNA; 268 BP.
XX
XX AAQ43935;
XX
XX 25-MAR-2003 (revised)
XX 22-OCT-1993 (first entry)
XX
XX MetTyr human proinsulin.
XX
XX Deletion; cistron; expression; human insulin; interferon; interleukin;
KW tissue plasminogen activator; growth hormone releasing factor;
KW translational activating sequence; HPI; human proinsulin; ds.
XX
XX Synthetic.
XX
XX EF547873-A2.
XX
XX 23-JUN-1993.
XX
XX 15-DEC-1992; 92EP-00311446.

XX PR 18-DEC-1991; 91US-00811045.
XX PA (ELIL) LILLY & CO ELI.
XX PI Hershberger CL, Sterner JL;
XX XX WPI; 1993-198846/25.
DR WPI; 1993-198846/25.
PT Translating activating sequence - used for high level expression of e.g.
PT human insulin precursors.
XX XX Example 3; Page 13; 55pp; English.
XX XX Example 3 describes the construction of plasmid pHD121. The gene
CC encoding MetTyr human proinsulin was produced from synthesised
CC oligonucleotides, which, when annealed, comprise both complementary
CC strands of the MetTyr human proinsulin gene with Ndel-BamHI cohesive
CC ends. (Updated on 25-MAR-2003 to correct PN field.)
XX XX Sequence 268 BP; 49 A; 75 C; 87 G; 57 T; 0 U; 0 Other;
SQ Query Match 0.6%; Score 21.6; DB 1; Length 268;
Best Local Similarity 53.6%; Pred. No. 1e+02;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 2550 CCAGTACTTTGGCCACCTGATCAGAGAGCTGACTCACTGGAAGACCCCTGATCTGGG 2609
DB 159 CCTGCACCCGGGCCACCCGACCTCCACCTGACCTGACCTGCTCTGCTCAGG 100
QY 2610 AGGGATTGGGGCAGGAGGAGAAG 2633
DB 99 CGGGTCTTCGGGGTGTAGAAGAAG 76
RESULT 154
AAQ05663/c
ID AAQ05663 standard; DNA; 281 BP.
AC AAQ05663;
XX 25-MAR-2003 (revised)
DT 04-JAN-1991 (first entry)
XX Human proinsulin gene.
XX Human proinsulin gene; human insulin analogues; ds; sticky ends.
XX Synthetic.
XX EP383472-A.
XX 22-AUG-1990.
XX 06-FEB-1990; 90EP-00301224.
XX 09-FEB-1989; 89US-00308352.
PR 04-AUG-1989; 89US-00388201.
XX (ELIL) LILLY & CO ELI.
XX Chance RE, Dimarchi RD, Frank BH, Shields JE;
PI WPI; 1990-255722/34.
DR New human insulin analogues - modified at position 29 to the B chain to
PT reduce dimerisation or self-association to high mol. wt. forms.
XX Example 29; Page 31; 67pp; English.
XX The gene was synthesised using standard techniques. The 5' end of the
CC sense strand overhangs the complementary strand by 4 bases, the 5' end of
CC the complementary strand overhangs the sense strand by 4 bases. This gene

CC was, together with other components, used in the construction of plasmid
CC PRB145. See also AAQ05662-3, AAR06443-4 and AAR07658-60. (Updated on 25-
CC MAR-2003 to correct PA field.)
XX XX Sequence 281 BP; 52 A; 79 C; 90 G; 60 T; 0 U; 0 Other;
SQ Query Match 0.6%; Score 21.6; DB 1; Length 281;
Best Local Similarity 53.6%; Pred. No. 1e+02;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 2550 CCAGTACTTTGGCCACCTGATCAGAGAGCTGACTCACTGGAAGACCCCTGATCTGGG 2609
DB 166 CCTGCACCCGGGCCACCCGACCTCCACCTGACCCACCTGAGTCTCTGCTCAGG 107
QY 2610 AGGGATTGGGGCAGGAGGAGAAG 2633
DB 106 CGGGTCTTCGGGGTGTAGAAGAAG 83
RESULT 155
AAQ38310/c
ID AAQ38310 standard; DNA; 281 BP.
XX XX AAQ38310;
AC AAQ38310;
XX 25-MAR-2003 (revised)
DT 19-JUL-1993 (first entry)
XX hpi gene.
XX Proinsulin; hpi; native; PCZR126S; expression vector; E. coli; human;
KW expression; immunological effect; ss.
XX Homo sapiens.
XX Key Location/Qualifiers
FT CDS 9..275
FT /*tag= a
XX EPS34705-A2.
XX 31-MAR-1993.
XX 22-SEP-1992; 92EP-00308601.
XX 24-SEP-1991; 91US-00764655.
XX (ELIL) LILLY & CO ELI.
XX Belagaje RM;
XX WPI; 1993-102806/13.
DR P-PSDE; AAR33855.
XX Expression of low molecular wt. polypeptide(s) e.g. insulin growth factor
PT I - by expressing as deriv. with N-terminal aminoacid to provide
PT increased expression levels.
XX Disclosure; Page 21-22; 40pp; English.
XX This sequence encodes an analogue of native human proinsulin (hpi). This
CC sequence was used in the construction of the expression vector of the
CC invention. The coding region of the hpi gene was synthesised and was
CC cloned into the expression plasmid pCZR126S (see also AAQ38307).
CC Expression of this gene lead to the inclusion of an extra amino acid
CC (Arg) in the second position from the N-terminal of mature hpi. The extra
CC amino acid provides increased expression levels of the protein and is
CC then cleaved off to avoid undesirable immuno- logical effects when used
CC in humans. (Updated on 25-MAR-2003 to correct PN field.)
XX XX Sequence 281 BP; 52 A; 79 C; 90 G; 60 T; 0 U; 0 Other;
SQ Query Match 0.6%; Score 21.6; DB 1; Length 281;

Best Local Similarity 53.6%; Pred. No. 1e+02;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 2550 CCACTTCTTTGGCCACTGATCAGAGAGCTGACTGAGAAAGACCTGATCTGGG 2609
166 CTTGCACCCCGGGCCACCGCCAGCTCCACTGACCCAGCTGAGGTCCTCTGCTTCAAGG 107

QY 2610 AGGATTGGGGCAGGAGGAGAG 2633
Db 106 CGGCTCTTCGGGTGTAGAAGAG 83

RESULT 156
ACR03539
ID ACA03539 standard; DNA; 360 BP.
XX
AC ACA03539;
XX
DT 22-MAY-2003 (first entry)
XX
DE Synthetic DNA encoding immunogenic HIV peptide #22.
XX
KW Immunogenic HIV polypeptide; human immunodeficiency virus; HIV; vaccine;
KW gene therapy; packaging cell line; humoral immune response;
KW cellular immune response; gene delivery vector; DNA immunisation; ds.
XX
OS Synthetic.
XX
PN WO2003004657-A1.
XX
PD 16-JAN-2003.
XX
PF 05-JUL-2002; 2002WO-US021421.
XX
PR 05-JUL-2001; 2001US-0303192P.
PR 31-AUG-2001; 2001US-0316860P.
PR 16-JAN-2002; 2002US-0349728P.
PR 16-JAN-2002; 2002US-0349753P.
PR 16-JAN-2002; 2002US-0349871P.
XX
PA (CHIR) CHIRON CORP.
XX
PI Zur Megede J, Barnett SW, Lian Y;
XX
DR WPI; 2003-221602/21.
XX
PT New synthetic polynucleotides encoding antigenic HIV type B and/or type C
PT polypeptides, useful as immunogenic compositions or vaccines for
PT generating humoral or cellular immune responses against HIV in a subject,
PT especially humans.
XX
PS Example 1; Fig 27; 262pp; English.
XX
CC The invention describes a synthetic polynucleotide encoding 2 or more
CC immunogenic HIV polypeptides, where at least 2 of the polypeptides are
CC derived from different HIV subtypes. The polynucleotide is useful for
CC immunisation, generation of packaging cell lines, or production of HIV
CC polypeptides. The polynucleotide and its encoded proteins are useful as
CC immunogenic compositions or vaccines for generating humoral or cellular
CC immune responses against HIV in a subject, or for inducing neutralising
CC antibodies against HIV. The gene delivery vector comprising the
CC polynucleotide is also useful for DNA immunisation of, or for generating
CC an immune response (e.g. a humoral or cellular immune response) in, a
CC subject such as a mammal, particularly a human. This sequence encodes a
CC human immunodeficiency virus immunogenic peptide

QY 2602 ATGCTGGAGGATTTGGGGCAGGAGGAGAGGGGACGACAGAGATGAGATGCTGGAT 2661
Query Match 0.6%; Score 21.6; DB 1; Length 360;
Best Local Similarity 50.0%; Pred. No. 1.1e+02;
Matches 54; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

Db 31 AAGTGGGCAAGCCGGCTACGTGACCGACCGGGCGGCGAGAGGTGTGACATCGCC 90
QY 2662 GGCACTACTGACTGATGGAGCTGAGTCTGGTGAATCTCTGGAGTTG 2709
Db 91 GACACCAACCAACGAGAGACCGAGCTGCAGGCCATCCACCTGGCCCTG 138

RESULT 157
ACC78504
ID ACC78504 standard; DNA; 360 BP.
XX
AC ACC78504;
XX
DT 27-OCT-2003 (revised)
DT 18-AUG-2003 (first entry)
XX
DE HIV p15RnaseH.opt.SF2 nucleotide sequence.
XX
KW HIV; gag; nef; prot; tat; rev; vif; vpr; vpu; env; anti-HIV; vaccine;
KW immune response; ds.
XX
OS Human immunodeficiency virus 1.
XX
PN WO2003020876-A2.
XX
PD 13-MAR-2003.
XX
PF 05-JUL-2002; 2002WO-US021342.
XX
PR 31-AUG-2001; 2001US-0316860P.
PR 16-JAN-2002; 2002US-0349728P.
XX
PA (CHIR) CHIRON CORP.
XX
PI Zur Megede J, Barnett SW, Lian Y;
XX
DR WPI; 2003-278761/27.
XX
PT New expression cassettes and polynucleotides encoding HIV Gag, Nef, Prot,
PT Tat, Rev, Vif, Vpr, Vpu, or Env polypeptides, useful for DNA immunization
PT or generating an immune response against HIV in a subject.
XX
PS Example; Fig 26; 214pp; English.
XX
CC The invention relates to an expression cassette comprising a
CC polynucleotide sequence encoding a polypeptide including an HIV Gag, Nef,
CC Prot, Tat, Rev, Vif, Vpr, Vpu, or Env polypeptide. The expression
CC cassettes, HIV polypeptides and polynucleotides encoding the HIV
CC polypeptides are useful for DNA immunization or generating an immune
CC response against HIV in a subject. The polynucleotides are also useful
CC for generating packaging cell lines or producing the HIV polypeptides.
CC The present sequence represents a HIV p15RnaseH.opt.SF2 nucleotide
CC sequence. (Updated on 27-OCT-2003 to standardise OS field)
XX
SQ Sequence 360 BP; 84 A; 113 C; 125 G; 38 T; 0 U; 0 Other;
Query Match 0.6%; Score 21.6; DB 1; Length 360;
Best Local Similarity 50.0%; Pred. No. 1.1e+02;
Matches 54; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

QY 2602 ATGCTGGAGGATTTGGGGCAGGAGGAGAGGGGACGACAGAGATGAGATGCTGGAT 2661
Db 31 AAGTGGGCAAGCCGGCTACGTGACCGACCGGGCGGCGAGAGGTGTGAGCATCGCC 90
QY 2662 GGCACTACTGACTGATGAGCTGAGTCTGGTGAATCTCTGGAGTTG 2709
Db 91 GACACCAACCAACGAGAGACCGAGCTGCAGGCCATCCACCTGGCCCTG 138

RESULT 158
ABX37095
ID ABX37095 standard; cDNA; 372 BP.

XX AC ABX37095;
XX DT 20-FEB-2003 (first entry)
XX DE Bovine EST associated with lactation/muscle/fat deposition #2260.
XX KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;
XX KW muscle deposition; fat deposition; genome mapping; gene identification;
XX KW gene analysis; cattle breeding.
XX OS Bos Taurus.
XX XX US2002137139-A1.
XX XX 26-SEP-2002.
XX XX 24-SEP-2001; 2001US-00960352.
XX XX 12-JAN-1999; 98US-0115707P.
XX XX 11-JAN-2000; 2000US-00480902.
XX XX (BYAT/) BYATT J C.
XX XX (MATH/) MATHIALAGAN N.
XX XX (TAON/) TAO N.
XX XX (WAER/) WARREN W C.
XX PI Byatt JC, Mathialagan N, Tao N, Warren WC;
XX DR WPI; 2003-110599/10.
XX XX New nucleic acid associated with lactation, and muscle and fat
XX PT deposition, useful for genome mapping, gene identification and analysis,
XX PT cattle breeding, or for genetically improving cattle.
XX XX Claim 2; SEQ ID NO 2260; 245pp; English.
XX XX The invention relates to a purified nucleic acid molecule associated with
XX CC lactation or muscle and fat deposition (designated LMFD), derived from
XX CC cattle, and the LMFD nucleic acid can specifically hybridize to a second
XX CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
XX CC appearing as ABX34836-ABX4947, or complements of them. Also included are
XX CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic
XX CC acid linked to a promoter and a 3' non-translated sequence that
XX CC functions in the cell to cause termination of transcription and addition
XX CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
XX CC (2) determining a level or pattern of a molecule in a bovine cell or
XX CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
XX CC of the 15112 nucleic acid sequences or its complement or fragment) with a
XX CC complementary nucleic acid molecule obtained from the bovine cell or
XX CC tissue, where hybridisation between the marker nucleic acid and the
XX CC complementary nucleic acid permits the detection of the molecule; and (b)
XX CC detecting the level or pattern of the complementary nucleic acid, where
XX CC the detection of the complementary nucleic acid is predictive of the
XX CC level or pattern of the molecule. The LMFD nucleic acid is used for
XX CC determining a level or pattern of a molecule in a bovine cell or tissue.
XX CC It is useful for genome mapping, gene identification and analysis, cattle
XX CC breeding, preparation of constructs for use in cattle gene expression, or
XX CC for genetically improving cattle. The present sequence is one of the
XX CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The
XX CC present sequence was not shown in the specification but was obtained in
XX CC electronic format from the USPTO web site:
XX CC seqdata.uspto.gov/sequence.html?DocID=20020137139
XX XX Sequence 372 BP; 113 A; 73 C; 87 G; 99 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.6; DB 1; Length 372;
Best Local Similarity 53.6%; Pred. No. 1.1e+02;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
OY 2957 GACTTGTATTTCTAATTAATTTACTTATTTCTAATTTACTTAAATGCACTATTATTGGA 3016
DB 269 GACTATTTTTCATACGACTACGAAATTTCTTGAGGCTGAAATTAATTTGGGATAA 328

OY 3017 TTTTCTTATAAAATCCAGTCCTT 3040
DB 329 CGTCACTCAAGCAACCAATCAAT 352
RESULT 159
AAK53749
ID AAK53749 standard; cDNA; 427 BP.
XX AC AAK53749;
XX XX 16-NOV-2001 (first entry)
XX DE Murine transport and binding associated protein encoding cDNA SEQ ID 314.
XX KW Murine; liver; gene library; amino acid synthesis; binding protein;
XX KW cell metabolism; energy metabolism; fatty acid metabolism; synthesis;
XX KW phospholipid metabolism; purine; pyrimidine; nucleoside; nucleotide;
XX KW replication; transcription; translation; transport protein; ss.
XX OS Mus musculus.
XX XX DE20103510-U1.
XX XX 07-JUN-2001.
XX XX 28-FEB-2001; 2001DE-02003510.
XX XX 28-FEB-2001; 2001DE-02003510.
XX XX (LION-) LION BIOSCIENCE AG.
XX XX WPI; 2001-368570/39.
XX PT Gene library containing sequences with specific 3'-ends and no polyA
XX PT tail, encoding proteins involved in a wide range of cellular processes.
XX PS Claim 15; Page 106; 251pp; German.
XX CC This invention describes a novel gene library (A) comprises a gene
XX CC sequence (or its part) encoding a protein involved in amino acid
XX CC synthesis, cellular/energy metabolism, metabolism of fatty
XX CC acids/phospholipids, synthesis or breakdown of
XX CC purines/pyrimidines/nucleosides/nucleotides, DNA
XX CC replication/transcription/translation, or is a transport/binding protein.
XX CC (A) are produced that correspond to the 3'-end of mRNA but without the
XX CC polyA tail. They can be prepared more efficiently and with less effort
XX CC than conventional libraries. AAK53436-AAK54275 represent fragments of the
XX CC gene library described in the method of the invention
XX XX Sequence 427 BP; 95 A; 126 C; 101 G; 105 T; 0 U; 0 Other;
XX XX Query Match 0.6%; Score 21.6; DB 1; Length 427;
XX XX Best Local Similarity 53.6%; Pred. No. 1.2e+02;
XX XX Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
OY 3457 TGGCTTTAAAGATTTGCTGTATTAACATGATTAAGTCTTATTGCACTATAGTG 3516
DB 326 TGGCTGCACACGATGTTCTCCGAGACCACTTCTCATGACCTCCACCACTCATTTC 385
OY 3517 GAGTCACAAAGAGTTGGACATGA 3540
DB 386 GAGCAACCAAGGATCGCGATGA 409
RESULT 160
ABX14193
ID ABX14193 standard; DNA; 6098 BP.
XX AC ABX14193;
XX XX 11-MAR-2003 (first entry)

CC hyperproliferative disease, inflammation, tumour formation and to prevent
CC or delay infection. As such, the present invention describes these
CC antisense oligos as having cytostatic, antiinflammatory and antimicrobial
CC activities. This polynucleotide is the DNA of the human oestrogen
CC receptor alpha splice variant designated ESR-alpha VII of the invention.
XX
XX Sequence 144 BP; 38 A; 48 C; 40 G; 18 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 21.4; DB 1; Length 144;
Best Local Similarity 61.8%; Pred. No. 97;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 2680 GACGTGAGTCTGGGTGAACCTGCTGAGTGTGGTATGACAGGAGGCTGCTCTG 2734
DB 106 GAGGAGGAGCTGGGCCGCGCTGCTGCTGCTGCTGAGGTACGGCTGCTGCTG 52
RESULT 162
AAD58758
ID AAD58758 standard; DNA; 172 BP.
XX AC AAD58758;
XX
XX 04-DEC-2003 (first entry)
XX Human transmembrane serine protease (TSP1-TSP34) gene exon 11.
DE Human; transmembrane serine protease; TSP; therapy; immunogen; cancer;
XX Human; transmembrane serine protease; TSP; therapy; immunogen; cancer;
XX autoimmune disease; immunomodulatory; immunosuppressive; enzyme; ds.
OS Homo sapiens.
XX WO2003064541-A1.
PN 07-AUG-2003.
XX 24-JAN-2003; 2003WO-EP000756.
XX 30-JAN-2002; 2002US-0352806P.
XX (GENE-) GENEPROT INC.
PA Bougueleret L, Niknejad A, Saudrais C;
PI WPI; 2003-627608/59.
XX New purified transmembrane serine protease polypeptides (TSP1-TSP34)
XX comprising a protease domain or its biologically active portion, useful
XX for identifying modulators of proteolysis.
PT Claim 6; Page 232; 276pp; English.
PS
XX The invention relates to purified human transmembrane serine protease
XX (TSP) polypeptide, comprising a protease domain of a type-II membrane-
XX type serine protease or its biologically active portion. The invention is
XX useful for cleaving a TSP substrate protein by contacting TSP with a
XX substrate protein under serine protease activity permissive conditions.
XX The invention is useful as an immunogen to generate antibodies that bind
XX TSP or TSP1-TSP43 proteins, useful for treating disease e.g. cancer and
XX autoimmune disease. The present sequence is human TSP1-TSP34 gene exon
XX
XX Sequence 172 BP; 26 A; 51 C; 66 G; 29 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 21.4; DB 1; Length 172;
Best Local Similarity 54.4%; Pred. No. 1e+02;
Matches 43; Conservative 0; Mismatches 36; Indels 0; Gaps 0;
QY 21 GGAGAGGTACCTCTCTCCAGGTAGGAGCAGTACCTGCTGCTGCTGGAGCACC 80
DB 66 GGGGAGGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 125
QY 81 GTAAAGAGATACCCACGC 99

DB 126 GTGCTGGGGGACCGCTGGC 144
RESULT 163
AAA49060
ID AAA49060 standard; DNA; 243 BP.
XX AC AAA49060;
XX 15-SEP-2003 (revised)
DT 16-NOV-2000 (first entry)
XX
XX Snut O-N-Lang DNA used in HIV DNA vaccine.
DE HIV; human immunodeficiency virus; vaccine; AIDS; snut;
XX silent nucleotide substitution; ds.
XX Human immunodeficiency virus 1.
XX WO200029561-A2.
PN 25-MAY-2000.
PD 27-MAR-2000; 2000WO-DK000144.
PF 29-MAR-1999; 99DK-00000427.
PR 09-APR-1999; 99US-0128558P.
XX (STAT-) STATENS SERUM INST.
PA Fomsgaard A;
XX WPI; 2000-387778/33.
DR P-PSDB; AAY99891.
XX Producing nucleotide sequence construct with optimized codons for human
XX immunodeficiency virus (HIV) genetic vaccine involves obtaining a first
XX nucleotide sequence from a HIV patient, redesigning and assembling it
XX with snuts.
XX Example 3; Page 94; 150pp; English.
XX The present invention relates to a nucleotide construct with optimised
XX codons for use as a human immunodeficiency virus (HIV) DNA vaccine. The
XX construct uses codons from highly expressed mammalian proteins to code
XX for each derivative of an early, primary HIV envelope gene. The first
XX stage in the production of the construct was the cloning of an HIV
XX envelope gene. A nucleotide sequence encoding this gene was then created
XX using codons from highly expressed mammalian genes. The present sequencing
XX is one of the snuts (AAA49060-A49079) that were created by redesigning
XX this nucleotide construct so that restriction enzyme sites surrounded
XX functional regions of the sequence. The snuts were then assembled into
XX pieces (AAA49080-A49092). Each derivative of the envelope gene (AAA49093-
XX A49097) was then built using the pieces. The HIV DNA vaccine may be used
XX as a prophylactic vaccine and as a therapeutic vaccine in HIV infected
XX patients. (Updated on 15-SEP-2003 to standardise OS field)
XX Sequence 243 BP; 53 A; 81 C; 77 G; 32 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 21.4; DB 1; Length 243;
Best Local Similarity 61.8%; Pred. No. 1.1e+02;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 1423 CATGACATTGTACAGGAGACAGGATCGACACCATCCCATGGAAGAAGATGCA 1477
DB 163 CAGGAGGTGTGCTGGGCAACGTCACCGAGACTTTCACATGGCGACAGAACACA 217
RESULT 164
ABV98158/C
ID ABV98158 standard; cDNA; 380 BP.
XX AC ABV98158;

XX	12-JUL-2002 (first entry)	Oligonucleotide for detecting cytosine methylation SEQ ID NO 34558.
DT		Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
XX		drug; side effect; cancer; central nervous system; cardiovascular;
DE		gastrointestinal; respiratory system; single nucleotide polymorphism;
XX		SNP; cell differentiation; ds.
XX		Homo sapiens.
OS		WO200218632-A2.
PN		07-MAR-2002.
XX		01-SEP-2001; 2001WO-EP010074.
PD		01-SEP-2000; 2000DE-01043826.
XX		05-SEP-2000; 2000DE-01044543.
PR		(EPIG-) EPIGENOMICS AG.
XX		Olek A, Piepenbrock C, Berlin K, Guetig D;
PI		WPI; 2002-371829/40.
XX		Determining the degree of cytosine methylation in genomic DNA, useful for
XX		diagnosis and prognosis, comprises selective hybridization of amplicons
PT		from chemically treated DNA.
PT		Claim 12; 56pp + Sequence Listing; 56pp; German.
XX		This invention describes a novel method for determining the degree of
CC		methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC		genomic sample of DNA. The sample is treated chemically to convert
CC		cytosine (C) but not methylated C, to uracil, then part of the genomic
CC		DNA that contains the target C is amplified to form a labeled amplicon.
CC		The amplicon is hybridised to two classes, each with at least one member,
CC		of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC		degree of hybridisation to both classes is determined from the label on
CC		the amplicon. From the ratio of labels hybridised to the two classes of
CC		oligomers, the degree of methylation is calculated. The method is used:
CC		(i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC		and of a wide range of diseases, e.g. cancer, disorders of the central
CC		nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC		particularly by detecting mutations or single nucleotide polymorphisms
CC		(SNP's); and (ii) for differentiation of cell or tissue types and for
CC		investigating cell differentiation. The method allows the methylation
CC		status of many C residues to be determined simultaneously. ABO13410-
CC		ABO54121 represent genomic DNA sequences used to illustrate the method
CC		for determining the degree of cytosine methylation described in the
CC		disclosure of the invention
XX		Sequence 612 BP; 236 A; 216 C; 72 G; 88 T; 0 U; 0 Other;
XX		Query Match 0.6%; Score 21.4; DS 1;
XX		Best Local Similarity 54.4%; Pred.No. 1.4e+02;
XX		Matches 43; Conservative 0; Mismatches 56; Indels 0; Gaps 0
QY	3206	TTCTTTGATAACAGCTTCAGTTCATGCGCTTAATAAAGTTTTTTTTTTTTTTTTTTT 3261
Db	84	TTTTTATATAGAAAATACGATTTCGAAAGATATATTAGGCTGTTTTTTTAAATTTT 25
QY	3266	AAAGAATGTCATTCTTTGT 3284
Db	24	AGGAGTTTTTTAGTTTT 6
XX		RESULT 167
XX		ABA74567
XX		ID ABA74567 standard; DNA; 177 BP.

AC	ABA74567;
XX	
DT	01-FEB-2002 (first entry)
XX	
DE	Human foetal liver single exon nucleic acid probe #22872.
XX	
KW	Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX	
OS	Homo sapiens.
XX	
PN	WC200157277-A2.
XX	
PD	09-AUG-2001.
XX	
PP	30-JAN-2001; 200IWO-US000669.
XX	
PR	04-FEB-2000; 200OUS-0180312P.
XX	
PR	26-MAY-2000; 200OUS-0207456P.
XX	
FR	30-JUN-2000; 200OUS-00808408.
XX	
PR	03-AUG-2000; 200OUS-00832366.
XX	
PR	21-SEP-2000; 200OUS-0234687P.
XX	
PR	27-SEP-2000; 200OUS-0236359P.
XX	
PR	04-OCT-2000; 200OGB-00024263.
XX	
PA	(MOLE-) MOLECULAR DYNAMICS INC.
XX	
PI	Penn SG, Hanzel DK, Chen W, Rank DR;
XX	
DR	WPI; 2001-483447/52.
XX	
PT	Human genome-derived single exon nucleic acid probes useful for analyzing
XX	gene expression in human fetal liver.
XX	
PS	Claim 4; SEQ ID NO 22872; 63pp + Sequence Listing; English.
XX	
CC	The invention relates to a single exon nucleic acid probe for measuring
XX	human gene expression in a sample derived from human foetal liver. The
CC	single exon nucleic acid probes may be used for predicting, measuring and
XX	displaying gene expression in samples derived from human fetal liver. The
CC	present sequence is a single exon nucleic acid probe of the invention.
XX	Note: The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
XX	at ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 177 BP; 44 A; 45 C; 44 G; 44 T; 0 U; 0 Other;
	Query Match 0.6%; Score 21.2; DB 1; Length 177;
	Best Local Similarity 53.7%; Fred.No. 1.2e+02;
	Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY	2764 ACAGCACTGCACAACCTGAACCTGACTGACTGCTACTGAAACCTTAGTGTATTACT 2823
Db	4 AGACCCTGGAACATGAGAGAGAGAGATTTCTACTGTCACAGACACTCTCTTGAT 63
QY	2824 CAGAAAATAGTAATTTCATATG 2845
Db	64 CTGCAAAATACGACTTCATCATG 85
RESULT 168	
AAI55048	
ID	RAI55048 standard; DNA; 177 BP.
XX	
AC	RAI55048;
XX	
DT	17-OCT-2001 (first entry)
XX	
DE	Probe #23734 used to measure gene expression in human placenta sample.
XX	
KW	Probe; microarray; human; placenta; antenatal diagnosis;
XX	genetic disorder; ss.
XX	
OS	Homo sapiens.

PT	New peptide useful as a marker for the diagnosis of breast cancer.
XX	
PS	Claim 1; Page 2657-2658; 3695pp; English.
XX	
CC	The invention relates to human breast cancer expressed polynucleotides
CC	(AA07544-AAL26789) and methods of assessing whether a patient is
CC	afflicted with breast cancer by examining the correlation between the
CC	expression of certain markers and the cancerous state of breast cells.
CC	The polynucleotides and encoded polypeptides are potential markers for
CC	detecting, diagnosing, monitoring, characterizing treating and
CC	potentially preventing breast cancer. The polynucleotides and encoded
CC	polypeptides are also useful for isolating compounds with cytostatic
CC	activity
XX	
SQ	Sequence 280 BP; 69 A; 70 C; 74 G; 67 T; 0 U; 0 Other;
Query Match	0.6%; Score 21.2; DB 1; Length 280;
Best Local Similarity	53.7%; Pred. No. 1.3e+02;
Matches	44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY	2764 ACACGACTCAGCAACTGAACCTGAACCTTACTGTGAAACCTTAGTTATATTACT 2823
Db	110 AGACCACCTGGACAATGAGAAGAGAGAACTTCTGGTCAGACAGACTCTTGAT 169
QY	2824 CAGAAAATAGTAATTTTCATATG 2845
Db	170 CTGCAAAATACGACTTCATCATG 191
RESULT 174	
ABK30273	
ID	ABK30273 standard; cDNA; 505 BP.
XX	
AC	ABK30273;
XX	
DT	23-APR-2002 (first entry)
XX	

XX	Human; ss; gene; G-protein-coupled protease; gene therapy; transgenic;
XX	protease mediated disorder; proliferative disorder;
KW	differentiative disorder; developmental disorder;
KW	haematopoietic disorder.
XX	
XX	Homo sapiens.
OS	
XX	US6331427-B1.
PN	
XX	18-DEC-2001.
PD	
XX	26-MAR-1999; 99US-00280116.
XX	
XX	26-MAR-1999; 99US-00280116.
PR	
XX	(WILL-) MILLENNIUM PHARM INC.
PA	
XX	Robison KE;
PI	
XX	WPI; 2002-129545/17.
DR	
XX	New polynucleotides encoding protease homologs of the G-protein-coupled
PT	protease family, useful in identifying agonists and antagonists for
PT	diagnosis and treatment of protease mediated disorders.
PT	
PS	Disclosure; Col 95-98; 246pp; English.
XX	
XX	The invention relates to an isolated human protease nucleic acid molecule
CC	comprising a nucleotide sequence of 546 base pairs, one of 268 fully
CC	defined in the specification. Also disclosed are production of an
CC	isolated polypeptide encoded by the nucleic acid, comprising introducing
CC	the nucleic acid into a host cell and culturing under conditions to
CC	express the protein from the nucleic acid, use of an antibody to detect
CC	the encoded protein in a sample and to modulate its in vivo activity,

CC identifying agents that bind to the protein and identification of a
 CC polynucleotide agent that modulates the expression of the nucleic acid or
 CC its complement (i.e. gene therapy). The nucleic acid can be used to
 CC identify an agent that modulates the expression or activity of the
 CC nucleic acid, and can be used to isolate the protein. The nucleic acid
 CC can be used in diagnostic assays for determining nucleic acid expression
 CC as well as activity in the context of a biological sample (e.g., blood,
 CC serum, cells, tissue) to determine whether an individual has a disease or
 CC disorder, or is at risk of developing a disease or disorder, associated
 CC with aberrant expression or activity of the nucleic acid. The nucleic
 CC acid can be used to detect mutations in protease genes and gene
 CC expression products such as mRNA. The nucleic acid can be used as
 CC hybridisation probes to detect naturally-occurring genetic mutations in a
 CC protease gene. The nucleic acid can be used in drug screening methods to
 CC identify agonists and antagonists that can be used to diagnose and treat
 CC such protease mediated disorders e.g., proliferative, differentiative,
 CC developmental or haematopoietic disorders. The nucleic acid can be used
 CC as probes, primers, in biological assays, to determine patterns of gene
 CC expression, to design ribozymes and to construct transgenic animals. The
 CC present sequence represents one of the 268 disclosed human G-protein-
 CC coupled protease cDNA sequences

XX
 SQ Sequence 505 BP; 95 A; 135 C; 170 G; 105 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.2; DB 1; Length 505;
 Best Local Similarity 69.0%; Pred. No. 1.5e+02;
 Matches 29; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 3253 TTTTCTTTTAAAGATGTCATCTTCTTGGAAGTTTGA 3294
 Db 1 TTTTCTTTTCTAAACAGATGCATTTAATGGAAATCTTAA 42

RESULT 175
 ADA50533
 ID ADA50533 standard; DNA; 609 BP.
 AC ADA50533;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human protease gene SEQ ID NO:37.
 XX
 KW ds; enzyme; gene; human; protease.
 XX
 OS Homo sapiens.
 XX
 PN WO2003040393-A2.
 XX
 PD 15-MAY-2003.
 XX
 PF 04-NOV-2002; 2002WO-1B004615.
 XX
 PR 06-NOV-2001; 2001US-0332633P.
 XX
 PA (DECO-) DECODE GENETICS EHF.
 XX
 PI Martinez RAM, Sigurdsson GT;
 XX
 DR WPI: 2003-441582/41.
 DR P-PSDB; ADA50486.
 XX

XX Novel isolated protease polypeptide and polynucleotide encoding the
 PT polypeptide useful for diagnosing and treating diseases or conditions
 PT associated with a protease.
 XX
 PS Claim 4; Page 80-81; 16pp; English.
 XX
 CC The invention relates to a novel isolated polypeptide comprising an amino
 CC acid sequence that has greater than 95 % identity to any one of 47 150-
 CC 350 residue protease polypeptide sequences, given in the specification.
 CC The nucleic acids, probes, primers, polypeptides and antibodies of the
 CC invention can be used in methods of diagnosis of a susceptibility to a

CC disease or condition associated with a protease. The present sequence
 CC represents a protease gene of the invention.
 XX
 SQ Sequence 609 BP; 139 A; 153 C; 156 G; 161 T; 0 U; 0 Other;
 Query Match 0.6%; Score 21.2; DB 1; Length 609;
 Best Local Similarity 47.1%; Pred. No. 1.6e+02;
 Matches 65; Conservative 0; Mismatches 73; Indels 0; Gaps 0;

Qy 2908 TGATTTTCTCTACTTATTAAATTTGGGATTTTAACTATTTCCTCAATGACTGTATTT 2967
 Db 143 TTTATTTGCCATATATAGATCATGCTGTGGCCCTTTTGTGTTTGGAAATTTCTTCCATTT 202

Qy 2968 CTAATATTACTTATTCTATTACTTTAATTCACCTTATTATTGATTTTCTTAATA 3027
 Db 203 GGAATGGGAACATTTACCAATACCTTACCTGCAATTTGTTTCTTACAGATGTAGTA 262

Qy 3028 AAATCCAGTCCTTTT 3045
 Db 263 TTTGTAGGATCATGTGT 280

RESULT 176
 ABK31769
 ID ABK31769 standard; DNA; 888 BP.
 XX
 AC ABK31769;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE DNA encoding novel human protease #26.
 XX
 KW Human; protease; cancer; immune-related disorder; cardiovascular disease;
 KW neuronal-associated disease; metabolic disorder; inflammatory disorder;
 KW nervous system disorder; sexual dysfunction; pain; mood disorder;
 KW hypertension; psychotic disorder; neurological disorder; dyskinesia;
 KW viral infection; human immunodeficiency virus; HIV; non-viral infection;
 KW ocular disease; cytostatic; gene; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200200860-A2.
 XX
 PD 03-JAN-2002.
 XX
 PF 26-JUN-2001; 2001WO-US020171.
 XX
 PR 26-JUN-2000; 2000US-0214047P.
 XX
 PA (SUGB-) SUGEN INC.
 XX
 PI Plowman G, Whyte D, Sudarsanam S, Manning G, Caenepeel S;
 PI Charyczak G;
 XX
 DR WPI: 2002-139913/18.
 DR P-PSDB; AAU82727.
 XX

XX Nucleic acids encoding novel human proteases, useful for useful for
 PT treating diseases and disorders such as cancers, immune-related diseases
 PT and disorders, cardiovascular disease (e.g. restenosis) and inflammatory
 PT disorders.
 XX
 PS Claim 26; Fig 1AA-BB; 313pp; English.
 XX
 CC The present invention relates to the isolation of novel human proteases,
 CC and the nucleic acids encoding them. The sequences of the invention are
 CC useful for treating diseases and disorders such as cancers (e.g. breast,
 CC colon, lung), immune-related diseases and disorders (e.g. inflammatory
 CC diseases and asthma), cardiovascular diseases (e.g. restenosis and
 CC coronary thrombosis), brain or neuronal-associated diseases, metabolic
 CC disorders (e.g. diabetes, obesity), inflammatory disorders (e.g.
 CC rheumatoid arthritis and psoriasis), central or peripheral nervous system
 CC diseases, migraines, pain, sexual dysfunction, mood disorders, attention

CC disorders, cognition disorders, hypotension, hypertension, psychotic
 CC disorders, neurological disorders (e.g. Alzheimer's disease, Parkinson's
 CC disease) and dyskinesias. The nucleic acids and polypeptides are also
 CC useful for treating viral infections caused by human immunodeficiency
 CC virus (HIV), and non-viral infections such as ocular disease (e.g.
 CC glaucoma) and macular degeneration. ABK31744-ABK31802 represent DNA
 CC sequences encoding for the novel human proteases of the invention
 XX
 SQ Sequence 888 BP; 163 A; 268 C; 269 G; 188 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.2; DB 1; Length 888;
 Best Local Similarity 52.2%; Pred. No. 1.8e+02;
 Matches 47; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 2683 GTGAGTCTGGTGAACCTCTGGAGTTGGTATGGACAGGAGGCTGCTCGCGCGATT 2742
 Db 620 GGGATTCCATGTTTGTGCTGTGCTGAGGATGGCAGTGTAGACACCTGCAAGGTGACT 679
 QY 2743 CATGGGTCACAAAGAGTTGGACAGACTG 2772
 Db 680 CAGGTGGACCTTGTCTGTGACAAAGGATG 709

RESULT 177
 AAI67198
 ID AAI67198 standard; DNA; 918 BP.
 XX
 AC AAI67198;
 XX
 DT 11-FEB-2002 (first entry)
 XX
 DE Nucleotide sequence of GSK gene ID 15037.
 XX
 KW Peptide hormone; antidiabetic; anorectic; antianorectic; antiaesthetic;
 KW antidepressant; nootropic; neuroprotectant; hypotensive; hypertensive;
 KW cytostatic; cerebroprotective; vasotropic; human; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200172961-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 22-MAR-2001; 2001WO-US009226.
 XX
 PR 24-MAR-2000; 2000US-0192158P.
 PR 28-MAR-2000; 2000US-0192668P.
 PR 27-APR-2000; 2000US-0200166P.
 XX
 PA (SMIK) SMITHKLINE BEECHAM CORP.
 PA (SMIK) SMITHKLINE BEECHAM PLC.
 XX
 PI Agarwal P, Murdock PR, Rizvi SK, Smith RP, Xiang Z, Kabnick KS;
 PI Lai Y;
 XX
 DR WPI; 2001-639223/73.
 DR P-PSDB; AAG65908.
 XX

XX Isolated polypeptides, which may be peptide hormones, which are
 PT identified by high throughput genome-based biology which identifies genes
 PT and gene products as therapeutic targets for treatment of diseases such
 PT as diabetes and cancer.
 XX
 PS Claim 2; Page 52; 99pp; English.
 XX
 CC The invention provides polypeptides (AAG65886-65918) which may be peptide
 CC hormones (including insulin, growth hormones, chemokines, cytokines,
 CC neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic
 CC hormones, neurotrophin, pituitary hormones, pleiotrophins, prostaglandins,
 CC secretogranins, selectins, thromboglobulin, thymosins) identified by
 CC high throughput genome-based biology and polynucleotides (AAI67176-67208)
 CC encoding them. The polypeptides can be expressed by standard recombinant
 CC methodology. The polypeptides are useful in the treatment of disease such

CC as diabetes, breast-, prostate-, colon cancer and other malignant tumors,
 CC hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities,
 CC asthma, manic depression, dementia, delirium, mental retardation,
 CC Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental
 CC or sexual development disorders, and dysfunctions of the blood cascade
 CC system including those leading to stroke. The polynucleotides may be used
 CC as diagnostic reagents through detecting mutations in the associated gene
 CC and for chromosome localization and for tissue expression studies. The
 CC polypeptides and polynucleotides may also be used as vaccines
 XX

SQ Sequence 918 BP; 170 A; 272 C; 282 G; 194 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.2; DB 1; Length 918;
 Best Local Similarity 52.2%; Pred. No. 1.8e+02;
 Matches 47; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 2683 GTGAGTCTGGTGAACCTCTGGAGTTGGTATGGACAGGAGGCTGCTCGCGCGATT 2742
 Db 647 GGGATTCCATGTTTGTGCTGTGCTGAGGATGGCAGTGTAGACACCTGCAAGGTGACT 706
 QY 2743 CATGGGTCACAAAGAGTTGGACAGACTG 2772
 Db 707 CAGGTGGACCTTGTCTGTGACAAAGGATG 736

RESULT 178
 AAF77000/C
 ID AAF77000 standard; cDNA; 1130 BP.
 XX
 AC AAF77000;
 XX
 DT 29-MAY-2001 (first entry)
 XX
 DE Fusion gene of protease T in a zymogen activation vector.
 XX
 KW Human; protease T; serine protease; dermatological; desquamation;
 KW skin care; laundry; detergent; shampoo; skin flaking; fusion;
 KW zymogen activation vector; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200116293-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 30-AUG-2000; 2000WO-US023823.
 XX
 PR 31-AUG-1999; 99US-00386653.
 XX
 PA (ORTH) ORTHO-MCNEIL PHARM INC.

PI Barrow AL, Qi J, Andrade-Gordon P;
 XX
 DR WPI; 2001-265889/27.
 DR P-PSDB; AAB73946.
 XX
 PT New serine protease termed protease T, useful for treating and preventing
 PT skin flaking or imbalance of desquamation.
 XX
 PS Claim 2; Fig 4; 83pp; English.

XX The present sequence encodes a protease T fusion protein. Protease T is
 CC useful for treating a condition mediated by protease T. It is useful for
 CC treating an imbalance of desquamation, by topical application of a
 CC pharmaceutical composition containing the protease. The composition is
 CC useful as a topical skin care composition. It is useful as a laundry
 CC detergent, shampoo, hard surface cleaning composition, and dish care
 CC cleaning composition. Protease T protein is useful for treating and
 CC preventing skin flaking. It is less immunogenic to sensitive individuals
 CC and it provides efficient proteolytic activity in a non-natural
 CC environment
 XX

SQ Sequence 1130 BP; 249 A; 329 C; 327 G; 225 T; 0 U; 0 Other;
Query Match 0.6%; Score 21.2; DB 1; Length 1130;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;
QY 2860 TCATATGTTGGTTAAGATATTAAGATTTTCAAAATTCATTTTATCTTTGATTTTCTCT 2919
Db 1110 TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCCAAATAAAGCATTTTTC 1051
QY 2920 ACTTATTAATTTGGGATTTTAACTATTCTTCAATGACTTGAT 2965
Db 1050 ACTGCATTCATGTTGGTTGTTCCAACTCAATCATGATCTTAT 1005
RESULT 179
AAD02991/C
ID AAD02991 standard; DNA; 1166 BP.
XX
AC AAD02991;
XX
DT 11-SEP-2003 (revised)
DT 31-MAY-2001 (first entry)
XX
DE Zymogen activation construct, PPEK2-C-E-HIS ERI-HCII DNA.
XX
KW Human; serine protease; protease C-E; therapy; desquamation; skin care;
KW laundry detergent; shampoo; cleaning agent; hair care; skin flaking;
KW neurodegenerative disorder; dermatological; immunogenic; proteolytic;
KW bovine; zymogen activation construct; PPEK2-C-E-HIS ERI-HCII;
KW fusion protein; chromosome 16p13.3; ds.
XX
OS Bos sp.
OS Homo sapiens.
OS Chimeric.
XX
FH Key Location/Qualifiers
CDS 13..996
FT /*tag= a
FT /product= "PPEK-C-E-HIS fusion protein"
XX
PN WO200116288-A2.
XX
PD 08-MAR-2001.
XX
PF 14-AUG-2000; 2000WO-US022117.
XX
PR 31-AUG-1999; 99US-00386629.
XX
PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX
PI Darrow A, Qi J, Andrade-Gordon P;
XX
DR WPI; 2001-226681/23.
DR P-PSDB; AAY72891.
XX
PT Novel serine protease termed protease C-E, useful for treating and
PT preventing skin flaking or imbalance of desquamation.
XX
PS Claim 2; Fig 4; 78pp; English.
XX
CC The present sequence is a zymogen activation construct, PPEK2-C-E-HIS ERI
CC -HCII DNA. It comprises bovine preprolactin signal sequence fused in-
CC frame with MoAbM2 anti-FLAG antibody epitope for the purpose of secretion
CC and antibody detection (PF), enterokinase cleavage site from human
CC trypsinogen I (EK), catalytic domain of protease C-E and six histidine
CC codons (6XHS). Protease C-E gene located on chromosome 16p13.3 is a
CC member of the S1 serine protease family and is expressed in pancreas,
CC placenta, prostate, small intestine, stomach, spleen, fibroblasts,
CC epidermis, cerebellum, cerebral cortex, pituitary and hippocampus.
CC Protease C-E is useful for treating an imbalance of desquamation, by
CC topical application. A non-pharmaceutical composition comprising the
CC protein may be formulated as a laundry detergent, shampoo, hard surface

CC cleaning composition, dish care cleaning composition, skin care
CC composition and hair care composition. Protease C-E is useful for
CC treating and preventing skin flaking, neurodegenerative disorders and
CC dermatological pathologies. It is less immunogenic to sensitive
CC individuals and it provides efficient proteolytic activity in a non-
CC natural environment. (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ Sequence 1166 BP; 232 A; 335 C; 349 G; 250 T; 0 U; 0 Other;
Query Match 0.6%; Score 21.2; DB 1; Length 1166;
Best Local Similarity 50.0%; Pred. No. 1.9e+02;
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;
QY 2860 TCATATGTTGGTTAAGATATTAAGATTTTCAAAATTCATTTTATCTTTGATTTTCTCT 2919
Db 1146 TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCCAAATAAAGCATTTTTC 1087
QY 2920 ACTTATTAATTTGGGATTTTAACTATTCTTCAATGACTTGAT 2965
Db 1086 ACTGCATTCATGTTGGTTGTTCCAACTCATCAATGATCTTAT 1041
RESULT 180
AAQ12680
ID AAQ12680 standard; DNA; 1529 BP.
XX
AC AAQ12680;
XX
DT 25-MAR-2003 (revised)
DT 30-SEP-1991 (first entry)
XX
DE PAP-I-protein C fusion construct.
XX
KW Phospholipid; binding protein; lipocortin; domain; vitamin K; PBP;
KW gla-domain; VKDP; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
CDS 1..408
FT /*tag= a
FT /label= PAP-I
FT /note= "amino acids 1-136"
FT 409..1529
FT /*tag= b
FT /label= protein C
FT /note= "amino acids 46-136"
XX
PN WO9109953-A.
XX
PD 11-JUL-1991.
XX
PF 29-DEC-1989; 89US-00459082.
XX
PR 29-DEC-1989; 89US-00459082.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Foster DC;
XX
DR WPI; 1991-222905/30.
DR P-PSDB; AARI3083.
XX
PT Recombinant prodn. of hybrid phospholipid-binding proteins - comprising
PT lipocortin phospholipid-binding domain and vitamin-K-dependent protein.
XX
PS Claim 19; Page 41; 57pp; English.
XX
CC The fusion was constructed using site-directed mutagenesis to fuse PAP-I
CC encoding amino acid 1-136 with a protein C DNA sequence at the codon for
CC amino acid 46. A plasmid contg. this construct was transfected into BHK
CC cells which were then cultured to produce PAP-I-protein C fusions which
CC were activated to a form fully active in both amidolytic and


```

PR 04-NOV-1999; 99US-0163508P.
PA (INCY-) INCYTE GENOMICS INC.
XX Sornasse T, Seilhamer JU, Watson GA;
XX WPI; 2001-291057/30.
XX
XX New cell and tissue specific polynucleotides useful for diagnosis,
XX prognosis or monitoring of treatments for disorders where the gene is
XX associated with a cancer, immunopathology or neuropathology.
XX
XX Claim 1; Page 127; 327pp; English.
XX
XX AAH57161 to AAH57576 represent cell and tissue specific polynucleotide
XX sequences (I). (I) can have cytostatic, immunomodulatory and
XX neuroprotective activities, and can be used in gene therapy. (I) and
XX proteins (II) encoded by then are used in high throughput screening
XX assays to select DNA molecules, RNA molecules, peptide nucleic acids,
XX mimetics, peptides, proteins, agonists, antagonists, antibodies or their
XX fragments, immunoglobulins, inhibitors, drug compounds and pharmaceutical
XX agents. Expression of (I) in a sample indicates the differentiation of
XX embryonic stem cells into a tissue selected from brain, heart, kidney,
XX liver, lung, skeletal muscle or pancreatic tissues. (I) and (II) are used
XX to produce an expression profile that defines a metabolic or
XX developmental process, treatment, condition, disease or disorder. The
XX gene profile can be used for diagnosis, prognosis or monitoring of
XX treatments and for investigating a predisposition to a disorder where the
XX gene is associated with a cancer, immunopathology or neuropathology
XX
XX Sequence 292 BP; 56 A; 76 C; 75 G; 58 T; 0 U; 17 Other;
XX
XX Query Match 0.6%; Score 21; DB 1; Length 292;
XX Best Local Similarity 62.3%; Pred. No. 1.5e+02;
XX Matches 33; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
XX
XX 922 CTTTGAACCTACACCCCAAAAGATGCTTCTCATATAGGGGACTGGAA 974
XX |||||
XX 81 CTCACAGGTGATGCCCCCAACAACTTGTGATCATCGTCAAGGGGACAGCAA 29
XX
XX RESULT 185
XX ACC46452
XX ID ACC46452 standard; cDNA; 631 BP.
XX AC ACC46452;
XX
XX 02-JUN-2003 (first entry)
XX
XX Human dithp protein modification/maintenance protein-encoding cDNA.
XX
XX Human; dithp; diagnostic and therapeutic polynucleotide; diagnosis;
XX cancer; cell proliferative disorder; autoimmune disorder;
XX inflammatory disorder; infection; hormonal disorder; metabolic disorder;
XX neurological disorder; gastrointestinal disorder; transport disorder;
XX connective tissue disorder; drug screening; proteome analysis;
XX gene therapy; antisense therapy; genotyping; transgenic animal; knock in;
XX disease model; toxicological testing; transcript imaging;
XX protein modification; protein maintenance; gene; ss.
XX
XX Homo sapiens.
XX
XX WC200297031-A2.
XX
XX 05-DEC-2002.
XX
XX 27-MAR-2002; 2002WO-US010056.
XX
XX 28-MAR-2001; 2001US-0279619P.
XX 29-MAR-2001; 2001US-0280067P.
XX 29-MAR-2001; 2001US-0280068P.
XX 16-MAY-2001; 2001US-0291280P.
XX 17-MAY-2001; 2001US-0291829P.
XX

```

17-MAY-2001; 2001US-0291849P.
19-JUN-2001; 2001US-0299428P.
20-JUN-2001; 2001US-0299776P.
20-JUN-2001; 2001US-0300001P.
XX (INCY-) INCYTE GENOMICS INC.
PA Daffo A, Jones AL, Tran AB, Dahl CR, Gietzen D, Chinn J;
PI Dufour GE, Hillman JL, Yu JY, Tuason O, Yap PE, Anshay SR;
PI Daugherty SC, Dam TC, Liu TF, Nguyen DA, Kleefeld Y, Gerstin EH;
PI Peralta CH, David MH, Lewis SA, Chen AJ, Panzer SR, Harris B;
PI Flores V, Marwaha R, Lo A, Jan RY, Urashka ME;
XX WPI; 2003-129518/12.
XX P-PSDB; ABR41514.
XX Novel human diagnostic and therapeutic polypeptide useful for identifying
XX test compound which specifically binds to a polypeptide encoded by human
XX diagnostic and therapeutic polynucleotide, and to induce antibodies.
XX
XX Claim 2; SEQ ID NO 373; 591pp; English.
XX
XX The invention relates to novel human diagnostic and therapeutic
XX polynucleotides designated dithp (ACC46080-ACC46749) and to their encoded
XX proteins (DITHP; ABR41136-ABR41812). The invention also relates to
XX polynucleotide sequences at least 90% identical to the dithp cDNA
XX sequences of the invention; recombinant vectors, host cells and
XX transgenic organisms comprising a dithp nucleic acid sequence; the
XX recombinant production of DITHP proteins; antibodies specific for DITHP
XX proteins; microarrays comprising dithp nucleic acid sequences; methods of
XX detecting dithp nucleotide and protein sequences; methods of screening
XX for compounds which specifically bind a DITHP protein; and methods of
XX assessing the toxicity of test compounds using a dithp hybridisation
XX probe. Dithp nucleic acid sequences and DITHP proteins may be used in the
XX diagnosis of a wide variety of conditions including cancer and other cell
XX proliferative disorders; autoimmune or inflammatory disorders; bacterial,
XX viral, fungal or parasitic infections; hormonal disorders; metabolic
XX disorders; neurological disorders; gastrointestinal disorders; transport
XX disorders; and connective tissue disorders. They may also be used to
XX screen for modulators of protein activity or gene expression. DITHP
XX proteins can additionally be used in analysis of the proteome of a tissue
XX or cell type and to induce antibodies. The dithp nucleic acids are
XX additionally useful in somatic or germline gene therapy of the disorders
XX mentioned above, as a source of antisense sequences, as a source of
XX probes and primers, in genotyping and identification of individuals, in
XX the generation of transgenic animal models of human disease or knock in
XX humanised animals, in toxicological testing, and in transcript imaging.
XX The present sequence represents a dithp cDNA encoding a DITHP protein.
XX which is involved in protein modification and/or maintenance. Note: The
XX sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 631 BP; 121 A; 179 C; 192 G; 139 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 21; DB 1; Length 631;
XX Best Local Similarity 54.5%; Pred. No. 1.8e+02;
XX Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX 813 TGTGTTTTCGAAGGCAACCATTCATATACAGTAATCCAGTCTATGCCCCCAACCAG 872
XX |||||
XX 435 TGTCTGGGGCCCGCCAGGTGCCCGAGATCCCACTCAGCACCTCCAGTCCACCCAG 494
XX |||||
XX 873 TAATGCTGAAGAAGCTG 889
XX |||||
XX 495 TGCTGCTGCTTGAGCTG 511
XX |||||
XX
XX RESULT 186
XX ABL65438/c
XX ID ABL65438 standard; DNA; 850 BP.
XX XX
XX AC ABL65438;

XX DT 15-MAY-2002 (first entry)
XX DE Lung cancer related gene sequence SEQ ID NO:3775.
XX KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
XX KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
XX KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
XX KW gene; ds.
XX OS Homo sapiens.
XX PN WO200194629-A2.
XX PD 13-DEC-2001.
XX PF 30-MAY-2001; 2001WO-US010838.
XX PR 05-JUN-2000; 2000US-0209473P.
XX PR 05-JUN-2000; 2000US-0209531P.
XX PR 18-SEP-2000; 2000US-0233133P.
XX PR 18-SEP-2000; 2000US-0233137P.
XX PR 20-SEP-2000; 2000US-0234009P.
XX PR 20-SEP-2000; 2000US-0234034P.
XX PR 20-SEP-2000; 2000US-0234052P.
XX PR 22-SEP-2000; 2000US-0234509P.
XX PR 22-SEP-2000; 2000US-0234567P.
XX PR 25-SEP-2000; 2000US-0234923P.
XX PR 25-SEP-2000; 2000US-0234924P.
XX PR 25-SEP-2000; 2000US-0235077P.
XX PR 25-SEP-2000; 2000US-0235082P.
XX PR 25-SEP-2000; 2000US-0235134P.
XX PR 25-SEP-2000; 2000US-0235280P.
XX PR 26-SEP-2000; 2000US-0235637P.
XX PR 26-SEP-2000; 2000US-0235638P.
XX PR 27-SEP-2000; 2000US-0235711P.
XX PR 27-SEP-2000; 2000US-0235720P.
XX PR 27-SEP-2000; 2000US-0235840P.
XX PR 27-SEP-2000; 2000US-0235863P.
XX PR 28-SEP-2000; 2000US-0236028P.
XX PR 28-SEP-2000; 2000US-0236032P.
XX PR 28-SEP-2000; 2000US-0236033P.
XX PR 28-SEP-2000; 2000US-0236034P.
XX PR 28-SEP-2000; 2000US-0236109P.
XX PR 28-SEP-2000; 2000US-0236111P.
XX PR 29-SEP-2000; 2000US-0236842P.
XX PR 29-SEP-2000; 2000US-0236891P.
XX PR 02-OCT-2000; 2000US-0237172P.
XX PR 02-OCT-2000; 2000US-0237173P.
XX PR 02-OCT-2000; 2000US-0237278P.
XX PR 02-OCT-2000; 2000US-0237294P.
XX PR 02-OCT-2000; 2000US-0237295P.
XX PR 02-OCT-2000; 2000US-0237316P.
XX PR 03-OCT-2000; 2000US-0237425P.
XX PR 03-OCT-2000; 2000US-0237598P.
XX PR 03-OCT-2000; 2000US-0237604P.
XX PR 03-OCT-2000; 2000US-0237606P.
XX PR 03-OCT-2000; 2000US-0237608P.
XX PR 01-NOV-2000; 2000US-0244867P.
XX PR 01-NOV-2000; 2000US-0245084P.
XX PA (AVAL-) AVALON PHARM.
XX PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
XX PI Soppet DR, Weaver Z;
XX WIPI; 2002-188264/24.
XX PT Screening for anti-neoplastic agent involves exposing cells to a chemical
XX PT agent to be tested for anti-neoplastic activity, and determining a change
XX PT in expression of a gene of a signature gene set.
XX Claim 1; SEQ ID NO 3775; 44pp; English.

XX CC The present invention describes a method (M1) for screening for an anti-
CC neoplastic agent. The method involves exposing cells to a chemical agent
CC to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening an
CC anti-neoplastic agent, and can be used for producing a product which is
CC the data collected with respect to the anti-neoplastic agent as a result
CC of M1, and the data is sufficient to convey the chemical structure and/or
CC properties of the agent. M1 can be used in the treatment of cancer such
CC as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney,
CC prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell
CC cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous
CC cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilm's
CC tumour
XX SQ Sequence 850 BP; 191 A; 253 C; 229 G; 177 T; 0 U; 0 Other;
Query Match 0.6%; Score 21; DB 1; Length 850;
Best Local Similarity 62.3%; Pred. No. 1.9e+02;
Matches 33; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 922 CTTTGAACACTACACCCCAAAAGATGCTCTTCTCATTTATAGGGGACTGGAA 974
Db 136 CTCACAGGTGTAGCCCCACAAATCTTGTCTCATCTCGTCAAGGGGACAGCAA 84
RESULT 187
AAV59135
ID AAV59135 standard; DNA; 933 BP.
XX AC AAV59135;
XX DT 07-JAN-1999 (first entry)
XX DE Nucleotide sequence of SP002LA, a homologue of HELA2.
XX KW Serine protease; regulation; cell activity; viability; HELA2; ATC2;
XX KW BCMO; testisin; fertility; suppressor; testicular germ cell cancer;
XX KW seminoma; testis-specific expression; antitumour; sperm development;
XX KW infertility; human; chromosome 16p13.3; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX CDS 3..872
FT /*tag= a
FT /product= "SP002LA"
XX WO9836054-A1.
XX PD 20-AUG-1998.
XX PF 13-FEB-1998; 98WO-AU0000085.
XX PR 13-FEB-1997; 97AU-00005101.
XX PR 18-NOV-1997; 97AU-00000422.
XX PA (AMRA-) AMRAD OPERATIONS PTY LTD.
XX PI Antalis TM, Hooper JD;
XX WIPI; 1998-480768/41.
XX DR P-PSDB; AAW77303.
XX PT New serine protease(s) and kinase involved in regulating cell activity
XX PT and viability - particularly the testis-specific protease HELA2 used for
XX PT modulation of fertility and as tumour suppressor.
XX Example 15; Fig 20B; 167pp; English.

XX
SQ Sequence 951 BP; 156 A; 310 C; 292 G; 193 T; 0 U; 0 Other;
Query Match 0.6%; Score 21; DB 1; Length 951;
Best Local Similarity 54.5%; Pred. No. 2e+02;
Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 813 TGTGTTGTTTCAAGGAAACCAATTCATATCAGAGTAAATCAAGTCTATGCCCAACACAG 872
Db 845 TGTCTGGGGCCGCCGCCAGGTGCCCCAGGATCCCACTCAGGCACCTCCAGATCCCAACCCAG 904
QY 873 TAATGCTGAAGAAGCTG 889
Db 905 TGCTGCTGCTGAGCTG 921
RESULT 189
AAS06059
ID AAS06059 standard; DNA; 1551 BP.
XX
AC AAS06059;
XX
DT 12-SEP-2001 (first entry)
XX
DE Angiotensin converting enzyme (ACEV) splice variant DNA #59.
XX
KW Angiotensin converting enzyme splice variant; ACEV; interleukin 6;
KW granulocyte colony stimulating factor receptor; glucagon; hypertrophy;
KW platelet-derived endothelial cell growth factor; cardiovascular disease;
KW platelet tumour antigen P53; cyclin-dependent kinase inhibitor 1C; ds;
KW cellular tumour antigen P53; cyclin-dependent kinase inhibitor 1C; ds;
KW vasactive intestinal polypeptide receptor 2; arteriosclerosis; cancer;
KW myocardial infarction; coronary arterial thrombosis; renal disease;
KW diabetic nephropathy; muscular disease; immune disorder; sarcoidosis;
KW multiple sclerosis; immune complex nephritis; deep vein thrombosis;
KW nonaroidotic pulmonary granulomatous disease; endothelial abnormality;
KW vascular disorder; asbestosis.
XX
OS Mus sp.
XX
FN WO200136632-A2.
XX
XX 25-MAY-2001.
XX
PD 17-NOV-2000; 2000WO-IL000766.
XX
XX 17-NOV-1999; 99IL-00132978.
PR 10-DEC-1999; 99IL-00133455.
XX
PA (COMP-) COMPUGEN LTD.
XX
PI Levine Z, David A, Azar I, Khosravi R, Bernstein J;
XX
DR WPI: 2001-336004/35.
XX
P-PSDB; AAU02959.
XX
PT Novel alternative splicing variants e.g. variant of angiotensin
PT converting enzyme (ACEV), useful in identifying candidate compounds
PT capable of binding to the variant and to detect anti-variant antibodies.
XX
PS Claim 1; Page 358; 519pp; English.
XX
CC The sequence represents a DNA encoding an angiotensin converting enzyme
CC splice variant (ACEV) polypeptide. The polypeptides of the invention
CC include variants of granulocyte colony stimulating factor receptor,
CC glucagon, interleukin 6, platelet-derived endothelial cell growth factor,
CC cyclin-dependent kinase inhibitor 1C, cellular tumour antigen P53, and
CC vasactive intestinal polypeptide receptor 2. The polypeptides and their
CC associated nucleic acids are useful for identification of variant
CC sequences and detection of candidate compounds capable of binding the
CC molecules. The sequences of the invention can be used in the treatment
CC and diagnosis of various disorders including cardiovascular diseases such
CC as arteriosclerosis, myocardial infarction and coronary arterial
CC thrombosis, renal diseases such as diabetic nephropathy, muscular

CC diseases such as hypertrophy, immune disorders such as immune complex
CC nephritis, multiple sclerosis, cancer, sarcoidosis, nonaroidotic
CC pulmonary granulomatous diseases such as asbestosis and vascular
CC pathologies involving an endothelial abnormality such as deep vein
CC thrombosis
XX
SQ Sequence 1551 BP; 364 A; 406 C; 454 G; 327 T; 0 U; 0 Other;
Query Match 0.6%; Score 21; DB 1; Length 1551;
Best Local Similarity 48.7%; Pred. No. 2.2e+02;
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1390 GACAGAGTACCTAATGCACTATGACAGAGGTTCATGACATTTACAGGAGACAGGATC 1449
Db 108 GAGGAGCACATGGTGTCTCTACACAGGCAAGCGTGCACACTCTCTCTGAGGAGCTT 167
QY 1450 GAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTCTCTGGGAGGCC 1506
Db 168 TGGCCCGGCTCTCTGAGAGAGAGTGCAATGAGGAACAGTCTCTCTTGGAGGAGGCC 224
RESULT 190
AAQ80296/C
ID AAQ80296 standard; cDNA; 2422 BP.
XX
AC AAQ80296;
XX
DT 25-MAR-2003 (revised)
DT 17-JUL-1995 (first entry)
XX
DE cDNA encoding Factor VII.
XX
KW Factor VII; plasma glycoprotein; derivative; tissue factor; TF;
KW inhibition; vascular restenosis; platelet deposition; catalytic centre;
KW factor IX; factor X; inactivation; thrombosis; embolism; stroke; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 41..1375
FT FT /*tag= a
FT FT /note= "wild type Factor VII"
XX
PN WO9427631-A1.
XX
XX 08-DEC-1994.
XX
XX 23-MAY-1994; 94WO-US005779.
XX
XX 21-MAY-1993; 93US-00065725.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX (NOVO) NOVO-NORDISK AS.
XX
PI Berkner KL, Petersen LC, Hart CE;
XX
XX WPI: 1995-022464/03.
XX
PT Inhibition of tissue factor, vascular restenosis and platelet deposition
PT - using modifier factor VII unable to activate factors IX and X, e.g. for
PT treating thrombosis, embolism, stroke etc.
XX
PS Disclosure; Page 39-40; 51pp; English.
XX
CC AAQ80296 shows the cDNA encoding human Factor VII. Factor VII is a trace
CC plasma glycoprotein that circulates in blood as a single-chain zymogen.
CC The zymogen is catalytically inactive, and is converted into a two-chain
CC active mol. by cleavage of an internal peptide bond located approx. in
CC the middle of the mol. Factor VIIa rapidly activates Factor X or Factor
CC IX by limited proteolysis. Modified Factor VII has anticoagulant
CC properties, for preventing the coagulation cascade. The modified Factor
CC VII has an active site modified by at least one amino acid substitution,
CC and in its modified form is capable of binding tissue factor and


```

Query Match          0.6%; Score 21; DB 1; Length 2422;
Best Local Similarity 100.0%; Pred. No. 2.2e-02;
Matches      21; Conservative    0; Mismatches    0; Indels     0; Gaps     0;

QY      3245 TTTTITTTTTTTTTTTTTTT 3265
         |||TTTTTTTTTTTTTTTT|||
DB       2422 TTTTITTTTTTTTTTTTTTT 2402

RESULT 194
ADC24226/c
ID      ADC24226 standard; cDNA; 2422 BP.
XX
AC      ADC24226;
XX
DT      18-DEC-2003 (first entry)
XX
DE      Human NOV8a encoding cDNA SEQ ID NO:33.
XX
KW      human; NOVX; cardiant; antiarteriosclerotic; hypotensive; vasotropic;
KW      dermatological; anorectic; immunosuppressive; cytostatic;
KW      antinfertility; haemostatic; anti-HIV; antiasthmatic; antinflammatory;
KW      neuroprotective; anaebolic; nootropic; antiparkinsonian; Gene therapy;
KW      cardiomyopathy; atherosclerosis; hypertension; congenital heart defect;
KW      pulmonary stenosis; scleroderma; obesity; metabolic disturbance; obesity;
KW      transplantation; adrenoleukodystrophy; congenital adrenal hyperplasia;
KW      prostate cancer; diabetes; metabolic disorder; neoplasms; adenocarcinoma;
KW      fertility; haemophilia; graft versus host disease; AIDS;
KW      bronchial asthma; Crohn's disease; multiple sclerosis;
KW      infectious disease; anorexia; neurodegenerative disorder;
KW      Alzheimer's disease; Parkinson's disease; immune disorder;
KW      haematopoietic disorder; dyslipidaemia; wasting disorder; gene; ss.
XX
OS      Homo sapiens.
XX
FH      Key Location/Qualifiers
FT      CDS 41..1375
FT              /*tag= a
FT              /product= "NOV8a"
XX
PN      WO2003076584-A2.
XX
PD      18-SEP-2003.
XX
PF      06-MAR-2003; 2003WO-US006951.
XX
PR      06-MAR-2002; 2002US-0361974P.
PR      19-MAR-2002; 2002US-0365477P.
PR      22-MAR-2002; 2002US-0366928P.
PR      06-AUG-2002; 2002US-0401661P.
PR      05-MAR-2003; 2003US-00401661.
XX
PA      (CURA-) CURAGEN CORP.
XX
PI      Alsobrook JP, Burgess CE, Edinger SR, Gerlach VL, Ji W, Kekuda R;
PI      Li L, Macdougall JR, Miller CB, Millet I, Patturajan M, Pena CEA;
PI      Rieger DK, Sciore P, Shenoy SG, Smithson G, Spytek KA, Stone DJ;
PI      Voss EZ, Zhong M;
XX
DR      WPI: 2003-7222330/69.
DR      P-PSDB; ADC24227.
XX
PT      New NOVX polypeptides and nucleic acids, useful for diagnosing or
PT      treating e.g. cardiomyopathy, atherosclerosis, hypertension, scleroderma,
PT      obesity, prostate cancer, AIDS, bronchial asthma, Crohn's disease, or
PT      multiple sclerosis.
XX
PS      Claim 20; SEQ ID NO 33; 229pp; English.
XX
CC      The present invention describes novel human proteins, designated NOVX
CC      proteins. The NOVX sequences have cardiant, antiarteriosclerotic,
CC      hypotensive, vasotropic, dermatological, anorectic, immunosuppressive,

```


functions in the cell to cause termination of transcription and addition of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and (2) determining a level or pattern of a molecule in a bovine cell or tissue comprising: (a) incubating a marker nucleic acid (comprising any of the 1512 nucleic acid sequences or its complement or fragment) with a complementary nucleic acid molecule obtained from the bovine cell or tissue, where hybridisation between the marker nucleic acid and the complementary nucleic acid permits the detection of the molecule; and (b) detecting the level or pattern of the complementary nucleic acid, where the detection of the complementary nucleic acid is predictive of the level or pattern of the molecule. The LMPD nucleic acid is used for determining a level or pattern of a molecule in a bovine cell or tissue. It is useful for genome mapping, gene identification and analysis, cattle breeding, preparation of constructs for use in cattle gene expression, or for genetically improving cattle. The present sequence is one of the 1512 bovine LMPD EST (expressed sequence tag) nucleic acids. Note: The present sequence was not shown in the specification but was obtained in electronic format from the USPTO web site:
 seqdata.uspto.gov/sequence.html?DocID=20020137139

XX SQ Sequence 432 BP; 140 A; 69 C; 107 G; 116 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.9; DB 1; Length 432;

Best Local Similarity 46.3%; Pred. No. 1.8e+02;

Matches 101; Conservative 0; Mismatches 116; Indels 1; Gaps 1;

QY 2800 GAAACCTTAGTATTATTTACTCAGAAATAGTAATTCATATGTTTC-AAAATTAT 2858

DB 171 GGAACCTTCAGAGAGAGTCTAAGAGAAATAGTTTGAAGAACGACGAGAGTTT 230

QY 2859 TTCATAATGTTGGTTAAGATAATAGATTTTCAAAATGATTTTATCTTGAATTTTCTC 2918

DB 231 TTGAAACACACTGAGAAACACTACTGAATTTTGAAGCAATATGTTGATGAGATCAGTGTG 290

QY 2919 TACTTATTATTTTGGGATTTTAACTATTTCTTCAATGACTTGTATTTCTAATATTAC 2978

DB 291 AATCCAAATCCATGTTTAATGCGGCGATGTCGAAGATGACATTAATTCCTATGATGTT 350

QY 2979 TTATTCATATTTTACATTTAATTCGACTTATTTTATTTATGA 3016

DB 351 GGTGTCAAGCTGGATTTGAAGGACGAACTGTGAATTA 388

RESULT 197

ABV97483

ID ABV97483 standard; cDNA; 197 BP.

XX AC ABV97483;

XX DT 14-JAN-2003 (first entry)

XX DE Human pancreatic cancer expressed cDNA SEQ ID NO 2891.

XX KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;

XX KW cytostatic; tumour; gene; ss.

OS Homo sapiens.

XX PN WO200260317-A2.

XX PD 08-AUG-2002.

XX PF 30-JAN-2002; 2002WO-US002781.

XX PR 30-JAN-2001; 2001US-0265305P.

XX PR 31-JAN-2001; 2001US-0265682P.

XX PR 09-FEB-2001; 2001US-0267568P.

XX PR 21-MAR-2001; 2001US-0278651P.

XX PR 28-APR-2001; 2001US-0287112P.

XX PR 16-MAY-2001; 2001US-0291631P.

XX PR 12-JUL-2001; 2001US-0305484P.

XX PR 20-AUG-2001; 2001US-0313999P.

XX PR 27-NOV-2001; 2001US-0333626P.

XX (CORI-) CORIXA CORP.

XX Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;

XX WPI; 2002-627435/67.

PT New isolated polynucleotide and pancreatic tumor polypeptides, useful for diagnosing, preventing and/or treating cancer, particularly pancreatic cancer.

XX Claim 1; SEQ ID NO 2891; 300pp + Sequence Listing; English.

XX The invention relates to an isolated polynucleotide (I) comprising: (a) any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b) complements of (a); (c) sequences consisting of at least 20 contiguous residues of (a); (d) sequences that hybridize to (a), under moderately stringent conditions; (e) sequences having at least 75% or 90% identity to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer in a patient and compositions comprising polypeptides, polynucleotides, antibodies, fusion proteins, T cell populations and antigen presenting cells expressing the polypeptide are useful in treating pancreatic cancer and stimulating an immune response. The polynucleotides can be used as probes or primers for nucleic acid hybridisation, in the design and preparation of ribozyme molecules for inhibiting expression of the tumour polypeptides and proteins in the tumour cells, in vaccines and for gene therapy. Note: The sequence data for this patent did not form part of the CC printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 197 BP; 59 A; 43 C; 65 G; 30 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.8; DB 1; Length 197;

Best Local Similarity 78.1%; Pred. No. 1.5e+02;

Matches 25; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1943 GAAACCTTGGCTGGAGAGACACACACTCGA 1974

DB 93 GAGACTCTGGCCAGGAGAGACTGAGCTCGA 124

RESULT 198

ABN18436/C

ID ABN18436 standard; cDNA; 252 BP.

XX AC ABN18436;

XX DT 24-JUN-2002 (first entry)

XX DE Human ORFX polynucleotide sequence SEQ ID NO:5349.

XX KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis; hyperproliferative disorder; psoriasis; benign tumour; haemorrhage; degenerative disorder; osteoarthritis; neurodegenerative disorder; cardiovascular disease; diabetes mellitus; systemic lupus erythematosus; hypertension; hypothyroidism; cholesterol ester storage disease; immune deficiency; immune disorder; infectious disease; autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis; myasthenia gravis; gene; ss.

OS Homo sapiens.

XX PN WO200192523-A2.

XX PD 06-DEC-2001.

XX PF 29-MAY-2001; 2001WO-US010836.

XX PR 30-MAY-2000; 2000US-0206132P.

XX PR 29-AUG-2000; 2000US-0228716P.

XX (CURA-) CURAGEN CORP.

XX	WN990650-A2.	
XX	11-FEB-1999.	
XX	31-JUL-1998;	98WO-IB001232.
XX	01-AUG-1997;	97US-00905144.
XX	(GEST) GENSET.	
XX	Dumas Milne Edwards J, Duclert A, Lacroix B;	
PI	WPI; 1999-153780/13.	
DR	P-PSDB; AAY11719.	
DR		
XX		
PT	New isolated prostate-derived nucleic acids - used to develop products	
PT	which may have cytokine, immune regulatory, haematopoiesis regulating,	
PT	anti-inflammatory or tumour inhibition activity.	
XX		
PS	Claim 1; Page 174-175; 675pp; English.	
XX		
CC	AAAX40438 to AAAX40715 represent 5' expressed sequence tags (ESTs) for	
CC	human secreted proteins expressed in prostate, and encode the proteins	
CC	given in AAY11716 to AAY1193 respectively. The proteins given represent	
CC	the signal peptide and an N-terminal fragment of a secreted protein. The	
CC	nucleic acid sequences can be used for producing secreted human gene	
CC	products. The proteins can also be used to develop products for diagnosis and	
CC	therapy. The proteins obtained may have cytokine activity, cell	
CC	proliferation and differentiation activity, haematopoiesis regulating	
CC	activity, tissue growth regulating activity, reproductive hormone	
CC	regulating activity, chemotactic/chemokinetic activity, haemostatic and	
CC	thrombolytic activity, receptor/ligand activity, anti-inflammatory	
CC	activity, tumour inhibition activity or other activities. The products	
CC	can be used in forensic, gene therapy and chromosome mapping procedures.	
CC	The sequences can also be used for obtaining corresponding promoter	
CC	sequences. The nucleic acids encoding the signal peptides can be used for	
CC	directing extracellular secretion of a polypeptide or the insertion of a	
CC	polypeptide into a membrane, or importing a polypeptide into a cell	
XX		
SQ	Sequence 323 BP; 59 A; 119 C; 89 G; 52 T; 0 U; 4 Other;	

W0200172781-A2.
04-OCT-2001.
27-MAR-2001; 2001WO-US009952.
28-MAR-2000; 2000US-0192583P.
(CHIR) CHIRON CORP.
(HYSE-) HYSEQ INC.
Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
Rainhard C, He Z, Randazzo F, Kennedy CC, Pot D, Kaseam A, Labat I;
Lanson G, Drmanac R, Ckvenjakov R, Dickson M, Drmanac S, Labat I;
Leshkowitz D, Kita D, Garcia V, Jones LW, Stache-Crain B;
WPI; 2001-626251/72.
New human polynucleotides useful for the treatment and diagnosis of
cancer.
Claim 1; Page 216-217; 240pp; English.
The invention relates to an isolated polynucleotide comprising a
nucleotide sequence which hybridises to a sequence selected from one of
316 fully defined sequences given in the specification, antisense
molecules complementary to the sequences, the polypeptides encoded by the
sequences and antibodies raised against the proteins. The nucleic acids
are useful for detecting differentially expressed genes which correlate
with a cancerous state of a mammalian cell i.e. diagnosing cancer
(especially lung cancer, colon cancer, breast cancer, prostate cancer and
adenocarcinoma). Modifying the gene products of the nucleic acids
results in inhibition of tumour growth. The nucleic acids are also useful
in gene mapping and tissue profiling. The present sequence is one of the
316 cancer related cDNA sequences
Sequence 380 BP; 106 A; 91 C; 92 G; 101 T; 0 U; 0 Other;
Query Match 0.6%; Score 20.8; DB 1; Length 380;
Best Local Similarity 44.3%; Pred. No. 1.8e+02;
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
QY 3129 ATCTTTTCTCAAGTTTGAATTCGGTCACGPACTATTATCTTTATTTTCTTAATTAATTA 3188
Db 259 AGCTCTGCAAGAGAAATATCATAGTCATGTGATGGTGTGTATTTCATGCACAATT 200
QY 3189 GCTCTTTTAATTCATTATCTTTTGATAACAGCTTCTAGTCTTATTAATAAGTTTT 3248
Db 199 ATTCTCGGAGACCCGGTTTCATTTTCGAAGTTTATTGTTACTCTCAAGGAGCAGTC 140
QY 3249 TTTTTTTTTTTTTTTTTAAAGATGTCATTCTTTGTGAAGTTTGTCAATGCTTTTGAGCA 3308
Db 139 CATCTGGCAGGGTCTTATATGTTGTAAAACAGTGAGCAGCACTCAAGCCATGTGGCA 80
QY 3309 ATAATTAGGAT 3320
Db 79 TTAATTAAAGTT 68
RESULT 202
ABX44987/c
ID ABX44987 standard; cDNA; 396 BP.
XX ABX44987;
XX
XX 21-FEB-2003 (first entry)
XX Bovine EST associated with lactation/muscle/fat deposition #10052.
XX Bovine; ss; EST; expressed sequence tag; lactation; LMPD;
XX muscle deposition; fat deposition; genome mapping; gene identification;
XX gene analysis; cattle breeding.

XX OS Bos Taurus.
 XX PN US2002137139-A1.
 XX PD 26-SEP-2002.
 XX PF 24-SEP-2001; 2001US-00960352.
 XX PR 12-JAN-1999; 99US-0115707P.
 XX PR 11-JAN-2000; 2000US-00480902.
 XX PA (BYAT/) BYATT J C.
 XX PA (MATH/) MATHIALAGAN N.
 XX PA (TAON/) TAO N.
 XX PA (WARR/) WARREN W C.
 XX PI Byatt JC, Mathialagan N, Tao N, Warren WC;
 XX DR WPI; 2003-110599/10.
 XX PT New nucleic acid associated with lactation, and muscle and fat
 XX PT deposition, useful for genome mapping. Gene identification and analysis,
 XX PT cattle breeding, or for genetically improving cattle.
 XX PS Claim 2; SEQ ID NO 10052; 245pp; English.
 XX CC The invention relates to a purified nucleic acid molecule associated with
 XX CC lactation or muscle and fat deposition (designated LMFD), derived from
 XX CC cattle, and the LMFD nucleic acid can specifically hybridise to a second
 XX CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
 XX CC appearing as AX34836-ABX49947, or complements of them. Also included are
 XX CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic
 XX CC acid linked to a promoter and a 3' non-translated sequence that
 XX CC functions in the cell to cause termination of transcription and addition
 XX CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
 XX CC (2) determining a level or pattern of a molecule in a bovine cell or
 XX CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
 XX CC of the 15112 nucleic acid sequences or its complement or fragment) with a
 XX CC complementary nucleic acid molecule obtained from the bovine cell or
 XX CC tissue, where hybridisation between the marker nucleic acid and the
 XX CC complementary nucleic acid permits the detection of the molecule; and (b)
 XX CC detecting the level or pattern of the complementary nucleic acid, where
 XX CC the detection of the complementary nucleic acid is predictive of the
 XX CC level or pattern of the molecule. The LMFD nucleic acid is used for
 XX CC determining a level or pattern of a molecule in a bovine cell or tissue.
 XX CC It is useful for genome mapping, gene identification and analysis, cattle
 XX CC breeding, preparation of constructs for use in cattle gene expression, or
 XX CC for genetically improving cattle. The present sequence is one of the
 XX CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The
 XX CC present sequence was not shown in the specification but was obtained in
 XX CC electronic format from the USPTO web site:
 XX CC seqdata.uspto.gov/sequence.html?DocID=20020137139
 XX SQ Sequence 396 BP; 109 A; 83 C; 95 G; 109 T; 0 U; 0 Other;
 Query Match 0.6%; Score 20.8; DB 1; Length 396;
 Best Local Similarity 57.8%; Pred. No. 1.8e+02;
 Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
 QY 1048 CAAGAAGCTAATAGAGTTTGGCCAGAAATGCTGGTCTATAGCAACACCTCTTCCAA 1107
 Db 92 CACAGAATGAGCAATTTTCCCATGCAAAAGGACCTGCCAAGGAATTGACCTCTTTCAG 33
 QY 1108 CAAC 1111
 Db 32 CATC 29
 RESULT 203
 AAS59112/c
 ID AAS59112 standard; cDNA; 400 BP.
 XX

AC AAS59112;
 XX 16-JAN-2002 (first entry)
 XX DE Human cancer related cDNA sequence #230.
 XX KW Human; ss; lung cancer; adenocarcinoma; breast cancer; colon cancer;
 XX KW prostate cancer; benign prostatic hypertrophy; BHP; cytostatic.
 XX OS Homo sapiens.
 XX PN WO200172781-A2.
 XX PD 04-OCT-2001.
 XX PF 27-MAR-2001; 2001WO-US009952.
 XX PR 28-MAR-2000; 2000US-0192583P.
 XX PA (CHIR) CHIRON CORP.
 XX PA (HYSE-) HYSEQ INC.
 XX PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
 XX PI Reinhard C, He Z, Randazzo F, Kennedy GC, Pot D, Kassem A;
 XX PI Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
 XX PI Leshkowitz D, Kita D, Garcia V, Jones LW, Stache-Crain B;
 XX DR WPI; 2001-626251/72.
 XX PT New human polynucleotides useful for the treatment and diagnosis of
 XX PT cancer.
 XX PS Claim 1; Page 215-216; 240pp; English.
 XX CC The invention relates to an isolated polynucleotide comprising a
 XX CC nucleotide sequence which hybridises to a sequence selected from one of
 XX CC 316 fully defined sequences given in the specification, antisense
 XX CC molecules complementary to the sequences, the polypeptides encoded by the
 XX CC sequences and antibodies raised against the proteins. The nucleic acids
 XX CC are useful for detecting differentially expressed genes which correlate
 XX CC with a cancerous state of a mammalian cell i.e. diagnosing cancer
 XX CC (especially lung cancer, colon cancer, breast cancer, prostate cancer and
 XX CC adenocarcinoma). Modifying the gene products of the nucleic acids
 XX CC results in inhibition of tumour growth. The nucleic acids are also useful
 XX CC in gene mapping and tissue profiling. The present sequence is one of the
 XX CC 316 cancer related cDNA sequences
 XX SQ Sequence 400 BP; 113 A; 83 C; 100 G; 104 T; 0 U; 0 Other;
 Query Match 0.6%; Score 20.8; DB 1; Length 400;
 Best Local Similarity 44.3%; Pred. No. 1.8e+02;
 Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
 QY 3129 ATCTTTCTCAAGTTTGAATTCGCTACGTAACCTATCTTATCTTTTCTTAATTA 3188
 Db 276 AGCTCTCGAAGAAATATCATAGTCATGTGATGGGTGTTGTTTTCATGCAAT 217
 QY 3189 GCTCTTTAAATTCATATTTCTTTGATAACAGCTTCAGTTTATGAGTTTAAATGTTT 3248
 Db 216 ATTCCTCGGAGACCCCGTTTCAITTTTCAAGGTTTATTTGTTACTCCAAAGGAGCAGTC 157
 QY 3249 TTTTCTTTTCTTTTAAAGATGTCATCTTTTGAAGTTTGTGACATGCTTTCAGCA 3308
 Db 156 CATCTGCGAGGTTCTTTATATGTTGTTAAACAGTGAGCAGCACTCAACCCATGTGGCA 97
 QY 3309 ATAATTTAGGAT 3320
 Db 96 TTAATTAAGTT 85
 RESULT 204
 ABA67855/c
 ID ABA67855 standard; DNA; 545 BP.

```
XX AC ABA67855;
XX XX
XX DT 01-FEB-2002 (first entry)
XX DE Human foetal liver single exon nucleic acid probe #16160.
XX KW Human, foetal liver; gene expression; single exon nucleic acid probe; ss.
XX OS Homo sapiens.
XX PN WO200157277-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000669.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX DR WPI; 2001-483447/52.
XX XX
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human fetal liver.
XX PS Claim 4; SEQ ID NO 16160; 639pp + Sequence Listing; English.
XX XX
XX CC The invention relates to a single exon nucleic acid probe for measuring
XX CC human gene expression in a sample derived from human foetal liver. The
XX CC single exon nucleic acid probes may be used for predicting, measuring and
XX CC displaying gene expression in samples derived from human fetal liver. The
XX CC present sequence is a single exon nucleic acid probe of the invention.
XX CC Note: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 545 BP; 175 A; 108 C; 122 G; 140 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.8; DB 1; Length 545;
Best Local Similarity 51.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 2827 AAAATAGTAATTCATATGTAATTCATAAATTTTCATATGTTGGTTAGATAAAGAT 2886
Db 118 AGAAGGCAATGCTATGTTGACTTATTATAGCTGCATTGTAGTTGGTGAGGAATA 59
QY 2887 TTTCAAATGATTTTATCTTTGATTTTCTACT 2922
Db 58 ATTCGAATCACATTTGCTTTTCTGCTGTATGTTCT 23

RESULT 205
ABS41612/c
ID ABS41612 standard; DNA; 545 BP.
XX AC ABS41612;
XX XX
XX DT 25-FEB-2003 (first entry)
XX DE Human liver single exon probe, SEQ ID NO 16602.
XX KW Human; single exon nucleic acid probe; liver; cirrhosis;
XX KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX KW coronary heart disease; ss.

XX XX Homo sapiens.
XX PN WO200157273-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX DR WPI; 2001-488898/53.
XX XX
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human adult liver.
XX PS Claim 4; SEQ ID NO 16602; 658pp; English.
XX XX
XX CC The invention relates to a single exon nucleic acid probe (SENAP) (I) for
XX CC measuring human gene expression in a sample derived from human adult
XX CC liver, comprising one of 13109 defined nucleotide sequences given in the
XX CC specification (or complements/ fragments). The probe hybridises at high
XX CC stringency to a nucleic acid molecule expressed in the human adult liver.
XX CC (I) may be used for predicting, measuring and displaying gene expression
XX CC in samples derived from human adult liver. The genes identified may be
XX CC involved in genetic liver diseases such as cirrhosis,
XX CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX CC associated with coronary heart disease. ABS25011-ABS51005 represent human
XX CC liver single exon nucleic acid probes of the invention. Note: The
XX CC sequence information for this patent does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 545 BP; 175 A; 108 C; 122 G; 140 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.8; DB 1; Length 545;
Best Local Similarity 51.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 2827 AAAATAGTAATTCATATGTAATTCATAAATTTTCATATGTTGGTTAGATAAAGAT 2886
Db 118 AGAAGGCAATGCTATGTTGACTTATTATAGCTGCATTGTAGTTGGTGAGGAATA 59
QY 2887 TTTCAAATGATTTTATCTTTGATTTTCTACT 2922
Db 58 ATTCGAATCACATTTGCTTTTCTGCTGTATGTTCT 23

RESULT 206
AAI99982
ID AAI99982 standard; cDNA; 1338 BP.
XX AC AAI99982;
XX XX
XX DT 07-FEB-2002 (first entry)
XX DE Human FVII encoding cDNA SEQ ID NO 2.
XX KW Factor VII; FVII; Factor VIIa; haemostatic; thrombolytic;
XX KW cardiant; hepatotrophic; cerebroprotective; haemophilia; liver disease;
XX KW myocardial infarction; thrombotic stroke; deep-vein thrombosis;
XX KW chromosome 13q35-9; ss.
XX XX
```



```
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234224P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 13-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 06-DEC-2000; 2000US-0256719P.
PR 08-DEC-2000; 2000US-0251472P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.

PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0239678P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Barash SC, Ruben SM;
XX WPI, 2001-455566/50.
XX P-PSDB; AAU23215.
XX Novel polypeptides and polynucleotides useful for diagnosing, preventing,
XX treating neural, immune system, muscular, reproductive, pulmonary,
XX cardiovascular, renal, proliferative disorders and cancerous diseases.
XX Claim 4; SEQ ID NO 311; 1180pp; English.
XX The present invention relates to the isolation of novel human enzyme
XX polypeptides (AAU22915-AAU23814), and the cDNA and genomic sequences
XX encoding them. The enzyme polypeptides of the invention may comprise the
XX functional classes of oxidoreductases, transferases, hydrolases, lyases,
XX isomerases or ligases. The sequences of the invention are useful in the
XX diagnosis, treatment, prevention and/or prognosis of a wide range of
XX disorders including hyperproliferative disorders (e.g. cancer),
XX immunodeficiency disorders (e.g. AIDS) autoimmune disorders (e.g.
XX arthritis), neurological disorders (e.g. Alzheimer's disease), metabolic
XX disorders (e.g. phenylketonuria), inflammatory disorders (e.g. asthma),
XX cardiovascular disorders (e.g. atherosclerosis), blood-related disorders
XX (e.g. haemophilia), reproductive disorders (e.g. infertility) and
XX infectious disorders (e.g. influenza). The polynucleotides of the
XX invention can also be used in gene therapy. AAS40785-AAS41684 represent
XX cDNA sequences encoding for the novel human enzyme polypeptides of the
XX invention. Note: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 1352 BP; 238 A; 446 C; 407 G; 261 T; 0 U; 0 Other;
Query Match 0.6%; Score 20.8; DB 1; Length 1352;
Best Local Similarity 70.0%; Pred. No. 2.4e+02;
Matches 28; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
Qy 3251 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT
Db 1352 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT
RESULT 208
AAS26942/C
ID AAS26942 standard; cDNA; 1352 BP.
XX AAS26942;
XX AC AAS26942;
XX DT 07-NOV-2001 (first entry)
XX DE Human cDNA encoding a novel secreted protein, SEQ ID 134.
XX Human; immunosuppressive; antiarthritic; ss; antirheumatic; cytostatic;
XX cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
XX antibacterial; virucide; fungicide; ophthalmological; vulnery;
XX secreted protein; rheumatoid arthritis; hyperproliferative disorder;
XX cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
XX cerebral ischaemia; angiogenesis; nervous system disorder;
XX Alzheimer's disease; infection; ocular disorder; corneal infection;
XX wound healing; epithelial cell proliferation; skin ageing; food additive;
XX preservative; antiproliferative.
XX Homo sapiens.
XX WO200155441-A2.
XX
```



```
PS Claim 1; SEQ ID NO 135; 601pp; English.
XX
CC The invention relates to isolated nucleic acid molecules and their
CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs before, to
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence encodes a novel secreted protein of the invention. Note: The
CC
XX
XX Query Match 0.6%; Score 20.8; DB 1; Length 1352;
XX Best Local Similarity 70.0%; Pred. No. 2.4e+02;
XX Matches 28; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
XX
XX 3251 TTTTITTTTTTTTAAAGATGTCATCTCTTTGTGAAGTT 3290
XX 1342 TTTTITTTTTTTTTCGAGATAAATAATTATTGAAATT 1303
XX
XX
XX RESULT 213
XX AAI199983
XX ID AAI199983 standard; cDNA; 1357 BP.
XX AC AAI199983;
XX
XX 07-FEB-2002 (first entry)
XX
XX Human FVII expression cassette SEQ ID NO 4.
XX
XX Factor VII; FVII; Factor VIIa; haemostatic; thrombolytic;
XX cardiant; hepatotrophic; cerebroprotective; haemophilia; liver disease;
XX myocardial infarction; thrombotic stroke; deep-vein thrombosis; SS.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 128..1348
XX FT /*tag= a
XX FT /product= "FVII"
XX FT /partial
XX FT /note= "CDS lacks an initiation codon"
XX
XX WO200158935-A2.
XX
XX 16-AUG-2001.
XX
XX 12-FEB-2001; 2001WO-DK000094.
XX
XX 11-FEB-2000; 2000DK-00000218.
XX 18-OCT-2000; 2000DK-00001558.
XX
XX (MAXY-) MAXYGEN APS.
XX
XX Andersen KV, Pedersen AH, Bornaes C;
XX
XX WPI; 2001-581807/65.
XX P-PSDB; AAM52172.
XX
XX
XX New conjugate, useful for treating Factor VIIa related diseases or
XX disorders such as hemophilia, liver disease, myocardial infarction and
XX deep-vein thrombosis, comprises non-polypeptide group covalently attached
XX to polypeptide group.
XX
XX Example 2; Page 63-64; 89pp; English.
XX
XX The invention relates to novel Factor VII (FVII) or Factor VIIa (FVIIa)
XX polypeptide conjugates, comprising at least one non-polypeptide group
XX covalently attached to a polypeptide, where the amino acid sequence of
XX polypeptide differs from that of the wildtype FVIIa (AAM52171) in that at
XX least one amino acid residue containing an attachment group for the non-
XX polypeptide group has been introduced or removed. The FVIIa conjugates
XX have haemostatic, thrombolytic, cardiant, hepatotrophic and
XX cerebroprotective activity and are useful for treating FVIIa/TF-related
XX diseases or disorders such as haemophilia, liver disease, myocardial
XX infarction, thrombotic stroke and deep-vein thrombosis. The conjugates
XX have increased functional in vivo half life and/or increased plasma half
XX life, increased bioavailability and or reduced sensitivity to proteolytic
XX degradation. Consequently medical treatment using the conjugates has a
XX number of advantages over currently available such as longer duration
XX between injections. The present sequence is that of a human FVII
XX expression cassette, encompassing the short form of the full length cDNA
XX encoding FVII, for expression of human FVII in mammalian cells
XX
XX
XX Query Match 0.6%; Score 20.8; DB 1; Length 1357;
XX Best Local Similarity 57.8%; Pred. No. 2.4e+02;
XX Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
XX
XX 1443 AGGATCGAGACCATCCCATGGAAAGAAATCCAAAAGCAAAATGCTGTCTGGGA 1502
XX 145 AGAGTCCGGCCCTGGCTCCTCGAAGCGAATGCAAGAGGACAGTGCAGCTTTGAGGA 204
XX
XX 1503 GGCC 1506
XX 205 AGCC 208
XX
XX
XX RESULT 214
XX AAZ32168/C
XX ID AAZ32168 standard; DNA; 1366 BP.
XX AC AAZ32168;
XX
XX 13-JAN-2000 (first entry)
XX
XX Human low density lipoprotein receptor exon 2 nucleotide sequence.
XX
XX Human; coding sequence polymorphism; vascular pathology gene;
XX polymorphic site; phenotype correlation; forensic; paternity testing;
XX medicine; genetic analysis; vascular disease; ds.
XX
XX Homo sapiens.
XX
XX WO9950454-A2.
XX
XX 07-OCT-1999.
XX
XX 26-MAR-1999; 99WO-US006473.
XX
XX 01-APR-1998; 98US-00054272.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Lander ES, Daley GQ, Cargill M, Ireland JS, Rozen SG;
XX
XX WPI; 1999-620066/53.
XX
XX Determination of polymorphisms in genes, especially those identifying
XX predisposition to vascular disease.
XX
```

```
XX PS Claim 1; Fig 12; 134pp; English.
XX CC AAZ32159 to AAZ32194 represent reference alleles for specifically claimed
XX CC nucleic acid sequences from the present invention which comprise
XX CC polymorphic sites as given in a table in the specification, selected from
XX CC 92 single nucleotide polymorphisms in which the nucleotide at the
XX CC polymorphic site is different from a nucleotide at the same site in a
XX CC reference allele. The nucleic acids, and primers and probes, are used to
XX CC identify polymorphisms, which may predispose an individual to disease,
XX CC especially a vascular disease. They can also be used in phenotype
XX CC correlations, forensic, paternity testing, medicine or genetic analysis.
XX CC AAY4950 to AAY49573 represent the proteins which correspond to some of
XX CC the reference alleles
XX SQ Sequence 1366 BP; 302 A; 388 C; 425 G; 251 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.8; DB 1; Length 1366;
XX Best Local Similarity 57.8%; Pred. No. 2.4e+02;
XX Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 453 CTCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
DB 1191 CTCAGAGAGCCCAAGAGAGGATGGAGGACAGACAGACAGAGGCGGTGCTTGTAC 1132
QY 513 TGGT 516
DB 1131 ATGT 1128
XX
XX RESULT 215
XX AAZ13357/c
XX ID AAZ13357 standard; cDNA; 1754 BP.
XX AC AAZ13357;
XX DT 25-MAR-2003 (revised)
XX DT 04-NOV-1991 (first entry)
XX DE Human protein C gene.
XX KW HPC; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX CDS 69..1454
XX FT /*tag= a
XX FT sig_peptide 69..194
XX FT /*tag= b
XX FT mat_peptide 195..1451
XX FT /*tag= c
XX FT misc_RNA 195..650
XX FT /*tag= d
XX FT /*note= "Light chain"
XX FT misc_RNA 702..1451
XX FT /*tag= e
XX FT /*note= "heavy chain"
XX
XX WO9112320-A.
XX PN
XX XX
XX PD 22-AUG-1991.
XX XX
XX PF 09-FEB-1990; 90US-00478084.
XX XX
XX PR 09-FEB-1990; 90US-00478084.
XX XX
XX PA (Zymo ) ZYMOGENETICS INC.
XX PA (TEIJ ) TEIJIN LTD.
XX
XX PI Miyagi F, Sumi Y, Wakabayash K, Foster DC;
XX WPI; 1991-267132/36.
XX
XX Claim 1; Fig 12; 134pp; English.
XX CC AAZ32159 to AAZ32194 represent reference alleles for specifically claimed
XX CC nucleic acid sequences from the present invention which comprise
XX CC polymorphic sites as given in a table in the specification, selected from
XX CC 92 single nucleotide polymorphisms in which the nucleotide at the
XX CC polymorphic site is different from a nucleotide at the same site in a
XX CC reference allele. The nucleic acids, and primers and probes, are used to
XX CC identify polymorphisms, which may predispose an individual to disease,
XX CC especially a vascular disease. They can also be used in phenotype
XX CC correlations, forensic, paternity testing, medicine or genetic analysis.
XX CC AAY4950 to AAY49573 represent the proteins which correspond to some of
XX CC the reference alleles
XX SQ Sequence 1366 BP; 302 A; 388 C; 425 G; 251 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.8; DB 1; Length 1366;
XX Best Local Similarity 57.8%; Pred. No. 2.4e+02;
XX Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 453 CTCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
DB 1191 CTCAGAGAGCCCAAGAGAGGATGGAGGACAGACAGACAGAGGCGGTGCTTGTAC 1132
QY 513 TGGT 516
DB 1131 ATGT 1128
XX
XX RESULT 216
XX AAZ12649/c
XX ID AAZ12649 standard; cDNA; 1754 BP.
XX AC AAZ12649;
XX DT 25-MAR-2003 (revised)
XX DT 02-OCT-1991 (first entry)
XX DE Protein C precursor gene.
XX KW Anticoagulant; fibrinolysis; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX CDS 72..110
XX FT /*tag= a
XX FT sig_peptide 72..110
XX FT /*tag= b
XX FT mat_peptide 195..1454
XX FT /*tag= b
XX
XX WO9109951-A.
XX PN
XX XX
XX PD 11-JUL-1991.
XX XX
XX PF 22-DEC-1989; 89US-00456092.
XX XX
XX PR 22-DEC-1989; 89US-00456092.
XX XX
XX PA (Zymo ) ZYMOGENETICS INC.
XX PA (TEIJ ) TEIJIN LTD.
XX
XX PI Foster DC, Holly RD, Suzuki M, Wakabayash K, Kumar AA;
XX WPI; 1991-222903/30.
XX DR P-PSDB; AAR13074.
XX
XX PT Recombinant protein C with truncated light chain - for use as an
XX PT anticoagulant.
```

10664775-2.rng

Mon Aug 9 17:46:53 2004

PS Disclosure; Fig 1; 60pp; English.

XX The sequence was determined from a clone isolated from a cDNA library

CC prep'd. from mRNA from Hep G2 cells. It encodes a protein C precursor,

CC including light and heavy chains, which is cleaved to produce activated

CC protein C (see protein file for details). The sequence can be manipulated

CC by genetic engineering techniques to express a protein comprising residues

CC activated) a heavy chain and a truncated light chain comprising residues

CC 1-149, 1-150, 1-151 or 1-152 of the natural sequence. The protein pref.

CC comprises the precursor of formula: Pre-pro-L-X-H Pre-pro = pre-pro

CC peptide of protein C with all/part replaced by the corresponding peptide

CC of either protein S, factors VII, IX or X, or prothrombin; L = AAs 1-149,

CC 150, 151 or 152 of light chain; X = 3-10 Lys/arg residues; and H = heavy

CC chain. Cells transformed with expression vectors contg. the modified DNA

CC sequences produce the new proteins which can be used to regulate

CC anticoagulant and fibrinolytic systems. See also WO9112320 (AAQ13357).

CC (Updated on 25-MAR-2003 to correct PA field.)

XX Sequence 1754 BP; 378 A; 505 C; 540 G; 331 T; 0 U; 0 Other;

SQ

Query Match 0.6%; Score 20.8; DB 1; Length 1754;

Best Local Similarity 57.8%; Pred. No. 2.4e+02; Indels 0; Gaps 0;

Matches 37; Conservative 0; Mismatches 27;

QY 453 CTCGAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512

DB 1573 CTCGAGAGAGCCCAAGAGGGATGGAGGACAGACAGACAGCGCGGTGCTGTGTAC 1514

QY 513 TGGT 516

DB 1513 ATGT 1510

RESULT 217

AAQ12678/c

ID AAQ12678 standard; cDNA; 1755 BP.

XX

AC AAQ12678;

XX

DT 25-MAR-2003 (revised)

DT 30-SEP-1991 (first entry)

XX

DE Human protein C.

XX

XX Phospholipid; binding protein; lipocortin; domain; vitamin K; PBP;

KW Gla-domain; VKDP; ss.

XX

OS Homo sapiens.

XX

XX Key Location/Qualifiers

FT CDS 70..1452

FT /tag= a

FT /product= "protein_C"

FT sig_peptide 70..195

FT /tag= b

FT mat_peptide 196..1452

FT /tag= c

FT polyA_signal 1502..1507

FT /tag= d

FT polyA_signal 1721..1726

FT /tag= e

XX

PN WO9109953-A.

XX

XX 11-JUL-1991.

XX

XX 29-DEC-1989; 89US-00459082.

XX

XX 29-DEC-1989; 89US-00459082.

XX (ZYMO) ZYMOGENETICS INC.

XX

XX Foster DC;

XX

XX WP1; 1991-222905/30.

DR P-PSDB; AAR13081.

XX

PT Recombinant prodn. of hybrid phospholipid-binding proteins - comprising

PT lipocortin phospholipid-binding domain and vitamin-K-dependent protein.

XX

PS Disclosure; Fig 2; 57pp; English.

XX This sequence, or a fragment of it, is used in the construction of DNA

CC sequences encoding hybrid phospholipid-binding proteins (PBP) having the

CC same biological activity as human protein C or human activated protein C.

CC The hybrid sequence would comprise at least one lipocortin phospholipid

CC binding domain (PBP), e.g. of PAP-I, joined to a gla-domainless protein C

CC or activated protein C. See AAQ12680-81 for such examples. A lambda gt11

CC cDNA library was prep'd. from human liver mRNA by conventional methods in

CC order to obtain this cDNA. See also AAQ12678-81. (Updated on 25-MAR-2003

XX to correct PA field.)

SQ Sequence 1755 BP; 378 A; 506 C; 541 G; 330 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.8; DB 1; Length 1755;

Best Local Similarity 57.8%; Pred. No. 2.4e+02; Indels 0; Gaps 0;

Matches 37; Conservative 0; Mismatches 27;

QY 453 CTCGAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512

DB 1574 CTCGAGAGAGCCCAAGAGGGATGGAGGACAGACAGACAGCGCGGTGCTGTGTAC 1515

QY 513 TGGT 516

DB 1514 ATGT 1511

RESULT 218

AAT32795/c

ID AAT32795 standard; cDNA; 1755 BP.

XX

AC AAT32795;

XX

DT 25-MAR-2003 (revised)

DT 05-NOV-1996 (first entry)

XX

DE Human protein C cDNA.

XX

XX Activated protein C; serine protease; thrombosis; thrombolytic;

KW fibrinolytic; antithrombotic; blood clotting; therapy; ss.

XX

XX Homo sapiens.

XX

XX Key Location/Qualifiers

FT CDS 70..1455

FT /tag= a

FT /product= "protein C prepro-protein"

FT sig_peptide 70..195

FT /tag= b

FT mat_peptide 196..1452

FT /tag= c

FT polyA_signal 1502..1507

FT /tag= d

FT polyA_signal 1721..1726

FT /tag= e

XX

PN US5516650-A.

XX

XX 14-MAY-1996.

XX

XX 08-APR-1994; 94US-00225253.

XX

XX 27-JUN-1985; 85US-00749600.

XX 29-OCT-1986; 86US-00924462.

XX 08-DEC-1987; 87US-00130370.

XX 28-FEB-1989; 89US-00317205.

XX 10-SEP-1990; 90US-00582131.

XX 04-DEC-1992; 92US-00987532.

XX

PA (ZYMO) ZYMOGENETICS INC.
XX Murray MJ, Berkner KL, Foster DC;
XX WPI; 1996-251006/25.
DR P-PSDB; AAW02600.
XX
XX New DNA encoding modified forms of opt. activated protein C - and related
PT transformed cells for prodn. of recombinant protein C for use e.g. as an
PT anti-thrombotic agent.
XX
XX Claim 3; Fig 2A-C; 34pp; English.
XX
XX A cDNA clone (AAT32795) codes for human full-length protein C (AAW02600),
CC a zymogen of a serine protease that plays an important role in blood
CC clotting and in the generation of fibrinolytic activity in vivo. It was
CC obtd. from a cDNA library produced from Hep G2 cells by screening with a
CC genomic fragment contg. an exon corresponding to amino acids -42 to -19
CC of the prepro-peptide. A genomic clone (AAT32796) was also obtd. The cDNA
CC can be used for large-scale prodn. of protein C, or versions of protein C
CC modified to improve cleavage between the heavy and light chains of the
CC circulating intermediate. (Updated on 25-MAR-2003 to correct PF field.)
XX
XX Sequence 1755 BP; 378 A; 506 C; 541 G; 330 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 20.8; DB 1; Length 1755;
Best Local Similarity 57.8%; Pred. No. 2.4e-02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 453 CTCGAGAGAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTGAC 512
DB 1574 CTCGAGAGAGAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTGAC 512
QY 513 TGGT 516
DB 1514 ATGT 1511
DE
RESULT 219
AAN81563/C
ID AAN81563 standard; cDNA; 1756 BP.
XX
XX AAN81563;
XX 25-MAR-2003 (revised)
DT 05-DEC-1990 (first entry)
XX
XX cDNA sequence encoding protein C.
DE
XX Human protein C; blood coagulation disorder; ss.
KW
XX Homo sapiens.
OS
XX Key Location/Qualifiers
FH 71..1456
FT CDS /tag= a
FT /label= protein C
FT
XX
XX EP266190-A.
PN
XX
XX 04-MAY-1988.
PD
XX
XX 28-OCT-1987; 87EP-00309528.
PF
XX
XX 29-OCT-1986; 86US-00924462.
PR
XX
XX (ZYMO) ZYMOGENETICS INC.
PA
XX
XX Foster DC, Murray MJ, Berkner KL;
PI
XX WPI; 1988-121259/18.
DR
XX P-PSDB; AAN81205.
XX

PT Protein C DNA coding sequence and expression vector for prodn. - used for
PT treating blood coagulation disorders.
XX
XX Disclosure; Page ?; 35pp; English.
XX
XX In the construction of the full length protein C gene this sequence is
CC joined to a genomic clone (following removal of the introns). The desired
CC genomic cDNA is then generated by looping out of unwanted sequences using
CC oligonucleotide-directed deletion mutagenesis. The protein produced upon
CC transformation of mammalian host cells, contg. the recombinant DNA, has
CC substantially the same biological activity as natural protein C and is
CC hence useful in the treatment of blood coagulation disorders. See also
CC AAN81564. (Updated on 25-MAR-2003 to correct PA field.)
XX
XX Sequence 1756 BP; 379 A; 507 C; 540 G; 330 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 20.8; DB 1; Length 1756;
Best Local Similarity 57.8%; Pred. No. 2.4e-02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 453 CTCGAGAGAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTGAC 512
DB 1575 CTCGAGAGAGAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTGAC 512
QY 513 TGGT 516
DB 1515 ATGT 1512
DE
RESULT 220
AAC02548/C
ID AAC02548 standard; cDNA; 228 BP.
XX
XX AAC02548;
XX
XX 06-OCT-2000 (first entry)
DT
XX
XX Human secreted protein 5' EST, SEQ ID NO: 2546.
DE
XX
XX Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW
XX gene therapy; chromosome mapping; ss.
XX
XX Homo sapiens.
OS
XX EP1033401-A2.
PN
XX
XX 06-SEP-2000.
PD
XX
XX 21-FEB-2000; 2000EP-00200610.
PF
XX
XX 26-FEB-1999; 99US-0122487P.
PR
XX
XX (GEST) GENSET.
PA
XX
XX Dumas Milne Edwards J, Duclert A, Giordano J;
PI
XX WPI; 2000-500381/45.
DR
XX P-PSDB; AAG02542.
DR
XX
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5' ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures.
PT
XX
XX Claim 1; SEQ ID NO 2546; 71pp + Sequence Listing; English.
PS
XX
XX The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. An ORF has been identified within the
CC sequence. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs
CC derived from 30 different tissues. EST sequences usually correspond
CC mainly to the 3' untranslated region (UTR) of the mRNA because they are
CC often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
CC well suited for isolating cDNA sequences derived from the 5' ends of
CC mRNAs and even in those cases where longer cDNA sequences have been

QY 1714 CTATGCAGAAAGCCTT 1728
Db 123 GTCGACCAAGGCTT 109

RESULT 223
ABX44887
ID ABX44887 standard; cDNA; 396 BP.
XX
AC ABX44887;
XX
DT 21-FEB-2003 (first entry)
XX
DE Bovine EST associated with lactation/muscle/fat deposition #10052.
XX
KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;
KW muscle deposition; fat deposition; genome mapping; gene identification;
KW gene analysis; cattle breeding.
XX
OS Bos Taurus.
XX
FN US2002137139-A1.
XX
PD 26-SEP-2002.
XX
PF 24-SEP-2001; 2001US-00960352.
XX
PR 12-JAN-1999; 99US-0115707P.
PR 11-JAN-2000; 2000US-00480902.
XX
PA (BYATT/) BYATT J C.
PA (MATH/) MATHIALAGAN N.
PA (TAON/) TAO N.
PA (WARR/) WARREN W C.
XX
PI Byatt JC, Mathialagan N, Tao N, Warren WC;
XX WPI; 2003-110599/10.
XX
PT New nucleic acid associated with lactation, and muscle and fat
PT deposition, useful for genome mapping, gene identification and analysis,
PT cattle breeding, or for genetically improving cattle.
XX
PS Claim 2; SEQ ID NO 10052; 245pp; English.
XX

The invention relates to a purified nucleic acid molecule associated with
lactation or muscle and fat deposition (designated LMFD), derived from
cattle, and the LMFD nucleic acid can specifically hybridise to a second
nucleic acid molecule comprising any of 15112 nucleotide sequences,
appearing as ABX34836-ABX4947, or complements of them. Also included are
; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic
acid linked to a promoter and a 3' non- translated sequence that
functions in the cell to cause termination of transcription and addition
of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
(2) determining a level or pattern of a molecule in a bovine cell or
tissue comprising: (a) incubating a marker nucleic acid (comprising any
of the 15112 nucleic acid sequences or its complement or fragment) with a
complementary nucleic acid molecule obtained from the bovine cell or
tissue, where hybridisation between the marker nucleic acid and the
complementary nucleic acid permits the detection of the molecule; and (b)
detecting the level or pattern of the complementary nucleic acid, where
the detection of the complementary nucleic acid is predictive of the
level or pattern of the molecule. The LMFD nucleic acid is used for
determining a level or pattern of a molecule in a bovine cell or tissue.
It is useful for genome mapping, gene identification and analysis, cattle
breeding, preparation of constructs for use in cattle gene expression, or
for genetically improving cattle. The present sequence is one of the
15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The
present sequence was not shown in the specification but was obtained in
electronic format from the USPTO web site:
seqdata.uspto.gov/sequence.html?DocID=20020137139

Sequence 396 BP; 109 A; 83 C; 95 G; 109 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.6; DB 1; Length 396;
Best Local Similarity 54.7%; Pred. No. 2.1e+02;
Matches 41; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 429 TACTGGAGATCAGTGGAGAAATACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAA 488
Db 160 TACTGTTGTTGTCAGGTGAGCATAACACCCGAGAGCCAGAACCTTACAGAGCAAAAGCAAAA 219
QY 489 AGAATACCCAGCTGT 503
Db 220 TGTGATCCGTGCTAT 234

RESULT 224
AAC71346/c
ID AAC71346 standard; DNA; 717 BP.
XX
AC AAC71346;
XX
DT 09-FEB-2001 (first entry)
XX
DE Single nucleotide polymorphism containing sequence #392.
XX
KW Single nucleotide polymorphism; SNP; human; genetic disease;
KW disease susceptibility; cardiovascular system; endocrine system;
KW neurological system; forensic testing; paternity testing; ds.
XX
OS Homo sapiens.
XX
FN WO2000058519-A2.
XX
PD 05-OCT-2000.
XX
PF 30-MAR-2000; 2000WO-US008440.
XX
PR 31-MAR-1999; 99US-0127248P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Altschuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
PI Lipshutz RJ, Patil N, Sklar P;
XX
DR WPI; 2000-611722/58.
XX
PT Nucleic acid selected from one of 106 genes comprising single nucleotide
PT polymorphisms, allele-specific oligonucleotides to the genes are useful
PT for phenotypic correlations, forensics, paternity testing, medicine and
PT genetic analysis.
XX
PS Claim 1; Fig 5; 214pp; English.
XX

The present invention is concerned with a number of human single
nucleotide polymorphisms (SNPs) which the inventors identified in human
genes. These SNPs can be used in disease diagnosis and prediction of an
individual's susceptibility to disease, in forensic and paternity testing
and in genetic mapping. In particular, the SNPs of the invention can be
used to diagnose susceptibility to diseases of the cardiovascular,
endocrine and neurological systems, such as coronary artery disease,
schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
diseases. Note: The degenerate codon within the sequence represents the
position of an SNP, for example the letter S represents a polymorphism
where the nucleotide may be C or G

Sequence 717 BP; 231 A; 133 C; 151 G; 201 T; 0 U; 1 Other;

Query Match 0.6%; Score 20.6; DB 1; Length 717;
Best Local Similarity 54.7%; Pred. No. 2.4e+02;
Matches 41; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 3139 AGCTTTGAATGGCTACGTAACCTATTTATTTTGTAAATAGCTCTTTAAA 3198


```

PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 181; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 31 A; 29 C; 15 G; 46 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.7e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTTCAGGCAACCATTC A 838
Db 54 GAAGTTTGGAAACACTGAAAGACAGTGAATTTCCACATAATACCTTCA 1

RESULT 230
ABA79566
ID ABA79566 standard; DNA; 121 BP.
XX
XX ABA79566;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2412.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.

```

```

XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192179P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 181; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 46 A; 15 C; 29 G; 31 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.7e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTTCAGGCAACCATTC A 838
Db 68 GAAGTTTGGAAACACTGAAAGACAGTGAATTTCCACATAATACCTTCA 121

RESULT 231
ABA79583/C
ID ABA79583 standard; DNA; 121 BP.
XX
XX ABA79583;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2429.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX

```

PF 27-MAR-2001; 2001WO-US009761.
 XX 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI WPI; 2001-639230/73.
 XX
 DR Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 182; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCAL, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 XX Sequence 121 BP; 31 A; 29 C; 16 G; 45 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 20.4; DB 1; Length 121;
 Best Local Similarity 61.1%; Pred. No. 1.7e+02;
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTTCACGACCAACCATTC A 838
 Db 59 GAAGTTTTCGAAACACTGGAAGACAGTGTATTTCCACATATACCTTCA 6
 RESULT 232
 ABA79595/c
 ID ABA79595 standard; DNA; 121 BP.
 XX ABA79595;
 AC ABA79595;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2441.
 DE
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCAL; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD

XX 27-MAR-2001; 2001WO-US009761.
 PF 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI WPI; 2001-639230/73.
 XX
 DR Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 182; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCAL, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 XX Sequence 121 BP; 29 A; 30 C; 16 G; 46 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 20.4; DB 1; Length 121;
 Best Local Similarity 61.1%; Pred. No. 1.7e+02;
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTTCACGACCAACCATTC A 838
 Db 61 GAAGTTTTCGAAACACTGGAAGACAGTGTATTTCCACATATACCTTCA 8
 RESULT 233
 ABA79591/c
 ID ABA79591 standard; DNA; 121 BP.
 XX ABA79591;
 AC ABA79591;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2437.
 DE
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCAL; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX

PD 04-OCT-2001.
 XX 27-MAR-2001; 2001WO-US009761.
 PF XX
 XX 27-MAR-2000; 2000US-0192176P.
 PR XX
 PR 27-MAR-2000; 2000US-0192179P.
 PR XX
 PR 01-JUN-2000; 2000US-0208538P.
 PR XX
 PR 30-OCT-2000; 2000US-0244989P.
 XX XX
 PA (UYDE) UNIV DELAWARE.
 XX XX
 XX Kmiec EB, Gamper HB, Rice MC;
 PI XX
 XX WPI; 2001-639230/73.
 DR XX
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX XX
 XX Claim 7; Page 182; 294pp; English.
 PS XX
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX XX
 SQ Sequence 121 BP; 29 A; 30 C; 16 G; 46 T; 0 U; 0 Other;
 Query Match 0.6%; Score 20.4; DB 1; Length 121;
 Best Local Similarity 61.1%; Pred. NO. 1.7e+02;
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTC A 838
 DB 61 GAAGTTTTCGAAACACTGAAAGACAGTGAATTTCCACATATACCTTCA 8

RESULT 234
 ABA79578
 ID ABA79578 standard; DNA; 121 BP.
 XX AC ABA79578;
 XX XX
 XX 24-JAN-2002 (first entry)
 DT XX
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2424.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX OS Homo sapiens.
 XX WO200173002-A2.
 PN

XX 04-OCT-2001.
 PD XX
 PF XX 27-MAR-2001; 2001WO-US009761.
 XX XX
 XX 27-MAR-2000; 2000US-0192176P.
 PR XX
 PR 27-MAR-2000; 2000US-0192179P.
 PR XX
 PR 01-JUN-2000; 2000US-0208538P.
 PR XX
 PR 30-OCT-2000; 2000US-0244989P.
 XX XX
 PA (UYDE) UNIV DELAWARE.
 XX XX
 XX Kmiec EB, Gamper HB, Rice MC;
 PI XX
 XX WPI; 2001-639230/73.
 DR XX
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX XX
 XX Claim 7; Page 182; 294pp; English.
 PS XX
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX XX
 SQ Sequence 121 BP; 45 A; 16 C; 29 G; 31 T; 0 U; 0 Other;
 Query Match 0.6%; Score 20.4; DB 1; Length 121;
 Best Local Similarity 61.1%; Pred. NO. 1.7e+02;
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTC A 838
 DB 63 GAAGTTTTCGAAACACTGAAAGACAGTGAATTTCCACATATACCTTCA 116

RESULT 235
 ABA79590
 ID ABA79590 standard; DNA; 121 BP.
 XX AC ABA79590;
 XX XX
 XX 24-JAN-2002 (first entry)
 DT XX
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2436.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX OS Homo sapiens.
 XX

PN WO200173002-A2.
 PD 04-OCT-2001.
 XX 27-MAR-2001; 2001WO-US009761.
 XX 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX (UYDE) UNIV DELAWARE.
 PA Kniec EB, Gamper HB, Rice MC;
 XX WPI; 2001-639230/73.
 DR Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX Claim 7; Page 182; 294pp; English.
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX Sequence 121 BP; 46 A; 16 C; 30 G; 29 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 20.4; DB 1; Length 121;
 Best Local Similarity 61.1%; Pred. No. 1.7e+02;
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAGGCAACCATTC 838
 Db 61 GAAGTTTGTGAACACTGAAAGACAGTGAAGTATTTCCACATATACCTTCA 114
 RESULT 236
 ABA79579/c
 ID ABA79579 standard; DNA; 121 BP.
 XX AC ABA79579;
 XX DT 24-JAN-2002 (first entry)
 XX DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2425.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 OS Homo sapiens.

XX WO200173002-A2.
 XX PD 04-OCT-2001.
 XX 27-MAR-2001; 2001WO-US009761.
 XX 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX (UYDE) UNIV DELAWARE.
 PA Kniec EB, Gamper HB, Rice MC;
 XX WPI; 2001-639230/73.
 DR Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX Claim 7; Page 182; 294pp; English.
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX Sequence 121 BP; 31 A; 29 C; 16 G; 45 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 20.4; DB 1; Length 121;
 Best Local Similarity 61.1%; Pred. No. 1.7e+02;
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAGGCAACCATTC 838
 Db 59 GAAGTTTGTGAACACTGAAAGACAGTGAAGTATTTCCACATATACCTTCA 6
 RESULT 237
 ABA79582
 ID ABA79582 standard; DNA; 121 BP.
 XX AC ABA79582;
 XX DT 24-JAN-2002 (first entry)
 XX DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2428.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.

```

OS Homo sapiens.
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 182; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 45 A; 16 C; 29 G; 31 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.4; DB 1; Length 121;
XX Best Local Similarity 61.1%; Pred. No. 1.7e-02;
XX Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
XX
XX 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTC A 838
XX
XX 63 GAAGTTTTCGAAACACTGAAAGACAGTGAGTATTTCCACATATACCCCTTC A 116
XX
XX
XX RESULT 238
XX ABA79586
XX ID ABA79586 standard; DNA; 121 BP.
XX
XX AC ABA79586;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2432.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.

```

```

XX Homo sapiens.
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 182; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 45 A; 15 C; 29 G; 32 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.4; DB 1; Length 121;
XX Best Local Similarity 61.1%; Pred. No. 1.7e-02;
XX Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
XX
XX 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTC A 838
XX
XX 64 GAAGTTTTCGAAACACTGAAAGACAGTGAGTATTTCCACATATACCCCTTC A 117
XX
XX
XX RESULT 239
XX ABA79594
XX ID ABA79594 standard; DNA; 121 BP.
XX
XX AC ABA79594;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2440.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.

```


XX PD 05-OCT-2000.
XX PF 30-MAR-2000; 2000WO-US008440.
XX PR 31-MAR-1999; 99US-0127248P.
XX PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX PA (AFHY-) AFFYMETRIX INC.
XX PI Alshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
XX PI Lipshutz RJ, Patil N, Sklar P;
XX DR WPI; 2000-611722/58.
XX PT Nucleic acid selected from one of 106 genes comprising single nucleotide
XX PT polymorphisms, allele-specific oligonucleotides to the genes are useful
XX PT for phenotypic correlations, forensics, paternity testing, medicine and
XX PT genetic analysis.
XX PS Claim 1; Fig 5; 214pp; English.
XX CC The present invention is concerned with a number of human single
XX CC nucleotide polymorphisms (SNPs) which the inventors identified in human
XX CC genes. These SNPs can be used in disease diagnosis and prediction of an
XX CC individual's susceptibility to disease, in forensic and paternity testing
XX CC and in genetic mapping. In particular, the SNPs of the invention can be
XX CC used to diagnose susceptibility to diseases of the cardiovascular,
XX CC endocrine and neurological systems, such as coronary artery disease,
XX CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
XX CC diseases. Note: the degenerate codon within the sequence represents the
XX CC position of an SNP, for example the letter S represents a polymorphism
XX CC where the nucleotide may be C or G
XX SQ Sequence 268 BP; 51 A; 89 C; 65 G; 62 T; 0 U; 1 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 268;
Best Local Similarity 62.5%; Pred. No. 2.1e+02;
Matches 30; Conservative 1; Mismatches 17; Indels 0; Gaps 0;

QY 1643 APTGCCACATCTCTGTATCATGGAAAGCAAGAGAGTTCCAGAA 1690
DB 170 ACTGGGCRCTGCTCTTCTCTATCCAGAGCAAGTGGTCTCAAA 123

RESULT 242
ADA49152/C
ID ADA49152 standard; DNA; 270 BP.
XX AC ADA49152;
XX DT 20-NOV-2003 (first entry)
XX DE Maize gene conferring disease resistance in plants.
XX KW disease resistance; pathogen tolerance; plant pathogen; ds; gene; plant;
XX KW maize.
XX OS Zea mays.
XX PN WO2003000906-A2.
XX PD 03-JAN-2003.
XX PF 21-JUN-2002; 2002WO-IB002453.
XX PR 22-JUN-2001; 2001US-0300112P.
XX PR 26-SEP-2001; 2001US-0352277P.
XX PR 22-MAR-2002; 2002US-0366535P.
XX PA (SYGN) SYNGENTA PARTICIPATIONS AG.
XX PI Glazebrook J, Briggs S, Cooper B, Goff SA, Moughamer T;

PI Katagiri F, Kreps J, Provart N, Ricke D, Zhu T;
XX WPI; 2003-184052/18.
XX PT New polynucleotide comprising a plant nucleotide sequence having an open
XX PT reading frame that encodes a polypeptide associated with disease
XX PT resistance, useful for conferring resistance or tolerance to a plant
XX PT pathogen.
XX PS Disclosure; SEQ ID NO 1222; 299pp; English.
XX CC The invention relates to a novel isolated polynucleotide comprising a
XX CC plant nucleotide sequence having an open reading frame that encodes a
XX CC polypeptide associated with disease resistance or its fragment having
XX CC substantially the same activity as the full-length polypeptide. The
XX CC polynucleotide of the invention is useful for conferring resistance or
XX CC tolerance to a plant pathogen. The present sequence represents a gene
XX CC conferring disease resistance used in the invention.
XX SQ Sequence 270 BP; 45 A; 74 C; 106 G; 45 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 270;
Best Local Similarity 61.1%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 708 CTCGGGCGAGCATCCCTCAGAGAAATGAGTAGCCATCATGGTCAACAAG 761
DB 183 CGCGCGGTTCCGAGGACTTCAGAGCCAGCCGATGGCTGCTGCCAAGAG 130

RESULT 243
AAH57325/C
ID AAH57325 standard; cDNA; 285 BP.
XX AC AAH57325;
XX DT 10-SEP-2001 (first entry)
XX DE Human pancreas specific cDNA sequence SEQ ID NO:165.
XX KW Human; tissue specific; diagnosis; brain; heart; skeletal muscle; lung;
XX KW liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss;
XX KW metabolic disease; developmental disease; cytostatic; immunomodulatory;
XX KW neuroprotective; gene therapy; cancer; immunopathology; neuropathology.
XX OS Homo sapiens.
XX PN WO200132927-A2.
XX PD 10-MAY-2001.
XX PF 02-NOV-2000; 2000WO-US030396.
XX PR 04-NOV-1999; 99US-0163508P.
XX PA (INCY-) INCYTE GENOMICS INC.
XX PI Sornasse T, Seilhamer JJ, Watson GA;
XX DR WPI; 2001-291057/30.
XX PT New cell and tissue specific polynucleotides useful for diagnosis,
XX PT prognosis or monitoring of treatments for disorders where the gene is
XX PT associated with a cancer, immunopathology or neuropathology.
XX PS Claim 1; Page 127; 327pp; English.
XX CC AAH57161 to AAH57576 represent cell and tissue specific polynucleotide
XX CC sequences (I). (I) can have cytostatic, immunomodulatory and
XX CC neuroprotective activities, and can be used in gene therapy. (I) and
XX CC proteins (II) encoded by then are used in high throughput screening
XX CC assays to select DNA molecules, RNA molecules, peptide nucleic acids,
XX CC mimetics, peptides, proteins, agonists, antagonists, antibodies or their

PF 19-NOV-1999; 99WO-JP006475.
 PR 20-NOV-1998; 98JP-00347785.
 XX (FUSO) FUSO PHARM IND LTD.
 PA Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;
 PI WPI; 2000-40082/34.
 DR P-PSDB; AAB11695.
 XX Serine protease BSSP2, useful in detecting homologs, mutants and
 PT polymorphic variants as markers for diagnosis of e.g. Alzheimer's
 PT disease, cancer, inflammation and prostate hypertrophy, using blood,
 PT urine or other tissues.
 XX Claim 2; Page 55-57; 92pp; Japanese.
 XX The invention relates to novel serine proteases designated BSSP2
 CC (AAB11695-B11699), and to nucleic acids encoding them (AAA61659-A61663).
 CC The invention also relates to vectors and transformants comprising BSSP2
 CC nucleic acids; transgenic animals in which the expression level of BSSP2
 CC can be varied; and an mBSSP2 knockout mouse. The invention additionally
 CC encompasses anti-BSSP2 antibodies and methods of production of such
 CC antibodies, methods of BSSP2 detection using the antibodies, and the use
 CC of BSSP2 proteins or fragments as diagnostic markers for certain medical
 CC conditions. Nucleotides encoding BSSP2 were initially isolated in a mouse
 CC brain cDNA library using degenerate PCR primers (AAA61673-AAA61674)
 CC based on conserved regions of serine proteases. The BSSP2 serine
 CC proteases and nucleotides encoding them are useful in detecting
 CC homologues, mutants and polymorphic variants in biological samples (e.g.,
 CC blood, urine, brain, prostate gland and testis) as diagnostic markers for
 CC conditions such as Alzheimer's disease, epilepsy, cancer, inflammation,
 CC infertility and prostatic hypertrophy. Sequences AAA61659-A61662
 CC represent cDNAs encoding murine BSSP2 variants (mBSSP2), and sequence
 CC AAA61663 represents cDNA encoding human BSSP2 (hBSSP2)
 XX Sequence 717 BP; 138 A; 204 C; 221 G; 154 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 20.4; DB 1; Length 717;
 Best Local Similarity 61.1%; Pred. No. 2.7e+02;
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
 QY 1200 CTCTATACGTACGCAAAACACAGACGAGGCTTACTGTGCTTCAGATCATGA 1253
 DB 242 CTTGTACAGTGCACAGACCATGACTATGATGTGCTCTGCTGAGCTCCGGA 295

RESULT 249
 ABK86038/c
 ID ABK86038 standard; DNA; 1383 BP.
 AC ABK86038;
 XX
 DT 23-AUG-2002 (first entry)
 XX
 DE Synthetic DNA encoding protein C precursor protein.
 XX Human; Protein C; precursor protein; ds; Gene; N-glycosylation;
 KW serum half-life; chromosome 2q13-q14; stroke; myocardial infarction;
 KW after venous thrombosis; disseminated intravascular coagulation; DIC;
 KW sepsis; septic shock; embolism; pulmonary embolism; burn; pregnancy;
 KW bone marrow transplantation; major surgery; trauma; ARDS; coagulant;
 KW adult respiratory distress syndrome; alpha-1 antitrypsin; APC;
 KW activated protein C.
 OS Homo sapiens.
 OS Synthetic.
 XX
 PH Key Location/Qualifiers
 FT CDS 1..1383
 FT /*tag= a
 FT /product= "Precursor protein C"

PT /partial
 FT /note= "No stop codon shown"
 FT 1..126
 FT /*tag= b
 FT mat_peptide 127..1383
 FT /*tag= c
 FT /product= "Mature protein C"
 XX
 PN WO200232461-A2.
 XX
 PD 25-APR-2002.
 XX
 PF 15-OCT-2001; 2001WO-DK000679.
 XX
 PR 18-OCT-2000; 2000DK-00001560.
 PR 18-OCT-2000; 2000US-0242268P.
 PR 21-JUN-2001; 2001DK-00000970.
 PR 21-JUN-2001; 2001US-0300154P.
 XX
 XX (MAXY-) MAXYGEN APS.
 XX (MAXY-) MAXYGEN HOLDINGS LTD.
 PA Andersen KV, Pedersen AH, Freskgaard PO;
 PI WPI; 2002-489875/52.
 DR P-PSDB; AAU99001.
 XX
 PT Novel conjugate useful for treating or preventing septic shock, stroke
 PT and myocardial infarction, comprises non-polypeptide group covalently
 PT attached to protein C polypeptide comprising an attachment group.
 XX
 PS Example 4; Page 74-76; 92pp; English.
 XX
 CC The invention relates to a conjugate (I) comprising at least one non-
 CC polypeptide moiety (II) (e.g. an N-glycosyl group) covalently attached to
 CC a protein C polypeptide comprising an amino acid sequence which differs
 CC from that of a parent protein C polypeptide (III) in at least one
 CC introduced and/or at least one removed amino acid residue comprising an
 CC attachment group for the non-polypeptide group (e.g. an N-glycosylation
 CC site). Also included are (1) a variant (IV) of (III) comprising a
 CC substitution in a position (P) where (P) is an amino acid with at least
 CC 25% of its side group exposed to the surface, with the proviso that the
 CC substitution is not Thr245Ser/Ala/His/Lys/Arg/Asn/Asp/Glu/Gly/Gln,
 CC His/Lys/Arg/Asn/Asp/Glu/Gly/Gln; (2) a nucleotide sequence (V) encoding
 CC (IV); (3) an expression vector (VI) comprising (V); (4) a host cell (VII)
 CC comprising (V) or (VI); (5) increasing (M2) the functional in vivo half-
 CC life of the serum half-life of a parent protein C polypeptide. The
 CC conjugates, variants and protein C proteins are useful as medicaments,
 CC and in the manufacture of medicaments for the treatment (and
 CC diagnosis/prevention) of stroke, myocardial infarction, after venous
 CC thrombosis, disseminated intravascular coagulation (DIC), sepsis, septic
 CC shock, emboli e.g. pulmonary emboli, transplantation such as bone marrow
 CC transplantation, burns, pregnancy, major surgery/trauma or adult
 CC respiratory distress syndrome (ARDS). The variant protein C has an
 CC increased resistance to activation by e.g. human plasma and alpha-1
 CC antitrypsin. The conjugates have an increased in vivo half-life,
 CC increased serum half-life, increased resistance to inhibitors, reduced
 CC renal clearance, reduced immunogenicity and/or increased bioavailability.
 CC The conjugate offers a number of advantages over the currently available
 CC APC products, including longer duration between injections,
 CC administration of less protein, and fewer side effects. Moreover, a
 CC reduced anticoagulant activity is beneficial to reduce the risk of
 CC bleeding while maintaining the antiinflammatory activity of APC
 CC (activated protein C) conjugates. This must be especially important when
 CC the conjugate has an extended plasma life. The gene for protein C is
 CC located on chromosome 2q13-q14. The present sequence encodes precursor
 CC protein C
 XX
 SQ Sequence 1383 BP; 286 A; 418 C; 440 G; 239 T; 0 U; 0 Other;
 Query Match 0.6%; Score 20.4; DB 1; Length 1383;
 Best Local Similarity 55.7%; Pred. No. 2.9e+02;

Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 2651 GATGGCTGATGGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGCTGCGGGAATTCGCCAGGTGG 35
QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 250

AAN90024/c

ID AAN90024 standard; DNA; 1386 BP.

XX AC AAN90024;

XX 25-MAR-2003 (revised)

DT 01-NOV-1989 (first entry)

XX DE Nascent human protein C DNA.

XX KW Human protein C; anti-coagulant; myocardial infarction;

XX KW deep vein thrombosis.

XX OS Homo sapiens.

XX PH Key Location/Qualifiers

FT CDS 1..1383

FT sig_peptide /*tag= a

FT misc_feature /*tag= b

FT misc_feature /*tag= c

FT misc_feature /*tag= d

FT misc_feature /*tag= e

FT misc_feature /*tag= f

XX EP319312-A.

XX 07-JUN-1989.

XX 02-DEC-1988; 88EP-00311421.

XX 04-DEC-1987; 87US-00129027.

XX (ELIL) LILLY & CO ELI.

XX Bang NU, Ehrlich HJ, Grinnell BW, Jaskunas SR;

XX WFI; 1989-167318/23.

XX New DNA cpds. and vectors - used for direct expression of activated human

XX protein C.

XX Disclosure; Page 4; 48pp; English.

XX Nascent human protein C produces inactive protein C. It is used as an

XX anti-coagulant in myocardial infarction and deep vein thrombosis. The

XX patent discloses a recombinant way of making activated protein C.

XX Nucleotides 1-125 encode the signal peptide and propeptide; 126-589

XX constitute the light chain of both the zymogen and activated forms; 587-

XX 592 residues are believed to be removed to form 2-chain protein C; 598-

XX 631 are the activation peptides removed from the zymogen to form

XX activated protein C; 634-1380 constitute the activated heavy chain after

XX post-translational modification. (Updated on 25-MAR-2003 to correct PD

XX field.) (Updated on 25-MAR-2003 to correct FR field.) (Updated on 25-MAR-

XX 2003 to correct PA field.)

XX Sequence 1386 BP; 287 A; 419 C; 440 G; 240 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGATGGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGCTGCGGGAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720

Db 34 CCACGAACAG 25

Search completed: August 9, 2004, 16:32:31

Job time : 1400 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:34:29 ; Search time 17 Seconds
(without alignments)
3.877 Million cell updates/sec

Title: us-10-664-775-2
Perfect score: 3572
Sequence: 1 GTCAGGAAGGCGGCGAGTGA.....GCAACAACAGCAGAAAGCTT 3572

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 20 seqs, 9225 residues

Total number of hits satisfying chosen parameters: 40

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database : rniidb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
1	18.4	0.5	1440	1	US-07-882-202A-3		Sequence 3, Appli
2	18.4	0.5	1440	1	US-08-021-615A-3		Sequence 3, Appli
3	18.4	0.5	1440	1	US-08-321-777-3		Sequence 3, Appli
4	18.4	0.5	1440	1	US-09-009-217-13		Sequence 13, Appl
5	18.4	0.5	1440	1	US-09-009-656-13		Sequence 13, Appl
6	18.4	0.5	1440	1	PCT-US93-04493-3		Sequence 3, Appli
7	17.4	0.5	1440	1	US-07-882-202A-3		Sequence 3, Appli
8	17.4	0.5	1440	1	US-08-021-615A-3		Sequence 3, Appli
9	17.4	0.5	1440	1	US-08-321-777-3		Sequence 3, Appli
10	17.4	0.5	1440	1	US-09-009-217-13		Sequence 13, Appl
11	17.4	0.5	1440	1	US-09-009-656-13		Sequence 13, Appl
12	17.4	0.5	1440	1	PCT-US93-04493-3		Sequence 3, Appli
13	14.6	0.4	141	1	US-08-849-248-6		Sequence 6, Appli
14	13	0.4	141	1	US-08-849-248-6		Sequence 6, Appli
15	12.4	0.3	42	1	US-08-955-638-8		Sequence 8, Appli
16	12.2	0.3	27	1	US-08-293-778-16		Sequence 16, Appl
17	12.2	0.3	45	1	US-08-756-506-13		Sequence 13, Appl
18	11.8	0.3	42	1	US-08-955-638-8		Sequence 8, Appli
19	11.4	0.3	35	1	US-07-998-972A-7		Sequence 7, Appli
20	11.4	0.3	35	1	US-08-463-953-7		Sequence 7, Appli
21	11.4	0.3	35	1	US-08-462-261-7		Sequence 7, Appli
22	11.4	0.3	35	1	PCT-US92-11357-7		Sequence 9, Appli
23	11.4	0.3	36	1	US-08-955-638-9		Sequence 9, Appli
24	11.4	0.3	36	1	US-08-955-638-10		Sequence 10, Appl
25	11	0.3	36	1	US-08-955-638-9		Sequence 9, Appli
26	11	0.3	36	1	US-08-955-638-10		Sequence 10, Appl
27	10.8	0.3	38	1	US-09-558-027-4		Sequence 4, Appli
28	10.4	0.3	45	1	US-08-756-506-13		Sequence 13, Appl
29	10	0.3	35	1	US-07-998-972A-7		Sequence 7, Appli
30	10	0.3	35	1	US-08-463-953-7		Sequence 7, Appli
31	10	0.3	35	1	US-08-462-261-7		Sequence 7, Appli
32	10	0.3	35	1	PCT-US92-11357-7		Sequence 9, Appli
33	9.8	0.3	27	1	US-08-293-778-17		Sequence 17, Appl

Sequence 4, Appli
Sequence 22, Appli
Sequence 20, Appli
Sequence 17, Appli
Sequence 16, Appli
Sequence 22, Appli
Sequence 20, Appli

ALIGNMENTS

RESULT 1

US-07-882-202A-3
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/882,202A
FILING DATE: 13-MAY-1992

CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Hansen, Eugenia S.
REGISTRATION NUMBER: 31,966
REFERENCE/DOCKET NUMBER: OMRF B34290
TELEPHONE: 214-939-4500
TELEFAX: 214-939-4600
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
TISSUE TYPE: Blood
FEATURE:
NAME/KEY: CDS
LOCATION: 36..1433
OTHER INFORMATION: /note= "Coding portion of human
factor VII cDNA"

US-07-882-202A-3
Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

1445 GGATCGAGACATCCCATCGAAAGAAATGCAAAAGCAAAATGCTCTCTGGGAGG 1504
621 GGAATAATCTATTCTTAGAAAAGAAATGCCAGCAACCCAGGCCAATGTGGG 680

```

1  TITLE OF INVENTION: Tissue Factor in Combination with FvIIa
2  NUMBER OF SEQUENCES: 4
3  CORRESPONDENCE ADDRESS:
4  ADDRESSEE: Richards, Medlock & Andrews
5  STREET: 1201 Elm Street, Suite 4500
6  CITY: Dallas
7  STATE: Texas
8  COUNTRY: US
9  ZIP: 75270-2197
10 COMPUTER READABLE FORM:
11 MEDIUM TYPE: Floppy disk
12 COMPUTER: IBM PC compatible
13 OPERATING SYSTEM: PC-DOS/MS-DOS
14 SOFTWARE: PatentIn Release #1.0, Version #1.25
15 CURRENT APPLICATION DATA:
16 APPLICATION NUMBER: US/08/321,777
17 FILING DATE:
18 CLASSIFICATION: 514
19 PRIOR APPLICATION DATA:
20 APPLICATION NUMBER: US 07/882202
21 FILING DATE: 13-MAY-1992
22 ATTORNEY/AGENT INFORMATION:
23 NAME: Hansen, Eugenia S.
24 REGISTRATION NUMBER: 31,966
25 REFERENCE/DOCKET NUMBER: OMRF B34290C
26 TELECOMMUNICATION INFORMATION:
27 TELEPHONE: 214-939-4500
28 TELEFAX: 214-939-4600
29 INFORMATION FOR SEQ ID NO: 3:
30 SEQUENCE CHARACTERISTICS:
31 LENGTH: 1440 base pairs
32 TYPE: nucleic acid
33 STRANDEDNESS: double
34 TOPOLOGY: linear
35 MOLECULE TYPE: cDNA
36 HYPOTHETICAL: NO
37 ANTI-SENSE: NO
38 ORIGINAL SOURCE:
39 ORGANISM: Homo sapiens
40 TISSUE TYPE: Blood
41 FEATURE:
42 NAME/KEY: CDS
43 LOCATION: 36..1433
44 OTHER INFORMATION: /note= "Coding portion of human
45 OTHER INFORMATION: factor VII cDNA"
46 US-08-321-777-3
47
48 Query Match 0.5%; Score 18.4; DB 1; Length 1440;
49 Best Local Similarity 56.7%; Pred. No. 2.7; Gaps 0;
50 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
51
52 QY 1445 GGATCGAGACCATCCCATCGGAAAGAAATGCAAAAAGACAAATGGCTGTCTGGGAGG 1504
53 |||||
54 DB 621 GCGAAATACCTATTCTAGAAAAAGAAATCCAGCAACCCCAAGCCGAATTGTGGGG 680
55 |||||
56
57 RESULT 4
58 US-09-009-217-13
59 Sequence 13, Application US/09009217
60 Patent No. 6132729
61 GENERAL INFORMATION:
62 APPLICANT: Thorpe, Philip E.
63 APPLICANT: King, Steven W.
64 APPLICANT: Gao, Boming
65 TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
66 TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
67 TITLE OF INVENTION: AND TUMOR TREATMENT
68 NUMBER OF SEQUENCES: 27
69 CORRESPONDENCE ADDRESS:
70 ADDRESSEE: Arnold, White & Durkee
71 STREET: P.O. Box 4433
72 CITY: Houston
73 STATE: Texas

```

```

RESULT 2
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,956
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4500
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-021-615A-3
;
Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1445 GGATCAGACCATCCCCATGGAAAAGAAATGCAAAAAGCAAAATGCTCTCTGGGGAGG 1504
DB 621 GGAAATACCTATTCTAGAAAAAGAAATGCCAGCAAAACCCCAAGCCCAATTGTGGGG 680
RESULT 3
US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified

```

; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504
DB 621 GGAATAATACCTTATTAGAAAAAGAAATGCCAGCAACCCCAAGCGCGAATTGTGGGG 680

RESULT 5

US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-656-13

Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504
DB 621 GGAATAATACCTTATTAGAAAAAGAAATGCCAGCAACCCCAAGCGCGAATTGTGGGG 680

RESULT 6

PCT-US93-04493-3
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs

Query Match 0.5%; Score 17.4; DB 1; Length 1440;
Best Local Similarity 53.7%; Pred. No. 8.3;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 871 AGTAATGCTGAAGAGCTGAAGTTCCTATGAAGAGCTCAAGACCTTTTAGAA 930
Db 344 AGAATCCAGAACAGCTTCCTCTCCCGCTCTTGAAGATCTCCCGGCTCTCTCGAA 285

Qy 931 CTAACAC 937
Db 284 GGAGCAC 278

RESULT 9
US-08-321-777-3/c
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE: 13-MAY-1992
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRP B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"

US-08-321-777-3

Query Match 0.5%; Score 17.4; DB 1; Length 1440;
Best Local Similarity 53.7%; Pred. No. 8.3;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 871 AGTAATGCTGAAGAGCTGAAGTTCCTATGAAGAGCTCAAGACCTTTTAGAA 930
Db 344 AGAATCCAGAACAGCTTCCTCTCCCGCTCTTGAAGATCTCCCGGCTCTCTCGAA 285

Qy 931 CTAACAC 937
Db 284 GGAGCAC 278

RESULT 10
US-09-009-217-13/c
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Benning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hidler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-009-217-13

Query Match 0.5%; Score 17.4; DB 1; Length 1440;
Best Local Similarity 53.7%; Pred. No. 8.3;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 871 AGTAATGCTGAAGAGCTGAAGTTCCTATGAAGAGCTCAAGACCTTTTAGAA 930
Db 344 AGAATCCAGAACAGCTTCCTCTCCCGCTCTTGAAGATCTCCCGGCTCTCTCGAA 285

Qy 931 CTAACAC 937
Db 284 GGAGCAC 278

RESULT 11
US-09-009-656-13/c
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-009-656-13
Query Match 0.5%; Score 17.4; DB 1; Length 1440;
Best Local Similarity 53.7%; Pred. No. 8.3;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 871 AGTATGCTGAGAGCTGAAGTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
Db 344 AGAATCCAGACAGCTTCTCGTCTCTTGAAGATCTCCCGGCTCTCTCGAA 285
QY 931 CTAACAC 937
Db 284 GGAGCAC 278
RESULT 12
PCT-US93-04493-3/c
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp. Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /product= "Tissue Factor"
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: /citation= ([1])
PCT-US93-04493-3
Query Match 0.5%; Score 17.4; DB 1; Length 1440;
Best Local Similarity 53.7%; Pred. No. 8.3;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 871 AGTATGCTGAGAGCTGAAGTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
Db 344 AGAATCCAGACAGCTTCTCGTCTCTTGAAGATCTCCCGGCTCTCTCGAA 285
QY 931 CTAACAC 937
Db 284 GGAGCAC 278
RESULT 13
US-08-849-248-6
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbym, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-07-998-972A-7

Query Match 0.3%; Score 11.4; DB 1; Length 35;
Best Local Similarity 71.4%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2484 CCAGTCCATTCTGAAGGAGAT 2504
DB 15 CCACTCTTCTCTGGAGGACT 35

RESULT 20
US-08-463-953-7
Sequence 7, Application US/08463953
Patent No. 5502034
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
STREET: Twentieth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,953
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-463-953-7

Query Match 0.3%; Score 11.4; DB 1; Length 35;
Best Local Similarity 71.4%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2484 CCAGTCCATTCTGAAGGAGAT 2504
DB 15 CCACTCTTCTCTGGAGGACT 35

RESULT 21
US-08-462-261-7
Sequence 7, Application US/08462261
Patent No. 5527692
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
STREET: Twentieth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,261
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/998,972
FILING DATE: 30-DEC-1992
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-462-261-7

Query Match 0.3%; Score 11.4; DB 1; Length 35;
Best Local Similarity 71.4%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 40 TCCAGGTAGGAGCAGTACTGCGCT 66
|||||
Db 5 TCCACGTTGCCGTGCCGACGCTCCTCT 31

RESULT 26

US-08-955-636-10/c
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.3%; Score 11; DB 1; Length 36;
Best Local Similarity 63.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 40 TCCAGGTAGGAGCAGTACTGCGCT 66
|||||
Db 32 TCCACGTTGCCGTGCCGACGCTCCTCT 6

RESULT 27

US-09-558-027-4
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: S565,204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

Query Match 0.3%; Score 10.8; DB 1; Length 38;
Best Local Similarity 60.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1716 ATCCAAAGCCTTGACTGCGGGTCACA 1745
|||||
Db 6 ATCCACTAGTCTAGGGAATGGGGCTCGCA 35

RESULT 28

US-08-756-506-13
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian

; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
; TITLE OF INVENTION: ANIMALS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSER: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/756,506
; FILING DATE:
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Sawislak, Deborah A
; REGISTRATION NUMBER: 37,438
; REFERENCE/DOCKET NUMBER: 95-28
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6672
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC6337
US-08-756-506-13

Query Match 0.3%; Score 10.4; DB 1; Length 45;
Best Local Similarity 70.0%; Pred. No. 3e+02;
Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 48 AAGGAGCAGTAGTCGCGCTT 67
|||||
Db 2 AGGAGGAGTTGGCGCGCTT 21

RESULT 29

US-07-998-972A-7/c
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/998,972A
FILING DATE: 19921230
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324

Query Match 0.3%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGTGTGACTCACTGGA 2591
Db 22 AGGAGTTGGCTCGCCGGA 5

RESULT 30
US-08-463-953-7/c
Sequence 7, Application US/08463953
Patent No. 5502034
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
STREET: Twentieth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,953
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600

TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-463-953-7

Query Match 0.3%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGTGTGACTCACTGGA 2591
Db 22 AGGAGTTGGCTCGCCGGA 5

RESULT 31
US-08-462-261-7/c
Sequence 7, Application US/08462261
Patent No. 5527692
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
STREET: Twentieth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,261
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/998,972
FILING DATE: 30-DEC-1992
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-462-261-7

Query Match 0.3%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 3.6e+02;

Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGCTGACTCTACTGGA 2591
| | | | | | | | | |
Db 22 AGGAGTTGGCTCGCCGGA 5

RESULT 32

PCT-US92-11357-7/c
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11357
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
PCT-US92-11357-7

Query Match 0.3%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGCTGACTCTACTGGA 2591
| | | | | | | | | |
Db 22 AGGAGTTGGCTCGCCGGA 5

RESULT 33

US-08-293-778-17
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren B.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard

; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agiris, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-293-778-17

Query Match 0.3%; Score 9.8; DB 1; Length 27;
Best Local Similarity 66.7%; Pred. No. 3.5e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 281 GAGAGATCTGACAGATGTGG 301
| | | | | | | | | |
Db 5 GGGAAATCTTCCAGGACGGG 25

RESULT 34

US-09-558-027-4/c
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0

```
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

Query Match      0.3%; Score 9.6; DB 1; Length 38;
Best Local Similarity 62.5%; Pred. No. 4.5e+02;
Matches 15; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 706 TACTGGGGGAGGAATCCCTCAGA 729
Db 38 TCCTGGAGGCCCATTCCTCAGA 15

RESULT 35
US-08-293-778-22
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NO. 5580560o No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-22

Query Match      0.3%; Score 9.4; DB 1; Length 26;
Best Local Similarity 62.5%; Pred. No. 4.5e+02;
Matches 15; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2749 GTCACAGAGAGTTGGACAC 2767
Db 7 GTCACGGAAGTCGGAGAC 25

RESULT 36
US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NO. 5580560o No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match      0.3%; Score 9.4; DB 1; Length 27;
Best Local Similarity 68.4%; Pred. No. 4.9e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2709 GGTGATGGACAGGGAGGCC 2727
Db 1 GCTGCTGACCTGGGGGCC 19
```


RESULT 38
US-08-293-778-16/c
; Sequence 16, Application US/08293778
; Patent No. 5380560
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else M.

7 GENERAL INFORMATION:
7 APPLICANT: Nicolaissen, Else M.
7
7 APPLICANT: Bjorn, Soren E.
7
7 APPLICANT: Wiberg, Finn C.
7
7 APPLICANT: Woodbury, Richard
7
7 TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
7
7 NUMBER OF SEQUENCES: 26
7
7 CORRESPONDENCE ADDRESS:
7 ADDRESSEE: No. 5580560 No. 5580560disk of

STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/293,778

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/104,509

FILING DATE:

APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/434,149

FILING DATE: 13-NOV-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/DK88/00103

FILING DATE: 24-JUN-1988

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/898,248

FILING DATE: 12-JUN-1992

ATTORNEY/AGENT INFORMATION:

NAME: Agnis, Cheryl H.

REGISTRATION NUMBER: 34,086

REFERENCE/DOCKET NUMBER: 3129.224-US

TELECOMMUNICATION INFORMATION:

TELEPHONE: 212-867-0123

TELEFAX: 212-867-0298

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 26 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cdna

US-08-293-778-22

Query Match 0.2%; Score 8.6; DB 1; Length 26;

Best Local Similarity 73.3%; Pred. No. 6.9e+02;

Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1786 CCACCTGACCTGACT 1800

Db 20 CGACCTTCGGTGACT 6

RESULT 40

US-08-293-778-20/c

Sequence 20, Application US/08293778

Patent No. 5580560

GENERAL INFORMATION:

APPLICANT: Nicolaisen, Else M.

APPLICANT: Bjorn, Soren E.

APPLICANT: Wiberg, Finn C.

APPLICANT: Woodbury, Richard

TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:

ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.

STREET: 405 Lexington Avenue, 62nd Floor

CITY: New York

STATE: New York

COUNTRY: United States of America

ZIP: 10174-6201

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/293,778

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/104,509

FILING DATE:

APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/434,149

FILING DATE: 13-NOV-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/DK88/00103

FILING DATE: 24-JUN-1988

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/898,248

FILING DATE: 12-JUN-1992

ATTORNEY/AGENT INFORMATION:

NAME: Agnis, Cheryl H.

REGISTRATION NUMBER: 34,086

REFERENCE/DOCKET NUMBER: 3129.224-US

TELECOMMUNICATION INFORMATION:

TELEPHONE: 212-867-0123

TELEFAX: 212-867-0298

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 27 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cdna

US-08-293-778-20

Query Match

Best Local Similarity 66.7%; Score 8.4; DB 1; Length 27;

Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 62 GCGCTTTGCTGGAGCAGC 79

Db 18 GCGCCAGGTCGAGCAGC 1

Search completed: August 9, 2004, 16:34:47

Job time: 18 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:35:17 ; Search time 48 seconds
(without alignments)

3.742 Million cell updates/sec

Title: us-10-664-775-2

Perfect score: 3572

Sequence: 1 gtcagaagggcgcagtgatg.....gcacacagcagaagctt 3572

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 61 seqs, 25143 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rnpbdb.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20.8	0.6	1338	1	US-09-782-587B-2
2	20.8	0.6	1357	1	US-09-782-587B-4
3	19.8	0.6	1338	1	US-09-782-587B-2
4	19.8	0.6	1357	1	US-09-782-587B-4
5	18.6	0.5	1361	1	US-10-382-248-35
6	18.4	0.5	1332	1	US-10-411-037-7
7	18.4	0.5	1332	1	US-10-411-026-7
8	18.4	0.5	1332	1	US-10-410-962-7
9	18.4	0.5	1332	1	US-10-411-049-7
10	18.4	0.5	1332	1	US-10-410-930-7
11	18.4	0.5	1332	1	US-10-410-997-7
12	18.4	0.5	1332	1	US-10-411-012-7
13	18.4	0.5	1332	1	US-10-287-994-7
14	18.4	0.5	1332	1	US-10-410-913-7
15	18.4	0.5	1440	1	US-10-375-741-13
16	18.4	0.5	2040	1	US-10-617-619-9
17	18.4	0.5	2106	1	US-10-617-619-9
18	18.1	0.5	555	1	US-10-029-386-9623
19	18.1	0.5	1361	1	US-10-382-248-35
20	17.4	0.5	1332	1	US-10-411-037-7
21	17.4	0.5	1332	1	US-10-411-026-7
22	17.4	0.5	1332	1	US-10-410-962-7
23	17.4	0.5	1332	1	US-10-411-049-7
24	17.4	0.5	1332	1	US-10-410-930-7
25	17.4	0.5	1332	1	US-10-410-997-7
26	17.4	0.5	1332	1	US-10-411-012-7
27	17.4	0.5	1332	1	US-10-287-994-7
28	17.4	0.5	1332	1	US-10-410-913-7
29	17.4	0.5	1440	1	US-10-375-741-13
30	17.4	0.5	2040	1	US-10-617-619-9
31	17.4	0.5	2106	1	US-10-617-619-9
32	17.1	0.5	222	1	US-10-029-386-9623
33	17	0.5	483	1	US-09-918-995-8429

555	1	US-10-029-386-9623	Sequence 9623, Ap
483	1	US-09-918-995-8429	Sequence 8429, Ap
100	1	US-10-272-665-107	Sequence 107, App
100	1	US-10-273-321-107	Sequence 107, App
100	1	US-10-272-756-107	Sequence 107, App
100	1	US-10-273-228-107	Sequence 107, App
100	1	US-10-272-665-106	Sequence 106, App
100	1	US-10-273-321-106	Sequence 106, App
100	1	US-10-272-756-106	Sequence 106, App
100	1	US-10-273-228-106	Sequence 106, App
38	1	US-10-398-4228-20	Sequence 20, Appl
38	1	US-09-959-357-2	Sequence 2, Appl
38	1	US-10-254-394-2	Sequence 2, Appl
60	1	US-10-272-665-22	Sequence 22, Appl
60	1	US-10-273-321-22	Sequence 22, Appl
60	1	US-10-272-756-22	Sequence 22, Appl
60	1	US-10-273-228-22	Sequence 22, Appl
100	1	US-10-272-665-106	Sequence 106, App
100	1	US-10-273-321-106	Sequence 106, App
100	1	US-10-272-756-106	Sequence 106, App
100	1	US-10-273-228-106	Sequence 106, App
60	1	US-10-272-665-22	Sequence 22, Appl
60	1	US-10-273-321-22	Sequence 22, Appl
60	1	US-10-272-756-22	Sequence 22, Appl
60	1	US-10-273-228-22	Sequence 22, Appl
100	1	US-10-272-665-107	Sequence 107, App
100	1	US-10-273-321-107	Sequence 107, App
100	1	US-10-272-756-107	Sequence 107, App
100	1	US-10-273-228-107	Sequence 107, App
31	1	US-10-017-122-4	Sequence 4, Appl
38	1	US-10-358-4228-20	Sequence 20, Appl
38	1	US-09-959-357-2	Sequence 2, Appl
38	1	US-10-254-394-2	Sequence 2, Appl
42	1	US-10-272-665-22	Sequence 22, Appl
42	1	US-10-273-321-22	Sequence 22, Appl
42	1	US-10-272-756-22	Sequence 22, Appl
42	1	US-10-273-228-22	Sequence 22, Appl
60	1	US-10-272-665-106	Sequence 106, App
60	1	US-10-273-321-106	Sequence 106, App
60	1	US-10-272-756-106	Sequence 106, App
60	1	US-10-273-228-106	Sequence 106, App
60	1	US-10-272-665-22	Sequence 22, Appl
60	1	US-10-273-321-22	Sequence 22, Appl
60	1	US-10-272-756-22	Sequence 22, Appl
60	1	US-10-273-228-22	Sequence 22, Appl
100	1	US-10-272-665-107	Sequence 107, App
100	1	US-10-273-321-107	Sequence 107, App
100	1	US-10-272-756-107	Sequence 107, App
100	1	US-10-273-228-107	Sequence 107, App
31	1	US-10-017-122-4	Sequence 4, Appl
60	1	US-10-272-665-23	Sequence 23, Appl
60	1	US-10-273-321-23	Sequence 23, Appl
60	1	US-10-272-756-23	Sequence 23, Appl
60	1	US-10-273-228-23	Sequence 23, Appl
222	1	US-10-029-386-23323	Sequence 23323, A
36	1	US-09-951-121A-8	Sequence 9, Appl
36	1	US-10-255-032-8	Sequence 8, Appl
36	1	US-10-255-032-9	Sequence 9, Appl
36	1	US-10-255-032-8	Sequence 8, Appl
36	1	US-10-255-032-9	Sequence 9, Appl
42	1	US-10-295-682-8	Sequence 8, Appl
42	1	US-09-803-810-8	Sequence 8, Appl
42	1	US-10-238-330-8	Sequence 8, Appl
33	1	US-09-951-121A-14	Sequence 14, Appl
33	1	US-10-295-682-14	Sequence 14, Appl
33	1	US-10-295-682-15	Sequence 15, Appl
33	1	US-09-951-121A-14	Sequence 14, Appl
33	1	US-10-295-682-14	Sequence 14, Appl
33	1	US-10-295-682-15	Sequence 15, Appl
33	1	US-10-295-682-14	Sequence 14, Appl
33	1	US-10-295-682-15	Sequence 15, Appl
34	1	US-10-349-858-8	Sequence 8, Appl
34	1	US-10-281-727-6	Sequence 6, Appl
32	1	US-10-281-727-7	Sequence 7, Appl
35	1	US-10-109-498-5	Sequence 5, Appl
35	1	US-10-109-498-6	Sequence 6, Appl
60	1	US-10-272-665-23	Sequence 23, Appl
60	1	US-10-273-321-23	Sequence 23, Appl
60	1	US-10-272-756-23	Sequence 23, Appl
60	1	US-10-273-228-23	Sequence 23, Appl
60	1	US-10-349-858-8	Sequence 8, Appl
54	1	US-09-951-121A-8	Sequence 9, Appl
36	1	US-10-255-032-9	Sequence 9, Appl
36	1	US-10-255-032-8	Sequence 8, Appl
36	1	US-10-255-032-9	Sequence 9, Appl
36	1	US-10-255-032-8	Sequence 8, Appl
36	1	US-10-295-682-9	Sequence 9, Appl
36	1	US-10-295-682-8	Sequence 8, Appl
36	1	US-10-295-682-9	Sequence 9, Appl
36	1	US-10-295-682-8	Sequence 8, Appl

C 107 10.4 0.3 36 1 US-10-281-727-2 Sequence 2, Appli
C 108 10.4 0.3 36 1 US-10-281-727-3 Sequence 3, Appli
C 109 10.4 0.3 36 1 US-10-281-727-3 Sequence 3, Appli
C 110 10 0.3 35 1 US-10-109-498-5 Sequence 5, Appli
C 111 10 0.3 35 1 US-10-109-498-5 Sequence 6, Appli
C 112 9.8 0.3 34 1 US-09-951-121A-2 Sequence 2, Appli
C 113 9.8 0.3 34 1 US-09-951-121A-2 Sequence 3, Appli
C 114 9.8 0.3 34 1 US-10-295-682-2 Sequence 2, Appli
C 115 9.8 0.3 34 1 US-10-295-682-2 Sequence 3, Appli
C 116 9.2 0.3 31 1 US-10-017-122-4 Sequence 4, Appli
C 117 8.8 0.2 32 1 US-10-281-727-6 Sequence 6, Appli
C 118 8.8 0.2 32 1 US-10-281-727-7 Sequence 7, Appli
C 119 8.6 0.2 34 1 US-09-951-121A-2 Sequence 2, Appli
C 120 8.6 0.2 34 1 US-09-951-121A-2 Sequence 3, Appli
C 121 8.6 0.2 34 1 US-10-295-682-2 Sequence 2, Appli
C 122 8.6 0.2 34 1 US-10-295-682-3 Sequence 3, Appli

ALIGNMENTS

RESULT 1
US-09-782-587B-2
; Sequence 2, Application US/09782587B
; Publication No. US2003096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match 0.6%; Score 20.8; DB 1; Length 1338;
Best Local Similarity 57.8%; Pred. No. 0.76; 27; Indels 0; Gaps 0;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 1443 AGGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGGCTGTCTGGGA 1502
DB 132 AGAGCTCCGCCCTGGCTCCCTGGACCGAATGCAAGAGGAACAGTGCAGCTTTGAGGA 191
QY 1503 GGCC 1506
DB 192 AGCC 195

RESULT 2
US-09-782-587B-4
; Sequence 4, Application US/09782587B
; Publication No. US2003096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US

; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match 0.6%; Score 20.8; DB 1; Length 1357;
Best Local Similarity 57.8%; Pred. No. 0.77; 27; Indels 0; Gaps 0;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 1443 AGGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGGCTGTCTGGGA 1502
DB 145 AGAGCTCCGCCCTGGCTCCCTGGACCGAATGCAAGAGGAACAGTGCAGCTTTGAGGA 204
QY 1503 GGCC 1506
DB 205 AGCC 208

RESULT 3
US-09-782-587B-2/c
; Sequence 2, Application US/09782587B
; Publication No. US2003096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match 0.6%; Score 19.8; DB 1; Length 1338;
Best Local Similarity 69.2%; Pred. No. 2.5; 12; Indels 0; Gaps 0;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
QY 44 AGTAAGGAGCAGTAGCTGGCTTTGTGTGAGGAGCCGT 82
DB 322 AGATATAGCTCTGCAGCTGGTCTTTGAGGAGCCCGT 284

RESULT 4
US-09-782-587B-4/c
; Sequence 4, Application US/09782587B

Publication No. US20030096338A1
GENERAL INFORMATION:
APPLICANT: PEDERSEN, ANDERS H.
APPLICANT: ANDERSON, KIM V.
APPLICANT: BORNAES, CLAUS
TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
FILE REFERENCE: 31-001100US
CURRENT APPLICATION NUMBER: US/09/782,587B
CURRENT FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: CA 2000 00218
PRIOR FILING DATE: 2000-02-11
PRIOR APPLICATION NUMBER: 60/184,036
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: 60/241,916
PRIOR FILING DATE: 2000-10-18
NUMBER OF SEQ ID NOS: 19
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 4
LENGTH: 1357
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Expression
OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4
Query Match 0.6%; Score 19.8; DB 1; Length 1357;
Best Local Similarity 69.2%; Pred. No. 2.6; Mismatches 0; Gaps 0;
Matches 27; Conservative 0; Indels 0; Indels 0; Gaps 0;
QY 44 AGGTAAGGAGCAGTAGCTGGCGTTTGTGGAGCAGCCGT 82
DB 335 AGATAGCTCGAGCTGGTCTTTGAGGAGCCCGCT 297
RESULT 5
US-10-382-248-35
Sequence 35, Application US/10382248
Publication No. US20040059347A1
GENERAL INFORMATION:
APPLICANT: Alsbrook, et al.
TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
FILE REFERENCE: 21402-568C
CURRENT APPLICATION NUMBER: US/10/382,248
CURRENT FILING DATE: 2003-03-05
PRIOR APPLICATION NUMBER: 60/366,928
PRIOR FILING DATE: 2002-03-22
PRIOR APPLICATION NUMBER: 60/361,974
PRIOR FILING DATE: 2002-03-06
PRIOR APPLICATION NUMBER: 60/365,477
PRIOR FILING DATE: 2002-03-19
PRIOR APPLICATION NUMBER: 60/401,661
PRIOR FILING DATE: 2002-08-06
NUMBER OF SEQ ID NOS: 82
SOFTWARE: CuraseqList version 0.1
SEQ ID NO 35
LENGTH: 1361
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: CDS
LOCATION: (45)...(1301)
US-10-382-248-35
Query Match 0.5%; Score 18.6; DB 1; Length 1361;
Best Local Similarity 49.5%; Pred. No. 10; Mismatches 49; Indels 0; Gaps 0;
Matches 48; Conservative 0; Indels 0; Indels 0; Gaps 0;
QY 1408 CTATGGCAGAGGTTTCATGACATTTACAGGAGCAGGATCGAGACCATCCCATGGAA 1457
DB 452 CGAGGCGCGGAACTGTGAGACGCTTGAATATCCATGTGCAAAATACCTATCTAGAAA 511
QY 1468 AAGAAATCAAAAAGCAAAATGGCTGTCTGGGAGG 1504

DB 512 AAGAAATCCAGCAACCCCAAGCCGAATTTGTGGG 548
RESULT 6
US-10-411-037-7
Sequence 7, Application US/10411037
Publication No. US20040043446A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bowe, Caryn
TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
TITLE OF INVENTION: GALACTOSIDASE A
FILE REFERENCE: 040853-01-5082
CURRENT APPLICATION NUMBER: US/10/411,037
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-411-037-7
Query Match 0.5%; Score 18.4; DB 1; Length 1332;
Best Local Similarity 56.7%; Pred. No. 12; Mismatches 26; Indels 0; Gaps 0;
Matches 34; Conservative 0; Indels 0; Indels 0; Gaps 0;
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
DB 520 GGAATAATACCTATTCTAGAAAAAGAAATGCCAAACCCCAAGCCGAATTTGTGGG 579
RESULT 7
US-10-411-026-7
Sequence 7, Application US/10411026
Publication No. US20040063911A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
TITLE OF INVENTION: METHODS
FILE REFERENCE: 040853-01-5053
CURRENT APPLICATION NUMBER: US/10/411,026
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292


```
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGCCGAAATTGTGGG 579

RESULT 11
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGCCGAAATTGTGGG 579

RESULT 12
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGCCGAAATTGTGGG 579
```

RESULT 12

```
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGCCGAAATTGTGGG 579

RESULT 13
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Bove, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
```



```
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; TITLE OF INVENTION: GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match      0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAAGCTGAAGTTCGCTCTCTCCGCGTCTTGAAGATCTCCCGGCGCTCTCGAA 930
DB 243 AGAATCCAGAACACAGCTTCGCTCTCTCCGCGTCTTGAAGATCTCCCGGCGCTCTCGAA 184

QY 931 CTAACAC 937
DB 183 GGAGCAC 177

RESULT 21
US-10-411-026-7/c
; Sequence 7, Application US/10411026
; Publication No. US20040063911A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-026-7

Query Match      0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAAGCTGAAGTTCGCTCTCTCCGCGTCTTGAAGATCTCCCGGCGCTCTCGAA 930
DB 243 AGAATCCAGAACACAGCTTCGCTCTCTCCGCGTCTTGAAGATCTCCCGGCGCTCTCGAA 184

QY 931 CTAACAC 937
DB 183 GGAGCAC 177

RESULT 22
US-10-410-962-7/c
; Sequence 7, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-962-7

Query Match      0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAAGCTGAAGTTCGCTCTCTCCGCGTCTTGAAGATCTCCCGGCGCTCTCGAA 930
DB 243 AGAATCCAGAACACAGCTTCGCTCTCTCCGCGTCTTGAAGATCTCCCGGCGCTCTCGAA 184

QY 931 CTAACAC 937
DB 183 GGAGCAC 177

RESULT 23
```

```
US-10-411-049-7/c
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-049-7

Query Match          0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTACAGACCTTTTAGAA 930
Db 243 AGAATCCAGAACAGCTTCTCTCCGCGTCTTGAAGATCTCCGGGCTCTCTCGAA 184

QY 931 CTAACAC 937
Db 183 GGAGCAC 177

RESULT 24
US-10-410-930-7/c
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-049-7

Query Match          0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTACAGACCTTTTAGAA 930
Db 243 AGAATCCAGAACAGCTTCTCTCCGCGTCTTGAAGATCTCCGGGCTCTCTCGAA 184

QY 931 CTAACAC 937
Db 183 GGAGCAC 177

RESULT 24
US-10-410-930-7/c
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match          0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTACAGACCTTTTAGAA 930
Db 243 AGAATCCAGAACAGCTTCTCTCCGCGTCTTGAAGATCTCCGGGCTCTCTCGAA 184

QY 931 CTAACAC 937
Db 183 GGAGCAC 177

RESULT 25
US-10-410-997-7/c
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match          0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
```

QY 871 AGTAATGCTGAAGAAGCTGAAGTTGAACGGTCTCTATGAAGACCTACAAGACCTTTTAGAA 930
DB 243 AGAATCCAGACAGCTTCGTCTCTCCGGTCTCTTGAAGATCTCCCGGCTCTCTCGAA 184

QY 931 CTAACAC 937
DB 183 GGAGCAC 177

RESULT 26

US-10-411-012-7/c
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: GLYCOPREGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/411,012
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match 0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAAGCTGAAGTTGAACGGTCTCTATGAAGACCTACAAGACCTTTTAGAA 930
DB 243 AGAATCCAGACAGCTTCGTCTCTCCGGTCTCTTGAAGATCTCCCGGCTCTCTCGAA 184

QY 931 CTAACAC 937
DB 183 GGAGCAC 177

RESULT 27

US-10-287-994-7/c
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Bove, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi

; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US/10/287,994
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match 0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAAGCTGAAGTTGAACGGTCTCTATGAAGACCTACAAGACCTTTTAGAA 930
DB 243 AGAATCCAGACAGCTTCGTCTCTCCGGTCTCTTGAAGATCTCCCGGCTCTCTCGAA 184

QY 931 CTAACAC 937
DB 183 GGAGCAC 177

RESULT 28

US-10-410-913-7/c
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn

; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5081
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US/10/410,913
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7

```
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match      0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 243 AGAAATCCAGAACAGCTTCGTCCTCTCCGGCTCTTGAAGATCTCCCGGGCTCTCTCGAA 184
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 931 CTAACAC 937
    |||||
Db 183 GGAGCAC 177

RESULT 29
US-10-375-741-13/c
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match      0.5%; Score 17.4; DB 1; Length 1440;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 344 AGAAATCCAGAACAGCTTCGTCCTCTCCGGCTCTTGAAGATCTCCCGGGCTCTCTCGAA 285
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 931 CTAACAC 937
    |||||
Db 284 GGAGCAC 278

RESULT 30
US-10-617-619-12/c
; Sequence 12, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
```

```
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match      0.5%; Score 17.4; DB 1; Length 2040;
Best Local Similarity 53.7%; Pred. No. 24;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 243 AGAAATCCAGAACAGCTTCGTCCTCTCCGGCTCTTGAAGATCTCCCGGGCTCTCTCGAA 184
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 931 CTAACAC 937
    |||||
Db 183 GGAGCAC 177

RESULT 31
US-10-617-619-9/c
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      0.5%; Score 17.4; DB 1; Length 2106;
Best Local Similarity 53.7%; Pred. No. 23;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 309 AGAAATCCAGAACAGCTTCGTCCTCTCCGGCTCTTGAAGATCTCCCGGGCTCTCTCGAA 250
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 931 CTAACAC 937
    |||||
Db 249 GGAGCAC 243

RESULT 32
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
```

```
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match 0.5%; Score 17.1; DB 1; Length 222;
Best Local Similarity 47.1%; Pred. No. 8;
Matches 82; Conservative 0; Mismatches 89; Indels 3; Gaps 1;

QY 11 GCGGAGTGGAGGAGTACCTCGTCCAAAGTAAAGGACAGTAGCT---GCGCTT 67
Db 2 GGTGAGGAGTGGAGGAGTACCTCGTCCAAAGTAAAGGACAGTAGCTCCAGGGCGG 61
QY 68 TGTGTGAGCAGCGGTAAAGAGATATCCCGCCGCGGAGTAAAGAGAAACCCAAAGTAAAGT 127
Db 62 TGGCGCCAGCGTCCAGCAGCTGCGCCCGCGCTGACCAATGAGAAGCGCAGAGGCCA 121
QY 128 GTAGGTGTTGAGGAGGATCAGAGGCGGAGCAGATCTGTAACCATCACCAGCAG 181
Db 122 GCGTCCTCTCAGAGAACTCCGTTCCGGCAGGCGAGAGGGGCACCATCGTGTGAG 175

RESULT 33
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)---(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match 0.5%; Score 17; DB 1; Length 483;
Best Local Similarity 59.2%; Pred. No. 21;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1458 CCCCATGGAAGAAGATGCAAAAAGCAAAATGGCTGTCTCGGGAGGCC 1506
```

```
Db 246 CTCCTCGAGGAGGAGTGTCAAGGAGGAGCAGTCTCTCTCGAGGAGGCC 294

RESULT 34
US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

Query Match 0.5%; Score 17; DB 1; Length 555;
Best Local Similarity 44.1%; Pred. No. 24;
Matches 71; Conservative 0; Mismatches 90; Indels 0; Gaps 0;

QY 20 AGGAGGAGTACCTACCTCGTCCAAAGTAAAGGAGCAGTAGCTGCGGTTTGTCTGGAGCAGC 79
Db 434 AGAAATGGCCACAGCCCATCCCATCCACAGGGGTGAGGTGGCAGGTGGTGGAAAGG 375
QY 80 CGTAAAGATATCCCGCCCGCCAGGTAAAGAGAAACCCAAAGTAAAGTGTAGTGTGTG 139
Db 374 CTTGAGGGGGGCTTCTTCCTCCAGCGGAGCAGACCTCAGCGAGCACCGGGGATGAG 315
QY 140 AGAGGGCATCAGAGGGCGACATCTGAAACCATACACGCA 180
Db 314 CAGAGCGCGGGGTGGCGGAGGTATCATCCCGCAGCACGTA 274

RESULT 35
US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
```

; NAME/KEY: misc feature
; LOCATION: (1)-(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match 0.5%; Score 16.6; DB 1; Length 483;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 44 AGGTAGGAGGAGTGGCTTGGTGGAGGACCGT 82
DB 421 AGATATAGGAGTGGCTTGGTGGAGGACCGT 383

RESULT 36

US-10-272-665-107
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; PRIOR FILING DATE: 2002-10-15
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

Query Match 0.4%; Score 14.8; DB 1; Length 100;
Best Local Similarity 59.5%; Pred. No. 49;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGATGTGTCCACTGGAGAGGGAATGCAACCACTTCAG 333
DB 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCACTACCG 53

RESULT 37

US-10-273-321-107
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-107

Query Match 0.4%; Score 14.8; DB 1; Length 100;
Best Local Similarity 59.5%; Pred. No. 49;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGATGTGTCCACTGGAGAGGGAATGCAACCACTTCAG 333
DB 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCACTACCG 53

RESULT 38

US-10-272-756-107
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match 0.4%; Score 14.8; DB 1; Length 100;
Best Local Similarity 59.5%; Pred. No. 49;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGATGTGTCCACTGGAGAGGGAATGCAACCACTTCAG 333
DB 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCACTACCG 53

RESULT 39

US-10-273-228-107
; Sequence 107, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251

```
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match
Best Local Similarity 0.4%; Score 14.8; DB 1; Length 100;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGATGTGTCCTCAGTGGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTACG 53

RESULT 40
US-10-272-665-106
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 100;
Matches 24; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 292 CAGATGTGTCCTCAGTGGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTAC 51

RESULT 41
US-10-273-321-106
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
```

```
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 100;
Matches 24; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 292 CAGATGTGTCCTCAGTGGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTAC 51

RESULT 42
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 100;
Matches 24; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 292 CAGATGTGTCCTCAGTGGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTAC 51

RESULT 43
US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
```



```
Query Match          0.4%; Score 14.2; DB 1; Length 38;
Best Local Similarity 84.2%; Pred. No. 33;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 63 CGCTTTGCTGGACGACCG 81
Db 15 CGCTTTCTGGAGGAGCTG 33

RESULT 47
US-10-272-665-22
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-665-22

Query Match          0.4%; Score 13.2; DB 1; Length 60;
Best Local Similarity 83.3%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675
Db 14 GGATGGCAGCAAGGACTC 31

RESULT 48
US-10-273-321-22
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
```

```
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-321-22

Query Match          0.4%; Score 13.2; DB 1; Length 60;
Best Local Similarity 83.3%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675
Db 14 GGATGGCAGCAAGGACTC 31

RESULT 49
US-10-272-756-22
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

Query Match          0.4%; Score 13.2; DB 1; Length 60;
Best Local Similarity 83.3%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675
Db 14 GGATGGCAGCAAGGACTC 31

RESULT 50
US-10-273-228-22
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
```

; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

Query Match 0.4%; Score 13.2; DB 1; Length 60;
Best Local Similarity 83.3%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675
|||||
Db 14 GGATGGCAGCAAGACTC 31

RESULT 51

US-10-272-665-106/c
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;
Best Local Similarity 69.2%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2597 CCTGTGCTGGAGGATGGGGC 2622
|||||
Db 56 CCTGTGTAGTGGTGGCATGTGGCC 31

RESULT 52

US-10-273-321-106/c
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;
Best Local Similarity 69.2%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2597 CCTGTGCTGGAGGATGGGGC 2622
|||||
Db 56 CCTGTGTAGTGGTGGCATGTGGCC 31

RESULT 53

US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;
Best Local Similarity 69.2%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2597 CCTGTGCTGGAGGATGGGGC 2622
|||||
Db 56 CCTGTGTAGTGGTGGCATGTGGCC 31

RESULT 54

US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033D

; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;
Best Local Similarity 59.2%; Pred. No. 2.2e+02;
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2597 CCTGTATCTGGAGGATGGGGC 2622
Db 56 CCTGTATCTGGAGGATGGGGC 31

RESULT 55
US-10-272-665-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO

; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-665-22

Query Match 0.4%; Score 13; DB 1; Length 60;
Best Local Similarity 59.5%; Pred. No. 2.2e+02;
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 1954 CTGGAAGACCAAGCTGGAATCAAGATTGCCGGA 1990
Db 38 CTGCAAGAGTCTTCTGCTCCATCCGAGTAGCGGCA 2

RESULT 56
US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1

; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-321-22

Query Match 0.4%; Score 13; DB 1; Length 60;
Best Local Similarity 59.5%; Pred. No. 2.2e+02;
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 1954 CTGGAAGACCAAGCTGGAATCAAGATTGCCGGA 1990
Db 38 CTGCAAGAGTCTTCTGCTCCATCCGAGTAGCGGCA 2

RESULT 57
US-10-272-756-22/c
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO

; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

Query Match 0.4%; Score 13; DB 1; Length 60;
Best Local Similarity 59.5%; Pred. No. 2.2e+02;
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 1954 CTGGAAGACCAAGCTGGAATCAAGATTGCCGGA 1990


```
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match      0.4%; Score 12.8; DB 1; Length 100;
Best Local Similarity 48.6%; Pred. No. 3.5e+02;
Matches 35; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2680 GACGTGAGTCTGGTGAACCTCTGGAGTTGGTGGACAGGAGGCGCTCTCGGGG 2739
      |||||
Db 78 GATGCCGTCAGTACCACGTGCCCCGGTAGTGGTGGCATGTGGCGCTCCACTGTCCCC 19

QY 2740 ATTCATGGGTC 2751
      |||||
Db 18 CTTGCAGGAGTC 7

RESULT 62
US-10-273-228-107/c
; Sequence 107, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.4%; Score 12.8; DB 1; Length 100;
Best Local Similarity 48.6%; Pred. No. 3.5e+02;
Matches 35; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2680 GACGTGAGTCTGGTGAACCTCTGGAGTTGGTGGACAGGAGGCGCTCTCGGGG 2739
      |||||
Db 78 GATGCCGTCAGTACCACGTGCCCCGGTAGTGGTGGCATGTGGCGCTCCACTGTCCCC 19

QY 2740 ATTCATGGGTC 2751
      |||||
Db 18 CTTGCAGGAGTC 7

RESULT 63
US-10-017-122-4/c
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
```

```
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match      0.4%; Score 12.6; DB 1; Length 31;
Best Local Similarity 66.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 737 GAGTAGCCATCATGGTCAACAAAGAG 763
      |||||
Db 27 GAGTACCCCTCATGGCACCAGCAGGAG 1

RESULT 64
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match      0.4%; Score 12.6; DB 1; Length 38;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2331 GCCCATCTAGTCAAGGCTATGTTT 2357
      |||||
Db 37 GCCGAGCTCTCCAGGAAGCGTTT 11

RESULT 65
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
```

```
/ APPLICANT: Pingel, Hans K
/ APPLICANT: Klausen, Niels K
/ TITLE OF INVENTION: Factor VII Glycoforms
/ FILE REFERENCE: 6207.510-US
/ CURRENT APPLICATION NUMBER: US/09/969,357
/ CURRENT FILING DATE: 2002-10-02
/ PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
/ PRIOR FILING DATE: 2000-10-02
/ PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
/ PRIOR FILING DATE: 2001-02-16
/ PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
/ PRIOR FILING DATE: 2001-03-14
/ PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
/ PRIOR FILING DATE: 2001-05-14
/ PRIOR APPLICATION NUMBER: US 60/238,944
/ PRIOR FILING DATE: 2000-10-10
/ PRIOR APPLICATION NUMBER: US 60/271,581
/ PRIOR FILING DATE: 2001-02-26
/ PRIOR APPLICATION NUMBER: US 60/276,322
/ PRIOR FILING DATE: 2001-03-16
/ NUMBER OF SEQ ID NOS: 2
/ SOFTWARE: Patent in version 3.2
/ SEQ ID NO 2
/ LENGTH: 38
/ TYPE: DNA
/ ORGANISM: Artificial
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match 0.4%; Score 12.6; DB 1; Length 38;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2331 GCCCATCTAGTCAAGGCTATGGTTT 2357
DB 37 GCGCAGCTCTCTCCAGGAAGCGTTT 11

RESULT 66
US-10-254-394-2/c
/ Sequence 2, Application US/10254394
/ Publication No. US20030096366A1
/ GENERAL INFORMATION:
/ APPLICANT: Krause, Ida Molgaard
/ TITLE OF INVENTION: Method for Production of Recombinant
/ TITLE OF INVENTION: Proteins in Eukaryote Cells
/ FILE REFERENCE: 6480.500-US
/ CURRENT APPLICATION NUMBER: US/10/254,394
/ CURRENT FILING DATE: 2002-09-25
/ PRIOR APPLICATION NUMBER: PCT/DK01/00632
/ PRIOR FILING DATE: 2001-10-02
/ PRIOR APPLICATION NUMBER: PCT/DK01/00634
/ PRIOR FILING DATE: 2001-10-02
/ PRIOR APPLICATION NUMBER: PA 2002 00460
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: 60/374,855
/ PRIOR FILING DATE: 2002-10-04
/ NUMBER OF SEQ ID NOS: 2
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 2
/ LENGTH: 38
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-10-254-394-2

Query Match 0.4%; Score 12.6; DB 1; Length 38;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2331 GCCCATCTAGTCAAGGCTATGGTTT 2357
```

```
DB 37 GCGCAGCTCTCTCCAGGAAGCGTTT 11

RESULT 67
US-09-803-810-8
/ Sequence 8, Application US/09803810
/ Publication No. US20010018414A1
/ GENERAL INFORMATION:
/ APPLICANT: Nelsestuen, Gary L.
/ TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
/ TITLE OF INVENTION: POLYPEPTIDES
/ FILE REFERENCE: 09531/002001
/ CURRENT APPLICATION NUMBER: US/09/803,810
/ CURRENT FILING DATE: 2001-03-12
/ NUMBER OF SEQ ID NOS: 18
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 8
/ LENGTH: 42
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match 0.3%; Score 12.4; DB 1; Length 42;
Best Local Similarity 63.3%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2597 CCTGATCTGCGAGGATTCGGGCGAGGA 2626
DB 12 CCAGGCTCTGCGAGGAGTCCTCCAGGA 41

RESULT 68
US-10-298-330-8
/ Sequence 8, Application US/10298330
/ Publication No. US20030100506A1
/ GENERAL INFORMATION:
/ APPLICANT: Nelsestuen, Gary L.
/ TITLE OF INVENTION: Modified Vitamin K-Dependent
/ TITLE OF INVENTION: Polypeptides
/ FILE REFERENCE: 09531-127001
/ CURRENT APPLICATION NUMBER: US/10/298,330
/ CURRENT FILING DATE: 2002-11-18
/ PRIOR APPLICATION NUMBER: 09/497,591
/ PRIOR FILING DATE: 2000-02-03
/ PRIOR APPLICATION NUMBER: 09/302,239
/ PRIOR FILING DATE: 1999-04-29
/ PRIOR APPLICATION NUMBER: 08/955,636
/ PRIOR FILING DATE: 1997-10-23
/ NUMBER OF SEQ ID NOS: 27
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 8
/ LENGTH: 42
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-10-298-330-8

Query Match 0.3%; Score 12.4; DB 1; Length 42;
Best Local Similarity 63.3%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2597 CCTGATCTGCGAGGATTCGGGCGAGGA 2626
DB 12 CCAGGCTCTGCGAGGAGTCCTCCAGGA 41

RESULT 69
US-10-272-665-23/c
/ Sequence 23, Application US/10272665
```

```

RESULT 71
US-10-272-756-23/c
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23

Query Match          0.3%; Score 12.4; DB 1; Length 60;
Best Local Similarity 57.9%; Pred.No.3.9e+02;
Matches 22; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2675 CGATGGACGTGAGTCTGGGTGAACCTCTCGAGTTGGTG 2712
Db 39 CGATGCCCGTCAGGTACCACTGCGCCCGGTAGTGGTG 2
|||||
|||||

RESULT 72
US-10-272-228-23/c
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23

Query Match          0.3%; Score 12.4; DB 1; Length 60;
Best Local Similarity 57.9%; Pred.No.3.9e+02;
Matches 22; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2675 CGATGGACGTGAGTCTGGGTGAACCTCTCGAGTTGGTG 2712

```


Db 39 CGATGCCGTCAGGTACACAGTCCCGGTCAGTGGTG 2

RESULT 73
US-10-029-386-23323/c
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: A60MICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match 0.3%; Score 12.2; DB 1; Length 222;
Best Local Similarity 50.9%; Pred. No. 2.3e+02;
Matches 29; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 2649 GAGATGGCTGGATGCATCAGTCGATGAGTCTGGTGAATCTCTGGA 2705
DB 129 GAGGACGTGGCTTCGTCGGCTTCATTTGTCAGCGGCTGGCCAGCTGCTGGA 73

RESULT 74
US-09-951-121A-8/c
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match 0.3%; Score 11.8; DB 1; Length 36;
Best Local Similarity 86.7%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013
DB 23 ACCTGGAGCACCAGG 9

RESULT 75
US-09-951-121A-9
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match 0.3%; Score 11.8; DB 1; Length 36;
Best Local Similarity 86.7%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013
DB 23 ACCTGGAGCACCAGG 9

RESULT 76
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A1c No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match 0.3%; Score 11.8; DB 1; Length 36;
Best Local Similarity 86.7%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013
DB 23 ACCTGGAGCACCAGG 9

RESULT 77
US-10-255-032-9
; Sequence 9, Application US/10255032

; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: NO. US20030100075A1c NO. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match 0.3%; Score 11.8; DB 1; Length 36;
Best Local Similarity 86.7%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013
Db 14 ACCTGGAGCACCAGG 28

RESULT 78

US-10-295-682-8/c
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224,200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match 0.3%; Score 11.8; DB 1; Length 36;
Best Local Similarity 86.7%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013
Db 23 ACCTGGAGCACCAGG 9

RESULT 79

US-10-295-682-9
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224,200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15

; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match 0.3%; Score 11.8; DB 1; Length 36;
Best Local Similarity 86.7%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013
Db 14 ACCTGGAGCACCAGG 28

RESULT 80

US-09-803-810-8/c
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match 0.3%; Score 11.8; DB 1; Length 42;
Best Local Similarity 69.6%; Pred. No. 5.4e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1192 TGGAGAGCTCTATACAGTCAGC 1214
Db 38 TGGAGAGCTCCGTCCACGAGC 16

RESULT 81

US-10-298-330-8/c
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8

```
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-951-121A-15
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 25 GGATGGCGGCAAGGACTC 8

RESULT 84
US-10-295-682-14
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 9 GGATGGCGGCAAGGACTC 26

RESULT 85
US-10-295-682-15/c
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 9 GGATGGCGGCAAGGACTC 26

RESULT 83
US-09-951-121A-15/c
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 9 GGATGGCGGCAAGGACTC 26

RESULT 82
US-09-951-121A-14
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14
Query Match 0.3%; Score 11.8; DB 1; Length 42;
Best Local Similarity 69.6%; Pred. No. 5.4e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1192 TGGAGAGCTCTATACAGTCAGC 1214
Db 38 TGGAGGAGCTCCGTCCCGCAGCAGC 16
```

QY 2658 GGATGGCCTCACTGACTC 2675
Db 25 GGATGGCGGCAAGGACTC 8

RESULT 86

US-09-951-121A-14/c
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGGCAAGAGTGAATGCAACATCTTAGGA 645
Db 32 TTGCAGAGTCTTGGCGCCATCCGAGTA 4

RESULT 87

US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGGCAAGAGTGAATGCAACATCTTAGGA 645
Db 2 TTGCAGAGTCTTGGCGCCATCCGAGTA 30

RESULT 89

US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGGCAAGAGTGAATGCAACATCTTAGGA 645
Db 32 TTGCAGAGTCTTGGCGCCATCCGAGTA 4

RESULT 89

US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGGCAAGAGTGAATGCAACATCTTAGGA 645
Db 2 TTGCAGAGTCTTGGCGCCATCCGAGTA 30

RESULT 90

US-10-349-858-8/c
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1

```
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; TITLE OF INVENTION: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; TYPE: DNA
; LENGTH: 54
; ORGANISM: Homo sapiens
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-349-858-8

Query Match      0.3%; Score 11.4; DB 1; Length 54;
Best Local Similarity 56.7%; Pred. No. 7.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1588 AGAAGTTCAGTGTTCAGCTGGTTTGTAGAAAAGTC 1624
Db 38 AGGACCGCGTGGCTTCCTCTGGGTACGAAGACTC 2

RESULT 91
US-10-281-727-6
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410-200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-281-727-6

Query Match      0.3%; Score 11.2; DB 1; Length 32;
Best Local Similarity 66.7%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2598 CTTGATGCTGGGAGGATTTGGGG 2621
Db 2 CTTGCAGCAGGACGGAAGGTGG 25

RESULT 92
US-10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286-200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match      0.3%; Score 11; DB 1; Length 35;
Best Local Similarity 63.0%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 2625 GAGGAGAGGGGACACAGAGGATGAG 2651
Db 28 GAGGACACGGGACACAGTCAGGCGGAG 2

RESULT 94
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286-200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
```

```
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410-200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match      0.3%; Score 11.2; DB 1; Length 32;
Best Local Similarity 66.7%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2598 CTTGATGCTGGGAGGATTTGGGG 2621
Db 31 CTTGCAGCAGGACGGAAGGTGG 8

RESULT 93
US-10-109-498-5/c
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286-200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match      0.3%; Score 11; DB 1; Length 35;
Best Local Similarity 63.0%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 2625 GAGGAGAGGGGACACAGAGGATGAG 2651
Db 28 GAGGACACGGGACACAGTCAGGCGGAG 2

RESULT 94
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286-200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
```



```
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23

Query Match          0.3%; Score 11; DB 1; Length 60;
Best Local Similarity 53.5%; Pred. No. 8.1e+02; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 116 CCAAGTAAGATGAGGTGTTGTGAGAGGGCATCAGAGGGCAG 158
Db 11 CCGGGCAGGTGTTACCTGACGGGCATCGTCAGCTGGGGCCAG 53

RESULT 99
US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1998-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.3%; Score 10.6; DB 1; Length 54;
Best Local Similarity 64.0%; Pred. No. 9.2e+02; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 1172 ATATCTTTGCGACCAAGATGAG 1196
Db 1 AGAGTCTTCGTAAACCGAGGGAAG 25

RESULT 100
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
US-09-951-121A-8

Query Match          0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 2341 GTCAAGGCTATGGTTTTCAGTGGTCA 2368
Db 36 GCCACGCCCTGGTGCTCCAGGTCCTCA 9

RESULT 102
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DX PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
```

```
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGTTTTCACAGTGGTCA 2368
DB 1 GCCACGGCCCTGGTCTCCAGGTCCTCA 28

RESULT 103
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGTTTTCACAGTGGTCA 2368
DB 36 GCCACGGCCCTGGTCTCCAGGTCCTCA 9

RESULT 104
US-10-295-682-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8
```

```
Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGTTTTCACAGTGGTCA 2368
DB 1 GCCACGGCCCTGGTCTCCAGGTCCTCA 28

RESULT 105
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGTTTTCACAGTGGTCA 2368
DB 36 GCCACGGCCCTGGTCTCCAGGTCCTCA 9

RESULT 106
US-10-281-727-2
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 55.6%; Pred. No. 1.3e+03;
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
```


QY 60 CTGCGCTTTGCTGGAGCAGCGCTAAAGAGATACCCC 95
DB 1 CTGCGCTGACAGGACGACGACGCTGGGAGACTCCCC 36

RESULT 107

US-10-281-727-2/c
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match 0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 55.6%; Pred. No. 1.3e+03;
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2576 GAGCTGACTCATCTGGAAGACCCCTGATCTGGGAG 2611
DB 36 GGGGAGCTCTCCACGTCGCGCTTCCTGCTGCAGGCAG 1

RESULT 108

US-10-281-727-3
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3

Query Match 0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 55.6%; Pred. No. 1.3e+03;
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2576 GAGCTGACTCATCTGGAAGACCCCTGATCTGGGAG 2611
DB 1 GGGGAGCTCTCCACGTCGCGCTTCCTGCTGCAGGCAG 36

RESULT 109

US-10-281-727-3/c
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3

Query Match 0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 55.6%; Pred. No. 1.3e+03;
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 60 CTGCGCTTTGCTGGAGCAGCGCTAAAGAGATACCCC 95
DB 36 CTGCGCTGACAGGACGACGCTGGGAGACTCCCC 1

RESULT 110

US-10-109-498-5
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match 0.3%; Score 10; DB 1; Length 35;
Best Local Similarity 61.5%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 2451 CTGAGAGTCCCTTGGACTGCAAGGA 2476
DB 8 CTGCACTGTCCCGTGTCTCTCACTGA 33

RESULT 111

US-10-109-498-6/c
; Sequence 6, Application US/10109498

; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-109-498-6

Query Match 0.3%; Score 10; DB 1; Length 35;
Best Local Similarity 61.5%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 2451 CTTGAGAGTCCCTTGACTGCAAGGA 2476
||| ||||| ||||| ||||| |||||
Db 28 CTGCACTGTCCCGTGTCTCTCACTGA 3

RESULT 112
US-09-951-121A-2
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.3%; Score 9.8; DB 1; Length 34;
Best Local Similarity 84.6%; Pred. No. 1.5e+03;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2200 TTTTGGGGGGCTC 2212
|||||
Db 6 TTGTGGGGGGCGC 18

RESULT 113
US-09-951-121A-3/c
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; FILE REFERENCE: 6224.200-US

; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.3%; Score 9.8; DB 1; Length 34;
Best Local Similarity 84.6%; Pred. No. 1.5e+03;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2200 TTTTGGGGGGCTC 2212
|||||
Db 29 TTGTGGGGGGCGC 17

RESULT 114
US-10-295-682-2
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.3%; Score 9.8; DB 1; Length 34;
Best Local Similarity 84.6%; Pred. No. 1.5e+03;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2200 TTTTGGGGGGCTC 2212
|||||
Db 6 TTGTGGGGGGCGC 18

RESULT 115
US-10-295-682-3/c
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; FILE REFERENCE: 6224.200-US

; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.3%; Score 9.8; DB 1; Length 34;
Best Local Similarity 84.6%; Pred. No. 1.5e+03;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2200 TTTGGGGGGCTC 2212
||| |||||
DB 29 TTGTGGGGGGCGC 17

RESULT 116
US-10-017-122-4
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: WMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match 0.3%; Score 9.2; DB 1; Length 31;
Best Local Similarity 78.6%; Pred. No. 1.6e+03;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 570 TGTGAGTCCATGA 593
||| |||||
DB 5 TGTGAGTCCATGA 18

RESULT 117
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII

US-10-281-727-6

Query Match 0.2%; Score 8.8; DB 1; Length 32;
Best Local Similarity 83.3%; Pred. No. 1.6e+03;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3217 CAGCTTCAGTTC 3228
||| |||||
DB 23 CACCTTCGGTTC 12

RESULT 118
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match 0.2%; Score 8.8; DB 1; Length 32;
Best Local Similarity 83.3%; Pred. No. 1.6e+03;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3217 CAGCTTCAGTTC 3228
||| |||||
DB 10 CACCTTCGGTTC 21

RESULT 119
US-09-951-121A-2/c
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.2%; Score 8.6; DB 1; Length 34;
Best Local Similarity 73.3%; Pred. No. 1.5e+03;

Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 246 CCGTGGGGCAACCC 260
Db 33 CCTTGGGGCACACC 19

RESULT 120

US-09-951-121A-3
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.2%; Score 8.6; DB 1; Length 34;
Best Local Similarity 73.3%; Pred. No. 1.5e+03;
Matches 11; Conservative 0; Mismatches 4; Indels 0;

QY 246 CCGTGGGGCAACCC 260
Db 2 CCTTGGGGCACACC 16

RESULT 121

US-10-295-682-2/C
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.2%; Score 8.6; DB 1; Length 34;
Best Local Similarity 73.3%; Pred. No. 1.5e+03;
Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 246 CCGTGGGGCAACCC 260
Db 33 CCTTGGGGCACACC 19

RESULT 122
US-10-295-682-3
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.2%; Score 8.6; DB 1; Length 34;
Best Local Similarity 73.3%; Pred. No. 1.5e+03;
Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 246 CCGTGGGGCAACCC 260
Db 2 CCTTGGGGCACACC 16

Search completed: August 9, 2004, 16:36:07
Job time : 50 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:36:28 ; Search time 5 Seconds
(without alignments)

3.936 Million cell updates/sec

Title: us-10-664-775-2
Perfect score: 3572
Sequence: 1 gtcaggaggcgccagtg.....gcaacacagcagaagctt 3572

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 4 segs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database: rstdb.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	23.2	0.6	1201	1	AL531727 ACCESSION:AL531727
2	21	0.6	609	1	AI099321 ACCESSION:AI099321
3	21	0.6	645	1	AI116939 ACCESSION:AI116939
C 4	18.4	0.5	609	1	AI099321 ACCESSION:AI099321
5	18.4	0.5	1201	1	AL531727 ACCESSION:AL531727
C 6	17.4	0.5	300	1	AU099140 ACCESSION:AU099140
C 7	17.2	0.5	645	1	AI116939 ACCESSION:AI116939
8	17	0.5	300	1	AU099140 ACCESSION:AU099140

ALIGNMENTS

RESULT 1
AL531727/c 1201 bp mRNA linear EST 23-MAY-2003
LOCUS
DEFINITION
AL531727 Homo sapiens FETAL LIVER EST 23-MAY-2003
CSODM003YI01 5-PRIME, mRNA sequence.
ACCESSION
AL531727 GI:31069559
VERSION
AL531727.2
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens

REFERENCE
1. (bases 1 to 1201)
Mammalia; Eutheria; Primates; Catarrhini; Homindae; Homo.
AUTHORS
L.W.B., Gruber,C., Jesse,J. and Polayes,D.
TITLE
Full-length cDNA libraries and normalization
JOURNAL
Unpublished (2001)
COMMENT
On Feb 13, 2001 this sequence version replaced gi:12795220.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France

Email: segref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 7252.f For more information about this cluster, see

http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODM003AE01QPI&cluster=7252.f. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CSODM003AE01QPI.

FEATURES

source

1..1201
/organism="Homo sapiens"
/mol_type="RNA"
/db_xref="taxon:9606"
/clone="CSODM003YI01"
/tissue_type="FETAL LIVER"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/note="Organ: liver; Vector: pCMVSPORT_6; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

Query Match 0.6%; Score 23.2; DB 1; Length 1201;
Best Local Similarity 40.0%; Pred. No. 0.17;
Matches 36; Conservative 17; Mismatches 37; Indels 0; Gaps 0;

QY 3192 CTTTAAATTCATTCTTTGATAACAGCTTCAGTCTCTATGCTTAAATAAGTTTTTTT 3251
DB 1201 CTTTAAATTCATTCTTTGATAACAGCTTCAGTCTCTATGCTTAAATAAGTTTTTTT 3251
QY 3252 TTTTCTTTTCTTTTAAAGATGCTTCTT 3281
DB 1141 CTTTCTTTTCTTTTAAAGATGCTTCTT 3281

RESULT 2

AI099321 609 bp mRNA linear EST 20-AUG-1998
LOCUS
DEFINITION
AI099321 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1482509 5', similar to gb:M13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN);, mRNA sequence.

ACCESSION
AI099321
VERSION
AI099321.1 GI:3448846
KEYWORDS
Mus musculus (house mouse)
SOURCE
Mus musculus
ORGANISM
Mus musculus
REFERENCE
1 (bases 1 to 609)
AUTHORS
Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
Eukaryota; Metazoa; Chordata; Rodentia; Sciurognathi; Muridae; Mus.
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wyllie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.

TITLE
The WashU-HMI Mouse EST Project
JOURNAL
Unpublished (1996)
COMMENT
Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project
Washington University School
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
MG1:930865
Seq primer: custom primer used
High quality sequence stop: 289.
Location/Qualifiers
1..609
/organism="Mus musculus"

FEATURES

source

```

/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTITTTTTTTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTCG and 3' end
primer CGACTCGAGCTCGAGCACA."

```

```

Query Match      0.6%; Score 21; DB 1; Length 609;
Best Local Similarity 48.7%; Pred. No. 1.1;
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1390 GACAGAGTACCTAATGACAGAGGTTTCATGACATGTGACAGGACAGAGGATC 1449
DB 73 GAGGAAGCACATGTTGTTCTTACACAGGCAAGGCGTGCCAACTCCTCTGGAGAGCTT 132
QY 1450 GAGACATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGGAGGCC 1506
DB 133 TGGCCGCGCTCTCTGGAGAGAGTGCAATGAGGAACAGTGCTCTTTGAGGAGGCC 189

```

```

RESULT 3
AII16939
LOCUS ue29g08.y1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:1481822 5', similar to gb:MI3232 COAGULATION FACTOR VII
PRECUSOR (HUMAN); mRNA sequence.
AII16939
VERSION AII16939.1 GI:3517262
KEYWORDS Mus musculus (house mouse)
SOURCE EST.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.

```

```

TITLE The WashU-HMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930178
Seq primer: custom primer used
High quality sequence stop: 483.
Location/Qualifiers
1..645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"

```

```

FEATURES
source
1..645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"

```

```

/db_xref="taxon:10090"
/clone="IMAGE:1481822"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTITTTTTTTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTCG and 3' end
primer CGACTCGAGCTCGAGCACA."

```

```

Query Match      0.6%; Score 21; DB 1; Length 645;
Best Local Similarity 48.7%; Pred. No. 1.1;
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1390 GACAGAGTACCTAATGACAGAGGTTTCATGACATGTGACAGGACAGAGGATC 1449
DB 108 GAGGAAGCACATGTTGTTCTTACACAGGCAAGGCGTGCCAACTCCTCTGGAGAGCTT 167
QY 1450 GAGACATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGGAGGCC 1506
DB 168 TGGCCGCGCTCTCTGGAGAGAGTGCAATGAGGAACAGTGCTCTTTGAGGAGGCC 224

```

```

RESULT 4
AII099321/c
LOCUS ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:1482509 5', similar to gb:MI3232 COAGULATION FACTOR VII
PRECUSOR (HUMAN); mRNA sequence.
AII099321
VERSION AII099321.1 GI:3448846
KEYWORDS Mus musculus (house mouse)
SOURCE EST.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.

```

```

TITLE The WashU-HMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.
Location/Qualifiers
1..609
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/clone="IMAGE:1482509"

```

```

FEATURES
source
1..609
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/clone="IMAGE:1482509"

```

```

/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
(note="Organ: liver; Vector: pME18S-FL3; Site 1: DralII
(CACTGTGTG); Site 2: DralII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCCTTTTATTTTATTTT]; double-stranded cDNA was
ligated to a DralII adaptor [GTGTGGCCTACTGG], digested
and cloned into distinct DralII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTTCTGCTCTAAAGCTGCG and 3' end
primer CGACCTCAGCTCGAGCA."
Query Match 0.5%; Score 18.4; DB 1; Length 609;
Best Local Similarity 49.0%; Pred. No. 4;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 799 GACGAGATGATCTCTGTTGTTTCCAGGCAACATTCATATCAGTAATCAAGTC 858
DB 405 GTCACAGTCACCAATTTTCATTGCACAGATCACTGTTTCATCTTCTTCACAGTT 346

QY 859 TATGCCCAACAGTAATGCTGAAGAGCTGAAGTTGAAC 898
DB 345 CCGACCTCAAGTCTAGGAGCGAGACGACGTAAGAC 306

RESULT 5
AL531727 1201 bp mRNA linear EST 23-MAY-2003
LOCUS AL531727 Homo sapiens FETAL LIVER Homo sapiens cDNA clone
DEFINITION CS0DM003YI01 5-PRIME, mRNA sequence.
ACCESSION AL531727.2 GI:31069559
VERSION AL531727.2
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1. (bases 1 to 1201)
Li, W.B., Gruber, C., Jesses, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished (2001)
On Feb 13, 2001 this sequence version replaced gi:12795220.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 7252.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DM003AE01QPI&cluster=7252.f. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DM003AE01QPI.
FEATURES
Location/Qualifiers
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DM003YI01"
/tissue_type="FETAL LIVER"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/notes="Organ: liver; Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6

```

vector. Library was not normalized."

```

Query Match 0.5%; Score 18.4; DB 1; Length 1201;
Best Local Similarity 56.7%; Pred. No. 2;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCGTGTCTGGGAGG 1504
DB 610 GGAATAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCAGGCGCAATTGTGGG 669

RESULT 6
AU099140 300 bp mRNA linear EST 05-APR-2001
LOCUS AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HVII2463, mRNA sequence.
ACCESSION AU099140
VERSION AU099140.1 GI:13550269
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1. (bases 1 to 300)
Suzuki, Y., Tsunoda, T., Taira, H., Mizushima-Sugano, J., Sese, J.,
Hata, H., Oca, T., Isogai, T., Tanaka, T., Nakamura, Y., Morishita, S.,
Okubo, K., Suyama, A. and Sugano, S.
In silico mapping of the 5'-ends of human mRNAs using full-length
enriched and 5'-end enriched cDNA libraries constructed by
Oligo-capping method
Unpublished (2001)
Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ims.u-tokyo.ac.jp
Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and
Sugano, S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
FEATURES
Location/Qualifiers
1..300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone_lib="Sugano Homo sapiens cDNA library"

Query Match 0.5%; Score 17.4; DB 1; Length 300;
Best Local Similarity 53.7%; Pred. No. 12;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTATGCTGAGAGAGCTGAAGTTGAAGCGTCTATGAAGACCTTACAGACCTTTTAGAA 930
DB 277 AGAATATCCAGACAGCTTGTCTCTCCGCGTCTTGAAGATCTCCGCGGCTCTCGAA 218

QY 931 CTAACAC 937
DB 217 GCAGCAC 211

RESULT 7
AU116939 645 bp mRNA linear EST 02-SEP-1998
LOCUS AU116939 ue29g08.V1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:1481822.5, similar to gb:M13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN);, mRNA sequence.
ACCESSION AU116939
VERSION AU116939.1 GI:3517263
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

```

10664775-2.rst

Mon Aug 9 17:46:54 2004

TITLE In silico mapping of the 5'-ends of human mRNAs using full-length enriched and 5'-end enriched cDNA libraries constructed by oligo-capping method

JOURNAL Unpublished (2001)

COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ims.u-tokyo.ac.jp
Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and Sugano, S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).

FEATURES Location/Qualifiers

source

1..300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone_lib="Sugano Homo sapiens cDNA library"

Query Match 0.5%; Score 17; DB 1; Length 300;
Best Local Similarity 59.2%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1458 CCCATGGAAAAAATGCAAAAAAGCAAAATGGCTGTCTGGGAGGCC 1506
DB 181 CTCCTGGAGAGGAGTGCAGAGGAGCAGTGCTCTTCGAGGAGGCC 229

Search completed: August 9, 2004, 16:36:34
Job time: 6 secs

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 645)

AUTHORS Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.

TITLE The WashU-HMI Mouse EST Project

JOURNAL Unpublished (1996)

COMMENT Contact: Marra M/Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
MG1:930178

Seq primer: custom primer used
High quality sequence stop: 483.

FEATURES Location/Qualifiers

source

1..645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1481822"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII (CACTGTGTG); Site 2: DraIII (CACTGTGTG); 1st strand cDNA was primed with an oligo(dT) primer (ATGTGGCTTTTCTTTTCTTTT) ligated to a DraIII adaptor (NGTGGCTACTGG), digested and cloned into distinct DraIII sites of the pME18S-FL3 vector (5' site CACTGTGTG, 3' site CACTGTGTG). XhoI should be used to isolate the cDNA insert. Size selection was performed to exclude fragments <1.5kb. Library constructed by Dr. Sumio Sugano (University of Tokyo Institute of Medical Science). Custom primers for sequencing: 5' end primer CTTCGTCTTAAAGCTCG and 3' end primer CGACTGCAGCTCGACACA."

Query Match 0.5%; Score 17.2; DB 1; Length 645;
Best Local Similarity 60.9%; Pred. No. 5.9;
Matches 28; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 1233 TTACTGTGCTCAGATCATGAACTCTTATTCGCCAAATTCAGACTT 1278
DB 426 TTTCATTGCACAGATCAGCTCTCATCTTCTGCTTTCTCAGATT 381

RESULT 8

LOCUS AU099140 300 bp mRNA linear EST 05-APR-2001

DEFINITION AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone HEP20983 similar to Human factor VII serine protease precursor mRNA clone lambda-HV112463, mRNA sequence.

ACCESSION AU099140

VERSION AU099140.1 GI:13550269

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 300)

REFERENCE Suzuki, Y., Tsunoda, T., Taira, H., Mizushima-Sugano, J., Sese, J., Hata, H., Ota, T., Isogai, T., Tanaka, T., Nakamura, Y., Morishita, S., Okubo, K., Suyama, A. and Sugano, S.

RESULT 2
US-08-021-615A-3/c
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/892,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-021-615A-3

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATGCTTTTATCTGCGAGACTTGTCTTTTGAATATGTTTCAATTTGG 934
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGTATTTTCCATGATATCACTGTGG 601

RESULT 3
US-08-321-777-3/c
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.

; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/892202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-321-777-3

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATGCTTTTATCTGCGAGACTTGTCTTTTGAATATGTTTCAATTTGG 934
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGTATTTTCCATGATATCACTGTGG 601

RESULT 4
US-09-009-217-13/c
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boming
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433

COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,217
FILING DATE: Concurrently Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/042,427
FILING DATE: 27-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/036,205
FILING DATE: 27-JAN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/035,920
FILING DATE: 22-JAN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Hibler, David W.
REGISTRATION NUMBER: 41,071
REFERENCE/DOCKET NUMBER: UTSD:536
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-009-217-13

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 876 TTCAATTGCTTTTATCTGCGACCTGCTTTGTTTGAATATGATTCATTTGG 934
DB 659 TTGCTGCGCATTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACGTGG 601

RESULT 5
US-09-009-656-13/c
Sequence 13, Application US/09009656
Patent No. 6132730
GENERAL INFORMATION:
APPLICANT: Thorpe, Philip E.
APPLICANT: King, Steven W.
APPLICANT: Gao, Boming
TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
TITLE OF INVENTION: TREATMENT
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P. O. Box 4433
CITY: Houston
STATE: Texas
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,656
FILING DATE: Concurrently Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/042,427
FILING DATE: 27-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/036,205
FILING DATE: 27-JAN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/035,920
FILING DATE: 22-JAN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Hibler, David W.
REGISTRATION NUMBER: 41,071
REFERENCE/DOCKET NUMBER: UTSD:537
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-009-656-13

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 876 TTCAATTGCTTTTATCTGCGACCTGCTTTGTTTGAATATGATTCATTTGG 934
DB 659 TTGCTGCGCATTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACGTGG 601

RESULT 6
PCT-US93-04493-3/c
Sequence 3, Application PC/TUS9304493
GENERAL INFORMATION:
APPLICANT: Morrissey, James H.
APPLICANT: Comp, Philip C.
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
TITLE OF INVENTION: FVII Activator for Blood Coagulation
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Richards, Medlock & Andrews
STREET: 1201 Elm Street, Suite 4500
CITY: Dallas
STATE: Texas
COUNTRY: US
ZIP: 75270-2197
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/04493
FILING DATE: 19930512
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/882202
FILING DATE: 13-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/021615
FILING DATE: 19-FEB-1993
ATTORNEY/AGENT INFORMATION:
NAME: Trujillo, Doreen Y.
REGISTRATION NUMBER: 35,719
REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 214-939-4500
TELEFAX: 214-939-4600
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs

```
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ ORIGINAL SOURCE:
/ ORGANISM: Homo sapiens
/ TISSUE TYPE: Blood
/ FEATURE:
/ NAME/KEY: CDS
/ LOCATION: 36..1433
/ OTHER INFORMATION: /product= "Tissue Factor"
/ OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
/ OTHER INFORMATION: /citation= ([1])
PCT-US93-04493-3

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3; Mismatches 0; Gaps 0;
Matches 35; Conservative 0; Indels 24;

Qy 876 TTCAATTGCTTTTATCTGTCGAGACTTGCTTGTGTTTGAATAATGTAATCAATTTGG 934
Db 659 TTTCCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCACTGG 601

RESULT 7
US-07-882-202A-3
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: /factor VII cDNA"

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3; Mismatches 0; Gaps 0;
Matches 35; Conservative 0; Indels 24;

Qy 876 TTCAATTGCTTTTATCTGTCGAGACTTGCTTGTGTTTGAATAATGTAATCAATTTGG 934
Db 659 TTTCCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCACTGG 601

RESULT 8
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"

US-08-021-615A-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
```

```
/ LOCATION: 36..1433
/ OTHER INFORMATION: /note= "Coding portion of human
/ OTHER INFORMATION: factor VII cDNA"
US-07-882-202A-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 374 ACAGCATGGCCATGGCTCCAGAGATTGCTCTTCCAGGTCCAGGC 419
Db 4 ACAGCAGGGCAGCAGCATGCGAGATTTCATCATGGTCTCCAGGC 49

RESULT 8
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"

US-08-021-615A-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
```

```
QY 374 ACAGGATGGCCATGGCTCCAGAGATTGCTCTCCAGGTGCAGGC 419
Db 4 ACAGGAGGGGCGAGCACTGCAGAGATTTTCATGTTCTCCAGGC 49

RESULT 9
US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FvIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-321-777-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGCATGGCCATGGCTCCAGAGATTGCTCTCCAGGTGCAGGC 419
Db 4 ACAGGAGGGGCGAGCACTGCAGAGATTTTCATGTTCTCCAGGC 49

RESULT 10
US-09-009-217-13
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGCATGGCCATGGCTCCAGAGATTGCTCTCCAGGTGCAGGC 419
Db 4 ACAGGAGGGGCGAGCACTGCAGAGATTTTCATGTTCTCCAGGC 49

RESULT 11
US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
```

```

; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-656-13
; Query Match 0.8%; Score 20.4; DB 1; Length 1440;
; Best Local Similarity 65.2%; Pred. No. 4.3;
; Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCCATGGCTCCAGAGATTGCCTCTTCCAGGTGCAGGC 419
Db 4 ACAGGCAGGGCGACACTGCAGAGATTTCATCATGCTGCCAGGC 49

RESULT 12
PCT-US93-04493-3
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; US-09-558-027-4
; Query Match 0.8%; Score 20.4; DB 1; Length 1440;
; Best Local Similarity 65.2%; Pred. No. 4.3;
; Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCCATGGCTCCAGAGATTGCCTCTTCCAGGTGCAGGC 419
Db 4 ACAGGCAGGGCGACACTGCAGAGATTTCATCATGCTGCCAGGC 49

RESULT 13
US-09-558-027-4
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; PRIOR FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
; US-09-558-027-4
; Query Match 0.5%; Score 14.2; DB 1; Length 38;
; Best Local Similarity 70.4%; Pred. No. 1.1;
; Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 434 GGTGATCACTCTCTAGTGAAGGTGG 460
Db 3 GGAATTCATGCTAGTGAAGGTGG 29

RESULT 14
US-08-849-248-6
```

```

; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husby, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6

```

```

Query Match 0.5%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```

```

QY 82 GCACGGGATGTCAGATGTCAG 105
DB 6 GCACAGGATGACGAGCTGATCG 29

```

```

RESULT 15
US-08-849-248-6/c
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husby, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6

```

```

Query Match 0.5%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```

```

QY 583 TCTGCTGGCAATCTTCTGGGGCT 606
DB 25 TCAGCTGGTCATCTTGTGGCTCT 2

```

```

RESULT 16
US-09-558-027-4/c
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Wolgike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565,204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

```

```

Query Match 0.4%; Score 12; DB 1; Length 38;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```

```

QY 1329 AGGGCCATTTCCTTAGAATA 1348
DB 31 AGCCCCATTTCCTTAGACTA 12

```

```

RESULT 17
US-08-293-778-22
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435

```

PRIOR APPLICATION DATA: US/08/104,509
FILING DATE: 25-JUN-1987
APPLICATION NUMBER: DX 3235/87
FILING DATE: 25-JUN-1987
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988
APPLICATION NUMBER: US 07/898,248
FILING DATE: 12-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Agis, Cheryl H.
REGISTRATION NUMBER: 34,086
REFERENCE/DOCKET NUMBER: 3129.224-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-867-0298
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 26 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-293-778-22

Query Match 0.4%; Score 11.8; DB 1; Length 26;
Best Local Similarity 86.7%; Pred. No. 15;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 294 GAGCAGGCGAGGAAG 308
|||||
Db 2 GAGCAGTCACGGAAG 16

RESULT 18
US-08-756-506-13/c
Sequence 13, Application US/08756506
Patent No. 5905185
GENERAL INFORMATION:
APPLICANT: Garter, Ian R.
APPLICANT: Cottingham, Ian R.
APPLICANT: Temperley, Simon M.
APPLICANT: Foster, Donald C.
APPLICANT: Sprecher, Cindy A.
APPLICANT: Prunkard, Donna E.
TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
TITLE OF INVENTION: ANIMALS
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/756,506
FILING DATE:
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Sawislak, Deborah A
REGISTRATION NUMBER: 37,438
REFERENCE/DOCKET NUMBER: 95-28

TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6672
TELEFAX: 206-442-6678
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 45 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC6337
US-08-756-506-13

Query Match 0.4%; Score 11.8; DB 1; Length 45;
Best Local Similarity 56.4%; Pred. No. 76;
Matches 22; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 408 CCAGGTGCGAGGCGCATGCTCTGTGTACTCTCT 446
|||||
Db 40 CCAGGTGCTGCAACGCGCAAGCGCGCAACTCTCTCT 2

RESULT 19
US-08-293-778-17/c
Sequence 17, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaisen, Else M.
APPLICANT: Bjorn, Soren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87
FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,248
FILING DATE: 12-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Agis, Cheryl H.
REGISTRATION NUMBER: 34,086
REFERENCE/DOCKET NUMBER: 3129.224-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-867-0298
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-293-778-17

Query Match 0.4%; Score 11.2; DB 1; Length 27;
Best Local Similarity 81.2%; Pred. No. 42;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2224 GCTTCTGGATGTTT 2239
||| ||||| |||||
DB 23 GCGTCTGGAGATT 8

RESULT 20
US-08-955-636-8
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8

Query Match 0.4%; Score 11.2; DB 1; Length 42;
Best Local Similarity 59.4%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 283 CACTCTCCAGGACGAGGAGGAGAGGCTC 314
||||| ||| ||||| |||||
DB 2 CACTCCCGCTCCAGGCTGCTGGAGGAGCTC 33

RESULT 21
US-08-293-778-16
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolson, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA: US 07/434,149
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA: PCT/DK88/00103
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA: US 07/898,248
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129,224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-293-778-16

Query Match 0.4%; Score 11; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2523 TCITCAAGGAC 2533
||||| |||||
DB 11 TCITCAAGGAC 21

RESULT 22
US-07-998-972A-7/C
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/998,972A
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-VAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990

REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-07-998-972A-7

Query Match 0.4%; Score 11; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 285 CTCCTCCAGGA 295
Db 33 CTCCTCCAGGA 23

RESULT 23
US-08-463-953-7/c
Sequence 7, Application US/08463953
Patent No. 5502034
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
STREET: Twentieth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,953
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-463-953-7

Query Match 0.4%; Score 11; DB 1; Length 35;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 285 CTCCTCCAGGA 295
Db 33 CTCCTCCAGGA 23

RESULT 24
US-08-462-261-7/c
Sequence 7, Application US/08462261
Patent No. 5527692
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
STREET: Twentieth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,261
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/998,972
FILING DATE: 30-DEC-1992
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-462-261-7

Query Match 0.4%; Score 11; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 285 CTCCTCCAGGA 295
Db 33 CTCCTCCAGGA 23

RESULT 25
PCT-US92-11357-7/c
Sequence 7, Application PC/TUS9211357
GENERAL INFORMATION:
APPLICANT: Holly, Richard D

APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11357
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; PCT-US92-11357-7

Query Match 0.4%; Score 11; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCCTCCAGCA 295
Db 33 CTCCTCCAGCA 23

RESULT 26
US-08-293-778-20/c
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolson, Elise M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560o No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-293-778-20

Query Match 0.4%; Score 10.6; DB 1; Length 27;
Best Local Similarity 64.0%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 6 GGAGAGCGCAGCGGCGCAGCGGC 30
Db 25 GGCGTGGCGCCCGAGTCCAGCAGC 1

RESULT 27
US-08-756-506-13
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian R.
; APPLICANT: Cottingham, Simon M.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/756,506

```
; FILING DATE:
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Sawislak, Deborah A
; REGISTRATION NUMBER: 37,438
; REFERENCE/DOCKET NUMBER: 95-28
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6672
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC6337
; US-08-756-506-13

Query Match 0.4%; Score 10.4; DB 1; Length 45;
Best Local Similarity 60.7%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1078 GTTGGAGAGAAATGGGGTATTGAAGTAGC 1105
      ||||| ||||| ||||| ||||| |||||
Db 10 GTTGGCGCGCTTGGCGGTTGCAGACC 37

RESULT 28
US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-9

Query Match 0.4%; Score 10; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 323 GCTCCTCTAG 332
      ||||| |||||
Db 24 GCTCCTCTAG 33

RESULT 29
US-08-955-636-10/c
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.4%; Score 10; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 323 GCTCCTCTAG 332
      ||||| |||||
Db 13 GCTCCTCTAG 4

RESULT 30
US-08-293-778-16/c
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESS: No. 55805600 No. 55805600 disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-293-778-16

Query Match 0.4%; Score 9.6; DB 1; Length 27;
```

```
Best Local Similarity 66.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 999 GTCGTAAATATCTCTAGGTC 1009
    ||| ||| ||| ||| |||
Db 21 GTCCTTGAAGATCTCCCGGC 1

RESULT 31
US-08-293-778-22/c
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-22

Query Match 0.4%; Score 9.6; DB 1; Length 26;
Best Local Similarity 75.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 311 CCTCAGGTGATGCTC 326
    ||| ||| ||| |||
Db 17 CCTTCGTGACTGCTC 2

Best Local Similarity 66.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 999 GTCGTAAATATCTCTAGGTC 1009
    ||| ||| ||| ||| |||
Db 21 GTCCTTGAAGATCTCCCGGC 1

RESULT 32
US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match 0.4%; Score 9.6; DB 1; Length 27;
Best Local Similarity 62.5%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 252 TGATGCAATTGGAGCTATGCTC 275
    ||| ||| ||| ||| |||
Db 3 TGCTGGACCTGGCGCCACGGCCC 26

RESULT 33
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
```

APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/998,972A
FILING DATE: 19921230
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-07-998-972A-7

Query Match 0.4%; Score 9.6; DB 1; Length 35;
Best Local Similarity 75.0%; Pred. No. 4.8e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 282 TCACTCTCCAGGAGC 297
Db 19 TCCTTCTCGAGGAGC 34

RESULT 34
US-08-463-953-7
Sequence 7, Application US/08463953
Patent No. 5502034
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,953
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-463-953-7
Query Match 0.4%; Score 9.6; DB 1; Length 35;
Best Local Similarity 75.0%; Pred. No. 4.8e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 282 TCACTCTCCAGGAGC 297
Db 19 TCCTTCTCGAGGAGC 34

RESULT 35
US-08-462-261-7
Sequence 7, Application US/08462261
Patent No. 5527692
GENERAL INFORMATION:
APPLICANT: Holly, Richard D.
APPLICANT: Foster, Donald C.
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: One Market Plaza, Stewart Street Tower,
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM: disk
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,261
FILING DATE: 05-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/998,972
FILING DATE: 30-DEC-1992
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W

Best Local Similarity 75.0%; Pred. No. 4.8e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 282 TCACCTCTCCAGGAC 297
Db 19 TCCTCTCGAGGAC 34

RESULT 37

US-08-293-778-17
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-8201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-17

Query Match 0.3%; Score 9.4; DB 1; Length 27;
Best Local Similarity 90.9%; Pred. No. 4.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2523 TCCTCAGGAC 2533
Db 11 TCCTCAGGAC 21

REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-08-462-261-7

Query Match 0.4%; Score 9.6; DB 1; Length 35;
Best Local Similarity 75.0%; Pred. No. 4.8e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 282 TCACCTCTCCAGGAC 297
Db 19 TCCTCTCGAGGAC 34

RESULT 36

PCT-US92-11357-7
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11357
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
PCT-US92-11357-7

Query Match 0.4%; Score 9.6; DB 1; Length 35;

```
RESULT 38
US-08-955-636-9/c
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-9

Query Match      0.3%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      286 TCCTCCAGGAGCAG 299
Db      35 TCCTAGAGGAGCTG 22

RESULT 39
US-08-955-636-10
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match      0.3%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      286 TCCTCCAGGAGCAG 299
Db      2 TCCTAGAGGAGCTG 15

RESULT 40
US-08-955-636-8/c
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
```

```
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8

Query Match      0.3%; Score 8.8; DB 1; Length 42;
Best Local Similarity 57.1%; Pred. No. 4.4e+02;
Matches 16; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY      286 TCCTCCAGGAGCAGGCGAGAGAGCCT 313
Db      41 TCCTGGAGGAGCTCCGTCGCCAGCAGCCT 14

Search completed: August 9, 2004, 15:29:04
Job time : 14 secs
```


GenCore version 5.1.6			Copyright (c) 1993 - 2004 Compugen Ltd.									
OM nucleic - nucleic search, using sw model												
Run on:	August 9, 2004, 15:30:00	Search time 34 Seconds (without alignments) 4.015 Million cell updates/sec										
Title:	us-10-664-775-1											
Perfect score:	2715											
Sequence:	1 ctgcaggaagagcgacagg.....ttgtaattctagggtgat 2715											
Scoring table:	IDENTITY_NUC											
Searched:	Gapop 10.0, Gapext 0.5											
Total number of hits satisfying chosen parameters:	61 segs, 25143 residues	122										
Minimum DB seq length:	0											
Maximum DB seq length:	2000000000											
Post-processing:	Minimum Match 0%											
	Maximum Match 100%											
	Listing first 250 summaries											
Database :	rnpdb:*											
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.												
SUMMARIES												
Result No.	Score	Query Match	Length	ID	Description							
1	24.6	0.9	1361	1	US-10-382-248-35							
2	20.6	0.8	1332	1	US-10-411-037-7							
3	20.6	0.8	1332	1	US-10-411-026-7							
4	20.6	0.8	1332	1	US-10-410-962-7							
5	20.6	0.8	1332	1	US-10-411-049-7							
6	20.6	0.8	1332	1	US-10-410-930-7							
7	20.6	0.8	1332	1	US-10-410-997-7							
8	20.6	0.8	1332	1	US-10-411-012-7							
9	20.6	0.8	1332	1	US-10-287-994-7							
10	20.6	0.8	1332	1	US-10-410-913-7							
11	20.6	0.8	1440	1	US-10-375-741-13							
12	20.6	0.8	2040	1	US-10-617-619-12							
13	20.6	0.8	2106	1	US-10-617-619-9							
14	20.4	0.8	483	1	US-09-918-995-8429							
15	20.4	0.8	1440	1	US-10-375-741-13							
16	19.4	0.7	1361	1	US-10-382-248-35							
17	19.2	0.7	1338	1	US-09-782-587B-2							
18	19.2	0.7	1337	1	US-09-782-587B-4							
19	18	0.7	1332	1	US-10-411-037-7							
20	18	0.7	1332	1	US-10-411-026-7							
21	18	0.7	1332	1	US-10-410-962-7							
22	18	0.7	1332	1	US-10-411-049-7							
23	18	0.7	1332	1	US-10-410-930-7							
24	18	0.7	1332	1	US-10-410-997-7							
25	18	0.7	1332	1	US-10-411-012-7							
26	18	0.7	1332	1	US-10-287-994-7							
27	18	0.7	1332	1	US-10-410-913-7							
28	18	0.7	2040	1	US-10-617-619-12							
29	18	0.7	2106	1	US-10-617-619-9							
30	17.1	0.6	1357	1	US-09-782-587B-4							
31	16.8	0.6	1338	1	US-09-782-587B-2							
32	16.4	0.6	483	1	US-09-918-995-8429							
33	14.8	0.5	222	1	US-10-029-386-23323							

34	14.8	0.5	555	1	US-10-029-386-9623	Sequence 9623, Ap
35	14.8	0.5	555	1	US-10-029-386-9623	Sequence 9623, Ap
36	14.4	0.5	222	1	US-10-029-386-23323	Sequence 23323, A
37	14.2	0.5	60	1	US-10-272-665-22	Sequence 22, Appl
38	14.2	0.5	60	1	US-10-273-321-22	Sequence 22, Appl
39	14.2	0.5	60	1	US-10-272-756-22	Sequence 22, Appl
40	14.2	0.5	60	1	US-10-273-228-22	Sequence 22, Appl
41	14.2	0.5	100	1	US-10-272-665-107	Sequence 107, App
42	14.2	0.5	100	1	US-10-273-321-107	Sequence 107, App
43	14.2	0.5	100	1	US-10-272-756-107	Sequence 107, App
44	14.2	0.5	100	1	US-10-273-228-107	Sequence 107, App
45	14.2	0.5	100	1	US-10-272-665-106	Sequence 106, App
46	14.2	0.5	100	1	US-10-273-321-106	Sequence 106, App
47	14.2	0.5	100	1	US-10-272-756-106	Sequence 106, App
48	14.2	0.5	100	1	US-10-273-228-106	Sequence 106, App
49	13.2	0.5	36	1	US-09-951-121A-8	Sequence 8, Appli
50	13.2	0.5	36	1	US-09-951-121A-9	Sequence 9, Appli
51	13.2	0.5	36	1	US-10-255-032-8	Sequence 8, Appli
52	13.2	0.5	36	1	US-10-255-032-9	Sequence 9, Appli
53	13.2	0.5	36	1	US-10-295-682-8	Sequence 8, Appli
54	13.2	0.5	36	1	US-10-295-682-9	Sequence 9, Appli
55	12.8	0.5	36	1	US-10-281-727-2	Sequence 2, Appli
56	12.8	0.5	36	1	US-10-281-727-3	Sequence 3, Appli
57	12.6	0.5	32	1	US-10-281-727-6	Sequence 6, Appli
58	12.6	0.5	32	1	US-10-281-727-7	Sequence 7, Appli
59	11.8	0.4	54	1	US-10-349-858-8	Sequence 8, Appli
60	11.6	0.4	32	1	US-10-281-727-6	Sequence 6, Appli
61	11.6	0.4	32	1	US-10-281-727-7	Sequence 7, Appli
62	11.4	0.4	38	1	US-10-398-422A-20	Sequence 20, Appl
63	11.4	0.4	38	1	US-09-969-357-2	Sequence 2, Appli
64	11.4	0.4	38	1	US-10-254-394-2	Sequence 2, Appli
65	11.4	0.4	60	1	US-10-272-665-22	Sequence 22, Appl
66	11.4	0.4	60	1	US-10-273-321-22	Sequence 22, Appl
67	11.4	0.4	60	1	US-10-272-756-22	Sequence 22, Appl
68	11.4	0.4	60	1	US-10-273-228-22	Sequence 22, Appl
69	11.4	0.4	100	1	US-10-272-665-107	Sequence 107, App
70	11.4	0.4	100	1	US-10-273-321-107	Sequence 107, App
71	11.4	0.4	100	1	US-10-272-756-107	Sequence 107, App
72	11.4	0.4	100	1	US-10-273-228-107	Sequence 107, App
73	11.4	0.4	100	1	US-10-272-665-106	Sequence 106, App
74	11.4	0.4	100	1	US-10-273-321-106	Sequence 106, App
75	11.4	0.4	100	1	US-10-272-756-106	Sequence 106, App
76	11.4	0.4	100	1	US-10-273-228-106	Sequence 106, App
77	11.2	0.4	33	1	US-09-951-121A-14	Sequence 14, Appl
78	11.2	0.4	33	1	US-09-951-121A-15	Sequence 15, Appl
79	11.2	0.4	33	1	US-10-295-682-14	Sequence 14, Appl
80	11.2	0.4	33	1	US-10-295-682-15	Sequence 15, Appl
81	11.2	0.4	35	1	US-10-109-498-5	Sequence 5, Appli
82	11.2	0.4	35	1	US-10-109-498-6	Sequence 6, Appli
83	11.2	0.4	42	1	US-09-803-810-8	Sequence 8, Appli
84	11.2	0.4	42	1	US-10-298-330-8	Sequence 8, Appli
85	11	0.4	38	1	US-10-398-422A-20	Sequence 20, Appl
86	11	0.4	38	1	US-09-969-357-2	Sequence 2, Appli
87	11	0.4	38	1	US-10-254-394-2	Sequence 2, Appli
88	10.6	0.4	31	1	US-10-017-122-4	Sequence 4, Appli
89	10.6	0.4	33	1	US-09-951-121A-14	Sequence 14, Appl
90	10.6	0.4	33	1	US-09-951-121A-15	Sequence 15, Appl
91	10.6	0.4	33	1	US-10-295-682-14	Sequence 14, Appl
92	10.6	0.4	33	1	US-10-295-682-15	Sequence 15, Appl
93	10.6	0.4	36	1	US-09-951-121A-8	Sequence 8, Appli
94	10.6	0.4	36	1	US-09-951-121A-9	Sequence 9, Appli
95	10.6	0.4	36	1	US-10-255-032-8	Sequence 8, Appli
96	10.6	0.4	36	1	US-10-255-032-9	Sequence 9, Appli
97	10.6	0.4	36	1	US-10-295-682-8	Sequence 8, Appli
98	10.6	0.4	36	1	US-10-295-682-9	Sequence 9, Appli
99	10.6	0.4	60	1	US-10-272-665-23	Sequence 23, Appl
100	10.6	0.4	60	1	US-10-272-665-23	Sequence 23, Appl
101	10.6	0.4	60	1	US-10-273-321-23	Sequence 23, Appl
102	10.6	0.4	60	1	US-10-273-321-23	Sequence 23, Appl
103	10.6	0.4	60	1	US-10-272-756-23	Sequence 23, Appl
104	10.6	0.4	60	1	US-10-272-756-23	Sequence 23, Appl
105	10.6	0.4	60	1	US-10-273-228-23	Sequence 23, Appl
106	10.6	0.4	60	1	US-10-273-228-23	Sequence 23, Appl

107	10.4	0.4	36	1	US-10-281-727-2	Sequence 2, Appl
108	10.4	0.4	36	1	US-10-281-727-3	Sequence 3, Appl
109	10.2	0.4	35	1	US-10-109-498-5	Sequence 5, Appl
110	10.2	0.4	35	1	US-10-109-498-6	Sequence 6, Appl
111	10	0.4	54	1	US-10-349-858-8	Sequence 8, Appl
112	9.4	0.3	31	1	US-10-017-122-4	Sequence 4, Appl
113	9.2	0.3	34	1	US-09-951-121A-2	Sequence 2, Appl
114	9.2	0.3	34	1	US-09-951-121A-3	Sequence 3, Appl
115	9.2	0.3	34	1	US-10-295-682-2	Sequence 2, Appl
116	9.2	0.3	34	1	US-10-295-682-3	Sequence 3, Appl
117	8.8	0.3	42	1	US-09-803-810-8	Sequence 8, Appl
118	8.8	0.3	42	1	US-10-298-330-8	Sequence 8, Appl
119	8.6	0.3	34	1	US-09-951-121A-2	Sequence 2, Appl
120	8.6	0.3	34	1	US-09-951-121A-3	Sequence 3, Appl
121	8.6	0.3	34	1	US-10-295-682-2	Sequence 2, Appl
122	8.6	0.3	34	1	US-10-295-682-3	Sequence 3, Appl

ALIGNMENTS

```

RESULT 1
US-10-382-248-35
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

```

```

RESULT 2
US-10-411-037-7/c
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neosec Technologies, Inc
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert

```

; APPLICANT: Chen, Xi
 ; APPLICANT: Bowe, Caryn
 ; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
 ; TITLE OF INVENTION: GALACTOSIDASE A
 ; FILE REFERENCE: 040853-01-5082
 ; CURRENT APPLICATION NUMBER: US/10/411,037
 ; CURRENT FILING DATE: 2003-04-09
 ; PRIOR APPLICATION NUMBER: US 60/328,523
 ; PRIOR FILING DATE: 2001-10-10
 ; PRIOR APPLICATION NUMBER: US 60/344,692
 ; PRIOR FILING DATE: 2001-10-19
 ; PRIOR APPLICATION NUMBER: US 60/387,292
 ; PRIOR FILING DATE: 2002-06-07
 ; PRIOR APPLICATION NUMBER: US 60/391,777
 ; PRIOR FILING DATE: 2002-06-25
 ; PRIOR APPLICATION NUMBER: US 60/396,594
 ; PRIOR FILING DATE: 2002-07-17
 ; PRIOR APPLICATION NUMBER: US 60/404,249
 ; PRIOR FILING DATE: 2002-08-16
 ; PRIOR APPLICATION NUMBER: US 60/407,527
 ; PRIOR FILING DATE: 2002-08-28
 ; NUMBER OF SEQ ID NOS: 75
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 7
 ; LENGTH: 1332
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-10-411-037-7

Query Match 0.8%; Score 20.6; DB 1; Length 1332;
 Best Local Similarity 59.3%; Pred. No. 4.9;
 Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATTGCTTTTATCGTCGACACTGCTTCGTTTGAATATGATTCAATTTGG 934
 Db 558 TTTCGTGCATTCCTTTTCTAGAAATAGGATTTTCCACATGGATATTCAACTGTGG 500

RESULT 3
 US-10-411-026-7/c
 ; Sequence 7, Application US/10411026
 ; Publication No. US2004006391A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Neose Technologies, Inc.
 ; APPLICANT: Defrees, Shawn
 ; APPLICANT: Zopf, David
 ; APPLICANT: Bayer, Robert
 ; APPLICANT: Hakes, David
 ; APPLICANT: Chen, Xi
 ; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
 ; FILE REFERENCE: 040853-01-5053
 ; CURRENT APPLICATION NUMBER: US/10/411,026
 ; CURRENT FILING DATE: 2003-04-09
 ; PRIOR APPLICATION NUMBER: US 60/328,523
 ; PRIOR FILING DATE: 2001-10-10
 ; PRIOR APPLICATION NUMBER: US 60/344,692
 ; PRIOR FILING DATE: 2001-10-19
 ; PRIOR APPLICATION NUMBER: US 60/387,292
 ; PRIOR FILING DATE: 2002-06-07
 ; PRIOR APPLICATION NUMBER: US 60/391,777
 ; PRIOR FILING DATE: 2002-06-25
 ; PRIOR APPLICATION NUMBER: US 60/396,594
 ; PRIOR FILING DATE: 2002-07-17
 ; PRIOR APPLICATION NUMBER: US 60/404,249
 ; PRIOR FILING DATE: 2002-08-16
 ; PRIOR APPLICATION NUMBER: US 60/407,527
 ; PRIOR FILING DATE: 2002-08-28
 ; NUMBER OF SEQ ID NOS: 75
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 7
 ; LENGTH: 1332

ORGANISM: Homo sapiens
US-10-411-026-7
Query Match 0.8%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 4.9;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 876 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATAATGATTCATTTGG 934
DB 558 TTGCTGGCAATTCCTTTTCTAGATAGGATTTTCCACATGGATATCAACTGTGG 500
RESULT 4
US-10-410-962-7/c
Sequence 7, Application US/10410962
Publication No. US20040077836A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bowe, Caryn
TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
FILE REFERENCE: 040853-01-5054
CURRENT APPLICATION NUMBER: US/10/410,962
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-410-962-7
Query Match 0.8%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 4.9;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 876 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATAATGATTCATTTGG 934
DB 558 TTGCTGGCAATTCCTTTTCTAGATAGGATTTTCCACATGGATATCAACTGTGG 500
RESULT 5
US-10-411-049-7/c
Sequence 7, Application US/10411049
Publication No. US20040082026A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bowe, Caryn
TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON

ORGANISM: Homo sapiens
US-10-411-026-7
Query Match 0.8%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 4.9;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 876 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATAATGATTCATTTGG 934
DB 558 TTGCTGGCAATTCCTTTTCTAGATAGGATTTTCCACATGGATATCAACTGTGG 500
RESULT 6
US-10-410-930-7/c
Sequence 7, Application US/10410930
Publication No. US20040115168A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bowe, Caryn
TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
FILE REFERENCE: 040853-01-5056
CURRENT APPLICATION NUMBER: US/10/410,930
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-410-930-7
Query Match 0.8%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 4.9;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 876 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATAATGATTCATTTGG 934
DB 558 TTGCTGGCAATTCCTTTTCTAGATAGGATTTTCCACATGGATATCAACTGTGG 500
RESULT 7
US-10-410-930-7/c
Sequence 7, Application US/10410930
Publication No. US20040115168A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bowe, Caryn
TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
FILE REFERENCE: 040853-01-5056
CURRENT APPLICATION NUMBER: US/10/410,930
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-410-930-7


```
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      0.8%; Score 20.6; DB 1; Length 2106;
Best Local Similarity 59.3%; Pred. No. 7;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATTGCTCTTTAATCTGTCGAGACTGCTTTGTTTGAATATATGATTCATTTGG 934
Db 624 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATTCAACTGTGG 566

RESULT 14
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match      0.8%; Score 20.4; DB 1; Length 483;
Best Local Similarity 65.2%; Pred. No. 2.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCCATGCTCCAGAGTTGCTCTTCCAGGTGCAGGC 419
Db 68 ACAGGCAGGGCAGCAGCTGAGAGATTCATCATGTTCTCCAGGC 113

RESULT 15
US-10-375-741-13
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; PRIOR FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
```

```
; PRIOR FILING DATE: 1997-01-27
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match      0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 6.1;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCCATGCTCCAGAGTTGCTCTTCCAGGTGCAGGC 419
Db 4 ACAGGCAGGGCAGCAGCTGCGAGATTCATCATGTTCTCCAGGC 49

RESULT 16
US-10-382-248-35/c
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-588C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)...(1301)
US-10-382-248-35

Query Match      0.7%; Score 19.4; DB 1; Length 1361;
Best Local Similarity 55.1%; Pred. No. 12;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2596 CTCAGGSCCTATTGTAATAGGGTTTACGAGGAGACATATTGCTGTTGTTATTCTG 2655
Db 1312 CTGCTGGCTAGGAAATGGGCTCCGAGGAGGACTCTTGGGGCTGCTCTGAGCCATG 1253

QY 2656 TGTTTTTC 2664
Db 1252 AGCTTTTC 1244

RESULT 17
US-09-782-587B-2/c
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001000S
; CURRENT APPLICATION NUMBER: US/09/782,587B
```

Query Match	Best Local Similarity	Score	DB 1	Length	Indels	Gaps
371	GGTACAGGATGGCCATGCTCCAGAGATTGCTTCCAGGTGCAGGCGGCGCATGGC	430				
619	GGACCTGCCAGGGCACTCCCTTAGGCGAGACCTTCCCGCGAGCATCGGCGCTGGG	560				
431	TCTGGTGATCACTCTCTAGTGAAGGTGGGGTCT	466				
559	GTTCCTAGCGTTCGCTTTTCTAGATGGGAATCT	524				
<p>Query Match 0.7%; Score 19.2; DB 1; Length 1338; Best Local Similarity 50.0%; Pred. No. 14; Indels 48; Mismatches 0; Gaps 0; Matches 48; Conservative 0; Mismatches 48; Indels 48; Gaps 0;</p>						
<p>US-09-782-587B-2</p> <p>Sequence 4, Application US/09782587B Publication No. US20030096338A1 GENERAL INFORMATION: APPLICANT: PEDERSEN, ANDERS H. APPLICANT: ANDERSON, KIM V. APPLICANT: BORNAES, CLAUS TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES FILE REFERENCE: 31-001100US CURRENT APPLICATION NUMBER: US/09/782,587B PRIORITY FILING DATE: 2002-03-26 PRIOR FILING DATE: 2000-02-11 PRIOR APPLICATION NUMBER: PA 2000 00218 PRIOR FILING DATE: 2000-02-22 PRIOR APPLICATION NUMBER: 60/184,036 PRIOR FILING DATE: 2000-10-18 NUMBER OF SEQ ID NOS: 19 SOFTWARE: PatentIn Ver. 2.1 SEQ ID NO 2 LENGTH: 1338 TYPE: DNA ORGANISM: Homo sapiens FEATURE: NAME/KEY: CDS LOCATION: (115)..(1332) US-09-782-587B-2</p>						
<p>Query Match 0.7%; Score 19.2; DB 1; Length 1357; Best Local Similarity 50.0%; Pred. No. 14; Indels 48; Mismatches 0; Gaps 0; Matches 48; Conservative 0; Mismatches 48; Indels 48; Gaps 0;</p>						
<p>US-09-782-587B-4</p> <p>Sequence 4, Application US/09782587B Publication No. US20030096338A1 GENERAL INFORMATION: APPLICANT: PEDERSEN, ANDERS H. APPLICANT: ANDERSON, KIM V. APPLICANT: BORNAES, CLAUS TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES FILE REFERENCE: 31-001100US CURRENT APPLICATION NUMBER: US/09/782,587B PRIORITY FILING DATE: 2002-03-26 PRIOR FILING DATE: 2000-02-11 PRIOR APPLICATION NUMBER: PA 2000 00218 PRIOR FILING DATE: 2000-02-22 PRIOR APPLICATION NUMBER: 60/184,036 PRIOR FILING DATE: 2000-10-18 NUMBER OF SEQ ID NOS: 19 SOFTWARE: PatentIn Ver. 2.1 SEQ ID NO 4 LENGTH: 1357 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: NAME/KEY: CDS LOCATION: (115)..(1332) US-09-782-587B-4</p>						
<p>Query Match 0.7%; Score 19.2; DB 1; Length 1357; Best Local Similarity 50.0%; Pred. No. 14; Indels 48; Mismatches 0; Gaps 0; Matches 48; Conservative 0; Mismatches 48; Indels 48; Gaps 0;</p>						
<p>US-09-782-587B-4</p> <p>Sequence 4, Application US/09782587B Publication No. US20030096338A1 GENERAL INFORMATION: APPLICANT: PEDERSEN, ANDERS H. APPLICANT: ANDERSON, KIM V. APPLICANT: BORNAES, CLAUS TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES FILE REFERENCE: 31-001100US CURRENT APPLICATION NUMBER: US/09/782,587B PRIORITY FILING DATE: 2002-03-26 PRIOR FILING DATE: 2000-02-11 PRIOR APPLICATION NUMBER: PA 2000 00218 PRIOR FILING DATE: 2000-02-22 PRIOR APPLICATION NUMBER: 60/184,036 PRIOR FILING DATE: 2000-10-18 NUMBER OF SEQ ID NOS: 19 SOFTWARE: PatentIn Ver. 2.1 SEQ ID NO 4 LENGTH: 1357 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: NAME/KEY: CDS LOCATION: (115)..(1332) US-09-782-587B-4</p>						

```
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-026-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db 560 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGTGTCCATGGCAGGTCC 619

QY 404 TCTTCAGGTGCGAGGAGGGCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db 620 TGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGACCCTGTATCAACACCATCTGGGTGG 679

QY 464 TCTGAGGCTCCAATGGTT 481
Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 22
US-10-411-049-7
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-049-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db 560 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGTGTCCATGGCAGGTCC 619

QY 404 TCTTCAGGTGCGAGGAGGGCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db 620 TGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGACCCTGTATCAACACCATCTGGGTGG 679

QY 464 TCTGAGGCTCCAATGGTT 481
Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 21
US-10-410-962-7
; Sequence 7, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-962-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db 560 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGTGTCCATGGCAGGTCC 619

QY 404 TCTTCAGGTGCGAGGAGGGCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db 620 TGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGACCCTGTATCAACACCATCTGGGTGG 679

QY 464 TCTGAGGCTCCAATGGTT 481
Db 680 TCTCCGGCGCCCACTGTT 697
```


Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 23

US-10-410-930-7

Sequence 7, Application US/10410930

Publication No. US20040115168A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON

TITLE OF INVENTION: BETA

FILE REFERENCE: 040853-01-5056

CURRENT APPLICATION NUMBER: US/10/410,930

PRIOR FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-410-930-7

Query Match 0.7%; Score 18; DB 1; Length 1332;

Best Local Similarity 45.7%; Pred. No. 28;

Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403

Db 560 CCCAAGCGCGAATTGTGGGGGCAAGTGTGCCCAAAGGGAGTGTCCATGGCAGGTCC 619

QY 404 TCTTCCAGGTGACAGGCGGCATGGCTCTGTGTATCACTCTCTAGTGAAGGTGGGG 463

Db 620 TGTGTTGGTGAATGAGCTCAGTTGTGTGGGGGACCCCTGATCAACACCATCTGGGTGG 679

QY 464 TCTGAGGCTCCAATGGTT 481

Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 24

US-10-410-997-7

Sequence 7, Application US/10410997

Publication No. US20040126838A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF

TITLE OF INVENTION: METHODS

FILE REFERENCE: 040853-01-5051

CURRENT APPLICATION NUMBER: US/10/411,012

PRIOR FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 25

US-10-411-012-7

Sequence 7, Application US/10411012

Publication No. US20040132640A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: GLYCOPSYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE

TITLE OF INVENTION: METHODS

FILE REFERENCE: 040853-01-5051

CURRENT APPLICATION NUMBER: US/10/411,012

PRIOR FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match 0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403
Db 560 CCCAAGGCCGAATGTGGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCATGGCAGGTCC 619
QY 404 TCTTCCAGTGCAGGCAGGGCCATGGCTCTGTGTGATCACTCTCTAGTCAAAAGGTGGGGG 463
Db 620 TGTGTGTGTGATGAGAGCTCAGTTGTGTGGGGGACCCCTGATCAACACCATCTCGGTGG 679
QY 464 TCTGAGGCTCCAATGTT 481
Db 680 TCTCCGGGCCCACTGTT 697

RESULT 26

US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994

; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match 0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403
Db 560 CCCAAGGCCGAATGTGGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCATGGCAGGTCC 619
QY 404 TCTTCCAGTGCAGGCAGGGCCATGGCTCTGTGTGATCACTCTCTAGTCAAAAGGTGGGGG 463

Db 620 TGTGTGTGGTGAATGGAGCTCAGTTGTGTGGGGGGACCCCTGATCAACACCATCTGGGTGG 679
QY 464 TCTGAGGCTCCAATGTT 481
Db 680 TCTCCGGGGCCCACTGTT 697

RESULT 27

US-10-410-913-7
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE

; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match 0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403
Db 560 CCCAAGGCCGAATGTGGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCATGGCAGGTCC 619
QY 404 TCTTCCAGTGCAGGCAGGGCCATGGCTCTGTGTGATCACTCTCTAGTCAAAAGGTGGGGG 463
Db 620 TGTGTGTGTGATGAGAGCTCAGTTGTGTGGGGGGACCCCTGATCAACACCATCTGGGTGG 679
QY 464 TCTGAGGCTCCAATGTT 481
Db 680 TCTCCGGGGCCCACTGTT 697

RESULT 28

US-10-617-619-12
; Sequence 12, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolson, Elise M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound

```
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match          0.7%; Score 18; DB 1; Length 2040;
Best Local Similarity 45.7%; Pred. No. 23;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGGTCCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403
DB 560 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCTATGGCAGGTCC 619
QY 404 TCTTCCAGTGCAGCAGGCCATGGCTCTGTGTGATCACTCTCTAGTAGAAAGTGGGG 463
DB 620 TGTGTGTGTGAATGGAGCTCAGTTGTGTGGGGGACCTGATCAACACCATCTGGGTGG 679
QY 464 TCTGAGGCTCCAATGTT 481
DB 680 TCTCCGGCGCCCACTGTT 697

RESULT 29
US-10-617-619-9
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match          0.7%; Score 18; DB 1; Length 2106;
Best Local Similarity 45.7%; Pred. No. 23;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGGTCCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403
DB 626 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCTATGGCAGGTCC 685
QY 404 TCTTCCAGTGCAGCAGGCCATGGCTCTGTGTGATCACTCTCTAGTAGAAAGTGGGG 463
DB 686 TGTGTGTGTGAATGAGCTCAGTTGTGTGGGGGACCTGATCAACACCATCTGGGTGG 745
QY 464 TCTGAGGCTCCAATGTT 481

; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match          0.7%; Score 18; DB 1; Length 2040;
Best Local Similarity 45.7%; Pred. No. 23;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGGTCCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403
DB 560 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCTATGGCAGGTCC 619
QY 404 TCTTCCAGTGCAGCAGGCCATGGCTCTGTGTGATCACTCTCTAGTAGAAAGTGGGG 463
DB 620 TGTGTGTGTGAATGGAGCTCAGTTGTGTGGGGGACCTGATCAACACCATCTGGGTGG 679
QY 464 TCTGAGGCTCCAATGTT 481
DB 680 TCTCCGGCGCCCACTGTT 697

RESULT 30
US-09-782-587B-4
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match          0.6%; Score 17.1; DB 1; Length 1357;
Best Local Similarity 62.7%; Pred. No. 35;
Matches 42; Conservative 0; Mismatches 24; Indels 1; Gaps 1;

QY 280 GATCACTCTCTCCAGGAGCAGGAGG-GAAGAGCCTCAGGTGATTGCTCTTAGATGCTG 338
DB 2 GATCCCGCCACCATGTGTCAGCAGGCCCTCCGCTCTCTGCTGCTCTCTGGGCTGCAG 61
QY 339 GCAGGCC 345
DB 62 GGCTGCC 68

RESULT 31
US-09-782-587B-2
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
```

US-09-782-587B-2

Query Match 0.6%; Score 16.8; DB 1; Length 1338;
Best Local Similarity 66.7%; Pred. No. 37;
Matches 24; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 310 GCCTCAGGTGATGCTCCCTCTAGATGCTGGCAGGCC 345
|||||
Db 20 GCCTCCTGTGCTGCTCCCTGGGCTGCAGGGTGC 55
|||||

RESULT 32

US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1

; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: PastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match 0.6%; Score 16.4; DB 1; Length 483;
Best Local Similarity 55.2%; Pred. No. 52;
Matches 32; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1122 AGTCAATGATGATTATGCTGTAGCTGCTGCTTTATGAACCTGGTGACATTG 1179
|||||
Db 415 AGGATGGAGCTGCTGCTTGCAGGAGCCCATCTGTCATGGACTTGAGGCACACTG 358
|||||

RESULT 33

US-10-029-386-23323/c
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1

; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122

; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match 0.5%; Score 14.8; DB 1; Length 222;
Best Local Similarity 53.4%; Pred. No. 1e+02;
Matches 31; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 415 CAGGCAGGCGCATGGCTCTGGTGATCACTCTCTAGTGAAGGTGGGGTCTGAGGCT 472
|||||
Db 133 CTGAGAGGACGCTGGCTTCGTCGGCTTCATCTGTCAGCGCTGGGCGCACTGCT 76
|||||

RESULT 34

US-10-029-386-9623
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1

; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

Query Match 0.5%; Score 14.8; DB 1; Length 555;
Best Local Similarity 56.0%; Pred. No. 8e;
Matches 28; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 690 TAGGGGCACTACCGCATTCCTCTCTCTCCAAACACTTCTATTCTTGA 739
|||||
Db 12 TGGGGAGTCTCCACCTTCGGTGACTGCTGCAGGCAGTCTCTGGTTCATCA 61
|||||

RESULT 35

US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1

; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens

```

;
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUATE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUATE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUATE 5.00e-76
;
US-10-029-386-9623

Query Match          0.5%; Score 14.8; DB 1; Length 555;
Best Local Similarity 53.4%; Pred. No. 88;
Matches 31; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 415 CAGCAGGGCATGGCTCTGGTATCACTCTCTAGTGAAGTGGGGTCTGAGGCT 472
Db 169 CTGAGAGACGCTGGCTCTGGCTCTCTATGGTCAGCGGCTGGCGAGCTGCT 112

RESULT 36
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AECOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUATE 1.00e-122
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUATE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUATE 3.00e-37
;
US-10-029-386-23323

Query Match          0.5%; Score 14.4; DB 1; Length 222;
Best Local Similarity 65.6%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 393 CAGCATTCCTCTTCCAGTCCAGGCAGGGC 424
Db 173 CAGTGAGGACCCAGGCGTGGTGCAGCGAGC 204

RESULT 37
US-10-029-386-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665

```

```

;
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
;
US-10-272-665-22

Query Match          0.5%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCCTTCTTCCCTTCTCTATTCCTT 2201
Db 58 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 38
US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
;
US-10-273-321-22

Query Match          0.5%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCCTTCTTCCCTTCTCTATTCCTT 2201
Db 58 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 39
US-10-272-756-22/c
; Sequence 22, Application US/10272756

```


Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201
| | | | | | | | | | | | | | | | | | | | | |
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 43

US-10-272-756-107/c
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match 0.5%; Score 14.2; DB 1; Length 100;

Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201
| | | | | | | | | | | | | | | | | | | | | |
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 44

US-10-273-228-107/c
; Sequence 107, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match 0.5%; Score 14.2; DB 1; Length 100;

Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201
| | | | | | | | | | | | | | | | | | | | | |
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 45

US-10-272-665-106/c
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match 0.5%; Score 14.2; DB 1; Length 100;

Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201
| | | | | | | | | | | | | | | | | | | | | |
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 46

US-10-273-321-106/c
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

```
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match      0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTTGACCTGCTTCTTCCCTTCTCTCTATTCCTT 2201
      |||||
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 47
US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 106
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match      0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTTGACCTGCTTCTTCCCTTCTCTCTATTCCTT 2201
      |||||
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 48
US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 106
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match      0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTTGACCTGCTTCTTCCCTTCTCTCTATTCCTT 2201
      |||||
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 49
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 423 GCCATGGCTCTGCTGATC 440
      |||||
Db 1 GCCACGGCCCTGGTGCTC 18

RESULT 50
US-09-951-121A-9/c
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```



```
US-09-951-121A-9
Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 19

RESULT 51
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-8
Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 19

RESULT 52
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9
Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 19

RESULT 53
US-10-295-682-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8
Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 1 GCCACGGCCCTGGTGCTC 18

RESULT 54
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9
Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 19

RESULT 55
US-10-281-727-2/c
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
```

; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; TYPE: DNA
; LENGTH: 36
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match 0.5%; Score 12.8; DB 1; Length 36;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 TTCCAGGTGCAGGCAG 421
||| |||||
DB 16 TTCCTGCTCAGGCAG 1

RESULT 56
US-10-281-727-3
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3

Query Match 0.5%; Score 12.8; DB 1; Length 36;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 TTCCAGGTGCAGGCAG 421
||| |||||
DB 21 TTCCTGCTCAGGCAG 36

RESULT 57
US-10-281-727-6
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII

; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match 0.5%; Score 12.6; DB 1; Length 32;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 290 CCAGGAGCAGGCAGGGAAG 308
||| |||||
DB 2 CCTGCAGCAGGAACGGAAG 20

RESULT 58
US-10-281-727-7/C
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match 0.5%; Score 12.6; DB 1; Length 32;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 290 CCAGGAGCAGGCAGGGAAG 308
||| |||||
DB 31 CCTGCAGCAGGAACGGAAG 13

RESULT 59
US-10-349-858-8/C
; Sequence 8, Application US/10349858
; Publication No. US2003020247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT CH

```
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match      0.4%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.8%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 2361 TGAGGTCCTCTGGGTTCTTAA 2383
Db 29 TGGGCTTCCTCTGGGTTACGAA 7

RESULT 60
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match      0.4%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 2.8e-02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2435 TTCCACTTCAGGTCCTG 2452
Db 26 TCCACCTTCGGTCTCTG 9

RESULT 61
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627

; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match      0.4%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.8%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 2361 TGAGGTCCTCTGGGTTCTTAA 2383
Db 29 TGGGCTTCCTCTGGGTTACGAA 7

RESULT 60
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match      0.4%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 2.8e-02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2435 TTCCACTTCAGGTCCTG 2452
Db 26 TCCACCTTCGGTCTCTG 9

RESULT 61
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627

; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match      0.4%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 3.7e-02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 563 TAATATATTTTCTGAAGCCTCTGCTGCG 591
Db 10 TAAACGCTTCTCTGGAGGAGTCTGCGCC 38

RESULT 63
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
```

APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
APPLICANT: Pingel, Hans K
APPLICANT: Klausen, Niels K
TITLE OF INVENTION: Factor VII Glycoforms
FILE REFERENCE: 6207.510-US
CURRENT FILING DATE: 2002-10-02
PRIOR APPLICATION NUMBER: US/09/969,357
PRIOR FILING DATE: 2000-10-02
PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
PRIOR FILING DATE: 2000-10-02
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
PRIOR FILING DATE: 2001-02-16
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
PRIOR FILING DATE: 2001-03-14
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
PRIOR FILING DATE: 2001-05-14
PRIOR APPLICATION NUMBER: US 60/238,944
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/271,581
PRIOR FILING DATE: 2001-02-26
PRIOR APPLICATION NUMBER: US 60/276,322
PRIOR FILING DATE: 2001-03-16
NUMBER OF SEQ ID NOS: 2
SOFTWARE: Patent in version 3.2
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match 0.4%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 563 TAATATATTTTCTGAAGCCTCTGCTGCC 591
DB 10 TAAACCGCTTCTCTGGAGGAGTGCGGCC 38

RESULT 64
US-10-254-394-2
Sequence 2, Application US/10254394
Publication No. US20030096366A1
GENERAL INFORMATION:
APPLICANT: Knudsen, Ida Molgaard
TITLE OF INVENTION: Method for Production of Recombinant
FILE REFERENCE: 6480.500-US
CURRENT APPLICATION NUMBER: US/10/254,394
CURRENT FILING DATE: 2002-09-25
PRIOR APPLICATION NUMBER: PCT/DR01/00632
PRIOR FILING DATE: 2001-10-02
PRIOR APPLICATION NUMBER: PCT/DR01/00634
PRIOR FILING DATE: 2001-10-02
PRIOR APPLICATION NUMBER: PA 2002 00460
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: 60/374,855
PRIOR FILING DATE: 2002-10-04
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-10-254-394-2

Query Match 0.4%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 563 TAATATATTTTCTGAAGCCTCTGCTGCC 591
DB 10 TAAACCGCTTCTCTGGAGGAGTGCGGCC 38

RESULT 65
US-10-272-665-22
Sequence 22, Application US/10272665
Publication No. US20030180748A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POLYMERASE CHAIN REACTION (PCR) PRODUCTS
FILE REFERENCE: 24736-2033E
CURRENT APPLICATION NUMBER: US/10/272,665
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 09/663,968
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:
OTHER INFORMATION: Probe
US-10-272-665-22

Query Match 0.4%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 4.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGCGCTATTCATAGGTTTACGAGGACATAT 2634
DB 23 CAAGGACTCTGCAAGGGGGACAGTGAGGCCACAT 59

RESULT 66
US-10-273-321-22
Sequence 22, Application US/10273321
Publication No. US20030180749A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POLYMERASE CHAIN REACTION (PCR) PRODUCTS
FILE REFERENCE: 24736-2033B
CURRENT APPLICATION NUMBER: US/10/273,321
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 09/663,968
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:

; OTHER INFORMATION: Probe
US-10-273-321-22
Query Match 0.4%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 4.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGACATAT 2634
| | | | | | | | | | | | | | | | | | | | | |
Db 23 CAAGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 59
| | | | | | | | | | | | | | | | | | | | | |
RESULT 67
US-10-272-756-22
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22
Query Match 0.4%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 4.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGACATAT 2634
| | | | | | | | | | | | | | | | | | | | | |
Db 23 CAAGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 59
| | | | | | | | | | | | | | | | | | | | | |
RESULT 68
US-10-273-228-22
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22
Query Match 0.4%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 4.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGACATAT 2634
| | | | | | | | | | | | | | | | | | | | | |
Db 23 CAAGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 59
| | | | | | | | | | | | | | | | | | | | | |
RESULT 69
US-10-272-665-107
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-665-107
Query Match 0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGACATAT 2634
| | | | | | | | | | | | | | | | | | | | | |
Db 3 CAAGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39
| | | | | | | | | | | | | | | | | | | | | |
RESULT 70
US-10-273-321-107
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19

```
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-107

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGGCCTATTGTAATAGGTTTTCAGCAGGACATAT 2634
DB 3 CAAGGACTCTCGAAGGGGGACAGTGGAGGCCACAT 39

RESULT 71
US-10-272-756-107
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGGCCTATTGTAATAGGTTTTCAGCAGGACATAT 2634
DB 3 CAAGGACTCTCGAAGGGGGACAGTGGAGGCCACAT 39

RESULT 72
US-10-273-228-107
; Sequence 107, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
```

```
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGGCCTATTGTAATAGGTTTTCAGCAGGACATAT 2634
DB 3 CAAGGACTCTCGAAGGGGGACAGTGGAGGCCACAT 39

RESULT 73
US-10-272-665-106
; Sequence 106, Application US/10272665
; Publication No. US20030190748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POI
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGGCCTATTGTAATAGGTTTTCAGCAGGACATAT 2634
DB 3 CAAGGACTCTCGAAGGGGGACAGTGGAGGCCACAT 39

RESULT 74
US-10-273-321-106
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POI
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
```

```
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2598 CAGGCGCTATTGTAATAGGTTTACGAGGACATAT 2634
Db 3 CAAGGACTCTCTCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 75
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2598 CAGGCGCTATTGTAATAGGTTTACGAGGACATAT 2634
Db 3 CAAGGACTCTCTCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 76
US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2598 CAGGCGCTATTGTAATAGGTTTACGAGGACATAT 2634
Db 3 CAAGGACTCTCTCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 77
US-09-951-121A-14/C
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match      0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1837 TGCAGTAGTCTGGCCTTGACATCTG 1860
Db 31 TGCAGGAGTCTTGGCCGCAATCCG 8

RESULT 78
US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
```

```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      3 TGCAGGAGTCCTTGGCGCCATCCG 26

RESULT 79
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      31 TGCAGGAGTCCTTGGCGCCATCCG 8

RESULT 80
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
```

```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      3 TGCAGGAGTCCTTGGCGCCATCCG 26

RESULT 79
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      31 TGCAGGAGTCCTTGGCGCCATCCG 8

RESULT 80
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
```

```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      3 TGCAGGAGTCCTTGGCGCCATCCG 26

RESULT 79
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match          0.4%; Score 11.2; DB 1; Length 35;
Best Local Similarity 59.4%; Pred. No. 4e+02;
Matches 19; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 393 CAGAGATTCCCTCTTCCAGGTGCAGCAGGCG 424
Db      32 CAGTGAGGACCCAGGAGCAGTGCAGCGGAGC 1

RESULT 82
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
```



```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-498-6

Query Match          0.4%; Score 11.2; DB 1; Length 35;
Best Local Similarity 59.4%; Pred. No. 4e+02;
Matches 19; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 393 CAGAGATTGCTCTCCAGGTCGACGGCAGGCGC 424
Db      4 CAGTGGAGACCACGGGACAGTGCAGGCGGAGC 35

RESULT 83
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match          0.4%; Score 11.2; DB 1; Length 42;
Best Local Similarity 59.4%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 283 CACTCTCCAGGACGAGCGAGAGAGCCCTC 314
Db      2 CACTCCCGCTCCAGGCTGCTGGACGGAGCTC 33

RESULT 84
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; POLYPEPTIDES
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match          0.4%; Score 11.2; DB 1; Length 42;
Best Local Similarity 59.4%; Pred. No. 4.5e+02;

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-498-6

Query Match          0.4%; Score 11; DB 1; Length 38;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCTCCAGCA 295
Db      30 CTCTCCAGCA 20

RESULT 86
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.4%; Score 11; DB 1; Length 38;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 CACTCTCCAGGACGAGCGAGAGCCCTC 314
Db      2 CACTCCCGCTCCAGGCTGCTGGACGGAGCTC 33

RESULT 85
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/006635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.4%; Score 11; DB 1; Length 38;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCTCCAGCA 295
Db      30 CTCTCCAGCA 20

RESULT 86
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
```

```
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 2
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match      0.4%; Score 11; DB 1; Length 38;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCCTCCAGGA 295
Db 30 CTCCTCCAGGA 20

RESULT 87
US-10-254-394-2/c
; Sequence 2, Application US/10254394
; Publication No. US20030096366A1
; GENERAL INFORMATION:
; APPLICANT: Knudsen, Ida Molgaard
; TITLE OF INVENTION: Method for Production of Recombinant
; FILE OF INVENTION: Proteins in Eukaryote Cells
; FILE REFERENCE: 6480.500-US
; CURRENT APPLICATION NUMBER: US/10/254,394
; CURRENT FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: PCT/DK01/00632
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PCT/DK01/00634
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PA 2002 00460
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: 60/374,855
; PRIOR FILING DATE: 2002-10-04
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-254-394-2

Query Match      0.4%; Score 11; DB 1; Length 38;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCCTCCAGGA 295
Db 30 CTCCTCCAGGA 20

RESULT 88
US-10-017-122-4/c
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14

; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match      0.4%; Score 10.6; DB 1; Length 31;
Best Local Similarity 64.0%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 280 GATCACTCTCTCCAGGACGACGAGG 304
Db 27 GAGTACCCCTCATGCGACGACGAGG 3

RESULT 89
US-09-951-121A-14
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match      0.4%; Score 10.6; DB 1; Length 33;
Best Local Similarity 76.5%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 261 TGGAGGCTATGGCTCTCT 277
Db 12 TGGCGCAAGGACTCTCT 28

RESULT 90
US-09-951-121A-15/c
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
```

```

Query Match      0.4; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY      2438 CACTTTCAGGTCCTGAA 2454

```

```

RESULT 32
US-10-295-682-15/c
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

```

Db 4 CACGTTGAGGACCTGGA 20
||||| ||| ||| ||| |||

RESULT 95
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: NO. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match 0.4%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 6.1e-02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454
||||| ||| ||| ||| |||

Db 33 CACGTTGAGGACCTGGA 17

RESULT 96
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: NO. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match 0.4%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 6.1e-02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454
||||| ||| ||| ||| |||

Db 4 CACGTTGAGGACCTGGA 20

RESULT 97
US-10-295-682-8/c
; Sequence 8, Application US/10295682
; Publication No. US200301000740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match 0.4%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 6.1e-02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454
||||| ||| ||| ||| |||

Db 33 CACGTTGAGGACCTGGA 17

RESULT 98
US-10-295-682-9
; Sequence 9, Application US/10295682
; Publication No. US200301000740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match 0.4%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 6.1e-02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454
||||| ||| ||| ||| |||

Db 4 CACGTTGAGGACCTGGA 20

RESULT 99
US-10-272-665-23
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POL
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483

```

; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      415 CAGCGAGGGCCATGGCT 431
      ||| ||||| |||||
Db      41 CAGCTGGGGCCAGGGCT 57

RESULT 100
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY      1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
      || ||||| ||||| |||||
Db      42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 101
US-10-273-321-23
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY      1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
      || ||||| ||||| |||||
Db      42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 102
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY      1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
      || ||||| ||||| |||||
Db      42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 103
US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; FILE REFERENCE: 24736-2033B
```

```

; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      415 CAGCGAGGGCCATGGCT 431
      ||| ||||| |||||
Db      41 CAGCTGGGGCCAGGGCT 57

RESULT 102
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY      1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
      || ||||| ||||| |||||
Db      42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 103
US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
```

```
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 415 CAGGCGAGGCCATGGCT 431
DB 41 CAGCTGGGGCCAGGGCT 57
```

RESULT 104

```
US-10-272-756-23/c
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
```

```
QY 1521 TGTGATCTTGTATCTTGTGCACTTGTGAAGTGTGTGTG 1561
DB 42 TGACGATGCCGTCAGGTACACCGTCCCCGGTAGTGGTG 2
```

RESULT 105

```
US-10-273-228-23
; Sequence 23, Application US/10273228
```

```
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 415 CAGGCGAGGCCATGGCT 431
DB 41 CAGCTGGGGCCAGGGCT 57
```

RESULT 106

```
US-10-273-228-23/c
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
```

```
QY 1521 TGTGATCTTGTATCTTGTGCACTTGTGAAGTGTGTGTG 1561
DB 42 TGACGATGCCGTCAGGTACACCGTCCCCGGTAGTGGTG 2
```

```
RESULT 107
US-10-281-727-2
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2
Query Match 0.4%; Score 10.4; DB 1; Length 36;
Best Local Similarity 70.0%; Pred. No. 7e+02;
Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 405 CTTCAGGTGCGAGCGGC 424
DB 1 CTGCCTGCGAGGAAACGC 20

RESULT 108
US-10-281-727-3/c
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3
Query Match 0.4%; Score 10.4; DB 1; Length 36;
Best Local Similarity 70.0%; Pred. No. 7e+02;
Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 405 CTTCAGGTGCGAGCGGC 424
DB 36 CTGCCTGCGAGGAAACGC 17

RESULT 109
US-10-109-498-5
; Sequence 5, Application US/10109498
```

```
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5
Query Match 0.4%; Score 10.2; DB 1; Length 35;
Best Local Similarity 80.0%; Pred. No. 7.7e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 73 GCTTCATCTGCACTG 87
DB 1 GCTCCGCTGCACTG 15

RESULT 110
US-10-109-498-6/c
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6
Query Match 0.4%; Score 10.2; DB 1; Length 35;
Best Local Similarity 80.0%; Pred. No. 7.7e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 73 GCTTCATCTGCACTG 87
DB 35 GCTCCGCTGCACTG 21

RESULT 111
US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US2003020247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
```

```
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match 0.4%; Score 10; DB 1; Length 54;
Best Local Similarity 61.5%; Pred. No. 8.3e+02;
Matches 16; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 394 AGAGTTGCTCTTCAGTGAGGC 419
Db 1 AGAGTCTCGTAACCCAGGAGGAGC 26

RESULT 112
US-10-017-122-4
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match 0.3%; Score 9.4; DB 1; Length 31;
Best Local Similarity 68.4%; Pred. No. 1.1e+03;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 131 TTCTGCTGTGTCATATG 149
Db 2 TCCTGCTGTCATATG 20

RESULT 113
US-09-951-121A-2
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```

```
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.3%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.8%; Pred. No. 1.2e+03;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1548 GAAGTGTGTGTGTGTGTGTG 1569
Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 114
US-09-951-121A-3/c
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.3%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.8%; Pred. No. 1.2e+03;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1548 GAAGTGTGTGTGTGTGTGTG 1569
Db 32 GAATTGTGGGGCGCGGTGTG 11

RESULT 115
US-10-295-682-2
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```



```

US-10-295-682-2
Query Match      0.3%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 1.2e+03;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1548 GAAGTGTGTGTGTGTGTGTGTG 1569
Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 116
US-10-295-682-3/c
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match      0.3%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 1.2e+03;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1548 GAAGTGTGTGTGTGTGTGTGTG 1569
Db 32 GAATTGTGGGGCGCGGTGTG 11

RESULT 117
US-09-803-810-8/c
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match      0.3%; Score 8.8; DB 1; Length 42;
Best Local Similarity 57.1%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 286 TCCTCCAGGAGCGAGGAGAGCGCT 313
Db 41 TCCTGAGGAGCTCCGTCCAGCAGCGCT 14

RESULT 118
US-10-298-330-8/c
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match      0.3%; Score 8.8; DB 1; Length 42;
Best Local Similarity 57.1%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 286 TCCTCCAGGAGCGAGGAGAGCGCT 313
Db 41 TCCTGAGGAGCTCCGTCCAGCAGCGCT 14

RESULT 119
US-09-951-121A-2/c
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match      0.3%; Score 8.6; DB 1; Length 34;
Best Local Similarity 54.8%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 177 CACTGTGTGTATCCCATCTCTTCTCTCAATT 207
Db 34 CCCTTGGGACACACCGCGCCCGCCCAATT 4

RESULT 120

```

US-09-951-121A-3
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.3%; Score 8.6; DB 1; Length 34;
Best Local Similarity 54.8%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
Qy 177 CACTGTGTTTACCCATCTCTTCTCCCAATT 207
Db 1 CCTTTGGGGCACACCGCGCCCCCACAATT 31

RESULT 121

US-10-295-682-2/c
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.3%; Score 8.6; DB 1; Length 34;
Best Local Similarity 54.8%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
Qy 177 CACTGTGTTTACCCATCTCTTCTCCCAATT 207
Db 34 CCTTTGGGGCACACCGCGCCCCCACAATT 4

RESULT 122

US-10-295-682-3
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3
Query Match 0.3%; Score 8.6; DB 1; Length 34;
Best Local Similarity 54.8%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
Qy 177 CACTGTGTTTACCCATCTCTTCTCCCAATT 207
Db 1 CCTTTGGGGCACACCGCGCCCCCACAATT 31

Search completed: August 9, 2004, 15:30:37
Job time : 36 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 15:31:08 ; Search time 4 seconds
(without alignments)
3.740 Million cell updates/sec

Title: us-10-664-775-1
Perfect score: 2715
Sequence: 1 ctgcaggaagagcgacagg.....ttgtaattctaggtgctgat 2715

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 4 seqs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database : rstdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES			
Result No.	Score	Query Match Length DB ID	Description
C 1	20.6	0.8 1201 1	AL531727 ACCESSION:AL531727
C 2	19.8	0.7 645 1	AL116939 ACCESSION:AL116939
C 3	18	0.7 1201 1	AL531727 ACCESSION:AL531727
C 4	17.2	0.6 609 1	AL099321 ACCESSION:AL099321
C 5	17.2	0.6 645 1	AL116939 ACCESSION:AL116939
C 6	17	0.6 300 1	AU099140 ACCESSION:AUC099140
C 7	16.3	0.6 609 1	AL099321 ACCESSION:AL099321
C 8	14	0.5 300 1	AUC099140 ACCESSION:AUC099140

ALIGNMENTS

RESULT 1
AL531727/c 1201 bp mRNA linear EST 23-MAY-2003
LOCUS
DEFINITION
AL531727 Homo sapiens PITAL LIVER Homo sapiens cDNA clone
CS0DM003Y101 5-PRIME, mRNA sequence.

ACCESSION
AL531727
VERSION
AL531727.2 GI:31069559
KEYWORDS
EST.
SOURCE
Homo sapiens (human)

ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1201)
Li W.B., Gruber C., Jessee J. and Polayes D.
Full-length cDNA libraries and normalization
Unpublished (2001)
JOURNAL
On Feb 13, 2001 this sequence version replaced gi:12795220.

CONTACT: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France

Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 7252.f For more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DM003AE01QP1&cluster=7252.f. Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Paraday Avenue Genoscope sequence ID : CS0DM003AE01QP1.

FEATURES
source

1. 1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DM003Y101"
/tissue_type="PITAL LIVER"
/dev_stage="fetal"
/clone_lib="Homo sapiens PITAL LIVER"
/notes="Organ: liver; Vector: pCMVSPORT 6; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

Query Match 0.8%; Score 20.6; DB 1; Length 1201;
Best Local Similarity 59.3%; Pred. No. 0.31;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATTGCTTTTATCTGCGAGACTTGTCTTTTGAATATGATTTCAATTTGG 934
DB 648 TTTCGCGCATTTCTTTTCTAGATAGTATTTTCCATGATATCACTGG 590

RESULT 2
AL116939/c
LOCUS

DEFINITION
AL116939 645 bp mRNA linear EST 02-SEP-1998
ue29q08.Y1 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1481822.5', similar to gb:M13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN) ; mRNA sequence.

ACCESSION
AL116939
VERSION
AL116939.1 GI:3517263

KEYWORDS
EST.
SOURCE
Mus musculus (house mouse)

ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
1 (bases 1 to 645)
Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T.,
Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M.,
Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B.,
Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and
Waterston, R.

AUTHORS
The WashU-HHMI Mouse EST Project
Unpublished (1996)

JOURNAL
COMMENT
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.

MGI:930178
Seq primer: custom primer used
High quality sequence stop: 483.

Location/Qualifiers
1. 645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1481822"

FEATURES
source

Email: mousestwatson.wustl.edu
 This clone is available royalty-free through LNL ; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 MGI:930865
 Fax: 314 286 1810

Seq primer: custom primer used
High quality sequence stop: 289.

FEATURES

source

1..609
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII (CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA was primed with an oligo(dT) primer [ATGTGGCTTTTCTTTTCTTTT]; double-stranded cDNA was ligated to a DraIII adaptor [TCGTGGCCTACTGG], digested and cloned into distinct DraIII sites of the pME18S-FL3 vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should be used to isolate the cDNA insert. Size selection was performed to exclude fragments <1.5kb. Library constructed by Dr. Sumio Sugano (University of Tokyo Institute of Medical Science). Custom primers for sequencing: 5' end primer CTCCTGCTCTAAAGACTGG and 3' end primer CGACCTGAGCTCGAGACA."

Query Match. 0.6%; Score 16.3; DB 1; Length 609;
Best Local Similarity 63.5%; Pred. No. 6.5;
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;
QY 602 GGGCTGCTCCCTTCTCCCTGCTGATTCCTAGGTGGGTGTAC-CACTGCTCTCTCTC 660
DB 209 GGGCTTCTGAAGATCTCCGGGCTCTCTCAAGAGGACACTGTTCTCTATTGACATCTCTC 150
QY 661 TCC 663
DB 149 TCC 147

RESULT 8

AU099140/c

LOCUS

DEFINITION AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HV112463, mRNA sequence.

ACCESSION

AU099140

VERSION

AU099140.1

KEYWORDS

EST.

SOURCE

Homo sapiens (human)

ORGANISM

Homo sapiens

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Contact: Yutaka Suzuki

Department of Virology

Institute of Medical Science, University of Tokyo

4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan

Email: ysuzuki@ims.u-tokyo.ac.jp

Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and

Sugano, S. Construction and characterization of a full

length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),

149-156 (1997).

FEATURES

source

1..300

/organism="Homo sapiens"

/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone_lib="Sugano Homo sapiens cDNA library"

Query Match 0.5%; Score 14; DB 1; Length 300;
Best Local Similarity 50.0%; Pred. No. 18;
Matches 35; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 324 CTCCTCTAGATGCTGGAGGCCCAATGATCATGTGTGTCAGTCCCTGGGTACAGGCATGG 383
DB 235 CTCCTGGGCTCTCTCGAAGGAGCACTGCTCTCTCTGCACTCCTCTCCAGGAGCCCG 176
QY 384 CCATGGCTCC 393
DB 175 CCGCAGCTCC 166

Search completed: August 9, 2004, 15:31:12
Job time : 4 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 15:32:59 ; Search time 1102 Seconds
(without alignments)
3.915 Million cell updates/sec

Title: us-10-664-775-2

Perfect score: 3572

Sequence: 1 gtcaggagggcgagtgag.....gcaacaacagcagaagctt 3572

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	39.4	1.1	289	1	ACCESSION:AR162089
2	39.4	1.1	289	1	ACCESSION:AR166614
3	37.6	1.1	1573	1	ACCESSION:BC040125
4	33.4	0.9	1671	1	ACCESSION:AY040345
5	30.8	0.9	1671	1	ACCESSION:AY040345
6	30.2	0.8	289	1	ACCESSION:AR162089
7	30.2	0.8	289	1	ACCESSION:AR166614
8	29.6	0.8	1792	1	ACCESSION:BC034377
9	28.8	0.8	1403	1	ACCESSION:BC009726
10	27.7	0.8	1843	1	ACCESSION:AR390799
11	27.7	0.8	1843	1	ACCESSION:AR411026
12	27.7	0.8	1843	1	ACCESSION:X02750
13	27.2	0.8	387	1	ACCESSION:AR263863
14	26.6	0.7	364	1	ACCESSION:AR425705
15	26.6	0.7	364	1	ACCESSION:BD121258
16	26.2	0.7	230	1	ACCESSION:AY022485
17	26.2	0.7	828	1	ACCESSION:E40571
18	25.8	0.7	829	1	ACCESSION:BC061135
19	25.6	0.7	2438	1	ACCESSION:107991
20	25.2	0.7	1869	1	ACCESSION:BC061149
21	25	0.7	882	1	ACCESSION:AX675583
22	24.9	0.7	364	1	ACCESSION:AR425705
23	24.9	0.7	364	1	ACCESSION:BD121258
24	24.8	0.7	227	1	ACCESSION:AY022941
25	24.8	0.7	251	1	ACCESSION:AY083553
26	24.8	0.7	873	1	ACCESSION:AY083553
27	24.8	0.7	2177	1	ACCESSION:E01075
28	24.6	0.7	352	1	ACCESSION:M57841
29	24.6	0.7	1332	1	ACCESSION:AF321182
30	24.6	0.7	1378	1	ACCESSION:AR410811
31	24.6	0.7	1378	1	ACCESSION:AX697671
32	24.6	0.7	1378	1	ACCESSION:BD075581
33	24.6	0.7	1378	1	ACCESSION:BD172441

34	24.6	0.7	1378	1	BD172760
35	24.6	0.7	1378	1	BD173079
36	24.6	0.7	1378	1	BD173398
37	24.6	0.7	1378	1	BD175432
38	24.6	0.7	1378	1	AY358936
39	24.6	0.7	1403	1	BC009726
40	24.6	0.7	1573	1	BC040125
41	23.8	0.7	813	1	PIGFXA
42	23.6	0.7	1580	1	AF318182
43	23.4	0.7	596	1	AX193364
44	23.4	0.7	1142	1	AR219285
45	23.4	0.7	1161	1	AX675581
46	23.4	0.7	1169	1	AR219284
47	23.4	0.7	1507	1	AX774765
48	23.4	0.7	1507	1	HUMFACX
49	23.4	0.7	1541	1	BC046125
50	23.4	0.7	1792	1	BC034377
51	23.2	0.6	429	1	AP459805S2
52	23.2	0.6	623	1	SHPFIXA
53	23	0.6	224	1	AY023240
54	23	0.6	244	1	HSB4901
55	23	0.6	873	1	HUMCFIX
56	23	0.6	1293	1	AP465275
57	23	0.6	2438	1	107991
58	22.8	0.6	264	1	BD180174
59	22.8	0.6	1373	1	BOVPBC
60	22.6	0.6	535	1	DLA6882
61	22.6	0.6	1416	1	AF465269
62	22.6	0.6	1722	1	AF515269
63	22.6	0.6	2177	1	E01075
64	22.4	0.6	186	1	AX310356
65	22.4	0.6	1302	1	AF465270
66	22.2	0.6	832	1	AF011900
67	22	0.6	534	1	AX527570
68	22	0.6	741	1	HUMMA
69	22	0.6	741	1	E01617
70	22	0.6	744	1	E09633
71	22	0.6	790	1	E15808
72	22	0.6	821	1	BC030238
73	22	0.6	853	1	HSTRPIV
74	21.8	0.6	121	1	AX265053
75	21.8	0.6	121	1	AX265054
76	21.8	0.6	121	1	AX265057
77	21.8	0.6	121	1	AX265058
78	21.8	0.6	170	1	HSMTOB3
79	21.8	0.6	227	1	AY023453
80	21.8	0.6	522	1	AX527564
81	21.8	0.6	603	1	BTTHRO
82	21.8	0.6	711	1	BD173590
83	21.8	0.6	1759	1	E01189
84	21.6	0.6	251	1	AY083553
85	21.6	0.6	375	1	AY179347
86	21.6	0.6	427	1	AX524284
87	21.6	0.6	427	1	AX553022
88	21.6	0.6	483	1	MUSBALB6
89	21.6	0.6	596	1	BV094002
90	21.6	0.6	139	1	MUSCP
91	21.6	0.6	1603	1	BC013896
92	21.6	0.6	1722	1	AF515269
93	21.6	0.6	6098	1	AX565990
94	21.4	0.6	172	1	AX814615
95	21.4	0.6	142	1	AX430737
96	21.4	0.6	243	1	AX028553
97	21.4	0.6	291	1	AX363229
98	21.4	0.6	352	1	HUMPS02
99	21.4	0.6	861	1	AF011352
100	21.4	0.6	1329	1	AF465274
101	21.4	0.6	1341	1	AF532184
102	21.2	0.6	1341	1	AF532184
103	21.2	0.6	505	1	AX263865
104	21.2	0.6	609	1	AX763043
105	21.2	0.6	888	1	AX360070
106	21.2	0.6	1130	1	AR234337
107	21.2	0.6	1166	1	AR221273

C 107	21.2	0.6	6098	1	AX565590	ACCESSION:AX565590	C 180	20.4	0.6	1386	1	I08112	ACCESSION:I08112
C 108	21	0.6	252	1	HSU29334	ACCESSION:U929334	C 181	20.4	0.6	1386	1	AR404692	ACCESSION:AR404692
C 109	21	0.6	255	1	HSU59442	ACCESSION:U59442	C 182	20.4	0.6	1386	1	AR404695	ACCESSION:AR404695
C 110	21	0.6	260	1	HUMHDP21A	ACCESSION:M84617	C 183	20.4	0.6	1386	1	AR404696	ACCESSION:AR404696
C 111	21	0.6	285	1	HUMHDP11I	ACCESSION:L00599	C 184	20.4	0.6	1386	1	AX044042	ACCESSION:AX044042
C 112	21	0.6	535	1	PA344566	ACCESSION:AF011901	C 185	20.4	0.6	1386	1	AX044043	ACCESSION:AX044043
C 113	21	0.6	836	1	AF011901	ACCESSION:AF011901	C 186	20.4	0.6	1386	1	AX149641	ACCESSION:AX149641
C 114	21	0.6	850	1	AX333366	ACCESSION:AX333366	C 187	20.4	0.6	1386	1	AX149643	ACCESSION:AX149643
C 115	21	0.6	850	1	HSTRY1VB	ACCESSION:X11345	C 188	20.4	0.6	1386	1	AX149646	ACCESSION:AX149646
C 116	21	0.6	933	1	AR253372	ACCESSION:AR253372	C 189	20.4	0.6	1386	1	AX077784	ACCESSION:AX077784
C 117	21	0.6	1416	1	AF465269	ACCESSION:AF465269	C 190	20.4	0.6	1386	1	AX212331	ACCESSION:AX212331
C 118	21	0.6	1551	1	AX147505	ACCESSION:AX147505	C 191	20.4	0.6	1386	1	AR070468	ACCESSION:AR070468
C 119	21	0.6	1850	1	MMU44795	ACCESSION:U44795	C 192	20.4	0.6	1386	1	BD246884	ACCESSION:BD246884
C 120	21	0.6	1869	1	BC061149	ACCESSION:BC061149	C 193	20.4	0.6	1386	1	AR404693	ACCESSION:AR404693
C 121	21	0.6	2078	1	AF272773	ACCESSION:AF272773	C 194	20.4	0.6	1386	1	AX044043	ACCESSION:AX044043
C 122	21	0.6	2422	1	AR030786	ACCESSION:AR030786	C 195	20.4	0.6	1386	1	AX149642	ACCESSION:AX149642
C 123	21	0.6	2422	1	AR045090	ACCESSION:AR045090	C 196	20.4	0.6	1386	1	AX149645	ACCESSION:AX149645
C 124	21	0.6	2422	1	AR052946	ACCESSION:AR052946	C 197	20.4	0.6	1386	1	AX207785	ACCESSION:AX207785
C 125	21	0.6	2422	1	AR122899	ACCESSION:AR122899	C 198	20.4	0.6	1386	1	AX207787	ACCESSION:AX207787
C 126	21	0.6	2422	1	AR127821	ACCESSION:AR127821	C 199	20.4	0.6	1386	1	AX212332	ACCESSION:AX212332
C 127	21	0.6	2483	1	E01076	ACCESSION:E01076	C 200	20.4	0.6	1386	1	BD246885	ACCESSION:BD246885
C 128	21	0.6	2483	1	I07990	ACCESSION:I07990	C 201	20.4	0.6	1386	1	AR404694	ACCESSION:AR404694
C 129	20.9	0.6	394	1	AX839180	ACCESSION:AX839180	C 202	20.4	0.6	1386	1	AX044044	ACCESSION:AX044044
C 130	20.8	0.6	252	1	I28675	ACCESSION:I28675	C 203	20.4	0.6	1386	1	AX207786	ACCESSION:AX207786
C 131	20.8	0.6	290	1	S55227	ACCESSION:S55227	C 204	20.4	0.6	1386	1	AX207788	ACCESSION:AX207788
C 132	20.8	0.6	323	1	BD076788	ACCESSION:BD076788	C 205	20.4	0.6	1386	1	AX212333	ACCESSION:AX212333
C 133	20.8	0.6	380	1	AX262154	ACCESSION:AX262154	C 206	20.4	0.6	1386	1	BD246886	ACCESSION:BD246886
C 134	20.8	0.6	400	1	AX262150	ACCESSION:AX262150	C 207	20.4	0.6	1386	1	AX044045	ACCESSION:AX044045
C 135	20.8	0.6	823	1	SHF1XA	ACCESSION:M62233	C 208	20.4	0.6	1386	1	AX212334	ACCESSION:AX212334
C 136	20.8	0.6	860	1	AF011898	ACCESSION:AF011898	C 209	20.4	0.6	1387	1	AR364387	ACCESSION:AR364387
C 137	20.8	0.6	1259	1	HUMPC7	ACCESSION:MI2712	C 210	20.4	0.6	1387	1	AR030786	ACCESSION:AR030786
C 138	20.8	0.6	1338	1	AX211659	ACCESSION:AX211659	C 211	20.4	0.6	2422	1	AR045090	ACCESSION:AR045090
C 139	20.8	0.6	1357	1	AX211661	ACCESSION:AX211661	C 212	20.4	0.6	2422	1	AR052946	ACCESSION:AR052946
C 140	20.8	0.6	1366	1	HUMPC	ACCESSION:K02059	C 213	20.4	0.6	2422	1	AR122899	ACCESSION:AR122899
C 141	20.8	0.6	1755	1	AR363767	ACCESSION:AR363767	C 214	20.4	0.6	2422	1	AR127821	ACCESSION:AR127821
C 142	20.8	0.6	1756	1	I05477	ACCESSION:I05477	C 215	20.4	0.6	2462	1	AR095304	ACCESSION:AR095304
C 143	20.6	0.6	228	1	AX886883	ACCESSION:AX886883	C 216	20.4	0.6	2462	1	AR103988	ACCESSION:AR103988
C 144	20.6	0.6	228	1	BD026293	ACCESSION:BD026293	C 217	20.4	0.6	2462	1	AX335083	ACCESSION:AX335083
C 145	20.6	0.6	312	1	AX661018	ACCESSION:AX661018	C 218	20.4	0.6	2462	1	AX049604	ACCESSION:AX049604
C 146	20.6	0.6	854	1	PVTRYP5IN	ACCESSION:X86369	C 219	20.4	0.6	2462	1	HUMFVII	ACCESSION:M13232
C 147	20.6	0.6	867	1	CMRECT	ACCESSION:X78490	C 220	20.4	0.6	2483	1	E01076	ACCESSION:E01076
C 148	20.6	0.6	1514	1	AF191307	ACCESSION:AF191307	C 221	20.4	0.6	2483	1	I07990	ACCESSION:I07990
C 149	20.6	0.6	1843	1	AR390799	ACCESSION:AR390799	C 222	20.2	0.6	240	1	HS88A12R	ACCESSION:Z63615
C 150	20.6	0.6	1843	1	AX411026	ACCESSION:AX411026	C 223	20.2	0.6	241	1	HS88A12P	ACCESSION:Z63614
C 151	20.6	0.6	1843	1	HSPTOC	ACCESSION:X02750	C 224	20.2	0.6	243	1	MACNAFAE	ACCESSION:L76725
C 152	20.4	0.6	121	1	AX265021	ACCESSION:AX265021	C 225	20.2	0.6	378	1	AB108823	ACCESSION:AB108823
C 153	20.4	0.6	121	1	AX265022	ACCESSION:AX265022	C 226	20.2	0.6	582	1	AY348554	ACCESSION:AY348554
C 154	20.4	0.6	121	1	AX265033	ACCESSION:AX265033	C 227	20.2	0.6	582	1	AY348553	ACCESSION:AY348553
C 155	20.4	0.6	121	1	AX265034	ACCESSION:AX265034	C 228	20.2	0.6	694	1	AB083690	ACCESSION:AB083690
C 156	20.4	0.6	121	1	AX265037	ACCESSION:AX265037	C 229	20.2	0.6	696	1	AB086852	ACCESSION:AB086852
C 157	20.4	0.6	121	1	AX265038	ACCESSION:AX265038	C 230	20.2	0.6	696	1	AB083693	ACCESSION:AB083693
C 158	20.4	0.6	121	1	AX265041	ACCESSION:AX265041	C 231	20.2	0.6	696	1	AB083695	ACCESSION:AB083695
C 159	20.4	0.6	121	1	AX265042	ACCESSION:AX265042	C 232	20.2	0.6	696	1	AB083696	ACCESSION:AB083696
C 160	20.4	0.6	121	1	AX265045	ACCESSION:AX265045	C 233	20.2	0.6	697	1	AB083694	ACCESSION:AB083694
C 161	20.4	0.6	121	1	AX265046	ACCESSION:AX265046	C 234	20.2	0.6	747	1	AY454079	ACCESSION:AY454079
C 162	20.4	0.6	121	1	AX265049	ACCESSION:AX265049	C 235	20.2	0.6	1341	1	AF532184	ACCESSION:AF532184
C 163	20.4	0.6	121	1	AX265050	ACCESSION:AX265050	C 236	20.2	0.6	1505	1	AX523898	ACCESSION:AX523898
C 164	20.4	0.6	160	1	AY254094	ACCESSION:AX254094	C 237	20.2	0.6	2462	1	AR095304	ACCESSION:AR095304
C 165	20.4	0.6	160	1	AY307359	ACCESSION:AY307359	C 238	20.2	0.6	2462	1	AR103988	ACCESSION:AR103988
C 166	20.4	0.6	160	1	AY307360	ACCESSION:AY307360	C 239	20.2	0.6	2462	1	AX335083	ACCESSION:AX335083
C 167	20.4	0.6	162	1	AY254095	ACCESSION:AX254095	C 240	20.2	0.6	2462	1	AX049604	ACCESSION:AX049604
C 168	20.4	0.6	196	1	HS2338514	ACCESSION:AJ238514	C 241	20.2	0.6	2462	1	HUMFVII	ACCESSION:M13232
C 169	20.4	0.6	199	1	S68634	ACCESSION:S68634	C 242	20	0.6	199	1	AX555170	ACCESSION:AX555170
C 170	20.4	0.6	315	1	AX040017	ACCESSION:AX040017	C 243	20	0.6	256	1	AF542508	ACCESSION:AF542508
C 171	20.4	0.6	334	1	BD071430	ACCESSION:BD071430	C 244	20	0.6	276	1	AF005089	ACCESSION:AF005089
C 172	20.4	0.6	394	1	AX814618	ACCESSION:AX814618	C 245	20	0.6	300	1	AR24808	ACCESSION:AR24808
C 173	20.4	0.6	414	1	SSU51135	ACCESSION:U51135	C 246	20	0.6	300	1	BD120361	ACCESSION:BD120361
C 174	20.4	0.6	855	1	AF011899	ACCESSION:AF011899	C 247	20	0.6	478	1	DO8CFVI	ACCESSION:D08CFVI
C 175	20.4	0.6	1326	1	AF465273	ACCESSION:AF465273	C 248	20	0.6	483	1	MUSBALB6	ACCESSION:D42755
C 176	20.4	0.6	1383	1	AX427734	ACCESSION:AX427734	C 249	20	0.6	488	1	AR263931	ACCESSION:AR263931
C 177	20.4	0.6	1386	1	AX149644	ACCESSION:AX149644	C 250	20	0.6	1129	1	AX464088	ACCESSION:AX464088
C 178	20.4	0.6	1386	1	BD246883	ACCESSION:BD246883							
C 179	20.4	0.6	1386	1	I06643	ACCESSION:I06643							

Matches 39; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 3235 TTTAATAAGTTTTTTTTTTTTTTTTTTTTTTTTTTAAAGAATGTCATCTTTGGGAAGTT 3290
 |||||
 Db 1380 TTTAATTTTTTTTTTTTTTTTTTTTTTTTTTTGGAGATAAATAATTTATTCGAATT 1325

RESULT 10
 AR390799/c AR390799 1843 bp DNA linear PAT 18-DEC-2003
 LOCUS Sequence 49 from patent US 6610906.
 DEFINITION AR390799
 ACCESSION AR390799
 VERSION AR390799.1 GI:40113146
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 1843)
 AUTHORS Kurachi, K. and Kurachi, S.
 TITLE Nucleotide sequences for gene regulation and methods of use thereof
 JOURNAL Patent: US 6610906-A 49 26-AUG-2003;
 FEATURES
 Location/Qualifiers
 1..1843
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.8%; Score 27.7; DB 1; Length 1843;
 Best Local Similarity 50.3%; Pred. No. 3.7;
 Matches 92; Conservative 0; Mismatches 88; Indels 3; Gaps 1;

QY 3225 GTTCATGCGCTTTAATAAGTTTTTTTTTTTTTTTTTTTTTTAAAGAATGTCATCTTTGT 3284
 |||||
 Db 1818 GTTTCGTTGTTGTTTTATT 1759

QY 3285 GAAGTTTGCACATGCTTTGACATAATTTAGGATATTTTGAATGTTTCATGATG 3344
 |||||
 Db 1758 CTTTTCATAACACAGAGTATCCCTCAACACACACAGCTTTAGACCCGCAAACTGG 1699

QY 3345 CTTTGTACTTGGCATTTTATTGAATTTAGATTTATGAATTTAGATCTTTTTTTGGG 3404
 |||||
 Db 1698 ATCTGCTCTCCCAACCCACAGAGT---TGCTCTAGGAGTTAAGATTCTATTCTAAGG 1642

QY 3405 CAT 3407
 |||||
 Db 1641 CAT 1639

RESULT 11
 AX411026/c AX411026 1843 bp DNA linear PAT 14-JUN-2002
 LOCUS Sequence 3673 from Patent WO0229103.
 DEFINITION AX411026
 ACCESSION AX411026
 VERSION AX411026.1 GI:21443731
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Alvares, C., Horne, D., Peres-da-Silva, S. and Vockley, J.G.
 TITLE Gene expression profiles in liver cancer
 JOURNAL Patent: WO 0229103-A 3673 11-APR-2002;
 FEATURES
 GENE LOGIC INC (US)
 Location/Qualifiers
 1..1843
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 /note="EMBL/GenBank Accession No. X02750"

Query Match 0.8%; Score 27.7; DB 1; Length 1843;
 Best Local Similarity 50.3%; Pred. No. 3.7;
 Matches 92; Conservative 0; Mismatches 88; Indels 3; Gaps 1;

QY 3225 GTTCATGCGCTTTAATAAGTTTTTTTTTTTTTTTTTTTTTTAAAGAATGTCATCTTTGT 3284
 |||||
 Db 1818 GTTTCGTTGTTGTTTTATT 1759

QY 3285 GAAGTTTGCACATGCTTTGACATAATTTAGGATATTTTGAATGTTTCATGATG 3344
 |||||
 Db 1758 CTTTTCATAACACAGAGTATCCCTCAACACACACAGCTTTAGACCCGCAAACTGG 1699

QY 3345 CTTTGTACTTGGCATTTTATTGAATTTAGATTTATGAATTTAGATCTTTTTTTGGG 3404
 |||||
 Db 1698 ATCTGCTCTCCCAACCCACAGAGT---TGCTCTAGGAGTTAAGATTCTATTCTAAGG 1642

QY 3405 CAT 3407
 |||||
 Db 1641 CAT 1639

RESULT 12
 HSPTOTC/c HSPTOTC 1843 bp mRNA linear PRI 05-APR-1995
 LOCUS Human liver mRNA for protein C.
 DEFINITION X02750
 ACCESSION X02750
 VERSION X02750.1 GI:35689
 KEYWORDS protein C; signal peptide.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1843)
 AUTHORS Beckmann, R.J., Schmidt, R.J., Santerre, R.F., Plutsky, J.,
 Crabtree, G.R. and Long, G.L.
 TITLE The structure and evolution of a 461 amino acid human protein C
 precursor and its messenger RNA, based upon the DNA sequence of
 cloned human liver cDNAs
 JOURNAL Nucleic Acids Res. 13 (14), 5233-5247 (1985)
 MEDLINE 85269639
 PUBMED 2991859
 COMMENT Data kindly reviewed (27-MAR-1986) by G. Long.
 FEATURES
 Location/Qualifiers
 1..1843
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 98..1483
 /note="unnamed protein product; protein C precursor"
 /codon_start=1
 /protein_id="CAA26528.1"
 /db_xref="GI:763120"
 /db_xref="GOA:P04070"
 /translation="MWQLTSLLLFVATWIGTTPAPLDSVFSSESAHQVLRIRKRA
 SFLELRHSLEECIEIECDFEAEKEIFQVDDTLAFWSKHVDGQCLVPLEHPCA
 SLCCGHGTCIDGIGSFCDRCSEGRFCQREVSLNCLDNGGCTHYCLEVGRRC
 SCAPGYKLGDDLLQCHPAVKFCGRPWKMEKRSKHLKRDTEQDQVDPRLDGKMT
 RGDSPQVLLDSKKKACGAVLIHPSWLTAACHWDSKKLLVGLGYDLRRWKW
 ELDDLKEVFPHPNYSKSTDDIALHLAQATLSQTIVPICLPDSGLAEELNQAG
 QETLVTWGTHSRSEKRNRTFVLNFKIPVPHNECESEVMSNVSNMLCAGILG
 DRQACEGSGGPMVASPHGTWFLVGLVSGEGCGLLHNYGVYTKVSRVLDLTHGHIR
 DKEAPQKSWAP"
 98..196
 /note="signal peptide (aa 42 to 10)"
 197..223
 /note="propeptide (aa 9 to 1)"
 224..688
 /note="light chain (aa 1-155)"
 224..358
 /note="gamma carboxylation domain (aa 1-45)"
 359..496
 /note="EGF-domain I (aa 46-91)"
 497..634
 /note="EGF-domain II (aa 92-137)"
 653..730
 /note="EGF-domain III (aa 138-196)"

COMMENT Contact: MGC help desk
Email: cgapbs-remail.nih.gov
Tissue Procurement: Dr. Michael Brownstein
cDNA Library Preparation: Michael Brownstein / Ted Usdin
Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: <http://www-shgc.stanford.edu>
Contact: (Dickson, Mark) mcdexapil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/ILNL at: <http://image.llnl.gov>
Series: IPAL Plate: 53 Row: n Column: 1
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 6753805.
Location/Qualifiers
1. .1869
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clones="MGC:74281 IMAGE:30305571"
/tissue_type="Liver, mouse"
/clone_lib="NIH MGC_177"
/lab_host="DH10B"
/note="Vector: pDNR-LIB"
1. .1869
/gene="F7"
/note="synonyms: FVII, mfVII"
/db_xref="LocusID:14068"
/db_xref="MGI:109325"
10. .1350
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAH61149.1"
/db_xref="GI:38511702"
/db_xref="LocusID:14068"
/translation="MVFQAGLLLLCFLLQLQGLPFAVITOEAEHGVLRHQRANS
LLELWPGSIRENECNEQFEEAREIKPRTKQFWIVSDQDCASNPQNGTTC
QHLKSVFCFLDFEGNRCBKNEOLICANENGDCDOYCRDHVGFKRTCSHEDYT
LOPEVCKPKVEYPCGRIPVVEKRNSSRQGRIVGVNVCPCGECPCAVLKINGLL
CGVLLDARWIVTAAHCFEDNIRYMGNTVMGEHDFSEKGDQVRVTVQVIMPDXYI
RGKINHDLALRLHRPVTFTDYVPLCPKSFENTLARIKRSVSGWQLLDGRGAT
ALELMSIEVPLMTQDCLEAKHSNTPKTENNFCAGYMDGDKACKGSGGPHATH
YHGTWYLTGVVSWGEGCAIGHIVYTRVSQYIDWLVRHMDSKLQGVFLPLI"
79. .264
/note="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues"
/db_xref="CDD:smart00069"
268. .378
/note="EGF_CA; Region: Calcium-binding EGF-like domain,
present in a large number of membrane-bound and
extracellular (mostly animal) proteins. Many of these
proteins require calcium for their biological function and
calcium-binding sites have been found to be located at the
N-terminus of particular EGF-like domains"
/db_xref="CDD:cd00054"
589. .1302
/note="Tryp SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 0.7%; Score 25.2; DB 1; Length 1869;
Best Local Similarity 78.9%; Pred. No.16;
Matches 30; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3245 TTTTITTTTTTTTTTTTTTTTTTTTTTAAAGATGTCATCTTT 3282
DB 1861 TTTTITTTTTTTTTTTTTTTTTTTTGACATGTTTCATT 1824

RESULT 21

AX675583/c
LOCUS AX675583 892 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 33 from Patent WO02055704.
ACCESSION AX675583
VERSION AX675583.1 GI:29333358
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Spytek, K.A., Zhong, M., Gangoli, E.A., Burgess, C.E., Patturajan, M.,
Vernet, C.A., Taylor, S., Thernev, V.T., Miller, C.E., Guo, X.,
Balogh, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J.,
Malyanar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1. .882
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 25; DB 1; Length 882;
Best Local Similarity 50.0%; Pred. No.15;
Matches 86; Conservative 0; Mismatches 80; Indels 6; Gaps 1;

QY 2560 GGCCACCTGATCAGAAAGCTGACTCAGTGGAAAAGACCTGATGCTGGAGGGATGGG 2619
DB 450 GGCCACATGACCCAGCCAGTGCAGTGGAGGCGCTTGGGAGAGGCGTGGC 391
QY 2620 GCACAGGAGAGGGGACACAGAGGATGAGTGCCTGATGGCATCTACTCTGATG 2679
DB 390 TGCAGGAGGCGAGATGGCGGATGATGCGGAGAGGGTGTGCTGCTGATTTGGAG 331
QY 2680 G-----AGTCAGTCTGGGTGAACCTCTCTGGAGTTGGTATGACACAGGAGG 2725
DB 330 GAGTGCATGTGCGCCCTGGAGGCCCTCTCTGGAGTAGTCTGGGTGGGGGATG 279

RESULT 22
LOCUS AR425705/c
DEFINITION Sequence 17202 from patent US 6639063.
ACCESSION AR425705
VERSION AR425705.1 GI:40180815
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 364)
AUTHORS Edwards, J.-B.D.M., Jobert, S. and Giordano, J.-Y.
TITLE EST's and encoded human proteins
JOURNAL Patent: US 6639063-A 17202 28-OCT-2003;
FEATURES
source
1. .364
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 24.9; DB 1; Length 364;
Best Local Similarity 12.4%; Pred. No.13;
Matches 32; Conservative 117; Mismatches 108; Indels 5; Gaps 1;

QY 2490 CATTCGAAGGAGATCAGCCCTGGGATTTCTTTGAAGGAATGATCTAAAGTAAAT 2549
DB 258 SWNTGYVRKSWWVGTRSCCTSKKXKKGSTSSKYASTSGKSKYKSTCRKSKCRYSA 199
QY 2550 CCAGTACTTTGGCCCACTGATCAGAAGAGCTACTCAGTGGAAAAGACCTGATGCTGGG 2609


```

FEATURES
  source
    1..251
      /location=Qualifiers
      /organism="Macaca mulatta"
      /mol_type="genomic DNA"
      /db_xref="taxon:9544"
      <1..>251
      /gene="GAP43"
      <1..>251
      /gene="GAP43"
      /product="growth associated protein 43"
      <1..>251
      /gene="GAP43"

  3'UTR
    Query Match
      Best Local Similarity 0.7%; Score 24.8; DB 1; Length 251;
      Matches 68; Conservative 0; Mismatches 72; Indels 0; Gaps 0;

  3172 TTAATTTTGAATAGCTCTTTAAATCAATTCTTTGATACAGCTTCAGTTCTAT 3231
  Db 190 TCATCAATACCAAACTGGCATACACACACCAAAATGTTAAGCCAC 131

  3232 GGCTTTAATAAGTTTTTTTTTTTTTTTTTTTTTAAAGATGTCATCTTTGTAAGTTT 3291
  Qy 130 TGTGTGACTTGGGATCTTCCTGCTTTTTTTTTTTTCTTTTCTTTTTTTTAAATGT 71
  Db 3292 TGCAATGCTTTGACATA 3311
  Qy 70 TTGCCACACAGAGAGATA 51

RESULT 26
HUMCFIX
LOCUS HUMCFIX 873 bp mRNA linear PRI 01-NOV-1994
DEFINITION Human coagulation factor IX mRNA, partial cds.
ACCESSION M35672
VERSION M35672.1 GI:180287
KEYWORDS coagulation factor IX; serine protease.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
  1 (bases 1 to 873)
  Jagaeswaran,P., Lavelle,D.E., Kaul,R., Mohandas,T. and
  Warren,S.T.
  Isolation and characterization of human factor IX cDNA:
  identification of Tag I polymorphism and regional assignment
  Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)
  84300526
  PUBMED 6089357
  COMMENT Original source text: Human adult liver, cDNA to mRNA.
  FEATURES
    source
      1..873
        /organism="Homo sapiens"
        /mol_type="mRNA"
        /db_xref="taxon:9606"
        /map="Xq26.3-q27.1"
      1..873
        /gene="P9"
        <1..>873
        /gene="P9"
        /note="coagulation factor IX"
        /codon_start=1
        /protein_id="AAA51981.1"
        /db_xref="GI:180288"
        /db_xref="GDB:G00-119-900"
        /translation="NANKILNPKRYNGKLEEFVQGNLRECEMEKCSFEAREVPE
        NTEETBEWKYVGDQCESNCLNGSKDDINSYECMCPGPEGNCELDVTCNIK
        NRGCEQCKNADKNKVCSTGCEYRLAENQKSCPEAPVFPFCGRVSVSQTSLTRAETV
        FPDVYVNSTEATILNITQTSFNDFTRVGVEDAKPGQFPWQVNLGVDAFCG
        GSIVNEKWIIVTAACVCTGVKIVTVAGEHNLEETEHTEQENRIVRIIPHNYNAANK
        YNHDIALLELDEPLV"

  gene
    CDS
      Query Match
        Best Local Similarity 0.7%; Score 24.8; DB 1; Length 873;
        Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

FEATURES
  source
    1..2177
      /product="factor VII peptide" FT
      polyA_signal 2106..2111
      FT exon <1..12
      FT 3'UTR 1129..<2177.
      Location/Qualifiers
        1..2177
          /organism="unidentified"
          /mol_type="genomic RNA"
          /db_xref="taxon:32644"

  Query Match
    Best Local Similarity 0.7%; Score 24.8; DB 1; Length 2177;
    Matches 32; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

  3245 TTTTCTCTAATAAAATCCAGTCCTT 3040
  Db 534 CATCACTCAAGCACCCCAATCATT 557

RESULT 27
E01075/c
LOCUS E01075/c 2177 bp RNA linear PAT 29-SEP-1997
DEFINITION cDNA sequence of factor VII fragment.
ACCESSION E01075
VERSION E01075.1 GI:2169334
KEYWORDS JP 1987000283-A/1.
SOURCE unidentified
ORGANISM unidentified
  1 (bases 1 to 2177)
  Furederitsuku,E.H., Maaku,J.M., Shiyaroon,J.B., Kiyasuriin,E.B.,
  Maagaretuto,W.I., Richiyasado,J.U. and Chiyaaruzu,E.G.
  DNA ENCODING FACTOR VII
  Patent: JP 1987000283-A 1 06-JAN-1987;
  HEMOUIENETITSUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD,
  TOYO SODA MFG CO LTD
  OS Human (Homo sapiens)
  PN JP 1987000283-A/1
  PD 06-JAN-1987
  PF 16-APR-1986 JP 1986087861
  PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI
  FUREDERITSUKU ESU HAAGEN, MAAKU JIEI MARII,
  PI SHIYAARON JIEI BAZUBII,
  PI KIIYASURIIN ERU BAKUNAA, MAAGARETSUTO WAI INSUREE, PI
  RICHIIYAADO JII UTSUDOBERRII, CHIIYAARUZU ERU GUREI PC
  C12N15/00,A61K37/465,C12N5/00,C12N9/50,(C12N9/50,C12R1:91); CC
  strandedness: Double;
  CC topology: Linear;
  CC hypothetical: No;
  CC anti-sense: No;
  CC *source: tissue type=liver;
  CC *source: library=cDNA library, lambdaagt11 cDNA library; CC
  *source: clone=lambdaVII 2115, lambdaVII 1923; FH Key
  Location/Qualifiers
    FH
      FT CDS 13..1128
      FT /product="factor VII peptide" FT
      polyA_signal 2106..2111
      FT exon <1..12
      FT 3'UTR 1129..<2177.
      Location/Qualifiers
        1..2177
          /organism="unidentified"
          /mol_type="genomic RNA"
          /db_xref="taxon:32644"

  3245 TTTTCTCTAATAAAATCCAGTCCTTCTTCTGTAAG 3288
  Db 2166 TTTTCTCTAATAAAATCCAGTCCTTCTTCTGTAAG 3288

RESULT 28
HUMPS02/c
LOCUS HUMPS02 352 bp DNA linear PRI 10-JAN-1995
DEFINITION Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION M57841 J02917

```

```

VERSION M57841.1 GI:190535
KEYWORDS S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT 2 of 14
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 352)
AUTHORS Schmidel,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
TITLE Organization of the human protein S genes
JOURNAL Biochemistry 29 (34), 7845-7852 (1990)
MEDLINE 9109444
PUBMED 2148110
COMMENT Original source text: Human liver DNA.
FEATURES
    Location/Qualifiers
        1..352
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /map="3p11-q11.2"
            /tissue_type="liver"
            join(M57840.1:837..912,135..181)
            /gene="PS-alpha"
            order(M57840.1:913..1014,1..134)
            /gene="PROS1"
            /number=1
            135..252
            /gene="PROS1"
            /note="G00-120-721"
            /number=2

sig_peptide
    intron
    exon

Query Match 0.7%; Score 24.6; DB 1; Length 352;
Best Local Similarity 51.4%; Pred. No. 16;
Matches 57; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

QY 2991 ACTTAAATGCCTATTTTATTCAGTTTCTTATGATTTCTTAAATCCAGTCCTCTTTTAA 3050
Db 125 ACAATCAGTTTATATGAAATTAATCATTTTCCATGTAATATATTTGTTTATTAAACA 66
QY 3051 AAAGACTTAAATTTATTAATTTCTTTAGTGGTTTACCAGTCTTTTCAG 3101
Db 65 TAAGAGTTAAATCATTTTTCGCTATGATGATGATGATGATGATGATGATGATGATGAT 15

RESULT 29
AF321182
LOCUS AF321182
DEFINITION Homo sapiens serine protease PRS22 mRNA, complete cds.
ACCESSION AF321182
VERSION AF321182.1 GI:11386012
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1332)
AUTHORS Wong,G.W., Yasuda,S., Madhusudhan,M.S., Li,L., Yang,Y.,
Kralis,S.A., Sali,A. and Stevens,R.L.
TITLE Human trypsin epsilon (PRS22), a new member of the chromosome
16p13.3 family of human serine proteases expressed in airway
epithelial cells
JOURNAL J. Biol. Chem. 276 (52), 49169-49182 (2001)
MEDLINE 21623609
PUBMED 11602603
REFERENCE 2 (bases 1 to 1332)
AUTHORS Wong,G.W.
TITLE Direct Submission
JOURNAL Submitted (14-NOV-2000) Rheumatology, Immunology and Allergy,
Brigham and Women's Hospital, Harvard Medical School, 1 Jimmy Fund
Way, Boston, MA 02115, USA
FEATURES
    Location/Qualifiers
        1..1332
            /organism="Homo sapiens"

```

```

/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosomes="16"
/map="16p13.3"
/tissue_type="pancreas"
18..971
/codon_start=1
/product="serine protease PRS22"
/protein_id="AAG35070.1"
/db_xref="GI:11386013"
/translation="MVVSCAPPALGGCGLTFTSLILLASTAILNAARIPVPPACCKP
QQLNRVGGEDSTDSEWPNVISQKNGTHHCAGSLTTSRWVITAAHCFKDLNKKYLF
SVLLGAKQLGNPGRSQKVGVAWPHVPVSWKEGACADIALVRLERSIQFSERVLP
CUPDASIHUPPNTHCMISGWSIQGVPLPHPQTQLKVLPIIDSEVSHLYWRGAGQ
GPITDMLCAGYLEGRDACLGSGLMCDQVGDGAWLLAGLISWEGGCAERNRPGVYI
SLSHRSWVEKIVQVQLRGAQGGALRAPSGSGGAARS"

Query Match 0.7%; Score 24.6; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 21;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTAAATGCCTATTTTATGATTTTCTTAAATCCAGTCCTTGT 3042
Db 1237 TTTTGTGTATATAAATGTTAATGATTTTATAGGATTTTGTAACTCCCTGCCCATATCTT 1296
QY 3043 TTTTTTAAAAGACTTTAAAATTTAATTTCTCT 3077
Db 1297 ATTATTCCTCAATTTCAATAAATTATTATTCT 1331

RESULT 30
AF410811
LOCUS AF410811
DEFINITION Sequence 262 from patent US 6635468.
ACCESSION AF410811
VERSION AF410811.1 GI:40162311
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1378)
AUTHORS Ashkenazi,A., Botstein,D., Desnoyers,L., Eaton,D.L., Ferrara,N.,
Filvaroff,E., Fong,S., Gao,W.-Q., Gexber,H., Gerritsen,M.E.,
Goddard,A., Godowski,P.J., Grimaldi,J.C., Gurney,A.L., Hillan,K.J.,
Kljavin,I.J., Mather,J.P., Pan,J., Paoni,N.F., Roy,M.A.,
Stewart,T.A., Tumas,D., Williams,P.M. and Wood,W.I.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: US 6635468-A 262 21-OCT-2003;
FEATURES
    Location/Qualifiers
        1..1378
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTAAATGCCTATTTTATGATTTTCTTAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGGATTTTGTAACTCCCTGCCCATATCTT 1331
QY 3043 TTTTTTAAAAGACTTTAAAATTTAATTTCTCT 3077
Db 1332 ATTATTCCTCAATTTCAATAAATTATTATTCT 1366

RESULT 31
AX697671
LOCUS AX697671
DEFINITION Sequence 262 from Patent WO0104311.
ACCESSION AX697671
VERSION AX697671.1 GI:29498757

```

```

KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Ashkenazi,A.J., Botstein,D., Desnovers,L., Eaton,D.L., Ferrara,N.,
              Filvaroff,E., Fong,S., Gao,W.Q., Gerber,H., Gerritsen,M.E.,
              Goddard,A., Godowski,P.J., Grimaldi,C.J., Gurney,A.L., Hillan,K.J.,
              Kljavin,I.J., Mather,J.P., Pan,J., Paoni,N.F., Roy,M.A.,
              Stewart,I.A., Tumas,D., Williams,P.W. and Wood,W.I.
TITLE        Secreted and transmembrane polypeptides and nucleic acids encoding
              the same
JOURNAL      Patent: WO 0104311-A 262 18-JAN-2001;
              Genentech Inc. (US)
FEATURES     Location/Qualifiers
              source
              1..1378
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
              0.7%; Score 24.6; DB 1; Length 1378;
              Best Local Similarity 53.7%; Pred. No. 22;
              Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTAATAAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGTATTTGTAACTCCGCCACATATCTT 1331
Qy 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077
Db 1332 ATTATTCCTCAATTTCAATAAATTTATTTCT 1366

RESULT 32
BD075581
LOCUS      BD075581      1378 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Secretory and transmembrane polypeptide and nucleic acid encoding
              the same.
ACCESSION  BD075581.1 GI:22621184
VERSION    JP 2001516580-A/214.
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1378)
AUTHORS    Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Chen,J. and Yuan,J.
TITLE      Secretory and transmembrane polypeptide and nucleic acid encoding
              the same
JOURNAL    Patent: JP 2001516580-A 214 02-OCT-2001;
              GENENTECH INC
COMMENT    OS Homo sapiens (human)
              PN JP 2001516580-A/214
              PD 02-OCT-2001
              PR 16-SEP-1998 JP 2000511867
              PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
              17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
              17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
              18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
              17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
              21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
              24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
              24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
              24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
              27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063128 PR
              28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063542 PR
              28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063541 PR
              28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
              29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
              29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
              29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR

```

```

29-OCT-1997 US 60/064103,31-OCT-1997 US 60/063870 PR
03-NOV-1997 US 60/064248,07-NOV-1997 US 60/064809 PR
12-NOV-1997 US 60/065186,17-NOV-1997 US 60/065846 PR
18-NOV-1997 US 60/065693,21-NOV-1997 US 60/066130 PR
21-NOV-1997 US 60/066364,24-NOV-1997 US 60/066772 PR
24-NOV-1997 US 60/066466,24-NOV-1997 US 60/066770 PR
24-NOV-1997 US 60/066511,24-NOV-1997 US 60/066453 PR
25-NOV-1997 US 60/066840
PI WILLIAM I WOOD,AUSTIN L GURNEY,AUDLEY GODDARD,DIANE PENICA, PI
JEAN CHEN
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K14/705,C07K16/18,C07K16/28,C07K19/00,
PC C12N1/19,
PC C12N1/21,C12N5/10,C12P21/02,C12P21/08,C12Q1/02//(C12P21/08, PC
C12R1/91),
PC C12N15/00,C12N5/00
CC Secretory and transmembrane polypeptide and nucleic acid CC
PH Key encoding the same
FT source 1..1378
FT /organism="Homo sapiens (human)"
FEATURES     Location/Qualifiers
              source
              1..1378
              /organism="Homo sapiens"
              /mol_type="genomic DNA"
              /db_xref="taxon:9606"
              0.7%; Score 24.6; DB 1; Length 1378;
              Best Local Similarity 53.7%; Pred. No. 22;
              Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTAATAAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGTATTTGTAACTCCGCCACATATCTT 1331
Qy 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077
Db 1332 ATTATTCCTCAATTTCAATAAATTTATTTCT 1366

RESULT 33
BD172441
LOCUS      BD172441      1378 bp      DNA      linear      PAT 18-FEB-2003
DEFINITION Secreted and transmembrane polypeptides and nucleic acids encoding
              the same.
ACCESSION  BD172441.1 GI:28413741
VERSION    JP 200223786-A/214.
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1378)
AUTHORS    Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
              Yuan,J.
TITLE      Secreted and transmembrane polypeptides and nucleic acids encoding
              the same
JOURNAL    Patent: JP 200223786-A 214 13-AUG-2002;
              GENENTECH INC
COMMENT    OS Homo sapiens (human)
              PN JP 200223786-A/214
              PD 13-AUG-2002
              PR 18-DEC-2001 JP 2001385135
              PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
              17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
              17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
              18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
              17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
              21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
              24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
              24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
              24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR

```

```

27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063543,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
17-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02,C12P21/08,(C12P21/02,C12R1:19),(C12P21/02,C12R1:91), PC
(C12P21/02,C12R1:645),C12N15/00,C12N5/00
CC Secreted and transmembrane polypeptides and nucleic CC acids
encoding the same
FH Key Location/Qualifiers
FT source 1..1378
/organism="Homo sapiens (human)".
FEATURES
source
Location/Qualifiers
1..1378
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGATATAATGTTAATGATTTTATAGGATTTGTAACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAATTTATTAATTTCTCT 3077
Db 1332 ATTATTCCTCCAATTCATAAATATTATTCT 1366
RESULT 34
BD172760
LOCUS
DEFINITION
Secreted and transmembrane polypeptides and nucleic acids encoding
the same.
ACCESSION
BD172760
VERSION
BD172760.1 GI:28414064
KEYWORDS
JP 2002238586-A/214.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1378)
AUTHORS
Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J.
TITLE
Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL
GENENTECH INC
Patent: JP 2002238586-A 214 27-AUG-2002;
COMMENT
OS Homo sapiens (human)
PN JP 2002238586-A/214
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385205
FR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR

```

```

17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
21-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
17-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02,C12P21/08,(C12N1/19,C12R1:645),(C12N1/21,C12R1:19),
(C12N5/10,C12R1:91),(C12P21/02,C12R1:91),(C12P21/02,C12R1:645), PC
(C12P21/02,C12R1:19),(C12P21/08,C12R1:91),C12N15/00,C12N5/00, PC
(C12N5/00,C12R1:91)
CC Secreted and transmembrane polypeptides and nucleic CC acids
encoding the same
FH Key Location/Qualifiers
FT source 1..1378
/organism="Homo sapiens (human)".
FEATURES
source
Location/Qualifiers
1..1378
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGATATAATGTTAATGATTTTATAGGATTTGTAACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAATTTATTAATTTCTCT 3077
Db 1332 ATTATTCCTCCAATTCATAAATATTATTCT 1366
RESULT 35
BD173079
LOCUS
DEFINITION
Secreted and transmembrane polypeptides and nucleic acids encoding
the same.
ACCESSION
BD173079
VERSION
BD173079.1 GI:28414388
KEYWORDS
JP 2002238587-A/214.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1378)
AUTHORS
Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J.
TITLE
Secreted and transmembrane polypeptides and nucleic acids encoding
the same

```

JOURNAL Patent: JP 2002238587-A 214 27-AUG-2002;
GENENTECH INC
OS Homo sapiens (human)
PN JP 2002238587-A/214
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385248
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR
18-SEP-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063128 PR
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
27-OCT-1997 US 60/063349, 28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064218 PR
29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09, C07K14/47, C07K16/18, C12N1/19, C12N1/21, C12N5/10, PC
C12N15/02,
C12P21/02, C12P21/08, C12P21/02, C12R1:91), (C12P21/02, C12R1:19), PC
(C12P21/02, C12R1:645), C12N15/00, C12N5/00, C12N15/00 CC Secreted
and transmembrane polypeptides and nucleic CC acids encoding the
same Key Location/Qualifiers
FH Key 1. .1378
FT source /organism='Homo sapiens (human)'.
FEATURES
source
1. .1378
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGCACCTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042
DB 1272 TTTTGTGATATAAATGTTAATGATTTTATAGGATTTTGAACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077
DB 1332 ATTTATCTCCCAATTCATTAATTTATTTCT 1366
RESULT 36
BD173398
LOCUS 1378 bp DNA linear PAT 18-FEB-2003
DEFINITION Secreted and transmembrane polypeptides and nucleic acids encoding the same.
ACCESSION BD173398
VERSION BD173398.1 GI:28414709
KEYWORDS JP 2002238588-A/214.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1378)
Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and
Yuan, J.
Secreted and transmembrane polypeptides and nucleic acids encoding
the same
Patent: JP 2002238588-A 214 27-AUG-2002;
GENENTECH INC
OS Homo sapiens (human)
PN JP 2002238588-A/214
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385315
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
18-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
24-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063128 PR
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
27-OCT-1997 US 60/063349, 28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064218 PR
29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09, C07K14/435, C07K16/18, C07K19/00, C12N1/19, C12N1/21, PC
C12N5/10,
C12P21/02, C12P21/08, C12N1/19, C12R1:645), (C12N1/21, C12R1:19),
PC (C12N5/10, C12R1:91), C12N15/00, C12N5/00, C12N5/00, C12R1:91) CC
Secreted and transmembrane polypeptides and nucleic CC acids
encoding the same
FH Key 1. .1378
FT source /organism='Homo sapiens (human)'.
FEATURES
source
1. .1378
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGCACCTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042
DB 1272 TTTTGTGATATAAATGTTAATGATTTTATAGGATTTTGAACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077
DB 1332 ATTTATCTCCCAATTCATTAATTTATTTCT 1366
RESULT 37
BD175432
LOCUS 1378 bp DNA linear PAT 18-MAR-2003
DEFINITION Secretory and transmembrane polypeptide and nucleic acid encoding

the same.
 BD175432
 BD175432.1 GI:29121130
 JP 2002253280-A/214
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and
 Yuan, J.
 Secretory and transmembrane polypeptide and nucleic acid encoding
 the same
 Patent: JP 2002253280-A 214 10-SEP-2002;
 GENENTECH INC
 OS Homo sapiens (human)
 PN JP 2002253280-A/214
 PD 10-SEP-2002 JP 2001385319
 PF 18-DEC-2001 JP 2001385319
 PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
 17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR
 17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
 17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
 18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR
 17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
 21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
 24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR
 24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR
 27-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
 27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
 28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR
 28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR
 28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR
 29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
 29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063435 PR
 29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/063735 PR
 31-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR
 07-NOV-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR
 17-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR
 21-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR
 24-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR
 24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066466 PR
 24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR
 24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI
 WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
 JIAN ZHENG,
 PI JEAN YUAN
 PC C12N15/09, A61K45/00, A61P1/00, A61P13/12, A61P17/00, A61P17/06, PC
 A61P25/00,
 PC A61P25/16, A61P25/28, A61P31/12, A61P35/00, C07K14/47, C07K16/18,
 PC C07K19/00,
 PC C12N1/19, C12N1/21, C12N5/10//A61K38/00, A61K39/395, A61K39/395,
 PC A61P43/00,
 PC C12P1/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19), (C12N5/10,
 PC C12R1:91),
 PC C12N15/00, C12N5/00, A61K37/02, (C12N5/00, C12R1:91) CC
 Secretory and transmembrane polypeptide and nucleic acid CC
 encoding the same
 FH Key Location/Qualifiers
 FT source 1..1378
 FT Location/Qualifiers
 1..1378
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

1272 TTTTGTATATAAATGTTAATGATTTTATAGTATTTTAACTGCTGCCACATATCTT 1331
 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077
 1332 ATTATCTCCCAATTCATTAATTAATTTATCT 1366

RESULT 38
 AY358396
 LOCUS 1378 bp mRNA linear PRI 03-OCT-2003
 DEFINITION Homo sapiens clone DNA43318 PRSS22 (UNQ302) mRNA, partial cds.
 VERSION AY358396.1 GI:37181916
 KEYWORDS FLI CDNA.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J.,
 Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B.,
 Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E.,
 Heldens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S.,
 Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C.,
 Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V.,
 Stinson, J., Vagts, A., Vandien, R., Watanabe, C., Wiedand, D., Woods, K.,
 Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z.,
 Goddard, A., Wood, W.I. and Godowski, P.
 The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
 Effort to Identify Novel Human Secreted and Transmembrane Proteins:
 A Bioinformatics Assessment
 Genome Res. 13 (10), 2265-2270 (2003)
 JOURNAL
 PUBMED 12975309
 REFERENCE 2 (bases 1 to 1378)
 AUTHORS Clark, H.F.
 TITLE Direct Submission
 JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
 Inc., 1 DNA Way, South San Francisco, CA 94080, USA
 FEATURES
 source
 1..1378
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="DNA43318"
 <1..1378
 /locus_tag="UNQ302"
 <1..1006
 /locus_tag="UNQ302"
 /note="PRO343"
 /codon_start=2
 /product="PRSS22"
 /protein_id="AAQ88762.1"
 /db_xref="GI:37181917"
 /translation="HRPGLSPACSPAPPVMSGAPPALGGCGCLGFTSLLILAST
 AILNAARIPVPACPKQQLNRVGGDSTSEWFIWISIQKHGTHHCAGSLTSSRW
 IYAAHCKDNLNPKYLFVLLGAWQLGNPGRSGKVGVAVWEPHPVYKMGKACADIA
 IYLRVLSQFSEVLPICLPDASIHLPNTHWISGWSIQDVPHPHPIQKLKVP
 IYDSEVCSHLYWRGAGQPIEDMLCAGYLEGRDACLDGSGPLMCOVDGAWLLAGI
 ISWGEGCAERNRPVYISLSAHSRWEXIVQGVQLRGRAGGGLRAIPSGSGAARS
 "

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
 Best Local Similarity 53.7%; Pred. No. 22;
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 2983 TCTATTTACTTTAATTCACCTATTTTATGATTTTCTAATAAATCCAGTCTTGT 3042
 1272 TTTTGTATATAAATGTTAATGATTTTATAGTATTTTAACTGCTGCCACATATCTT 1331
 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077
 1332 ATTATCTCCCAATTCATTAATTAATTTATCT 1366


```

/feature="PRSS22"
/feature="synonyms: BSSP-4, MGC9599, SP001LA, hbSSP-4"
/db_xref="locusID:64063"
39..992
/codon_start=1
/product="protease, serine, 22"
/protein_id="AAH09726.1"
/db_xref="GI:16307275"
/db_xref="GI:16307275"
/translation="MVVSGAPALGGGCLGTFSTLLASTALLNAARIPVPACGKP
QQLNRVGGEDSTSEWPIVSIQKNGTHHCAGSLTGRWVITAAHCFADNUNKPYLF
SYLLAGWQLNGPSSQKQVAVPHVPSYKWEKACADIALVRLERSIQFSEVLPFI
CLPDASIHLPNTHCWSIGVSIQDQVPLPHQPTLQKUPFIIDSEVSHLWRGAGQ
GPITDMLCAGYLEGEDACIGSGPLMCOVDGAWLLAGIISWEGGCAERNRPVGYI
SLSAHSRWEKIVQVQLRGAQGGGALRAPSGSGAARS"
misc_feature
186..902
/notes="Tryp_SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 0.7%; Score 24.6; DB 1; Length 1403;
Best Local Similarity 53.7%; Pident 51; Mismatches 44; Indels 0; Gaps 0;
Matches 51; Conservative 0;

QY 2983 TCATTTTACTTTAATGCACTTTATTTTATTTGATTTTCTAATAAATCCAGTCCTTCT 3042
DB 1253 TTTTGTGTATATAATGTTAATGATTTTATAGGTATTTGTAACCTGCCACATATCTT 1312
QY 3043 TTTTAAAAAGACTTTAAAAATTTAATTTCTCT 3077
DB 1313 ATTATTCCTCAATTTCAATAAATTTATTTCT 1347

RESULT 40
LOCUS BC040125 1573 bp mRNA linear PRI 26-NOV-2002
DEFINITION Homo sapiens, similar to coagulation factor X, clone IMAGE:5764698,
mRNA.
ACCESSION BC040125
VERSION BC040125.1 GI:25455627
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 1573)
AUTHORS Strausberg,R.
TITLE Direct Submission
JOURNAL Submitted (22-NOV-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
Email: cgapbs@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
http://www.systemsbio.org
Contact: amadan@systemsbiology.org
Anup Madan, Jessica Fahney, Erin Helton, Mark Kettman, Anuradha
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAK Plate: 84 Row: m Column: 9
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 9961350.

FEATURES
source
1..1573
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

```

```

BC009726 1403 bp mRNA linear PRI 12-NOV-2003
LOCUS IMAGE:3899480, complete cds.
ACCESSION BC009726
VERSION BC009726.1 GI:16307274
KEYWORDS MGC.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 1403)
AUTHORS Strausberg,R.L., Feingold,B.A., Grouse,L.H., Derge,J.G.,
Klauser,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Mariani,K., Farmer,A.A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
Carninci,P., Prange,C., Raha,S.S., Iqbal,N.A., Peters,G.J.,
Aramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,
McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Fahney,J., Helton,E., Kettman,M., Madan,A., Rodriguez,S.,
Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smailus,D.E.,
Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
12477932
2 (bases 1 to 1403)
AUTHORS Strausberg,R.
TITLE Direct Submission
JOURNAL Submitted (29-JUN-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
Email: cgapbs@mail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www.shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAK Plate: 14 Row: 1 Column: 15
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 21614535.

FEATURES
source
1..1403
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:9599 IMAGE:3899480"
/tissue_type="Pancreas, epithelioid carcinoma"
/clone_lib="NIH_MGC_70"
/lab_host="DH10B"
/notes="Vector: pCMV-SPORT6"
1..1403

```

gene


```

FEATURES
Curagen Corporation (US)
Location/Qualifiers
1..1161
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match          0.7%; Score 23.4; DB 1; Length 1161;
Best Local Similarity 49.4%; Pred.No.42;
Matches      85; Conservative    0; Mismatches   81; Indels     6; Gaps     1;

QY      2560  GCCCACCTGATCAGAGACCTCACTCACTGGAAAGACCCTCATGTCTGGAGGATTGGG 2619
|||||

```

Qy
2620 GGCAGGAGGAGGAGGAGCGACAGAGGATGAGATGCTGGATGGCATCTACTGCTCGATG 2679
|||||
678 TGCAGGAGGCAGATGGGCCGATGTAGCGGAGAGGTGATGGGTCTCTCAGATTGGAG 619
Db

Db 618 GAGTCGAATGCGCCCTGGGAGCCCTCTCGGAGGTAGCTGGGTGGGGGATG 567

RESULT 46
LOCUS AR219284/c
DEFINITION Sequence 7 from patent US 6420157.
ACCESSION AR219284
VERSION AR219284.1 GI:23320254
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE	AUTHORS	TITLE
1 (bases 1 to 1169)	Darrow A., Qi, J. and Andrade-Grodon, P.	Zymogen activation system

FEATURES	Location/Qualifiers
source	1..1169
	/organism="unknown"
	/mol_type="genomic DNA"
Query Match	0.7%; Score 23.4; DB 1; Length 1169;
Best Local Similarity	49.4%; Pred. No. 42;
Matches	85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;
QY	2560 GGCCACCTGATCAGAAAGACTGACTCCTCTGGAAAGACCCCTGATGCTGGAGGAGTGGG 2619

	Qy	Db
2620	GGCAGGAGGAAGGCGACGACAGGATGATGGCTGGATGGCATCTACTCTCGATG	504
2679		445

QY	2680	G-----ACGTGAGTCTGGGTGAACTCCTGGAGTCTGGTGATGCACAGGGAGG	2725
DB	444	GAGTGCAATGTCGCCCTGGGAGCCCTCCTGGAGGTAGCTGGGGTGGGGGATG	393
RESULT	47		
AX774765/c			
LOCUS	AX774765	1507 bp	DNA
DEFINITION	Sequence 81 from Patent WO03038129.		linear
ACCESSION	AX774765		
VERSION	AX774765.1	GI:32486281	
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
	1	Raponi, M.	

Methods for assessing and treating leukemia
Patent: WO 03038129-A 81 08-MAY-2003;
Ortho-Clinical Diagnostics, Inc. (US)

Query Match 0.7%; Score 23.4; DB 1; Length 1507;
Best Local Similarity 81.8%; Pred. No. 44;
Matches 27; Conservative 0; Mismatches 6; Indels 0

```
misc_feature  
1004..1060  
/note="putative VECTOR sequence Bacteriophage lambda  
(J02459): putative"  
/gene="F10"
```

Query Match 0.7%; Score 23.4; DB 1; Length 1507;
Best Local Similarity 81.8%; Pred. No. 44;
Matches 27; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

[illegible]

Qy

```
/lab_host="DH10B"
/note="vector: pCMV-SPORT6"
1..1541
/gene="F10"
/note="synonyms: FX, FXA"
/db_xref="LocusID:2159"
/db_xref="MIM:227600"
39..1595
/codon_start=1
/product="coagulation factor X precursor"
/protein_id="AAH46125.1"
/db_xref="GI:28374356"
/db_xref="LocusID:2159"
/translation="MGRLHVLISASLAGLLIGSLFIRRECAANILARVTRANSF
LEEMKGLRECEHETCSYBEAREVETSDKTFNFWNKIDGQCCTSCQMGKCK
DGLGEYTCLEGEFGNKLFTKRLSLDNGCDQCFBEEQNSVCARGYFLADN
KACITPGCPYCGTLEPRKRSVAQATSSGEAPDSITWPKYDAALDPTENFDLL
DFNQTQPERGNNTIRIVGQECDECPWQALLINEEGFCGGTILSFYILTAAH
CLYAKRKFVRGVRVQEGGEAVHEVVIKHNFTKTYDFDIARLRLKTPTF
RMVYAPACLPRDAESTLMTQKTVIGSGFGRTHKGRQSTRLKMLEVPVYDANSCKL
SSSELIQNMFACADYTKQEDACQDGGSGGPHVTRKDTYFVTGIVSWGECARCKGYG
IYTKVAFKMLIDRSMKIRGLFKASHPAVITSSPLK"
111..293
/note="GLA; Region: Domain containing Gla
(gamma-carboxylglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
318..401
/note="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
738..1424
/note="Tryp SPc; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"

Query Match 0.7%; Score 23.4; DB 1; Length 1541;
Best Local Similarity 81.8%; Pred. No. 44;
Matches 27; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3245 TTTTITTTTTTTTTTTTTTTTAAAGATGTCAT 3277
|||||
Db 1539 TTTTITTTTTTTTTTTTTTTTGGTGGGAT 1507

RESULT 50
BC034377 1792 bp mRNA linear PRI 12-NOV-2003
LOCUS Homo sapiens protein C (inactivator of coagulation factors Va and
DEFINITION VIIa), mRNA (CDNA clone MGC:34565 IMAGE:5188604), complete cds.
ACCESSION BC034377
VERSION BC034377.1 GI:21707770
KEYWORDS MGC.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 1792)
Strausberg,R.I., Feingold,E.A., Grouse,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusik,K., Farmer,A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.P., Casavant,T.L.,
Scheetz,T.E., Brownstein,M.J., Ustin,T.B., Toshiyuki,S.,
Carninci,P., Frange,C., Raha,S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,
```

McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Morley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Fahey, J., Helton, E., Kettman, M., Madan, A., Rodrigues, S.,
Bouffard, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
Sanczarek, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smallos, D.E.,
Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.,
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
2 (bases 1 to 1792)
Strausberg, R.
Direct Submission
Submitted (02-JUL-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgabs@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Baylor College of Medicine Human Genome
Sequencing Center
Center code: BCM-HGSC
Web site: <http://www.hgsc.bcm.tmc.edu/cdna/>
Contact: angbcm.tmc.edu
Gunaratne, P.H., Garcia, A.M., Lu, X., Hulyk, S.W., Lounseged, H.,
Kowis, C.R., Sneed, A.J., Martin, R.G., Muzny, D.M., Nanavati,
A.N., Gibbs, R.A.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAK Plate: 50 Row: h Column: 4
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 4506114.

FEATURES
Location/Qualifiers
1..1792
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:34565 IMAGE:5188604"
/tissue_type="Colon, Kidney, Stomach, adult, whole pooled"
/clone_lib="NIH MGC_116"
/lab_host="DH10B"
/notes="Vector: pCMV-SPORT6"
1..1792
/genes="PROC"
/db_xref="LocusID:5624"
/db_xref="MIM:176860"
56..1441
/codon_start=1
/product="protein C (inactivator of coagulation factors Va
and VIIa)"
/protein_id="AAH34377.1"
/db_xref="GI:21707771"
/db_xref="LocusID:5624"
/translation="MWQLTSLLLVATWGISCTPAPLDSVFSSSEHRAHOVLIRKREAN
SLIELRHSLSRECEIEECDEEAKEIFQNVDDTLAFWSKVDGQCLVLEHPCA
SUCCGHGTCDIGSFSCDGRGFCOREVFLNCSLDNGGCTHYCLEEVGMRC
SCAPYKIGDDLQCHPAVKFGPRGEMKXKSHKRDTEQDQDPRLDIGKMT
RGDSQPWVLLDSKKKACGAVLIHPSWLVTAACHMCDKSLVLDGPRLDIGKMT
EQLDITKEVHPVNSKSTNDIALHIAQAPATISQITVPCLPDGLAEELNQAQ
OETLVGMGVHSSRKEAKRNFVLIKIPVPHNECSVMNSVSNMLCAGTIG
DRDACEGSGGPMVASFTGTLVLVSWGEGCLLHNYGYTKVSRVLDVHGHIR
DKRAPKSWAP"
125..316
/note="GLA; Region: Domain containing Gla

QY 1690 AACATCTATTCTGCTTTATTGACTATGCAAAAGCGCTTGTGCTGTGGGGTGCACATTA 174
 Db 181 ATTGGATATGGCTAGCTAGTGGCTGGGGAAAGTCTTCAAAAGGCGACCGCTAC 240
 QY 1750 ACTGTGAAAATTTCTGAAAG 1769
 Db 241 AATCTTCAGTACCTTAAAG 260
 RESULT 52
 SHPFIKA 823 bp mRNA linear MAM 27-APR-1993
 LOCUS Sheep factor IX mRNA, partial cds.
 DEFINITION M26233
 ACCESSION M26233.1 GI:165878
 VERSION factor IX.
 KEYWORDS Ovis aries (sheep)
 SOURCE Ovis aries
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 Bovidae; Caprinae; Ovis.
 1 (bases 1 to 823)
 SARKAR,G., KOBERL,D.D. and SOMMER,S.S.
 TITLE Direct sequencing of the activation peptide and the catalytic
 domain of the factor IX gene in six species
 JOURNAL Genomics 6 (1), 133-143 (1990)
 MEDLINE 90152675
 PUBMED 2302354
 COMMENT Original source text: Sheep liver, cDNA to mRNA.
 Draft entry and computer-readable sequence for [1] kindly provided
 by G.Sarkar, 18-JUL-1989.
 FEATURES
 source
 1..823
 /organism="Ovis aries"
 /mol_type="mRNA"
 /db_xref="taxon:9940"
 <1..>823
 /note="factor IX"
 /codon_start=1
 /protein_id="AAA31520.1"
 /db_xref="GI:552419"
 /translation="RASVLHTSKLTRAETISNNYENSSEABIIWNVVTSNQSF
 DFNRVGGEDAAAGQFPWVLLHGEITAFCGSIVNEKVVTAACHCKEFGVKITVVG
 EYNTKPEPTQKRVIRAIPIYGHYNASINKYSHDIALLEDELPLNSLYVTPICIA
 RVTNIFLKFQGYGVGWRGVRNGRSASILQYLVLDRTATCLRSTFTIYNHMF
 AGYHGGKDCSCQDSGPHVTEVGTGTFLTGISWGECAMKGYIYTKVSRVEY"
 Query Match 0.6%; Score 23.2; DB 1; Length 823;
 Best Local Similarity 54.8%; Pred.No.44;
 Matches 46; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
 QY 2957 GACTTGTATTCTCAATATTACTTATCTATCTATTCTTAATTCGACTTATTTTATGA 3016
 Db 45 GACTATTTTTCATATGAAGCTAATGAAATCTCTGAGCTGAATAATTGGGATTA 104
 QY 3017 TTTTTCATAAAATCCAGTCCTT 3040
 Db 105 CGTCACTCAAGCAATCAATCATT 128
 RESULT 53
 AY023240
 LOCUS Oryza sativa microsatellite MRG5565 containing (GGA)X8, genomic
 DEFINITION sequence.
 ACCESSION AY023240
 VERSION AY023240
 KEYWORDS AY023240.1 GI:12706456
 SOURCE Oryza sativa
 ORGANISM Oryza sativa
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.

Query Match 0.6%; Score 23; DB 1; Length 244;
 Best Local Similarity 60.3%; Pred. No. 37;
 Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 2691 GGGTCAACTCCTGGAGTGGTGATGACACAGGAGGCGCTCTCTGCGCGGATTCATCGGGT 2750
 DB 67 GGGCGACCCGGCGCGTACGTGGGGATGGGGAGTCTGTGACCTGCGCCCGGCGCGGGT 8

QY 2751 CAC 2753
 DB 7 CAC 5

RESULT 55
 HUMCFIX/C
 LOCUS HUMCFIX 873 bp mRNA linear PRI 01-NOV-1994
 DEFINITION Human coagulation factor IX mRNA, partial cds.
 ACCESSION M35672
 VERSION M35672.1 GI:180287
 KEYWORDS coagulation factor IX; serine protease.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 873)
 Jagadeeswaran,P., Lavelle,D.E., Kaul,R., Mohandas,T. and Warren,S.T.
 Isolation and characterization of human factor IX cDNA: identification of Tag I polymorphism and regional assignment Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)

MEDLINE
 6089357
 COMMENT Original source text: Human adult liver, cDNA to mRNA.
 FEATURES
 source
 1..873
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /map="Xq26.3-q27.1"
 1..873
 /gene="F9"
 <1..>873
 /gene="F9"
 /note="coagulation factor IX"
 /codon_start=1
 /protein_id="AAAS1981.1"
 /db_xref="GI:180288"
 /translation="NANKILNRPKNRYNSGKLEFVQGNLERECMEEKSCFEAREYVE
 NTRCTPEFKQVDDQDCESNPCLNGGSKDINSVEQWCPFGKNCGLDVTCKIK
 NRCRQEPKSNADNKVCSCTGEGYLAENCKSDCEPAVPFCGRVSYSQTSKLTRAFTV
 PPDVYNSTAEATLIDNITOSTQSFNDFTRVVGGEDAKPGQFPMQVILNGKVDACFG
 PSVYNKEIVYTAHCVGTVGKLTIVVAGEHNIEETHTQKRVIRILPHNNYNAALNK
 YNHDLALLEDEPLV"

gene
 CDS

Query Match 0.6%; Score 23; DB 1; Length 873;
 Best Local Similarity 45.0%; Pred. No. 50;
 Matches 86; Conservative 0; Mismatches 105; Indels 0; Gaps 0;

QY 2827 AAAATAGTAATTTCATATGATTCAAAATATTTCATATGTTGGTAGATAATAAGAT 2886
 DB 851 AGAAGGCAATGCAAGTTGTACTTTAATAGTCGATTGTGGTAGGAATA 792

QY 2887 TTTCAAATGATTATTTATCTTTGATTTTTCTCTACTTATTTAATTTTGGATTTTAAC 2946
 DB 791 ATTCAATACATTTTCGGTTTGGCTGTGTATCTTCTCTCAATATTATGTTCACT 732

QY 2947 TTTCTCAATGACTTGTTATTTCAATATTACTTATCTATTTTACTTTAATGCACTTA 3006
 DB 731 GCGCAACTGTAATTTTAAACACGAGTTCAACACAGTGGCGACAGTTCAATCCATTTT 672
 Y 3007 TTTTATTGAT 3017

Db 671 TCATTACGAT 661

RESULT 56
AF465275/c
LOCUS
DEFINITION
TAKIFUGU RUBRIPES COAGULATION FACTOR VIIc PRECURSOR, mRNA, COMPLETE CDS.
ACCESSION
AF465275
VERSION
AF465275.1 GI:28194021
KEYWORDS
SOURCE
ORGANISM
Takifugu rubripes (Fugu rubripes)
Takifugu rubripes
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Perciformes; Tetraodontiformes; Tetraodontidae; Tetraodontidae; Takifugu.

REFERENCE
AUTHORS
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G., Tuddenham, E.G.D. and McVey, J.H.
TITLE
Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL
Unpublished
REFERENCE
AUTHORS
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
TITLE
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences Centre, The Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK
JOURNAL

FEATURES
source
LOCUS
BD180174
DEFINITION
Highly thermophilic bacterium-derived protein and gene encoding it.
ACCESSION
BD180174
VERSION
BD180174.1 GI:30791092
KEYWORDS
JP 2002325574-A/665.
SOURCE
Thermus thermophilus
ORGANISM
Thermus thermophilus
Bacteria; Deinococcus-Thermus; Deinococci; Thermaceae; Thermus.

REFERENCE
AUTHORS
Kuranitsu, N. and Yokoyama, S.
TITLE
Highly thermophilic bacterium-derived protein and gene encoding it
JOURNAL
Patent: JP 2002325574-A 665 12-NOV-2002;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH
COMMENT
OS Thermus thermophilus
PN JP 2002325574-A/665
PD 12-NOV-2002
PF 23-FEB-2001 JP 2001116171
PI NARUKI KURAMITSU, SHIGEYUKI YOKOYAMA
PC C12N15/09, C12N15/09, C07K14/195, C12N1/15, C12N1/19, C12N1/21, PC C12N5/10,
PC C12N9/88, C12P21/02, C12P21/01, C12N15/09, C12R1/01, C12R1/01,
PC C12P21/02, C12R1/01, C12N15/00, C12N15/00, C12N15/00, C12N15/00,
CC Highly thermophilic bacterium-derived protein and gene CC encoding it

PH Key Location/Qualifiers
FT CDS Location/Qualifiers
FEATURES
source
1..264
/organism="Thermus thermophilus"
/mol_type="genomic DNA"
/db_xref="taxon:274"

Query Match 0.6%; Score 22.8; DB 1; Length 264;
Best Local Similarity 54.9%; Pred. No. 42;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 4 AGGAAGCGCGCAGTGAAGAGAGTACCTACCTCGTCCAGGTAGGAGAGTACTGCTC 63
|||
Db 26 AGGAAGCGGTGCAAGAGGTTGGGTACCGGCGCTTCGCCAAGAGAGGCGCTGAGCTCG 85
|||
QY 64 GCTTTGCTGAGCAGCGCGTAAA 85
|||

Query Match 0.6%; Score 23; DB 1; Length 1293;
Best Local Similarity 49.6%; Pred. No. 54;
Matches 59; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 171 CATACAGCAGAAACTAGTCAATCAATCACTAGGACACAGCCTTGCTTCACTCAA 230
|||
Db 160 CAAACAGGAATATTAGCCGCTCGAGTCGATGCGAGACAGCTTGCCCTCGGCTTTTCCA 101
|||

QY 231 TGAATAAGCATGCCGCTGGGGCAACCCAGATGAGTATGCTGAGAGATCT 289
|||
Db 100 TAAATACTCCCGCTCCCGAACCAGAGCATCTAGGACCGTATGATGAGAGTTT 42
|||

RESULT 57
I07991
LOCUS
DEFINITION
Sequence 6 from Patent EP 0200421.
ACCESSION
I07991
VERSION
I07991.1 GI:589297

Db 86 GCCTTCGGCTACGCCGAGAA 107

RESULT 59
BOVPRC/c
LOCUS BOVPRC Bovine protein C mRNA. 1373 bp mRNA linear MAM 27-APR-1993
DEFINITION K02435.1 GI:163486
ACCESSION autoprothrombin IIA; protein C; serine protease.
VERSION Bos taurus (ccw)
KEYWORDS Bos taurus
SOURCE Bos taurus
ORGANISM Bos taurus

REFERENCE
AUTHORS Long, G.L., Belagaje, R.M. and MacGillivray, R.T.
TITLE Cloning and sequencing of liver cDNA coding for bovine protein C
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)
MEDLINE 85014826
PUBMED 6091100

COMMENT
Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and pBC-7.
The sequence reported in [1] included homopolymeric tails on the 5' and 3' ends (not shown here).

FEATURES
source
1..1373
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
<1..1370
/note="protein C prepropeptide"
/codon_start=3
/protein_id="AAA30695.1"
/db_xref="GI:163487"

CDS
1..1370
/translation="TSLLLFTVITWGISSTPAPDSVFSSQRAHVLIRKRANSFLE
ELRPNVRECEVEEPEAREIFONTEDTMAFWSYSDGQCEPRSGSPCDLPC
GRGKIDGLGFRCDCAEGWGRFLHEVRSNCSAENGCAHYCMEEGRHRCSCAP
GYRLEDHQLCVSKVTPFCGLKEMEKRTKLRDITNOVDKQDLPRLVDGQACW
GESPWQVLLSKKLVCCAVLIHVSWLVTHAGLDSRKKLIVRLGSDMARWESWV
DLDIKEVLIHNYTSDNDIALLRAPATLSQITVPICLPSGSESRKLTGVGE
TVWTGWRDRETKRNTFLVFIKVPVVPYNACVHAKENKISENMLCAGILGDRAC
EGDSGGPMVTFRTGTFWLVGLVSWGEGGRLNYGVYTKVSRYLDTWYGHKAQEAFL
ESQVP"

sig_peptide
1..86
/note="protein C signal peptide"
mat_peptide
117..581
/product="protein C light chain"
mat_peptide
588..1367
/product="protein C inactive heavy chain"
mat_peptide
630..1367
/product="protein C active heavy chain"

Query Match 0.6%; Score 22.8; DB 1; Length 1373;
Best Local Similarity 56.8%; Pred. No. 61;
Matches 42; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

Qy 2651 GATGCTGGTGGCTACTGCTGATGACGTGAGCTGGTGGTGAACCTCCTGGAGTGG 2710
Db 84 GTGCTGCTGGAGACACTGAGTCAGGAGGAGCTGGTGGTGAATTCCTCCAGATGG 25

Qy 2711 TCATGACAGGAGG 2724
Db 24 TCACGAACAGTAAG 11

RESULT 60
DLA6882
LOCUS DLA6882 535 bp mRNA linear VRT 12-OCT-1998
DEFINITION DLA6882 Dicotylarchus labrax mRNA for trypsin, partial.
ACCESSION AJ006882
VERSION AJ006882.1 GI:3228220
KEYWORDS trypsin.

Dicotylarchus labrax (European sea bass)
Dicentrarchus labrax
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percormorpha; Perciformes;
Percoidae; Moronidae; Dicentrarchus.
1
Peres, A., Zambonino Infante, J.L. and Cahu, C.L.
Dietary regulation of activities and mRNA levels of trypsin and
amylase in sea bass (Dicentrarchus labrax) larvae
Fish Physiol. Biochem. 19, 145-152 (1998)
2 (bases 1 to 535)
Zambonino Infante, J.L.
Direct Submission
Submitted (11-JUN-1998) Zambonino Infante J.L., Unite Mixte
Inra-Ifremer de Nutrition des Poissons, Ifremer, BP 70, 29280
Plouzane, FRANCE
Location/Qualifiers
1..535
/organism="Dicentrarchus labrax"
/mol_type="mRNA"
/db_xref="taxon:113489"
/dev_stage="larvae"
<1..535
/EC_number="3.4.21.4"
/codon_start=1
/product="trypsin"
/protein_id="CAA07315.1"
/db_xref="GI:3242120"
/db_xref="GOA:O93594"
/db_xref="SPTREMBL:O93594"
/translation="QVLSNGYHFCGSLNWNVVAASAHYKSRVEVLGHEHNRVT
ENTEQFISRRVIRHPRYSYINIDNDIMLIKSKPATLNQYVQPVALPSCAPAGTMC
TVSGNGTMSADRNLKQLCLNIPILSFKDCNSYPMITDAFCAGYLEGGKDCSCQ
DSGGPVVCGSELQGVSW"

Query Match 0.6%; Score 22.6; DB 1; Length 535;
Best Local Similarity 52.7%; Pred. No. 56;
Matches 49; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 881 AAGAGCTGAGTGTGACGGTCTCTATGACACCTTCTTAGAATTAACACCA 940
Db 355 AAGCTGAGTGTGACCTCCATCTCTCTCAAGATTGTGACAACTCCTACCT 414

Qy 941 AAAAGATGCTCTCTCAATTATAGGGGACTGGA 973
Db 415 GGCATGATCACTGATGCTATGTTCTGGCTGGA 447

RESULT 61
AF465269
LOCUS AF465269.1 1416 bp mRNA linear VRT 02-FEB-2003
DEFINITION Gallus gallus coagulation factor IX precursor (F9) mRNA, complete cds.
ACCESSION AF465269
VERSION AF465269.1 GI:28194009
KEYWORDS Gallus gallus (chicken)
SOURCE Gallus gallus
ORGANISM Gallus gallus

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 1416)
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
2 (bases 1 to 1416)
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith

FEATURES
Source
Campus, Du Cane Road, London W12 0NN, UK
1. .1416
Location/Qualifiers
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1. .1416
/gene="p9"
1. .1416
/gene="p9"
/EC_number="3.4.21.22"
/function="converts factor X to its active form in the presence of Ca++ ions, phospholipids, and factor VIIa"
/note="vitamin K dependent serine protease; Christmas factor; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"
/codon_start=1
/product="coagulation factor IX precursor"
/protein_id="AA033364.1"
/db_xref="GI:28194010"
/translation="MAKIPILILFLCLFLAFLGAESTVFIENKEASTVLSRTRGNSNR LDELIPGLERECIEKCSFEAREVFENTKTEFWFKIYIDQOCNSNPKNGAVCK DGVSVECMCPGVGRCEIDSTCATKNGCEHPCRHDTPOKAVCSGASGKLEHDK KSKPAVPVPCGRIITAPEMRGKVITENTIERWNIATDEGDADEALDITEPPPT TSAAPKIVPITNTRVGVGVDSVKGGLPQVHLVDSRGLGFCGGSILNEKVVTA HCLPEGDNVAVAGYNTKEDDHTQRQVVKILPYPTNTRNKHNDIALLEDQP LTFNSYVTPICIGSDFNLLSGFTVSGWMLYGRSAIVLQVLTVPFVDRVTC LKSTSTLHNSFCAGYAGGDKTCGDSGGPYNSIGETWFLTGVTWSGECAPKG YGIVTKVAKYVKEWIEETRLT"
Query Match 0.6%; Score 22.6; DB 1; Length 1416;
Best Local Similarity 55.8%; Pred. No. 69;
Matches 43; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
QY 1461 CATGGAAGAAGAAATCAAAAGCAAAATGGCTGCTGGGAGGCGCTTACAAATAGCTGT 1520
Db 156 CCTCGAGAGAGATCATAGAGAAATGCAGCTTTGAAGAAGCCCGGAGGTGTTGA 215
QY 1521 GAAAGAGAGAGATGA 1537
Db 216 GAACAGAGAGAAACGA 232
RESULT 62
AF515269
LOCUS
DEFINITION
Danio rerio coagulation factor VIII mRNA, complete cds.
ACCESSION
AF515269
VERSION
AF515269.1 GI:25005098
KEYWORDS
Danio rerio (zebrafish)
SOURCE
Danio rerio
AUTHORS
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.
1 (bases 1 to 1722)
Comprehensive analysis of blood coagulation pathways in teleostei: Evolution of coagulation factor genes and identification of zebrafish factor VIII
Blood Cells Mol. Dis. (2002) In press
2 (bases 1 to 1722)
Jagadeeswaran,P. and Hanumanthaiah,R.
Submitted (24-MAY-2002) Cellular & Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
Location/Qualifiers
1. .1722
/organism="Danio rerio"
/mol_type="mRNA"
/db_xref="taxon:7955"
27. .1358
CDS

/notes="clotting factor"
/codon_start=1
/product="coagulation factor VIII"
/protein_id="AA033364.1"
/db_xref="GI:25005099"
/translation="MTLGAADVLLCVLIRTSVAFLSKDEASALLQRRFRANSGLFE EMKAGNLERECVEEICDYEAREVDEDDRTQFMLSNSKPCITNCRNNGTCVYL ADSYCLSEGEGYKCEGLBETLXQVYNGCEQFCDSGARS CSCAEGYALADD GTCVSQVDYPCGKIPIQKNTSONQFLGGHCPRGHCPWQVLIDYNGSVCCGALLG PFLITAAHCHOKDTRFLKAVTGEHDLVDLGDSEEPYSAVFIHNPVDPETLDSLA LLRLRVQVRSIYAVPICLPTQLARSELMAAREHTLSCMGTRTAGHNLREKGLKGP ASGTLORLAVPULLPAAQCGNANTANMFCAGYTEGDSHSCRGHDSPLVTRGETSFL TGVVSWRGCGPGPYIWTIKVENFLIMWDTVKNKNTEDKRSQIANVSTKN"
Query Match 0.6%; Score 22.5999; DB 1; Length 1722;
Best Local Similarity 42.9%; Pred. No. 72;
Matches 112; Conservative 0; Mismatches 149; Indels 0; Gaps 0;
QY 2836 ATTCATATGTTTCAAAATATTTTCATATGTTGTTAGATAATAAGATTTTCAAT 2895
Db 1332 ATTGCTAATGTTTCCCACTAAATTTAGTATTTAGTCTTAAACAGATTAAATGGCTGT 1391
QY 2896 GATTTTATCTTTGATTTTCTCTACTTATTTAAATTTGGGATTTTAACTATTCTTCAA 2955
Db 1392 GATTTCTGTCAGAGCTTTGCTTTAGAGGAAATATGAGTTATGTGGAAGTAAAGAGC 1451
QY 2956 TGACTTGATTTCTAATATTTACTTATTTACTTTTAACTTTAACTTTGCACTTTTATTG 3015
Db 1452 CCTCAAACTCTTTACTTCCACCTCATCTTGGATGATTAATGATATATAATAAT 1511
QY 3016 ATTTTCTAATAATCCAGTCTCTGTTTAAAGAGCTTTAAATTTAAATTTCT 3075
Db 1512 AATAACATAATAATCTTAGTATCATATTAATAACAGACACTGATCAATAGCGTCTTC 1571
QY 3076 CTTTAGTGTTTTACCAGTTCT 3096
Db 1572 CTAAGGTTAATTAATCTTCT 1592
RESULT 63
E01075
LOCUS
DEFINITION
CDNA sequence of factor VII fragment.
ACCESSION
E01075
VERSION
E01075.1 GI:2169334
KEYWORDS
JP 1987000283-A/1.
SOURCE
unidentified
ORGANISM
unclassified.
REFERENCE
1 (bases 1 to 2177)
AUTHORS
Fureditsuko,E.H., Maaku,J.M., Shiyaron,J.B., Kiyasuriin,E.B., Maagaretudo,W.I., Richiyaado,J.U. and Chiyaaruzu,E.G.
TITLE
DNA ENCODING FACTOR VII
JOURNAL
Patent: JP 1987000283-A 1 06-JAN-1987;
HMOJIEITEITSUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD,
TOYO SODA MFG CO LTD
OS Human (Homo sapiens)
PN JP 1987000283-A/1
PD 06-JAN-1987
PF 16-APR-1986 JP 1986087861
PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI
FUREDEITSUKO ESU HAAGEN, MAAKU JIEI MARII,
PI SHIYAARON JIEI BAZUBII,
PI KIIYAURIIN ERU BAKUNAA, MAAGARETSUTO WAI INSUREE, PI
RICHIIYADO JII UTSUDOBERRII, CHIIYAARUZU ERU GUREI PC
C12N15/00,A61K37/465,C12N5/00,C12N9/50,(C12N9/50,C12R1:91); CC
Strandedness: Double;
CC topology: Linear;
CC anti-sense: No;
CC hypothetical: No;
CC *source: tissue type=liver;
CC *source: library=CDNA library, lambdaagt11 CDNA library; CC
*source: clone=lambdaviI 2115, lambdaviI 1923; FH Key

Location/Qualifiers
FH CDS 13..1128
FT /product='factor VII peptide' FT
FT polyA_signal 2106..2111
FT exon 41..12
FT 3'UTR 1129..2177.
Location/Qualifiers
1..2177
/organism='unidentified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'

Query Match 0.6%; Score 22.4; DB 1; Length 2177;
Best Local Similarity 48.8%; Pred. No. 75;
Matches 61; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

QY 2186 TGTCAGACTTTATTTTGGGGGCTCCAAATCACTGCAGATGGTGAAGTGCAGCCATGA 2245
DB 2045 TTTCCTCTCGTGGTGGCGGCTGCACAGACTATTCACCTGCTTCCAGCTTCA 2104
QY 2246 AATTAAGAAGACACTTCTCTTGGAGAAAGTTAACCACTAGATAGCATATTGAAA 2305
DB 2105 CAATAACGGTGGTCTCTCGCAAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAA 2164
QY 2306 GCAGA 2310
DB 2165 AAAAA 2169

RESULT 64
AX310356/c 186 bp DNA linear PAT 14-DEC-2001
LOCUS Sequence 3341 from Patent WO0190366.
ACCESSION AX310356
VERSION AX310356.1 GI:17896408
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1 Leach, M.D. and Shinkets, R.A.
Human polynucleotides and polypeptides encoded thereby
Patent: WO 0190366-A 3341 29-NOV-2001;
Curagen Corporation (US)

FEATURES
source
1..186
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.6%; Score 22.4; DB 1; Length 186;
Best Local Similarity 53.4%; Pred. No. 49;
Matches 47; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 2670 TGACTCGATGGAGTCTGGTGAATCTCTGGAGTTGGTGGACAGGAGGCGTGT 2729
DB 148 TGCGCCGGTGGTGGGCTAGATCAAGTTCAGGCCCGGGTGTGCCAGTCCCGA 89
QY 2730 TCTCGGGGATTCATGGGTGACAAAG 2757
DB 88 GCAGGCGGGCTTGTGTCTAGGTAG 61

RESULT 65
AF465270 1302 bp mRNA linear VRT 02-FEB-2003
LOCUS Gallus gallus anticoagulant protein C precursor (PROC) mRNA,
DEFINITION complete cds.
ACCESSION AF465270
VERSION AF465270.1 GI:28194011
KEYWORDS

SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE

Gallus gallus (chicken)
Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
2 (bases 1 to 1302)
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
Location/Qualifiers
1..1302
/organism='Gallus gallus'
/mol_type='mRNA'
/db_xref='taxon:9031'
1..1302
/genes='PROC'
1..1302
/genes='PROC'
/EC number='3.4.21.69'
/function='inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids'
/note='vitamin K dependent serine protease;
autoprothrombin IIA, coagulation factor XIV; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma'
/codon_start=1
/product='anticoagulant protein C precursor'
/protein_id='AAO33365.1'
/db_xref='GI:28194012'
/translation='MMKLITIGVLLAACSPPCHASIFVSKDANOVLIKREANSFL
EELKPGVERECNEECNFEASEIFETREATLEFWSKYVDGDCQKPCSGNCAKDN
IGSYCTCDKRGWEGACNVKNCSDVNGGQHFCKEDPAKQCRKCCASGYQLTN
DNMCTPVPFPCGRVMDYTEGAENFRLIGNSGGGRFSPWRVNLQKGLFCG
GVLIHPSWLTAAHCVETGETLKVRLGKTHRLAENSEQTIRVYKVRHNEITKLTSD
NDIAMHLAPVMYKVALPICLPTDRLAEHLTKGRQMLVTGWSTSDMENYSGAL
LSYIEIPVKNCAQVMNTISDNMLCAGSLGDRKDCSGSDSGGPMATKYKDTWFLV
GLVSGEGCGKKEKFGVYKVSQLEWQHINKSGSWRG'

Query Match 0.6%; Score 22.4; DB 1; Length 1302;
Best Local Similarity 56.9%; Pred. No. 76;
Matches 41; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2234 CTGCAGCCATGAATTAAGACACTTACTCTTGAAGAAAAGTTAACCACTAGATA 2293
DB 1139 CTATGGCCACTAATAATAGGATCTTGGTCTTGTAGACTGGTGGGGAAG 1198
QY 2294 GCATATTGAAAA 2305
DB 1199 GCTGTGGAAAA 1210

RESULT 66
AF011900/c 832 bp mRNA linear VRT 09-SEP-1997
LOCUS Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.
DEFINITION
ACCESSION AF011900
VERSION AF011900.1 GI:2367498
KEYWORDS
SOURCE Petromyzon marinus (sea lamprey)
ORGANISM Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
1 (bases 1 to 832)
Roach, J.C.
The Molecular Evolution of the Vertebrate Trypsinogens

```

JOURNAL      Unpublished
REFERENCE    2 (bases 1 to 832)
AUTHORS      Roach, J.C.
TITLE        Direct Submission
JOURNAL      Submitted (01-JUL-1997) Molecular Biotechnology, University of
              Washington, Seattle, WA 98195, USA
FEATURES
  source
    1..832
      /organism="Petromyzon marinus"
      /mol_type="mRNA"
      /db_xref="taxon:7757"
      /dev_stage="amocoete"
      /tissue_lib="anterior intestine"
      <1..832
      /gene="TRYPB1"
      <1..736
      /gene="TRYPB1"
      /codon_start=2
      /product="trypsinogen B1"
      /protein_id="AAB69656.1"
      /db_xref="GI:2367499"
      /translation="LIPALLVGTAAAPYEDHIVGGVECAAHSPQWQVSLNIGYHF
CGSLISSWVYSAHCYCTASRISVRIGEHNFVTEGTGEORIQAKAIRHPQYSSAT
INDIMLIKSSPALTNOYAOAVPLPSSCVGTGVMCTISGGETOTSVSGSDYLMCVQ
APVLDTSRNSYPGDIINMILICYLEGGKDCSCGDSGGPVVNCGLQGIIVSWGRGC
ALPNPVGVTYKVNINSWIASTMAAN"
    sig_peptide
      <1..37
      /gene="TRYPB1"
      /evidence=not_experimental
    mat_peptide
      38..733
      /gene="TRYPB1"
      /product="trypsin b1"
      /evidence=not_experimental

Query Match      0.6%; Score 22.2; DB 1; Length 832;
Best Local Similarity 77.1%; Pred. No. 78;
Matches 27; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3248 TTTTITTTTTTTTTTTTAAAGAAATGCTATCTTT 3282
Db 832 TTTTITTTTTTTTTTTTCAATATATTTTATTAAT 798

RESULT 67
AX527570/c
LOCUS      AX527570      534 bp      DNA      linear      PAT 21-NOV-2002
DEFINITION Sequence 97 from Patent WO0212331.
ACCESSION  AX527570
VERSION     AX527570.1  GI:25172149
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Euteleostomi;
             Chordata; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE    1
AUTHORS      Pyle, R.A., Xu, J. and Kalos, M.D.
TITLE        Compositions and methods for the therapy and diagnosis of
             pancreatic cancer
JOURNAL      Patent: WO 0212331-A 97 14-FEB-2002;
             CORIXA CORPORATION (US)
FEATURES
  source
    1..534
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      0.6%; Score 22; DB 1; Length 534;
Best Local Similarity 63.0%; Pred. No. 80;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAAGCTAACACCCCAAGAGATGCTCTCTCATTATAGGGGACTGGAA 974
Db 64 CCTCAGATGTAGCCCAACGATCTTGTCATCATCATCAAGGGGGCAGCAA 11

JOURNAL      Unpublished
REFERENCE    2 (bases 1 to 832)
AUTHORS      Roach, J.C.
TITLE        Direct Submission
JOURNAL      Submitted (01-JUL-1997) Molecular Biotechnology, University of
              Washington, Seattle, WA 98195, USA
FEATURES
  source
    1..832
      /organism="Petromyzon marinus"
      /mol_type="mRNA"
      /db_xref="taxon:7757"
      /dev_stage="amocoete"
      /tissue_lib="anterior intestine"
      <1..832
      /gene="TRYPB1"
      <1..736
      /gene="TRYPB1"
      /codon_start=2
      /product="trypsinogen B1"
      /protein_id="AAB69656.1"
      /db_xref="GI:2367499"
      /translation="LIPALLVGTAAAPYEDHIVGGVECAAHSPQWQVSLNIGYHF
CGSLISSWVYSAHCYCTASRISVRIGEHNFVTEGTGEORIQAKAIRHPQYSSAT
INDIMLIKSSPALTNOYAOAVPLPSSCVGTGVMCTISGGETOTSVSGSDYLMCVQ
APVLDTSRNSYPGDIINMILICYLEGGKDCSCGDSGGPVVNCGLQGIIVSWGRGC
ALPNPVGVTYKVNINSWIASTMAAN"
    sig_peptide
      <1..37
      /gene="TRYPB1"
      /evidence=not_experimental
    mat_peptide
      38..733
      /gene="TRYPB1"
      /product="trypsin b1"
      /evidence=not_experimental

Query Match      0.6%; Score 22.2; DB 1; Length 832;
Best Local Similarity 77.1%; Pred. No. 78;
Matches 27; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3248 TTTTITTTTTTTTTTTTAAAGAAATGCTATCTTT 3282
Db 832 TTTTITTTTTTTTTTTTCAATATATTTTATTAAT 798

RESULT 67
AX527570/c
LOCUS      AX527570      534 bp      DNA      linear      PAT 21-NOV-2002
DEFINITION Sequence 97 from Patent WO0212331.
ACCESSION  AX527570
VERSION     AX527570.1  GI:25172149
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Euteleostomi;
             Chordata; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE    1
AUTHORS      Pyle, R.A., Xu, J. and Kalos, M.D.
TITLE        Compositions and methods for the therapy and diagnosis of
             pancreatic cancer
JOURNAL      Patent: WO 0212331-A 97 14-FEB-2002;
             CORIXA CORPORATION (US)
FEATURES
  source
    1..534
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      0.6%; Score 22; DB 1; Length 534;
Best Local Similarity 63.0%; Pred. No. 80;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAAGCTAACACCCCAAGAGATGCTCTCTCATTATAGGGGACTGGAA 974
Db 64 CCTCAGATGTAGCCCAACGATCTTGTCATCATCATCAAGGGGGCAGCAA 11

```

```

RESULT 68
HUMMA/c
LOCUS      HUMMA      741 bp      mRNA      linear      PRI 10-FEB-1999
DEFINITION Human mRNA for mesotrypsinogen, partial cds.
ACCESSION  D45417
VERSION     D45417.1  GI:644884
KEYWORDS    mesotrypsinogen; trypsin.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE    1 (bases 1 to 741)
AUTHORS      Fukuoaka, S.
JOURNAL      Unpublished
             2 (bases 1 to 741)
             Fukuoaka, S.-I.
             Direct Submission
             Submitted (03-FEB-1995) Shin-Ichi Fukuoaka, Kyoto University,
             Research Institute for Food Science; Gokancho, Uji, Kyoto 611,
             Japan (E-mail: fukuoka@soya.food.kyoto-u.ac.jp, tel:0774-33-6905,
             fax:0774-33-3004)
             Location/Qualifiers
             1..741
               /organism="Homo sapiens"
               /mol_type="mRNA"
               /db_xref="taxon:9606"
               /clone="107-1,107-2,107-3"
               /clone_lib="lambda gt10"
               /dev_stage="adult"
             1..5741
               /EC number="3.4.21.4"
               /note="An isoform of human trypsinogen which is not
               inhibited by naturally occurring trypsin inhibitors."
               /codon_start=1
               /product="mesotrypsinogen"
               /protein_id="BAA08257.1"
               /db_xref="GI:1321640"
               /translation="MNPFLILAFVGAAVPDDDDKIVGGYTCBNSLPYQVSLNSG
               SHFGGSLISEQWVSAHCYKTRIQVRLEHNIKVLGNEQFINAAKIRHPKYNRD
               TLNDIMLIKSSPAINARVSTISLPTAPPAAGTECLISGAGNTLSFGADYVDELKC
               LDAPVLTQAEKASYPGKITNSMFCVGLGEGKDCSQDSDSGSPVVCNGLQGVSWGCH
               GCANKRPGVYTKVINYVDWIKDTAANS"
             sig_peptide
               1..45
             mat_peptide
               46..69
               /product="activation peptide"
             mat_peptide
               70..741
               /product="mature enzyme"

Query Match      0.6%; Score 22; DB 1; Length 741;
Best Local Similarity 63.0%; Pred. No. 86;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAAGCTAACACCCCAAGAGATGCTCTCTCATTATAGGGGACTGGAA 974
Db 94 CCTCAGATGTAGCCCAACGATCTTGTCATCATCATCAAGGGGGCAGCAA 41

RESULT 69
E01617/c
LOCUS      E01617      741 bp      RNA      linear      PAT 29-SEP-1997
DEFINITION cDNA encoding human pancreatic trypsinogen 3.
ACCESSION  E01617
VERSION     E01617.1  GI:2169870
KEYWORDS    JF 1986160582-A/1.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE    1 (bases 1 to 741)
AUTHORS      Takiguchi, H., Tani, T. and Kawashima, I.
TITLE        NOVEL HUMAN PANCREATIC TRYPsin

```

```

JOURNAL Patent: JP 1988160582-A 1 04-JUL-1988;
SANKYO CO LTD
COMMENT OS Homo sapiens
PN JP 1988160582-A/1
PD 04-JUL-1988
PF 25-DEC-1986 JP 1986307770
PI TAKIGUCHI HIROSHI, TANI TOKIO, KAWASHIMA ICHIRO PC
C12N9/76,A61K37/24,C12N1/20,C12N15/00//C07K13/00,(C12N9/76, PC
C12R1.91),
PC (C12N1/20,C12R1:19),(C12N1/20,C12R1:125);
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: tissue_type=Pancreas;
FH Key Location/Qualifiers
FH sig_peptide 1..45
FT mat_peptide 46..741
FT mat_peptide /product='pancreatic trypsinogen 3' FT
mat_peptide replace(46..69,'.')
FT mat_peptide /product='pancreatic trypsin 3'.
FEATURES source
source 1..741
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 0.6%; Score 22; DB 1; Length 741;
Best Local Similarity 63.0%; Pred. No. 86;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 921 CCTTTAGACTACACCCAAAAGATGCTCTTCATTATAGGGACTGGAA 974
|||||
DB 94 CCTCACAGGTAGTACCCCAACAATCTTGTCATCATCGTCAAAGGGGACAGCAA 41

RESULT 71
E15808/c
LOCUS Human mRNA for trypsinogen-like protein, complete cds.
DEFINITION E15808 790 bp DNA linear PAT 28-JUL-1999
ACCESSION E15808
VERSION E15808.1 GI:5710491
SOURCE JP 1998099080-A/1..
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 790)
AUTHORS Nakanishi,J. and Koyama,J.
TITLE DNA CAPABLE OF CODING TRYPSINOGEN-LIKE PROTEIN AND ITS PROTEIN
JOURNAL Patent: JP 1998099080-A 1 21-APR-1998;
COMMENT SHISEIDO CO LTD
OS Homo sapiens (human)
PN JP 1998099080-A/1
PD 21-APR-1998
PF 26-SEP-1996 JP 1996273923
PI NAKANISHI JIYOUTAROU, KOYAMA JUNICHI
PC C12N15/09,C07H21/04,C07K14/47,C12N9/64//A61K38/43; CC
strandedness: Double;
CC topology: Linear;
FH Key Location/Qualifiers
FH sig_peptide 1..48.
FT source 1..790
FT /organism='Homo sapiens'
FT /cell_type='keratinocyte',
FT CDS 1..723
FT /product='trypsinogen-like protein' FT
FEATURES source
source 1..790
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'
Query Match 0.6%; Score 22; DB 1; Length 790;
Best Local Similarity 63.0%; Pred. No. 87;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 921 CCTTTAGACTACACCCAAAAGATGCTCTTCATTATAGGGACTGGAA 974
|||||
DB 73 CCTCACAGGTAGTACCCCAACAATCTTGTCATCATCGTCAAAGGGGACAGCAA 20

RESULT 72
BC030238/c
LOCUS Homo sapiens, clone IMAGE:4537998, mRNA, partial cds.
DEFINITION BC030238
ACCESSION BC030238
VERSION BC030238.1 GI:20988416
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Patent: JP 1995184655-A 1 25-JUL-1995;
SANKYO CO LTD
COMMENT OS Homo sapiens (human)
PN JP 1995184655-A/1
PD 25-JUL-1995
PF 25-DEC-1986 JP 1994311512
PI TAKIGUCHI HIROSHI, TANI TOKIO, KAWASHIMA ICHIRO PC
C12N15/09,C07H21/04,C12N5/10,C12N9/76//A61K38/46; CC
strandedness: Double;
CC topology: Linear;
FH Key Location/Qualifiers
FH sig_peptide 1..45
FT mat_peptide 46..741
FT mat_peptide /product='Spleen TrypsinogenIII' FT
FT variation replace(744,'g')
FT variation replace(743,'g').

```

REFERENCE 1 (bases 1 to 821)
 AUTHORS Strausberg,R.
 TITLE Direct Submission
 JOURNAL National Institutes of Health, Mammalian
 Submitted (07-MAY-2002) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA
 REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov
 COMMENT Contact: MGC help desk
 Email: cgabs-remail.nih.gov
 Tissue Procurement: DCTD/DMP
 CDNA Library Preparation: Life Technologies, Inc.
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: National Institutes of Health Intramural
 Sequencing Center (NISC),
 Gaithersburg, Maryland;
 Web site: http://www.nisc.nih.gov/
 Contact: nisc.mgc@nih.gov
 Akhter,N., Ayale,K., Beckstrom-Sternberg,S.M., Benjamin,B.,
 Blakesley,R.W., Bouffard,G.G., Breen,K., Brinkley,C., Brooks,S.,
 Dietrich,N.L., Granite,S., Guan,X., Gupta,J., Haghighi,P.,
 Hansen,N., Ho,S.-L., Karlins,E., Laric,P., Legaspi,R., Maduro,Q.L.,
 Masello,C., Maskeri,B., Mastrian,S.D., McCloskey,J.C., McDowell,J.,
 Pearson,R., Staniripop,S., Thomas,P.J., Touchman,J.W., Tsurgeon,C.,
 Vogt,J.L., Walker,M.A., Wetherby,K.D., Wiggins,L., Young,A.,
 Zhang,L.-H. and Green,E.D.

Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
 Series: IRAK Plate: 62 Row: C Column: 1
 This clone was selected for full length sequencing because it
 passed the following selection criteria: GenomScan gene
 prediction.

FEATURES
 source
 1..821
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:4537998"
 /tissue_type="Prostate, adenocarcinoma."
 /clone_lib="NIH_MGC_91"
 /lab_host="DH10B"
 /note="Vector: pCMV-SPORT6"
 <1..756
 /codon_start=1
 /product="Unknown (protein for IMAGE:4537998)"
 /protein_id="AAH30238.1"
 /db_xref="GI:20988417"
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLS
 LNSGSHFCGSLISEQWVSAHCVKTRIQVRLGHNKIVLEGEQFINAKIRHPK
 YNRDLNDIMLKSSPAVINARVSTISLTPAPAAAGTECLISGWNTLSFGADYDP
 ELKCLDAPLVTCACCKASYPGKINTSMFCVGLGGKXDCQDSDSGFVPCNGQLQGVV
 SWGHCANRPGVYTKVYVVDIKDTIAANS"

CDS
 <1..756
 /codon_start=1
 /product="Unknown (protein for IMAGE:4537998)"
 /protein_id="AAH30238.1"
 /db_xref="GI:20988417"
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLS
 LNSGSHFCGSLISEQWVSAHCVKTRIQVRLGHNKIVLEGEQFINAKIRHPK
 YNRDLNDIMLKSSPAVINARVSTISLTPAPAAAGTECLISGWNTLSFGADYDP
 ELKCLDAPLVTCACCKASYPGKINTSMFCVGLGGKXDCQDSDSGFVPCNGQLQGVV
 SWGHCANRPGVYTKVYVVDIKDTIAANS"

Query Match 0.6%; Score 22; DB 1; Length 821;
 Best Local Similarity 63.0%; Pred. No. 57;
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTAGACTAACACCCAAAAGATGCTCTTCATTATAGGGACTGAA 974
 Db 106 CCTCAGGTGTAGCCCCAACATCTTGTATCATCTCAAGGGGACAGCA 53

RESULT 73
 HSTRPIV/c
 LOCUS HSTRPIV 853 bp mRNA linear PRI 15-OCT-1999
 DEFINITION Homo sapiens mRNA for trypsinogen IV a-form.
 ACCESSION X72781
 VERSION X72781.1 GI:3928429
 KEYWORDS trypsin IV; trypsinogen; zymogen.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 (bases 1 to 821)
 AUTHORS Strausberg,R.
 TITLE Direct Submission
 JOURNAL National Institutes of Health, Mammalian
 Submitted (07-MAY-2002) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA
 REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov
 COMMENT Contact: MGC help desk
 Email: cgabs-remail.nih.gov
 Tissue Procurement: DCTD/DMP
 CDNA Library Preparation: Life Technologies, Inc.
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: National Institutes of Health Intramural
 Sequencing Center (NISC),
 Gaithersburg, Maryland;
 Web site: http://www.nisc.nih.gov/
 Contact: nisc.mgc@nih.gov
 Akhter,N., Ayale,K., Beckstrom-Sternberg,S.M., Benjamin,B.,
 Blakesley,R.W., Bouffard,G.G., Breen,K., Brinkley,C., Brooks,S.,
 Dietrich,N.L., Granite,S., Guan,X., Gupta,J., Haghighi,P.,
 Hansen,N., Ho,S.-L., Karlins,E., Laric,P., Legaspi,R., Maduro,Q.L.,
 Masello,C., Maskeri,B., Mastrian,S.D., McCloskey,J.C., McDowell,J.,
 Pearson,R., Staniripop,S., Thomas,P.J., Touchman,J.W., Tsurgeon,C.,
 Vogt,J.L., Walker,M.A., Wetherby,K.D., Wiggins,L., Young,A.,
 Zhang,L.-H. and Green,E.D.

Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
 Series: IRAK Plate: 62 Row: C Column: 1
 This clone was selected for full length sequencing because it
 passed the following selection criteria: GenomScan gene
 prediction.

FEATURES
 source
 1..821
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:4537998"
 /tissue_type="Prostate, adenocarcinoma."
 /clone_lib="NIH_MGC_91"
 /lab_host="DH10B"
 /note="Vector: pCMV-SPORT6"
 <1..756
 /codon_start=1
 /product="Unknown (protein for IMAGE:4537998)"
 /protein_id="AAH30238.1"
 /db_xref="GI:20988417"
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLS
 LNSGSHFCGSLISEQWVSAHCVKTRIQVRLGHNKIVLEGEQFINAKIRHPK
 YNRDLNDIMLKSSPAVINARVSTISLTPAPAAAGTECLISGWNTLSFGADYDP
 ELKCLDAPLVTCACCKASYPGKINTSMFCVGLGGKXDCQDSDSGFVPCNGQLQGVV
 SWGHCANRPGVYTKVYVVDIKDTIAANS"

CDS
 <1..756
 /codon_start=1
 /product="Unknown (protein for IMAGE:4537998)"
 /protein_id="AAH30238.1"
 /db_xref="GI:20988417"
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLS
 LNSGSHFCGSLISEQWVSAHCVKTRIQVRLGHNKIVLEGEQFINAKIRHPK
 YNRDLNDIMLKSSPAVINARVSTISLTPAPAAAGTECLISGWNTLSFGADYDP
 ELKCLDAPLVTCACCKASYPGKINTSMFCVGLGGKXDCQDSDSGFVPCNGQLQGVV
 SWGHCANRPGVYTKVYVVDIKDTIAANS"

Query Match 0.6%; Score 22; DB 1; Length 821;
 Best Local Similarity 63.0%; Pred. No. 57;
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTAGACTAACACCCAAAAGATGCTCTTCATTATAGGGACTGAA 974
 Db 106 CCTCAGGTGTAGCCCCAACATCTTGTATCATCTCAAGGGGACAGCA 53

RESULT 73
 HSTRPIV/c
 LOCUS HSTRPIV 853 bp mRNA linear PRI 15-OCT-1999
 DEFINITION Homo sapiens mRNA for trypsinogen IV a-form.
 ACCESSION X72781
 VERSION X72781.1 GI:3928429
 KEYWORDS trypsin IV; trypsinogen; zymogen.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 1
 Wiegand,U., Corbach,S., Minn,A., Kang,J. and Muller-Hill,B.
 Cloning of the cDNA encoding human brain trypsinogen and
 characterization of its product
 Gene 136 (1-2), 167-175 (1993)
 94123994
 MEDLINE
 PUBMED 8294000
 REFERENCE 2 (bases 1 to 853)
 AUTHORS Wiegand,U.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) U. Wiegand, Institut fuer Genetik der Univ.
 zu Koeln, Weyertal 121, 5000 Koeln 41, FRG
 REMARK sequence revised by author 01-OCT-93
 COMMENT On Nov 26, 1998 this sequence version replaced gi:405754.
 FEATURES
 Location/Qualifiers
 1..853
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /cell_line="human brain poly(A) + RNA"
 /tissue_type="brain"
 <1..787
 /codon_start=2
 /product="trypsinogen IV a-form"
 /protein_id="CA558178.1"
 /db_xref="GI:6066378"
 /db_xref="GOA:P35030"
 /translation="GLEHPLLGRTWRAADGCEALGTVAVPFDDDDKIVGGYTC
 ENSLPYQVLSNSGSHFCGSLISEQWVSAHCVKTRIQVRLGHNKIVLEGEQFIN
 NAAKIRHPKYNRDLNDIMLKSSPAVINARVSTISLTPAPAAAGTECLISGWNT
 LLSFGADYDPVLTCACCKASYPGKINTSMFCVGLGGKXDCQDSDSGFVPCNGQLQGVV
 VCNQQLQGVVSWGHCANRPGVYTKVYVVDIKDTIAANS"
 <1..83
 /number=1
 84..243
 /number=2
 134..139
 /note="allelic polymorphism"
 244..497
 /number=3
 498..634
 /number=4
 635..>853
 /number=5
 818..823
 polyA_signal
 Query Match 0.6%; Score 22; DB 1; Length 853;
 Best Local Similarity 63.0%; Pred. No. 88;
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTAGACTAACACCCAAAAGATGCTCTTCATTATAGGGACTGAA 974
 Db 137 CCTCAGGTGTAGCCCCAACATCTTGTATCATCTCAAGGGGACAGCA 84

RESULT 74
 AX265053 121 bp DNA linear PAT 26-OCT-2001
 LOCUS Sequence 2444 from Patent WO0173002.
 DEFINITION AX265053
 ACCESSION AX265053
 VERSION AX265053.1 GI:16513852
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 1
 Knies,E.B., Gamber,H.B. and Rice,M.C.
 Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
 Patent: WO 0173002-A 2444 04-OCT-2001;

```
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 50 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCCACATATACCCCTTCAGATGCA 109
    |||||
QY 845 CAGTA 849
    |||
Db 110 GAGCA 114

RESULT 75
AX265054/c
LOCUS AX265054 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2445 from Patent WO0173002.
ACCESSION AX265054
VERSION AX265054.1 GI:16513853
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2445 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 72 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCCACATATACCCCTTCAGATGCA 13
    |||||
QY 845 CAGTA 849
    |||
Db 12 GAGCA 8

RESULT 76
AX265057
LOCUS AX265057 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2448 from Patent WO0173002.
ACCESSION AX265057
VERSION AX265057.1 GI:16513856
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2448 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 70 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCCACATATACCCCTTCAGATGCA 11
    |||||
QY 845 CAGTA 849
    |||
Db 10 GAGCA 6

RESULT 77
AX265058/c
LOCUS AX265058 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2449 from Patent WO0173002.
ACCESSION AX265058
VERSION AX265058.1 GI:16513857
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2449 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 70 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCCACATATACCCCTTCAGATGCA 11
    |||||
QY 845 CAGTA 849
    |||
Db 10 GAGCA 6

RESULT 78
AX265059
LOCUS AX265059 170 bp DNA linear PRI 08-OCT-1996
DEFINITION H.sapiens gene encoding beta-myosin heavy chain, exon 3.
ACCESSION X04629
VERSION X04629.1 GI:34851
KEYWORDS beta-myosin; myosin; myosin heavy chain.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 170)
AUTHORS Licher, P., Umeda, P.K., Levin, J.E. and Vosberg, H.P.
TITLE Partial characterization of the human beta-myosin heavy-chain gene
which is expressed in heart and skeletal muscle
JOURNAL Eur. J. Biochem. 160 (2), 419-426 (1986)
MEDLINE 87030293
PUBMED 3021460
```



```

Query Match          0.6%; Score 21.8; DB 1; Length 603;
Best Local Similarity 52.8%; Pred. No. 92;
Matches 47; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 1399 CCTAATGAATATGACAGAGGTTTCATGACATTGTACAGGACAGAGGATCGAGCCATC 1458
      |||||
Db 439 CCTGAAGAAGTGGATACAGAGGTCATGTCGTAGGAGTTAGGAGCCACCCACAT 498

QY 1459 CCCATGGAAGAAATGCAAAAAGCAA 1487
      |||||
Db 499 TCCAAGGCTCCTCACTGCAAAATCTCAG 527

RESULT 82
LOCUS BD173590 711 bp DNA linear PAT 18-FEB-2003
DEFINITION Novel serine protease MP493.
ACCESSION BD173590
VERSION BD173590.1 GI:28414921
KEYWORDS WO 02059295-A/3.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 711)
AUTHORS Nakamura,Y., Sugano,S., Matsusue,T., Okamoto,A. and Okawa,K.
TITLE Novel serine protease MP493
JOURNAL Patents: WO 02059295-A 3 01-AUG-2002;
MOCHIDA PHARMACEUTICAL CO LTD,YUSUKE NAKAMURA,SUMIO SUGANO,
TOMOKAZU MATSUSUE,ATSUSHI OKAMOTO,KAZUFUMI OKAWA
COMMENT OS Homo sapiens (human)
PN WO 02059295-A/3
PD 01-AUG-2002
PF 23-JAN-2002 WO 2002JP000465
PR 23-JAN-2001 JP 01P 014963
PI YUSUKE NAKAMURA,SUMIO SUGANO,TOMOKAZU MATSUSUE,ATSUSHI
OKAMOTO,
PI KAZUFUMI OKAWA
PC C12N15/09,C12N15/12,C12N9/64,C12N1/15,C12N1/19,C12N1/21 PC
,C12N5/10,C07K16/40,
PC C12Q1/02
CC Novel serine protease MP493
FH Key Location/Qualifiers
FT source
   location/Qualifiers
   1..711
   /organism="Homo sapiens"
   /mol_type="genomic DNA"
   /db_xref="taxon:9606"

Query Match          0.6%; Score 21.8; DB 1; Length 711;
Best Local Similarity 56.2%; Pred. No. 95;
Matches 41; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 195 ACTAGTCAATCTATCAGATAGGACACACGCTTGCTACTCAATCAACTAAGCAT 244
      |||||
Db 188 ACAAATCCAGCCCACTCCCACTGGTGGAGAGATGCTACACAGCAAGTACAGCAA 247

QY 245 GCCCGTGGGGCAA 257
      |||||
Db 248 AGAGGCTGGCAA 260

RESULT 83
LOCUS E01189/c 1759 bp RNA linear PAT 29-SEP-1997
DEFINITION cDNA encoding human protein C.
ACCESSION E01189
VERSION E01189.1 GI:2169448
KEYWORDS JP 1987111690-A/1.
SOURCE Homo sapiens (human)

```

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1759)
AUTHORS Maaku,J.M., Kiyasuriin,E.B., Donarudo,S.F. and Aaru,D.D.
TITLE HUMAN PROTEIN C AND ITS PRODUCTION
JOURNAL Patent: JP 1987111690-A 1 22-MAY-1987;
ZAIMOJIENTEIKUSU INC
COMMENT OS human
PN JP 1987111690-A/1
PD 22-MAY-1987
PF 27-JUN-1986 JP 1986151303
PR 27-JUN-1985 US 85 749600, 15-AUG-1985 US 85 766109 PI
MAKU JIEI MAAREI, KIYASURIIN ERU BRAKUNAA,
PI DONARUDO SHII FUOSUTAA,
PI AARU DABURIYU DEIBII
PC C12N15/00,A61K35/74,A61K37/465,C07H21/04,C07K13/00,C12N5/00,
C12N9/64,
PC C12P21/02, (C12N9/64,C12R1/91), (C12P21/02,C12R1/91); CC
strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: tissue_type=eiver;
CC *source: clone=PHC6L;
FH Key Location/Qualifiers
FH 5'UTR 1..70
FT CDS 71..1456
   /product="human pre-pro protein C" FT
FT sig_peptide 71..703
   /product="human protein C"
FT polyA_site 704..1453
   join(1503..1508,1732..1737)
FT 3'UTR 1457..1759.
FEATURES
   source
     location/Qualifiers
     1..1759
     /organism="Homo sapiens"
     /mol_type="genomic RNA"
     /db_xref="taxon:9606"

Query Match          0.6%; Score 21.8; DB 1; Length 1759;
Best Local Similarity 58.5%; Pred. No. 11e+02;
Matches 39; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 453 CTCGAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
      |||||
Db 1575 CTCGAGAGAGCCCAAGAGAGGATGGAAGGACAGACAGACAGCGCGGTGCTTGTAC 1516

QY 513 TGGTG 517
      |||
Db 1515 ATGTG 1511

RESULT 84
LOCUS AY083553 251 bp DNA linear PRI 13-APR-2002
DEFINITION Macaca mulatta growth associated protein 43 (GAP43) gene, 3' UTR.
ACCESSION AY083553
VERSION AY083553.1 GI:20146915
KEYWORDS
SOURCE Macaca mulatta (rhesus monkey)
ORGANISM Macaca mulatta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Cercopitheidae;
Cercopithecinæ; Macaca.
REFERENCE 1 (bases 1 to 251)
AUTHORS Norgren,R.B., Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.
TITLE Construction of a targeted rhesus macaque microarray
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 251)
AUTHORS Norgren,R.B., Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.
TITLE Direct Submission

```

JOURNAL Submitted (11-MAR-2002) Molecular and Cellular Biology Core, Oregon Regional Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA

FEATURES source

Location/Qualifiers

1..251

/organism="Macaca mulatta"

/mol_type="genomic DNA"

/db_xref="taxon:9544"

<1..>251

/gene="GAP43"

<1..>251

/gene="GAP43"

/product="growth associated protein 43"

<1..>251

/gene="GAP43"

3'UTR

Query Match 0.6%; Score 21.6; DB 1; Length 251;

Best Local Similarity 51.0%; Pred. No. 85;

Matches 51; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 1522 ABAAGAGAGAGTGAAGCAAGCAAGAAAGGAAGCAATGAAGCAATCTGAATGCAGAG 1581

|||||

Db 85 AAAAAAGAAAGAAAAAGAAAGCAAGCAAGCAAGTCCCAAGTCAACAGTGGCTTAAACA 144

|||||

QY 1582 TTCCAAAGAACTCCAGTGTTCAGAGCTGGTTTAGAAAA 1621

|||||

Db 145 TTTTGTGTTGTTGTTGTTGTTATGCGGAGTTTGTGTA 184

|||||

RESULT 85

AY179347

LOCUS

DEFINITION Spherooides annulatus trypsin precursor, mRNA, partial cds.

ACCESSION AY179347

VERSION AY179347.1 GI:27802523

KEYWORDS

SOURCE Spherooides annulatus (bullseye puffer)

ORGANISM Spherooides annulatus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes; Tetraodontidae; Tetraodontidae; Spherooides.

1 (bases 1 to 375)

Galaviz, M.A., Garcia-Ortega, A. and Garcia-Gasca, A.

Trypsin gene expression and enzymatic activity during embryonic and larval development of the bullseye puffer (Spherooides annulatus)

Unpublished

2 (bases 1 to 375)

Galaviz, M.A. and Garcia-Gasca, A.

Direct Submission

Submitted (13-NOV-2002) Molecular Biology, CIAD, Avenida Sabalo Cerritos s/n, Mazatlan, Sin 82010, Mexico

Location/Qualifiers

1..375

/organism="Spherooides annulatus"

/mol_type="mRNA"

/db_xref="taxon:168377"

/tissue_type="intestine"

<1..>375

/note="trypsinogen; protease"

/codon_start=1

/product="trypsin precursor"

/protein_id="AA021468.1"

/db_xref="GI:27802524"

/translation="DIMLIKSKATLNQYVQVALPTSCAPAGTCKVSGWNTMS

TADKNQLQCLNIPILSDRCKNSYPMITDAMFCAGYLEGGKDSQGDSPGVVVCNQ

LOGVVSWGYGCAERDHPGVYAKV"

CDS

Query Match 0.6%; Score 21.6; DB 1; Length 375;

Best Local Similarity 52.2%; Pred. No. 93;

Matches 48; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 881 AAGAAGCTGAAGTGAACGGTCTCTATGAAGCACTTCAAGACCTTTTAGAAGCTTACACCCA 940

|||||

Db 148 AAGCTCAGTGGCTGAATATATCCCTGTCGGACAGGCACTGTGAAGAACTCTTACCCA 207

|||||

QY 941 AAAAGATGTCCTTCTCAITATAGGGACTGG 972

|||||

Db 208 GGCATGATCACAGACGCCCATGTTCTGTGCTGG 239

|||||

RESULT 86

AX524284

LOCUS

DEFINITION Sequence 314 from Patent EP1236798.

ACCESSION AX524284

VERSION AX524284.1 GI:25169380

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1

Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and Schlueter, T.

Gene library and method for its production

Patent: EP 1236798-A 314 04-SEP-2002;

LION Bioscience AG (DE)

Location/Qualifiers

1..427

/organism="Mus musculus"

/mol_type="unassigned DNA"

/db_xref="taxon:10090"

Query Match 0.6%; Score 21.6; DB 1; Length 427;

Best Local Similarity 53.6%; Pred. No. 96;

Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 3457 TGGCTTTAAAGTATTTCTGCTATTAAACATGAATTAAGTCTTTTGGACTATAGTG 3516

|||||

Db 326 TGCTTCACACAGCATGTTCTCGAGACCACTTCTCATGACCTCCAGCACTATTC 385

|||||

QY 3517 GAGTCACAAAAGAGTTGGACATCA 3540

|||||

Db 386 GAGCAACCAAGGGATCGGATCA 409

|||||

RESULT 87

AX553022

LOCUS

DEFINITION Sequence 314 from Patent WO02074953.

ACCESSION AX553022

VERSION AX553022.1 GI:25897022

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1

Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and Schlueter, T.

Gene library and a method for producing the same

Patent: WO 02074953-A 314 26-SEP-2002;

LION Bioscience AG (DE)

Location/Qualifiers

1..427

/organism="Mus musculus"

/mol_type="unassigned DNA"

/db_xref="taxon:10090"

Query Match 0.6%; Score 21.6; DB 1; Length 427;

Best Local Similarity 53.6%; Pred. No. 96;

Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 3457 TGGCTTTAAAGTATTTCTGCTATTAAACATGAATTAAGTCTTTTGGACTATAGTG 3516

|||||

Db 326 TGCCTGCACACAGATGTTCTCCGAGACACACATTCTTCATGACCTCCACGCACTCATTTTC 385

QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540

Db 386 GAGCAACCAAGAGGATGCGGATGA 409

RESULT 88
MUSBALB6/c
LOCUS
DEFINITION Mouse gene for protein C (precursor of vitamin K-dependent serine protease), partial cds (catalytic region).
ACCESSION D43755
VERSION 1
KEYWORDS protein C; serine protease zymogen; vitamin K-dependent serine protease; blood coagulation-related.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Nihori, Y.
AUTHORS A comparative study of partial primary structures of the catalytic region of mammalian protein C
TITLE 94318474
MEDLINE 8043441
PUBMED 2 (bases 1 to 483)
REFERENCE Murakawa, M.
AUTHORS Direct Submission
TITLE Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
JOURNAL Location/Qualifiers
FEATURES
source 1. 483
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="Balb/c"
/db_xref="taxon:10090"
CDS <1..>483
/function="regulation of blood coagulation"
/note="catalytic region"
/codon_start=1
/product="protein C"
/protein_id="BAA07812.1"
/db_xref="GI:1304147"
/translation="DHWELDLDIKEILVHPNVTSSNDIALLRLAQPATLSKTIYP ICLPNGLAQQLTQAGQETVVTGWSQDFIKDGRNRCFFLFIPLVARNECVG VMKNVVSNNMLCAGLIGNTRDACDGDGGPWFVRGTWFLVGLVSGCGHTNNYGI"

Query Match 0.6%; Score 21.6; DB 1; Length 483;
Best Local Similarity 53.6%; Pred. No. 98;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 3457 TGGCTTTAAAGATTTTGGCTATTAAACATGAATTAAGTCTTATTGGACTATAGTG 3516

Db 349 TGCCGTCACACAGAGTGTCTCCGAGACACACATTCTTCATGACCTCCACGCACTCATTTTC 290

QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540

Db 289 GAGCAACCAAGAGGATGCGGATGA 266

RESULT 89
BV094002/c
LOCUS
DEFINITION RPAMWSEC0005940 Roche Palo Alto Mus musculus STS genomic, sequence tagged site.
ACCESSION BV094002
VERSION BV094002.1
KEYWORDS STS. GI:37671481

SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. Usuka, J., Liao, G., Cheng, J., Nguyen, A., Bach, C., Puech, A., McPherson, J.D., Foerzler, D. and Peltz, G.
AUTHORS Mus musculus SNPs
TITLE Unpublished (2003)
JOURNAL
COMMENT Contact: Jonathan Usuka
Roche Palo Alto Genetics and Genomics Department
Roche Palo Alto
3431 Hillview Ave, Mailstop S3-1, Palo Alto, CA 94024, USA
Tel: 6508555807
Email: Jonathan.Usuka@roche.com
Primer A: No primer submitted
Primer B: No primer submitted
Location/Qualifiers
FEATURES
source 1. 596
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/map="18-10064-9474-AC126686.3.1.232817"
/clone_lib="Roche Palo Alto"
/note="SNPs developed from assay sequences derived from 15 different strains of mice (as of October 1, 2003). Those strains include A/J, A/HeJ, -129/Sv, AXB/J, B10.D2-H2/OsNj, BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, -CAST/Ei, DBA/2J, MRL/MpJ, NZB/BINJ, NZW/Lac, SPRET/Ei." <1..>596

STS
Query Match 0.6%; Score 21.6; DB 1; Length 596;
Best Local Similarity 53.6%; Pred. No. 1e+02;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 3457 TGGCTTTAAAGATTTTGGCTATTAAACATGAATTAAGTCTTATTGGACTATAGTG 3516

Db 344 TGCCGTCACACAGAGTGTCTCCGAGACACACATTCTTCATGACCTCCACGCACTCATTTTC 285

QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540

Db 284 GAGCAACCAAGAGGATGCGGATGA 261

RESULT 90
MUSCP/c
LOCUS
DEFINITION Mouse mRNA for protein C, complete cds.
ACCESSION D10445
VERSION D10445.1
KEYWORDS GI:220385
anti-clotting activity; anti-coagulation factor; blood coagulation factor; calcium binding; mouse protein C; phospholipid binding; serine protease.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. Tada, N., Sato, M., Tsujimura, A., Iwase, R. and Hashimoto-Gotoh, T.
AUTHORS Isolation and characterization of a mouse protein C cDNA
TITLE J. Biochem. 111 (4), 491-495 (1992)
JOURNAL
MEDLINE 92316897
PUBMED 1618739
REFERENCE 2 (bases 1 to 1499)
DIRECT SUBMISSION Sato, M.
TITLE Direct Submission
JOURNAL Submitted (31-JAN-1992) Masahiro Sato, Hoechst Japan Co., Ltd., Pharma Research Laboratories; 1-3-2 Minamidai, Kawagoe, Saitama 350, Japan (E-mail:rxikuno@dbj.nig.ac.jp, Tel:0492-43-6149, Fax:0492-41-6475)
COMMENT Submitted (31-JAN-1992) to DDBJ by: Masahiro Sato
Laboratory for Molecular Biology

Pharma Research Laboratories
Hoechst Japan Co., Ltd.
1-3-2 Minamida, Kawagoe
Saitama 350
Japan
Phone: 0492-43-6149
Fax: 0492-41-6475
Email: rikuno@dbj.nig.jc.ap.
Location/Qualifiers

FEATURES
source

1..1499
/organism="Mus musculus"
/mol_type="mRNA"
/strain="BALB/c"
/sub_species="domesticus"
/db_xref="taxon:10090"

CDS

11..11396
/codon_start=1
/product="protein C"
/protein_id="BAA01235.1"
/db_xref="GI:220386"
/translation="MQQFRVLLMTGWISSIPAHPPDPVFSSEHAHQVLRVRANS
FLEMRPSLRECEVEICDEEAEQIFONVEDTLAFWIKYDGDQCSAPELDHCQDS
PCGGHTCIDIGTSCDCKGEGKFCQQLRFQDCRVNNGGLHYCLEENGRCA
CAPGYELADDMKRSCTVNFPGKGRWIEKRLKRDITDLEDELPDPRLVNGTLT
KQDGPWQAILLDSKKLACGGVLIHTSWLTAACHVEGKTLTVRLGEYDLRRDHW
EQLDIKILVHPNTYTRSSNDIALRLAQPATLSKTIVPICLPNNGLAQELTQAG
OETVTGQYQSDRIKDGRRNRTFLTIRIPLVARNECEVMKNVSENMLCAGIIG
NTRDADGDSGPMVFRGTWFLVGLVSWGEGGHTNNYGIYTKVGSYLKWIHSYIG
EKGVSLSKQKL"

sig_peptide
mat_peptide
mat_peptide

Query Match 0.6%; Score 21.6; DB 1; Length 1499;
Best Local Similarity 53.6%; Pred. No. 1.2e+02;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 3457 TGCTTTAAAGATATTCTGCTATTAAACACGATTAAGTCTTATTGGACTATAGT 3516
Db 1178 TGCTTCACACGACGATTTCTCGACACACATTTCTGATGACCTCCAGCACTCATTT 1119
QY 3517 GAGTCACAAAAGATTGGACATGA 3540
Db 1118 GAGCAACCAAGGATGCGGATGA 1095

RESULT 91
BC013896/c
LOCUS BC013896 1603 bp mRNA linear ROD 03-OCT-2003
DEFINITION Mus musculus protein C, mRNA (CDNA clone MGC:13870 IMAGE:4211329), complete cds.
ACCESSION BC013896.1 GI:15530229
VERSION BC013896.1
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 1603)
AUTHORS Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., Altshuler S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan J., Moore J., Max S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Brownstein M.J., Ustin T.B., Casavant T.L., Scheetz T.E., Brownstein M.J., Ustin T.B., Loquellano N.A., Peters G.J., Carninci P., Prange C., Raha S.S., Bosak S.A., McEwan P.J., Abramson R.D., Mullaby S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

Fahey, J., Helton, E., Kettman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakeley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Wyers, R.M., Butlerfield, Y.S., Krzywinski, M.I., Skalska, U., Smalusz, D.E., Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
12477932
2 (bases 1 to 1603)
Strausberg, R.
Direct Submission
Submitted (07-SEP-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabs@mail.nih.gov
Tissue Procurement: Jeffrey E. Green, M.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
http://www.systemsbio.org
contact: anadan@systemsbiology.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettman, Anuradha Madan, Stephanie Rodriguez, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov Series: IRAC Plate: 18 Row: n Column: 8
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6679476.

FEATURES
source

1..1603
/organism="Mus musculus"
/mol_type="mRNA"
/strain="FVB/N"
/db_xref="taxon:10090"
/clone="MGC:13870 IMAGE:4211329"
/tissue_type="Liver, normal, 5 month old male mouse."
/clone_lib="NCI CGAP_Li9"
/lab_host="DH10B"
/notes="Vector: pCMV-SPORT6"
1..1603
/gene="Proc"
/notes="synonym: PC"
/db_xref="LocusID:19123"
/db_xref="MGI:97771"

gene

100..1482
/codon_start=1
/product="protein C"
/protein_id="AAH13896.1"
/db_xref="GI:15530230"
/db_xref="LocusID:19123"
/translation="MQQFRVLLMTGWISSIPAHPPDPVFSSEHAHQVLRVRANS
FLEMRPSLRECEVEICDEEAEQIFONVEDTLAFWIKYDGDQCSAPELDHCQDS
PCGGHTCIDIGTSCDCKGEGKFCQQLRFQDCRVNNGGLHYCLEENGRCA
CAPGYELADDMKRSCTVNFPGKGRWIEKRLKRDITDLEDELPDPRLVNGTLT
KQDGPWQAILLDSKKLACGGVLIHTSWLTAACHVEGKTLTVRLGEYDLRRDHW
EQLDIKILVHPNTYTRSSNDIALRLAQPATLSKTIVPICLPNNGLAQELTQAG
OETVTGQYQSDRIKDGRRNRTFLTIRIPLVARNECEVMKNVSENMLCAGIIG
NTRDADGDSGPMVFRGTWFLVGLVSWGEGGHTNNYGIYTKVGSYLKWIHSYIG
KGVSLKQKL"

CDS

misc_feature

175..357
/note="GLA; Region: Domain containing Gla (gamma-carboxyglutamate) residues. A hyaluronan-binding domain found in proteins associated with the extracellular matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
400..489
misc_feature

/note="EGF; Region: EGF-like domain. There is no clear separation between noise and signal. pfam0053 is very similar, but has 8 instead of 6 conserved cysteines. Includes some cytokine receptors. The EGF domain misses the N-terminus regions of the Ca2+ binding EGF domains. The family is hard to model due to many similar but different sub-types of EGF domains. Pfam certainly misses a number of EGF domains"
 /db_xref="CDD:pfam00008"
 730..1431
 /note="Tryp SPC; Region: Trypsin-like serine protease"
 /db_xref="CDD:smart00020"

misc_feature

Query Match 0.6%; Score 21.6; DB 1; Length 1603;
 Best Local Similarity 53.6%; Pred. No. 1.2e+02;
 Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
 QY 3457 TGGCTTTAAAGATTTGCTGCTATTAAACATGAATTAAGTCTTATTGACATATAGTG 3516
 Db |||||
 QY 1264 TGGCTGCACACAGCATGTTCTCCGAGACCATCTTCATCAGCTCCAGGACTCATTTC 1205
 Db |||||
 QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540
 Db |||||
 QY 1204 GAGCAACCAAGGGATGGGATGA 1181
 Db |||||

RESULT 92
 AF515269/c
 LOCUS AF515269 1722 bp mRNA linear VRT 15-NOV-2002
 DEFINITION Danio rerio coagulation factor VIII mRNA, complete cds.
 ACCESSION AF515269
 VERSION AF515269.1 GI:25005098
 KEYWORDS
 SOURCE Danio rerio (zebrafish)
 ORGANISM Danio rerio
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.
 1 (bases 1 to 1722)
 Hanumanthaiah, R., Day, K. and Jagadeeswaran, P.
 Comprehensive analysis of blood coagulation pathways in teleostei: evolution of coagulation factor genes and identification of zebrafish factor VIII.
 Blood Cells Mol. Dis. (2002) In press
 2 (bases 1 to 1722)
 Jagadeeswaran, P. and Hanumanthaiah, R.
 Direct Submission
 Submitted (24-MAY-2002) Cellular & Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
 Location/Qualifiers
 1..1722
 /organism="Danio rerio"
 /mol_type="mRNA"
 /db_xref="taxon:7955"
 27..1358
 /note="clotting factor"
 /codon_start=1
 /product="coagulation factor VIII"
 /protein_id="AA071000.1"
 /db_xref="GI:25005098"
 /translation="MTIGAAAVLLCVTLSTSAVFLSKDEASALLQFRFRANSFGLE EMKAGLERECVEICDEAREVFEDDTKQFWSYKNKEPCLNPNCRNNGTCVYL ADSYICSEGYEKGCEKLEETLKQYVNGGCEQFCDSGARRSCSCAEGYALAD GTSCSVQVDYPCGKIPYQKNTSQNQLGSHCPRGHCPQVQLIDYNGESVCGGALLEG PWLITAAHCHVQKTRFLKAVTGHDLVDLSDGSEPEYSAVFTHPNYDPTLSDLA LLRLRVQVSLVAVPCLPTPOLARSELWAARPHITSGWGTAGTNLRREKLGKP ASGTLORLAVPLPAAQGNANTANMFCAGYTEGDHASCSEHGDSPLTRYGETSFL TGVVSGRGCGGPGFYIYTKVENFLIMVTWKNTEDKSEQIANVSTKN"

FEATURES

source
 1..1722
 /organism="Danio rerio"
 /mol_type="mRNA"
 /db_xref="taxon:7955"
 27..1358
 /note="clotting factor"
 /codon_start=1
 /product="coagulation factor VIII"
 /protein_id="AA071000.1"
 /db_xref="GI:25005098"
 /translation="MTIGAAAVLLCVTLSTSAVFLSKDEASALLQFRFRANSFGLE EMKAGLERECVEICDEAREVFEDDTKQFWSYKNKEPCLNPNCRNNGTCVYL ADSYICSEGYEKGCEKLEETLKQYVNGGCEQFCDSGARRSCSCAEGYALAD GTSCSVQVDYPCGKIPYQKNTSQNQLGSHCPRGHCPQVQLIDYNGESVCGGALLEG PWLITAAHCHVQKTRFLKAVTGHDLVDLSDGSEPEYSAVFTHPNYDPTLSDLA LLRLRVQVSLVAVPCLPTPOLARSELWAARPHITSGWGTAGTNLRREKLGKP ASGTLORLAVPLPAAQGNANTANMFCAGYTEGDHASCSEHGDSPLTRYGETSFL TGVVSGRGCGGPGFYIYTKVENFLIMVTWKNTEDKSEQIANVSTKN"
 CDS
 1..1722
 /organism="Danio rerio"
 /mol_type="mRNA"
 /db_xref="taxon:7955"
 27..1358
 /note="clotting factor"
 /codon_start=1
 /product="coagulation factor VIII"
 /protein_id="AA071000.1"
 /db_xref="GI:25005098"
 /translation="MTIGAAAVLLCVTLSTSAVFLSKDEASALLQFRFRANSFGLE EMKAGLERECVEICDEAREVFEDDTKQFWSYKNKEPCLNPNCRNNGTCVYL ADSYICSEGYEKGCEKLEETLKQYVNGGCEQFCDSGARRSCSCAEGYALAD GTSCSVQVDYPCGKIPYQKNTSQNQLGSHCPRGHCPQVQLIDYNGESVCGGALLEG PWLITAAHCHVQKTRFLKAVTGHDLVDLSDGSEPEYSAVFTHPNYDPTLSDLA LLRLRVQVSLVAVPCLPTPOLARSELWAARPHITSGWGTAGTNLRREKLGKP ASGTLORLAVPLPAAQGNANTANMFCAGYTEGDHASCSEHGDSPLTRYGETSFL TGVVSGRGCGGPGFYIYTKVENFLIMVTWKNTEDKSEQIANVSTKN"

Query Match 0.6%; Score 21.6; DB 1; Length 1722;
 Best Local Similarity 45.3%; Pred. No. 1.2e+02;
 Matches 78; Conservative 0; Mismatches 94; Indels 0; Gaps 0;

QY 2966 TTCTAATATTACTATTCTATTCTTTTACTTTAATTAATGCACTTTATTATTGATTTCTAA 3025
 Db |||||
 QY 1547 TTTTCATAATATGATGATCACTAAGATTATATGCTTTATTAAATATTATATATGCAATTAT 1488
 Db |||||
 QY 3026 TAAATCCAGTCTCTGTTTGTATTTTAAAGACCTTTAAAAATTAAATTTCTTTAGTGT 3085
 Db |||||
 QY 1487 CCATCCAGATGAGGTGGAGTAAAGAGTTGAGGGCTCTTTTACTTCCACATACTCAT 1428
 Db |||||
 QY 3086 TTACCAAGTCTTTTACGCTACTTCTTTTGTATTTATTGTCCTTCTTTCT 3137
 Db |||||
 QY 1427 ATTTCTCTTTAAGCAACCTCATCAGAAATCAGACCCATTTAATCT 1376
 Db |||||

RESULT 93
 AX565990
 LOCUS AX565990 6098 bp DNA linear PAT 29-NOV-2002
 DEFINITION Sequence 2 from Patent WO02077218.
 ACCESSION AX565990
 VERSION AX565990.1 GI:26001242
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Persson, B.
 TITLE Coagulation factor vii derivatives
 JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;
 NOVO NORDISK A/S (DK)
 FEATURES
 Location/Qualifiers
 source
 1..6098
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Plasmid DNA pLN174"

Query Match 0.6%; Score 21.6; DB 1; Length 6098;
 Best Local Similarity 55.3%; Pred. No. 1.2e+02;
 Matches 42; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
 QY 3000 GCATTTATTTTATTGATTTTCTTAATAAAATCCAGTCTCTGTTTAAAAAGACTTT 3059
 Db |||||
 QY 2690 GAACCCCTATTGTTTATTATTTTCTAAATACATTCATCAATATGATCGCTCATGAGACAAT 2749
 Db |||||
 QY 3060 AAAATTATTAAATTTCT 3075
 Db |||||
 QY 2750 AACCTGATAAATGCT 2765
 Db |||||

RESULT 94
 AX814615
 LOCUS AX814615 172 bp DNA linear PAT 05-DEC-2003
 DEFINITION Sequence 53 from Patent WO03064641.
 ACCESSION AX814615
 VERSION AX814615.1 GI:39103828
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Bougueleret, L., Niknejad, A. and Saudrais, C.
 TITLE Gene encoding serine proteases
 JOURNAL Patent: WO 03064641-A 53 07-AUG-2003;
 Geneprot, Inc. (CH)
 FEATURES
 Location/Qualifiers
 source
 1..172
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 1..172
 /note="exon 11"

RESULT 94
 AX814615
 LOCUS AX814615 172 bp DNA linear PAT 05-DEC-2003
 DEFINITION Sequence 53 from Patent WO03064641.
 ACCESSION AX814615
 VERSION AX814615.1 GI:39103828
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Bougueleret, L., Niknejad, A. and Saudrais, C.
 TITLE Gene encoding serine proteases
 JOURNAL Patent: WO 03064641-A 53 07-AUG-2003;
 Geneprot, Inc. (CH)
 FEATURES
 Location/Qualifiers
 source
 1..172
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 1..172
 /note="exon 11"

RESULT 94
 AX814615
 LOCUS AX814615 172 bp DNA linear PAT 05-DEC-2003
 DEFINITION Sequence 53 from Patent WO03064641.
 ACCESSION AX814615
 VERSION AX814615.1 GI:39103828
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Bougueleret, L., Niknejad, A. and Saudrais, C.
 TITLE Gene encoding serine proteases
 JOURNAL Patent: WO 03064641-A 53 07-AUG-2003;
 Geneprot, Inc. (CH)
 FEATURES
 Location/Qualifiers
 source
 1..172
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 1..172
 /note="exon 11"

```

Query Match      0.6%; Score 21.4; DB 1; Length 172;
Best Local Similarity 54.4%; Pred. No. 87;
Matches 43; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 21 GGAGAGGTACCTCGTCAAGGTAAGAGCAGTAGCTGCGCTTGTCTGGAGCACC 80
Db 66 GGGGAGGTCCCTGCGCAGGTGAGCTGAAGGAAGGTCCTCCGCGCACTTCTGCGGAGCACT 125
QY 81 GTAAGAGATACCCCAAGC 99
Db 126 GTGGTGGGGACCGCTGCG 144

RESULT 95
LOCUS AR430737
DEFINITION Sequence 1 from patent US 6649409.
ACCESSION AR430737
VERSION AR430737.1 GI:40191666
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 243)
AUTHORS Fomsgaard,A.
TITLE Method for producing a nucleotide sequence construct with optimized codons for an HIV genetic vaccine based on a primary, early HIV isolate and synthetic envelope BX08 constructs
JOURNAL Patent: US 6649409-A 18-NOV-2003;
FEATURES
    source
        1..243
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match      0.6%; Score 21.4; DB 1; Length 243;
Best Local Similarity 61.8%; Pred. No. 95;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1423 CATGACATTGTACAGAGACAGGATCGAGACCATCCCGTGAAGAAAGATGCA 1477
Db 163 CAGGAGGTGCTGCTGGCAACGTGACCGAGAACTTCAACATGGGCAAGACAACA 217

RESULT 96
LOCUS AX028553
DEFINITION Sequence 1 from Patent WO0029561.
ACCESSION AX028553
VERSION AX028553.1 GI:10189710
KEYWORDS Human immunodeficiency virus
SOURCE Human immunodeficiency virus
ORGANISM Viruses; Retroviral viruses; Retroviridae; Lentivirus; Primate lentivirus group.
REFERENCE 1
AUTHORS Fomsgaard,A.
TITLE Method for producing a nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope bx08 constructs
JOURNAL Patent: WO 0029561-A 1 25-MAY-2000;
STATENS SERUMINSTITUT (DK) ; FOMSGAARD ANDERS (DK)
FEATURES
    source
        1..243
        /organism="Human immunodeficiency virus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:12721"
        <1..>243
        /note="unnamed protein product"
        /codon_start=1
        /protein_id="CAC09208.1"
        /db_xref="GI:10189711"
        /db_xref="REMTREMBL:CAC09208"
        /translation="ASAADRLMTVYVYGVVPWKDATTTTLCASDAKAYDTEVHNWAT"

CDS

```

```

HACVTFDPNFBQEVVLGNVTENFMGKNMVFQMHEDI"

Query Match      0.6%; Score 21.4; DB 1; Length 243;
Best Local Similarity 61.8%; Pred. No. 95;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1423 CATGACATTGTACAGAGACAGGATCGAGACCATCCCGTGAAGAAAGATGCA 1477
Db 163 CAGGAGGTGCTGCTGGCAACGTGACCGAGAACTTCAACATGGGCAAGACAACA 217

RESULT 97
LOCUS AF336229
DEFINITION Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*5901 allele, exon 2 and partial cds.
ACCESSION AF336229
VERSION AF336229.1 GI:13430239
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 291)
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Sequence of complete exon 2 and partial intron 2 of HLA-DPB1*5901 allele
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 291)
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Direct Submission
JOURNAL Submitted (16-JAN-2001) Biochemistry Department, Zhongshan (Sun Yat-sen) University, 135 W. Xingang Rd, Guangzhou, Guangdong 510275, P.R. China

FEATURES
    source
        1..291
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /chromosome="6"
        /map="6p21.3"
        <1..>283
        /gene="HLA-DPB1"
        /allele="HLA-DPB1*5901"
        <1..>264
        /gene="HLA-DPB1"
        <1..>264
        /gene="HLA-DPB1"
        /codon_start=3
        /product="MHC class II antigen"
        /protein_id="AAK25784.1"
        /db_xref="GI:13430240"
        /translation="NYLFGROECYAFNGTFRFLERYLYNREEFVRFSDVGEFRAVT ELGRPDEYWNQKLLLEKRAVPDRMCRHNYELGPMTLQRR"
        1..264
        /gene="HLA-DPB1"
        /number=2

Query Match      0.6%; Score 21.4; DB 1; Length 291;
Best Local Similarity 46.9%; Pred. No. 99;
Matches 67; Conservative 0; Mismatches 76; Indels 0; Gaps 0;

QY 2551 CAGTACTTTGGCCACTGATCAGAAGAGCTGACTCTACTGGAAGACCCCTGATGCTGGGA 2610
Db 133 CGGAGCTGGGGCGCGCTGATGAGGACTTGTGAACAGCAGGACCTCTCTGGAGAGA 192
QY 2611 GGGATTGGGGGCAGGAGGAGAGGGGACGACAGAGGATGAGATGGCTGGATGCACTACT 2670
Db 193 AGCGGGCAGTGCCTGGACAGGATGTGCAGACACAACTACGAGCTGGCGCGCCATGACCC 252
QY 2671 GACTCTGATGACCTGAGTCTGGG 2693
Db 253 TGCAGCGCCGAGGTGAGTGAGGG 275

```

```

RESULT 98
HUMPS02
LOCUS      Human S protein-alpha (PS-alpha) gene, exon 2.
DEFINITION Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION M57841 J02917
VERSION    M57841.1 GI:1290535
KEYWORDS   S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT    2 of 14
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 352)
            Schmeidel,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
            Organization of the human protein S genes
            Biochemistry 29 (34), 7845-7852 (1990)
MEDLINE    91084444
PUBMED     2148110
COMMENT    Original source text: Human liver DNA.
FEATURES   source
            Location/Qualifiers
            1..352
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /map="3p11-q11.2"
            /tissue_type="liver"
            join(M57840.1:837..912,135..181)
            /gene="PS-alpha"
            order(M57840.1:913..1014,1..134)
            /gene="PROS1"
            /number=1
            135..292
            /gene="PROS1"
            /note="G00-120-721"
            /number=2

            sig_peptide
            intron
            exon

Query Match      0.6%; Score 21.4; DB 1; Length 352;
Best Local Similarity 54.4%; Pred. No.1e+02;
Matches 43; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

Qy 3200 TCATATTCCTTGTGTAACAGCTTCACTCTATGCTTAAAGTTTATTTTATTTT 3259
Db 10 TCATACGATTTTAAAGTCTACAAATTCATAGCAGAAATGATTTAACTCTATGT 69

Qy 3260 TTTTTTAAAGATGTCATT 3278
Db 70 TTAATAAACATATATT 88

RESULT 99
AF011352/c
LOCUS      Petromyzon marinus trypsinogen A1 mRNA, complete cds.
DEFINITION Petromyzon marinus trypsinogen A1 mRNA, complete cds.
ACCESSION AF011352
VERSION    AF011352.1 GI:2293477
KEYWORDS   Petromyzon marinus (sea lamprey)
SOURCE     Petromyzon marinus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
            Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE  1 (bases 1 to 861)
            Roach,J.C.
            The molecular evolution of the vertebrate trypsinogenase
            Unpublished
            2 (bases 1 to 861)
            Roach,J.C.
            Direct Submission
            Submitted (25-JUN-1997) Molecular Biotechnology, University of
            Washington, Seattle, WA 98185, USA
FEATURES   source
            Location/Qualifiers
            1..861

```

```

/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/tissue_type="anterior intestine"
/dev_stage="ammocoete"
6..749
/codon_start=1
/product="trypsinogen A1"
/protein_id="AAB63411.1"
/db_xref="GI:2293478"
/translation="MHGLILALLVGAAPWYEDHIVGGSECAAHQSPWQVSLNIG
YHFCGSLINSQWVVAACHQVTSRISVRIGRHEHNFVNEGTEQOIQASKAIHQPOYN
SWTIDNDMLIKLSPATLNQYQAIALPSCVNTGVMTISGGETQTSVGSPPVLM
CVQAPVLSITCRNSYPGDI TNMIMICLVLEGGKDCQCGSGPVVNCNGELQIVSWG
RCCALPNYGVYTKVCYNNAIAQTIAA"
6..50
/evidence=not_experimental
51..746
/product="trypsin A1"
/evidence=not_experimental

            sig_peptide
            mat_peptide

Query Match      0.6%; Score 21.4; DB 1; Length 861;
Best Local Similarity 66.0%; Pred. No.1.2e+02;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 3250 TTTTITTTTTTTTTTAAAGATGTCATTCTTTGTGAAGTTTGTACA 3296
Db 861 TTTTITTTTTTTTTTATATGTTTCACATTTTATTCATTGTTGTACA 815

RESULT 100
AF465274
LOCUS      Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete
DEFINITION cds.
ACCESSION AF465274
VERSION    AF465274.1 GI:28194019
KEYWORDS   Takifugu rubripes (Fugu rubripes)
            Takifugu rubripes
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
            Tetraodontidae; Tetraodontidae; Takifugu.
REFERENCE  1 (bases 1 to 1329)
            Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
            Tuddenham,E.G.D. and McVey,J.H.
            Comparative sequence analysis and molecular evolution of blood
            coagulation genes from Gallus gallus and Fugu rubripes
            Unpublished
            2 (bases 1 to 1329)
            McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
            Direct Submission
            Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
            Centre, The Faculty of Medicine, Imperial College, Hammersmith
            Campus, Du Cane Road, London W12 0NN, UK
FEATURES   source
            Location/Qualifiers
            1..1329
            /organism="Takifugu rubripes"
            /mol_type="mRNA"
            /db_xref="taxon:31033"
            1..1329
            /EC_number="3.4.21.21"
            /function="serum prothrombinconversion accelerator"
            /note="vitamin K dependent serine protease; similar to
            Fugu rubripes FVII; synthesized in liver; contains 2
            EGF-like domains; member of peptidase family S1/trypsin
            family"
            /codon_start=1
            /product="coagulation factor VIIb precursor"
            /protein_id="AA033369.1"
            /db_xref="GI:28194020"
            /translation="MLIRICCTWILFSAATAAAVFERDDASTVLQRRRRANSGLFE

```



```

ACCESSION   AX360070
VERSION     AX360070.1  GI:18675696
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Plowman,G., Whyte,D., Sudarsanam,S., Manning,G., Caenepeel,S. and
            Charyczak,G.
TITLE       Novel proteases
JOURNAL     Patent: WO 0200860-A 26 03-JAN-2002;
            Sugen, Inc. (US)
FEATURES
source      Location/Qualifiers
            1..888
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 21.2; DB 1; Length 888;
Best Local Similarity 52.2%; Pred.No.1.4e+02;
Matches 47; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

Qy  2683 GTGACTCTGGTGAACCTCTGGTGTGATGGACAGGAGGCGCTGTCCTGCGCGGATT 2742
Db  620 GGGATTCATGTTTGTCTGCTGCTGAGGATGGCAGTGTAGACACCTGCAAGGTGACT 679
Qy  2743 CATGGGGTCACAAAGAGTTGGACACGACTG 2772
Db  680 CAGGTGGACCTTGTCTGTGCAAGGATG 709

RESULT 105
AR234337/c
LOCUS       AR234337                1130 bp            DNA            linear            PAT 20-DEC-2002
DEFINITION Sequence 8 from patent US 6458564.
ACCESSION   AR234337
VERSION     AR234337.1  GI:27277021
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 1130)
AUTHORS     Darrow,A., Qi,J. and Andrade-Grodon,P.
TITLE       DNA encoding the human serine protease T
JOURNAL     Patent: US 6458564-A 8 01-OCT-2002;
            Location/Qualifiers
FEATURES
source      1..1130
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.6%; Score 21.2; DB 1; Length 1130;
Best Local Similarity 50.0%; Pred.No.1.5e+02;
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

Qy  2860 TCATAATGTTGGTTAAGATAATAAGATTTTCAAAATGATTTTATCTTTGATTTTCTCT 2919
Db  1110 TTATAATGTTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAAGCATTTTTC 1051
Qy  2920 ACTTATTAAATTTGGATTTTAACTATTCTTCAATGACTTGAT 2965
Db  1050 ACTGCATCTAGTTGGTTTGTCCAAACTCATCAATGATCTTAT 1005

RESULT 106
AR221273/c
LOCUS       AR221273                1166 bp            DNA            linear            PAT 26-SEP-2002
DEFINITION Sequence 2 from patent US 6426199.
ACCESSION   AR221273
VERSION     AR221273.1  GI:23328188
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1
AUTHORS     Noble,J.A., Cavalli,A.S. and Erlich,H.A.
TITLE       DBP1*5901a: a novel HLA-DPB1 allele from a Caucasian family with
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
            1 (bases 1 to 252)
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.6%; Score 21.2; DB 1; Length 1166;
Best Local Similarity 50.0%; Pred.No.1.5e+02;
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

Qy  2860 TCATAATGTTGGTTAAGATAATAAGATTTTCAAAATGATTTTATCTTTGATTTTCTCT 2919
Db  1146 TTATAATGTTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAAGCATTTTTC 1087
Qy  2920 ACTTATTAAATTTGGATTTTAACTATTCTTCAATGACTTGAT 2965
Db  1086 ACTGCATCTAGTTGGTTTGTCCAAACTCATCAATGATCTTAT 1041

RESULT 107
AX565990/c
LOCUS       AX565990                6098 bp            DNA            linear            PAT 29-NOV-2002
DEFINITION Sequence 2 from Patent WO02077218.
ACCESSION   AX565990
VERSION     AX565990.1  GI:26001242
KEYWORDS
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM    1
            Persson,E.
            Coagulation factor vii derivatives
            Patent: WO 02077218-A 2 03-OCT-2002;
            NOVO NORDISK A/S (DK)
            Location/Qualifiers
FEATURES
source      1..6098
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Plasmid DNA pLN174"

Query Match      0.6%; Score 21.2; DB 1; Length 6098;
Best Local Similarity 50.0%; Pred.No.1.4e+02;
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

Qy  2860 TCATAATGTTGGTTAAGATAATAAGATTTTCAAAATGATTTTATCTTTGATTTTCTCT 2919
Db  4956 TTATAATGTTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAAGCATTTTTC 4897
Qy  2920 ACTTATTAAATTTGGATTTTAACTATTCTTCAATGACTTGAT 2965
Db  4896 ACTGCATCTAGTTGGTTTGTCCAAACTCATCAATGATCTTAT 4851

RESULT 108
HSU29534
LOCUS       HSU29534                252 bp            DNA            linear            PRI 18-APR-1997
DEFINITION Human MHC class II antigen HLA-DP-beta (HLA-DPB1) gene, exon 2,
            partial cds..
ACCESSION   U29534
VERSION     U29534.1  GI:903973
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
            1 (bases 1 to 252)
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.6%; Score 21.2; DB 1; Length 1166;
Best Local Similarity 50.0%; Pred.No.1.5e+02;
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

Qy  2860 TCATAATGTTGGTTAAGATAATAAGATTTTCAAAATGATTTTATCTTTGATTTTCTCT 2919
Db  1110 TTATAATGTTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAAGCATTTTTC 1051
Qy  2920 ACTTATTAAATTTGGATTTTAACTATTCTTCAATGACTTGAT 2965
Db  1050 ACTGCATCTAGTTGGTTTGTCCAAACTCATCAATGATCTTAT 1005

```

```

insulin-dependent diabetes mellitus
Tissue Antigens 47 (2), 159-162 (1996)
JOURNAL MEDLINE 97004423
PUBMED 8851734
REFERENCE 2 (bases 1 to 252)
AUTHORS Noble, J.A. and Erlich, H.A.
TITLE Direct Submission
JOURNAL Submitted (19-JUN-1995) Janelle A. Noble, Human Genetics, Roche
Molecular Systems, 1145 Atlantic Ave., Alameda, CA 94501, USA
FEATURES
    source
        Location/Qualifiers
            1..252
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /map="6p"
                /chromosome="6"
            /cell_line="cell lines HB01242, HB01243, HB01244 available
            from the Human Biological Data Interchange (HBDI),
            Philadelphia, PA"
            /note="cloned from PCR amplification products"
            1..252
                /gene="HLA-DPB1"
            <1..>252
                /gene="HLA-DPB1"
                /codon_start=1
                /product="MHC class II antigen HLA-DP-beta"
                /protein_id="AAB52511.1"
                /db_xref="GI:903974"
                /translation="NYLFGROECYAFNGTQRFLERYIYNREEFVRFSDVGEFRAVT
                ELGRPDEEYWSQDLLEKRAVPDRMCRHNYELGSPMTLQ"

Query Match      0.6%; Score 21; DB 1; Length 252;
Best Local Similarity 49.5%; Pred. No. 1.2e+02;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2551 CAGTACTTTGGCCACTGATCAGAGAGTGCTACTCTGGAAGAACCCCTGATGCTGGGA 2610
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 131 CGAGCTGGGGCGGCTGATGAGGAGTACTGGAACAGCAGGACCTCTCTGGAGGAGA 190

QY 2611 GGGATTGGGGCAGAGGAGGAGGACGACAGAGGATGAGTGGCTGG 2659
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 191 AGCGGCAGTGGCGGACAGGATGTCAGACACAACTACGAGCTGGCGG 239

RESULT 109
HSU59442
LOCUS Human MHC class II antigen DPbeta1 gene (DPB1*5901 allele), partial
DEFINITION cds..
ACCESSION U59442.1 GI:4097404
VERSION U59442.1
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 255)
AUTHORS Noreen, H., Steiner, L., Davidson, M., Johnson, S., Segall, M. and
Begovich, A.B.
TITLE Six new DPB1 alleles identified in a study of 1,302 unrelated bone
marrow donor-recipient pairs
JOURNAL Tissue Antigens 49 (5), 512-516 (1997)
MEDLINE 97316872
PUBMED 9174146
REFERENCE 2 (bases 1 to 255)
AUTHORS Steiner, L., Begovich, A. and Noreen, H.
TITLE Direct Submission
JOURNAL Submitted (29-MAY-1996) Human Genetics, Roche Molecular Systems,
1145 Atlantic Avenue, Alameda, CA 94501, USA
FEATURES
    source
        Location/Qualifiers
            1..255
                /organism="Homo sapiens"
                /mol_type="genomic DNA"

```

```

        /db_xref="taxon:9606"
        /chromosome="6"
        1..255
            /genes="HLA-DPB1"
            <1..>255
                /genes="HLA-DPB1"
                /note="Allele: DPB1*5901"
                /codon_start=1
                /product="MHC class II antigen DPbeta1"
                /protein_id="AAD09486.1"
                /db_xref="GI:4097405"
                /translation="NYLFGROECYAFNGTQRFLERYIYNREEFVRFSDVGEFRAVT
                ELGRPDEEYWSQDLLEKRAVPDRMCRHNYELGSPMTLQ"

Query Match      0.6%; Score 21; DB 1; Length 255;
Best Local Similarity 49.5%; Pred. No. 1.2e+02;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2551 CAGTACTTTGGCCACTGATCAGAGAGTGCTACTCTGGAAGAACCCCTGATGCTGGGA 2610
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 131 CGAGCTGGGGCGGCTGATGAGGAGTACTGGAACAGCAGGACCTCTCTGGAGGAGA 190

QY 2611 GGGATTGGGGCAGAGGAGGAGGACGACAGAGGATGAGTGGCTGG 2659
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 191 AGCGGCAGTGGCGGACAGGATGTCAGACACAACTACGAGCTGGCGG 239

RESULT 110
HUMHCD21A
LOCUS Human major histocompatibility complex class II (HLA-DPB21) gene,
DEFINITION exon 2.
ACCESSION M84617.1 GI:187834
VERSION M84617.1
KEYWORDS cell surface glycoprotein; class II gene; integral membrane
protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 260)
AUTHORS Begovich, A.B., Moonsamey, P., Suraj, V., Bugawan, T.L., Stoneking, M.,
Roudier, J. and Hills, A.V.S.
TITLE Genetic diversity within the HLA class II region: ten new DPB1
alleles and their population distribution
JOURNAL Immunogenetics 40, 153-157 (1992)
COMMENT Original source text: Homo sapiens (individual isolate Indonesian
57) DNA.
FEATURES
    source
        Location/Qualifiers
            1..260
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /isolate="Indonesian 57"
                /db_xref="taxon:9606"
                /map="6p21.3"
                /haplotype="DPB21"
                /cell_type="lymphocyte"
            1..260
                /gene="HLA-DPB21"
            1..260
                /gene="HLA-DPB21"
                /number=2

Query Match      0.6%; Score 21; DB 1; Length 260;
Best Local Similarity 49.5%; Pred. No. 1.2e+02;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2551 CAGTACTTTGGCCACTGATCAGAGAGTGCTACTCTGGAAGAACCCCTGATGCTGGGA 2610
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 136 CGAGCTGGGGCGGCTGATGAGGAGTACTGGAACAGCAGGACCTCTCTGGAGGAGA 195

QY 2611 GGGATTGGGGCAGAGGAGGAGGACGACAGAGGATGAGTGGCTGG 2659
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

```

Db      196 AGCGGGCAGTCCGGACAGGAGTGTGCAGACACACTACGAGCTGGTCGG 244

RESULT 111
LOCUS   HUMDPB111
DEFINITION Human MHC class II HLA-DP-beta1 (HLA-DPB1) gene, allele 2.
ACCESSION L00599
VERSION   L00599.1 GI:181737
KEYWORDS cell surface glycoprotein; class II gene; integral membrane glycoprotein; major histocompatibility complex; major histocompatibility complex class II.

SOURCE  Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS   Eastaugh, S. and Croft, L.
TITLE     Two new HLA-DPB1 alleles from Java, Indonesia
JOURNAL   Unpublished (1992)
COMMENT   Original source text: Homo sapiens blood DNA.
FEATURES  Location/Qualifiers
            source
            1..285
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /map="6p21.3"
                /tissue_type="blood"
            20..283
                /gene="HLA-DPB1"
            20..283
                /gene="HLA-DPB1"
            /note="G00-120-636"

Query Match      0.6%; Score 21; DB 1; Length 285;
Best Local Similarity 49.5%; Pred. No. 1.2e+02;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY      2551 CAGTACTTTGCCACCTGATCAGAGAGCTGACTACTCTGGAAGAGACCTGATGCTGGGA 2610
Db      152 CGGAGCTGGGGCGGCTGATGAGGAGTACTGGACAGCCAGAGACCTCTGGAGGAGA 211
QY      2611 GGGATGGGGCAGAGAGAGAGAGGAGCAGAGGATGAGATGGCTGG 2659
Db      212 AGCGGGCAGTCCGGACAGGAGTGTGCAGACACACTACGAGCTGGTCGG 260

RESULT 112
LOCUS   PMA344566
DEFINITION Paralabrax maculatofasciatus partial mRNA for trypsin.
ACCESSION AJ344566
VERSION   AJ344566.1 GI:15706275
KEYWORDS trypsin.
SOURCE    Paralabrax maculatofasciatus (spotted sand bass)
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Percoidae; Serranidae; Paralabrax.
REFERENCE 1
AUTHORS   Tovar-Ramirez, D., Zambonino-Infante, J.L., Gatesoupe, J., Cahu, C., Nolasco-Soria, H. and Vazquez-Juarez, R.
TITLE     Properties of polyamines producers yeast as potential probiotics for the spotted sand bass Paralabrax maculatofasciatus larvae
JOURNAL   Unpublished
AUTHORS   Tovar-Ramirez, D.
TITLE     Direct Submission
JOURNAL   Submitted (29-AUG-2001)
FEATURES  Location/Qualifiers
            1..535
                /organism="Paralabrax maculatofasciatus"
                /mol_type="mRNA"
                /db_xref="taxon:147646"
                /tissue_type="hepatopancreas"
                /country="Mexico:Baja California Sur"
                <1..535
                /product="trypsin"
                <1..5178
                /EC number="3.4.21.4"
                /function="proteolysis"
                /codon_start=1
                /product="trypsin"
                /protein_id="CAC69999.1"
                /db_xref="GI:15706276"
                /db_xref="GOA:Q90WQ4"
                /db_xref="SPTREMBL:Q90WQ4"
                /translation="OVSLNSGVHFCGGSLVNVWVSAAHCKYSRVEVRLGHNIRVT EGSQFISSSRVIRH"

Query Match      0.6%; Score 21; DB 1; Length 535;
Best Local Similarity 51.6%; Pred. No. 1.4e+02;
Matches 48; Conservative 0; Mismatches 45; Indels 0; Gaps 0;

QY      881 AAGAAGCTGAGTTGAACGGTCTCTATGAGAGCTACAGACCTTTTAGAACACACCA 940
Db      355 AAGCTCCAGTGGCTGGACCTCCCATCTCTTTCCAGAGCTGTGACAACTCCTACCT 414
QY      941 AAAAAGATGTCCTTCTCATTTATAGGGGAGCTGGA 973
Db      415 GGATGATCACCAGCGCCATGTAATGCGCTGGA 447

RESULT 113
LOCUS   AF011901/c
DEFINITION Petromyzon marinus trypsinogen b2 (TRYPB2) mRNA, partial cds.
ACCESSION AF011901
VERSION   AF011901.1 GI:2367500
KEYWORDS Petromyzon marinus (sea lamprey)
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia; Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE 1 (bases 1 to 836)
AUTHORS   Roach, J.C.
TITLE     The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL   Unpublished
AUTHORS   Roach, J.C.
TITLE     Direct Submission
JOURNAL   Submitted (01-JUL-1997)
FEATURES  Location/Qualifiers
            1..836
                /organism="Petromyzon marinus"
                /mol_type="mRNA"
                /db_xref="taxon:7757"
                /dev_stage="ammocoete"
                /tissue_lib="anterior intestine"
                <1..836
                /gene="TRYPB2"
                <1..740
                /gene="TRYPB2"
                /codon_start=3
                /product="trypsinogen b2"
                /protein_id="AA569857.1"
                /db_xref="GI:2367501"
                /translation="GLIFALLVGTAAAPVMEHDHIVGGYCAHSPQWVSNIGYH FCGSLTSSSEWVVAACHQTSASRISVRIGEHNIIVTEGTEQRIOASKAIRHPQVNSA TIDNDMLIKLSPPATLNOVAQAIPLPSSCGVTGVMCTISGWTGTQVSGSPDLMCV QAPVLSDTSCNSYPGDIITNNMICLVGLEGGKDCQCGDSGPGVVCNQLQGIWGRG CALPNYPGVTKVNCYNYSIASTMAAN"
                <1..41

sig_peptide

```



```
RESULT 117
AF465269/c
LOCUS
DEFINITION
  AF465269
  Gallus gallus coagulation factor IX precursor (P9) mRNA, complete
  cds.
ACCESSION
  AF465269
  GI:28194009
KEYWORDS
  Gallus gallus (chicken)
SOURCE
  Gallus gallus
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
  Phasianinae; Gallus.
REFERENCE
  1 (bases 1 to 1416)
  Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
  Tuddenham, E.G.D. and McVey, J.H.
  Comparative sequence analysis and molecular evolution of blood
  coagulation genes from Gallus gallus and Fugu rubripes
  Unpublished
  2 (bases 1 to 1416)
  McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
  Direct Submission
  Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
  Centre, The Faculty of Medicine, Imperial College, Hammersmith
  Campus, Du Cane Road, London W12 0NN, UK
  Location/Qualifiers
    1..1416
      /organism="Gallus gallus"
      /mol_type="mRNA"
      /db_xref="taxon:9031"
    gene="F9"
    1..1416
      /gene="F9"
    1..1416
      /EC_number="3.4.21.22"
      /function="converts factor X to its active form in the
      presence of Ca++ ions, phospholipids, and factor VIIa"
      /note="vitamin K dependent serine protease; Christmas
      factor; contains 2 EGF-like domains; member of peptidase
      family S1/trypsin family"
      /codon_start=1
      /product="coagulation factor IX precursor"
      /protein_id="AAO33364.1"
      /db_xref="GI:28194010"
      /translation="MAKIPLLSCLLEAFLEAESTVFIENKEASTVLSRTRGNSNR
      LEEIPGNLEECIEKSPFEAREVFENKTEFWKVIYDGCNSNCKNGAVCK
      DGVSCEMCPGGRCEIDSTCATKNGGCEHFCHRDTPQKAVCSAGYKLUHEDG
      KSCPAPVPCGRITAPEMRGKVTRENTIENWITADHDEADALDITEPPPTT
      TSAAPKIVPTITVGGYDVKQLPMQVHLVDSRGLGFCGSGIINEKVVYTA
      HLEPGDNVTAGEYNKEDDHTEQRRQVVKILPYPTNTRKNKHNDIALLELDQ
      LTPSYVTPIGIGSEDTNNLLSNGPGTVSCGSMLYGRSAIVQLVTPVVDRTVC
      LKSTTILHNFCAGYTAGKDTCCGDSGSGPYNSIGETWFLTGVTISWGECAKPK
      YGIYTKVAKYVKNIREITRLI"
  Query Match 0.6%; Score 21; DB 1; Length 1416;
  Best Local Similarity 54.5%; Pred. No. 1.7e+02;
  Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
  QY 1209 GTCACAAAACACACGAGGCTTACTGTGGCTCAGATCATGACCTTATTCGCAA 1268
  Db 340 GTGGGCATGCACCTATAGGAGCTTACTCGCTCTTGACACGCTCCATTITGATG 281
  QY 1269 ATTACAGCTTAATGCA 1285
  Db 280 GGTGGAGTTACACTGA 264
  RESULT 118
  AX147505
  LOCUS
  DEFINITION
    AX147505
    Sequence 59 from Patent WO0136632.
  ACCESSION
```

```
AX147505.1 GI:14346662
VERSION
KEYWORDS
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini, Hominidae; Homo.
REFERENCE
  1
  Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.
  Variants of alternative splicing
  Patent: WO 0136632-A 59 25-MAY-2001;
  Compugen Ltd. (IL)
FEATURES
  Location/Qualifiers
    1..1551
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"
  Query Match 0.6%; Score 21; DB 1; Length 1551;
  Best Local Similarity 48.7%; Pred. No. 1.7e+02;
  Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
  QY 1390 GACAGAGTACCTAATGAACATGTCAGAGAGGTTTCATGACATTGTACAGAGACAGGGATC 1449
  Db 108 GAGGAAGCACATGGTGTCTCTACACAGGCAAGCGGTGCCAATCTCACTCTCTGGAGGACTT 167
  QY 1450 GAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGGCC 1506
  Db 168 TGGCCCGGCTCTCTGGAGAGAGTGCATGAGACAGTGTCTCTTTCAGGAGGCC 224
  RESULT 119
  MMU44795
  LOCUS
  DEFINITION
    MMU44795
    1850 bp mRNA linear ROD 23-MAY-1996
  ACCESSION
    U44795
  VERSION
    U44795.1 GI:1184738
  KEYWORDS
  SOURCE
    Mus musculus (house mouse)
  ORGANISM
    Mus musculus
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  REFERENCE
    1 (bases 1 to 1850)
    Idusogie, E., Rosen, E., Geng, J.P., Carmeliet, P., Collen, D. and
    Castellino, F.J.
    Characterization of a cDNA encoding murine coagulation factor VII
    Thromb. Haemost. 75 (3), 481-487 (1996)
    95276538
    8701412
  JOURNAL
  MEDLINE
  PUBMED
  REFERENCE
    2 (bases 1 to 1850)
    Rosen, E.D., Idusogie, E., Carmeliet, P., Collen, D. and
    Castellino, F.J.
    Direct Submission
    Submitted (05-JAN-1996) Elliot D. Rosen, Chemistry, Univ. of Notre
    Dame, Notre Dame, IN 46556, USA
  TITLE
  JOURNAL
  FEATURES
  Location/Qualifiers
    1..1850
      /organism="Mus musculus"
      /mol_type="mRNA"
      /db_xref="taxon:10090"
      /tissue_type="liver"
    1..1850
      /gene="FVII"
    16..1356
      /gene="FVII"
      /note="initiation of extrinsic pathway of blood
      coagulation; serine protease"
      /codon_start=1
      /product="coagulation factor VII"
      /protein_id="AAC52570.1"
      /db_xref="GI:1184739"
  gene
  CDS
  QY 1209 GTCACAAAACACACGAGGCTTACTGTGGCTCAGATCATGACCTTATTCGCAA 1268
  Db 340 GTGGGCATGCACCTATAGGAGCTTACTCGCTCTTGACACGCTCCATTITGATG 281
  QY 1269 ATTACAGCTTAATGCA 1285
  Db 280 GGTGGAGTTACACTGA 264
  RESULT 118
  AX147505
  LOCUS
  DEFINITION
    AX147505
    Sequence 59 from Patent WO0136632.
  ACCESSION
```

LQDEVSCRPVEYPCGRIPVVEKNSRQRIYGVNCPKGECPQWALVINGLL
 CGAVLLDARIWITAAHCFDNIYWGNIIVMGEHDFSEKDGDEQVRRVTQVIMPKYI
 RKNINDIALLRLRPVFTDVPVPLCLPKSFSENTLARIFRSVGSGQLDRGAT
 ALEMSIEVPLMTODCLHAKHSNTPKITENMFCAGYMDGTCKADKSGSGPHATH
 YHGTWYLTGVSWGEGCAALGHIGYTRVSQIDVLRHMDSKLVGVFRPLLL
 1850

polyA_site

/gene="fvii"
 /note="54 A nucleotides"

Query Match 0.6%; Score 21; DB 1; Length 1850;

Best Local Similarity 48.7%; Pred. No. 1.7e+02;
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1390 GACAGAGTACCTAATGAACATGACAGAGGTTTCATGACATTTGACAGGACAGGATC 1449
 |||
 DB 103 GAGGAGACATGCTGCTCCTACACAGGCAAGGCGTGCACACTCACTCTCTGAGGAGCTT 162
 |||
 QY 1450 GAGACCATCCCATGAAAGAAATGCCAAAGAAAGAAATGCTCTCTGGGAGGCC 1506
 |||
 DB 163 TGCCCCGCTCTCTGAGAGAGAGTCAATGAGGACAGTCTCTCTTTGAGAGGCC 219
 |||

RESULT 120

BC061149 1869 bp mRNA linear ROD 25-NOV-2003
 LOCUS Mus musculus coagulation factor VII, mRNA (CDNA clone MGC:74281
 IMAGE:30305571), complete cds.

ACCESSION BC061149
 VERSION MGC.
 KEYWORDS
 SOURCE MGC.
 ORGANISM Mus musculus (house mouse)

REFERENCE

1 (bases 1 to 1869)
 Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS

Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
 Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
 Altshul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
 Hopkins, R.F., Jordan, M., Moore, T., Max, S.I., Wang, J., Hsieh, P.,
 Diachenko, L., Marusina, K., Farmer, A.A., Rubin, G.W., Hong, L.,
 Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
 Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
 Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
 Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,
 McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
 Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
 Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
 Fahey, J., Helton, E., Kettner, M., Madan, A., Rodriguez, S.,
 Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y.,
 Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
 Dickinson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
 Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalish, D.E.,
 Scherch, A., Schein, J.E., Jones, S.J. and Marra, M.A.

Generation and initial analysis of more than 15,000 full-length

human and mouse cDNA sequences

Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

JOURNAL MEDLINE

PUBMED 22388257

REFERENCE 2 (bases 1 to 1869)

AUTHORS Strausberg, R.

TITLE Direct Submission

Submitted (03-NOV-2003) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA

NIH-MGC Project URL: <http://mgc.nci.nih.gov>

Contact: MGC help desk

Email: cgabbs@mail.nih.gov

Tissue Procurement: Dr. Michael Brownstein

cDNA Library Preparation: Michael Brownstein / Ted Usdin

Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILLNL)

DNA Sequencing by: Sequencing Group at the Stanford Human Genome

Center, Stanford University School of Medicine, Stanford, CA 94305
 Web site: <http://www-shgc.stanford.edu>
 Contact: (Dickson, Mark) mcd@paxil.stanford.edu
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
 R. M.

Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/ILLNL at: <http://image.llnl.gov>
 Series: IRAL Plate: 53 Row: n Column: 1
 This clone was selected for full length sequencing because it
 passed the following selection criteria: matched mRNA gi: 6753805.

FEATURES

source

1..1869
 /organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="taxon:10090"
 /clone="MGC:74281 IMAGE:30305571"
 /tissue_type="Liver, mouse"
 /clone_lib="NIH MGC_177"
 /lab_host="DH10B"
 /notes="Vector: pDNR-LIB"
 1..1869
 /gene="F7"
 /note="synonyms: FVII, mFVII"
 /db_xref="LocusID:14068"
 /db_xref="MGI:109325"
 10..1350
 /codon_start=1
 /product="coagulation factor VII"
 /protein_id="AAH61149.1"
 /db_xref="GI:38511702"
 /db_xref="LocusID:14068"
 /translation="MPQAHGLLLCLLQLOGLTAVFTQBEAHGVLRHRRANS
 LLEFLWPGVSEECNEQSEAEKIFKSPERTQFVIYSDGDCASNPQNGGTC
 OHLKSYGFCILLDFEGNECKSKNEQICANENGDCQYCRDHVTGRTSCSHDYT
 LQFDEVCSPKVEYPCGRIPVVEKNSRQRIYGVNCPKGECPQWALVINGLL
 CGAVLLDARIWITAAHCFDNIYWGNIIVMGEHDFSEKDGDEQVRRVTQVIMPKYI
 RKNINDIALLRLRPVFTDVPVPLCLPKSFSENTLARIFRSVGSGQLDRGAT
 ALEMSIEVPLMTODCLHAKHSNTPKITENMFCAGYMDGTCKADKSGSGPHATH
 YHGTWYLTGVSWGEGCAALGHIGYTRVSQIDVLRHMDSKLVGVFRPLLL"
 79..264
 /notes="GLA; Region: Domain containing Gla
 (gamma-carboxyglutamate) residues"
 /db_xref="CDD:smart00069"
 268..378
 /note="EGF_CA; Region: Calcium-binding EGF-like domain,
 present in a large number of membrane-bound and
 extracellular (mostly animal) proteins. Many of these
 proteins require calcium for their biological function and
 calcium-binding sites have been found to be located at the
 N-terminus of particular EGF-like domains"
 /db_xref="CDD:cd00054"
 589..1302
 /note="Tryp_SPC; Region: Trypsin-like serine protease"
 /db_xref="CDD:cd00190"

CDS

misc_feature

268..378
 /note="EGF_CA; Region: Calcium-binding EGF-like domain,
 present in a large number of membrane-bound and
 extracellular (mostly animal) proteins. Many of these
 proteins require calcium for their biological function and
 calcium-binding sites have been found to be located at the
 N-terminus of particular EGF-like domains"
 /db_xref="CDD:cd00054"

misc_feature

589..1302
 /note="Tryp_SPC; Region: Trypsin-like serine protease"
 /db_xref="CDD:cd00190"

Query Match 0.6%; Score 21; DB 1; Length 1869;

Best Local Similarity 48.7%; Pred. No. 1.7e+02;

Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1390 GACAGAGTACCTAATGAACATGACAGAGGTTTCATGACATTTGACAGGACAGGATC 1449

DB 97 GAGGAGACATGCTGCTCCTACACAGGCAAGGCGTGCACACTCACTCTCTGAGGAGCTT 156

QY 1450 GAGACCATCCCATGAAAGAAATGCCAAAGAAAGAAATGCTCTCTGGGAGGCC 1506

DB 157 TGCCCCGCTCTCTGAGAGAGAGTCAATGAGGACAGTCTCTCTTTGAGGAGGCC 213

RESULT 121

LOCUS

AF272773 2078 bp mRNA linear SYN 17-AUG-2000

DEFINITION Synthetic construct mutated mouse factor VII molecule

```

ORGANISM Unknown;
Unclassified.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner,K.L., Petersen,L.Christian. and Hart,C.E.
TITLE Modified Factor VII
JOURNAL Patent: US 5861374-A 1 19-JAN-1999;
FEATURES
    source          Location/Qualifiers
    1..2422
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match          0.6%; Score 21; DB 1; Length 2422;
Best Local Similarity 100.0%; Pred.No.1.7e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3245 TTTT-----TTTTTTTTTTT 3265
      |||-----|||
DB 2422 TTTT-----TTTTTTTTTTT 2402
      |||-----|||

RESULT 123
AR045090/c
LOCUS AR045090 2422 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5817788.
ACCESSION AR045090
VERSION AR045090.1 GI:5966555
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown;
Unclassified.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and Bregengaard,C.
TITLE Modified factor VII
JOURNAL Patent: US 5817788-A 1 06-OCT-1998;
FEATURES
    source          Location/Qualifiers
    1..2422
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match          0.6%; Score 21; DB 1; Length 2422;
Best Local Similarity 100.0%; Pred.No.1.7e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3245 TTTT-----TTTTTTTTTTT 3265
      |||-----|||
DB 2422 TTTT-----TTTTTTTTTTT 2402
      |||-----|||

RESULT 124
AR052946/c
LOCUS AR052946 2422 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5833982.
ACCESSION AR052946
VERSION AR052946.1 GI:5977808
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown;
Unclassified.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and Bregengaard,C.
TITLE Modified factor VII
JOURNAL Patent: US 5833982-A 1 10-NOV-1998;
FEATURES
    source          Location/Qualifiers
    1..2422
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match          0.6%; Score 21; DB 1; Length 2422;
Best Local Similarity 100.0%; Pred.No.1.7e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3245 TTTT-----TTTTTTTTTTT 3265
      |||-----|||
DB 2422 TTTT-----TTTTTTTTTTT 2402
      |||-----|||

RESULT 125
AR052946/c
LOCUS AR052946 2422 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5833982.
ACCESSION AR052946
VERSION AR052946.1 GI:5977808
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown;
Unclassified.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and Bregengaard,C.
TITLE Modified factor VII
JOURNAL Patent: US 5833982-A 1 10-NOV-1998;
FEATURES
    source          Location/Qualifiers
    1..2422
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match          0.6%; Score 21; DB 1; Length 2422;
Best Local Similarity 100.0%; Pred.No.1.7e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```


RESULT 129	AX839180/c	AX839180	394 bp	DNA	linear	PAT 15-DEC-2003
LOCUS	Sequence 23 from Patent WO03076610.					
DEFINITION	AX839180					
ACCESSION	AX839180					
VERSION	AX839180.1	GI:39922629				
KEYWORDS						
SOURCE	Homo sapiens (human)					
ORGANISM	Homo sapiens					
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.					
AUTHORS	1 Bracco, L., Brinkman, B. and Coignard, F.					
TITLE	Variants of human kallikrein-2 and kallikrein-3 and uses thereof					
JOURNAL	Patent: WO 03076610-A 23 18-SEP-2003;					
EXONHIT	Exonhit Therapeutics S.A. (FR)					
FEATURES	Location/Qualifiers					
source	1..394					
	/organism="Homo sapiens"					
	/mol_type="unassigned DNA"					
	/db_xref="taxon:9606"					
Query Match	0.6%; Score 20.9; DB 1; Length 394;					
Best Local Similarity	50.0%; Pred. No. 1.4e+02;					
Matches	77; Conservative 0; Mismatches 76; Indels 1; Gaps 1;					
QY	2587 CTGAAAGACCTGATGCTGGGAGGATTTGGGGCAGGAGGAGGAGGACGACAGG 2646					
DB	298 CTGCGACAGAGATACAGGGTGAGACACACTGGCTAGAGAGGGACTGAGAGGACAGAGA 239					
QY	2647 ATGAGATGGCTGGATGGCATCACTGACTCGATGGACGCTGAGTCTGGGTGAACCTCCTGGAG 2706					
DB	238 GAGGGGGGAT-ATGGAGATTCCTGATGCAGTGGGACGCTGTGAGGACCCACTGGGGGTG 180					
QY	2707 TTGTGTATGACAGGAGGAGGCGCTGTCTCGGGCGGA 2740					
DB	179 CACCAGAACACCGCCGACAGCTGCCCTGCCACGA 146					
RESULT 130						
LOCUS	I28675	I28675	252 bp	DNA	linear	PAT 06-FEB-1997
DEFINITION	Sequence 26 from patent US 5573910.					
ACCESSION	I28675					
VERSION	I28675.1	GI:1819451				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 252)					
AUTHORS	Dereic, V. and Martin, D.W.					
TITLE	Detection of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients involving the algu gene					
JOURNAL	Patent: US 5573910-A 26 12-NOV-1996;					
FEATURES	Location/Qualifiers					
source	1..252					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	0.6%; Score 20.8; DB 1; Length 252;					
Best Local Similarity	55.6%; Pred. No. 1.4e+02;					
Matches	40; Conservative 0; Mismatches 32; Indels 0; Gaps 0;					
QY	24 GAGGTACTACTCCCTCGTCCAGGTAAGAGCAGTAGCTGGCGCTTTGCTGGAGCAGCCGTA 83					
DB	178 GTGCAACAATCCGCGCTCAGTGGTACAGAGAGCGCGCTGCCCTACGCTCGGCAGCCAGC 237					
QY	84 AAGAGATACCCC 95					
DB	238 CTGGAACCCG 249					

```
PF 31-JUL-1998 JP 2000505291
PR 01-AUG-1997 US 08/905144
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,AYMBERIC DUCLERT,BRUNO PI
LACROIX
PC C12N15/09,C07K14/47,C12P21/02,C12Q1/02,C12Q1/68,C12N15/00 CC
Von Heijne matrix
CC score 10.7
CC seq LILLALATGLVGG/ET
CC n=a, g, c or t
FH Key Location/Qualifiers
FT sig peptide 117..170
FT misc feature 67..
FT misc Location/Qualifiers
FEATURES
source
1..323
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.8; DB 1; Length 323;
Best Local Similarity 46.5%; Pred. No. 1.4e+02;
Matches 67; Conservative 0; Mismatches 77; Indels 0; Gaps 0;
QY 249 GTGGGGACCCCAAGATGGCGAGGTGATGTCGAGAGATCTGACAGAAATGTGGTCCACTG 308
DB 267 GCGTGGCCCCACAGAGTAGCCGCGTCTCTCGAACAGGGCTGCTGCCAGGGCTGGGAGT 208
QY 309 GAGAGGGGAATCGAACCACTTCAGTATCTTCCTTGAGAACCCCATGAACAGATGAA 368
DB 207 GAGGCTTGACATCGAACCCCTTGATGATCCTGCTCTCCCTACAAAGCCCTGTGGCA 148
QY 369 AAGGCAAAATGATAGGATCTGAA 392
DB 147 GAGCAAGCAGGATTAACTGCAGAA 124
RESULT 133
AX262154/c
LOCUS
DEFINITION
Sequence 234 from Patent WO0172781.
ACCESSION
AX262154
VERSION
AX262154.1 GI:16511106
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
REFERENCE
1
AUTHORS
Williams,L.T., Escobedo,J., Innis,M.A., Garcia,P.D.,
Sudduth-Klinger,J., Reinhard,C., He,Z., Randazzo,F., Kennedy,G.C.,
Pot,D., Kassam,A., Lamson,G., Drmanac,R., Crkvenjakov,R.,
Dickson,M., Drmanac,S., Labat,I., Leshkowitz,D., Kita,D.,
Garcia,V., Jones,L.W. and Stache-Crain,B.
JOURNAL
Patent: WO 0172781-A 234 04-OCT-2001;
Chiron Corporation (US); Hyseq Inc. (US)
FEATURES
source
1..380
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.8; DB 1; Length 380;
Best Local Similarity 44.3%; Pred. No. 1.5e+02;
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
QY 3129 ATCTTTCTCAAGTTTGAATGGTACGTAAGTCACTTATCTTTATTTTGTAAATTA 3188
DB 259 AGCTCTGCAAGAGAAATATCATAGTCATGTGGTGTGTTATTTTCATGGACAATT 200
QY 3189 GCTCTTTAAATTCATATCTTTGTATGATACAGCTTCAGTCTATGCTTTTAAATAGTTT 3248
DB 199 ATTCTCCGAGACCCCGTTCATTTTCGAAAGGTTTATTTGTTACTCCAAAGGAAGCAGTC 140
QY 3249 TTTTCTTTTCTTTTAAAGAAATGTCATCTTTGTGAAGTTTGTGACATGCTTTGAGCA 3308
PF 01-AUG-1997 US 08/905144
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,AYMBERIC DUCLERT,BRUNO PI
LACROIX
PC C12N15/09,C07K14/47,C12P21/02,C12Q1/02,C12Q1/68,C12N15/00 CC
Von Heijne matrix
CC score 10.7
CC seq LILLALATGLVGG/ET
CC n=a, g, c or t
FH Key Location/Qualifiers
FT sig peptide 117..170
FT misc feature 67..
FT misc Location/Qualifiers
FEATURES
source
1..380
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.8; DB 1; Length 380;
Best Local Similarity 44.3%; Pred. No. 1.5e+02;
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
QY 3129 ATCTTTCTCAAGTTTGAATGGTACGTAAGTCACTTATCTTTATTTTGTAAATTA 3188
DB 259 AGCTCTGCAAGAGAAATATCATAGTCATGTGGTGTGTTATTTTCATGGACAATT 200
QY 3189 GCTCTTTAAATTCATATCTTTGTATGATACAGCTTCAGTCTATGCTTTTAAATAGTTT 3248
DB 199 ATTCTCCGAGACCCCGTTCATTTTCGAAAGGTTTATTTGTTACTCCAAAGGAAGCAGTC 140
QY 3249 TTTTCTTTTCTTTTAAAGAAATGTCATCTTTGTGAAGTTTGTGACATGCTTTGAGCA 3308
```

```
DB 139 CATCTGGCAGGGTCTTATATATGTTGTAAACAGTGAGCAGCACTCACAAGCCATGTGGCA 80
QY 3309 ATAATTTAGGAT 3320
DB 79 TTAATTAAGGTT 68
RESULT 134
AX262150/c
LOCUS
DEFINITION
Sequence 230 from Patent WO0172781.
ACCESSION
AX262150
VERSION
AX262150.1 GI:16511102
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
REFERENCE
1
AUTHORS
Williams,L.T., Escobedo,J., Innis,M.A., Garcia,P.D.,
Sudduth-Klinger,J., Reinhard,C., He,Z., Randazzo,F., Kennedy,G.C.,
Pot,D., Kassam,A., Lamson,G., Drmanac,R., Crkvenjakov,R.,
Dickson,M., Drmanac,S., Labat,I., Leshkowitz,D., Kita,D.,
Garcia,V., Jones,L.W. and Stache-Crain,B.
JOURNAL
Patent: WO 0172781-A 230 04-OCT-2001;
Chiron Corporation (US); Hyseq Inc. (US)
FEATURES
source
1..400
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.8; DB 1; Length 400;
Best Local Similarity 44.3%; Pred. No. 1.5e+02;
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
QY 3129 ATCTTTCTCAAGTTTGAATGGTACGTAAGTCACTTATCTTTATTTTGTAAATTA 3188
DB 276 AGCTCTGCAAGAGAAATATCATAGTCATGTGGTGTGTTATTTTCATGGACAATT 217
QY 3189 GCTCTTTAAATTCATATCTTTGTATGATACAGCTTCAGTCTATGCTTTTAAATAGTTT 3248
DB 216 ATTCTCCGAGACCCCGTTCATTTTCGAAAGGTTTATTTGTTACTCCAAAGGAAGCAGTC 157
QY 3249 TTTTCTTTTCTTTTAAAGAAATGTCATCTTTGTGAAGTTTGTGACATGCTTTGAGCA 3308
DB 156 CATCTGGCAGGGTCTTATATATGTTGTAAACAGTGAGCAGCACTCACAAGCCATGTGGCA 97
QY 3309 ATAATTTAGGAT 3320
DB 96 TTAATTAAGGTT 85
RESULT 135
SHPFIXA/c
LOCUS
DEFINITION
Sheep factor IX mRNA, partial cds.
ACCESSION
M26233
VERSION
M26233.1 GI:165878
KEYWORDS
factor IX.
SOURCE
Ovis aries (sheep)
ORGANISM
Ovis aries
REFERENCE
1
AUTHORS
Sarkar,G., Koeberl,D.D. and Sommer,S.S.
TITLE
Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL
Genomics 6 (1), 133-143 (1990)
MEDLINE
90152675
PUBMED
2303254
```

```
COMMENT      Original source text: Sheep liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
FEATURES
  source
    1..823
      /organism="Ovis aries"
      /mol_type="mRNA"
      /db_xref="taxon:9940"
      <1..>823
      /note="factor IX"
      /codon_start=1
      /protein_id="AAA31520.1"
      /db_xref="GI:552419"
      /translation="RASVLTHTSKLTRAETIFSNMNVENSEAEIWDVNTQSNQSPD
      DFNVVGGEAARQGFQWVLLHGEIAFCGGSIVNEKVVVTAHCICPKGVKITVVG
      EHNTKEPTEKRNVRAPYHGYNASINKYSHDIALBELDFPLELNSVYPTICAD
      REYNTIFKFGYGVGSVRFNRGASLIQYLPVDRATCLRSKRTKRTIYNHMPF
      AGYHEGKDGQCGSGSPHVEVTEGTSFLTGLISWGECAKMGKGYIYTKVSRYEY"
  CDS
    Query Match      0.6%; Score 20.8; DB 1; Length 823;
    Best Local Similarity 57.8%; Pred. No. 1.7e+02;
    Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
  QY 1048 CAAGACTAATAGAGTTTGGCAGAAATGCATGTCATAGCAACACCCCTCTTCCAA 1107
      |||
  Db 223 CACAGAATGCACAAATTCACCATGCAAGAGGACCTGCCAAGGAAATGCCTCTTGCAG 164
      |||
  QY 1108 CAAC 1111
      |||
  Db 163 CATC 160
      |||
  RESULT 136
  AF011898/c
  LOCUS      AF011898      860 bp      mRNA      linear      VRT 09-SEP-1997
  DEFINITION Petromyzon marinus trypsinogen a2 (TRYPA2) mRNA, complete cds.
  ACCESSION  AF011898
  VERSION     AF011898.1 GI:2367494
  KEYWORDS
  SOURCE      Petromyzon marinus (sea lamprey)
  ORGANISM    Petromyzon marinus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
              Petromyzontiformes; Petromyzontidae; Petromyzon.
  REFERENCE  1 (bases 1 to 860)
              Roach,J.C.
              The Molecular Evolution of the Vertebrate Trypsinogens
              Unpublished
  REFERENCE  2 (bases 1 to 860)
              Roach,J.C.
  TITLE      Direct Submission
  JOURNAL    Submitted (01-JUL-1997) Molecular Biotechnology, University of
              Washington, Seattle, WA 98195, USA
  FEATURES
    source
      1..860
        /organism="Petromyzon marinus"
        /mol_type="mRNA"
        /db_xref="taxon:7757"
        /dev_stage="amocoete"
        /tissue_lib="anterior intestine"
      1..860
      6..749
      /gene="TRYPA2"
      /note="TRYPA2"
      /product="trypsinogen a2"
      /protein_id="AAB69654.1"
      /db_xref="GI:2367495"
      /translation="MHGLIALLVGAAPMYEDHIVGSECAHSPQWVQSLNIG
      YHFCGSLNSQWVSAHCYQARSIVRGNEIFVNEGTQEQIOAKSIAIOHPQYN
      SWTIDNIMLJKLSPATLNQYAAIALPSSCVNTGYMCTISGNETQTISGSPDLIM
      CQAPVLSDTSCRSYSPEDITNNMICLGLIEGGKSCQSGSGGPPVNCNGLQGVISWG
      RGCAIPNYPGYTKVQYNWIAQTIAAN"
    sig_peptide
      6..50
  Query Match      0.6%; Score 20.8; DB 1; Length 860;
  Best Local Similarity 47.1%; Pred. No. 1.7e+02;
  Matches 64; Conservative 0; Mismatches 72; Indels 0; Gaps 0;
  QY 2587 CTGAAAAGACCCCTGATGCTGGAGGGATTGGGGCAGGAGGAGGAGGACGACAGAGG 2646
      |||
  Db 520 CAGGAGGTGCTGCTACGACCGCGCGCTGCAGCCACATGAGGACGCTGCGGACTGCCGATG 461
      |||
  QY 2647 ATGAGATGCTGGATGGCATCACTGACTCGATGGAGCTGAGTGGTGAACCTCCTGGAG 2706
      |||
  Db 460 CTGCTCTGGTCTCGCCCCAGCGGAGATGGTGCACATCACTCCGCTGTTGACGACGAG 401
      |||
  QY 2707 TTGTCATGTCACAGGG 2722
      |||
  Db 400 GAGGCGAGCGCATGG 385
      |||
  RESULT 137
  HUMPRC7/c
  LOCUS      HUMPRC7      1259 bp      DNA      linear      PRI 08-JAN-1995
  DEFINITION Human protein C gene, exon 9 of 9.
  ACCESSION  M12712
  VERSION     M12712.1 GI:190330
  KEYWORDS    glycoprotein; protease; protein C; serine protease.
  SEGMENT     7 of 7
  SOURCE      Homo sapiens (human)
  ORGANISM    Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  REFERENCE  1 (bases 1 to 1259)
              Plutsky,J., Hoskins,J.A., Long,G.L. and Crabtree,G.R.
              Evolution and organization of the human protein C gene
              Proc. Natl. Acad. Sci. U.S.A. 83 (3), 546-550 (1986)
  MEDLINE    86120978
  PUBMED     3511471
  COMMENT     Original source text: Human liver, DNA clones lambda-pc4,
              lambda-pc14 and lambda-pc17.
  FEATURES
    source
      1..1259
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /map="2q13-q21"
      join(M12682..1198..300,M12683..1..430,M12684..1..1..710,
      M12685..1..1..733,M12686..1..411,M12687..1..1..1190,1..797)
      /gene="PROC"
      join(M12683..1:106..175,M12684..1:354..520,M12685..1:58..82,
      M12685..1:174..311,M12685..1:414..548,M12686..1:45..187,
      M12687..1:397..514,205..797)
      /note="PROC"
      /note="Protein C"
      /codon_start=1
      /protein_id="AAA60165.1"
      /db_xref="GI:190332"
      /translation="MWQTSLLLFVATWGISCTPAPLDSVFSSESRHQLVLRKRN
      SFLELRHSLRECIETEDFEAKEIFQNVDDTLAFWSKHVDGQCLVPLEHPCA
      SCACGHTCIDIGISFCDCRSRGWRFCOREVSLNCSLDNGGCTHYCLEVGNRR
      SCAPYKLGDDLLQHPVFCGPRWMEKRSKSLKEDTDQDQVDPRIDGKWT
      RKGDSFWQVLLDSKRGACGAVLHPSWLTAAHMCNDESKLLVRLGEYDLRRKRW
      EQLDITKEVFPHPNSKSTNDIALLAQATLSQITVPCILPDSGLAEELNQAG
      QETLVGWGYSRREKARNRTFVNFIKIEVPHNCESEYMSNMVSEMLCAGILG
      DRQACGDSGGPVMASFGHTFVLVLSWGSQGLLHNYGVYTKVSRVLDWILHGI
      RKEAPEKSWAP"
    prim_transcript
      <1..1093
    intron
      <1..204
      /gene="PROC"
```

[illegible]

```
mrna
<1..1366
/gene="PROC"
/note="G00-120-317"
<1..1140
/gene="PROC"
/note="G00-120-317"
<1..1073
/gene="PROC"
/codon_start=2
/product="protein C"
/protein_id="AAA60164.1"
/db_xref="GI:190323"
/db_xref="GDB:G00-120-317"
/translation="GGHGTCTDGGSPSCDSCSGWGRFCOREVSLNCSLDNGGCTH
YCLEVGHRRCSAPGVKLDLLOCHPAVKPCGRPWKMEKRSKLRDTEQEDQ
VPLRIDGMRTRGDSWQVLLDKKLAGAVLIHPSWLTAAHCDMSKLLVRL
GEYLRWRKWELELDKEVFPHPNYSKSTDDNDIALHQAQATLSQTIPICLPDS
GLARELNQAQETLVGWGYHSREKAKRNTFLNF.KIPVPHNECSYMSNV
SEMLCAGILGDRDACEGDSGPMVASFHGTWFLVGLVSGEGCGILLHNYGVYTKVS
RYLDWIHGHIRDKAPQKSWAP"
<1..277
/gene="PROC"
/product="protein C light chain"
/note="G00-120-317"
284..1069
/gene="PROC"
/product="protein C heavy chain"
/note="G00-120-317"
320..1069
/gene="PROC"
/product="protein C activated heavy chain"
/note="G00-120-317"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1366;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 453 CTCAGAAGATGAAGAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
|||||
Db 1191 CTCAGAAGAGCCCAAGAGAGATGGAGGAGACAGACAGCAGCGCGTGTGCTTTGTAC 1132
|||||

Qy 513 TGGT 516
Db 1131 ATGT 1128

RESULT 141
AR363767/c
LOCUS AR363767 1755 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 1 from patent US 5225537.
ACCESSION AR363767
VERSION AR363767.1 GI:34425772
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Foster,D.C.
AUTHORS Methods for producing hybrid phospholipid-binding proteins
JOURNAL Patent: US 5225537-A 1 06-JUL-1993;
FEATURES
source
1..1755
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1755;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 453 CTCAGAAGATGAAGAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
|||||
Db 1574 CTCAGAAGAGCCCAAGAGAGATGGAGGAGACAGACAGCAGCGCGTGTGCTTTGTAC 1515
|||||

mrna
<1..1366
/gene="PROC"
/note="G00-120-317"
<1..1140
/gene="PROC"
/note="G00-120-317"
<1..1073
/gene="PROC"
/codon_start=2
/product="protein C"
/protein_id="AAA60164.1"
/db_xref="GI:190323"
/db_xref="GDB:G00-120-317"
/translation="GGHGTCTDGGSPSCDSCSGWGRFCOREVSLNCSLDNGGCTH
YCLEVGHRRCSAPGVKLDLLOCHPAVKPCGRPWKMEKRSKLRDTEQEDQ
VPLRIDGMRTRGDSWQVLLDKKLAGAVLIHPSWLTAAHCDMSKLLVRL
GEYLRWRKWELELDKEVFPHPNYSKSTDDNDIALHQAQATLSQTIPICLPDS
GLARELNQAQETLVGWGYHSREKAKRNTFLNF.KIPVPHNECSYMSNV
SEMLCAGILGDRDACEGDSGPMVASFHGTWFLVGLVSGEGCGILLHNYGVYTKVS
RYLDWIHGHIRDKAPQKSWAP"
<1..277
/gene="PROC"
/product="protein C light chain"
/note="G00-120-317"
284..1069
/gene="PROC"
/product="protein C heavy chain"
/note="G00-120-317"
320..1069
/gene="PROC"
/product="protein C activated heavy chain"
/note="G00-120-317"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1366;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 453 CTCAGAAGATGAAGAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
|||||
Db 1191 CTCAGAAGAGCCCAAGAGAGATGGAGGAGACAGACAGCAGCGCGTGTGCTTTGTAC 1132
|||||

Qy 513 TGGT 516
Db 1131 ATGT 1128

RESULT 141
AR363767/c
LOCUS AR363767 1755 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 1 from patent US 5225537.
ACCESSION AR363767
VERSION AR363767.1 GI:34425772
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Foster,D.C.
AUTHORS Methods for producing hybrid phospholipid-binding proteins
JOURNAL Patent: US 5225537-A 1 06-JUL-1993;
FEATURES
source
1..1755
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1755;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 453 CTCAGAAGATGAAGAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
|||||
Db 1574 CTCAGAAGAGCCCAAGAGAGATGGAGGAGACAGACAGCAGCGCGTGTGCTTTGTAC 1515
|||||

mat_peptide
<1..277
/gene="PROC"
/product="protein C light chain"
/note="G00-120-317"
284..1069
/gene="PROC"
/product="protein C heavy chain"
/note="G00-120-317"
320..1069
/gene="PROC"
/product="protein C activated heavy chain"
/note="G00-120-317"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1756;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 453 CTCAGAAGATGAAGAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
|||||
Db 1575 CTCAGAAGAGCCCAAGAGAGATGGAGGAGACAGACAGCAGCGCGTGTGCTTTGTAC 1516
|||||

Qy 513 TGGT 516
Db 1515 ATGT 1512

RESULT 142
105477/c
LOCUS 105477 1756 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 12 from Patent EP 0266190.
ACCESSION 105477
VERSION 105477.1 GI:591031
KEYWORDS Unknown.
ORGANISM Unknown.
REFERENCE Foster,D.C., Murray,M.J. and Berkner,K.L.
AUTHORS Expression of protein C
TITLE Patent: EP 0266190-A2 12 04-MAY-1988;
JOURNAL Location/Qualifiers
FEATURES
source
1..1756
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1756;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 453 CTCAGAAGATGAAGAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
|||||
Db 1575 CTCAGAAGAGCCCAAGAGAGATGGAGGAGACAGACAGCAGCGCGTGTGCTTTGTAC 1516
|||||

Qy 513 TGGT 516
Db 1515 ATGT 1512

RESULT 143
AX886683/c
LOCUS AX886683 228 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 2546 from Patent EP1033401.
ACCESSION AX886683
VERSION AX886683.1 GI:40044089
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
AUTHORS Expressed sequence tags and encoded human proteins
TITLE Patent: EP 1033401-A 2546 06-SEP-2000;
JOURNAL Genset (FR)
FEATURES
source
1..228
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
44..>226
/note="unnamed protein product"
/codon_start=1
/protein_id="CAF00821.1"
/db_xref="GI:40044090"
/translation="MLVHCHPSAXCQDVHSLTSLWIPXFAXXXRXSDLYLSNVSL
SXDFEXALALXPFQSVSE"

Query Match
Best Local Similarity 0.6%; Score 20.6; DB 1; Length 228;
Matches 33; Conservative 8; Mismatches 28; Indels 0; Gaps 0;

Qy 773 CAGTACTTGGATGTCAGTCTCAAAACAGCAGAGATGATCTCTGTTCTTCCAGGCAAC 832
|||||
Db 188 CAAATCTTKAGACAGTGCACATTGTATAGATACAGATCTGAGMWTTCCTWAKKAAG 129
|||||
```

```

QY      833 CATTCAATA 841
Db      128 CWKAAATD 120

RESULT 144
BD026293/c
LOCUS   BD026293          228 bp    DNA          linear    PAT 27-AUG-2002
DEFINITION
Sequence tag and encoded human protein.
ACCESSION
BD026293.1 GI:22567516
VERSION  JP 2001269182-A/2539.
KEYWORDS
Homo sapiens (human)
SOURCE   Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 228)
Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
Sequence tag and encoded human protein
TITLE    Patent: JP 2001269182-A 2539 02-OCT-2001;
JOURNAL  GENSET
COMMENT  OS Homo sapiens (human)
PN JP 2001269182-A/2539
PD 02-OCT-2001
PF 24-FEB-2000 JP 2000118773
PR 26-FEB-1999 US 60/122487
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,EMERIC DUCLAIR,JEAN YVES
PC C12N15/09,C07K14/435,C07K16/18,C12N1/15,C12N1/19,C12N1/21,PC
C12N5/10,
PC C12P21/02,C12P21/08,C12Q1/68//G06F17/30,C12N15/00,C12N5/00,PC
G06F15/40
CC
FH Key Location/Qualifiers
FT CDS 44..226.

FEATURES
source
1..228
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.6%; Score 20.6; DB 1; Length 228;
Matches 33; Conservative. 8; Mismatches 28; Indels 0; Gaps 0;

QY      773 CAGTACTGGATGCGAGTCTCAAAAACGACAGATGATCTCTGTTGTTTCCAAAGCAAC 832
Db      188 CAAATCTKAGACAGTGCACACATTGTGATAGATACAGATCTGAGWTTKCTWAKAAAG 129

QY      833 CATTCAATA 841
Db      128 CWKAAATD 120

RESULT 145
AX661018/c
LOCUS   AX661018          312 bp    DNA          linear    PAT 22-MAR-2003
DEFINITION
Sequence 1375 from Patent WO03000906.
ACCESSION
AX661018
VERSION  AX661018.1 GI:29162782
KEYWORDS
Zea mays
SOURCE   Zea mays
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACAD
clade; Panicoideae; Andropogoneae; Zea.
REFERENCE
1
Glazebrook,J., Briggs,S., Cooper,B., Goff,S.A., Moughamer,T.,
Katagiri,F., Kreps,J., Provart,N., Rickes,D. and Zhu,T.
Plant disease resistance genes
TITLE    Patent: WO 03000906-A 1375 03-JAN-2003;
JOURNAL  Syngenta Participations AG (CH)

FEATURES
source
1..312
Location/Qualifiers
/organism="Zea mays"
/mol_type="unassigned DNA"
/db_xref="taxon:4577"

Query Match
Best Local Similarity 0.6%; Score 20.6; DB 1; Length 312;
Matches 41; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

QY      1654 CCTCTGATCATGCAAAAAGCAGAGATTCAGAAAAACATCTATTCTGCTTTATTCGA 1713
Db      183 CATCTTGATCATGGACCTCGCAAACTGTGCTGAAAGTCGCTCGCCGACCAAGGA 124

QY      1714 CTATGCAAAAAGCCTT 1728
Db      123 GTCGACCAGGCGCTT 109

RESULT 146
PVTRYPSIN/c
LOCUS   P.vannamei mRNA for trypsin. 854 bp    mRNA    linear    INV 01-OCT-1996
DEFINITION
P.vannamei mRNA for trypsin.
ACCESSION
X86369
VERSION  X86369.1 GI:785034
KEYWORDS
trypsin.
SOURCE   Litopenaeus vannamei (Pacific white shrimp)
ORGANISM
Litopenaeus vannamei
Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;
Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;
Penaeidae; Litopenaeus.
REFERENCE
1
Klein,B., Le Moullac,G., Sellos,D. and Van Wormhoudt,A.
Molecular cloning and sequencing of trypsin cDNAs from Penaeus
vannamei (Crustacea, Decapoda): use in assessing gene expression
during the moult cycle
JOURNAL  Int. J. Biochem. Cell Biol. 28 (5), 551-563 (1996)
MEDLINE  86252881
PUBMED  8697100
AUTHORS  Van Wormhoudt,A.E.
TITLE    Direct Submission
JOURNAL  Submitted (18-APR-1995) A.E. Van Wormhoudt, College de France /
CNRS, Laboratoire de Biologie Marine, BP 225, 29182 Concarneau,
FRANCE

FEATURES
source
1..854
Location/Qualifiers
/organism="Litopenaeus vannamei"
/mol_type="mRNA"
/db_xref="taxon:6689"
/tissue_type="hepatopancreas"
/dev_stage="adult"
3..803
/EC_number="3.4.21.4"
/codon_start=1
/product="trypsin"
/protein_id="CAA60129.1"
/db_xref="GI:785035"
/db_xref="GOA:Q27761"
/db_xref="SPTREMBL:Q27761"
/translation="MKTLICVLLAGFAAPSRKPTFRGLNKIVGGTDATFGELPYQ
LSFDISFGFAWHFCGASINENWAICAGHCVCQGDMMNPDLQVWAGELNQDVEGT
EQTVLSKTIQHEHYNGFTISNDLSLKLSQELSFNDNVRADIFAQGHASGDCIVS
GWTGTSSEGSTPSVLQKVTPIVSDDECRDAYQSDIEDSMICAGVPEGKDCQCGDS
GGPLACSDASTYLAGIVSMGYGCARPGVPGVYAEVSYHVDWIKANAV"
3..41
sig_peptide

Query Match
Best Local Similarity 67.4%; Score 20.6; DB 1; Length 854;
Matches 29; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY      1293 AGGGAACCACTTAGATCACTCAGGTAAGACCTAAATCCAATC 1335

```

```

Db      819 ATGTTAAACACTTGATTAAACAGCATTTGGCCTTAATCCAATC 777
LOCUS   867 bp      mRNA      linear      VRT 23-JAN-1995
DEFINITION G.morhua mRNA for prechymotrypsinogen.
ACCESSION X78490
VERSION   X78490.1 GI:468750
KEYWORDS  chymotrypsin; prechymotrypsinogen.
SOURCE    Gadus morhua
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthomorpha; Paracanthopterygii; Gadiformes; Gadidae; Gadus.
REFERENCE 1 Guthmundsdottir,A., Oskarsson,S., Eakin,A.E., Craik,C.S. and
            Bjarnason,J.B.
            Atlantic cod cDNA encoding a psychrophilic chymotrypsinogen
            Biochim. Biophys. Acta 1219 (1), 211-214 (1994)
JOURNAL   Submitted (24-MAR-1994) A. Gudmundsdottir, Science Institute,
            University of Iceland, Dunhagi 3, IS-107 Reykjavik, ICELAND
FEATURES             Location/Qualifiers
     source          1..867
                     /organism="Gadus morhua"
                     /mol_type="mRNA"
                     /db_xref="taxon:8049"
     sig_peptide     1..18
                     /clone_lib="lambda UNI-ZAP XR"
     CDS             1..794
                     /EC_number="3.4.21.1"
                     /note="prechymotrypsinogen"
                     /codon_start=1
                     /product="chymotrypsin"
                     /protein_id="CAA55242.1"
                     /db_xref="GI:468751"
                     /db_xref="GOA:P47796"
                     /db_xref="SWISS-PROT:P47796"
                     /translation="MGHEVDSVLPGLFRRTYGGRPAISPVITGYRIYNGEAAVPHS
                     WSOVSLQDQTFHFQGSGLINENWVTAHKNYHVRVVLGHEHRSNSSEGVQVMT
                     VGOVFKHPRYNGFTINNDILLVKLATPATLNMVSPVCLAETDDVDFEGMKCVTSYWG
                     LTRYNADPTLALQALPLLTNEOCKFWGNKISLMI CAGAAGASSCMGDSGGPLV
                     CQKAGSWTLVGIVSWGSTCTPTMEGVYARVTELRAWVDQTIAAN"
     mat_peptide     34..791
                     /product="chymotrypsin"
                     /note="prechymotrypsinogen"
                     /EC_number="3.4.21.1"

Query Match      0.6%; Score 20.6; DB 1; Length 867;
Best Local Similarity 48.0%; Pred. No. 1.9e+02;
Matches 59; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 2374 GGAATGTGAGAGTGGACTGTGAGAAAGCTGAGCACTCAAGAATGTGCTTTTGAACGTG 2433
DB 46 GCACGTATGGCTGTGGCGTGCAGGCATCTCCAGTAATCACTGGTTACTCCCGTATTG 105
QY 2434 TGGTGTGGAGAGACTCTTGAGACTCCCTGGACTGCAAGAGATCCAAACAGTCCATT 2493
DB 106 TCAACGGAGAGAGGAGCTGTTCCTCCACTCTCTGTGTCGTGAGAGGTGTCCTCGAGGACCAAA 165
QY 2494 CTG 2496
DB 166 CTG 168

Query Match      0.6%; Score 20.6; DB 1; Length 1843;
Best Local Similarity 59.3%; Pred. No. 2.1e+02;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

RESULT 148
AF191307/c
LOCUS   1514 bp      mRNA      linear      MAM 01-NOV-2000
DEFINITION Sus scrofa protein C mRNA, complete cds.
ACCESSION AF191307
VERSION   AF191307.1 GI:11065893
KEYWORDS
SOURCE    Sus scrofa (pig)
ORGANISM  Sus scrofa
            Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Eukaryota; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 1514)
            Grimm,D.R., Colter,M.B. and Kim,H.
            Cloning of the complete cDNA sequences encoding porcine factor V
            and protein C
            Unpublished
            2 (bases 1 to 1514)
            Grimm,D.R., Colter,M.B. and Kim,H.
            Direct Submission
            Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
            North Pine Drive, Tampa, FL 33612, USA
FEATURES             Location/Qualifiers
     source          1..1514
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="92N.4; 58/86.2; 12N3.1"
                     /tissue_type="liver"
                     22..1401
                     /note="serine protease"
                     /codon_start=1
                     /product="protein C"
                     /protein_id="AAG28380.1"
                     /db_xref="GI:11065894"
                     /translation="MKQLASLLLLIIWAVSTPPVPPDSVFSSORAHQMLRSKRANS
                     FLELRPSSLERECKEETCDPEAREIFQNTENTMAFSKYHDGQCAVSPPEHLCD
                     PCGRGTGIDGLGGFRCDCAQGWEGRCFLHEVRFNGCSTENGCGCAHYCLEEGGRRCA
                     CAGVELGDDHLCQCPKVRSPGRLNGMEKKRKNLRTDQDVQKEDDIDRLVNGK
                     QSPWGESPWQVILLDSKKKLACGAVLIHVSWLTAHCLDDYKKLTVRLGEYDLRRE
                     KMEVDLDIKFELVHNTRYTSDNDIALRLAEPATFSTQIVPICLPDGLSERELTR
                     VQGETVVTGWGVSAAKTRSFILNPKVPVAPHNECVQAMHNKISENMLCAGILGDS
                     RDACGDSGPMVASFRTGTFVLVGLVSWGEGGRLHNYGVYTKVSKYLDWIHIRM
                     EAFHNKQVP"

Query Match      0.6%; Score 20.6; DB 1; Length 1514;
Best Local Similarity 74.3%; Pred. No. 2.1e+02;
Matches 26; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 3109 CTTTTCATTATTGGTCTCTATCTTTCTCAAGTT 3143
DB 660 CCTCGATCTATTGTGTCCTCTTTTGTCAACTT 626

RESULT 149
AR390799
LOCUS   1843 bp      DNA      linear      PAT 18-DEC-2003
DEFINITION Sequence 49 from patent US 6610906.
ACCESSION AR390799
VERSION   AR390799.1 GI:40113146
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
            1 (bases 1 to 1843)
            Kurachi,K. and Kurachi,S.
            Nucleotide sequences for gene regulation and methods of use thereof
            Patent: US 6610906-A 49 26-AUG-2003;
            Location/Qualifiers
     source          1..1843
                     /organism="unknown"
                     /mol_type="genomic DNA"

Query Match      0.6%; Score 20.6; DB 1; Length 1843;
Best Local Similarity 59.3%; Pred. No. 2.1e+02;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

```



```
ACCESSION AX265022
VERSION AX265022.1 GI:16513821
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2413 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAACCAATTCA 838
Db 54 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 1
RESULT 154
LOCUS AX265033 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2424 from Patent WO0173002.
ACCESSION AX265033
VERSION AX265033.1 GI:16513832
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2424 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTCCAAAGGCAACCAATTCA 838
Db 54 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 1
RESULT 155
LOCUS AX265034 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2425 from Patent WO0173002.
ACCESSION AX265034
VERSION AX265034.1 GI:16513833
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2429 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTCCAAAGGCAACCAATTCA 838
Db 63 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 116
RESULT 157
LOCUS AX265038 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2429 from Patent WO0173002.
ACCESSION AX265038
VERSION AX265038.1 GI:16513837
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2429 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTCCAAAGGCAACCAATTCA 838
Db 63 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 116
RESULT 158
LOCUS AX265037 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2428 from Patent WO0173002.
ACCESSION AX265037
VERSION AX265037.1 GI:16513836
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2428 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTCCAAAGGCAACCAATTCA 838
Db 59 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 6
```

```
Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 59 GAAGTTTTTGAAACACTGAAGACAGTGAAGTATTTCCACATATACCTTC A 6

RESULT 158
AX265041
LOCUS AX265041 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2432 from Patent WO0173002.
ACCESSION AX265041
VERSION AX265041.1 GI:16513840
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2432 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
    source      Location/Qualifiers
    1..121
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 64 GAAGTTTTTGAAACACTGAAGACAGTGAAGTATTTCCACATATACCTTC A 117

RESULT 159
AX265042/c
LOCUS AX265042 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2433 from Patent WO0173002.
ACCESSION AX265042
VERSION AX265042.1 GI:16513841
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2433 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
    source      Location/Qualifiers
    1..121
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 64 GAAGTTTTTGAAACACTGAAGACAGTGAAGTATTTCCACATATACCTTC A 117

RESULT 160
AX265045
LOCUS AX265045 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2436 from Patent WO0173002.
ACCESSION AX265045
VERSION AX265045.1 GI:16513844
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2436 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
    source      Location/Qualifiers
    1..121
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 61 GAAGTTTTTGAAACACTGAAGACAGTGAAGTATTTCCACATATACCTTC A 114

RESULT 161
AX265046/c
LOCUS AX265046 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2437 from Patent WO0173002.
ACCESSION AX265046
VERSION AX265046.1 GI:16513845
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2437 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
    source      Location/Qualifiers
    1..121
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 61 GAAGTTTTTGAAACACTGAAGACAGTGAAGTATTTCCACATATACCTTC A 114

RESULT 162
AX265049
LOCUS AX265049 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2440 from Patent WO0173002.
ACCESSION AX265049
VERSION AX265049.1 GI:16513848
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2440 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)

FEATURES
source Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAACCATCA 838
DB 61 GAAGTTTGTGAACACTGAAAGACAGTGTGATTTCCACATAATACCTTCA 114

RESULT 163
LOCUS AX265050/1 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2441 from Patent WO0173002.
ACCESSION AX265050
VERSION AX265050.1 GI:165113849
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2441 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)

FEATURES
source Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAACCATCA 838
DB 61 GAAGTTTGTGAACACTGAAAGACAGTGTGATTTCCACATAATACCTTCA 8

RESULT 164
LOCUS AY254094/1 160 bp DNA linear PRI 28-MAY-2003
DEFINITION Homo sapiens nonfunctional trypsin 1 (PRSS1) gene, PRSS1-Y37X allele, partial cds.
ACCESSION AY254094
VERSION AY254094.1 GI:31095598
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 160)
AUTHORS Chen, J.M., Le Marechal, C., Lucas, D., Raguene, O., and Ferec, C.
TITLE Loss of function mutations in the cationic trypsinogen gene (PRSS1) may act as a protective factor against pancreatitis
JOURNAL Mol. Genet. Metab. 79 (1), 67-70 (2003)

22651503
12765848
2 (bases 1 to 160)
Chen, J.-M., Le Marechal, C., Raguene, O. and Ferec, C.
Direct Submission
Submitted (11-MAR-2003) INSERM 0115, Universite de Bretagne Occidentale, 46 rue Felix Le Dantec, Brest 29275, France

FEATURES
source Location/Qualifiers
1..160
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="7"
/map="7q34"
<1..>160
/genes="PRSS1"
/allele="Y37X"
<1..>160
/genes="PRSS1"
/product="truncated trypsin 1"
1..160
/genes="PRSS1"
/number=2
<1..>71
/gene="PRSS1"
/EC_number="3.4.21.4"
/note="serine protease 1; cationic trypsinogen; truncated protein results from a mutation that creates a premature stop codon"
/codon_start=3
/product="nonfunctional trypsin 1"
/protein_id="AAP42827.1"
/db_xref="GI:31095599"
/translation="AAPFDDDDKIVGYNCENSVP"

Query Match 0.6%; Score 20.4; DB 1; Length 160;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 921 CCCTTGAAGTAAACACCCGAAAAGATGCTCTCTCATATAGGGACCTGGAA 974
DB 54 CCTCACAGTTGTAGCCCCCAACGATCTTGTCATCATCATCAAGGGGACGAA 1

RESULT 165
LOCUS AY307359/c 160 bp DNA linear PRI 25-JUN-2003
DEFINITION Homo sapiens cationic trypsinogen (PRSS1) gene, PRSS1-K23R allele, exon 2 and partial cds.
ACCESSION AY307359
VERSION AY307359.1 GI:32250961
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 160)
AUTHORS Ferec, C., Raguene, O., Salomon, R., Roche, C., Bernard, J.P., Guillot, M., Quere, J., Faure, C., Mercier, B., Audrezet, M.P., Guillaudeau, P.J., Dupont, C., Munnich, A., Bignon, J.D. and Le Bodic, L.
TITLE Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis
J. Med. Genet. 36 (3), 228-232 (1999)

JOURNAL MEDLINE 99219545
PUBMED 10204851
REFERENCE 2 (bases 1 to 160)
AUTHORS Chen, J.M., Piepoli, B., Le Bodic, L., Ruszniewski, P., Robaszkiewicz, M., Deprez, P.H., Raguene, O., Quere, J., Andriulli, A. and Ferec, C.
TITLE Mutational screening of the cationic trypsinogen gene in a large cohort of subjects with idiopathic chronic pancreatitis
J. Clin. Genet. 59 (3), 189-193 (2001)

```

MEDLINE      21159653
PUBMED      11260229
REFERENCE    3 (bases 1 to 160)
AUTHORS      Chen,J.M., Raguenes,O. and Ferec,C.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAY-2003) INSERM 0115, EFS-Bretagne, Universite de
              Bretagne Occidentale, 46 rue Felix Le Dantec, Brest 29220, France
FEATURES
source      1..160
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /chromosome="7"
            /map="7q34"
            <1..>160
            /gene="PRSS1"
            /allele="K23R"
            <1..>160
            /gene="PRSS1"
            /product="cationic trypsinogen"
            <1..>160
            /gene="PRSS1"
            /EC_number="3.4.21.4"
            /notes="digestive zymogen"
            /codon_start=3
            /product="cationic trypsinogen"
            /protein_id="AAP74363.1"
            /db_xref="GI:32250962"
            /translation="AAPFDDDDRIKIVGYNCENSVYQVSLNSGYHFCGSLINEQWV
              VSAGCHYKS"
            1..160
            /gene="PRSS1"
            /number=2

exon
Query Match      0.6%; Score 20.4; DB 1; Length 160;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY  921 CCTTTAGAACTAACCCCAAAAAGATGCTCTTCATTATAGGGGACTGGAA 974
    |||
Db   54 CCTCACAGTTGTAGCCCCCAACGATCTTGTGCATCATCAAGGGGGCAGCAA 1

RESULT 165
LOCUS      AY307360/c
DEFINITION Homo sapiens cationic trypsinogen (PRSS1) gene, PRSS1-P36R allele,
            exon 2 and partial cds.
ACCESSION  AY307360
VERSION     AY307360.1 GI:32250963
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 160)
AUTHORS      Chen,J.M., Raguenes,O., Deprez,F.H., Raguenes,O., Quere,I., Andriulli,A.
              Robaszkiewicz,M.,
              and Ferec,C.
TITLE        Mutational screening of the cationic trypsinogen gene in a large
              cohort of subjects with idiopathic chronic pancreatitis
JOURNAL      Clin. Genet. 59 (3), 189-193 (2001)
MEDLINE      21159653
PUBMED      11260229
REFERENCE    2 (bases 1 to 160)
AUTHORS      Chen,J.M., Raguenes,O. and Ferec,C.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAY-2003) INSERM 0115, EFS-Bretagne, Universite de
              Bretagne Occidentale, 46 rue Felix Le Dantec, Brest 29220, France
FEATURES
source      1..160
            /organism="Homo sapiens"
            /mol_type="genomic DNA"

```

```

            /db_xref="taxon:9606"
            /chromosome="7"
            /map="7q34"
            <1..>160
            /gene="PRSS1"
            /allele="P36R"
            <1..>160
            /gene="PRSS1"
            /product="cationic trypsinogen"
            <1..>160
            /gene="PRSS1"
            /EC_number="3.4.21.4"
            /notes="digestive zymogen"
            /codon_start=3
            /product="cationic trypsinogen"
            /protein_id="AAP74364.1"
            /db_xref="GI:32250964"
            /translation="AAPFDDDDKIVGYNCENSVYQVSLNSGYHFCGSLINEQWV
              VSAGCHYKS"
            1..160
            /gene="PRSS1"
            /number=2

exon
Query Match      0.6%; Score 20.4; DB 1; Length 160;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY  921 CCTTTAGAACTAACCCCAAAAAGATGCTCTTCATTATAGGGGACTGGAA 974
    |||
Db   54 CCTCACAGTTGTAGCCCCCAACGATCTTGTGCATCATCAAGGGGGCAGCAA 1

RESULT 167
LOCUS      AY254095/c
DEFINITION Homo sapiens nonfunctional trypsin 1 (PRSS1) gene, PRSS1-IVS2+IG>A
            allele, partial cds.
ACCESSION  AY254095
VERSION     AY254095.1 GI:31095600
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 162)
AUTHORS      Chen,J.M., Le Marechal,C., Lucas,D., Raguenes,O. and Ferec,C.
TITLE        'Loss of function' mutations in the cationic trypsinogen gene
              (PRSS1) may act as a protective factor against pancreatitis
JOURNAL      Mol. Genet. Metab. 79 (1), 67-70 (2003)
MEDLINE      22651503
PUBMED      12765848
REFERENCE    2 (bases 1 to 162)
AUTHORS      Chen,J.-M., Le Marechal,C., Raguenes,O. and Ferec,C.
TITLE        Direct Submission
JOURNAL      Submitted (11-MAR-2003) INSERM 0115, Universite de Bretagne
              Occidentale, 46 rue Felix Le Dantec, Brest 29275, France
FEATURES
source      1..162
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /chromosome="7"
            /map="7q34"
            <1..>162
            /gene="PRSS1"
            /allele="IVS2+IG>A"
            <1..>162
            /gene="PRSS1"
            /product="trypsin 1"
            <1..>162
            /gene="PRSS1"
            /EC_number="3.4.21.4"
            /note="serine protease 1; cationic trypsinogen"

```

```

/codon_start=3
/product="nonfunctional trypsin 1"
/protein_id="AAP42828.1"
/db_xref="GI:31095601"
/translation="AAPFDDDDKIVGGYCNCEENSVPYQVSLNSGYHFCGSLNEQWV
VSAGHCYKS"
1. .>162
/gene="PRSS1"
/number=2
variation
161
/gene="PRSS1"
/notes="mutation in the splice donor consensus site results
in an aberrant spliced mRNA"
/replacement="g"
Query Match 0.6%; Score 20.4; DB 1; Length 162;
Best Local Similarity 61.1%; Pred. No. 1.6e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
Oy 921 CCTTTGAAGTACACCCAAAGAGTGTCTTCTCTATATAGGGGACTGGAA 974
Db 54 CCTCAGTTGTAGCCCCCAACAGATCTTGTCTCATCATCAAGGGGGCAGCA 1

RESULT 168
HSA238514 196 bp DNA linear PRI 01-DEC-2000
LOCUS Homo sapiens MVP gene, partial, exon 3.
DEFINITION AJ238514
ACCESSION AJ238514.1 GI:5851634
VERSION major vault protein; MVP gene.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Lange, C., Walther, W., Schwabe, H. and Stein, U.
Cloning and initial analysis of the human multidrug
resistance-related MVP/LRP gene promoter
JOURNAL Biochem. Biophys. Res. Commun. 278 (1), 125-133 (2000)
MEDLINE 20525416
PUBMED 11071864
REFERENCE 2 (bases 1 to 196)
AUTHORS Stein, U.
TITLE Direct Submission
JOURNAL Submitted (21-APR-1999) Stein U., Oncology and Surgical Oncology,
Max Delbrueck Center for Molecular Medicine, Robert-Roesle-Str.
10, Berlin 13092, Germany
FEATURES
Location/Qualifiers
1..196
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/cell_line="SW 1573"
/feature_type="non small cell lung cancer"
1..196
/gene="MVP"
1..196
/gene="MVP"
1..196
/number=3
/usedin=AJ238512:MVP_CDS
/usedin=AJ238519:MVP_alt
gene
exon
Query Match 0.6%; Score 20.4; DB 1; Length 196;
Best Local Similarity 58.1%; Pred. No. 1.6e+02;
Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Oy 1445 GGATCAGACCATCCCTCCATGGAAAGAAATGCAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 21 GCATGTGACCGTCCCTCCCACTACTGACAGTGGCCCAACCCCTGTGTCTGGGATG 80
Oy 1505 CC 1506

```

```

Db 81 CC 82
RESULT 169
S68634 199 bp DNA linear PRI 17-AUG-2001
LOCUS CRM+ factor IX Strasbourg 2-cross reacting material positive factor
DEFINITION IX Strasbourg 2 [exon 2] [human, hemophilia B patient J-C L, blood,
Genomic Mutant, 199 nt].
S68634
S68634.1 GI:545020
ACCESSION Homo sapiens (human)
VERSION Homo sapiens
KEYWORDS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
SOURCE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
ORGANISM
REFERENCE 1 (bases 1 to 199)
AUTHORS de la Salle, C., Charmantier, J.L., Ravanat, C., Ohlmann, P.,
Hartmann, M.L., Schuhler, S., Bischoff, R., Ebel, C., Roecklin, D.,
Balland, A. et al.
TITLE The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation
JOURNAL by factor Xla
MEDLINE 94126308
PUBMED 8295921
REMARK GenBank staff at the National Library of Medicine created this
entry [NCBI gibbsg 143652] from the original journal article.
COMMENT G6365 to A transition.
FEATURES
Location/Qualifiers
1..199
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="hemophilia B patient J-C L"
/db_xref="taxon:9606"
/tissue_type="blood"
<4..>168
/notes="cross reacting material positive factor IX
Strasbourg 2; Arg-4 to Gln transition; Method: conceptual
translation with partial peptide sequencing"
/codon_start=1
/product="CRM+ factor IX Strasbourg 2"
/protein_id="AAB29758.1"
/db_xref="GI:545021"
/translation="VFLDHENANKILNQPKRYNSGKLEEFVQGNLERECWEKCSFEE
AREVFENTERT"
Query Match 0.6%; Score 20.4; DB 1; Length 199;
Best Local Similarity 61.1%; Pred. No. 1.6e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
Oy 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTTCGAAGCAACCATTC 838
Db 142 GAAGTTTTTGAAAACACTGAAGACAGTGAAGTATTTCCACATAATACCCCTCA 195

RESULT 170
AX040017/C 315 bp DNA linear PAT 18-NOV-2000
LOCUS Sequence 33 from Patent WO0063435.
DEFINITION AX040017
ACCESSION AX040017.1 GI:11230031
VERSION
KEYWORDS Rattus sp.
SOURCE Rattus sp.
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1
AUTHORS Gould-Rothberg, B.E. and Dipippo, V.A.
TITLE Method of identifying toxic agents using differential gene express
ion
JOURNAL Patent: WO 0063435-A 33 26-OCT-2000;
Curagen Corporation (US)

```


AUTHORS Andersen,K.V., Freskgaard,P.O. and Pedersen,A.H.
TITLE Protein C or activated protein C-like molecules
PATENT: WO 0232461-A 1 25-APR-2002;
MAXYGEN APS (DK); MAXYGEN HOLDINGS LTD (US)

FEATURES

source
1..1383
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
1..1383
/note="unnamed protein product"
/codon_start=1
/protein_id="CAD35579.1"
/db_xref="GI:21537842"
/db_xref="REMBL:CAD35979"

CDS

1..1383
/translation="MKQLTSLLLFVATWIGSTPAPLDSVFSSSRAHQVLRIRKRA
SFLERHSLSRECEIECFEEAKEIFQNVDDTLAFWSKHVDGQCLVLPHPCA
SLCCGGTIGDIGSCDCRSGWGRFCQREVSFLNGSGGTHYCLVEVWGRRC
SCAPGYLGDLLDQCHPAVPCGRPWKRMEKRSKLRDTEDDVDPLIDGKMT
RGDSQWQVVLDSKKLACGAVLHPSWLTAACMDSESKLILVRLGYDLRWKX
ELDLKEVEVHPNYSKSTNDIDIALHLAGPATLSOTIVPICLPDGLAERLNQAG
QSLTVGWGSHSRKEAKRRTFVLNFIKIFVPHNECSSEVMNSNMLCAGILG
DRQDACEGDSGSPWASPHGTWFLVGLVSWGEGCLLHNYGVYTKVSKYLDWIHGHIR
DEAPQKSWAP"
127..1383
/product="unnamed"

mat_peptide

127..1383

Query Match 0.6%; Score 20.4; DB 1; Length 1383;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 2651 GATGGTGGATGGCATCACTGATGAGCGTGGTGGTGAACCTCTGGAGTTGG 2710
DB 94 GCTCGTGTGCGAGAACACTGATGACAGAGAGCTGCTGCGGAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720

DB 34 CCACGAACAG 25

RESULT 177

LOCUS AX149644 1386 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 14 from Patent WO0136462.
ACCESSION AX149644
VERSION AX149644.1 GI:14348043

KEYWORDS

Homo sapiens (human)

SOURCE

Homo sapiens
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

1 Gerlitz,B.E., Grinnell,B.W., Huang,L. and Jones,B.E.

AUTHORS

Protein C derivatives

TITLE

PATENT: WO 0136462-A 14 25-MAY-2001;

JOURNAL

ELI LILLY AND COMPANY (US)

FEATURES

source
1..1386
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 2651 GATGGTGGATGGCATCACTGATGAGCGTGGTGGTGAACCTCTGGAGTTGG 2710
DB 94 GCTCGTGTGCGAGAACACTGATGACAGAGAGCTGCTGCGGAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720

DB 34 CCACGAACAG 25

RESULT 178

LOCUS BD246883 1386 bp DNA linear PAT 17-JUL-2003
DEFINITION Protein C derivatives.
ACCESSION BD246883
VERSION BD246883.1 GI:33056653
KEYWORDS JP 2002542832-A/2.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE

1 (bases 1 to 1386)
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

AUTHORS

Gerlitz,B.E. and Jones,B.E.

TITLE

Protein C derivatives

JOURNAL

PATENT: JP 2002542832-A 2 17-DEC-2002;

COMMENT

ELI LILLY AND CO

OS

Homo sapiens (human)

PD

JP 2002542832-A/2

PF

17-DEC-2002

PR

13-APR-2000 JP 2000615776

PI

30-APR-1999 US 60/131801

PC

BRUCE EDWARD GERLITZ,BRYAN EDWARD JONES

PC

C12N15/09,A61K38/48,A61P7/02,A61P7/06,A61P9/10,A61P11/00, PC

PC

A61P13/00, A61P17/02,A61P31/00,A61P31/12,A61P37/06,C12N1/15,C12N1/19, PC

PC

C12N1/21

PC

C12N5/10,C12N9/64,C12N15/00,C12N5/00,A61K37/547 CC Protein C

PC

Derivatives

FH

Key

FT

source
1..1386
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

FT

Location/Qualifiers

Query Match

0.6%; Score 20.4; DB 1; Length 1386;

Best Local

Similarity 55.7%; Pred. No. 2.3e+02;

Matches

39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY

2651 GATGGTGGATGGCATCACTGATGAGCGTGGTGGTGAACCTCTGGAGTTGG 2710

DB 94 GCTCGTGTGCGAGAACACTGATGACAGAGAGCTGCTGCGGAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720

DB 34 CCACGAACAG 25

RESULT 179

LOCUS I06643 1386 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 1 from Patent EP 0323149.
ACCESSION I06643
VERSION I06643.1 GI:590170
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

1 (bases 1 to 1386)

AUTHORS

Bang,N.O., Ehrlich,H.J., Grinnell,B.W. and Van,S.-C.B.

TITLE

Vectors and compounds for expression of zymogen forms of human

JOURNAL

PATENT: EP 0323149-A2 1 05-JUL-1989;

FEATURES

source
1..1386
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

0.6%; Score 20.4; DB 1; Length 1386;


```
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACCTCGATGGACGCTGGAGTCTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 180
I08112/c
LOCUS I08112 1386 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 1 from Patent EP 0319312.
ACCESSION I08112
VERSION I08112.1 GI:589175
KEYWORDS
SOURCE Unknown.
ORGANISM Unassigned.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Bang,N.U., Ehrlich,H.J., Grinnell,B.W. and Jaskunas,S.R.J.
TITLE Vectors and compounds for direct expression of activated human
protein C
JOURNAL Patent: EP 0319312-A2 1 07-JUN-1989;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACCTCGATGGACGCTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 181
AR404692/c
LOCUS AR404692 1386 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 8 from patent US 6630138.
ACCESSION AR404692
VERSION AR404692.1 GI:40153404
KEYWORDS
SOURCE Unknown.
ORGANISM Unassigned.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE Protein C derivatives
JOURNAL Patent: US 6630138-A 8 07-OCT-2003;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACCTCGATGGACGCTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720
```

```
Db 34 CCACGAACAG 25

RESULT 182
AR404695/c
LOCUS AR404695 1386 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 11 from patent US 6630138.
ACCESSION AR404695
VERSION AR404695.1 GI:40153407
KEYWORDS
SOURCE Unknown.
ORGANISM Unassigned.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE Protein C derivatives
JOURNAL Patent: US 6630138-A 11 07-OCT-2003;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACCTCGATGGACGCTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 183
AR404696/c
LOCUS AR404696 1386 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 12 from patent US 6630138.
ACCESSION AR404696
VERSION AR404696.1 GI:40153408
KEYWORDS
SOURCE Unknown.
ORGANISM Unassigned.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE Protein C derivatives
JOURNAL Patent: US 6630138-A 12 07-OCT-2003;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACCTCGATGGACGCTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 184
AX044042/c
LOCUS AX044042 1386 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 7 from Patent WO0066754.
ACCESSION AX044042
```


REFERENCE 1
AUTHORS Gerlitz,B.E., Grinnell,B.W., Huang,L. and Jones,B.E.
TITLE Protein c derivatives
JOURNAL Patent: WO 0136462-A 16 25-MAY-2001;
ELI LILLY AND COMPANY (US)
FEATURES source
1. .1386
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGGCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 199
AX207784/c
LOCUS AX207784 1386 bp DNA linear PAT 31-AUG-2001
DEFINITION Sequence 8 from Patent WO0157193.
ACCESSION AX207784
VERSION AX207784.1 GI:15422460
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gerlitz,B.E. and Jones,B.E.
TITLE Protein c derivatives
JOURNAL Patent: WO 0157193-A 8 09-AUG-2001;
ELI LILLY AND COMPANY (US)
FEATURES source
1. .1386
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGGCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 190
AX212331/c
LOCUS AX212331 1386 bp DNA linear PAT 06-SEP-2001
DEFINITION Sequence 7 from Patent WO0159084.
ACCESSION AX212331
VERSION AX212331.1 GI:15524087
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE Protein c derivatives

JOURNAL Patent: WO 0159084-A 7 16-AUG-2001;
ELI LILLY AND COMPANY (US)
FEATURES source
1. .1386
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGGCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 192
BD246884/c
LOCUS BD246884 1386 bp DNA linear PAT 17-JUL-2003
DEFINITION Protein C derivatives.
ACCESSION BD246884
VERSION BD246884.1 GI:33056654
KEYWORDS JP 2002542832-A/3.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1386)
TITLE Gerlitz,B.E. and Jones,B.E.
JOURNAL Patent: JP 2002542832-A 3 17-DEC-2002;
ELI LILLY AND CO
COMMENT OS Homo sapiens (human)
PN JP 2002542832-A/3
PD 17-DEC-2002

PF 13-APR-2000 JP 2000615776
PR 30-APR-1999 US 60/131801
PI BRUCE EDWARD GERLITZ, BRYAN EDWARD JONES
PC C12N15/09, A61K38/48, A61P7/02, A61P9/10, A61P11/00, PC
A61P13/00,
PC A61P17/02, A61P31/00, A61P31/12, A61P37/06, C12N1/15, C12N1/19, PC
C12N1/21,
PC C12N5/10, C12N9/64, C12N15/00, C12N5/00, A61K37/547 CC Protein C
derivatives
FH Key Location/Qualifiers
FT source 1..1386
/organism="Homo sapiens (human)".

FEATURES

source
1..1386
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGCTGGTGTGCCGGAATATCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 193

AR404693/c
LOCUS 1386 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 9 from patent US 6630138.
ACCESSION AR404693
VERSION AR404693.1 GI:40153405
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 1386)
AUTHORS Gerlitz, B.E., Grinnell, B.W. and Jones, B.E.

TITLE Protein C derivatives
JOURNAL Patent: US 6630138-A 9 07-OCT-2003;

FEATURES
source
1..1386
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGCTGGTGTGCCGGAATATCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 194

AX044043/c
LOCUS 1386 bp DNA linear PAT 24-NOV-2000

DEFINITION Sequence 8 from Patent WO0066754.
ACCESSION AX044043
VERSION AX044043.1 GI:11342922

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gerlitz, B.E. and Jones, B.E.

TITLE Protein C derivatives
JOURNAL Patent: WO 0066754-A 8 09-NOV-2000;

FEATURES
source
1..1386
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGCTGGTGTGCCGGAATATCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 195

AX149642/c
LOCUS 1386 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 12 from Patent WO0136462.
ACCESSION AX149642
VERSION AX149642.1 GI:14348041
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Gerlitz, B.E., Grinnell, B.W., Huang, L. and Jones, B.E.

TITLE Protein C derivatives
JOURNAL Patent: WO 0136462-A 12 25-MAY-2001;

FEATURES
source
1..1386
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGCTGGTGTGCCGGAATATCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 196

AX149645/c
LOCUS 1386 bp DNA linear PAT 08-JUN-2001

DEFINITION Sequence 15 from Patent WO0136462.
ACCESSION AX149645
VERSION AX149645.1 GI:14348044

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

Gerlitz, B.E., Grinnell, B.W., Huang, L. and Jones, B.E.

TITLE Protein c derivatives
 JOURNAL Patent: WO 0136462-A 15 25-MAY-2001;
 ELI LILLY AND COMPANY (US)
 FEATURES Location/Qualifiers
 source 1..1386
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
 Best Local Similarity 55.7%; Pred. No. 2.3e+02;
 Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGTGAACTCTGGAGTTGG 2710
 DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGCTGGTGTCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
 DB 34 CCACGAACAG 25

RESULT 197
 AX207785/c
 LOCUS 1386 bp DNA linear PAT 31-AUG-2001
 DEFINITION Sequence 9 from Patent WO0157193.
 ACCESSION AX207785
 VERSION AX207785.1 GI:15422461
 KEYWORDS Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Gerlitz, B.E. and Jones, B.E.
 TITLE Protein c derivatives
 JOURNAL Patent: WO 0157193-A 9 09-AUG-2001;
 ELI LILLY AND COMPANY (US)
 FEATURES Location/Qualifiers
 source 1..1386
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
 Best Local Similarity 55.7%; Pred. No. 2.3e+02;
 Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGTGAACTCTGGAGTTGG 2710
 DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGCTGGTGTCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
 DB 34 CCACGAACAG 25

RESULT 198
 AX207787/c
 LOCUS 1386 bp DNA linear PAT 31-AUG-2001
 DEFINITION Sequence 11 from Patent WO0157193.
 ACCESSION AX207787
 VERSION AX207787.1 GI:15422463
 KEYWORDS Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Gerlitz, B.E. and Jones, B.E.
 TITLE Protein c derivatives
 JOURNAL Patent: WO 0157193-A 11 09-AUG-2001;
 ELI LILLY AND COMPANY (US)

FEATURES Location/Qualifiers
 source 1..1386
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
 Best Local Similarity 55.7%; Pred. No. 2.3e+02;
 Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGTGAACTCTGGAGTTGG 2710
 DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGCTGGTGTCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
 DB 34 CCACGAACAG 25

RESULT 199
 AX212332/c
 LOCUS 1386 bp DNA linear PAT 06-SEP-2001
 DEFINITION Sequence 8 from Patent WO0159084.
 ACCESSION AX212332
 VERSION AX212332.1 GI:15524088
 KEYWORDS Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Gerlitz, B.E., Grinnell, B.W. and Jones, B.E.
 TITLE Protein c derivatives
 JOURNAL Patent: WO 0159084-A 8 16-AUG-2001;
 ELI LILLY AND COMPANY (US)
 FEATURES Location/Qualifiers
 source 1..1386
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
 Best Local Similarity 55.7%; Pred. No. 2.3e+02;
 Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGTGAACTCTGGAGTTGG 2710
 DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGCTGGTGTCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
 DB 34 CCACGAACAG 25

RESULT 200
 BD246885/c
 LOCUS 1386 bp DNA linear PAT 17-JUL-2003
 DEFINITION Protein C derivatives.
 ACCESSION BD246885
 VERSION BD246885.1 GI:33056655
 KEYWORDS JP 2002542832-A/4.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1386)
 AUTHORS Gerlitz, B.E. and Jones, B.E.
 TITLE Protein C derivatives
 JOURNAL Patent: JP 2002542832-A 4 17-DEC-2002;
 ELI LILLY AND CO
 COMMENT OS Homo sapiens (human)
 PN JP 2002542832-A/4
 PD 17-DEC-2002


```

TITLE      Protein c derivatives
JOURNAL    Patent: WO 0157193-A 12 09-AUG-2001;
            ELI LILLY AND COMPANY (US)
FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGATCGATGCGAGCTGAGTCTGGGTAACCTCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 205
AX212333/c
LOCUS      AX212333      1386 bp      DNA      linear      PAT 06-SEP-2001
DEFINITION Sequence 9 from Patent WO0159084.
ACCESSION AX212333
VERSION   AX212333.1 GI:15524089
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE     Protein c derivatives
JOURNAL   Patent: WO 0159084-A 9 16-AUG-2001;
            ELI LILLY AND COMPANY (US)
FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGATCGATGCGAGCTGAGTCTGGGTAACCTCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 206
BD246886/c
LOCUS      BD246886      1386 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Protein c derivatives.
ACCESSION BD246886
VERSION   BD246886.1 GI:33056656
KEYWORDS  JP 2002542832-A/5.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1386)
AUTHORS   Gerlitz,B.E. and Jones,B.E.
TITLE     Protein c derivatives
JOURNAL   Patent: JP 2002542832-A 5 17-DEC-2002;
            ELI LILLY AND CO

COMMENT     OS Homo sapiens (human)
            PN JP 2002542832-A/5
            PD 17-DEC-2002
            PP 13-APR-2000 JP 2000615776
            PR 30-APR-1999 US 60/131801
            PT BRUCE EDWARD GERLITZ,BRYAN EDWARD JONES
            PC C12N15/09,A61K38/48,A61P7/02,A61P9/10,A61P11/00,PC,
            A61P13/00,
            PC A61P17/02,A61P31/00,A61P31/12,A61P37/06,C12N1/15,C12N1/19,PC
            C12N1/21,
            PC C12N5/10,C12N9/64,C12N15/00,C12N5/00,A61K37/547 CC Protein C
            derivatives
            FH Key Location/Qualifiers
            FT source 1..1386
            FT /organism="Homo sapiens (human)".

FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGATCGATGCGAGCTGAGTCTGGGTAACCTCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 207
AX044045/c
LOCUS      AX044045      1386 bp      DNA      linear      PAT 24-NOV-2000
DEFINITION Sequence 10 from Patent WO0066754.
ACCESSION AX044045
VERSION   AX044045.1 GI:11342924
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Gerlitz,B.E. and Jones,B.E.
TITLE     Protein c derivatives
JOURNAL   Patent: WO 0066754-A 10 09-NOV-2000;
            ELI LILLY AND COMPANY (US)
FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGATCGATGCGAGCTGAGTCTGGGTAACCTCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 208
AX212334/c
LOCUS      AX212334      1386 bp      DNA      linear      PAT 06-SEP-2001
DEFINITION Sequence 10 from Patent WO0159084.
```

ACCESSION AX212334
VERSION AX212334.1 GI:15524090
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gerlitz, B.E., Grinnell, B.W. and Jones, B.E.
TITLE Protein c derivatives
JOURNAL Patent: WO 0159084-A 10 16-AUG-2001;
ELI LILLY AND COMPANY (US)
FEATURES Location/Qualifiers
source
1..1386
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 2651 GATGGCTGATGGCATCACTGCTGATGCGTGGTGAAGTCTGGTGAAGTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACTGAGTCAAGAGAGTGGTGTCCCGAAATTCCTCCAGGTGG 35
QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25
RESULT 209
LOCUS AR364387/c 1387 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 1 from patent US 5270178.
ACCESSION AR364387
VERSION AR364387.1 GI:34426931
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1387)
AUTHORS Gerlitz, B.E. and Grinnell, B.W.
TITLE Vectors and compounds for expression of zymogen forms of human protein C
JOURNAL Patent: US 5270178-A 1 14-DEC-1993;
FEATURES Location/Qualifiers
source
1..1387
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 20.4; DB 1; Length 1387;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 2651 GATGGCTGATGGCATCACTGCTGATGCGTGGTGAAGTCTGGTGAAGTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACTGAGTCAAGAGAGTGGTGTCCCGAAATTCCTCCAGGTGG 35
QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25
RESULT 210
LOCUS AR030786 2422 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5861374.
ACCESSION AR030786
VERSION AR030786.1 GI:5944000
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner, K.L., Petersen, L. Christian. and Hart, C.E.
TITLE Modified Factor VII
JOURNAL Patent: US 5861374-A 1 19-JAN-1999;
FEATURES Location/Qualifiers
source
1..2422
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCCAAGCAAAAGATACCCAGCTGTGGATGTA 511
Db 1870 ACACCGGATGCACACACAGATGGTCACACAGAGATACGCAAAACACACCGATGCACACGC 1929
QY 512 CTGGTGATATAAGCAAGGTCGGATGC 537
Db 1930 ACATAGAGATATGCACACACAGATGC 1955
RESULT 211
LOCUS AR045090 2422 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5817788.
ACCESSION AR045090
VERSION AR045090.1 GI:5966555
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner, K.L., Petersen, L. Christian., Hart, C.E., Hedner, U. and Bregengaard, C.
TITLE Modified factor VII
JOURNAL Patent: US 5817788-A 1 06-OCT-1998;
FEATURES Location/Qualifiers
source
1..2422
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCCAAGCAAAAGATACCCAGCTGTGGATGTA 511
Db 1870 ACACCGGATGCACACACAGATGGTCACACAGAGATACGCAAAACACACCGATGCACACGC 1929
QY 512 CTGGTGATATAAGCAAGGTCGGATGC 537
Db 1930 ACATAGAGATATGCACACACAGATGC 1955
RESULT 212
LOCUS AR052946 2422 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5833982.
ACCESSION AR052946
VERSION AR052946.1 GI:5977808
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner, K.L., Petersen, L. Christian., Hart, C.E., Hedner, U. and Bregengaard, C.
TITLE Modified factor VII
JOURNAL Patent: US 5833982-A 1 10-NOV-1998;
FEATURES Location/Qualifiers
source
1..2422


```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTA 511
DB 1870 ACACACGGATGCACACAGATGGTTCACACAGATACGCAAAACACACCCGATGCACACGC 1929

QY 512 CTGGTGATATAGCAAGTCCGATGC 537
DB 1930 ACATAGAGATATGCACACAGATGC 1955

RESULT 213
LOCUS AR122899 2422 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1 from patent US 6168789.
ACCESSION AR122899
VERSION AR122899.1 GI:14107865
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and Bregengaard,C.
TITLE Modified factor VII
JOURNAL Patent: US 6168789-A 1 02-JAN-2001;
FEATURES Location/Qualifiers
source
1. 2422
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTA 511
DB 1870 ACACACGGATGCACACAGATGGTTCACACAGATACGCAAAACACACCCGATGCACACGC 1929

QY 512 CTGGTGATATAGCAAGTCCGATGC 537
DB 1930 ACATAGAGATATGCACACAGATGC 1955

RESULT 214
LOCUS AR127821 2422 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1 from patent US 6183743.
ACCESSION AR127821
VERSION AR127821.1 GI:14115483
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Hart,C.E., Petersen,L.C., Hedner,U. and Rasmussen,M.E.
TITLE Modified factor VII
JOURNAL Patent: US 6183743-A 1 06-FEB-2001;
FEATURES Location/Qualifiers
source
1. 2422
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTA 511
DB 1870 ACACACGGATGCACACAGATGGTTCACACAGATACGCAAAACACACCCGATGCACACGC 1929

QY 512 CTGGTGATATAGCAAGTCCGATGC 537
DB 1930 ACATAGAGATATGCACACAGATGC 1955

RESULT 215
LOCUS AR095304 2462 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 25 from patent US 6004555.
ACCESSION AR095304
VERSION AR095304.1 GI:10023060
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2462)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods for the specific coagulation of vasculature
JOURNAL Patent: US 6004555-A 25 21-DEC-1999;
FEATURES Location/Qualifiers
source
1. 2462
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTA 511
DB 1931 ACACACGGATGCACACAGATGGTTCACACAGATACGCAAAACACACCCGATGCACACGC 1990

QY 512 CTGGTGATATAGCAAGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016

RESULT 216
LOCUS AR103988 2462 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 25 from patent US 6093399.
ACCESSION AR103988
VERSION AR103988.1 GI:12816696
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2462)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods and compositions for the specific coagulation of vasculature
JOURNAL Patent: US 6093399-A 25 25-JUL-2000;
FEATURES Location/Qualifiers
source
1. 2462
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTA 511
DB 1931 ACACACGGATGCACACAGATGGTTCACACAGATACGCAAAACACACCCGATGCACACGC 1990

QY 512 CTGGTGATATAGCAAGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016
```

```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTA 511
DB 1931 ACACACGGATGCACACAGATGGTTCACACAGATACGCAAAACACACCCGATGCACACGC 1990

QY 512 CTGGTGATATAGCAAGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016

RESULT 217
LOCUS AR103988 2462 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 25 from patent US 6093399.
ACCESSION AR103988
VERSION AR103988.1 GI:12816696
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2462)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods and compositions for the specific coagulation of vasculature
JOURNAL Patent: US 6093399-A 25 25-JUL-2000;
FEATURES Location/Qualifiers
source
1. 2462
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGTA 511
DB 1931 ACACACGGATGCACACAGATGGTTCACACAGATACGCAAAACACACCCGATGCACACGC 1990

QY 512 CTGGTGATATAGCAAGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016
```

```

RESULT 217
AX335083
LOCUS AX335083 2462 bp DNA linear PAT 09-JAN-2002
DEFINITION Sequence 5592 from Patent WO0194629.
ACCESSION AX335083
VERSION AX335083.1 GI:18125802
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,
Horigan, S., Soppet, D.R. and Weaver, Z.
TITLE Cancer gene determination and therapeutic screening using signature
gene sets
JOURNAL Patent: WO 0194629-A 5592 13-DEC-2001;
Avalon Pharmaceuticals (US)
FEATURES
source
1..2462
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTA 511
|||
Db 1931 ACACACGGATGCACACACAGATGGTCACACAGATACGCAACACACCGATGCACACGC 1990
|||
QY 512 CTGGTGATATAGCAAGTCCGATGC 537
|||
Db 1991 ACATAGAGATATGCACACACAGATGC 2016
|||

RESULT 218
AX409604
LOCUS AX409604 2462 bp DNA linear PAT 14-JUN-2002
DEFINITION Sequence 2251 from Patent WO0229103.
ACCESSION AX409604
VERSION AX409604.1 GI:21442309
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Alvares, C., Horne, D., Peres-da-Silva, S. and Vockley, J.G.
TITLE Gene expression profiles in liver cancer
JOURNAL Patent: WO 0229103-A 2251 11-APR-2002;
GENE LOGIC INC (US)
FEATURES
source
1..2462
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/notes="EMBL/GenBank Accession No. M13232"
Query Match 0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTA 511
|||
Db 1931 ACACACGGATGCACACACAGATGGTCACACAGATACGCAACACACCGATGCACACGC 1990
|||
QY 512 CTGGTGATATAGCAAGTCCGATGC 537
|||
Db 1991 ACATAGAGATATGCACACACAGATGC 2016
|||

```

```

RESULT 219
HUMFVII
LOCUS HUMFVII 2462 bp mRNA linear PRI 13-FEB-1996
DEFINITION Human factor VII serine protease precursor mRNA, complete cds,
clone lambda-HVII2463.
ACCESSION M13232
VERSION M13232.1 GI:182799
KEYWORDS factor VII; serine protease; serum glycoprotein.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Hagen, F.S., Gray, C.L., O'Hara, P.J., Grant, F.J., Saari, G.C.,
Woodbury, R.G., Hart, C.E., Insley, M., Kistler, W., Kurachi, K. and
Davie, E.W.
TITLE Characterization of a cDNA coding for human factor VII
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 83 (8), 2412-2416 (1986)
MEDLINE 86205965
PUBMED 3486420
COMMENT Original source text: Homo sapiens liver cDNA to mRNA.
Draft entry and sequence in computer-readable form for [1] kindly
provided by F.S.Hagen.
[1] sequenced two alternatively spliced mRNAs that produced
shortened signal peptides. One is presented as factor VIIb below.
FEATURES
source
Location/Qualifiers
1..2462
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue_type="liver"
<1..2462
/product="FVIIa mRNA"
36..1436
/notes="precursor for factor VIIa and b"
/codon_start=1
/product="coagulation factor VII"
/protein_id="AA88040.1"
/db_xref="GI:182801"
/translation="MVSQLRLCLLLGLQGLAAGVAKASGGTRDMPWKPGRPHRV
FYQEGAVLHRRRANAFLEIRPGSLERECEKEQCFEAREIFKDAERTKLFWI
SYSDGQACASPCQNGSKDQIQSYICFLPAFGRNCETHKDQLICVNEGCEQ
YCSDHGTRKSCRCHEGSLADGVSCTPEYPCGKIPILEKNASKPQGRIVGGKV
CPKGCPCMVLLVNGAQLCGGTLINTVWSAAHCFDKIKNRNLIALVGHDSLSEH
DGDEQSRVAQVIIPSTYVPTNHDILRLHQPVLTDDVVPICLPERTSEETLA
FRFSLVSGWGLLDGATALEMNLVFRMLMIQCLQSKRVGDSFNITFPCAGY
SOGSKDCKDGGPHATHTGTWLTGIVSWGQCATVGHFGVTRVSVQYIEWLQKL
MRSEPRPGVLLRAPFP"
36..215
/notes="factor VIIa signal peptide"
join(36..99,166..1436)
/notes="preprofactor VIIb"
/codon_start=1
/protein_id="AA88041.1"
/db_xref="GI:182800"
/translation="MVSQLRLCLLLGLQGLAAVFVTOEAGHGLHRRRANAFLE
EIRPGSLERECEKEQCFEAREIFKDAERTKLFWISYSDGQACASPCQNGSKDQ
LOSVCFLPAFGRNCETHKDQLICVNEGCEQYCSDHGTRKSCRCHEGSLA
DGVSCTPEYPCGKIPILEKNASKPQGRIVGGVCPKGCPCMVLLVNGAQLCGG
TLINTVWSAAHCFDKIKNRNLIALVGHDSLSEHDSGDSRRVAQVIIPSTYVPT
TNHDILRLHQPVLTDDVVPICLPERTSEETLAIFRFLVSGWGLLDGATALE
LWLVNPLMTQCLQSKRVGDSFNITFPCAGYSDGSKDCKDGGPHATHTYRG
TWLTGIVSWGQCATVGHFGVTRVSVQYIEWLQKLMRSEPRPGVLLRAPFP"
join(36..99,166..215)
/notes="factor VIIb signal peptide"
216..671
/product="coagulation factor VII"
/notes="light chain"
672..1433
/product="coagulation factor VII"
/notes="heavy chain"
<36..99
/notes="preprofactor VIIb"
sig_peptide
CDS
join(36..99,166..1436)
/notes="preprofactor VIIb"
mat_peptide
exon

```

exon /number=1
100..165
/note="alternate exon; putative"
exon 166..2462
/note="factor VIIb"
/number=2

Query Match 0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAGAGATGAGCCAAAGCAAGATACCCAGCTGTGGATGTA 511
|||
Db 1931 ACACAGGATGACACACAGATGTCACACAGATAGCGAACACACCGATGCACACGC 1990
|||

QY 512 CTGTGTATTAAGCAAGTCCGATGC 537
|||
Db 1991 ACATAGAGATATGCACACACAGATGC 2016
|||

RESULT 220
LOCUS E01076 2483 bp RNA linear PAT 29-SEP-1997
DEFINITION cDNA sequence of Factor VII fragment.
ACCESSION E01076
VERSION E01076.1 GI:2169335
KEYWORDS JP 1987000283-A/2.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 2483)
AUTHORS Furederitsuku,E.H., Maaku,J.M., Shivaaron,J.B., Kiyasuriin,E.B.,
Magaratsuko,W.I., Richiyaado,J.U. and Chiyaaruzu,E.G.
TITLE DNA ENCODING FACTOR VII
JOURNAL Patent: JP 1987000283-A 2 06-JAN-1987;
HEMOJENETITSUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD,
TOYO SODA MFG CO LTD
PN JP 1987000283-A/2
PD 06-JAN-1987
PF 16-APR-1986 JP 1986087861
PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI
FUREDERITSUKU ESU HAAGEN, MAAKU JIEI MARII,
PI SHIVAARON JIEI BAZUBII,
PI KIVASURIN ERU BAAKUNAA, MAAGARETSUTO WAI INSUREE, PI
RICHIVADO JII UTSUBOBERII, CHIYAARUZU ERU GUREI PC
C12N15/00.A61K37/465.C12N5/00.C12N9/50.C12N19/50.C12N1/91; CC
strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: library=cDNA library;
CC *source: clones=lambdaviI 2463;
PH Key Location/Qualifiers
FH
FT 5'UTR 1..35
FT sig_peptide 36..215
FT CDS 216..1436
FT /product="factor VII"
FT 3'UTR 1437..2462
FT misc_recomb 2462..<2480
FT /note="polyA tail".
FEATURES
source Location/Qualifiers
1..2483
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 20.4; DB 1; Length 2483;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAGAGATGAGCCAAAGCAAGATACCCAGCTGTGGATGTA 511
|||

Db 1931 ACACAGGATGACACACACAGATGTCACACAGATAGCGAACACACCGATGCACACGC 1990
QY 512 CTGTGTATTAAGCAAGTCCGATGC 537
|||
Db 1991 ACATAGAGATATGCACACACAGATGC 2016
|||

RESULT 221
LOCUS 107990 2483 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 3 from Patent EP 0200421.
ACCESSION 107990
VERSION 107990.1 GI:589296
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2483)
AUTHORS Hagen,F.S., Murray,M.J., Busby,S.J., Berkner,K.L., Inasley,M.Y.,
Woodbury,R.G. and Gray,C.L.
TITLE Expression of factor VII and IX activities in mammalian cells
JOURNAL Patent: EP 0200421-A2 3 10-DEC-1986;
FEATURES Location/Qualifiers
source 1..2483
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 2483;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAGAGATGAGCCAAAGCAAGATACCCAGCTGTGGATGTA 511
|||
Db 1931 ACACAGGATGACACACACAGATGTCACACAGATAGCGAACACACCGATGCACACGC 1990
|||

QY 512 CTGTGTATTAAGCAAGTCCGATGC 537
|||
Db 1991 ACATAGAGATATGCACACACAGATGC 2016
|||

RESULT 222
LOCUS HS8A12R/c 240 bp DNA linear PRI 22-OCT-1995
DEFINITION H8.sapiens CpG island DNA genomic MseI fragment, clone 88a12,
reverse read cp98a12.rt1a.
ACCESSION Z63615
VERSION Z63615.1 GI:1035993
KEYWORDS CpG island; genomic MseI fragment.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Cross,S.H., Charlton,J.A., Nan,X. and Bird,A.P.
TITLE Purification of CpG islands using a methylated DNA binding column
JOURNAL Nat. Genet. 6 (3), 236-244 (1994)
MEDLINE 94282070
PUBMED 8012384
REFERENCE 2 (bases 1 to 240)
AUTHORS MacDonald,M., Huckle,E., Wilkinson,P. and Micklen,G.
TITLE Direct Submision
JOURNAL Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire,
CB10 1RQ, England. E-mail contact: humquery@sanger.ac.uk
COMMENT Vector: pGEM-5zf(-)
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: biohelp@hgmp.mrc.ac.uk.
FEATURES
source Location/Qualifiers
1..240
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match	0.6%;	Score 20.2;	DB 1;	Length 240;
Best Local Similarity	63.3%;	Pred. No. 1.9e+02;		
Matches	31;	Conservative	0;	Mismatches 18; Indels 0; Gaps 0;
QY	2688	TCTGGTGAACTCCTGGAGTGGTGATGGACAGGAGGAGCCCTGCTCGG	2736	
Db	107	TGTGGTGGAAGTCCCGACACTCGTCCAGGAAGCGAGTCCCTTCTCGG	59	
RESULT 223				
HS88A12F				
LOCUS	HS88A12F	241 bp	DNA	linear PRI 22-OCT-1995
DEFINITION	H.sapiens CpG island DNA genomic MseI fragment, clone 88a12,			
ACCESSION	263614	1	GI:1035992	
KEYWORDS	CpG island; genomic MseI fragment.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
REFERENCE				
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
JOURNAL	Cross, S.H., Charlton, J.A., Nan, X. and Bird, A.P.			
MEDLINE	Purification of CpG islands using a methylated DNA binding column			
COMMENT	Nat. Genet. 6 (3), 236-244 (1994)			
PURVED	94282070			
REFERENCE	8012384			
AUTHORS	2 (bases 1 to 241)			
TITLE	Macdonald, M., Huckle, E., Wilkinson, P. and Micklen, G.			
JOURNAL	Direct Submission			
COMMENT	Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire, CB10 1RQ, England. E-mail contact: humquery@sanger.ac.uk			
	Vector: pGEM-5zf(-)			
	Clones are available from the UK MRC Human Genome Mapping Project			
	Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:			
	http://www.hgmp.mrc.ac.uk/ for details			
	or contact: biohelp@hgmp.mrc.ac.uk.			
FEATURES				
source	Location/Qualifiers			
	1..241			
	/organism="Homo sapiens"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:9606"			
	/clone="88a12"			
	/sex="male"			
	/tissue_type="blood"			
	/clone_lib="CGI-1"			
	/dev_stage="adult"			
Query Match	0.6%;	Score 20.2;	DB 1;	Length 241;
Best Local Similarity	63.3%;	Pred. No. 1.9e+02;		
Matches	31;	Conservative	0;	Mismatches 18; Indels 0; Gaps 0;
QY	2688	TCTGGTGAACTCCTGGAGTGGTGATGGACAGGAGGAGCCCTGCTCGG	2736	
Db	134	TGTGGTGGAAGTCCCGACACTCGTCCAGGAAGCGAGTCCCTTCTCGG	182	
RESULT 224				
MACMAFAE				
LOCUS	MACMAFAE	243 bp	DNA	linear PRI 06-APR-1996
DEFINITION	Macaca fascicularis (individual isolate 2368) MHC-DRB5 class II			
ACCESSION	L76725	1	GI:1256304	
KEYWORDS	cell surface glycoprotein; class II gene; integral membrane			
SOURCE	protein; major histocompatibility complex.			
	Macaca fascicularis (crab-eating macaque).			

Query Match 0.6%; Score 20.2; DB 1; Length 582;
 Best Local Similarity 53.1%; Pred. No. 2.3e+02;
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 703 TACTACTGGCGGAGGATCCCTCAGAGAAATGGAGTAGCCATCATGTCACACAAAGA 762
 DB 92 TGCACCTGGGAGAGGCTCCCGCAGCCCACTGACTGTGCCCTCTGCCCTGCAGGAGA 151

QY 763 GTCCGAAATGCAGTACTTGA 783
 DB 152 GTATGACCTGGCGGCTGGGA 172

RESULT 228
 AB083690
 LOCUS
 DEFINITION Homo sapiens PROC gene for Protein C, partial cds, isolate:patient;
 PC 4.
 ACCESSION AB083690
 VERSION AB083690.1 GI:23978599
 KEYWORDS
 SOURCE
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Kinoshita, S., Iida, H., Inoue, S., Watanabe, K., Kurihara, M., Wada, Y.,
 Ono, M., Dongchon, K. and Hamasaki, N.
 TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic
 Patients. Genetic Background of Thrombophilia in Japan
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 694)
 AUTHORS Hamasaki, N.
 TITLE Direct Submission
 JOURNAL Submitted (13-APR-2002) Naotaka Hamasaki, Kyushu University
 Hospital, Department of clinical chemistry and laboratory medicine;
 3-1-1 maidashi, Higashi-ku Fukuoka 812-8582, Japan
 (E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,
 Fax:81-92-642-5772)

FEATURES
 source
 1..694
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /isolate="patient: PC 4"
 /db_xref="taxon:9606"
 61..694
 /gene="PROC"
 <61..694
 /gene="PROC"
 /codon_start=3
 /product="Protein C"
 /protein_id="BAC21165.1"
 /db_xref="GI:23978600"
 /translation="EYDLRRWEKWLDDIKEVFNHNSKSTTNDIALHLAQPAT
 LSQTIPICLPDSSLAERLNQAGQETLVGWGYSREKREKRNRTFVNLFIPIPV
 PHNECEVMNSMVMSCAGILGDRQDACEGDSGPMVASPHGTWFLVGLVSWGEGC
 GLLHNYGVVTSQPLRLDPWAHQSGSPPEELGTLATLPAGLGFCAMDGT"

exon
 61..694
 /gene="PROC"
 /product="Protein C"
 /number=9
 573..574
 /gene="PROC"
 /replace="aa"

variation
 573..574
 /gene="PROC"
 /replace="aa"

Query Match 0.6%; Score 20.2; DB 1; Length 594;
 Best Local Similarity 53.1%; Pred. No. 2.3e+02;
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 703 TACTACTGGCGGAGGATCCCTCAGAGAAATGGAGTAGCCATCATGTCACACAAAGA 762
 DB 5 TGCACCTGGGAGAGGCTCCCGCAGCCCACTGACTGTGCCCTCTGCCCTGCAGGAGA 64

QY 763 GTCCGAAATGCAGTACTTGA 783
 DB 65 GTATGACCTGGCGGCTGGGA 85

RESULT 229
 AB086852
 LOCUS
 DEFINITION Homo sapiens PROC1 gene for Protein C, partial cds,
 isolate:Patient:PC11.
 ACCESSION AB086852
 VERSION AB086852.1 GI:27531708
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Kinoshita, S., Iida, H., Inoue, S., Watanabe, K., Kurihara, M., Wada, Y.,
 Ono, M., Dongchon, K. and Hamasaki, N.
 TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic
 Patients. Genetic Background of Thrombophilia in Japan
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 696)
 AUTHORS Hamasaki, N.
 TITLE Direct Submission
 JOURNAL Submitted (23-JUN-2002) Naotaka Hamasaki, Kyushu University
 Hospital, Department of clinical chemistry and laboratory medicine;
 3-1-1 maidashi, Higashi-ku Fukuoka 812-8582, Japan
 (E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,
 Fax:81-92-642-5772)

FEATURES
 Location/Qualifiers
 1..696
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /isolate="Patient:PC11"
 /db_xref="taxon:9606"
 61..650
 /gene="PROC1"
 <61..650
 /gene="PROC1"
 /codon_start=3
 /product="Protein C"
 /protein_id="BAC54280.1"
 /db_xref="GI:27531709"
 /translation="EYDLRRWEKWLDDIKEVFNHNSKSTTNDIALHLAQPAT
 LSQTIPICLPDSSLAERLNQAGQETLVGWGYSREKREKRNRTFVNLFIPIPV
 PHNECEVMNSMVMSCAGILGDRQDACEGDSGPMVASPHGTWFLVGLVSWGEGC
 GLLHNYGVVTKVSRVLDWIHGIROKAPQKSWAP"
 61..650
 /gene="PROC1"
 /product="Protein C"
 /number=9
 234
 /gene="PROC1"
 /replace="g"

exon
 61..650
 /gene="PROC1"
 /product="Protein C"
 /number=9
 234
 /gene="PROC1"
 /replace="g"

variation
 234
 /gene="PROC1"
 /replace="g"

Query Match 0.6%; Score 20.2; DB 1; Length 696;
 Best Local Similarity 53.1%; Pred. No. 2.3e+02;
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 703 TACTACTGGCGGAGGATCCCTCAGAGAAATGGAGTAGCCATCATGTCACACAAAGA 762
 DB 5 TGCACCTGGGAGAGGCTCCCGCAGCCCACTGACTGTGCCCTCTGCCCTGCAGGAGA 64

QY 763 GTCCGAAATGCAGTACTTGA 783
 DB 65 GTATGACCTGGCGGCTGGGA 85

RESULT 230
 AB083693
 LOCUS
 DEFINITION Homo sapiens PROC gene for Protein C, partial cds, isolate:patient;
 PC 4.
 ACCESSION AB083693
 VERSION AB083693.1 GI:23978599
 KEYWORDS
 SOURCE
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Kinoshita, S., Iida, H., Inoue, S., Watanabe, K., Kurihara, M., Wada, Y.,
 Ono, M., Dongchon, K. and Hamasaki, N.
 TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic
 Patients. Genetic Background of Thrombophilia in Japan
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 694)
 AUTHORS Hamasaki, N.
 TITLE Direct Submission
 JOURNAL Submitted (13-APR-2002) Naotaka Hamasaki, Kyushu University
 Hospital, Department of clinical chemistry and laboratory medicine;
 3-1-1 maidashi, Higashi-ku Fukuoka 812-8582, Japan
 (E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,
 Fax:81-92-642-5772)

FEATURES
 source
 1..694
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /isolate="patient: PC 4"
 /db_xref="taxon:9606"
 61..694
 /gene="PROC"
 <61..694
 /gene="PROC"
 /codon_start=3
 /product="Protein C"
 /protein_id="BAC21165.1"
 /db_xref="GI:23978600"
 /translation="EYDLRRWEKWLDDIKEVFNHNSKSTTNDIALHLAQPAT
 LSQTIPICLPDSSLAERLNQAGQETLVGWGYSREKREKRNRTFVNLFIPIPV
 PHNECEVMNSMVMSCAGILGDRQDACEGDSGPMVASPHGTWFLVGLVSWGEGC
 GLLHNYGVVTSQPLRLDPWAHQSGSPPEELGTLATLPAGLGFCAMDGT"

exon
 61..694
 /gene="PROC"
 /product="Protein C"
 /number=9
 573..574
 /gene="PROC"
 /replace="aa"

variation
 573..574
 /gene="PROC"
 /replace="aa"

Query Match 0.6%; Score 20.2; DB 1; Length 594;
 Best Local Similarity 53.1%; Pred. No. 2.3e+02;
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 703 TACTACTGGCGGAGGATCCCTCAGAGAAATGGAGTAGCCATCATGTCACACAAAGA 762
 DB 5 TGCACCTGGGAGAGGCTCCCGCAGCCCACTGACTGTGCCCTCTGCCCTGCAGGAGA 64

```

DEFINITION Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:
PC 3.
ACCESSION AB083693
VERSION AB083693.1 GI:23978603
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic
PATIENTS. Genetic Background of Thrombophilia in Japan
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 696)
AUTHORS Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Direct Submission
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University
Hospiat, Department of clinical chemistry and laboratory medicine;
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel.81-92-642-5770,
Fax:81-92-642-5772)
FEATURES
source
Location/Qualifiers
1..696
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="patient: PC 3"
/db_xref="taxon:9606"
61..650
/gene="PROC"
<61..650
/gene="PROC"
/codon_start=3
/product="Protein C"
/protein_id="BAC21166.1"
/db_xref="GI:23978604"
/translation="EYDLRWEKWEKLDLKEVFPVHNPYSKSTTDNDIALHLAQAPT
LSQTVPLCLPDSGLAEINQAGQETLVGTGYSRREKEAKRNTFVLFNFKIPV
PHNECEVMNSMNSVSNMLCAGILGRDQACEGSGGPMVASFHGTWFLVLVSGEGC
GLLHNYGVYTKVSRVLDWIHGHIRDKEAPQKSWAP"
61..650
/gene="PROC"
/product="Protein C"
/number=9
variation
/gene="PROC"
/replace="C"
252
Query Match 0.6%; Score 20.2; DB 1; Length 696;
Best Local Similarity 53.1%; Pred. No. 2.3e+02;
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 703 TACTACTGCGGCGAGGAGTCCCTCAGAGAAATGGAGTACCATCATGTGTCAACAAAGA 762
Db 5 TGCACCTGGGAGAGCTCCCGAGCCACTCTGACTGTGCCCTCTGCCCTGCAGGAGA 64
QY 763 GTCCGAAATGCAGTACTTGA 783
Db 65 GTATGACCTGGCGGCTGGGA 85
RESULT 231
AB083695
LOCUS Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:
DEFINITION PC 6.
ACCESSION AB083695
VERSION AB083695.1 GI:23978610
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic
PATIENTS. Genetic Background of Thrombophilia in Japan
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 696)
AUTHORS Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Direct Submission
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University
Hospiat, Department of clinical chemistry and laboratory medicine;
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel.81-92-642-5770,
Fax:81-92-642-5772)
FEATURES
source
Location/Qualifiers
1..696
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="patient: PC 3"
/db_xref="taxon:9606"
61..650
/gene="PROC"
<61..650
/gene="PROC"
/codon_start=3
/product="Protein C"
/protein_id="BAC21166.1"
/db_xref="GI:23978604"
/translation="EYDLRWEKWEKLDLKEVFPVHNPYSKSTTDNDIALHLAQAPT
LSQTVPLCLPDSGLAEINQAGQETLVGTGYSRREKEAKRNTFVLFNFKIPV
PHNECEVMNSMNSVSNMLCAGILGRDQACEGSGGPMVASFHGTWFLVLVSGEGC
GLLHNYGVYTKVSRVLDWIHGHIRDKEAPQKSWAP"
61..650
/gene="PROC"
/product="Protein C"
/number=9
variation
/gene="PROC"
/replace="C"
252
Query Match 0.6%; Score 20.2; DB 1; Length 696;
Best Local Similarity 53.1%; Pred. No. 2.3e+02;
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 703 TACTACTGCGGCGAGGAGTCCCTCAGAGAAATGGAGTACCATCATGTGTCAACAAAGA 762
Db 5 TGCACCTGGGAGAGCTCCCGAGCCACTCTGACTGTGCCCTCTGCCCTGCAGGAGA 64
QY 763 GTCCGAAATGCAGTACTTGA 783
Db 65 GTATGACCTGGCGGCTGGGA 85

```

```

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic
PATIENTS. Genetic Background of Thrombophilia in Japan
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 696)
AUTHORS Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Direct Submission
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University
Hospiat, Department of clinical chemistry and laboratory medicine;
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel.81-92-642-5770,
Fax:81-92-642-5772)
FEATURES
source
Location/Qualifiers
1..696
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="patient: PC 6"
/db_xref="taxon:9606"
61..650
/gene="PROC"
<61..650
/gene="PROC"
/codon_start=3
/product="Protein C"
/protein_id="BAC21167.1"
/db_xref="GI:23978611"
/translation="EYDLRWEKWEKLDLKEVFPVHNPYSKSTTDNDIALHLAQAPT
LSQTVPLCLPDSGLAEINQAGQETLVGTGYSRREKEAKRNTFVLFNFKIPV
PHNECEVMNSMNSVSNMLCAGILGRDQACEGSGGPMVASFHGTWFLVLVSGEGC
GLLHNYGVYTKVSRVLDWIHGHIRDKEAPQKSWAP"
61..650
/gene="PROC"
/product="Protein C"
/number=9
variation
/gene="PROC"
/replace="A"
273
Query Match 0.6%; Score 20.2; DB 1; Length 696;
Best Local Similarity 53.1%; Pred. No. 2.3e+02;
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 703 TACTACTGCGGCGAGGAGTCCCTCAGAGAAATGGAGTACCATCATGTGTCAACAAAGA 762
Db 5 TGCACCTGGGAGAGCTCCCGAGCCACTCTGACTGTGCCCTCTGCCCTGCAGGAGA 64
QY 763 GTCCGAAATGCAGTACTTGA 783
Db 65 GTATGACCTGGCGGCTGGGA 85
RESULT 232
AB083696
LOCUS Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:
DEFINITION PC 2.
ACCESSION AB083696
VERSION AB083696.1 GI:23978613
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic
PATIENTS. Genetic Background of Thrombophilia in Japan
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 696)
AUTHORS Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,
TITLE Direct Submission
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University
Hospiat, Department of clinical chemistry and laboratory medicine;
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel.81-92-642-5770,
Fax:81-92-642-5772)
FEATURES
source
Location/Qualifiers
1..696
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="patient: PC 2"
/db_xref="taxon:9606"
61..650
/gene="PROC"
<61..650
/gene="PROC"
/codon_start=3
/product="Protein C"
/protein_id="BAC21167.1"
/db_xref="GI:23978611"
/translation="EYDLRWEKWEKLDLKEVFPVHNPYSKSTTDNDIALHLAQAPT
LSQTVPLCLPDSGLAEINQAGQETLVGTGYSRREKEAKRNTFVLFNFKIPV
PHNECEVMNSMNSVSNMLCAGILGRDQACEGSGGPMVASFHGTWFLVLVSGEGC
GLLHNYGVYTKVSRVLDWIHGHIRDKEAPQKSWAP"
61..650
/gene="PROC"
/product="Protein C"
/number=9
variation
/gene="PROC"
/replace="A"
273
Query Match 0.6%; Score 20.2; DB 1; Length 696;
Best Local Similarity 53.1%; Pred. No. 2.3e+02;
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 703 TACTACTGCGGCGAGGAGTCCCTCAGAGAAATGGAGTACCATCATGTGTCAACAAAGA 762
Db 5 TGCACCTGGGAGAGCTCCCGAGCCACTCTGACTGTGCCCTCTGCCCTGCAGGAGA 64
QY 763 GTCCGAAATGCAGTACTTGA 783
Db 65 GTATGACCTGGCGGCTGGGA 85

```


SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 2462)
AUTHORS Thorpe, P.E. and Edgington, T.S.
TITLE Methods and compositions for the specific coagulation of vasculature
JOURNAL Patent: US 6093399-A 25 JUL-2000;
FEATURES Location/Qualifiers
source 1. 2462
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 20.2; DB 1; Length 2462;
Best Local Similarity 49.5%; Pred. No. 2.5e+02;
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2571 CAGAAGAGCTGACTCACTCGAAAGACCTGATGCTGGAGGATTTGGGGCAGAGGAG 2630
DB 1846 CAGAGAGAGCTGAGGGCCAGCAGATCACGTGAGGTGGGCTTGGCTGAAGGGAGGT 1787

QY 2631 AAGGGACACACAGAGGATGAGTGGCTGGATGCATCACTGACTC 2675
DB 1786 AAGGAGGCTCAGCTGGGCTGTCTGCTCCAGGACACCTTGGCAC 1742

RESULT 239
AX335083/c
LOCUS AX335083 2462 bp DNA linear PAT 09-JAN-2002
DEFINITION Sequence 5592 from Patent WO0194629.
ACCESSION AX335083
VERSION AX335083.1 GI:18125802
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
YOUNG, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G., Horigan, S., Soppet, D.R. and Weaver, Z.
TITLE Cancer gene determination and therapeutic screening using signature gene sets
JOURNAL Patent: WO 0194629-A 5592 13-DEC-2001;
Avalon Pharmaceuticals (US)
FEATURES Location/Qualifiers
source 1. 2462
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20.2; DB 1; Length 2462;
Best Local Similarity 49.5%; Pred. No. 2.5e+02;
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2571 CAGAAGAGCTGACTCACTCGAAAGACCTGATGCTGGAGGATTTGGGGCAGAGGAG 2630
DB 1846 CAGAGAGAGCTGAGGGCCAGCAGATCACGTGAGGTGGGCTTGGCTGAAGGGAGGT 1787

QY 2631 AAGGGACACACAGAGGATGAGTGGCTGGATGCATCACTGACTC 2675
DB 1786 AAGGAGGCTCAGCTGGGCTGTCTGCTCCAGGACACCTTGGCAC 1742

RESULT 240
AX409604/c
LOCUS AX409604 2462 bp DNA linear PAT 14-JUN-2002
DEFINITION Sequence 2251 from Patent WO0229103.
ACCESSION AX409604
VERSION AX409604.1 GI:21442309
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Alvares, C., Horne, D., Peres-da-Silva, S. and Vockley, J.G.
TITLE Gene expression profiles in liver cancer
JOURNAL Patent: WO 0229103-A 2251 11-APR-2002;
GENE LOGIC INC (US)
FEATURES Location/Qualifiers
source 1. 2462
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="EMBL/GenBank Accession No. M13232"

Query Match 0.6%; Score 20.2; DB 1; Length 2462;
Best Local Similarity 49.5%; Pred. No. 2.5e+02;
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2571 CAGAAGAGCTGACTCACTCGAAAGACCTGATGCTGGAGGATTTGGGGCAGAGGAG 2630
DB 1846 CAGAGAGAGCTGAGGGCCAGCAGATCACGTGAGGTGGGCTTGGCTGAAGGGAGGT 1787

QY 2631 AAGGGACACACAGAGGATGAGTGGCTGGATGCATCACTGACTC 2675
DB 1786 AAGGAGGCTCAGCTGGGCTGTCTGCTCCAGGACACCTTGGCAC 1742

RESULT 241
HUMFVII/c
LOCUS HUMFVII 2462 bp mRNA linear PRI 13-FEB-1996
DEFINITION Human factor VII serine protease precursor mRNA, complete cds, clone lambda-HVII2463.
ACCESSION M13232
VERSION M13232.1 GI:182799
KEYWORDS factor VII; serine protease; serum glycoprotein.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
HAGEN, F.S., Gray, C.L., O'Hara, P.J., Grant, F.J., Saari, G.C., Woodbury, R.G., Hart, C.E., Insley, M., Kiesel, W., Kurachi, K. and Davie, E.W.
TITLE Characterization of a cDNA coding for human factor VII
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 83 (8), 2412-2416 (1986)
MEDLINE 86205965
PubMed 3486420
COMMENT Original source text: Homo sapiens liver cDNA to mRNA. Draft entry and sequence in computer-readable form for [1] kindly provided by F.S.Hagen.
[1] sequenced two alternatively spliced mRNAs that produced shortened signal peptides. One is presented as factor VIIb below.

FEATURES Location/Qualifiers
source 1. 2462
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue type="liver"
<1. 2462
/product="FVIIa mRNA"
36. 1436
/note="precursor for factor VIIa and b"
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAA88040.1"
/db_xref="GI:182801"
/translation="MWSQALRLCLLGLQCLLAGGVAKASGGSTRDMPKPHGRV
FVTEAEHGVLLHRRRANAFLEELPGSLERECEECFSEARIEFDKARTKLFWI
YSGDGDQASSPCQNGSKQDQSYICFLPAFEGNCTHKKDQDLTCVNEGCEQ
YSDHTGTRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKNASPGQRIYGGKV
CPKQCPWQVLLVNGAQLCGTTLINTIWWSAHCFDKIKNWNLIATVGHDLSEH
DGDEQRRVAQVIIPTVPTGTTNDIALHLHPVLTLDHVPLCLPFTFSEETLA
FVRFSLVSGWGLLDRGATALELMVLPRLMTQDCLQOSKVGDSNITETMPCAGY
SDGSKDSCKSGSGGPHATHTGTWLTGIVSWGQCATVGHFVYTRVSQVLEWLQKL

```
MRSEPRFGVLLRAPFP"
36. .215
/notes="factor VIIa signal peptide"
join(36. .99,166. .1436)
CDS
/notes="preprofactor VIIb"
/codon_start=1
/protein_id="AAA88041.1"
/db_xref="GI:182800"
/translation="MVSQLRLCLLLGLQCLAAVFTQBEAHGVLRHRRANAFLE
ELRPSLERECKEQCFEAREIFKDAERTKLFWISYDQDCASSPCQNGSKDQ
LQSYICFLPAFEGNCEHDKDOLI CVNENGCEQYCSDHGTGTRKSCRCHEGYSLIA
DGVSCTPVEYPCGKIPILEKRNASKPQRTVGGKVPKGECPWQVLLLVNQAQLCGG
TLNITMVVSAHGFCDIKWNLIAVLGHDLSEHGDQSRRAVOIIPSTVVPQT
TNHIALRLHQPVLVDHVPVLCIPERTSEPTLAVRSLVSGWQLLDGRTALE
LMVNLNPKMTQDCQKRVGDSFNITEYFCAGISDGSKGSGSGGPHATHRG
TWYLTGVISWQGCATVGHGFYTRVQSYIEWLQKMRSEPRFGVLLRAPFP"
sig_peptide
join(36. .99,166. .215)
mat_peptide
216. .671
/product="coagulation factor VII"
/mat_peptide
672. .1433
/product="coagulation factor VII"
/notes="heavy chain"
<36. .99
/notes="preprofactor VIIb"
/number=1
100. .165
/notes="alternate exon; putative"
166. .2462
/notes="factor VIIb"
/number=2
Query Match 0.6%; Score 20.2; DB 1; Length 2462;
Best Local Similarity 49.5%; Pred. No. 2.5e+02;
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;
QY 2571 CAGAGAGTGCTACTGCTGAAAGACCTGATGCTGGAGGGATGGGGCAGGAGGAG 2630
|||||
DB 1846 CAGACGACGAGCTGAGGCGCAGACATCAGCTGAGGCTGGCTGAGGAGGCT 1787
|||||
QY 2631 AAGGGAGCAGACAGAGATGAGATGGCTGGATGGCTACTGACTC 2675
|||||
DB 1786 AAGGAGGCTCAGCTGGGCTGTCTGCTCCAGGACACCTTGGCAC 1742
|||||
RESULT 242
AX655170/c
LOCUS 199 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 5040 from Patent WO03000898.
ACCESSION AX655170
VERSION AX655170.1 GI:29157984
KEYWORDS
SOURCE Oryza sativa
ORGANISM Oryza sativa
REFERENCE
1 Chang, H. S., Chen, W., Cooper, B., Glazebrook, J., Goff, S. A., Hou, Y. M.,
Kateriri, F., Qian, S., Tag, Y., Whitham, S., Xie, Z., Zhu, T. and Zou, G.
Plant genes involved in defense against pathogens
Patent: WO 03000898-A 5040 03-JAN-2003;
Syngenta Participations AG (CH)
FEATURES
Location/Qualifiers
1. .199
/organism="Oryza sativa"
/mol_type="unassigned DNA"
/db_xref="taxon:4530"
Query Match 0.6%; Score 20; DB 1; Length 199;
Best Local Similarity 47.6%; Pred. No. 2.1e+02;
Matches 59; Conservative 0; Mismatches 65; Indels 0; Gaps 0;
MRSEPRFGVLLRAPFP"
36. .215
/notes="factor VIIa signal peptide"
join(36. .99,166. .1436)
CDS
/notes="preprofactor VIIb"
/codon_start=1
/protein_id="AAA88041.1"
/db_xref="GI:182800"
/translation="MVSQLRLCLLLGLQCLAAVFTQBEAHGVLRHRRANAFLE
ELRPSLERECKEQCFEAREIFKDAERTKLFWISYDQDCASSPCQNGSKDQ
LQSYICFLPAFEGNCEHDKDOLI CVNENGCEQYCSDHGTGTRKSCRCHEGYSLIA
DGVSCTPVEYPCGKIPILEKRNASKPQRTVGGKVPKGECPWQVLLLVNQAQLCGG
TLNITMVVSAHGFCDIKWNLIAVLGHDLSEHGDQSRRAVOIIPSTVVPQT
TNHIALRLHQPVLVDHVPVLCIPERTSEPTLAVRSLVSGWQLLDGRTALE
LMVNLNPKMTQDCQKRVGDSFNITEYFCAGISDGSKGSGSGGPHATHRG
TWYLTGVISWQGCATVGHGFYTRVQSYIEWLQKMRSEPRFGVLLRAPFP"
sig_peptide
join(36. .99,166. .215)
mat_peptide
216. .671
/product="coagulation factor VII"
/mat_peptide
672. .1433
/product="coagulation factor VII"
/notes="heavy chain"
<36. .99
/notes="preprofactor VIIb"
/number=1
100. .165
/notes="alternate exon; putative"
166. .2462
/notes="factor VIIb"
/number=2
Query Match 0.6%; Score 20.2; DB 1; Length 2462;
Best Local Similarity 49.5%; Pred. No. 2.5e+02;
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;
QY 2571 CAGAGAGTGCTACTGCTGAAAGACCTGATGCTGGAGGGATGGGGCAGGAGGAG 2630
|||||
DB 1846 CAGACGACGAGCTGAGGCGCAGACATCAGCTGAGGCTGGCTGAGGAGGCT 1787
|||||
QY 2631 AAGGGAGCAGACAGAGATGAGATGGCTGGATGGCTACTGACTC 2675
|||||
DB 1786 AAGGAGGCTCAGCTGGGCTGTCTGCTCCAGGACACCTTGGCAC 1742
|||||
RESULT 244
AF005089
LOCUS 276 bp mRNA linear PLN 18-FEB-2000
DEFINITION Triticum aestivum phenylalanine ammonia lyase (War7.2) mRNA,
partial cds.
ACCESSION AF005089
VERSION AF005089.1 GI:6996627
KEYWORDS
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
REFERENCE
1 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Pooidae; Triticeae; Triticum.
1 (bases 1 to 276)
CTGGAGGATTTGGGGCAGAGGAGGAGGACACAGAGATGAGATGGCTGGATGC 2664
147 CTGGGATTTCTCGGACCGGAGGAGGAGGAGGCGGGGTGGATTTGGGGATTTC 88
2665 ATCACTGACTCGATGACCTGAGTCTGGGTGAACCTCTCTGATGATGACAGGAG 2724
87 GGCGTCGGGAAGGAAGTTGGGGGCGGAGATTGGAAGTTGGGATATTTAGGCG 28
2725 GCCT 2728
|||||
27 GCCT 24
|||||
RESULT 243
AF542508
LOCUS 256 bp mRNA linear ROD 03-OCT-2002
DEFINITION Rattus norvegicus adenylyl cyclase 7 mRNA, partial cds.
ACCESSION AF542508
VERSION AF542508.1 GI:23477371
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
REFERENCE
1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 256)
Haunso, A. and Antoni, P.
Direct Submission
Submitted (02-SEP-2002) Department of Neuroscience, University of
Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK
FEATURES
Location/Qualifiers
1. .256
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Sprague-Dawley"
/db_xref="taxon:10116"
/tissue_type="anterior pituitary gland"
<1. .256
/codon_start=2
/product="adenylyl cyclase 7"
/protein_id="AAN34659.1"
/db_xref="GI:23477372"
/translation="LLLPKFSQVEKIKTIGSTYMAAGISVPSCGHENQDLERKHVHI
GVLFESMALMSKLDGINRHSFNSRLRGINHPVIAGVI"
Query Match 0.6%; Score 20; DB 1; Length 256;
Best Local Similarity 51.1%; Pred. No. 2.2e+02;
Matches 47; Conservative 0; Mismatches 45; Indels 0; Gaps 0;
QY 651 CGAAGTAAATGGACTCGAATGGTGAATTTAACTCAGATGACATATATCTACTG 710
DB 15 CCAAGTTTCAGTGTGTGGAGAGATCAAGACCATTTGGCAGCACCCTACATGCTGCTG 74
QY 711 CGGGCAGGAATCCCTCAGAGAAATGGAGTAG 742
DB 75 GGCTCAGTGTCCCTCAGGACATCAGAACCCAG 106
RESULT 244
AF005089
LOCUS 276 bp mRNA linear PLN 18-FEB-2000
DEFINITION Triticum aestivum phenylalanine ammonia lyase (War7.2) mRNA,
partial cds.
ACCESSION AF005089
VERSION AF005089.1 GI:6996627
KEYWORDS
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
REFERENCE
1 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Pooidae; Triticeae; Triticum.
1 (bases 1 to 276)
```

AUTHORS Hamel, F., Breton, C. and Houde, M.
 TITLE Isolation and characterization of wheat aluminum-regulated genes:
 possible involvement of aluminum as a pathogenesis response
 elicitor
 JOURNAL Planta 205 (4), 531-538 (1998)
 MEDLINE 98348982
 PUBMED 9684357
 REFERENCE 2 (bases 1 to 276)
 AUTHORS Hamel, F., Breton, C. and Houde, M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAY-1997) Departement des Sciences Biologiques,
 Universite du Quebec a Montreal, C.P. 8988, Succ. Centre-ville,
 Montreal, Quebec H3C 3P8, Canada
 FEATURES
 source Location/Qualifiers
 1..276
 /organism="Triticum aestivum"
 /mol_type="mRNA"
 /cultivar="Atlas-66"
 /db_xref="taxon:4565"
 /clone="WAR13.2"
 /tissue_type="root tips"
 /dev_stage="5 days old seedlings"
 /note="hexaploid"
 <1..>276
 /gene="War7.2"
 <1..>276
 /gene="War7.2"
 /note="up-regulated by aluminum"
 /codon_start=2
 /product="phenylalanine ammonia lyase"
 /protein_id="AAF34815.1"
 /db_xref="GI:6996428"
 /translation="RARGEDRGRQLRVQGVAAVAQAKDASGISVELDEEARPRVKASS
 EWILSLGARHLRHHRLRHLPPHQRARPPGAPQASERNWLP"
 Query Match 0.6%; Score 20; DB 1; Length 276;
 Best Local Similarity 55.9%; Pred. No. 2.2e+02;
 Matches 38; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
 QY 1192 TGGAGAGCTCTATACAGTCACGACAAACAGACAGAGCTTACTGTGGCTCAGATCAT 1251
 DB 10 TGGTGAAGATCAGGGCGGCAGCTCGGCTCGGCAGGTGGCGCGTGGCCCGAGCCAA 69
 QY 1252 GAATCCT 1259
 DB 70 GGACGGT 77
 RESULT 245
 LOCUS AR424808/c 300 bp DNA linear PAT 18-DEC-2003
 DEFINITION Sequence 16305 from patent US 6639063.
 ACCESSION AR424808
 VERSION AR424808.1 GI:40179918
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 300)
 AUTHORS Edwards, J.-B.D.M., Jobert, S. and Giordano, J.-Y.
 TITLE EST's and encoded human proteins
 JOURNAL Patent: US 6639063-A 16305 28-OCT-2003;
 FEATURES
 source Location/Qualifiers
 1..300
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 0.6%; Score 20; DB 1; Length 300;
 Best Local Similarity 48.9%; Pred. No. 2.2e+02;
 Matches 44; Conservative 3; Mismatches 43; Indels 0; Gaps 0;
 QY 11 GCGGAGTGAGGAGGAGTACCTACCTCGTCCAAAGTAAAGGAGCAGTAGCTGGCTTGC 70
 DB 10 TGGTGAAGATCAGGGCGGCAGCTCGGCTCGGCAGGTGGCGCGTGGCCCGAGCCAA 69
 QY 1252 GAATCCT 1259
 DB 70 GGACGGT 77
 RESULT 246
 LOCUS BD120361/c 300 bp DNA linear PAT 18-SEP-2002
 DEFINITION EST and encoded human protein.
 ACCESSION BD120361
 VERSION BD120361.1 GI:23215271
 KEYWORDS JP 2002010789-A/12438.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 300)
 AUTHORS Edwards, J.B.D.M., Jobert, S. and Giordano, J.E.
 TITLE EST and encoded human protein
 JOURNAL Patent: JP 2002010789-A 12438 15-JAN-2002;
 COMMENT GENSET CORP
 OS Homo sapiens (human)
 PN JP 2002010789-A/12438
 PD 15-JAN-2002
 PF 07-AUG-2000 JP 2002080989
 PR 05-AUG-1999 US 60/147499
 PI JEAN BAPTIST DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
 GIORDANO
 PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
 C12N1/21,
 PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
 C12N15/00
 CC EST and encoded human protein
 FH Key Location/Qualifiers
 FT source 1..300
 /organism="Homo sapiens (human)".
 FEATURES
 source Location/Qualifiers
 1..300
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 Query Match 0.6%; Score 20; DB 1; Length 300;
 Best Local Similarity 48.9%; Pred. No. 2.2e+02;
 Matches 44; Conservative 3; Mismatches 43; Indels 0; Gaps 0;
 QY 11 GCGGAGTGAGGAGGAGTACCTACCTCGTCCAAAGTAAAGGAGCAGTAGCTGGCTTGC 70
 DB 10 TGGTGAAGATCAGGGCGGCAGCTCGGCTCGGCAGGTGGCGCGTGGCCCGAGCCAA 69
 QY 71 TGGAGCAGCGGTAAAGAGATACCCACGCC 100
 DB 108 TCGTGAACCATSSAAACAGCCGCCSCGC 79
 RESULT 247
 LOCUS DOGCFVII 478 bp DNA linear MAM 05-FEB-1999
 DEFINITION Dog gene for coagulation factor VII, partial cds.
 ACCESSION D21213
 VERSION D21213.1 GI:415264
 KEYWORDS coagulation factor VII.
 SOURCE Canis familiaris (dog)
 ORGANISM Canis familiaris
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 REFERENCE 1 (bases 1 to 478)
 AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and
 Niho, Y.
 TITLE Analysis of the partial nucleotide sequences and deduced primary
 structures of the protease domains of mammalian blood coagulation

Db 168 GCTGCTCTGCCACCTSGAGCCACCCCTGGCATGGGATGAGCAGCTGGTGGTCTCTAA 109
 QY 71 TGGAGCAGCGGTAAAGAGATACCCACGCC 100
 DB 108 TCGTGAACCATSSAAACAGCCGCCSCGC 79
 RESULT 246
 LOCUS BD120361/c 300 bp DNA linear PAT 18-SEP-2002
 DEFINITION EST and encoded human protein.
 ACCESSION BD120361
 VERSION BD120361.1 GI:23215271
 KEYWORDS JP 2002010789-A/12438.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 300)
 AUTHORS Edwards, J.B.D.M., Jobert, S. and Giordano, J.E.
 TITLE EST and encoded human protein
 JOURNAL Patent: JP 2002010789-A 12438 15-JAN-2002;
 COMMENT GENSET CORP
 OS Homo sapiens (human)
 PN JP 2002010789-A/12438
 PD 15-JAN-2002
 PF 07-AUG-2000 JP 2002080989
 PR 05-AUG-1999 US 60/147499
 PI JEAN BAPTIST DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
 GIORDANO
 PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
 C12N1/21,
 PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
 C12N15/00
 CC EST and encoded human protein
 FH Key Location/Qualifiers
 FT source 1..300
 /organism="Homo sapiens (human)".
 FEATURES
 source Location/Qualifiers
 1..300
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 Query Match 0.6%; Score 20; DB 1; Length 300;
 Best Local Similarity 48.9%; Pred. No. 2.2e+02;
 Matches 44; Conservative 3; Mismatches 43; Indels 0; Gaps 0;
 QY 11 GCGGAGTGAGGAGGAGTACCTACCTCGTCCAAAGTAAAGGAGCAGTAGCTGGCTTGC 70
 DB 108 TCGTGAACCATSSAAACAGCCGCCSCGC 79
 RESULT 247
 LOCUS DOGCFVII 478 bp DNA linear MAM 05-FEB-1999
 DEFINITION Dog gene for coagulation factor VII, partial cds.
 ACCESSION D21213
 VERSION D21213.1 GI:415264
 KEYWORDS coagulation factor VII.
 SOURCE Canis familiaris (dog)
 ORGANISM Canis familiaris
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 REFERENCE 1 (bases 1 to 478)
 AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and
 Niho, Y.
 TITLE Analysis of the partial nucleotide sequences and deduced primary
 structures of the protease domains of mammalian blood coagulation

REFERENCE 1
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,
Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L.,
Sherwood, S., Smith, V., Stewart, T.A., Tamas, D., Watanabe, C.K.,
Wood, W.L. and Zhang, Z.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
same
JOURNAL Patent: WO 0140466-A 221 07-JUN-2001;
Genentech Inc. (US)
FEATURES Location/Qualifiers
source 1..1129
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 20; DB 1; Length 1129;
Best Local Similarity 53.9%; Pred. No. 2.8e+02;
Matches 41; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 3004 TTATTTTATGATTTTCTATAATAATCCAGTCCTGTGTTTTTAAAGACTTTAAAA 3063
|||
Db 1128 TTTTITTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTTTTATTTGGGAGAACATAAA 1069
|||
QY 3064 TTATTAATTTCCTTT 3079
|||
Db 1068 TAAATAAGGTAATT 1053

Search completed: August 9, 2004, 15:51:29
Job time : 1110 secs



Creation date: 08-26-2004
Indexing Officer: NKIDANE - NIGIST M. KIDANE
Team: OIPEScanning
Dossier: 10664775

Legal Date: 08-05-2004

No.	Doccode	Number of pages
1	SRNT	296

Total number of pages: 296

Remarks:

Order of re-scan issued on

